



International Journal of
Molecular Sciences

Molecular Research on Platelet Activity in Health and Disease

Edited by

Isabella Savini, Valeria Gasperi and Maria Valeria Catani

Printed Edition of the Special Issue Published in
International Journal of Molecular Sciences

Molecular Research on Platelet Activity in Health and Disease

Molecular Research on Platelet Activity in Health and Disease

Editors

Isabella Savini

Valeria Gasperi

Maria Valeria Catani

MDPI • Basel • Beijing • Wuhan • Barcelona • Belgrade • Manchester • Tokyo • Cluj • Tianjin



Editors

Isabella Savini
Tor Vergata University of Rome
Italy

Valeria Gasperi
Tor Vergata University of Rome
Italy

Maria Valeria Catani
Tor Vergata University of Rome
Italy

Editorial Office

MDPI
St. Alban-Anlage 66
4052 Basel, Switzerland

This is a reprint of articles from the Special Issue published online in the open access journal *International Journal of Molecular Sciences* (ISSN 1422-0067) (available at: https://www.mdpi.com/journal/ijms/special_issues/Molecular_Research_on_Platelet_Activity_in_Health_and_Disease).

For citation purposes, cite each article independently as indicated on the article page online and as indicated below:

| |
|---|
| LastName, A.A.; LastName, B.B.; LastName, C.C. Article Title. <i>Journal Name</i> Year , Article Number, Page Range. |
|---|

ISBN 978-3-03936-690-3 (Pbk)

ISBN 978-3-03936-691-0 (PDF)

© 2020 by the authors. Articles in this book are Open Access and distributed under the Creative Commons Attribution (CC BY) license, which allows users to download, copy and build upon published articles, as long as the author and publisher are properly credited, which ensures maximum dissemination and a wider impact of our publications.

The book as a whole is distributed by MDPI under the terms and conditions of the Creative Commons license CC BY-NC-ND.

Contents

| | |
|---|-----|
| About the Editors | vii |
| Maria Valeria Catani, Isabella Savini and Valeria Gasperi Molecular Research on Platelet Activity in Health and Disease Reprinted from: <i>Int. J. Mol. Sci.</i> 2020 , <i>21</i> , 3804, doi:10.3390/ijms21113804 | 1 |
| Stephanie Makhoul, Stephanie Dorschel, Stepan Gambaryan, Ulrich Walter and Kerstin Jurk Feedback Regulation of Syk by Protein Kinase C in Human Platelets Reprinted from: <i>Int. J. Mol. Sci.</i> 2020 , <i>21</i> , 176, doi:10.3390/ijms21010176 | 5 |
| Katharina Grundler Groterhorst, Hanna Mannell, Joachim Pircher and Bjoern F Kraemer Platelet Proteasome Activity and Metabolism Is Upregulated during Bacterial Sepsis Reprinted from: <i>Int. J. Mol. Sci.</i> 2019 , <i>20</i> , 5961, doi:10.3390/ijms20235961 | 25 |
| Bjoern F. Kraemer, Hanna Mannell, Tobias Lamkemeyer, Mirita Franz-Wachtel and Stephan Lindemann Heat-Shock Protein 27 (HSPB1) Is Upregulated and Phosphorylated in Human Platelets during ST-Elevation Myocardial Infarction Reprinted from: <i>Int. J. Mol. Sci.</i> 2019 , <i>20</i> , 5968, doi:10.3390/ijms20235968 | 35 |
| Bjoern F Kraemer, Tobias Lamkemeyer, Mirita Franz-Wachtel and Stephan Lindemann The Integrin Activating Protein Kindlin-3 Is Cleaved in Human Platelets during ST-Elevation Myocardial Infarction Reprinted from: <i>Int. J. Mol. Sci.</i> 2019 , <i>20</i> , 6154, doi:10.3390/ijms20246154 | 45 |
| Mariangela Scavone, Silvia Bozzi, Tatiana Mencarini, Gianmarco Podda, Marco Cattaneo and Alberto Redaelli Platelet Adhesion and Thrombus Formation in Microchannels: The Effect of Assay-Dependent Variables Reprinted from: <i>Int. J. Mol. Sci.</i> 2020 , <i>21</i> , 750, doi:10.3390/ijms21030750 | 57 |
| Yana Roka-Moiia, Silvia Bozzi, Chiara Ferrari, Gabriele Mantica, Annalisa Dimasi, Marco Rasponi, Andrea Santoleri, Mariangela Scavone, Filippo Consolo, Marco Cattaneo, Marvin J. Slepian and Alberto Redaelli The MICELI (MICrofluidic, ELectrical, Impedance): Prototyping a Point-of-Care Impedance Platelet Aggregometer Reprinted from: <i>Int. J. Mol. Sci.</i> 2020 , <i>21</i> , 1174, doi:10.3390/ijms21041174 | 69 |
| Matthias Canault and Marie-Christine Alessi RasGRP2 Structure, Function and Genetic Variants in Platelet Pathophysiology Reprinted from: <i>Int. J. Mol. Sci.</i> 2020 , <i>21</i> , 1075, doi:10.3390/ijms21031075 | 91 |
| Cristina Barale and Isabella Russo Influence of Cardiometabolic Risk Factors on Platelet Function Reprinted from: <i>Int. J. Mol. Sci.</i> 2020 , <i>21</i> , 623, doi:10.3390/ijms21020623 | 111 |
| Maria Valeria Catani, Isabella Savini, Valentina Tullio and Valeria Gasperi The "Janus Face" of Platelets in Cancer Reprinted from: <i>Int. J. Mol. Sci.</i> 2020 , <i>21</i> , 788, doi:10.3390/ijms21030788 | 139 |

Erminia Mariani and Lia Pulsatelli

Platelet Concentrates in Musculoskeletal Medicine

Reprinted from: *Int. J. Mol. Sci.* **2020**, *21*, 1328, doi:10.3390/ijms21041328 **163**

Francesca Salamanna, Melania Maglio, Maria Sartori, Matilde Tschon and Milena Fini

Platelet Features and Derivatives in Osteoporosis: A Rational and Systematic Review on the Best Evidence

Reprinted from: *Int. J. Mol. Sci.* **2020**, *21*, 1762, doi:10.3390/ijms21051762 **207**

About the Editors

Isabella Savini is Associate Professor of Nutritional Sciences & Dietetics at the Department of Experimental Medicine University of Rome Tor Vergata. She received a degree in Biological Sciences in 1985 and a Ph.D degree in Biochemistry in 1988 at La Sapienza University of Rome (Rome, Italy) She also received in 1990 a MS degree in Protein Chemistry Cranfield Institute of Technology (UK) and a Specialization in Nutritional Sciences, at La Sapienza University of Rome Piazzale (Rome, Italy) in 1993. Her research activity focuses on the following topics: (i) redox control of platelet function by bioactive compounds; (ii) the anticancer activity of phytochemical compounds; (iii) the blood and chemical parameters for the evaluation of the redox state in platelets, in relation to physical activity and the degree of obesity. The global research activity of Prof. Savini has led to the publication of over 50 articles and several book chapters in international scientific journals (H-index = 23).

Valeria Gasperi is Assistant Professor of Biochemistry at the Department of Experimental Medicine University of Rome Tor Vergata, a post she has held since 2008. She received a degree in Medical Biotechnology at the University of Naples "Federico II" (Naples, Italy) in 2001 and a Ph.D. in Biochemistry and Molecular Biology at the University of Rome Tor Vergata (Rome, ITALY) in 2006. From 2006 to 2008 she carried out her post-doc training at the University of Rome Tor Vergata and at the University of Teramo, where she focused on signal cascades activated by bioactive lipids in cell differentiation and death, in both central and peripheral organs. Her main fields of interest are: i) the cellular differentiation and death of haematological cells, with a particular focus on megakaryopoiesis and thrombopoiesis; ii) the role of specific microRNAs released by platelets in breast cancer, and of the modulation of cross-talk platelets-tumor cells by bioactive compounds ($\Omega 3$ and $\Omega 6$ polyunsaturated fatty acids, polyphenols and other phytochemicals); iii) the regulation of platelet activity during physiological conditions, and during inflammatory processes and tumor progression. The global research activity of Dr. Gasperi has led to the publication of over 50 articles and six book chapters in international scientific journals (H-index = 25), and to two monographs and more than 50 presentations at National and International Congresses.

Maria Valeria Catani is Associated Professor of Biochemistry at the Department of Experimental Medicine, Faculty of Medicine and Surgery, University of Rome "Tor Vergata", a post she has held since 2007. In the same University, she was a research fellow from 2001 to 2006 and I.D.I. Research assistant from 1999 to 2000. She received her doctoral degree in Biology in 1989 at the University of Rome La Sapienza, her Ph.D. degree in Biology and Physiopathology of Epithelia in 1995 at the University of Rome Tor Vergata and her specialization degree in Microbiology and Virology in 1998 at the University of Rome La Sapienza. In 1992, she spent three months at the Skin Biology Branch, NIAMS, National Institute of Health, Bethesda, MD, USA, working on keratinocyte differentiation. Her interests embrace the mechanisms of action of several biological processes, including: i) the redox regulation of gene expression; ii) the differentiation, survival and death of hematological cells, especially megakaryopoiesis and thrombopoiesis; iii) platelet activity and cell-to-cell cross-talk in pathophysiological conditions (i.e., inflammation, tumor progression); iv) the role of platelet-derived microRNAs and bioactive compounds ($\Omega 3$ and $\Omega 6$ polyunsaturated fatty acids, polyphenols and other phytochemicals) in breast cancer. The global research activity of Prof Catani has led to the publication of over 60 articles and nine book chapters in international scientific journals (H-index = 28), and to one book of Biochemistry and more than 50 presentations at National and International Congresses.



Editorial

Molecular Research on Platelet Activity in Health and Disease

Maria Valeria Catani *, Isabella Savini and Valeria Gasperi *

Department of Experimental Medicine, Tor Vergata University of Rome, 00133 Rome, Italy; savini@uniroma2.it

* Correspondence: catani@uniroma2.it (M.V.C.); gasperi@med.uniroma2.it (V.G.)

Received: 30 April 2020; Accepted: 26 May 2020; Published: 27 May 2020

Abstract: This editorial summarizes and discusses the themes of eleven articles (five reviews and six original studies) published in the Special Issue “Molecular Research On Platelet Activity in Health and Disease”. They give an international picture of the up-to-date understanding of (i) platelet signalling under physiological and pathological conditions, (ii) novel technologies for monitoring platelet functions and (iii) clinical applications of platelet-based-therapy for management of pathological conditions, not directly related to haemostasis and thrombosis.

Keywords: cardiovascular disease; microfluidic flow chambers; platelet-cancer cross-talk; platelet activation; platelet concentrate transfusion; stress conditions

Further insights into the regulation of platelet signalling were derived from Makhoul and collaborators, who report a novel feedback inhibition mechanism in human platelet activity. They report a new site of phosphorylation of spleen tyrosine kinase (Syk), occurring on Ser297, that is mediated by protein kinase C (PKC)- and cyclic adenosine monophosphate (cAMP)-dependent pathways [1]. Considering the central role played by Syk in platelets (as well as in other cells), this finding highlights that a better understanding of Syk regulation is essential for development of drug-based therapies capable of modulating its activity in diseased conditions.

Grundel and collaborators gave further insights into the functional role of the proteasome system in platelets. Key proteins of this pathway, together with proteins of the ubiquitination system, are indeed expressed by platelets, although the exact role of these proteolytic systems is unclear. By using living *E. coli* in vitro and in sepsis patients, the authors demonstrate, for the first time, that platelets play a key role in sepsis, by increasing proteasome activity, as well as by upregulating the proteasome activator PA28 (PSME1) and inducing proteolytic cleavage of proteasome substrates, such as Talin-1. Upregulation of platelet proteasome activity and protein metabolism in response to infection under conditions of sepsis indicate, therefore, that proteasome is dynamic and responds to inflammatory environmental stress conditions [2].

The crucial role of platelets in response to environmental stress conditions is also the object of Kraemer and colleague’s study. They show that acute myocardial infarction leads to significant changes in heat-shock proteins (HSP), acting as chaperones and cytoskeleton stabilizers [3], and kindlins, important proteins involved in integrin signalling and cytoskeleton regulation [4]. Indeed, they report a significant increase of HSP27 protein levels and phosphorylation, as well as intracellular translocation from cytoskeleton to membrane-associated protein fractions in human platelets during myocardial infarction, compared to matched controls with non-ischemic chest [3]. They also describe another platelet phenotype associated to myocardial infarction, i.e., significantly decreased kindlin-3 proteolysis, occurring in soluble and cytoskeletal fractions, but not in membrane fractions [4].

Particular attention should be paid to development of novel technologies for monitoring platelet activity, under both physiological and pathological conditions. In this context, a valuable tool for research in hemostasis and thrombosis is represented by microfluidic flow chambers (MFCs), which can

mimic healthy and stenotic blood vessels and recreate various physiological and pathological shear stress conditions. These microchannels, therefore, are commonly used to study platelet adhesion over different adhesive proteins and thrombus formation, as well as inhibitory effects of antiplatelet agents. Nonetheless, the existence of several experimental variables prevents a real standardization, so the definition of common protocols is a compelling challenge. In this context, Scavone's study is particularly interesting and promising, as the authors investigate critical aspects of microfluidic platelet adhesion assays and of common antiplatelet drugs, i.e., aspirin and cangrelor, through a new microfluidic device [5]. This novel MFC allows us to assess that platelet adhesion on collagen-coated surfaces is a shear-dependent process, not affected by blood storage temperature before perfusion and collagen concentration (beyond a value of 10 $\mu\text{g/mL}$). Importantly, cangrelor does not inhibit platelet accumulation, at any shear rate and concentration of collagen, while aspirin exerts inhibitory effects at low collagen concentrations. These findings demonstrate the need of considering different aspects of thrombus formation before approaching MFC experiments. A further contribution comes from a novel, easy-to-use, accurate and portable impedance aggregometer prototype called "MICELI" (MICrofluidic, ELectrical, Impedance) designed and fabricated by Roka-Moiia and co-workers [6]. MICELI aggregometer shows several advantages when compared with other commercial devices: it decreases footprint, assay complexity, and time to obtain results. These evidences, together with further validations of operational performance, might give the bases for usage of MICELI aggregometer as diagnostic device for monitoring platelet function during pharmacological thrombosis and bleeding management.

Canault and Alessi exhaustively provide an update of structure and pathophysiological role of RasGRP2, the essential regulator of $\alpha\text{IIb}\beta\text{3}$ integrin activation in platelets. They show how RasGRP2 genetic variants are related to the inherited platelet-type bleeding disorder-18 (BDPLT18), also discussing strategies for diagnosis and management of patients with this congenital bleeding disorder [7]. Barale and Russo [8] illustrate the intersection complexity between several cardiometabolic risks (among them, obesity, dyslipidemia, impaired glucose homeostasis, hypertension and disturbed microhemorrheology) and thrombosis, focusing their attention on the molecular mechanisms through which all components of metabolic syndrome are involved in prothrombotic tendency observed in obese and diabetic patients. In our Review, we discuss the unexpected central role of platelets in cancer, with particular emphasis on molecular mechanisms underlying platelet-cancer cross-talk and on how modulation of platelet count and secretion (i.e., by bioactive molecules and microvesicle-derived miRNAs) might be related to either a protective or a deleterious action in all steps of cancer progression [9].

Another important aspect in platelet research concerns clinical applications of platelet concentrate transfusion, for treating musculoskeletal conditions (such as osteoarthritis, muscle injuries, tendinopathies, and intervertebral disc degeneration). This is the object of the narrative review from Mariani and Pulsatelli, who discuss different types of methodological procedures used to prepare platelet concentrates and how these preparations may differ in composition, depending on the protocol adopted. Clinical application in musculoskeletal medicine, as well as efficacy and main reported controversies, are illustrated here [10]. The fundamental role of platelets and their derivatives in pathophysiological conditions, not strictly related to hemostasis and thrombosis, is further examined by Salamanna and collaborators: starting from experimental evidence of platelet involvement in bone remodeling, their systematic review highlights the positive correlation between platelet size/volume and bone mineralization, as well as improved bone regeneration by using platelet-derived bioactive growth factors and other derivatives, such as platelet concentrates [11].

Altogether, the studies reported in this Special Issue reveal novel aspects of platelet biology and we hope that they will be helpful towards new insights and a research impetus for those who are interested in developing new therapeutic tools for the management of pathological conditions depending on platelet dysfunctions.

Funding: This research received no external funding.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Makhoul, S.; Dorschel, S.; Gambaryan, S.; Walter, U.; Jurk, K. Feedback Regulation of Syk by Protein Kinase C in Human Platelets. *Int. J. Mol. Sci.* **2019**, *21*, 176. [[CrossRef](#)] [[PubMed](#)]
2. Groterhorst, K.G.; Mannell, H.; Pircher, J.; Kraemer, B.F. Platelet proteasome activity and metabolism is upregulated during bacterial sepsis. *Int. J. Mol. Sci.* **2019**, *20*, 5961. [[CrossRef](#)] [[PubMed](#)]
3. Kraemer, B.F.; Mannell, H.; Lamkemeyer, T.; Franz-Wachtel, M.; Lindemann, S. Heat-shock protein 27 (HSPB1) is upregulated and phosphorylated in human platelets during ST-elevation myocardial infarction. *Int. J. Mol. Sci.* **2019**, *20*, 5968. [[CrossRef](#)] [[PubMed](#)]
4. Kraemer, B.F.; Lamkemeyer, T.; Franz-Wachtel, M.; Lindemann, S. The integrin activating protein kindlin-3 is cleaved in human platelets during st-elevation myocardial infarction. *Int. J. Mol. Sci.* **2019**, *20*, 6154. [[CrossRef](#)] [[PubMed](#)]
5. Scavone, M.; Bozzi, S.; Mencarini, T.; Podda, G.; Cattaneo, M.; Redaelli, A. Platelet adhesion and thrombus formation in microchannels: The effect of assay-dependent variables. *Int. J. Mol. Sci.* **2020**, *21*, 750. [[CrossRef](#)] [[PubMed](#)]
6. Roka-Moia, Y.; Bozzi, S.; Ferrari, C.; Mantica, G.; Dimasi, A.; Rasponi, M.; Santoleri, A.; Scavone, M.; Consolo, E.; Cattaneo, M.; et al. The MICELI (MICrofluidic, ELectrical, impedance): Prototyping a point-of-care impedance platelet aggregometer. *Int. J. Mol. Sci.* **2020**, *21*, 1174. [[CrossRef](#)] [[PubMed](#)]
7. Canault, M.; Alessi, M.-C. RasGRP2 Structure, Function and Genetic Variants in Platelet Pathophysiology. *Int. J. Mol. Sci.* **2020**, *21*, 1075. [[CrossRef](#)] [[PubMed](#)]
8. Barale, C.; Russo, I. Influence of Cardiometabolic Risk Factors on Platelet Function. *Int. J. Mol. Sci.* **2020**, *21*, 623. [[CrossRef](#)] [[PubMed](#)]
9. Catani, M.V.; Savini, I.; Tullio, V.; Gasperi, V. The “Janus Face” of Platelets in Cancer. *Int. J. Mol. Sci.* **2020**, *21*, 788. [[CrossRef](#)] [[PubMed](#)]
10. Mariani, E.; Pulsatelli, L. Platelet concentrates in musculoskeletal medicine. *Int. J. Mol. Sci.* **2020**, *21*, 1328. [[CrossRef](#)] [[PubMed](#)]
11. Salamanna, F.; Maglio, M.; Sartori, M.; Tschon, M.; Fini, M. Platelet Features and Derivatives in Osteoporosis: A Rational and Systematic Review on the Best Evidence. *Int. J. Mol. Sci.* **2020**, *21*, 1762. [[CrossRef](#)] [[PubMed](#)]



© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).



Article

Feedback Regulation of Syk by Protein Kinase C in Human Platelets

Stephanie Makhoul¹, Stephanie Dorschel¹, Stepan Gambaryan^{1,2}, Ulrich Walter¹
and Kerstin Jurk^{1,*}

¹ Center for Thrombosis and Hemostasis (CTH), University Medical Center Mainz of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany; stephanie.makhoul@uni-mainz.de (S.M.); stephanie.dorschel@gmail.com (S.D.); s.gambaryan@klin-biochem.uni-wuerzburg.de (S.G.); ulrich.walter@uni-mainz.de (U.W.)

² Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, 194223 St. Petersburg, Russia

* Correspondence: kerstin.jurk@unimedizin-mainz.de

Received: 28 November 2019; Accepted: 20 December 2019; Published: 25 December 2019

Abstract: The spleen tyrosine kinase (Syk) is essential for immunoreceptor tyrosine-based activation motif (ITAM)-dependent platelet activation, and it is stimulated by Src-family kinase (SFK)/Syk-mediated phosphorylation of Y352 (interdomain-B) and Y525/526 (kinase domain). Additional sites for Syk phosphorylation and protein interactions are known but remain elusive. Since Syk S297 phosphorylation (interdomain-B) was detected in platelets, we hypothesized that this phosphorylation site regulates Syk activity via protein kinase C (PKC)-and cyclic adenosine monophosphate (cAMP)-dependent pathways. ADP, the GPVI-agonist convulxin, and the GPIIb α -agonist echicetin beads (EB) were used to stimulate human platelets with/without effectors. Platelet aggregation and intracellular messengers were analyzed, along with phosphoproteins, by immunoblotting using phosphosite-specific antibodies or phos-tags. ADP, convulxin, and EB upregulated Syk S297 phosphorylation, which was inhibited by iloprost (cAMP pathway). Convulxin-stimulated Syk S297 phosphorylation was stoichiometric, transient, abolished by the PKC inhibitor GF109203X, and mimicked by the PKC activator PDBu. Convulxin/EB stimulated Syk S297, Y352, and Y525/526 phosphorylation, which was inhibited by SFK and Syk inhibitors. GFX and iloprost inhibited convulxin/EB-induced Syk S297 phosphorylation but enhanced Syk tyrosine (Y352/Y525/526) and substrate (linker adaptor for T cells (LAT), phospholipase γ 2 (PLC γ 2)) phosphorylation. GFX enhanced convulxin/EB-increases of inositol monophosphate/Ca²⁺. ITAM-activated Syk stimulates PKC-dependent Syk S297 phosphorylation, which is reduced by SFK/Syk/PKC inhibition and cAMP. Inhibition of Syk S297 phosphorylation coincides with enhanced Syk activation, suggesting that S297 phosphorylation represents a mechanism for feedback inhibition in human platelets.

Keywords: spleen tyrosine kinase (Syk); protein kinase C; cyclic adenosine monophosphate (cAMP); platelets; glycoprotein VI; glycoprotein Ib α

1. Introduction

Human platelets are small circulating blood cells, which control, monitor, and preserve the integrity of the vessel wall. These anucleate cells prevent blood loss during vascular injury and, on the other hand, have prominent roles in thrombotic, inflammatory, and immune pathologies [1,2]. After vascular injury, distinct platelet receptors sense and bind newly exposed proteins immobilized within the extracellular matrix or on activated endothelial cells. This is followed by receptor-mediated platelet activation resulting in a plethora of cellular responses, including cytoskeletal remodeling, integrin activation (e.g., integrin $\alpha_{IIb}\beta_3$), degranulation, synthesis/release of thromboxane A2 (TxA2), and surface exposure

of anionic phospholipids, leading to platelet shape change, adhesiveness, aggregation, and coagulant activity to form a protective thrombus [2,3]. These essential physiological processes are often impaired in diseases and are tightly controlled by numerous hormones, vasoactive factors, and adhesive proteins, which activate, modulate, or inhibit these platelet functions. Two major classes of platelet activators include soluble agonists and adhesion molecules, e.g., von Willebrand factor (vWF), collagen, fibrin, and podoplanin, which stimulate specific G-protein-coupled receptors (GPCRs) [4,5] and cell membrane-spanning adhesion receptors, respectively [6–8]. GPCR-coupled agonists activate phospholipase (PLC) β , elevate cytosolic Ca^{2+} concentration, and activate Ca^{2+} -dependent protein kinases, such as protein kinase C (PKC), thereby inducing platelet activation [4,5].

The adhesion molecules collagen, vWF, podoplanin, fibrinogen, and fibrin bind to and activate platelet membrane receptors such as glycoprotein (GP) VI (GPVI), GPIb-V-IX, CLEC-2, integrin $\alpha_{\text{IIb}}\beta_3$ [6,7], and subsequently Src-family tyrosine protein kinases (SFKs) causing platelet activation [8]. The SFKs tyrosine-phosphorylate other proteins/protein kinases including membrane proteins with the immunoreceptor tyrosine-based activation motif (ITAM) [6,8,9], which then recruits src homology 2 (SH2) domain-containing proteins, in particular the spleen tyrosine kinase (Syk). In human platelets, ITAM-mediated Syk activation is mediated by the Fc receptor γ -chain and the low-affinity IgG receptor Fc γ RIIa [10,11], while it is only mediated by the Fc receptor γ -chain in murine platelets [12–15]. Mice embryos presenting with a homozygous targeted mutation in the *Syk* gene (by deletion of one exon on *Syk* gene encoding for 41 residues in the Syk kinase domain in embryonic stem cells) die from severe hemorrhages before birth [16], and mice lacking platelet Syk were protected from arterial thrombosis and ischemic stroke [17], highlighting the important role of Syk in platelets. Tyrosine-phosphorylated ITAM proteins recruit Syk from the cytosol to the cell membrane and activate Syk via two distinct overlapping mechanisms, the described ITAM-dependent process and a tyrosine phosphorylation-dependent process [15,18–20]. The Syk Y-phospho-sites closely associated with activation, Y348/Y352 and Y525/Y526, are two pairs within the interdomain-B and kinase domains, respectively. Syk activation is initiated when these Y-sites are phosphorylated by SFKs or when dually Y-phosphorylated ITAM-containing membrane proteins recruit the two Syk-SH2 domains followed by Syk autophosphorylation, leading to the activation of the LAT-signalosome [18,19]. However, in addition to these Syk tyrosine phosphorylation sites involved in kinase activation, it was demonstrated, primarily with murine and human B-cells, that Syk contains multiple tyrosine, serine, and threonine phosphorylation sites, and that some of them are important for recruiting additional regulatory binding proteins [21–23]. Syk serine phosphorylation at S297 (S291 in murine cells) is observed in B-cells [23,24]. While Syk S291 phosphorylation in murine B-cell lines was reported to enhance Syk coupling to the B-cell antigen receptor (BCR) [24], Syk S297 phosphorylation diminished antigen–receptor signaling in human B-cell lines [23]. However, the role of Syk S297 phosphorylation in human platelets remains unknown. In our recent phosphoproteomic studies with human platelets, the cyclic adenosine monophosphate (cAMP)-elevating platelet inhibitor and stable prostacyclin analog iloprost (cAMP/protein kinase A (PKA) pathway), as well as adenosine diphosphate (ADP), affected the phosphorylation of many protein kinases including several tyrosine protein kinases such as Janus kinase (JAK) 3, activated CDC42 kinase 1 (ACK1), Bruton-tyrosine kinase (BTK), and Syk [25,26]. Interestingly, ADP, which activates platelet Ca^{2+} /calmodulin-dependent protein kinases such as PKC, but not iloprost, stimulated Syk S297 phosphorylation. Very recently, we established methods for the selective quantitative assessment of GPVI- and GPIb α -mediated activation and function of human platelet Syk [27,28]. We observed that cAMP- and cyclic guanosine monophosphate (cGMP)-elevating platelet inhibitors strongly inhibited GPIb α -GPVI-mediated platelet activation but enhanced the initial Syk activation [28]. These phosphoproteomic and functional approaches suggest that there is a network of interacting protein kinases at the level of Syk in platelets [29,30].

Based on previously published data and our own findings on Syk S297 phosphorylation in human platelets, and considering the crucial Syk interdomain location of S297 [20], we hypothesized that this serine site is phosphorylated in response to the activation of several signaling pathways. In particular,

we hypothesized that PKC- and cAMP-dependent pathways, via their respective protein kinases, regulate the phosphorylation of Syk S297, thereby affecting activation and/or activity of Syk in human platelets. With this approach, we aimed to show that phosphorylation of Syk S297 in platelets modulates Syk activity and, subsequently, further Syk substrates important for platelet function.

2. Results

2.1. ADP, Convulxin, and Echinectin Beads Upregulate Syk S297 Phosphorylation, Which Is Inhibited by Iloprost

Our previous phosphoproteomic studies with human platelets showed that ADP induced Syk serine phosphorylation at S297, which is located in the interdomain-B of Syk [26]. Using a phosphospecific antibody against this site, we investigated the regulation of this phosphorylation site by ADP, by its functional inhibitor (iloprost) and by agonists, which activate platelets via ITAM-/Syk-dependent mechanisms. As expected, ADP-induced platelet aggregation was completely inhibited by iloprost (Supplementary Materials Figure S1a). ADP increased Syk S297 phosphorylation 3–4-fold within 4 min of stimulation, which was strongly inhibited by iloprost (Figure 1a). Then, a rapid (within 1 min) but transient phosphorylation of S297 was observed upon platelet stimulation with the selective GPVI agonist convulxin (cvx), as well as with the specific GPIIb α agonist echicetin beads (EB) (Figure 1b,c), which was also strongly inhibited by iloprost. Furthermore, cvx/EB-induced S297 phosphorylation was significantly downregulated by the blockage of the TxA2 receptor and the ADP receptor P2Y₁₂ (Supplementary Materials Figure S2a,b). These data demonstrate that Syk S297 is upregulated by distinct signaling pathways in human platelets and, with both GPIIb α and GPVI, is significantly dependent on the secondary mediators ADP and TxA2.




Figure 1. Platelet Syk S297 is upregulated by ADP, convulxin, and echicetin beads. Human washed platelets were pre-incubated with iloprost (2 nM; 3 min) at 37 °C prior to stimulation with (a) 25 μ M ADP, (b) 50 ng/mL convulxin (cvx), or (c) 0.5% (v/v) echicetin beads (EB). Platelet aggregation was stopped after 1, 2, or 5 min of stimulation under stirring conditions by adding Laemmli buffer. Syk S297

phosphorylation was analyzed in the presence or absence of iloprost by immunoblotting compared to total protein. Quantitative data are represented as means \pm SD from three independent experiments with platelets from three healthy donors. * $p < 0.05$, untreated versus iloprost-treated platelets in response to ADP at 2 min; # $p < 0.0001$, untreated versus iloprost-treated platelets at 4 min in response to ADP and at 1 min in response to cvx or EB.

2.2. Transient GPVI/GPIIb α -Stimulated Syk S297 Phosphorylation Parallels Syk Tyrosine Phosphorylation

To better understand a possible link between the phosphorylation of S297 and Syk activation, we studied simultaneously the phosphorylation of Syk on S297, on Y525/526 (a Syk activation marker), and on Syk Y352 (important for Syk activity enhancement and for binding other proteins). Syk S297 showed a transient phosphorylation, which increased within 1 min of stimulation and then decreased both with convulxin (Figure 2a,ai) and EB (Figure 2b,bi) stimulation. A very similar transient time course was observed with Syk Y525/526 and Y352 phosphorylation in response to cvx (Figure 2a,aii) and EB (Figure 2b,bii). In contrast, ADP did not induce Syk Y525/526 or Y352 phosphorylation [26]. The observed Syk phosphorylation declined after initial stimulation, suggesting that a protein phosphatase is active.




Figure 2. Cvx and EB induce a transient Syk S297 phosphorylation in parallel with Syk tyrosine phosphorylation. Washed human platelets were stimulated under stirring conditions with (a) 50 ng/mL cvx or (b) 0.5% (v/v) EB. (ai,bi) Syk phosphorylation on S297 and tyrosine sites (525/526 and 352) mediated by cvx or by EB were analyzed in a time-dependent manner (1, 2, and 5 min) compared to total Syk. (aii,bii) The kinetics of the phosphorylation patterns are represented as means \pm SD from three independent experiments with platelets from three healthy donors. # $p < 0.0001$, *** $p < 0.001$, ** $p < 0.01$, untreated versus cvx-or EB-stimulated platelets at 1 min.

2.3. Syk S297 Phosphorylation Is Dependent on Src Family Kinases (SFKs) and Syk Kinase Activity

EB/cvx-mediated Syk tyrosine phosphorylation is mediated by SFKs and Syk autophosphorylation [18,19,28]. Therefore, we evaluated the role of SFKs and Syk for Syk S297 phosphorylation. The SFK inhibitor PP2 abolished Syk S297 phosphorylation induced by cvx and EB (Figure 3a,b), which was also observed with the two different Syk inhibitors OXSI-2 and PRT-060318

(Figure 3c,d). These data indicate that GPVI-/GPIb α -increased Syk S297 phosphorylation is highly dependent on SFK-stimulated Syk kinase activity.




Figure 3. Cvx-and EB-mediated Syk S297 upregulation is dependent on SFKs and Syk activation. Washed human platelets were pre-incubated with vehicle control (DMSO) or with the SFK inhibitor PP2 (10 μ M) for 5 min at 37 $^{\circ}$ C prior to stimulation, under stirring conditions with (a) 50 ng/mL cvx or (b) 0.5% (v/v) EB or with two different Syk inhibitors, OXSI-2 (2 μ M) and PRT-060318 (1 μ M) for 5 min at 37 $^{\circ}$ C prior to stimulation with (c) cvx or (d) EB. Phosphorylation of Syk S297 was analyzed by immunoblotting compared to total Syk. Data are represented as means \pm SD from three independent experiments with platelets from three healthy donors. # $p < 0.0001$, DMSO versus inhibitor-treated (PP2, OXSI-2, or PRT-060318) platelets at 1 min in response to cvx or EB.

2.4. Convulxin-Induced Syk S297 Phosphorylation Is Stoichiometric and Abolished by Inhibition of PKC

Upon BCR stimulation in murine B-cells, Syk S291, in addition to several tyrosine sites, was a major PKC phosphorylation site in the interdomain-B of Syk which corresponds to S297 in human Syk [24]. Therefore, we tested the role of PKC in Syk S297 regulation in human platelets using a global and potent PKC inhibitor, GF109203X (GFX). Pre-incubation of platelets with GFX completely inhibited cvx-stimulated Syk S297 phosphorylation (Figure 4a).




Figure 4. Syk S297 phosphorylation is stoichiometric and completely blocked by PKC inhibition. Washed human platelets were pre-incubated with DMSO as vehicle control or with pan-PKC inhibitor GF109203X (GFX) (5 μ M) at 37 $^{\circ}$ C for 5 min prior to stimulation with 50 ng/mL cvx. **(a)** Platelet aggregation was stopped by adding Laemmli buffer directly in the cuvettes after 1, 2, and 5 min of stimulation under stirring conditions, and Syk S297 phosphorylation was analyzed by standard SDS-PAGE/Western blot analysis compared to total Syk. Quantitative analyses are represented as means \pm SD from three independent experiments with platelets from three healthy donors. # $p < 0.0001$, DMSO versus GFX-treated platelets at 1 min. **(bi–biii)** Washed human platelets were stimulated under non-stirring conditions at 37 $^{\circ}$ C, and platelets were lysed after the indicated time points by using Laemmli buffer for phos-tag SDS-PAGE. **(bi)** Samples were analyzed by phos-tag SDS-PAGE followed by immunoblotting using total Syk antibody. Same samples were analyzed by standard SDS-PAGE followed by immunoblotting using **(bii)** total Syk antibody or **(biii)** anti-Syk S297. Blots are representative of two independent experiments from two healthy donors.

To analyze quantitative aspects of Syk phosphorylation, we used the phos-tag SDS- polyacrylamide gel-electrophoresis (PAGE) method developed by the group of Koike [31,32]. This method separates phosphorylated and non-phosphorylated forms of proteins including tyrosine kinases depending on their degree of phosphorylation. Immunoblotting using anti-Syk antibody revealed the presence of four migration bands (Figure 4bi). At basal conditions, one major Syk band was detected (band 1), which was not affected by the PKC inhibitor GFX. After 30 sec of activation with cvx, a complete shift of Syk was detected with several bands (2–4), while the major band 1 disappeared and a major band 2 appeared. With GFX pre-treatment, the major band 2 completely disappeared and the basal band 1 reappeared, while the other minor bands (3, 4) were not downregulated. These data indicate that the cvx-induced appearance of band 2 is highly dependent on PKC activity.

In parallel, we analyzed total Syk with the standard SDS-PAGE method and detected only one constant major Syk band in all samples but a row of very minor bands (higher than 72 kDa), especially GFX-treated samples (Figure 4bii), which may be due to Syk ubiquitination [33].

These samples from cvx-treated platelets were also analyzed by standard SDS-PAGE blots using phosphoantibodies. The phosphorylation of Syk S297 was strongly stimulated by cvx and completely inhibited by the PKC inhibitor GFX (Figure 4biii), which closely resembled the appearance/disappearance of band 2 in the phos-tag gel analysis. Overall, the major cvx-induced shift of Syk in phos-tag gels is completely prevented by PKC inhibition and due to Syk S297 phosphorylation.

2.5. PKC Activator, PDBu, Stimulates a Stoichiometric Syk S297 Phosphorylation, Which Is Prevented by PKC Inhibition

To obtain further evidence for PKC-mediated phosphorylation of Syk S297 in human platelets, we tested the effects of a global PKC activator, the phorbol ester phorbol 12, 13-dibutyrate (PDBu). PDBu induced strong platelet aggregation (Supplementary Materials Figure S3) and a very fast and strong phosphorylation of Syk on S297, which appeared within 15 s of stimulation and was stable for the first two minutes (Figure 5a). In addition, we incubated washed human platelets under non-stirring conditions with PDBu and analyzed the Syk phosphorylation profile by phos-tag SDS-PAGE/immunoblotting. At basal conditions, unstimulated Syk showed only one band (band 1), which was completely shifted (band 2) upon PDBu stimulation in a time-dependent manner (Figure 5bi). In parallel, the standard SDS-PAGE/Western blot analysis showed one Syk band for all samples (Figure 5bii) and a time-dependent PDBu stimulated Syk S297 phosphorylation (Figure 5bii,biii). These data support the role of PKC in regulating Syk through S297 phosphorylation.




Figure 5. Syk S297 phosphorylation is upregulated by PKC activation in a stoichiometric manner. Washed human platelets were pre-incubated with GF109203X (5 μM) for 5 min at 37 °C prior to stimulation with

the phorbol ester PDBu, a global PKC activator (0.2 μ M). (a) Platelet aggregation was stopped by adding Laemmli buffer directly in the cuvettes after 15, 60, 120, and 300 s of stimulation under stirring conditions, and Syk S297 phosphorylation was analyzed by standard SDS-PAGE/Western blot analysis compared to total Syk. Quantitative analyses are represented as means \pm SD from three independent experiments with platelets from three healthy donors. # $p < 0.0001$, untreated versus GFX treated platelets at 1 min. (bi–biii) Washed human platelets were stimulated under non-stirring conditions at 37 $^{\circ}$ C, and platelets were lysed after the indicated time points by using Laemmli buffer for phos-tag SDS-PAGE/immunoblotting analysis. (bi) Samples were analyzed by phos-tag SDS-PAGE followed by immunoblotting using total Syk antibody. Same samples were analyzed by standard SDS-PAGE followed by immunoblotting using (bii) total Syk antibody or (biii) anti-pSyk S297. Blots are representative of two independent experiments from two healthy donors.

2.6. PDBu-Mediated S297 Phosphorylation Is Independent of Syk and Only Partially Inhibited by PKA

We then investigated the role of Syk kinase activity on the phosphorylation of S297 mediated by PKC activation. Firstly, we validated the effects of PDBu and GFX by analyzing myristoylated alanine-rich C-kinase substrate (MARCKS) phosphorylation, a well-established PKC substrate, also in platelets [34,35]. MARCKS was significantly phosphorylated on S159/163 in response to PDBu and convulxin, which was completely abolished by GFX (Figure 6a). Secondly, Syk inhibition by PRT-060318 did not affect PDBu-induced Syk S297 or MARCKS phosphorylation (Figure 6b), showing that PDBu-caused PKC activation does not require Syk, in contrast to S297 phosphorylation caused by cvx and EB (Figure 3c,d). Thirdly, PDBu/PKC-induced Syk S297 phosphorylation was only partially inhibited by iloprost, and PDBu/PKC-induced MARCKS phosphorylation was even increased by iloprost (Figure 6c). These data suggest that PKC per se was not inhibited by iloprost in intact platelets, but iloprost (PKA) inhibited signaling pathways upstream of PKC activation.




Figure 6. PKC activation induces Syk S297 phosphorylation, which is independent from Syk and only partially inhibited by PKA. Washed human platelets were pre-incubated with DMSO (vehicle control) or with pan-PKC inhibitor, GF109203X (5 μ M) at 37 $^{\circ}$ C for 5 min prior to stimulation with 0.2 μ M PDBu or 50 ng/mL cvx. (a) Platelet aggregation was stopped by adding Laemmli buffer after 1 min of stimulation under stirring conditions. MARCKS S159/163 phosphorylation was analyzed by standard

SDS-PAGE analysis compared to the loading control β -actin. Washed human platelets were pre-incubated with (b) Syk inhibitor, PRT-060318 (1 μ M) for 5 min or (c) iloprost (2 nM) for 3 min prior to stimulation with PDBu. Syk S297 and MARCKS S159/163 phosphorylation was analyzed compared to total Syk or β -actin, respectively. The corresponding quantifications are represented as means \pm S.D from three independent experiments with platelets from three healthy donors. **** p < 0.0001, ** p < 0.01, * p < 0.05, ns: not significant.

2.7. PKC Inhibition Abolished cvx/EB-Induced Syk S297 Phosphorylation But Increased Syk Tyrosine 352 and 525/526 Phosphorylation (Hyperphosphorylation)

Next, we investigated the role of PKC on Syk activation in GPVI- and GPIIb α -mediated platelet activation. PKC inhibition by GFX completely prevented the S297 phosphorylation induced by cvx (Figure 7a,ai) and EB (Figure 7b,bi). In contrast, Syk tyrosine phosphorylation on 525/526 was significantly increased upon stimulation for 1 min compared to the control and subsequently prolonged in both GPVI-(Figure 7a,aii) and GPIIb α -mediated signaling (Figure 7b,bii). Syk Y352 phosphorylation showed a similar hyperphosphorylation profile in GPVI-(Figure 7a,aiii), and EB/GPIIb α -mediated signaling (Figure 7b,biii). These data demonstrate a striking differential regulation of Syk tyrosine phosphorylation and serine phosphorylation by PKC.




Figure 7. Syk phosphorylation is differentially regulated by PKC. Washed human platelets were pre-incubated with DMSO (vehicle control) or with pan-PKC inhibitor GF109203X (5 μ M) at 37 $^{\circ}$ C for 5 min prior to stimulation with (a) 50 ng/mL cvx or (b) 0.5% (v/v) EB. Platelet aggregation was stopped by adding Laemmli buffer after 1, 2, or 5 min of stimulation under stirring conditions. The kinetics of the phosphorylation of Syk on (ai,bi) S297, (aii,bii) Y525/526, and (aiii,biii) Y352 compared to total Syk are represented as means \pm SD from three independent experiments with platelets from three healthy donors. # p < 0.0001, DMSO-versus GFX-treated platelets at 1 min in response to cvx or EB.

2.8. PKC Inhibition Caused Hyperphosphorylation of Y-Sites of Syk Substrates

To validate the possible functional consequence of Syk tyrosine hyperphosphorylation, we investigated the phosphorylation of Syk downstream substrates linker adaptor for T cells (LAT) and PLC γ 2 on Y191 and Y759, respectively. Cvx- and EB-induced LAT phosphorylation was remarkably increased in the presence of the PKC inhibitor compared to the control (Figure 8a,b,ai,bi). In addition, PLC γ 2 also showed an increase and prolongation in the Y759 phosphorylation in both signaling pathways cvx/GPVI (Figure 8a,aii) and EB/GPIIb α (Figure 8b,bii). These data demonstrate that Syk hyperphosphorylation is associated with direct increased tyrosine phosphorylation of LAT and PLC γ 2.




Figure 8. PKC inhibition induces hyperphosphorylation of Y-sites of Syk substrates. Washed human platelets were pre-incubated with DMSO (vehicle control) or with pan-PKC inhibitor GF109203X (5 μ M) at 37 $^{\circ}$ C for 5 min prior to stimulation with (a) 50 ng/mL cvx or (b) 0.5% (v/v) EB. Platelet aggregation was stopped by adding Laemmli buffer after 1, 2, or 5 min of stimulation under stirring conditions. The kinetics of the phosphorylation of (ai,bi) LAT on Y191 and (aii,bii) PLC γ 2 on Y759 compared to the adequate loading control are represented as means \pm SD from three independent experiments with platelets from three healthy donors. # $p < 0.0001$, * $p < 0.05$, DMSO-versus GFX-treated platelets at 1 min or 2 min in response to cvx or EB, respectively.

2.9. PKC Inhibition Enhances cvx/EB-Mediated InsP3 Production and Intracellular Ca²⁺ Mobilization

Furthermore, we aimed to measure the activity of PLC γ 2 by monitoring intracellular inositol triphosphate (InsP3) production (via inositol monophosphate (InsP1) accumulation) and intracellular Ca²⁺ mobilization. In the presence of GFX, cvx- and EB-evoked InsP3 production was significantly enhanced compared to the control in the absence of the PKC inhibitor (Figure 9a). Moreover, this InsP3 production, mediated by cvx and EB, led to a significant increase of intracellular Ca²⁺ mobilization, which was even more pronounced in the presence of GFX (Figure 9b). These data show that Syk hyperphosphorylation is followed by an increase in LAT/PLC γ 2 phosphorylation leading to an increase of InsP3 production and subsequent Ca²⁺ mobilization.




Figure 9. PKC inhibition significantly enhances InsP1 accumulation and intracellular Ca²⁺ mobilization. (a) Washed human platelets were pre-treated with GF109203X (5 μ M) as previously described in the presence of 1 mM LiCl. Platelet aggregation was stopped after 5 min using lysis buffer provided by the manufacturer. (b) Washed human platelets were pre-incubated with Fluo-3 AM (5 μ M) for 30 min at 37 $^{\circ}$ C, and platelet stimulation was performed directly before measurement. Ca²⁺_i mobilization was monitored for 120 s by flow cytometry. Quantitative data are represented as means \pm SD from three independent experiments with platelets from three healthy donors. **** $p < 0.0001$, * $p < 0.05$.

3. Discussion

In this study, we show (1) that activation of human platelets via GPVI and GPIb α , as well as by pharmacological activation of PKC, caused phosphorylation of Syk S297, and (2) that pharmacological PKC inhibition or receptor-linked inhibition of PKC by cAMP/PKA abolished Syk S297 phosphorylation, but enhanced Syk tyrosine phosphorylation/activity and phosphorylation of Syk substrates. These data suggest that Syk S297 phosphorylation is mediated by PKC and represents a mechanism of feedback inhibition of Syk in human platelets.

Several lines of evidence show that a classical, diacylglycerol/phorbol ester-responsive protein kinase C (PKC) phosphorylates Syk S297 in human platelets:

Increased Syk S297 phosphorylation is observed when ADP receptors, GPVI, and GPIb α are stimulated by selective agonists, which also stimulate PLC and PKC activation.

- GPVI- and GPIb α -caused Syk S297 phosphorylation is Syk-dependent and requires, at least predominantly, the release of secondary mediators ADP and TxA₂.
- GPVI-/GPIb α -induced Syk S297 phosphorylation is blocked by a selective PKC inhibitor (GFX) and mimicked by an established, membrane permeable PKC activator (PDBu).
- This agonist-induced Syk S297 phosphorylation is also inhibited by the cAMP/PKA pathway, which is known to strongly inhibit receptor-stimulated Ca²⁺ responses and PKC activation [30,36,37].
- The peptide sequence around Syk S297* 9ISRIKSYS*FPPKPGHR) in humans (in the murine form S291, ISRIKSYS*FPPKPGHK) agrees well with the PKC phosphosite consensus sequence [24] (see also other phosphosite databases).

While the evidence for a conventional PKC as a responsible Syk S297 kinase in intact human platelets is quite strong, we do not know which PKC isoform (or perhaps more than one) is involved. PKC isoforms consist of conventional forms (α , β I, β II, γ) activated by Ca²⁺/diacylglycerol, novel forms (δ , ϵ , η , θ) activated by diacylglycerol alone, and atypical forms, which are diacylglycerol-independent. Human and mouse platelets highly express the conventional PKC isoforms α/β and the novel isoforms δ and θ [36,38], which all have important but diverse roles in platelets, which may be inhibitory or activating [36,39]. Therefore, we cannot rule out that more than one member of the PKC family is capable of phosphorylating platelet Syk S297. Previously, a functional interaction of PKC α with both

Src and Syk was reported for human platelets, which occurred together with a Syk-dependent tyrosine phosphorylation of PKC α , but not the other way around, i.e., PKC α -dependent serine phosphorylation of Syk [40]. An Src/SFK-dependent phosphorylation and activation of PKC δ was observed in platelets, as well as a PKC δ -dependent activation of Syk in endothelial cells [41], indicating interactions between Syk, other tyrosine kinases, and the PKC family.

In our study, we observed a rapid receptor-mediated Syk S297 phosphorylation (onset within 15 s of stimulation), which reached stoichiometry and then declined back to the basal status. This conclusion was possible due to the combination of regular Western blot/pSyk S297 phosphoantibody analysis with phos-tag analysis. The initial major Syk band in phos-tag gels was almost completely shifted to another major band, which was completely shifted back to the basal state when platelets were pre-treated with the PKC inhibitor GFX. This major band was the only Syk band with this property, a pattern also observed by regular Syk pS297 phosphoantibody analysis. The conclusion that these effects are PKC-mediated is strongly supported by observations made with the direct PKC activator PDBu. Treatment of platelets with PDBu caused, as detected in phos-tag gels, a time-dependent, complete shift of this major Syk band, which was also completely prevented by the PKC inhibitor. Compared to cvx treatment, no minor additional shifted band appeared in the PDBu treatment detected in phos-tag gels. The phos-tag data with PDBu additionally suggest that PKC phosphorylates only one major site (S297) in Syk, although Syk contains a number of serine/threonine protein kinase phosphosites [23]. The other, minor cvx-shifted Syk bands, detected in phos-tags, are not downregulated by GFX and correspond to tyrosine-phosphorylated sites of Syk. Altogether, Syk S297 phosphorylation in human platelets is mediated by PKC, in a stoichiometric and reversible manner.

While the phosphorylation of Syk S297 can reach stoichiometry in our studies with human platelets, the corresponding stoichiometry of Syk tyrosine phosphorylation appears to be much smaller. Interestingly, Syk phosphorylation data obtained with murine B-cells suggested that phosphorylation of Syk at tyrosines is restricted to a subset of the kinase physically associated with ITAM-containing membrane proteins, whereas the interdomain serine sites are also phosphorylated in Syk, when Syk is not membrane-bound [24].

Another feature of GPVI/GPIb α -mediated Syk phosphorylation and activation in platelets is the transient nature of both tyrosine (Y352, Y525/Y526) and serine (S297) phosphorylation. Onset and decline of Cvx/EB stimulated SykS297 phosphorylation resemble the time course of Syk Y352/Y525/526 phosphorylation, which indicates Syk activation [18,19]. The state of protein phosphorylation is determined, for each individual site, by both protein kinases and protein phosphatases, and it can be decreased, for example, by kinase inhibition, phosphatase activation, or both. When murine B-cell Syk activation is discontinued, both Syk and its substrates are rapidly tyrosine-dephosphorylated, and the downstream signaling effects end [22,42]. Several protein tyrosine phosphatases were identified to dephosphorylate tyrosine phosphorylated Syk including the SH2 domain-containing tyrosine protein phosphatase-1 (SH-1; PTPN6), e.g., T-cell ubiquitin ligand 2 (TULA-2; UBASH3B) [22], and most of them are present in human platelets [29,38]. TULA-2 is an unconventional protein tyrosine phosphatase with a ubiquitin-associated domain (UAB), a SH3 domain and a special histidine phosphatase domain, and TULA-2 binds and uses Syk as substrate [43,44]. This is of functional significance since the state of Syk tyrosine phosphorylation is reduced in cells overexpressing TULA-2, but enhanced when TULA-2 is impaired or deficient. In both murine and human platelets, strong evidence was obtained that TULA-2 suppresses the GPVI-induced, FcR γ -mediated Syk activation by dephosphorylating primarily Syk Y346 (Y352 in human) [45], which also belongs to the interdomain-B. Compared to the tyrosine dephosphorylation of Syk, there is no information available on serine/threonine dephosphorylation, which is most likely catalyzed by one or more of the many serine/threonine protein phosphatases present in human platelets [29].

A remarkable result reported here is that the specific inhibition of Syk S297 phosphorylation by the PKC inhibitor GFX closely coincided with enhanced cvx/EB-stimulated Syk Y352/Y525/526 phosphorylation (indicating enhanced Syk activity), enhanced Syk substrate phosphorylation

(LAT, PLC γ 2), and enhanced cvx/EB-induced InsP1/InsP3 increase. Considering the dynamic aspects of Syk activity by phosphorylation/dephosphorylation observed in other cells [22], the effects observed here are substantial. Interestingly, the PKC inhibitor GFX was reported to enhance GPVI-mediated Syk phosphorylation at Y525/526 without affecting the Y352 and Y323 sites in human platelets, effects not observed with murine platelets [46]. However, direct PKC substrates were not investigated. In our studies, platelet agonists, but also the PKC activator PDBu, stimulated not only Syk S297 phosphorylation, but also, used here as a control, the phosphorylation of MARCKS, a well-established PKC substrate [35], and both responses were prevented by the PKC inhibitor GFX.

There is another line of evidence for the conclusion that PKC inhibition enhances Syk and Syk substrate tyrosine phosphorylation with the possible involvement of Syk S297 phosphorylation. We recently showed that both cAMP- and cGMP-elevating platelet inhibitors (iloprost, riociguat), enhance Syk tyrosine phosphorylation/Syk activity [28]. Now, we show that iloprost (PKA pathway) strongly inhibits cvx/EB-stimulated Syk S297 phosphorylation. It is likely that, under our conditions, iloprost inhibits the platelet effects of ADP and TxA2, which, when released during cvx/EB stimulation, are important secondary messengers and (as we clearly showed for ADP) are able to stimulate PKC-mediated Syk S297 phosphorylation.

Our study demonstrates the regulation of Syk S297 phosphorylation in a primary human cell, the platelet, in response to several agonists such as ADP, cvx, and EB (Figure 10). Increased S297 phosphorylation is mediated by PKC and negatively affects the tyrosine phosphorylation state of Syk at both the interdomain-B (Y352) and the kinase domain (Y525/526). The S297 serine site of Syk is located at a crucial site of Syk regulation and activation, the interdomain-B, just at the border of the c-terminal SH2-domain [18,20] (Figure 10).




Figure 10. Model showing feedback regulation of Syk upon GPVI and GPIb α activation in human platelets. Clustering of GPVI and GPIb α upon agonist binding activates platelets initiated by src family kinases (SFKs) and the spleen tyrosine kinase (Syk). SFK activation leads to dual phosphorylation of the “immunoreceptor tyrosine-based activation motifs” (ITAMs), which represents a docking site for the two src homology 2 (SH2) domains of Syk. The interaction between Syk-(SH2)² domains and dually tyrosine-phosphorylated ITAMs recruits and translocates Syk to lipid rafts of the platelet cell membrane. Syk tyrosine phosphorylation of Y525/526 (kinase domain) and Y352 (interdomain-B) by autophosphorylation and SFKs leads to a fully activated kinase. Consequently, specific Syk substrates and regulatory proteins, such as LAT, PLC γ 2, SLP65, vav, and phosphoinositide-3 kinase (PI3k) are

tyrosine-phosphorylated and recruited to a “LAT signalosome” complex. Activation of the Syk substrate PLC γ 2 produces the release of ADP (from platelet δ -granules) and of TxA2 via elevation of InsP3 and Ca²⁺. These secondary messengers enhance platelet activation via specific GPCRs, which also involves activation of distinct PKC isoforms. GPVI/GPIb α not only induce Syk tyrosine phosphorylation but also Syk phosphorylation on S297, which is located within the interdomain-B. GPVI/GPIb α -induced Syk S297 phosphorylation is mediated by PKC and decreases Syk tyrosine phosphorylation/activation. The cAMP/PKA pathway reduces the PKC response. It is proposed that Syk S297 phosphorylation represents an important mechanism for Syk feedback inhibition.

ITAM-and/or tyrosine phosphorylation-dependent Syk activation occurs at the membrane and alters the interaction of the various Syk domains, releasing the autoinhibition and producing an active kinase. Although there is functional and structural information that the interdomain-B with its phosphorylation and various interacting proteins is essential for the transition of inactive to activated Syk, the exact molecular mechanism(s) for this transition inside a cell are unknown. A major part of the crucial interdomain-B (amino acids 262–337) was unfortunately not defined in the otherwise impressive crystal structure of full-length inactive Syk [20], perhaps due to the flexible nature of interdomain-B.

The role of Syk phosphorylation including serine 297 (S291 in murine Syk) was extensively investigated by two groups in the chicken B-cell model system DT40, but discrepant functional data were obtained [23,24]. With murine Syk, PKC-mediated Syk S291 phosphorylation enhanced the ability of Syk to couple and activate the antigen receptor complex, perhaps involving the interaction of the interlinker domain B with the chaperone prohibitin [24]. These murine Syk effects were impaired when the murine S291A Syk mutant was tested. The other investigation with human Syk reported the presence of multiple Syk phosphorylation sites and also multiple Syk-interacting proteins. The major Syk phosphosite S297 (when phosphorylated) was reported to recruit the adapter protein 14-3-3 γ , which prevented the translocation of Syk to the plasma membrane and subsequent Syk activation and downstream effects [23]. These effects were impaired when the experiments were carried out with the human Syk S297A mutant. The discrepancies between these two important studies are yet to be resolved, but a striking difference was the interaction with adapter proteins recruited to the phosphorylated interdomain-B.

Enhanced Syk tyrosine phosphorylation mediated by downregulation of Syk S297 phosphorylation through PKC inhibition is very likely due to decreased tyrosine dephosphorylation. There are several possible mechanisms via which Syk S297 phosphorylation could regulate this.

- (a) Syk S297 phosphorylation could alter the structure/properties of Syk, which could make Syk a better substrate for tyrosine phosphatases (e.g., TULA-2).
- (b) Syk S297 phosphorylation could recruit adapter proteins to this site (e.g., 14-3-3 γ , prohibitin), which could decrease Syk translocation to ITAM proteins and, therefore, diminish Syk tyrosine phosphorylation/activation.
- (c) PKC could phosphorylate and activate TULA-2/other tyrosine phosphatases resulting in enhanced Syk tyrosine dephosphorylation. However, there is no evidence for PKC-mediated phosphorylation and activation of TULA-2 [43].
- (d) PKC could regulate other proteins, which affect Syk phosphorylation/dephosphorylation.

It is also possible that there are cell-specific mechanisms of Syk regulation, perhaps due to different binding/adapter proteins. These aspects should be investigated with platelets in the future. Our data with human platelets suggest that ITAM-dependent activation of Syk tyrosine phosphorylation is limited by Syk-dependent, PKC-mediated increased S297 phosphorylation, which can be prevented by PKC inhibition. This may represent a feedback inhibition important to prevent hyperactivation of Syk. Feedback inhibition is often observed with receptor-dependent signaling including tyrosine kinases. For example, PKC-stimulated phosphorylation of the epidermal growth factor receptor (EGFR) was reported to represent negative feedback inhibition of this signaling by converting the active EGFR

dimer back to the inactive monomer [47]. Of special interest with respect to soluble tyrosine kinases, it was reported that PKC β -mediated phosphorylation of the Bruton-tyrosine kinase BTK on S180 prevented membrane association and further tyrosine phosphorylation/activation of BTK in B and mast cells [48].

Considering the central role of Syk in immune cells and platelets, its established role in many disease processes including myeloid malignancies [15,49,50], and its increasingly recognized role as a therapeutic target [51,52], it will be now very important to elucidate the precise mechanism via which Syk is controlled by S297 phosphorylation.

Clinically used Syk inhibitors not only target Syk but also other tyrosine protein kinases. A clear direction of further development would be to find more specific Syk inhibitors, perhaps inhibitors, which do not directly target the kinase domain but a Syk-specific regulatory/allosteric domain such as the interdomain-B. Another problem with clinically used protein kinase inhibitors and also Syk inhibitors is the emergence of resistance, which was very recently addressed in a large genomic screen in acute myeloid leukemia (AML) [50]. This screen identified activation of the RAS/MAPK/ERK pathway as one major mechanism of resistance to Syk inhibitors, which was further validated in AML cell lines with innate and acquired resistance to Syk inhibitors. The authors discussed their data, whereby resistance to tyrosine kinase inhibitors during targeted therapies may be due to secondary mutations of the target kinase, activation of other upstream stimulators or downstream effectors of the pathway, or the activation of parallel pathways. These very recent clinical findings highlight that improvement of our understanding of Syk regulation at the tyrosine kinase level directly, but also at the level of both upstream and downstream of this crucial component of platelet, immune, and myeloid cell activation, is essential for further advances in the area of Syk pathophysiology and inhibitors. Our present study on the feedback inhibition of Syk is perhaps one small step in this direction and also provides a human-relevant model of Syk signaling.

4. Materials and Methods

4.1. Ethics Approval

All healthy donors gave their informed consent for inclusion before they participated in the study. The study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the local Ethics Committee of the University Medical Center Mainz (Study No. 837.302.12; 25.07.12; FF109/2015).

4.2. Preparation and Stimulation of Human Platelets

Whole blood was collected in citrate tubes from healthy volunteers who did not take any medication at least 10 days before the experiments. Platelet washing and the isolation procedure were performed as previously described [28]. A modified washing procedure was used for the experiments with ADP stimulation. PRP was diluted 1:1 with CGS buffer (120 mM NaCl, 12.9 mM Tri-Na-citrate, 30 mM glucose, pH 6.5) then centrifuged at 400 \times g for 10 min at room temperature (RT). The platelet pellet was resuspended directly with HEPES buffer (150 mM NaCl, 5 mM KCl, 1 mM MgCl₂, 10 mM glucose, 10 mM HEPES, pH 7.4). Human washed platelets were adjusted to 3 \times 10⁸ platelets/mL and kept at 37 °C prior to stimulation under stirring conditions with the corresponding platelet agonist or activator in the presence or absence of vehicle control or effectors.

4.3. Platelet Aggregometry

Aggregation of washed human platelets was monitored by light transmission aggregometry (LTA) using an Apact4S Plus aggregometer (DiaSys Greiner, Flacht, Germany). Platelets were stimulated by ADP (Sigma-Aldrich, Saint Louis, MO, USA), convulxin (Enzo life sciences, Lausen, Switzerland), echicetin beads (EB) (prepared as previously described [28,53]), or PDBu (Sigma-Aldrich, Saint Louis, MO, USA) under stirring conditions (1000 s⁻¹) at 37 °C. Platelets were pre-treated with different effectors

prior to stimulation: Src family kinase inhibitor PP2 (Abcam, Cambridge, UK), Syk inhibitors OXSI-2 (Merck, Darmstadt, Germany) and PRT-060318 (Sellckem, Houston, TX, USA), PKC pan-inhibitor GF109203X (Enzo life sciences, Lausen, Switzerland), or cAMP-elevating agent iloprost (Bayer AG, Leverkusen, Germany).

4.4. SDS-PAGE and Western Blot Analysis

Platelet samples for Western blot analysis were prepared by adding 3× Lämmli buffer (200 mM tris/HCl, 15% (v/v) glycerol, 6% (w/v) SDS, 0.06% (w/v) bromphenol blue, 1:10 β-mercaptoethanol) directly in the aggregation cuvettes to stop platelet responses, then boiled at 95 °C for 10 min under gentle shaking. Platelet proteins were separated by electrophoresis using 8% SDS-polyacrylamide gels followed by immunoblotting as previously described [28].

Phospho-antibodies against Syk S297, Syk Y525/526, Syk Y352, LAT Y191, PLCγ2 Y759, and MARCKS S159/163 (Cell Signaling Technologies, Danvers, MA, USA) were used diluted 1:1000 in 5% BSA or 1:700 for MARCKS. Blots probed with phospho-antibodies were stripped and reprobed with a corresponding antibody detecting the total protein, anti-Syk, or anti-PLCγ2 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), or other loading controls anti-β-actin or anti-α-actinin (Cell Signaling Technologies, Danvers, MA, USA) diluted 1:1000 in 5% BSA. After incubation with the appropriate secondary antibody, horseradish peroxidase (HRP)-conjugated goat anti-rabbit and anti-mouse IgG (BioRad Laboratories, Hercules, CA, USA) enhanced chemiluminescence (ECL) detection was performed using Fusion FX7 (Vilber Loumat GmbH, Eberhardzell, Germany).

4.5. Zn²⁺-Phos-Tagtm-SDS-PAGE and Western Blot Analysis

The phos-tag method was developed and described by the group of Koike [31,32] and used here for platelet Syk. Platelets were lysed using 3× Laemmli buffer for phos-tag (200 mM tris, 15% (v/v) glycerol, 6% (w/v) SDS, 2% (w/v) bromphenol blue, 1:10 β-mercaptoethanol) in the absence of EDTA. Samples were boiled at 95 °C for 10 min under gentle shaking. Platelet proteins were separated by electrophoresis using gels containing 6% w/v polyacrylamide, 35 μM phos-tagTM compound, and 69 μM ZnCl₂ in the separating gel. Then, 1× phos-tag running buffer was used for gel electrophoresis (0.1 M tris, 0.1 M MOPS, 0.1% (w/v) SDS, 5 mM sodium bisulfite, pH 7.8). Prior to protein membrane transfer, gels were washed twice for 10 min with 1× transfer buffer containing 1 mM EDTA to remove the Zn²⁺ ions. A third washing step was performed with 1× transfer buffer without EDTA before the proteins were transferred to polyvinylidene difluoride (PVDF) membranes using a transfer buffer for phos-tag (25 mM tris, 192 mM glycine, 10% (v/v) methanol, 5% (w/v) SDS, pH 8.4).

Immunoblotting was performed as previously described [28]. Mouse monoclonal Syk antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) was used as primary antibody (1:1000 in 5% BSA) and HRP-conjugated mouse antibody was used as secondary antibody (1:5000 in 5% BSA).

4.6. Inositol Monophosphate (InsP1) Measurement

Accumulated inositol monophosphate (InsP1), reflecting the produced inositol triphosphate (InsP3) upon platelet stimulation, was measured by using the IP-One ELISA kit (Cisbio, Codolet, France) in the presence of LiCl (1 mM), which prevents the degradation of InsP1 into myo-inositol. Washed platelets (3 × 10⁸ platelets/mL) were stimulated with convulxin or EB in the absence or presence of effectors at 37 °C under stirring conditions, lysed after 5 min of activation, and centrifuged at 16,000× g for 10 min at 4 °C. InsP1–HRP conjugate and anti-InsP1 monoclonal antibody were pre-incubated with platelet lysates for 3 h prior to measurement, and InsP1 was quantified according to the manufacturer's instructions.

4.7. Intracellular Ca²⁺-Release Measurement

Washed platelets (3×10^8 platelets/mL) were loaded for 30 min at 37 °C with 5 µM Fluo-3 acetoxymethyl (AM) esters (Life Technologies, Carlsbad, CA, USA), a Ca²⁺ indicator dye with excitation/emission of 506 nm/526 nm for the Ca²⁺-bound form. Intracellular Ca²⁺ was monitored as mean fluorescence intensity for 2 min detected by flow cytometry (BD FACSCANTO II, BD Biosciences, Heidelberg, Germany) after stimulation with cvx or EB, without supplementation of extracellular Ca²⁺ and in the absence or presence of effectors. Data were analyzed by FACSDiva software v6.1.3 (BD Biosciences, Heidelberg, Germany) expressing the ratio of mean fluorescence intensity over time of treated platelets vs. basal platelet condition.

4.8. Statistical Analysis

Each dataset represents at least three different experiments from at least three different healthy volunteers when data are expressed as means ± standard deviation (SD). Statistical analysis was performed using GraphPad Prism 8 (GraphPad Software, San Diego, CA, USA). One-way or two-way ANOVA, followed by Tukey's multiple comparison test for comparison of more than two groups, or the two-tailed Student's *t*-test for comparison of two groups were used. A *p*-value < 0.05 was considered as significant.

Supplementary Materials: Supplementary Materials can be found at <http://www.mdpi.com/1422-0067/21/1/176/s1>. Supplementary Figures 1–3/File1.

Author Contributions: Conceptualization, K.J. and U.W.; methodology, S.G., S.M., and S.D.; data curation, S.M. and S.D.; formal analysis, S.M. and K.J.; writing—original draft preparation, S.M. and U.W.; writing—review and editing, S.M., S.D., S.G., U.W., and K.J.; supervision, K.J. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the German Federal Ministry of Education and Research (BMBF 01EO1003/01EO1503). S.G. was supported by a grant from Ministry of Science and Higher Education of the Russian Federation (№АААА-А18-118012290371-3).

Acknowledgments: We are grateful to Ulrich Grädler (Merck KGaA, Darmstadt, Germany) for his fruitful discussions on the Syk structure.

Conflicts of Interest: The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Abbreviations

| | |
|--------|--|
| ACK1 | Activated CDC42 kinase 1 |
| ADP | Adenosine diphosphate |
| BCR | B-cell antigen receptor |
| BTK | Bruton-tyrosine kinase |
| cAMP | Cyclic adenosine monophosphate |
| cGMP | Cyclic guanosine monophosphate |
| cvx | Convulxin |
| EB | Echicetin beads |
| GFX | 2-[1-(3-Dimethylaminopropyl)indol-3-yl]-3-(indol-3-yl) maleimide |
| HRP | Horseradish peroxidase |
| InsP1 | Inositol monophosphate |
| InsP3 | Inositol triphosphate |
| ITAM | Immunoreceptor tyrosine-based activation motif |
| JAK | Janus kinase |
| LAT | Linker adaptor for T cells |
| MARCKS | Myristoylated alanine-rich C-kinase substrate |
| PDBu | Phorbol 12, 13-dibutyrate |
| PI3k | Phosphoinositide-3 kinase |

| | |
|----------------|------------------------------------|
| PKA | Protein kinase A |
| PKC | Protein kinase C |
| PLC γ 2 | Phospholipase C γ 2 |
| S | Serine |
| PAGE | Polyacrylamide gel-electrophoresis |
| SH2 | Src homology 2 |
| Syk | Spleen tyrosine kinase |
| T | Threonine |
| TxA2 | Thromboxane A2 |
| vWF | Von Willebrand factor |
| Y | Tyrosine |

References

1. Jurk, K.; Kehrel, B.E. Platelets: Physiology and biochemistry. *Semin. Thromb. Hemost.* **2005**, *31*, 381–392. [[CrossRef](#)] [[PubMed](#)]
2. Versteeg, H.H.; Heemskerk, J.W.M.; Levi, M.; Reitsma, P.H. New fundamentals in hemostasis. *Physiol. Rev.* **2013**, *93*, 327–358. [[CrossRef](#)] [[PubMed](#)]
3. Jurk, K. Analysis of platelet function and dysfunction. *Hamostaseologie* **2015**, *35*, 60–72. [[CrossRef](#)] [[PubMed](#)]
4. Offermanns, S. Activation of platelet function through G protein-coupled receptors. *Circ. Res.* **2006**, *99*, 1293–1304. [[CrossRef](#)]
5. Brass, L.F.; Ma, P.; Tomaiuolo, M.; Diamond, S.L.; Stalker, T.J. A Systems Approach to the Platelet Signaling Network and the Hemostatic Response to Injury. In *Platelets in Thrombotic and Non-Thrombotic Disorders*; Springer: Berlin/Heidelberg, Germany, 2017; pp. 367–378.
6. Gardiner, E.E.; Andrews, R.K. Platelet Adhesion. In *Platelets in Thrombotic and Non-Thrombotic Disorders: Pathophysiology, Pharmacology and Therapeutics: An Update*; Gresele, P., Kleiman, N.S., Lopez, J.A., Page, C.P., Eds.; Springer: Cham, Switzerland, 2017; pp. 309–319. [[CrossRef](#)]
7. Rayes, J.; Watson, S.P.; Nieswandt, B. Functional significance of the platelet immune receptors GPVI and CLEC-2. *J. Clin. Investig.* **2019**, *129*, 12–23. [[CrossRef](#)]
8. Senis, Y.A.; Mazharian, A.; Mori, J. Src family kinases: At the forefront of platelet activation. *Blood* **2014**, *124*, 2013–2024. [[CrossRef](#)]
9. Ozaki, Y.; Suzuki-Inoue, K.; Inoue, O. Platelet receptors activated via multimerization: Glycoprotein VI, GPIb-IX-V, and CLEC-2. *J. Thromb. Haemost.* **2013**, *11* (Suppl. S1), 330–339. [[CrossRef](#)]
10. Falati, S.; Edmead, C.E.; Poole, A.W. Glycoprotein Ib-V-IX, a receptor for von Willebrand factor, couples physically and functionally to the Fc receptor gamma-chain, Fyn, and Lyn to activate human platelets. *Blood* **1999**, *94*, 1648–1656. [[CrossRef](#)]
11. López, J.A. The Platelet Glycoprotein Ib-IX-V Complex. In *Platelets in Thrombotic and Non-Thrombotic Disorders: Pathophysiology, Pharmacology and Therapeutics: An Update*; Gresele, P., Kleiman, N.S., Lopez, J.A., Page, C.P., Eds.; Springer: Cham, Switzerland, 2017; pp. 85–97. [[CrossRef](#)]
12. Stegner, D.; Haining, E.J.; Nieswandt, B. Targeting Glycoprotein VI and the Immunoreceptor Tyrosine-Based Activation Motif Signaling Pathway. *Arterioscler. Thromb. Vasc. Biol.* **2014**, *34*, 1615–1620. [[CrossRef](#)]
13. Zeiler, M.; Moser, M.; Mann, M. Copy Number Analysis of the Murine Platelet Proteome Spanning the Complete Abundance Range. *Mol. Cell. Proteom.* **2014**, *13*, 3435–3445. [[CrossRef](#)]
14. Poole, A.; Gibbins, J.M.; Turner, M.; van Vugt, M.J.; van de Winkel, J.G.J.; Saito, T.; Tybulewicz, V.L.J.; Watson, S.P. The Fc receptor gamma-chain and the tyrosine kinase Syk are essential for activation of mouse platelets by collagen. *EMBO J.* **1997**, *16*, 2333–2341. [[CrossRef](#)] [[PubMed](#)]
15. Mocsai, A.; Ruland, J.; Tybulewicz, V.L.J. The SYK tyrosine kinase: A crucial player in diverse biological functions. *Nat. Rev. Immunol.* **2010**, *10*, 387–402. [[CrossRef](#)] [[PubMed](#)]
16. Cheng, A.M.; Rowley, B.; Pao, W.; Hayday, A.; Bolen, J.B.; Pawson, T. Syk tyrosine kinase required for mouse viability and b-cell development. *Nature* **1995**, *378*, 303–306. [[CrossRef](#)] [[PubMed](#)]

17. van Eeuwijk, J.M.; Stegner, D.; Lamb, D.J.; Kraft, P.; Beck, S.; Thielmann, I.; Kiefer, F.; Walzog, B.; Stoll, G.; Nieswandt, B. The Novel Oral Syk Inhibitor, BI1002494, Protects Mice From Arterial Thrombosis and Thromboinflammatory Brain Infarction. *Arterioscler. Thromb. Vasc. Biol.* **2016**, *36*, 1247–1253. [[CrossRef](#)] [[PubMed](#)]
18. Bradshaw, J.M. The Src, Syk, and Tec family kinases: Distinct types of molecular switches. *Cell. Signal.* **2010**, *22*, 1175–1184. [[CrossRef](#)]
19. Tsang, E.; Giannetti, A.M.; Shaw, D.; Dinh, M.; Tse, J.K.Y.; Gandhi, S.; Ho, H.D.; Wang, S.; Papp, E.; Bradshaw, J.M. Molecular Mechanism of the Syk Activation Switch. *J. Biol. Chem.* **2008**, *283*, 32650–32659. [[CrossRef](#)]
20. Gradler, U.; Schwarz, D.; Dresing, V.; Musil, D.; Bomke, J.; Frech, M.; Greiner, H.; Jakel, S.; Rysiok, T.; Muller-Pompalla, D.; et al. Structural and Biophysical Characterization of the Syk Activation Switch. *J. Mol. Biol.* **2013**, *425*, 309–333. [[CrossRef](#)]
21. Sada, K.; Takano, T.; Yanagi, S.; Yamamura, H. Structure and function of Syk protein-tyrosine kinase. *J. Biochem.* **2001**, *130*, 177–186. [[CrossRef](#)]
22. Geahlen, R.L. Syk and pTyr'd: Signaling through the B cell antigen receptor. *Biochim. Biophys. Acta-Mol. Cell Res.* **2009**, *1793*, 1115–1127. [[CrossRef](#)]
23. Bohnenberger, H.; Oellerich, T.; Engelke, M.; Hsiao, H.H.; Urlaub, H.; Wienands, J. Complex phosphorylation dynamics control the composition of the Syk interactome in B cells. *Eur. J. Immunol.* **2011**, *41*, 1550–1562. [[CrossRef](#)]
24. Paris, L.L.; Hu, J.J.; Galan, J.; Ong, S.S.; Martin, V.A.; Ma, H.Y.; Tao, W.A.; Harrison, M.L.; Geahlen, R.L. Regulation of Syk by Phosphorylation on Serine in the Linker Insert. *J. Biol. Chem.* **2010**, *285*, 39844–39854. [[CrossRef](#)] [[PubMed](#)]
25. Beck, F.; Geiger, J.; Gambaryan, S.; Veit, J.; Vaudel, M.; Nollau, P.; Kohlbacher, O.; Martens, L.; Walter, U.; Sickmann, A.; et al. Time-resolved characterization of cAMP/PKA-dependent signaling reveals that platelet inhibition is a concerted process involving multiple signaling pathways. *Blood* **2014**, *123*, e1–e10. [[CrossRef](#)] [[PubMed](#)]
26. Beck, F.; Geiger, J.; Gambaryan, S.; Solari, F.A.; Dell'Aica, M.; Loroch, S.; Mattheij, N.J.; Mindukshev, I.; Potz, O.; Jurk, K.; et al. Temporal quantitative phosphoproteomics of ADP stimulation reveals novel central nodes in platelet activation and inhibition. *Blood* **2017**, *129*, E1–E12. [[CrossRef](#)] [[PubMed](#)]
27. Trabold, K.; Makhoul, S.; Gambaryan, S.; van Ryn, J.; Walter, U.; Jurk, K. The Direct Thrombin Inhibitors Dabigatran and Lepirudin Inhibit GPIIb/IIIa-Mediated Platelet Aggregation. *Thromb. Haemost.* **2019**, *119*, 916–929. [[PubMed](#)]
28. Makhoul, S.; Trabold, K.; Gambaryan, S.; Tenzer, S.; Pillitteri, D.; Walter, U.; Jurk, K. cAMP- and cGMP-elevating agents inhibit GPIIb/IIIa-mediated aggregation but not GPIIb/IIIa-stimulated Syk activation in human platelets. *Cell Commun. Signal.* **2019**, *17*, 1–10. [[CrossRef](#)] [[PubMed](#)]
29. Jurk, K.; Walter, U. New Insights into Platelet Signalling Pathways by Functional and Proteomic Approaches. *Hamostaseologie* **2019**, *39*, 140–151. [[CrossRef](#)]
30. Nagy, Z.; Smolenski, A. Cyclic nucleotide-dependent inhibitory signaling interweaves with activating pathways to determine platelet responses. *Res. Pract. Thromb. Haemost.* **2018**, *2*, 558–571. [[CrossRef](#)]
31. Kinoshita, E.; Kinoshita-Kikuta, E.; Kubota, Y.; Takekawa, M.; Koike, T. A Phos-tag SDS-PAGE method that effectively uses phosphoproteomic data for profiling the phosphorylation dynamics of MEK1. *Proteomics* **2016**, *16*, 1825–1836. [[CrossRef](#)]
32. Kinoshita, E.; Kinoshita-Kikuta, E.; Koike, T. Advances in Phos-tag-based methodologies for separation and detection of the phosphoproteome. *Biochim. Biophys. Acta-Proteins Proteom.* **2015**, *1854*, 601–608. [[CrossRef](#)]
33. Dangelmaier, C.A.; Quinter, P.G.; Jin, J.G.; Tsygankov, A.Y.; Kunapuli, S.P.; Daniel, J.L. Rapid ubiquitination of Syk following GPVI activation in platelets. *Blood* **2005**, *105*, 3918–3924. [[CrossRef](#)]
34. Thelen, M.; Rosen, A.; Nairn, A.C.; Aderem, A. Regulation by phosphorylation of reversible association of a myristoylated protein kinase C substrate with the plasma membrane. *Nature* **1991**, *351*, 320–322. [[CrossRef](#)] [[PubMed](#)]
35. Albert, K.A.; Nairn, A.C.; Greengard, P. The 87-KDA protein, a major specific substrate for protein-kinase-C—purification from bovine brain and characterization. *Proc. Natl. Acad. Sci. USA* **1987**, *84*, 7046–7050. [[CrossRef](#)] [[PubMed](#)]
36. Gilio, K.; Harper, M.T.; Cosemans, J.M.; Konopatskaya, O.; Munnix, I.C.; Prinzen, L.; Leitges, M.; Liu, Q.; Molkentin, J.D.; Heemskerk, J.W.; et al. Functional divergence of platelet protein kinase C (PKC) isoforms in thrombus formation on collagen. *J. Biol. Chem.* **2010**, *285*, 23410–23419. [[PubMed](#)]

37. Makhoul, S.; Walter, E.; Pagel, O.; Walter, U.; Sickmann, A.; Gambaryan, S.; Smolenski, A.; Zahedi, R.P.; Jurk, K. Effects of the NO/soluble guanylate cyclase/cGMP system on the functions of human platelets. *Nitric Oxide Biol. Chem.* **2018**, *76*, 71–80. [[CrossRef](#)]
38. Burkhart, J.M.; Vaudel, M.; Gambaryan, S.; Radau, S.; Walter, U.; Martens, L.; Geiger, J.; Sickmann, A.; Zahedi, R.P. The first comprehensive and quantitative analysis of human platelet protein composition allows the comparative analysis of structural and functional pathways. *Blood* **2012**, *120*, e73–e82.
39. Kunapuli, S.P.; Bhavanasi, D.; Kostyak, J.C.; Manne, B.K. Platelet Signaling: Protein Phosphorylation. In *Platelets in Thrombotic and Non-Thrombotic Disorders: Pathophysiology, Pharmacology and Therapeutics: An Update*; Gresele, P., Kleiman, N.S., Lopez, J.A., Page, C.P., Eds.; Springer: Cham, Switzerland, 2017; pp. 297–308. [[CrossRef](#)]
40. Pula, G.; Crosby, D.; Baker, J.; Poole, A.W. Functional interaction of protein kinase C alpha with the tyrosine kinases Syk and Src in human platelets. *J. Biol. Chem.* **2005**, *280*, 7194–7205. [[CrossRef](#)]
41. Bijli, K.M.; Fazal, F.; Minhajuddin, M.; Rahman, A. Activation of Syk by protein kinase C-delta regulates thrombin-induced intercellular adhesion molecule-1 expression in endothelial cells via tyrosine phosphorylation of RelA/p65. *J. Biol. Chem.* **2008**, *283*, 14674–14684. [[CrossRef](#)]
42. Oh, H.; Ozkirimli, E.; Shah, K.; Harrison, M.L.; Geahlen, R.L. Generation of an analog-sensitive syk tyrosine kinase for the study of signaling dynamics from the B cell antigen receptor. *J. Biol. Chem.* **2007**, *282*, 33760–33768. [[CrossRef](#)]
43. Tsygankov, A.Y. TULA proteins as signaling regulators. *Cell. Signal.* **2019**, *65*, 109424. [[CrossRef](#)]
44. Thomas, D.H.; Getz, T.M.; Newman, T.N.; Dangelmaier, C.A.; Carpino, N.; Kunapuli, S.P.; Tsygankov, A.Y.; Daniel, J.L. A novel histidine tyrosine phosphatase, TULA-2, associates with Syk and negatively regulates GPVI signaling in platelets. *Blood* **2010**, *116*, 2570–2578. [[CrossRef](#)]
45. Reppschlager, K.; Gosselin, J.; Dangelmaier, C.A.; Thomas, D.H.; Carpino, N.; McKenzie, S.E.; Kunapuli, S.P.; Tsygankov, A.Y. TULA-2 Protein Phosphatase Suppresses Activation of Syk through the GPVI Platelet Receptor for Collagen by Dephosphorylating Tyr(P)(346), a Regulatory Site of Syk. *J. Biol. Chem.* **2016**, *291*, 22427–22441. [[CrossRef](#)] [[PubMed](#)]
46. Buitrago, L.; Bhavanasi, D.; Dangelmaier, C.; Manne, B.K.; Badolia, R.; Borgognone, A.; Tsygankov, A.Y.; McKenzie, S.E.; Kunapuli, S.P. Tyrosine phosphorylation on spleen tyrosine kinase (Syk) is differentially regulated in human and murine platelets by protein kinase C isoforms. *J. Biol. Chem.* **2013**, *288*, 29160–29169. [[CrossRef](#)] [[PubMed](#)]
47. Kluba, M.; Engelborghs, Y.; Hofkens, J.; Mizuno, H. Inhibition of Receptor Dimerization as a Novel Negative Feedback Mechanism of EGFR Signaling. *PLoS ONE* **2015**, *10*, e0139971.
48. Kang, S.W.; Wahl, M.I.; Chu, J.; Kitaura, J.; Kawakami, Y.; Kato, R.M.; Tabuchi, R.; Tarakhovsky, A.; Kawakami, T.; Turck, C.W.; et al. PKCbeta modulates antigen receptor signaling via regulation of Btk membrane localization. *EMBO J.* **2001**, *20*, 5692–5702. [[CrossRef](#)]
49. Geahlen, R.L. Getting Syk: Spleen tyrosine kinase as a therapeutic target. *Trends Pharmacol. Sci.* **2014**, *35*, 414–422. [[CrossRef](#)]
50. Cremer, A.; Ellegast, J.M.; Alexe, G.; Frank, E.S.; Ross, L.; Chu, S.H.; Pikman, Y.; Robichaud, A.; Goodale, A.; Haupt, B.; et al. Resistance mechanisms to SYK inhibition in acute myeloid leukemia. *Cancer Discov.* **2019**. [[CrossRef](#)]
51. Fueyo, J.; Alonso, M.M.; Kerrigan, B.C.P.; Gomez-Manzano, C. Linking inflammation and cancer: The unexpected SYK world. *Neuro-Oncology* **2018**, *20*, 582–583. [[CrossRef](#)]
52. Szilveszter, K.P.; Nemeth, M.; Mocsai, A. Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases. *Front. Immunol.* **2019**, *10*, 1862. [[CrossRef](#)]
53. Navdaev, A.; Subramanian, H.; Petunin, A.; Clemetson, K.J.; Gambaryan, S.; Walter, U. Echinectin coated polystyrene beads: A novel tool to investigate GPIIb-specific platelet activation and aggregation. *PLoS ONE* **2014**, *9*, e93569.





Article

Platelet Proteasome Activity and Metabolism Is Upregulated during Bacterial Sepsis

Katharina Grundler Groterhorst ^{1,2,†}, Hanna Mannell ^{2,3,†}, Joachim Pircher ^{1,4} and Bjoern F Kraemer ^{1,*}

¹ Medizinische Klinik und Poliklinik I, Klinikum der Universität München, Marchioninistrasse 15, 81377 Munich, Germany; gruendler.k@gmail.com (K.G.G.); Joachim.Pircher@med.uni-muenchen.de (J.P.)

² Walter Brendel Centre of Experimental Medicine, University Hospital, Ludwig-Maximilians-University, Marchioninstr. 27, 81377 Munich, Germany; Hanna.Mannell@med.uni-muenchen.de

³ Biomedical Center, Ludwig-Maximilians-University, Großhaderner Str. 9, 82152 Planegg, Germany

⁴ DZHK (German Center for Cardiovascular Research), Partner Site Munich Heart Alliance, 80802 Munich, Germany

* Correspondence: bjoern.kraemer@klinik-ebe.de

† These authors contributed equally to this work.

Received: 27 October 2019; Accepted: 25 November 2019; Published: 27 November 2019

Abstract: Dysregulation of platelet function can contribute to the disease progression in sepsis. The proteasome represents a critical and vital element of cellular protein metabolism in platelets and its proteolytic activity has been associated with platelet function. However, the role of the platelet proteasome as well as its response to infection under conditions of sepsis have not been studied so far. We measured platelet proteasome activity by fluorescent substrates, degradation of poly-ubiquitinated proteins and cleavage of the proteasome substrate Talin-1 in the presence of living *E. coli* strains and in platelets isolated from sepsis patients. Upregulation of the proteasome activator PA28 (PSME1) was assessed by quantitative real-time PCR in platelets from sepsis patients. We show that co-incubation of platelets with living *E. coli* (UTI89) results in increased degradation of poly-ubiquitinated proteins and cleavage of Talin-1 by the proteasome. Proteasome activity and cleavage of Talin-1 was significantly increased in α -hemolysin (HlyA)-positive *E. coli* strains. Supporting these findings, proteasome activity was also increased in platelets of patients with sepsis. Finally, the proteasome activator PA28 (PSME1) was upregulated in this group of patients. In this study we demonstrate for the first time that the proteasome in platelets is activated in the septic milieu.

Keywords: proteasome activity; platelets; sepsis; bacteria

1. Introduction

Sepsis is a life-threatening disease caused by a dysregulated inflammatory host response, often induced upon a systemic bacterial infection. In this context, *E. coli* is a frequent cause of sepsis. Apart from an exaggerated systemic inflammatory response, a pro-coagulant and pro-thrombotic state is present during sepsis and the uncontrolled activation of platelets can contribute to the progression of the disease [1]. Recent work has demonstrated that platelets also possess a functional proteasome [2] and others and we have shown that platelet function is associated with proteolytic regulation of proteins by the proteasome [3,4]. Moreover, the expression as well as the proteolytic activity of the proteasome were shown to be increased in muscle tissue during sepsis [5–7]. However, proteasome activity has not yet been studied in platelets during sepsis.

The proteasome represents a critical element for protein processing in human cells and is crucial for protein degradation, turnover and antigen presentation [8]. Proteins designated for proteasome processing are tagged with ubiquitin to be unfolded and identified by the proteasomal

catalytic subunits [9]. Especially, in platelets, as anucleate cells, the proteolytic cleavage of proteins is an important mechanism for regulation of their cellular functions [10]. Indeed, proteasomal activity was shown to be important for platelet aggregation and thrombosis formation in vitro and in vivo and interestingly, these physiological processes could be efficiently prevented by proteasome inhibition [2–4,10,11]. Moreover, by studying the proteasomal cleavage of proteins involved in cytoskeletal regulation, such as Filamin A and Talin-1, our group was able to identify a link between the proteasome and NF κ B in the regulation of collagen-induced platelet aggregation [3]. During inflammatory conditions, additional proteasomal subunits (PSME1 and PSME2) are expressed and form an immunoproteasome together with subunits of the conventional proteasome [12]. Apart from its important role in antigen presentation by MHC class I molecules, the immunoproteasome has been shown to exhibit a higher proteolytic activity and to prevent cellular damage during inflammation [13]. Of note, a functional immunoproteasome as well as the capacity to process and present antigens is present also in platelets [14,15]. Malfunction of the proteasome has been associated with several disease processes [16]. However, our knowledge about its role and function in platelets, especially under disease conditions, is still scarce.

In this study, we therefore investigated the activity of the proteasome in platelets in the septic milieu using living *E. coli* in vitro and in sepsis patients. We observed an upregulation of the immuno-proteasome subunit and activator PA28 (PSME1) in platelets from sepsis patients and increased processing of polyubiquitinated proteins as well as the proteasome substrate Talin-1 under conditions of sepsis. Proteasome activation was more pronounced when platelets were exposed to pathogenic *E. coli* (UTI89) expressing the exotoxin α -hemolysin compared to toxin-negative *E. coli* strains. Our novel data demonstrate that the proteasome in platelets responds to the septic environment and is upregulated in patients with sepsis.

2. Results

2.1. Platelet Proteasome Activity and Protein Metabolism is Increased in the Septic Milieu

As systemic *E. coli* infection is a frequent cause of sepsis, we were first interested in whether *E. coli* affects platelet proteasome activity. Incubation of isolated human platelets with the pathogenic *E. coli* strain UTI89 led to increased proteasome activity in vitro. This effect was specific, as it was effectively inhibited by the proteasome inhibitor epoxomicin (Figure 1A). Poly-ubiquitinated proteins, which represent proteins marked for proteasomal processing, were excessively degraded over time during coinubation with *E. coli* UTI89. This process was equally inhibited by treatment with epoxomicin (Figure 1B).

2.2. *E. coli* Exotoxin α -Hemolysin (*hlyA*) may be a Contributing Factor to Increased Proteasome Activity in Platelets

E. coli α -hemolysin is a potent exotoxin, which can activate proteases in a calcium-dependent fashion [17,18]. Platelet proteasome activity, assessed by fluorescent substrate cleavage, was significantly enhanced in the presence of *E. coli* UTI89 (Figure 2A). Effects were less pronounced during coinubation with *E. coli* strains, where the α -hemolysin gene was knocked-out (UTI89 Δ hlyA). Typical cleavage of the proteasome substrate Talin-1 by the proteasome from a 235 kDa fragment to a 190 kDa fragment was also increased in the presence of *E. coli* UTI89 (ratio 190/235 kDa). This effect was again weaker when platelets were coinubated with the hlyA-negative *E. coli* strain UTI89 Δ hlyA (Figure 2B).




Figure 1. Bacteria induce proteasome activation and increased protein degradation in human platelets. (A) Co-incubation of platelets with living *E. coli* (UTI89) for 4 h induced a significant increase in platelet proteasome activity measured by fluorescent substrate cleavage, compared to control platelets ($*p < 0.05$, $n = 3$). Increased activation of the proteasome was effectively reversed with the proteasome inhibitor epoxomicin (10 μ M; $*p < 0.05$, $n = 3$). (B) Platelet coincubation with living *E. coli* (UTI89) led to accelerated degradation of polyubiquitinated proteins (U/mL) in platelets after 2 and 4 h of incubation, as assessed by ELISA. This was effectively inhibited by proteasome inhibition (epoxomicin, 10 μ M; $*p < 0.05$, $n = 3$).




Figure 2. α -hemolysin expression in *E. coli* enhances platelet proteasome activation. (A) Platelet proteasome activity was enhanced upon incubation (4 h) with α -hemolysin expressing *E. coli* (UTI89 WT), whereas incubation with *E. coli* lacking functional α -hemolysin (UTI89 Δ hlyA) showed a trend towards less proteasome activation, as assessed by fluorescent peptide cleavage ($*p < 0.05$, $n = 5$). (B) The proteasome substrate Talin-1 was increasingly cleaved during coincubation with *E. coli* (UTI89) (ratio of 190 kDa to 235 kDa fragments) compared to control platelets. Increase of cleavage was less with the α -hemolysin negative strain UTI89 Δ hlyA compared to platelet control ($n = 2$).

2.3. Platelet Proteasome Activity is Increased in Platelets from Sepsis Patients

Having observed that pathogenic *E. coli* enhances platelet proteasome activity, we next studied the platelet proteasome in patients with bacterial sepsis. Clinical information on sepsis patients is shown in Table 1. As seen in Figure 3A, proteasome activity in platelets from sepsis patients was significantly upregulated compared to healthy controls. In addition, cleavage of the proteasome substrate Talin-1, expressed as a 190 to 235 kDa ratio, was also significantly increased in platelets of sepsis patients compared to controls (Figure 3B). As the immunoproteasome has been shown to be upregulated

upon inflammatory conditions, we next investigated immunoproteasome activator PA28 (PSME1) expression in platelets from sepsis patients. mRNA expression analysis using real-time PCR revealed an upregulation of PA28 (PSME1) in platelets of sepsis patients compared to controls (Figure 3C).




Figure 3. Platelets proteasome activity is increased in platelets of sepsis patients. (A) Platelet proteasome activity is increased in patients with sepsis ($*p < 0.05$, $n = 7$) compared to healthy controls ($n = 9$). (B) Cleavage of the proteasome substrate Talin-1 from a 235 to a 190 kDa fragment is significantly increased in platelets of the sepsis population ($n = 5$) compared to controls ($n = 3$; $*p < 0.05$). Proteasome activity was expressed as a ratio of cleaved 190 kDa to intact 235 kDa Talin-1 products by immunoblotting. The protein bands from a healthy control and a sepsis patient in the western blot image are derived from the same blot but cropped out and placed next to each other (white dotted line) for illustrative purposes. (C) mRNA expression analysis by real-time PCR revealed that the proteasome activator PA28 (PSME1) was overexpressed in platelets of sepsis patients compared to healthy individuals ($n = 4$, $*p < 0.05$).

2.4. Clinical Characteristics of Sepsis Patients

We have summarized clinical characteristics of sepsis patients in Table 1.

Table 1. Clinical characteristics of seven patients with bacterial sepsis are shown. Patients were diagnosed with bacterial sepsis based on clinical presentation and positive bacterial culture results. Markers of inflammation including leukocyte count, C-reactive protein (CRP) and procalcitonin were markedly elevated. SOFA score (sequential organ failure assessment) showed multi-organ dysfunction and all patients were treated with antibiotics. Data is presented as median and (interquartile range (IQR)), $n = 7$.

| Clinical Characteristics of Seven Patients with Bacterial Sepsis | | |
|--|--|---------------------|
| Age | | 63 [IQR 49; 69] |
| Leukocyte count (1000/ μ L) | | 16 [IQR 11.0; 21.0] |
| CRP level (mg/dl) | | 25 [IQR 19.5; 28.5] |
| Procalcitonin (ng/mL) | | 5.5 [IQR 4.0; 9.8] |
| Positive bacterial culture | | 7 of 7 |
| Antibiotic treatment | | 7 of 7 |
| SOFA score | | 9 [IQR 6; 11] |

3. Discussion

In the present study, we demonstrated for the first time that the proteasome of platelets was not static but responded to environmental stress conditions, such as a septic milieu, by increasing proteasome activity and protein metabolism. We know that the proteasome is activated in muscle tissue and in muscle wasting in sepsis [6,7], but in platelets its activity and response under septic conditions has not been studied so far. In vitro, we demonstrated that exposure of platelets with

living *E. coli*, which is frequently identified in blood cultures of sepsis patients, increased platelet proteasome activity and subsequently resulted in increased degradation of poly-ubiquitinated proteins in platelets. This metabolic activation was effectively inhibited with the proteasome inhibitor epoxomicin. Polyubiquitination is a characteristic mechanism for labeling proteins for proteasomal processing and thus levels of polyubiquitinated proteins represent a good marker for proteasomal activity. More precisely, we showed that the proteasome substrate Talin-1 is excessively cleaved by the proteasome from a 235 to a 190 kDa fragment after co-incubation with *E. coli* (UTI89). Talin-1 has been shown to be a classical target of the proteasome and functional aspects of platelet aggregation and shape change have been associated with proteolytic regulation by the proteasome [3,4]. Talin-1-derived peptides were found to be presented on HLA-1 molecules on the platelet surface, which also confirms that Talin-1 is processed by the (immuno)-proteasome of platelets (unpublished observations). To investigate underlying mechanisms how septic processes may affect the proteasome, we compared pathogenic *E. coli* strains expressing functional α -hemolysin (UTI89) to strains lacking α -hemolysin (UTI89 Δ hlyA) [19,20]. α -hemolysin is a strong pathogenic factor of bacteria that can induce cell death in platelets as previously shown [17]. By measuring platelet proteasome activity by fluorescent substrate and Talin-1 cleavage during coincubation with living *E. coli*, we observed that the increase of proteasome activity seemed to be more pronounced in wild-type α -hemolysin positive UTI89 strains compared to strains not expressing α -hemolysin (UTI89 Δ hlyA). Although this needs further confirmation, the results suggest that α -hemolysin may be one of the pathogenic factors mediating the activation of the platelet proteasome. As previously shown for calpain [17], this process likely involves calcium-dependent activation of proteasomal subunits to increase proteolytic activity, although the precise mechanism remains to be elucidated in future studies. Finally, to study platelet proteasome activity in a complex sepsis environment, we compared platelets from patients with bacterial sepsis to healthy patients on an mRNA expression level *ex vivo*. Using real-time PCR we observed upregulation of the proteasome activator PA28 (PSME1) in platelets specifically in the sepsis population in line with increased proteasome activity. This finding was of particular interest, as PA28 (PSME1) is primarily an activator of the immunoproteasome that processes peptides for antigen presentation and which is activated during inflammation [5]. The presented data support our concept that the proteasome in platelets is involved in cellular adaptation to inflammatory environmental stress, such as sepsis, on different levels. PA28 (PSME1) encodes for the 11S proteasomal subunit that replaces the 19S regulatory subunit when the immunoproteasome is assembled. PA28 (PSME1) is expressed in platelets at the mRNA level [15] and protein level [21] as previously shown. Interestingly, the complete machinery to process and present antigens on the cell surface via MHC-I is present in platelets, which underscores that platelets play an active role in the immune defense [14,15]. As an example, previous work shows that HLA-1 expression in platelets is altered during infection with dengue virus [22]. Supporting our *in vitro* findings, we observed increased platelet proteasome activity in platelets of patients with sepsis by fluorescent substrate cleavage as well as significantly increased cleavage of the proteasome substrate Talin-1 in the sepsis population *ex vivo*. Although this finding supports the observation that *E. coli* induces proteasomal proteolytic activity, we cannot exclude that the inflammatory environment *per se* additionally contributes to increased proteasome activity in sepsis patients. It also still remains to be investigated, which specific effects an increased proteasome activity has on platelet function in sepsis. Nevertheless, our collected data implied that platelet proteasome activity was affected both in terms of activity and function but also on an mRNA expression level during sepsis.

4. Materials and Methods

4.1. Materials

Talin-1 antibody was purchased from Cell Signaling, Danvers, USA, and horseradish peroxidase-conjugated secondary antibody was from Merck Millipore (Billerica, MA, USA). Epoxomicin

was purchased from EMD Biosciences (LaJolla, CA, USA). All other chemicals were purchased from Sigma Aldrich (Darmstadt, Germany).

4.2. Bacteria

E. coli bacteria of the α -hemolytic strain (hlyA) UTI89 [19] as well as the *E. coli* strain with deletion of hlyA (UTI89 Δ hlyA) [20] were a kind gift from Dr. Matthew Mulvey, Department of Pathology at the University of Utah (Salt Lake City, UT, USA). Similar to recent work [17], bacteria were expanded on blood agar plates overnight at 37 °C until they reached a stationary growth phase. Bacteria were then resuspended in phosphate-buffered saline (PBS) and their concentration was determined by colorimetry (VITEK Colorimeter, bioMerieux, Inc., Durham, NC, USA). Prior to experiments, *E. coli* bacteria were resuspended in M199 culture. For every experiment, the soluble agonists or bacteria were incubated in the presence of freshly isolated platelets (1×10^8 platelets at bacteria to platelet ratio of 1:30) for 4 h in M199 culture media under cell culture conditions.

4.3. Platelet Isolation and Preparation

As previously described [3,17,23], washed platelets were freshly isolated from healthy human subjects and patients with bacterial sepsis, who consented to participate in the study. All studies involving patients and human cells were performed in accordance with the declaration of Helsinki and were approved by the local ethics committee (No. 290-11, approved at 12 July 2011). For inhibitor studies of the proteasome, platelets were incubated with epoxomicin (10 μ M) for the indicated time in warm M199 media under cell culture conditions (5% CO₂, 37 °C).

4.4. RNA Isolation

Platelets (1×10^9) were isolated from healthy donors and patients with bacterial sepsis and were exposed to CD45 positive selection, which effectively depletes contaminating leukocytes as previously described [24]. Cells were lysed in Trizol (Invitrogen, Carlsbad, CA, USA) and glycogen was added to the aqueous phase before precipitation with isopropanol to optimize RNA yields. The RNA was treated with DNase (DNA free Kit, Ambion, Austin, TX, USA), precipitated with ethanol and dissolved in 12 μ L of RNase-free water. RNA (1 μ g) was used to generate cDNA to characterize the expression of PSME1. Integrin α IIb was used as a positive control for platelet-specific RNA. The relative abundance of the PSME1 RNA was measured by real-time PCR. Primer sets for these studies were as follows: PSME1, forward-GAAGCCAACCTTGAGCAATCTGA, reverse-AGCCTTCTAGCTTGGTGTGGAG; and β 2-Microglobulin, forward-ACACTATTCTAGCAGGAGGGTTGG, reverse- CAGGGCTCAGTCTCTTTATTAGGC.

4.5. Detection of Platelet Proteasome Activity

Proteasome activity was measured using a proteasome activity assay with fluorescent substrate according to the manufacturer's instructions (Millipore, Billerica, MA, USA) and as previously described [3]. For experiments where platelets were exposed to living *E. coli* bacteria (see above), cells were pelleted and lysed after 4 h of incubation. As a negative control equal amounts of bacteria were incubated under identical conditions, pelleted, lysed and incubated with the proteasome substrate. Platelet proteasome activity (relative fluorescent units, RFU) was detected at 4 h under cell culture conditions at 450 nm using a fluorescence microplate reader (Tecan Group, Mannedorf, Switzerland).

4.6. Quantification of Polyubiquitinated Protein in Human Platelets

After incubation with living *E. coli* or the proteasome inhibitor epoxomicin, cells were pelleted and lysed in 200 μ L of ubiquitinated protein lysis buffer according to the manufacturer's protocol (human poly-ubiquitinated protein ELISA, MBL International, Woburn, MA, USA). Platelet lysates were diluted 1:200 in the provided dilution buffer and then added to the ELISA plate. ELISA was carried out

according to the manufacturer's instructions. Quantitative changes of total poly-ubiquitinated protein (U/mL) in platelets were measured at 450 nm with an ELISA plate reader (BMG LabTec, Worchester, MA, USA).

4.7. Immunoblotting

Immunoblotting for Talin-1 was performed as previously described [3]. In brief, pellets were lysed in cell lysis buffer (Cell Signaling, Danvers, MA, USA) containing 1 mM PMSF. After centrifugation at 10,000 g for 5 min at 4 °C, protein quantification was performed through the bicinchoninic acid assay (ThermoScientific, Waltham, MA, USA) according to the manufacturer's protocol. Equal volumes of sample were separated by SDS-PAGE using 10% gels and blotted onto PVDF membrane. Membranes were blocked in 5% milk and dissolved in Tris buffered saline with 0.1% Tween and were subsequently incubated with the primary antibody against Talin-1 (1:1000 dilution) at 4 °C overnight. Membranes were washed and incubated with horseradish peroxidase-conjugated secondary antibodies at room temperature for 1 h. Enzymatic activity was detected with a chemiluminescence detection kit according to the supplier's protocol and recorded with a digital camera (Hamamatsu Photonics, Hamamatsu City, Japan). Protein band density measurements for Talin-1 235 kDa and 190 kDa fragments were performed with Image J software. For evaluation of proteasomal cleavage of Talin-1, the ratio 235 kDa/190 kDa was calculated.

4.8. Statistical Analysis

All data are presented as means \pm SEM. Statistical analyses were performed with Sigma Plot 10.0. For comparisons between two groups of normal distributed data, the student's *t*-test was used. For the comparison of two groups without normal distributed data, a rank-sum test was performed. For multiple comparisons between groups of normal distributed data, the one-way analysis of variance (1-way ANOVA) was used. Differences were considered significant at an error probability level of $p < 0.05$.

5. Conclusions

In summary, our study provided novel evidence that the proteasome of platelets responded to the septic environment by increased proteasome activity, increased proteolytic cleavage of proteasome substrates such as Talin-1 and upregulation of (immuno)proteasome activator PA28 (PSME1). Although we still know little about the precise function of the proteasome in platelets, it appeared that the proteasome was an important element in the response to severe cellular stress situations such as sepsis. Future studies will have to show if this response is simply a matter of increased metabolic protein turnover required during systemic inflammation or if it serves the purpose of anti-pathogenic defense strategies, antigen processing, hemostasis or all of them. This study, however, provides a basis to further characterize the precise role and regulation of the proteasome in platelets in complex disease processes, such as sepsis.

Author Contributions: Conceptualization and project administration: B.F.K.; Supervision: H.M., B.F.K.; Investigation: K.G.G., J.P., B.F.K.; Methodology: K.G.G., J.P., B.F.K.; Visualization: K.G.G., H.M.; Writing—original draft preparation: H.M., B.F.K.

Funding: This research was funded by the Dr. Kleist-Stiftung to B.F.K.

Acknowledgments: We thank the group of Professor Matthew Mulvey, Department of Pathology at the University of Utah (Salt Lake City, USA) for generously providing the *E. coli* strains used in the study. We are grateful to the group of Professor Andrew Weyrich, Eccles Institute of Human Genetics at the University of Utah (Salt Lake City, USA) for their support in establishing some of the methods used in the study and to the group of Professor Stefan Stevanovic, Department of Immunology at the University of Tuebingen, Germany for sharing their expertise with antigen presentation.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

1. Assinger, A.; Schrottmaier, W.C.; Salzmann, M.; Rayes, J. Platelets in Sepsis: An Update on Experimental Models and Clinical Data. *Front. Immunol.* **2019**, *10*, 1687. [[CrossRef](#)] [[PubMed](#)]
2. Nayak, M.K.; Kumar, K.; Dash, D. Regulation of proteasome activity in activated human platelets. *Cell Calcium* **2011**, *49*, 226–232. [[CrossRef](#)] [[PubMed](#)]
3. Grundler, K.; Rotter, R.; Tilley, S.; Pircher, J.; Czermak, T.; Yakac, M.; Gaitzsch, E.; Massberg, S.; Krotz, F.; Sohn, H.Y.; et al. The proteasome regulates collagen-induced platelet aggregation via nuclear-factor-kappa-B (NFkB) activation. *Thromb. Res.* **2016**, *148*, 15–22. [[CrossRef](#)] [[PubMed](#)]
4. Gupta, N.; Li, W.; Willard, B.; Silverstein, R.L.; McIntyre, T.M. Proteasome proteolysis supports stimulated platelet function and thrombosis. *Arterioscler. Thromb. Vasc. Biol.* **2014**, *34*, 160–168. [[CrossRef](#)] [[PubMed](#)]
5. Ferrington, D.A.; Gregerson, D.S. Immunoproteasomes: Structure, function, and antigen presentation. *Prog. Mol. Biol. Transl. Sci.* **2012**, *109*, 75–112. [[PubMed](#)]
6. Hobler, S.C.; Williams, A.; Fischer, D.; Wang, J.J.; Sun, X.; Fischer, J.E.; Monaco, J.J.; Hasselgren, P.O. Activity and expression of the 20S proteasome are increased in skeletal muscle during sepsis. *Am. J. Physiol.* **1999**, *277*, R434–R440. [[CrossRef](#)] [[PubMed](#)]
7. Klaude, M.; Fredriksson, K.; Tjader, I.; Hammarqvist, F.; Ahlman, B.; Rooyackers, O.; Wernerman, J. Proteasome proteolytic activity in skeletal muscle is increased in patients with sepsis. *Clin. Sci. (Lond.)* **2007**, *112*, 499–506. [[CrossRef](#)]
8. Tanaka, K. The proteasome: Overview of structure and functions. *Proc. Jpn. Acad. Ser. B Phys. Biol. Sci.* **2009**, *85*, 12–36. [[CrossRef](#)]
9. Hershko, A.; Ciechanover, A. The ubiquitin system. *Annu. Rev. Biochem.* **1998**, *67*, 425–479. [[CrossRef](#)]
10. Kraemer, B.F.; Weyrich, A.S.; Lindemann, S. Protein degradation systems in platelets. *Thromb. Haemost.* **2013**, *110*, 920–924. [[CrossRef](#)]
11. Avcu, F.; Ural, A.U.; Cetin, T.; Nevruz, O. Effects of bortezomib on platelet aggregation and ATP release in human platelets, in vitro. *Thromb. Res.* **2008**, *121*, 567–571. [[CrossRef](#)] [[PubMed](#)]
12. Kimura, H.; Caturegli, P.; Takahashi, M.; Suzuki, K. New Insights into the Function of the Immunoproteasome in Immune and Nonimmune Cells. *J. Immunol. Res.* **2015**, *2015*, 541984. [[CrossRef](#)] [[PubMed](#)]
13. Seifert, U.; Bialy, L.P.; Ebstein, F.; Bech-Otschir, D.; Voigt, A.; Schroter, F.; Prozorovski, T.; Lange, N.; Steffen, J.; Rieger, M.; et al. Immunoproteasomes preserve protein homeostasis upon interferon-induced oxidative stress. *Cell* **2010**, *142*, 613–624. [[CrossRef](#)] [[PubMed](#)]
14. Chapman, L.M.; Aggrey, A.A.; Field, D.J.; Srivastava, K.; Ture, S.; Yui, K.; Topham, D.J.; Baldwin, W.M., 3rd; Morrell, C.N. Platelets present antigen in the context of MHC class I. *J. Immunol.* **2012**, *189*, 916–923. [[CrossRef](#)]
15. Klockenbusch, C.; Walsh, G.M.; Brown, L.M.; Hoffman, M.D.; Ignatchenko, V.; Kislinger, T.; Kast, J. Global proteome analysis identifies active immunoproteasome subunits in human platelets. *Mol. Cell. Proteomics* **2014**, *13*, 3308–3319. [[CrossRef](#)]
16. Dahlmann, B. Role of proteasomes in disease. *BMC Biochem.* **2007**, *8* (Suppl. 1), S3. [[CrossRef](#)]
17. Kraemer, B.F.; Campbell, R.A.; Schwartz, H.; Franks, Z.G.; Vieira de Abreu, A.; Grundler, K.; Kile, B.T.; Dhakal, B.K.; Rondina, M.T.; Kahr, W.H.; et al. Bacteria differentially induce degradation of Bcl-xL, a survival protein, by human platelets. *Blood* **2012**, *120*, 5014–5020. [[CrossRef](#)]
18. Ristow, L.C.; Welch, R.A. Hemolysin of uropathogenic Escherichia coli: A cloak or a dagger? *Biochim. Biophys. Acta* **2016**, *1858*, 538–545. [[CrossRef](#)]
19. Mulvey, M.A.; Schilling, J.D.; Hultgren, S.J. Establishment of a persistent Escherichia coli reservoir during the acute phase of a bladder infection. *Infect. Immun.* **2001**, *69*, 4572–4579. [[CrossRef](#)]
20. Wiles, T.J.; Dhakal, B.K.; Eto, D.S.; Mulvey, M.A. Inactivation of host Akt/protein kinase B signaling by bacterial pore-forming toxins. *Mol. Biol. Cell* **2008**, *19*, 1427–1438. [[CrossRef](#)]
21. Ostrowska, H.; Ostrowska, J.K.; Worowski, K.; Radziwon, P. Human platelet 20S proteasome: Inhibition of its chymotrypsin-like activity and identification of the proteasome activator PA28. A preliminary report. *Platelets* **2003**, *14*, 151–157. [[CrossRef](#)] [[PubMed](#)]
22. Trugilho, M.R.O.; Hottz, E.D.; Brunoro, G.V.F.; Teixeira-Ferreira, A.; Carvalho, P.C.; Salazar, G.A.; Zimmerman, G.A.; Bozza, F.A.; Bozza, P.T.; Perales, J. Platelet proteome reveals novel pathways of platelet activation and platelet-mediated immunoregulation in dengue. *PLoS Pathog.* **2017**, *13*, e1006385. [[CrossRef](#)] [[PubMed](#)]

23. Weyrich, A.S.; Elstad, M.R.; McEver, R.P.; McIntyre, T.M.; Moore, K.L.; Morrissey, J.H.; Prescott, S.M.; Zimmerman, G.A. Activated platelets signal chemokine synthesis by human monocytes. *J. Clin. Invest.* **1996**, *97*, 1525–1534. [[CrossRef](#)] [[PubMed](#)]
24. Kraemer, B.F.; Campbell, R.A.; Schwertz, H.; Cody, M.J.; Franks, Z.; Tolley, N.D.; Kahr, W.H.; Lindemann, S.; Seizer, P.; Yost, C.C.; et al. Novel anti-bacterial activities of beta-defensin 1 in human platelets: Suppression of pathogen growth and signaling of neutrophil extracellular trap formation. *PLoS Pathog.* **2011**, *7*, e1002355. [[CrossRef](#)] [[PubMed](#)]



© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).



Communication

Heat-Shock Protein 27 (HSPB1) Is Upregulated and Phosphorylated in Human Platelets during ST-Elevation Myocardial Infarction

Bjoern F. Kraemer¹, Hanna Mannell^{2,3}, Tobias Lamkemeyer⁴, Mirita Franz-Wachtel⁵ and Stephan Lindemann^{6,7,8,*}

- ¹ Medizinische Klinik und Poliklinik I, Klinikum der Universität München, Marchioninistrasse 15, 81377 Munich, Germany; bjoern.kraemer@klinik-ebe.de
 - ² Walter Brendel Centre of Experimental Medicine, University Hospital, Ludwig-Maximilians-University, Marchioninistr. 27, 81377 Munich, Germany; Hanna.Mannell@med.uni-muenchen.de
 - ³ Biomedical Center, Ludwig-Maximilians-University, Großhaderner Str. 9, 82152 Planegg, Germany
 - ⁴ Cluster of Excellence Cologne (CEDAD), Mass Spectrometry Facility at the Institute for Genetics, University of Köln, Josef-Stelzmann-Str. 26, 50931 Köln, Germany; tobias_lamkemeyer@yahoo.de
 - ⁵ Proteasome Center Tuebingen, University of Tuebingen, Auf der Morgenstelle 15, 72076 Tübingen, Germany; mirita.franz@uni-tuebingen.de
 - ⁶ FB 20–Medizin, Philipps Universität Marburg, Baldingerstraße, 35032 Marburg, Germany
 - ⁷ Medizinische Klinik II, Klinikum Warburg, Hüffertstr. 50, 34414 Warburg, Germany
 - ⁸ Medizinische Klinik und Poliklinik III, Universitätsklinikum Tübingen, Otfried-Muller-Str. 10, 72076 Tübingen, Germany
- * Correspondence: lindemanns@aol.com; Tel.: +49-5641-915-402

Received: 27 October 2019; Accepted: 25 November 2019; Published: 27 November 2019

Abstract: Heat-shock proteins are a family of proteins which are upregulated in response to stress stimuli including inflammation, oxidative stress, or ischemia. Protective functions of heat-shock proteins have been studied in vascular disease models, and malfunction of heat-shock proteins is associated with vascular disease development. Heat-shock proteins however have not been investigated in human platelets during acute myocardial infarction *ex vivo*. Using two-dimensional electrophoresis and immunoblotting, we observed that heat-shock protein 27 (HSPB1) levels and phosphorylation are significantly increased in platelets of twelve patients with myocardial infarction compared to patients with nonischemic chest pain (6.4 ± 1.0 -fold versus 1.0 ± 0.9 -fold and 5.9 ± 1.8 -fold versus 1.0 ± 0.8 -fold; $p < 0.05$). HSP27 (HSPB1) showed a distinct and characteristic intracellular translocation from the cytoskeletal fraction into the membrane fraction of platelets during acute myocardial infarction that did not occur in the control group. In this study, we could demonstrate for the first time that HSP27 (HSPB1) is upregulated and phosphorylated in human platelets during myocardial infarction on a cellular level *ex vivo* with a characteristic intracellular translocation pattern. This HSP27 (HSPB1) phenotype in platelets could thus represent a measurable stress response in myocardial infarction and potentially other acute ischemic events.

Keywords: platelets; myocardial infarction; HSP27; heat-shock proteins

1. Introduction

Heat-shock proteins (HSPs) are expressed in many cells of the cardiovascular system such as endothelial cells, cardiac muscle cells, monocytes, and platelets. They are upregulated in response to inflammation, oxidative stress, or ischemia [1] and protect cells against extracellular stress factors. In order to protect the cell against stress stimuli, heat-shock proteins function as chaperone proteins, stabilize the cytoskeleton [2], and prevent apoptosis [3–5]. Functions of HSP27 (HSPB1) are modulated

by phosphorylation, although the precise mechanisms and functions of HSP27 regulation are not fully understood. Previous reports imply that phosphorylation of HSP27 appears to reflect cell protective functions [2,3,6] and seems to be the initiating step prior to intracellular translocation enabling HSP27 to interact with the cytoskeleton [7]. Increased phosphorylation of HSP27 has been observed during different modes of platelet activation [8–10] or cardiovascular risk conditions such as diabetes mellitus [11]. HSP27 directly interacts with the actin cytoskeleton and thus downregulates inflammatory cell migration [12]. Other heat-shock proteins such as HSP70 and HSP90 are also actively involved in integrin-mediated platelet adhesion [13], and HSP90 associates with the platelet glycoprotein Ib-IX-V complex [14]. Inactivation of heat-shock proteins has been associated with progression of atherosclerosis and acute vascular events. Increased expression or release of heat-shock proteins further seem to reflect systemic stress responses or ischemia [15]. Oxidized low density lipoprotein (LDL) molecules, for example, induce expression of heat-shock proteins [16], whereas decreased expression of protective HSPs was found in atherosclerotic vessel areas [17,18]. In patients with acute coronary syndrome, increased plasma levels of HSP27 and HSP70 were detected, although the source of HSP27 remained unknown [19–21]. Phosphorylated HSP27 is further released from platelets in patients with diabetes, which is a major risk factor for vascular disease [11].

In this work, we demonstrate for the first time that HSP27 (HSPB1) is upregulated and phosphorylated in platelets of patients with ST-elevation myocardial infarction compared to control patients with nonischemic chest pain. HSP27 in platelets showed a distinct intracellular translocation pattern that was not observed in the control group.

2. Results

2.1. HSP27 Is Upregulated in Human Platelets during Myocardial Infarction

Protein spots that showed differential regulation in platelets during myocardial infarction in two-dimensional gel electrophoresis were sampled and analyzed by mass spectrometry. Figure 1 shows a protein that was consistently upregulated in platelets during myocardial infarction. We identified this protein as heat-shock protein 27 (HSP27) by amino acid sequencing in mass spectrometry. Increased HSP27 levels were observed in twelve patients with myocardial infarction compared to control samples.




Figure 1. Heat-shock protein 27 (HSP27) is upregulated in platelets during myocardial infarction. Two-dimensional electrophoresis shows a protein spot that was upregulated in patients with ST-elevation myocardial infarction (black circles), which was identified as heat-shock protein 27 (HSP27) by mass spectrometry. Images show a representative sample of a patient with myocardial infarction and a matched control patient, which are representative of twelve independent patient pairs. Protein spots are visualized in a 2-fold magnification.

2.2. HSP27 Is Upregulated and Phosphorylated in Human Platelets during Myocardial Infarction

Increased HSP27 levels in platelets of patients with myocardial infarction compared to controls were confirmed by immunoblotting (Figure 2A). Detection of phosphorylated HSP27 (pHSP27) with a

specific antibody also showed increased phosphorylation of HSP27 in myocardial infarction (Figure 2A). Four representative, independent patient pairs are shown that illustrate the increased HSP27 levels and phosphorylation in patients with myocardial infarction. Band densitometry of the Western blot results ($n = 12$ in each group) showed a significant increase of HSP27 protein and HSP27 phosphorylation in platelets from patients with myocardial infarction (MI) compared to controls (6.4 ± 1.0 -fold versus 1.0 ± 0.9 and 5.9 ± 1.8 -fold versus 1.0 ± 0.8 ; $p < 0.05$) (Figure 2B,C).




Figure 2. HSP27 is upregulated and phosphorylated in platelets during myocardial infarction. (A) HSP27 levels and phosphorylation (pHSP27) in four representative patients with nonischemic chest pain (controls, lanes 1–4) and four patients with myocardial infarction (MI) (lanes 5–8) are shown. β -actin served as loading control. (B) Quantitative analysis of HSP27 levels and phosphorylation (C) in the group of patients with myocardial infarction (MI) ($n = 12$) compared to controls ($n = 12$); $* p < 0.05$. Mean HSP27 and phospho-HSP27 to actin ratio for the control group was set as 1. The blot is representative of 12 independent patient pairs.

2.3. HSP27 Levels Are Increased by Thrombin Stimulation

Platelets were stimulated with thrombin (0.5 U/L) for up to two hours, and HSP27 levels were quantified by immunoblotting. After thrombin stimulation, we observed a gradual increase of HSP27 with a peak value at 30 min, which declined with longer stimulation (Figure 3). Heat-shock treatment of platelets (HS, 42 °C, 10 min) induced a robust upregulation of HSP27 and served as a positive control.




Figure 3. Thrombin activation induces upregulation of HSP27 in platelets. Platelets were stimulated with thrombin (0.5 U/mL) for 1, 5, 15, 30, 60, and 120 min, and HSP27 levels were quantified by immunoblotting. Heat activation at 42 °C for 10 min (HS) served as positive control. The immunoblot time course for HSP27 levels is representative of 3 independent experiments.

2.4. HSP27 Translocates from the Cytoskeletal into the Membrane Fraction of Platelets during Myocardial Infarction

Thrombin stimulation of platelets induced an intracellular translocation of HSP27 from the cytoskeletal into the membrane-associated fraction of platelets as illustrated by confocal microscopy

(Figure 4A). To quantify intracellular HSP27 distribution, platelet lysates were separated into the cytoskeletal and plasma membrane fraction by stepwise ultracentrifugation. Figure 4B shows a representative Western blot of a patient pair from the study population. Resting control platelets only showed small HSP27 levels in both the membrane and cytoskeletal fraction. During myocardial infarction, HSP27 was found at increased levels in the membrane fraction, which was not observed in control patients.




Figure 4. HSP27 translocates into the membrane fraction of platelets during myocardial infarction. (A) Confocal microscopy of resting (left) and thrombin activated platelets (0.5 U/L) (right) illustrates the characteristic translocation of HSP27 into the cell membrane of platelets with activation; scale bars represent 5 μm. (B) HSP27 distribution in platelets was further quantified in the membrane and cytoskeletal fraction of platelets from patients with nonischemic chest pain (controls, lanes 1–2) and patients with myocardial infarction (lanes 3–4). The immunoblot is representative of twelve independent patient pairs.

3. Discussion

In the present study, we used two-dimensional electrophoresis to analyze proteomic changes of platelets from patients with acute myocardial infarction and nonischemic chest pain and observed increased phosphorylation (pHSP27) and upregulation of HSP27 in platelets during myocardial infarction. So far, intracellular modulation of HSP27 has not been studied in human platelets during myocardial infarction *ex vivo*.

Patients with ST-elevation myocardial infarction were treated with aspirin immediately after diagnosis, and additional loading with ADP receptor antagonists such as clopidogrel was initiated immediately after blood was drawn. All control patients were also treated with aspirin by the time of blood sampling due to acute onset chest pain and suspected coronary artery disease. Therefore, there was no difference in antiplatelet therapy between groups at the time of blood sampling to make sure that the observed effects can be attributed to the acute vascular event and not to drug-related effects.

Phosphorylation of HSP27 seems to indicate that the protein is in a cell protective, anti-oxidative, and antiapoptotic functional state [2,3,22]. The role of heat-shock proteins in inflammation and its

anti-oxidative capacity is of paramount interest, and animal studies have been conducted to investigate the use of heat-shock proteins in anti-atherosclerotic therapy [8,18,23]. Heat-shock proteins are activated in response to oxidized LDL and mediate an anti-inflammatory response through release of Interleukin 10 (IL-10) [24], through increased levels of glutathione [25], and through inactivation of Nuclear Factor kappa B (NFκB) [26]. Low-density lipoproteins in return induce dephosphorylation of HSP27 [27], which alters anti-oxidative functions of HSP27. Malfunction or downregulation of heat-shock proteins has been associated with vascular disease progression and atherosclerosis [17,18,21]. Furthermore, decreased expression of heat-shock proteins was observed in atherosclerotic vascular areas and vulnerable plaques, which could be a sign of defective local anti-oxidative protection [1,2].

Heat-shock proteins were found in increased concentrations in the plasma of patients with acute myocardial infarction or coronary artery disease although the source remained unknown [8,28,29], and HSP27 levels were increased after global ischemia in coronary sinus blood samples of patients after surgical aortic clamping [15]. Altogether, heat-shock protein expression appears to be increased in response to vascular ischemia and compromised function of heat-shock proteins favors vascular disease development. Release of phosphorylated HSP27 from platelets was found in patients with diabetes who are at great risk for vascular disease [11].

Although we found a robust HSP27 phenotype in platelets during myocardial infarction, it remains to be determined if this is a result of the ischemic process or whether these changes occur prior to the acute event. Further studies suggest that HSP27 also regulates the cytoskeleton and that phosphorylation of HSP27 is a step that immediately precedes the association of HSP27 with the activated cytoskeleton of platelets [7] to stabilize actin fibers.

In this study, we consistently observed a distinct intracellular redistribution pattern from the cytoskeletal into the membrane-associated protein fraction in platelets during myocardial infarction, which was not observed in patients with nonischemic chest pain. Previous observations demonstrate that HSP27 translocates between cellular compartments in platelets after thrombin stimulation [7]. Supporting these observations, we could demonstrate that thrombin induces an upregulation of HSP27 with a peak value at 30 min and a characteristic translocation into the platelet membrane in confocal microscopy. In addition, phosphorylation of HSP27 in platelets has been closely correlated with platelet dense granule secretion [8–10], which is another characteristic of platelet activation. Plasma levels of phosphorylated HSP27 correlated closely with platelet aggregation in patients with diabetes; however, it remains unclear if this finding is functionally connected [11].

Since HSP27 directly associates with the cytoskeleton to execute signaling functions, intracellular translocation of HSP27 during cellular activation or in response to stress signals appears to make sense physiologically.

Others have reported that HSP27 interacts with the cytoskeleton through actin fiber stabilization, which has also been associated with decreased migratory capacity of inflammatory cells and anti-inflammatory functions [12]. We have previously shown that platelets also gain migratory capacity in response to inflammatory signals and that platelets can transmigrate into the vessel wall [30]. The role of heat-shock proteins in this context however is still unknown.

Besides direct regulatory effects on a cytoskeletal level, HSP27 controls translation factors such as eIF4F through binding of eIF4G, which then results in inhibition of translation [31]. Likely HSP27 prevents production of inflammatory proteins as part of an anti-inflammatory response that way. The above findings support the hypothesis and give reason to believe that phosphorylation of HSP27 may be a step that enables HSP27 to execute its cell protective effects.

An elegant study by Liu and colleagues demonstrates increased levels of CCL2 (Chemokine CC-motif ligand 2) in plasma, platelets, and thrombus material of patients with myocardial infarction. Activation of platelets with CCL2 in return resulted in increased phosphorylation of HSP27 and other signaling proteins [32].

It is tempting to speculate that increased phosphorylation of HSP27 in platelets from patients with myocardial infarction could be a sign of an ischemic stress response. We do not know however if

this phenotype is a direct result of the acute vascular events or a consequence of platelet activation. The question whether heat-shock protein phosphorylation is an anti-inflammatory reaction in platelets while unphosphorylated HSP27 may contribute to accelerated aggregation or if it is a passive result of the stress stimulus remains to be determined in future studies. Further research will additionally be necessary to investigate the regulatory mechanisms of HSP27 protein and its phosphorylation during myocardial infarction.

In summary, we observed a significant increase of HSP27 (HSPB1) protein levels and phosphorylation of HSP27 in human platelets during myocardial infarction compared to matched controls with nonischemic chest pain in this study. Supporting previous observations in platelets, a characteristic intracellular translocation of HSP27 from the cytoskeletal into the membrane associated protein fraction was also observed during myocardial infarction. This platelet phenotype was distinctly different in platelets from patients with myocardial infarction compared to controls. It will be interesting to extend the observed characteristics of the HSP27 phenotype in platelets during myocardial infarction to other acute vascular events such as ischemic stroke or peripheral artery disease.

4. Material and Methods

4.1. Study Design

Twelve patients with acute ST-elevation myocardial infarction (mean age 62 years) and obstruction of a proximal left dominant or right coronary artery as well as twelve age-matched control patients with acute onset typical chest pain but rule-out for acute myocardial infarction by electrocardiogram (ECG) and cardiac enzymes were enrolled in the study. Due to suspected coronary artery disease, control patients underwent coronary angiography in which coronary artery disease was ruled out. According to guideline recommendations, patients with ST-elevation myocardial infarction were treated with aspirin immediately after diagnosis. Blood for this study was drawn in the cath lab before other antiplatelet agents such as clopidogrel or tirofiban were administered for acute myocardial infarction. All control patients were also on aspirin treatment by the time of blood sampling. Written informed consent was obtained from all patients. The study was approved by the local ethics committee of the University of Tübingen (No. 264/2007BO2, approved 25 October 2007) in accordance with the Declaration of Helsinki. Blood was drawn on admission after indication for coronary angiography had been established and blood samples were processed immediately.

4.2. Platelet Isolation

Platelets were isolated according to standard protocols in our lab as previously described [30,33]. For some experiments, platelets were stimulated with thrombin (Sigma-Aldrich, Taufkirchen, Germany) 0.1 U/mL for different time points or were heat-activated at 42 °C for 10 min prior to lysis. A total of 1×10^9 platelets was lysed in 100 μ L of CHAPS lysis buffer (8 M Urea, 4% CHAPS, and 2% DTT) and stored for two-dimensional gel analysis and immunoblotting at -20 °C.

4.3. Fractionation of Cytoskeletal and Membrane Proteins of Platelets

Freshly isolated platelets (1×10^9) were lysed in 1 mL Triton X-lysis buffer (containing complete protease inhibitor, Roche, Penzberg, Germany) for 10 min on ice. The pellet containing the cytoskeletal cell fraction was collected after centrifugation at $15,600 \times g$ for 4 min after supernatants had been carefully removed. Supernatants were centrifugated again at $100,000 \times g$, and pellets containing the membrane fraction were collected. Both fractions were resuspended in SDS loading buffer before electrophoresis.

4.4. Two-Dimensional Electrophoresis

Platelets from patients with myocardial infarction and nonischemic chest pain were lysed in 100 μ L of CHAPS lysis buffer (8 M Urea, 4% CHAPS, and 2% DTT) and purified using a 2D clean-up kit (GE Healthcare, Freiburg, Germany) according to the manufacturer's instructions. Comparative 2D

gel analysis of the proteomes was performed as described previously with slight modifications [34,35]. First dimension isoelectric focusing was performed using a Protean IEF Cell focusing unit (BioRad, Hercules, CA, USA) with pH 3–10 NL gel strips (11 cm, GE Healthcare, for some subsequent gels pH 4–7). For the second dimension equilibrated (5.7 M Dithiothreitol and 1.5 M Iodoacetamide) gel strips were applied to 12% polyacrylamide gels. Proteins were stained with Lava purple fluorescent staining (Fluorotechnics, Sydney, Australia). Protein spots of interest were excised manually from the gels, digested with trypsin, and analyzed by LC ESI-MS/MS (Applied Biosystems/MDS Sciex, Darmstadt, Germany) as described previously [35].

4.5. Immunoblotting

Platelets lysed in Laemmli buffer were separated by SDS PAGE gel electrophoresis and probed for HSP27, phospho-HSP27, and β -actin. After protein transfer to a nitrocellulose membrane, membranes were blocked in 5% nonfat milk in Tris-buffered saline with Tween-20 (TBS-T, Sigma-Aldrich, Taufkirchen, Germany) for 1 h. Afterwards, primary monoclonal antibody to HSP27 or phospho-HSP27 (1:1000, Santa Cruz Biotechnologies, Dallas, TX, USA) were added and incubated overnight at 4 °C with constant agitation. Membranes were washed in TBS-T repeatedly, and HRP-conjugated secondary antibody (1:10000) (GE Healthcare, Freiburg, Germany) was added for 1 h at room temperature. After washing, chemiluminescent substrate (ECL reagent, Amersham Biosciences, Munich, Germany) was added for 1–5 min and bands were visualized on plain film. β -Actin served as loading control (1:000, rabbit anti-human β -Actin, Cell Signaling Technology, Dallas, TX, USA). HSP27 and phospho-HSP27 levels were quantified by band densitometry analysis with the help of HSP27- and pHSP27-to-actin ratios. Mean HSP27- and pHSP27-to-actin ratios for the myocardial infarction group were set as 1 and relative increases in HSP27 and pHSP27 levels in the control group were compared accordingly. Relative HSP27 and pHSP27 levels between groups based on actin loading are shown.

4.6. Confocal Microscopy

Immunofluorescence staining was performed as previously described [30]. In brief, washed platelets were allowed to adhere to a fibrinogen surface (50 μ g/mL) on a chamber slide for 20 min and were then fixed with paraformaldehyde (2%) and permeabilized with Triton-X-100 (TX-100, 0.025%). The adherent platelets were washed and blocked with 2% bovine serum albumin for 30 min followed by incubation with the primary antibody for 2 h at room temperature. Primary antibody against HSP27 (Santa Cruz Biotechnologies, Dallas, TX, USA) was used in a 1:100 dilution in TBS with 1% BSA (Bovine Serum Albumine). Slides were then washed and incubated with an Alexa488-linked secondary antibody (Dianova, Hamburg, Germany) for 1 h. Confocal microscopy was performed using a Zeiss LSM 5 EXCITER confocal laser scanning microscope (Carl Zeiss Micro Imaging, Jena, Germany).

4.7. Statistical Analysis

All data are presented as means \pm SEM. Statistical analyses were performed with Sigma Plot 10.0. For comparisons between two groups of normal distributed data, the student's t-test was used. For the comparison of two groups without normal distributed data, a rank-sum test was performed. For multiple comparisons between groups of normal distributed data, the one-way analysis of variance (1-way ANOVA) was used. Differences were considered significant at an error probability level of $p < 0.05$.

5. Conclusions

We observed a significant increase of HSP27 (HSPB1) levels and phosphorylation of HSP27 in platelets during myocardial infarction compared to matched controls with nonischemic chest pain in this study. Supporting previous observations in platelets, a characteristic intracellular translocation of HSP27 from the cytoskeletal into the membrane-associated protein fraction was also observed during myocardial infarction. This platelet phenotype was distinctly different in platelets from patients with

myocardial infarction compared to controls. It will be interesting to extend the observed characteristics of the HSP27 phenotype in platelets during myocardial infarction to other acute vascular events such as ischemic stroke or peripheral artery disease.

Author Contributions: Conceptualization and project administration: S.L.; supervision: S.L.; investigation and data analysis: S.L., T.L., and M.F.-W.; methodology: S.L., T.L., and M.F.-W.; visualization: S.L. and B.F.K.; writing—original draft preparation: S.L., H.M., and B.F.K.

Funding: This work was supported by grants of the Deutsche Forschungsgemeinschaft (DFG:Li849/3-1) to S.L. and the Friedrich-Bauer Stiftung to B.F.K.

Acknowledgments: The authors wish to thank the Proteome Center Tübingen for supporting the 2D gel analysis. The Proteome Center Tübingen was supported by the Ministerium für Wissenschaft und Kunst, Landesregierung Baden-Württemberg.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Madrigal-Matute, J.; Martin-Ventura, J.L.; Blanco-Colio, L.M.; Egido, J.; Michel, J.B.; Meilhac, O. Heat-shock proteins in cardiovascular disease. *Adv. Clin. Chem.* **2011**, *54*, 1–43. [[PubMed](#)]
2. Wettstein, G.; Bellaye, P.S.; Micheau, O.; Bonniaud, P. Small heat shock proteins and the cytoskeleton: An essential interplay for cell integrity? *Int. J. Biochem. Cell Biol.* **2012**, *44*, 1680–1686. [[CrossRef](#)] [[PubMed](#)]
3. Acunzo, J.; Katsogiannou, M.; Rocchi, P. Small heat shock proteins HSP27 (HspB1), alphaB-crystallin (HspB5) and HSP22 (HspB8) as regulators of cell death. *Int. J. Biochem. Cell Biol.* **2012**, *44*, 1622–1631. [[CrossRef](#)] [[PubMed](#)]
4. Gorman, A.M.; Szegezdi, E.; Quigney, D.J.; Samali, A. Hsp27 inhibits 6-hydroxydopamine-induced cytochrome c release and apoptosis in PC12 cells. *Biochem. Biophys. Res. Commun.* **2005**, *327*, 801–810. [[CrossRef](#)]
5. Paul, C.; Simon, S.; Gibert, B.; Viroit, S.; Manero, F.; Arrigo, A.P. Dynamic processes that reflect anti-apoptotic strategies set up by HspB1 (Hsp27). *Exp. Cell Res.* **2010**, *316*, 1535–1552. [[CrossRef](#)]
6. Stetler, R.A.; Gao, Y.; Zhang, L.; Weng, Z.; Zhang, F.; Hu, X.; Wang, S.; Vosler, P.; Cao, G.; Sun, D.; et al. Phosphorylation of HSP27 by protein kinase D is essential for mediating neuroprotection against ischemic neuronal injury. *J. Neurosci.* **2012**, *32*, 2667–2682. [[CrossRef](#)]
7. Zhu, Y.; O'Neill, S.; Saklatvala, J.; Tassi, L.; Mendelsohn, M.E. Phosphorylated HSP27 associates with the activation-dependent cytoskeleton in human platelets. *Blood* **1994**, *84*, 3715–3723. [[CrossRef](#)]
8. Harats, D.; Yacov, N.; Gilburd, B.; Shoenfeld, Y.; George, J. Oral tolerance with heat shock protein 65 attenuates Mycobacterium tuberculosis-induced and high-fat-diet-driven atherosclerotic lesions. *J. Am. Coll. Cardiol.* **2002**, *40*, 1333–1338. [[CrossRef](#)]
9. Bennett, W.F.; Belville, J.S.; Lynch, G. A study of protein phosphorylation in shape change and Ca⁺⁺-dependent serotonin release by blood platelets. *Cell* **1979**, *18*, 1015–1023. [[CrossRef](#)]
10. Lyons, R.M.; Stanford, N.; Majerus, P.W. Thrombin-induced protein phosphorylation in human platelets. *J. Clin. Invest.* **1975**, *56*, 924–936. [[CrossRef](#)]
11. Tokuda, H.; Kuroyanagi, G.; Tsujimoto, M.; Enomoto, Y.; Matsushima-Nishiwaki, R.; Onuma, T.; Kojima, A.; Doi, T.; Tanabe, K.; Akamatsu, S.; et al. Release of Phosphorylated HSP27 (HSPB1) from Platelets Is Accompanied with the Acceleration of Aggregation in Diabetic Patients. *PLoS ONE* **2015**, *10*, e0128977. [[CrossRef](#)] [[PubMed](#)]
12. Rayner, K.; Chen, Y.X.; McNulty, M.; Simard, T.; Zhao, X.; Wells, D.J.; de Belleruche, J.; O'Brien, E.R. Extracellular release of the atheroprotective heat shock protein 27 is mediated by estrogen and competitively inhibits acLDL binding to scavenger receptor-A. *Circ. Res.* **2008**, *103*, 133–141. [[CrossRef](#)] [[PubMed](#)]
13. Gear, A.R.; Simon, C.G.; Polanowska-Grabowska, R. Platelet adhesion to collagen activates a phosphoprotein complex of heat-shock proteins and protein phosphatase 1. *J. Neural Transm.* **1997**, *104*, 1037–1047. [[CrossRef](#)] [[PubMed](#)]
14. Staron, M.; Wu, S.; Hong, F.; Stojanovic, A.; Du, X.; Bona, R.; Liu, B.; Li, Z. Heat-shock protein gp96/grp94 is an essential chaperone for the platelet glycoprotein Ib-IX-V complex. *Blood* **2011**, *117*, 7136–7144. [[CrossRef](#)]

15. Jin, C.; Cleveland, J.C.; Ao, L.; Li, J.; Zeng, Q.; Fullerton, D.A.; Meng, X. Human myocardium releases heat shock protein 27 (HSP27) after global ischemia: The proinflammatory effect of extracellular HSP27 through toll-like receptor (TLR)-2 and TLR4. *Mol. Med.* **2014**, *20*, 280–289. [[CrossRef](#)]
16. Dupont, A.; Chwastyniak, M.; Beseme, O.; Guihot, A.L.; Drobecq, H.; Amouyel, P.; Pinet, F. Application of saturation dye 2D-DIGE proteomics to characterize proteins modulated by oxidized low density lipoprotein treatment of human macrophages. *J. Proteome Res.* **2008**, *7*, 3572–3582. [[CrossRef](#)]
17. Lepedda, A.J.; Cigliano, A.; Cherchi, G.M.; Spirito, R.; Maggioni, M.; Carta, F.; Turrini, F.; Edelstein, C.; Scanu, A.M.; Formano, M. A proteomic approach to differentiate histologically classified stable and unstable plaques from human carotid arteries. *Atherosclerosis* **2009**, *203*, 112–118. [[CrossRef](#)]
18. Martin-Ventura, J.L.; Duran, M.C.; Blanco-Colio, L.M.; Meilhac, O.; Leclercq, A.; Michel, J.B.; Jensen, O.N.; Hernandez-Merida, S.; Tunon, J.; Vivanco, F.; et al. Identification by a differential proteomic approach of heat shock protein 27 as a potential marker of atherosclerosis. *Circulation* **2004**, *110*, 2216–2219. [[CrossRef](#)]
19. Dybdahl, B.; Slordahl, S.A.; Waage, A.; Kierulf, P.; Espevik, T.; Sundan, A. Myocardial ischaemia and the inflammatory response: Release of heat shock protein 70 after myocardial infarction. *Heart* **2005**, *91*, 299–304. [[CrossRef](#)]
20. Ghayour-Mobarhan, M.; Rahsepar, A.A.; Tavallaie, S.; Rahsepar, S.; Ferns, G.A. The potential role of heat shock proteins in cardiovascular disease: Evidence from In Vitro and in vivo studies. *Adv. Clin. Chem.* **2009**, *48*, 27–72.
21. Park, H.K.; Park, E.C.; Bae, S.W.; Park, M.Y.; Kim, S.W.; Yoo, H.S.; Tudev, M.; Ko, Y.H.; Choi, Y.H.; Kim, S.; et al. Expression of heat shock protein 27 in human atherosclerotic plaques and increased plasma level of heat shock protein 27 in patients with acute coronary syndrome. *Circulation* **2006**, *114*, 886–893. [[CrossRef](#)] [[PubMed](#)]
22. Gawad, A.; Ptak-Belowska, A.; Brzozowski, T.; Pawlik, W.W. Monocytes and vascular endothelial cells apoptosis. Role of p-HSP27. *J. Physiol. Pharmacol.* **2009**, *60*, 55–61. [[PubMed](#)]
23. Jun, L.; Jie, L.; Dongping, Y.; Xin, Y.; Taiming, L.; Rongyue, C.; Jie, W.; Jingjing, L. Effects of nasal immunization of multi-target preventive vaccines on atherosclerosis. *Vaccine* **2012**, *30*, 1029–1037. [[CrossRef](#)] [[PubMed](#)]
24. De, A.K.; Kodys, K.M.; Yeh, B.S.; Miller-Graziano, C. Exaggerated human monocyte IL-10 concomitant to minimal TNF- α induction by heat-shock protein 27 (Hsp27) suggests Hsp27 is primarily an antiinflammatory stimulus. *J. Immunol.* **2000**, *165*, 3951–3958. [[CrossRef](#)] [[PubMed](#)]
25. Preville, X.; Salvemini, F.; Giraud, S.; Chaufour, S.; Paul, C.; Stepien, G.; Ursini, M.V.; Arrigo, A.P. Mammalian small stress proteins protect against oxidative stress through their ability to increase glucose-6-phosphate dehydrogenase activity and by maintaining optimal cellular detoxifying machinery. *Exp. Cell Res.* **1999**, *247*, 61–78. [[CrossRef](#)] [[PubMed](#)]
26. Rinaldi, B.; Romagnoli, P.; Bacci, S.; Carnuccio, R.; Maiuri, M.C.; Donniacuo, M.; Capuano, A.; Rossi, F.; Filippelli, A. Inflammatory events in a vascular remodeling model induced by surgical injury to the rat carotid artery. *Br. J. Pharmacol.* **2006**, *147*, 175–182. [[CrossRef](#)]
27. Garcia-Arguinzonis, M.; Padro, T.; Lugano, R.; Llorente-Cortes, V.; Badimon, L. Low-density lipoproteins induce heat shock protein 27 dephosphorylation, oligomerization, and subcellular relocalization in human vascular smooth muscle cells. *Arterioscler. Thromb. Vasc. Biol.* **2010**, *30*, 1212–1219. [[CrossRef](#)]
28. Satoh, M.; Shimoda, Y.; Akatsu, T.; Ishikawa, Y.; Minami, Y.; Nakamura, M. Elevated circulating levels of heat shock protein 70 are related to systemic inflammatory reaction through monocyte Toll signal in patients with heart failure after acute myocardial infarction. *Eur. J. Heart Fail.* **2006**, *8*, 810–815. [[CrossRef](#)]
29. Zhang, X.; He, M.; Cheng, L.; Chen, Y.; Zhou, L.; Zeng, H.; Pockley, A.G.; Hu, F.B.; Wu, T. Elevated heat shock protein 60 levels are associated with higher risk of coronary heart disease in Chinese. *Circulation* **2008**, *118*, 2687–2693. [[CrossRef](#)]
30. Kraemer, B.F.; Borst, O.; Gehring, E.M.; Schoenberger, T.; Urban, B.; Ninci, E.; Seizer, P.; Schmidt, C.; Bigalke, B.; Koch, M.; et al. PI3 kinase-dependent stimulation of platelet migration by stromal cell-derived factor 1 (SDF-1). *J. Mol. Med.* **2010**, *88*, 1277–1288. [[CrossRef](#)]
31. Cuesta, R.; Laroia, G.; Schneider, R.J. Chaperone hsp27 inhibits translation during heat shock by binding eIF4G and facilitating dissociation of cap-initiation complexes. *Genes Dev.* **2000**, *14*, 1460–1470. [[PubMed](#)]
32. Liu, D.; Cao, Y.; Zhang, X.; Peng, C.; Tian, X.; Yan, C.; Liu, Y.; Liu, M.; Han, Y. Chemokine CC-motif ligand 2 participates in platelet function and arterial thrombosis by regulating PKC α -P38MAPK-HSP27 pathway. *Biochim. Biophys. Acta Mol. Basis Dis.* **2018**, *1864*, 2901–2912. [[CrossRef](#)] [[PubMed](#)]

33. Weyrich, A.S.; Elstad, M.R.; McEver, R.P.; McIntyre, T.M.; Moore, K.L.; Morrissey, J.H.; Prescott, S.M.; Zimmerman, G.A. Activated platelets signal chemokine synthesis by human monocytes. *J. Clin. Invest.* **1996**, *97*, 1525–1534. [[CrossRef](#)] [[PubMed](#)]
34. Tiffert, Y.; Franz-Wachtel, M.; Fladerer, C.; Nordheim, A.; Reuther, J.; Wohlleben, W.; Mast, Y. Proteomic analysis of the GlnR-mediated response to nitrogen limitation in *Streptomyces coelicolor* M145. *Appl. Microbiol. Biotechnol.* **2011**, *89*, 1149–1159. [[CrossRef](#)]
35. Hala, M.; Cole, R.; Synek, L.; Drdova, E.; Pecenkova, T.; Nordheim, A.; Lamkemeyer, T.; Madlung, J.; Hochholdinger, F.; Fowler, J.E.; et al. An exocyst complex functions in plant cell growth in *Arabidopsis* and tobacco. *Plant Cell* **2008**, *20*, 1330–1345. [[CrossRef](#)]



© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).



Communication

The Integrin Activating Protein Kindlin-3 Is Cleaved in Human Platelets during ST-Elevation Myocardial Infarction

Bjoern F. Kraemer¹, Tobias Lamkemeyer², Mirita Franz-Wachtel³ and Stephan Lindemann^{4,5,6,*}

¹ Medizinische Klinik und Poliklinik I, Klinikum der Universität München, Marchioninistrasse 15, 81377 Munich, Germany; bjoern.kraemer@klinik-ebe.de

² Cluster of Excellence (CECAD) Cologne, Mass Spectrometry Facility at the Institute for Genetics, University of Köln, Josef-Stelzmann-Str. 26, 50931 Köln, Germany; tobias_lamkemeyer@yahoo.de

³ Proteasome Center Tuebingen, University of Tuebingen, Auf der Morgenstelle 15, 72076 Tübingen, Germany; mirita.franz@uni-tuebingen.de

⁴ FB 20–Medizin, Philipps Universität Marburg, Baldingerstraße, 35032 Marburg, Germany

⁵ Medizinische Klinik II, Klinikum Warburg, Hüffertstr. 50, 34414 Warburg, Germany

⁶ Medizinische Klinik und Poliklinik III, Universitätsklinikum Tübingen, Otfried-Müller-Str. 10, 72076 Tübingen, Germany

* Correspondence: lindemanns@aol.com

Received: 27 October 2019; Accepted: 4 December 2019; Published: 6 December 2019

Abstract: Kindlins are important proteins for integrin signaling and regulation of the cytoskeleton, but we know little about their precise function and regulation in platelets during acute ischemic events. In this work, we investigated kindlin-3 protein levels in platelets isolated from patients with ST-elevation myocardial infarction (STEMI) compared to patients with non-ischemic chest pain. Platelets from twelve patients with STEMI and twelve patients with non-ischemic chest pain were isolated and analyzed for kindlin-3 protein levels and intracellular localization by immunoblotting and two-dimensional gel electrophoresis. Platelet proteome analysis by two-dimensional gel electrophoresis and protein sequencing identified kindlin-3 as a protein that is cleaved in platelets from patients with myocardial infarction. Kindlin-3 full-length protein was significantly decreased in patients with STEMI compared to patients with non-ischemic chest pain (1.0 ± 0.2 versus 0.28 ± 0.2 , $p < 0.05$) by immunoblotting. Kindlin-3 showed a differential distribution and was primarily cleaved in the cytosolic and membrane compartment of platelets in myocardial infarction. Platelet activation with thrombin alone did not affect kindlin-3 protein levels. The present study demonstrates that kindlin-3 protein levels become significantly reduced in platelets of patients with myocardial infarction compared to controls. The results suggest that kindlin-3 cleavage in platelets is associated with the ischemic event of myocardial infarction.

Keywords: platelets; proteolysis; kindlin-3; myocardial infarction

1. Introduction

Kindlins are a group of intracellular proteins that have a central role in cellular adhesion and cell-matrix interactions. Three kindlin family members, kindlin-1, -2 and -3 have been identified which differ in tissue distribution [1]. Kindlins have emerged as elementary components for integrin signaling and activation and interact with cytoskeletal proteins like talin [2]. Kindlins also interact directly with $\beta 1$, $\beta 2$ and $\beta 3$ integrins and contain FERM (Fermitin family) domains for interaction with extracellular matrix [3]. Especially kindlin-3 is expressed in hematopoietic cells, primarily platelets and megakaryocytes, and a lack of kindlin-3 expression results in compromised hemostasis and inflammation [4,5]. Kindlin-3 directly interacts with $\alpha(\text{IIb})\beta(3)$ -receptors during platelet

aggregation [6], independently of talin [7]. Inherited kindlin-3 deficiency thus results in impaired platelet aggregation and bleeding, as well as osteopetrosis and leukocyte related immune deficiency due to impaired cell adhesion [4,7]. Uncontrolled bleeding in kindlin-3 deficient mice was due to impaired platelet integrin activation and led to early mortality within a few weeks [6,8]. Mutations or defects in interaction partners of kindlin induced a similar, yet less extreme disease phenotype as the kindlin defect. Glanzmann's thrombasthenia, which is caused by direct mutations of alpha(IIb)beta(3)-integrins, is also characterized by prolonged bleeding. Likewise, mutations of kindlin-3 were identified as the cause of leukocyte adhesion defects [9]. During myocardial infarction platelet activation and aggregation are rapidly initiated and promote obstruction of diseased blood vessels [10,11]. Anti-aggregatory therapy that targets activation and integrin receptors of platelets has thus become a mainstay of therapy for myocardial infarction and has markedly improved patient survival [12,13]. Numerous markers of platelet activation have been studied in myocardial infarction, some of which correlate with disease severity [14–17]. Cleavage of kindlin-3 has been shown to be a mechanism to regulate cell shape changes in platelets [18]. We and others have previously demonstrated that cytoskeletal proteins such as talin-1 are regulated by proteolytic cleavage during platelet aggregation and shape change [19,20]. Although the central role of kindlins for integrin activation and platelet aggregate formation is well studied, kindlin protein levels in human platelets during myocardial infarction have not been investigated. Two-dimensional electrophoresis of platelet lysates from patients with myocardial infarction revealed increased kindlin-3 cleavage in patients with myocardial infarction. In contrast, kindlin-3 levels were unaffected in matched control platelets. Western blot analysis confirmed a significant decrease of full-length kindlin-3 protein and altered intracellular distribution of kindlin-3 in platelets of the myocardial infarction group. We provide the first evidence that kindlin-3 undergoes quantitative changes and processing, with distinct intracellular distribution in platelets during myocardial infarction, that could provide the basis for future investigations of this platelet phenotype in other ischemic conditions.

2. Results

2.1. The Proteome of Platelets from Patients with Myocardial Infarction Shows Distinct Changes

To identify protein targets that are differentially regulated in platelets during myocardial infarction, platelet lysates were analyzed by two-dimensional gel electrophoresis. Figure 1 shows platelet protein expression in platelets by 2D-gel electrophoresis from patients with myocardial infarction compared to matched controls with non-ischemic chest pain. Visibly few proteins are differentially regulated and show increases or decreases in protein quantity in myocardial infarction in comparison to patients with non-ischemic chest pain. Representative gels from a patient with ST-elevation myocardial infarction (right) and a control patient with non-ischemic chest pain (left) are shown. The region where differential protein regulation is visible and where kindlin-3 is located is marked by boxes. Clinical characteristics of control patients and patients with myocardial infarction are shown in Table 1.




Figure 1. The platelet proteome displays distinct changes during myocardial infarction. (A) Two-dimensional gel electrophoresis of the platelet proteome demonstrates few distinct changes of protein expression during myocardial infarction (right) compared to platelets from patients with non-ischemic chest pain and without coronary artery disease (left). The area of differential protein regulation and identification of kindlin-3 is marked by boxes. The gel is representative of twelve independent patient pairs. The Y-axis indicates the protein size marker (kDa), the x-axis shows the pH range (PI). (B) Quantitative analysis of kindlin-3 cleavage by 2D-gel analysis in control patients (Co, $n = 12$) versus patients with myocardial infarction (MI, $n = 12$). Level of cleaved kindlin-3 in control patients was set as 1 and relative increase in protein cleavage is expressed as fold-increase versus control. * $p < 0.05$.

2.2. Kindlin-3 Is Cleaved in Platelets during Myocardial Infarction

Protein spots of interest that were differentially regulated were sampled and analyzed by mass spectrometry. Figure 2A shows an example of new protein spots that appear in platelets from patients with myocardial infarction in two-dimensional gel electrophoresis. The double spot was identified as a cleavage product of kindlin-3 by mass spectrometry and was therefore found in the ~30 kDa region instead of the expected 75 kDa molecular weight region. Representative two-dimensional electrophoresis gels from two patients (I and II) with ST-elevation myocardial infarction and matched controls with non-ischemic chest pain are shown in Figure 2A. Western blot analysis using a specific anti-kindlin-3 antibody for full-length protein (75 kDa) showed a significant decrease of kindlin-3 protein in platelets from patients with myocardial infarction (1.0 ± 0.2 vs. 0.28 ± 0.2 , * $p < 0.05$) (Figure 2B).




Figure 2. Kindlin-3 is cleaved in platelets during myocardial infarction. **(A)** Protein spots that represent fragments of kindlin-3 according to mass spectrometry appear in patients with ST-elevation myocardial infarction, whereas they are not detectable in patients with non-ischemic chest pain (red circles). Images show sample pairs of two patients with myocardial infarction and control (I and II) which are representative of twelve independent patient pairs. **(B)** Proteolytic processing of full-length kindlin-3 in platelets from patients with myocardial infarction (MI) was confirmed by Western blot. Quantitative analysis of kindlin-3 protein in the group of patients with myocardial infarction ($n = 12$) showed a significant decrease of full-length kindlin-3 protein levels compared to controls ($n = 12$); * $p < 0.05$. Mean kindlin-3 to actin ratio for the MI group was set as 1 and relative decrease in kindlin-3 protein in the control group was compared accordingly. A representative platelet sample pair from a patient with myocardial infarction (MI) illustrates the decreased full-length kindlin-3 protein (right lane) compared to a patient with non-ischemic chest pain (Co, left lane).

2.3. Kindlin-3 Cleavage Is not Induced by Thrombin Stimulation

In order to determine if cleavage of kindlin-3 in platelets during myocardial infarction was a result of thrombin activation, platelets were activated with thrombin (0.1 U/mL) for 1, 5, 10, 15, 30, 60 and 90 min. No quantitative differences in kindlin-3 protein were detectable with thrombin activation in repeated experiments ($n = 4$) (Figure 3A,B).




Figure 3. Cleavage of kindlin-3 is not a result of thrombin activation (A) Platelets (3×10^7) were stimulated with thrombin (0.1 U/mL) for 1, 5, 10, 15, 30, 60 and 90 min and kindlin-3 levels were quantified by immunoblotting. Thrombin activation did not induce kindlin-3 degradation in platelets. β -actin served as loading control. The blot is representative of 4 independent experiments. (B) Quantitative analysis of kindlin-3 protein levels during thrombin stimulation. Mean kindlin-3 protein level of controls (Co) was set as 1 and protein levels after thrombin stimulation at time points 1, 5, 10, 15, 30, 60 and 90 min were compared (x-fold expression) and showed no differences.

2.4. Kindlin-3 Is Located in the Cytoskeleton, the Plasma Membrane, and the Soluble Fraction of Human Platelets and Becomes Redistributed during Myocardial Infarction

To quantify intracellular kindlin-3 distribution, platelet lysates of patients with myocardial infarction and controls were separated into the soluble, cytoskeletal, and plasma membrane fraction by step-wise ultracentrifugation. Western blot analysis of the protein fractions revealed that proteolytic processing of kindlin-3 primarily occurred in those parts of the platelet that are associated with the soluble and cytoskeletal fractions isolated by ultracentrifugation, whereas the platelet structures that are associated with the membrane fraction showed no quantitative differences between the control and myocardial infarction groups (Figure 4A,B). Platelets from control patients showed a widely homogenous distribution of kindlin-3 in all cell fractions. Figure 4 shows a representative Western blot of twelve sample pairs.




Figure 4. Intracellular distribution of kindlin-3 changes during myocardial infarction (A) Kindlin-3 protein levels in parts of the platelet that are associated with the soluble, cytoskeletal, and membrane fraction of platelets were analyzed by Western blot. The soluble protein fraction represents the cytoplasmic proteins. Lanes 1 to 3 represent cellular fractions of control platelets, lanes 4–6 fractions of

platelets from myocardial infarction. Full-length kindlin-3 is reduced in the soluble and cytoskeletal fraction of platelets during myocardial infarction (lanes 4 and 5) whereas the membrane fraction is unaffected (lane 6). The blot is representative of twelve independent patient pairs. **(B)** Quantitative analysis of kindlin-3 protein levels in patients with myocardial infarction (MI) compared to control patients in the soluble fraction (SF), cytoskeletal fraction (CF), and membrane fraction (MF) of platelets. Mean kindlin-3 level of controls (Co) was set as 1 and quantitative changes are shown as x-fold expression versus control (x-fold).

2.5. Patient Characteristics

We have summarized clinical characteristics of control patients and patients with ST-elevation myocardial infarction in Table 1.

Table 1. Clinical characteristics of 12 patients with ST-elevation myocardial infarction (STEMI) and 12 age matched control patients are shown. Cardiovascular risk factors such as arterial hypertension, diabetes mellitus, and smoking, as well as renal function are listed. Numbers indicate *n* of 12 with positive baseline characteristics in each group. Impaired renal function was defined as an elevated serum creatine level above 1.2 mg/dL.

| | Control Group (<i>n</i> = 12) | Myocardial Infarction (STEMI) (<i>n</i> = 12) |
|-------------------------------------|--------------------------------|--|
| Age (years, mean ± SEM) | 65 ± 3 | 67 ± 4 |
| Arterial Hypertension; <i>n</i> = | 6 | 7 |
| Diabetes mellitus; <i>n</i> = | 3 | 2 |
| Smoking; <i>n</i> = | 6 | 7 |
| Impaired renal function; <i>n</i> = | 2 | 2 |

3. Discussion

In the present study, we analyzed protein levels of kindlin-3 in platelets from patients with acute myocardial infarction which we compared to matched control patients with non-ischemic chest pain. So far, levels of kindlin-3 in platelets have not been studied in acute myocardial infarction.

We demonstrated for the first time that protein levels of full-length kindlin-3 were significantly reduced in platelets of patients with acute myocardial infarction compared to patients with non-ischemic chest pain. We observed that kindlin-3 is cleaved to a 30 kDa fragment in platelets during myocardial infarction. There was no difference in antiplatelet therapy between groups by the time of blood sampling as control patients had all been treated with aspirin due to suspected coronary artery disease, and additional antiplatelet therapy in myocardial infarction patients was administered immediately after blood sampling to make sure that the observed effects could be attributed to the acute vascular event and not to drug-related effects.

Kindlin-3, which has become an interesting target to modulate integrin activation, could represent a so far unidentified platelet protein that is associated with acute vascular events. Interestingly, previous work found increased kindlin-3 expression in unstable plaque tissue prone to rupture, likely due to accumulation of platelets and monocytes [21]. Kindlins are a group of proteins that have been shown to be critically involved in platelet integrin activation, platelet aggregation, and interaction with extracellular matrix proteins. Therefore, defects in kindlin expression or function result in adhesion defects of tissue and blood cells. As a consequence, skin blistering, defective leukocyte adhesion, and impaired platelet aggregation are attributable to impaired kindlin function [4,22,23]. Especially in platelets, which perform elementary functions in hemostasis, defects in kindlin-3 and subsequently impaired integrin alpha(IIb)beta(3) activation have been observed [7]. Acute myocardial infarction is characterized by excessive platelet activation and aggregation which has become a central target for therapy. Several markers of platelet activation have been studied in platelets during acute myocardial

infarction, including adhesion receptors such as GPVI [13] and pro-inflammatory mediators like SDF-1 [17]. In this context, it seems plausible that kindlin-3, which is directly connected to platelet integrin activity, shows measurable changes in acute myocardial infarction. Initially, we analyzed the platelet proteome during myocardial infarction and control platelets by two-dimensional gel electrophoresis, which led to the identification of new protein spots in the myocardial infarction group. Protein sequencing by mass spectrometry identified the new protein fragments as kindlin-3 cleavage products, which was initially a surprise as the proteins were found in the ~30 kDa region instead of the expected 75 kDa molecular weight area. Cleavage of other structural proteins such as filamin A and talin-1 has been shown to be a regulatory mechanism for platelet shape change during platelet activation [19,20]. A study by Zhao and colleagues reveals that cleavage of kindlin-3 by calpain controls the dynamics of integrin adhesion complexes [18]. Therefore, decreased full-length kindlin-3 levels and detection of kindlin-3 cleavage products in platelets in the process of myocardial infarction makes perfect sense. Cleavage products were not detected by immunoblotting because the target epitope that is recognized by the detection antibody was no longer intact, but cleavage products of kindlin-3 were consistently detected on 2D gels. Microparticle release is also considered to be a result of degradation or cleavage of structural proteins (e.g., talin) by intracellular proteases like calpain, as shown in hepatocytes [24]. Platelet microparticle release is also mediated through calpain activation, although the precise mechanisms are not fully understood [25]. In previous work, we were able to identify protein degradation of the antiapoptotic protein Bcl-xL by calpain as a mechanism for programmed cell death [26]. It appears likely that more platelet functions and processes are regulated through selective proteolysis of structural or regulatory proteins. Interestingly, our data show that cleavage of kindlin-3 occurs in selected protein fractions, which likely depends on the intracellular distribution of proteases that cleave kindlin-3 protein. We observed proteolytic processing of kindlin-3 preferentially in the soluble and cytoskeletal fraction of platelets from patients with myocardial infarction whereas the membrane fraction was unaffected. Kindlin-3 protein levels were further unaffected by thrombin stimulation which underscores that the underlying mechanism is not purely activation-dependent. It thus seems likely that the intracellular localization of kindlins may further change based on cellular function and receptor activation. Previous work has also speculated that kindlins enable cells to rearrange their cytoskeleton and to enable migration [27,28]. Especially kindlin-3 is present in podosomes and integrin adhesion sites in migrating cells [1,29]. Interestingly, proteolytic cleavage of kindlin-3 by calpain was also identified as one of the processes that control the adhesion dynamics that enable leukocytes to migrate [18]. We have previously been able to demonstrate the capacity of platelets to migrate along an SDF-1 gradient and to transmigrate into inflamed vessel walls [30,31]. This involves activation of cytoskeletal regulators and rearrangement of the cytoskeleton for focal adhesion formation [32]. It thus seems possible that kindlins may play a role in both platelet adhesion and platelet migration. Overall, it remains to be determined if cleavage of kindlin-3 in platelets during acute myocardial infarction is a result of the disease process itself or if its differential regulation during platelet aggregation affects acute vascular events. Mutations of kindlin-3 can result in antithrombotic effects as previously described [7], which may also occur with differential proteolytic cleavage of kindlin-3. In this work, we demonstrate for the first time that kindlin-3, which is paramount for integrin activation, is cleaved in platelets during myocardial infarction following a reproducible intracellular distribution. Due to its physiological role in cytoskeletal regulation and its distinct protein phenotype during myocardial infarction in platelets, kindlin-3 could be an interesting platelet marker in vascular ischemia. Whether this phenotype is prothrombotic or whether it is a stress response to the ischemic environment remains to be determined. Further research will be necessary to elucidate the complex mechanisms of kindlin functions in platelets *in vitro* and under acute ischemic conditions. The observed platelet phenotype described in this study lays the groundwork for future investigations and it will be interesting to also extend the observed association of kindlin-3 cleavage in myocardial infarction to other acute ischemic conditions such as stroke or peripheral artery disease.

4. Material and Methods

4.1. Study Design

Twelve patients with acute ST-elevation myocardial infarction (STEMI) and obstruction of a proximal left dominant or right coronary artery as well as twelve age-matched control patients which presented with typical chest pain but showed no coronary artery disease in coronary angiography were enrolled in the study. Myocardial infarction was eventually ruled out by electrocardiogram and serially negative cardiac enzymes in control patients. Patients with ST-elevation myocardial infarction were treated with aspirin immediately after diagnosis. Blood for this study was drawn in the cath lab before other antiplatelet agents such as clopidogrel or tirofiban were administered for acute myocardial infarction. All control patients were also on aspirin treatment by the time of blood sampling due to acute onset chest pain and suspected coronary artery disease. Clinical characteristics of patients are shown in Table 1. Written informed consent was obtained from all patients. The study was approved by the local ethics committee of the University of Tübingen (No. 264/2007BO2, approved 25 October 2007) in accordance with the Declaration of Helsinki. Blood was drawn on admission after indication for coronary angiography had been established and blood samples were processed immediately.

4.2. Platelet Isolation

Platelets were isolated according to standard protocols in our lab as previously described [20,30,33]. In brief, whole blood was drawn directly into plastic tubes containing sodium citrate (1:10). After centrifugation of the whole blood without brake at $340\times g$ for 15 min at room temperature (RT), the platelet-rich plasma (PRP) was carefully removed. Platelets in PRP were pelleted at $600\times g$ for 10 min at RT and carefully resuspended in warm M199 culture media. For some experiments, platelets (1×10^9) were stimulated with thrombin (Sigma-Aldrich, Taufkirchen, Germany) 0.1 U/mL for 1, 5, 10, 15, 30, 60 and 90 min prior to lysis and at $-20\text{ }^{\circ}\text{C}$.

4.3. Fractionation of Soluble, Cytoskeletal and Platelet Membrane Proteins

Freshly isolated platelets (1×10^9) were lysed in 1 mL Triton X-lysis buffer (containing Complete protease inhibitor, Roche, Penzberg, Germany) for 10 min on ice. The pellets containing the cytoskeletal cell fraction were collected after centrifugation at $15,600\times g$ for 4 min, after the supernatants had been carefully removed. Supernatants were centrifuged again at $100,000\times g$ and pellets containing the membrane fraction were collected. Soluble proteins were concentrated from the supernatant by acetone precipitation. All fractions were resuspended in SDS loading buffer before electrophoresis and immunoblotting was performed as described below.

4.4. Two-Dimensional Gel Electrophoresis

Platelets from patients with myocardial infarction and non-ischemic chest pain were lysed in 100 μL of CHAPS lysis buffer (8M Urea, 4% CHAPS, 2% DTT) and purified using a 2D Clean-up kit (GE Healthcare, Freiburg, Germany) according to the manufacturer's instructions. Comparative 2D gel analysis of the proteomes was performed as described previously with slight modifications [34]. First dimension isoelectric focusing was performed using a Protean IEF Cell focusing unit (BioRad, Hercules, CA, USA) with pH 3–10NL gel strips (11 cm, GE Healthcare, for some subsequent gels pH 4–7). For the second dimension, equilibrated (5.7M Dithiothreitol and 1.5M Iodoacetamide) gel strips were applied to 12% polyacrylamide gels. Proteins were stained with Lava purple fluorescent staining (Fluorotechnics, Sydney, Australia). Protein spots of interest were excised manually from the gels, digested with trypsin and analyzed by LC ESI-MS/MS as described previously [35]. Peptide sequence analysis by mass spectrometry of the isolated protein spots resulted in the identification of the differential cleavage of kindlin-3 in the myocardial infarction group.

4.5. Immunoblotting

Platelets (1×10^9) lysed in Laemmli buffer were separated by SDS PAGE and stained for kindlin-3. After protein transfer to a nitrocellulose membrane, membranes were blocked in 5% nonfat milk in TBS-T for 1 h. Afterward, primary antibody to full-length kindlin-3 (1:100 in 3% nonfat milk/TBS-T, Abcam, Cambridge, UK) was added and incubated overnight at 4 °C with constant agitation. Membranes were washed in TBS-T repeatedly and HRP-conjugated secondary antibody (1:10,000, GE Healthcare, Freiburg, Germany) was added for 1 h at room temperature. After washing, chemiluminescent substrate (ECL reagent, Amersham Biosciences, Munich, Germany) was added for 1–5 min and bands were visualized on plain film. β -Actin served as loading control (rabbit anti-human β -Actin, Cell Signaling Technology, Dallas, TX, USA). Kindlin-3 protein levels were quantified by band densitometry analysis with the help of a kindlin-3 to actin ratio.

4.6. Statistical Analysis

All data are presented as means \pm SEM. Statistical analyses were performed with Sigma Plot 10.0. For comparisons between two groups of normally distributed data, the student's t-test was used. For the comparison of two groups without normally distributed data, a rank-sum test was performed. For multiple comparisons between groups of normally distributed data, the one-way analysis of variance (one-way ANOVA) was used. Differences were considered significant at an error probability level of $p < 0.05$.

Author Contributions: Conceptualization and project administration: S.L.; supervision: S.L.; investigation and data analysis: S.L., T.L., M.F.-W., B.F.K.; methodology: S.L., T.L.; visualization: S.L., B.F.K.; writing—original draft preparation: S.L., B.F.K.

Funding: This work was supported by grants of the Deutsche Forschungsgemeinschaft to S.L. (DFG:Li849/3-1).

Acknowledgments: The authors wish to thank the Proteome Center Tübingen, Tübingen, Germany for supporting the 2D gel analysis. The Proteome Center Tübingen was supported by the Ministerium für Wissenschaft und Kunst, Landesregierung Baden-Württemberg.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

1. Ussar, S.; Wang, H.V.; Linder, S.; Fassler, R.; Moser, M. The Kindlins: Subcellular localization and expression during murine development. *Exp. Cell Res.* **2006**, *312*, 3142–3151. [[CrossRef](#)] [[PubMed](#)]
2. Tadokoro, S.; Shattil, S.J.; Eto, K.; Tai, V.; Liddington, R.C.; de Pereda, J.M.; Ginsberg, M.H.; Calderwood, D.A. Talin binding to integrin beta tails: A final common step in integrin activation. *Science* **2003**, *302*, 103–106. [[CrossRef](#)] [[PubMed](#)]
3. Malinin, N.L.; Plow, E.F.; Byzova, T.V. Kindlins in FERM adhesion. *Blood* **2010**, *115*, 4011–4017. [[CrossRef](#)] [[PubMed](#)]
4. Moser, M.; Bauer, M.; Schmid, S.; Ruppert, R.; Schmidt, S.; Sixt, M.; Wang, H.V.; Sperandio, M.; Fassler, R. Kindlin-3 is required for beta2 integrin-mediated leukocyte adhesion to endothelial cells. *Nat. Med.* **2009**, *15*, 300–305. [[CrossRef](#)]
5. Svensson, L.; Howarth, K.; McDowall, A.; Patzak, I.; Evans, R.; Ussar, S.; Moser, M.; Metin, A.; Fried, M.; Tomlinson, I.; et al. Leukocyte adhesion deficiency-III is caused by mutations in KINDLIN3 affecting integrin activation. *Nat. Med.* **2009**, *15*, 306–312. [[CrossRef](#)]
6. Xu, Z.; Chen, X.; Zhi, H.; Gao, J.; Bialkowska, K.; Byzova, T.V.; Pluskota, E.; White, G.C.; Liu, J.; Plow, E.F.; et al. Direct interaction of kindlin-3 with integrin α IIb β 3 in platelets is required for supporting arterial thrombosis in mice. *Arterioscler. Thromb. Vasc. Biol.* **2014**, *34*, 1961–1967. [[CrossRef](#)]
7. Moser, M.; Nieswandt, B.; Ussar, S.; Pozgajova, M.; Fassler, R. Kindlin-3 is essential for integrin activation and platelet aggregation. *Nat. Med.* **2008**, *14*, 325–330. [[CrossRef](#)]

8. Kruger, M.; Moser, M.; Ussar, S.; Thievensen, I.; Lubner, C.A.; Forner, F.; Schmidt, S.; Zanivan, S.; Fassler, R.; Mann, M. SILAC mouse for quantitative proteomics uncovers kindlin-3 as an essential factor for red blood cell function. *Cell* **2008**, *134*, 353–364. [[CrossRef](#)]
9. Kuijpers, T.W.; van de Vijver, E.; Weterman, M.A.; de Boer, M.; Tool, A.T.; van den Berg, T.K.; Moser, M.; Jakobs, M.E.; Seeger, K.; Sanal, O.; et al. LAD-1/variant syndrome is caused by mutations in *FERMT3*. *Blood* **2009**, *113*, 4740–4746. [[CrossRef](#)]
10. Gawaz, M. Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium. *Cardiovasc. Res.* **2004**, *61*, 498–511. [[CrossRef](#)]
11. Gawaz, M.; Neumann, F.J.; Ott, I.; Schiessler, A.; Schomig, A. Platelet function in acute myocardial infarction treated with direct angioplasty. *Circulation* **1996**, *93*, 229–237. [[CrossRef](#)] [[PubMed](#)]
12. Bhatt, D.L.; Fox, K.A.; Hacke, W.; Berger, P.B.; Black, H.R.; Boden, W.E.; Cacoub, P.; Cohen, E.A.; Creager, M.A.; Easton, J.D.; et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. *N. Engl. J. Med.* **2006**, *354*, 1706–1717. [[CrossRef](#)] [[PubMed](#)]
13. Boersma, E.; Harrington, R.A.; Moliterno, D.J.; White, H.; Theroux, P.; Van de Werf, F.; de Torbal, A.; Armstrong, P.W.; Wallentin, L.C.; Wilcox, R.G.; et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: A meta-analysis of all major randomised clinical trials. *Lancet* **2002**, *359*, 189–198. [[CrossRef](#)]
14. Bigalke, B.; Haap, M.; Stellos, K.; Geisler, T.; Seizer, P.; Kremmer, E.; Overkamp, D.; Gawaz, M. Platelet glycoprotein VI (GPVI) for early identification of acute coronary syndrome in patients with chest pain. *Thromb. Res.* **2010**, *125*, e184–e189. [[CrossRef](#)] [[PubMed](#)]
15. Geisler, T.; Feceks, L.; Wurster, T.; Chiribiri, A.; Schuster, A.; Nagel, E.; Miller, S.; Gawaz, M.; Stellos, K.; Bigalke, B. Association of platelet-SDF-1 with hemodynamic function and infarct size using cardiac MR in patients with AMI. *Eur. J. Radiol.* **2012**, *81*, e486–e490. [[CrossRef](#)] [[PubMed](#)]
16. Michelson, A.D.; Barnard, M.R.; Krueger, L.A.; Valeri, C.R.; Furman, M.I. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: Studies in baboons, human coronary intervention, and human acute myocardial infarction. *Circulation* **2001**, *104*, 1533–1537. [[CrossRef](#)]
17. Stellos, K.; Bigalke, B.; Langer, H.; Geisler, T.; Schad, A.; Kogel, A.; Pfaff, F.; Stakos, D.; Seizer, P.; Muller, L.; et al. Expression of stromal-cell-derived factor-1 on circulating platelets is increased in patients with acute coronary syndrome and correlates with the number of CD34+ progenitor cells. *Eur. Heart J.* **2009**, *30*, 584–593. [[CrossRef](#)]
18. Zhao, Y.; Malinin, N.L.; Meller, J.; Ma, Y.; West, X.Z.; Bledzka, K.; Qin, J.; Podrez, E.A.; Byzova, T.V. Regulation of cell adhesion and migration by Kindlin-3 cleavage by calpain. *J. Biol. Chem.* **2012**, *287*, 40012–40020. [[CrossRef](#)]
19. Gupta, N.; Li, W.; Willard, B.; Silverstein, R.L.; McIntyre, T.M. Proteasome proteolysis supports stimulated platelet function and thrombosis. *Arterioscler. Thromb. Vasc. Biol.* **2014**, *34*, 160–168. [[CrossRef](#)]
20. Grundler, K.; Rotter, R.; Tilley, S.; Pircher, J.; Czermak, T.; Yakac, M.; Gaitzsch, E.; Massberg, S.; Krotz, F.; Sohn, H.Y.; et al. The proteasome regulates collagen-induced platelet aggregation via nuclear-factor-kappa-B (NFkB) activation. *Thromb. Res.* **2016**, *148*, 15–22. [[CrossRef](#)]
21. Oksala, N.; Parssinen, J.; Seppala, I.; Klopp, N.; Illig, T.; Laaksonen, R.; Levula, M.; Raitoharju, E.; Kholova, I.; Sioris, T.; et al. Kindlin 3 (*FERMT3*) is associated with unstable atherosclerotic plaques, anti-inflammatory type II macrophages and upregulation of beta-2 integrins in all major arterial beds. *Atherosclerosis* **2015**, *242*, 145–154. [[CrossRef](#)] [[PubMed](#)]
22. Mory, A.; Feigelson, S.W.; Yarali, N.; Kilic, S.S.; Bayhan, G.I.; Gershoni-Baruch, R.; Etzioni, A.; Alon, R. Kindlin-3: A new gene involved in the pathogenesis of LAD-III. *Blood* **2008**, *112*, 2591. [[CrossRef](#)] [[PubMed](#)]
23. Siegel, D.H.; Ashton, G.H.; Penagos, H.G.; Lee, J.V.; Feiler, H.S.; Wilhelmsen, K.C.; South, A.P.; Smith, F.J.; Prescott, A.R.; Wessagowitz, V.; et al. Loss of kindlin-1, a human homolog of the *Caenorhabditis elegans* actin-extracellular-matrix linker protein UNC-112, causes Kindler syndrome. *Am. J. Hum. Genet.* **2003**, *73*, 174–187. [[CrossRef](#)] [[PubMed](#)]
24. Miyoshi, H.; Umeshita, K.; Sakon, M.; Imajoh-Ohmi, S.; Fujitani, K.; Gotoh, M.; Oiki, E.; Kambayashi, J.; Monden, M. Calpain activation in plasma membrane bleb formation during tert-butyl hydroperoxide-induced rat hepatocyte injury. *Gastroenterology* **1996**, *110*, 1897–1904. [[CrossRef](#)]
25. Pasquet, J.M.; Dachary-Prigent, J.; Nurden, A.T. Calcium influx is a determining factor of calpain activation and microparticle formation in platelets. *Eur. J. Biochem.* **1996**, *239*, 647–654. [[CrossRef](#)]

26. Kraemer, B.F.; Campbell, R.A.; Schwertz, H.; Franks, Z.G.; Vieira de Abreu, A.; Grundler, K.; Kile, B.T.; Dhakal, B.K.; Rondina, M.T.; Kahr, W.H.; et al. Bacteria differentially induce degradation of Bcl-xL, a survival protein, by human platelets. *Blood* **2012**, *120*, 5014–5020. [[CrossRef](#)]
27. Herz, C.; Aumailley, M.; Schulte, C.; Schlotzer-Schrehardt, U.; Bruckner-Tuderman, L.; Has, C. Kindlin-1 is a phosphoprotein involved in regulation of polarity, proliferation, and motility of epidermal keratinocytes. *J. Biol. Chem.* **2006**, *281*, 36082–36090. [[CrossRef](#)]
28. Tu, Y.; Wu, S.; Shi, X.; Chen, K.; Wu, C. Migfilin and Mig-2 link focal adhesions to filamin and the actin cytoskeleton and function in cell shape modulation. *Cell* **2003**, *113*, 37–47. [[CrossRef](#)]
29. Block, M.R.; Badowski, C.; Millon-Fremillon, A.; Bouvard, D.; Bouin, A.P.; Faurobert, E.; Gerber-Scockaert, D.; Planus, E.; Albiges-Rizo, C. Podosome-type adhesions and focal adhesions, so alike yet so different. *Eur. J. Cell Biol.* **2008**, *87*, 491–506. [[CrossRef](#)]
30. Kraemer, B.F.; Borst, O.; Gehring, E.M.; Schoenberger, T.; Urban, B.; Ninci, E.; Seizer, P.; Schmidt, C.; Bigalke, B.; Koch, M.; et al. PI3 kinase-dependent stimulation of platelet migration by stromal cell-derived factor 1 (SDF-1). *J. Mol. Med.* **2010**, *88*, 1277–1288. [[CrossRef](#)]
31. Schmidt, E.M.; Kraemer, B.F.; Borst, O.; Munzer, P.; Schonberger, T.; Schmidt, C.; Leibrock, C.; Towhid, S.T.; Seizer, P.; Kuhl, D.; et al. SGK1 sensitivity of platelet migration. *Cell Physiol. Biochem.* **2012**, *30*, 259–268. [[CrossRef](#)] [[PubMed](#)]
32. Kraemer, B.F.; Schmidt, C.; Urban, B.; Bigalke, B.; Schwanitz, L.; Koch, M.; Seizer, P.; Schaller, M.; Gawaz, M.; Lindemann, S. High shear flow induces migration of adherent human platelets. *Platelets* **2011**, *22*, 415–421. [[CrossRef](#)] [[PubMed](#)]
33. Weyrich, A.S.; Elstad, M.R.; McEver, R.P.; McIntyre, T.M.; Moore, K.L.; Morrissey, J.H.; Prescott, S.M.; Zimmerman, G.A. Activated platelets signal chemokine synthesis by human monocytes. *J. Clin. Investig.* **1996**, *97*, 1525–1534. [[CrossRef](#)] [[PubMed](#)]
34. Tiffert, Y.; Franz-Wachtel, M.; Fladerer, C.; Nordheim, A.; Reuther, J.; Wohlleben, W.; Mast, Y. Proteomic analysis of the GlnR-mediated response to nitrogen limitation in *Streptomyces coelicolor* M145. *Appl. Microbiol. Biotechnol.* **2011**, *89*, 1149–1159. [[CrossRef](#)] [[PubMed](#)]
35. Hala, M.; Cole, R.; Synek, L.; Drdova, E.; Pecenkova, T.; Nordheim, A.; Lamkemeyer, T.; Madlung, J.; Hochholdinger, F.; Fowler, J.E.; et al. An exocyst complex functions in plant cell growth in *Arabidopsis* and tobacco. *Plant Cell* **2008**, *20*, 1330–1345. [[CrossRef](#)]



© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).



Article

Platelet Adhesion and Thrombus Formation in Microchannels: The Effect of Assay-Dependent Variables

Mariangela Scavone ^{1,†}, Silvia Bozzi ^{2,†}, Tatiana Mencarini ², Gianmarco Podda ¹,
Marco Cattaneo ¹ and Alberto Redaelli ^{2,*}

¹ Unità di Medicina 2, ASST Santi Paolo e Carlo, Dipartimento di Scienze della Salute, Università degli Studi di Milano, 20142 Milan, Italy; mariangela.scavone@guest.unimi.it (M.S.); gianmarco.podda@unimi.it (G.P.); marco.cattaneo@unimi.it (M.C.)

² Department of Electronics, Information and Bioengineering, Politecnico di Milano, 20133 Milan, Italy; silvia.bozzi@polimi.it (S.B.); tatiana.mencarini@mail.polimi.it (T.M.)

* Correspondence: alberto.redaelli@polimi.it

† These authors have equally contributed to this work.

Received: 16 December 2019; Accepted: 21 January 2020; Published: 23 January 2020

Abstract: Microfluidic flow chambers (MFCs) allow the study of platelet adhesion and thrombus formation under flow, which may be influenced by several variables. We developed a new MFC, with which we tested the effects of different variables on the results of platelet deposition and thrombus formation on a collagen-coated surface. Methods: Whole blood was perfused in the MFC over collagen Type I for 4 min at different wall shear rates (WSR) and different concentrations of collagen-coating solutions, keeping blood samples at room temperature or 37 °C before starting the experiments. In addition, we tested the effects of the antiplatelet agent acetylsalicylic acid (ASA) (antagonist of cyclooxygenase-1, 100 µM) and cangrelor (antagonist of P2Y₁₂, 1 µM). Results: Platelet deposition on collagen (I) was not affected by the storage temperature of the blood before perfusion (room temperature vs. 37 °C); (II) was dependent on a shear rate in the range between 300/s and 1700/s; and (III) was influenced by the collagen concentration used to coat the microchannels up to a value of 10 µg/mL. ASA and cangrelor did not cause statistically significant inhibition of platelet accumulation, except for ASA at low collagen concentrations. Conclusions: Platelet deposition on collagen-coated surfaces is a shear-dependent process, not influenced by the collagen concentration beyond a value of 10 µg/mL. However, the inhibitory effect of antiplatelet drugs is better observed using low concentrations of collagen.

Keywords: platelets; thrombus formation; microfluidics; flow assays; platelet adhesion; platelet aggregation; shear rate; antiplatelet agents

1. Introduction

Platelets play a central pathogenic role in thrombosis; they aggregate at sites of atherosclerotic plaques, forming thrombi that can occlude the lumen of the artery [1–3]. In coronary arteries, this process causes acute coronary syndromes, which are a major cause of morbidity and mortality [4]. Atherosclerotic plaques favor the formation of thrombi by exposing thrombogenic surfaces, to which platelets adhere, and by causing stenosis of the arterial lumen, which contributes to platelet activation by increasing the shear rate of blood flow [5,6]. Patients with acute coronary syndrome are treated with antiplatelet drugs, inhibiting cyclooxygenase-1 (COX-1) (acetylsalicylic acid) and P2Y₁₂ receptors (clopidogrel, ticagrelor or prasugrel).

Microfluidic flow chambers (MFCs) designed to observe platelet adhesion and thrombus formation on surfaces coated with adhesive proteins, such as collagen, have become a valuable tool for research

in hemostasis and thrombosis [7–9]. These devices can characterize platelet function under flow with low blood volume requirements and controlled conditions. They can mimic the anatomy of healthy and stenotic blood vessels [7,10], recreate a range of physiological and pathological shear stress conditions [11–13] and investigate platelet accumulation over different adhesive proteins [14,15]. Furthermore, these devices allow to study the inhibitory effect of antiplatelets agents on platelet adhesion and thrombus formation [16,17].

However, as a consequence of their high flexibility, MFCs are poorly standardized [18]. Limited studies have been performed to assess the variability of platelet accumulation in relation with the experimental variables. With regards to platelet deposition on collagen, most of the works have focused on the role of the mechanical stresses, reporting on the significant shear-rate dependency of the platelet adhesion and thrombus formation processes, e.g., [12,19,20]. The sensitivity to collagen concentration was investigated by Savage et al. [21] and Neeves and colleagues, who performed the most comprehensive study on the sources of variability in platelet accumulation on collagen, exploring also the effect of phenotypic and genetic factors [19]. The inhibitory effect of antiplatelet drugs on platelet accumulation has been studied by Diamond’s research group in a number of works [16,17,22]. Despite these studies and some attempts to define common protocols [18,23], no real standardization has been achieved and the effect of a number of assay-dependent variables still remains to be fully elucidated.

Given this background, the current study aims at investigating a number of critical aspects in the study of platelet adhesion and thrombus formation with MFCs: The effect of the storage temperature of the blood samples before testing; the influences of wall shear rate and of the concentration of the adhesive protein collagen in the surface coating solution; and the inhibitory effect of some antiplatelet drugs.

2. Results

2.1. Effect of Blood Storage Temperature

We measured the effect of blood storage temperature at room temperature (RT) and 37 °C on platelet accumulation on collagen (200 µg/mL)-coated channels, at 300/s, 1100/s and 1700/s wall shear rates (Figure 1). In all conditions tested, no statistical difference was found between the results obtained at RT and 37 °C.




Figure 1. Effect of storage temperature (room temperature (RT) and 37 °C) on platelet accumulation on collagen (200 µg/mL)-coated channels at different wall shear rates ($n = 4$). Black: RT; grey: 37 °C. (a) Surface coverage; (b) mean fluorescence intensity; (c) number of thrombi; (d) mean thrombus area. Data are represented as column bar graphs, with means \pm standard errors of the mean and analyzed by Wilcoxon matched pairs.

2.2. Effect of Wall Shear Rate

Platelet accumulation, as measured by surface coverage and fluorescence intensity, increased as a function of wall shear rate (Figure 2; Figure 3a,b). The number of thrombi significantly decreased while the mean thrombus area significantly increased as a function of wall shear rate (Figures 2 and 3c,d).




Figure 2. Representative images (6.3×) of platelet accumulation at different shear rates and collagen concentrations. Images are acquired after 4 min of perfusion. Flow is from left to right. The first row shows platelet accumulation over collagen (200 μg/mL)-coated perfusion chamber at (a) 300/s, (b) 1100/s and (c) 1700/s. The second row shows platelet accumulation at 300/s for collagen concentrations equal to (d) 10 μg/mL, (e) 50 μg/mL and (f) 100 μg/mL.




Figure 3. Effect of wall shear rate on platelet accumulation on collagen (200 μg/mL)-coated microchannels ($n = 7$). (a) Surface coverage; (b) mean fluorescence intensity; (c) number of thrombi; (d) mean thrombus area. Data are represented as column bar graphs, with means \pm standard errors of the mean, and analyzed by Kruskal–Wallis tests or ANOVA tests as appropriate. Internal Contrasts: (a) 300/s vs. 1700/s, $p < 0.001$; (b) 300/s vs. 1100/s $p < 0.001$; 300/s vs. 1700/s, $p < 0.001$; (c) 300/s vs. 1100/s $p < 0.01$; 300/s vs. 1700/s, $p < 0.001$; (d) 300/s vs. 1700/s, $p < 0.001$.

2.3. Effect of Collagen Concentration

Surface coverage and fluorescence intensity at a shear rate of 300/s were affected by collagen concentration: They were lowest at 1 µg/mL and slowly increased with increasing collagen concentration up to 100 µg/mL; at 200 µg/mL the surface coverage tended to decrease (Figure 4). The internal contrast showed that there were no statistically significant differences over the range 5 to 200 µg/mL (Figures 2 and 4a,b). The number of thrombi significantly increased while their area significantly decreased as a function of collagen concentrations from 1 to 200 µg/mL (Figures 2 and 4c,d).




Figure 4. Effect of collagen concentration on platelet accumulation at 300/s ($n = 7$). (a) Surface coverage; (b) mean fluorescence intensity; (c) number of thrombi; (d) mean thrombus area. Data are represented as column bar graphs, with means \pm standard errors of the mean, and analyzed by ANOVA tests plus Bonferroni's multiple comparison post-hoc tests. Internal Contrast: (a) 1 vs. 5 µg/mL of collagen, $p < 0.05$; 1 vs. 50 µg/mL of collagen, $p < 0.01$; 1 vs. 100 µg/mL of collagen, $p < 0.001$; (b) 1 vs. 100 µg/mL of collagen, $p < 0.05$; (c) 1 vs. 50, 100 and 200 µg/mL of collagen, $p < 0.001$; 5 vs. 50, 100 and 200 µg/mL, $p < 0.001$; 10 vs. 50 µg/mL of collagen, $p < 0.01$; 10 vs. 100 and 200 µg/mL of collagen, $p < 0.001$; (d) 1 vs. 10 µg/mL of collagen, $p < 0.01$; 1 vs. 50, 100, 200 µg/mL, $p < 0.001$; 5 vs. 50, 200, $p < 0.01$; 5 vs. 100 µg/mL, $p < 0.05$.

2.4. Effect of ASA on Platelet Accumulation

- Collagen Concentration = 1 µg/mL. ASA (100 µM) induced a statistically significant decrease in surface coverage (4.4% vs. 1.6%; $p = 0.025$) and mean thrombus area, but did not significantly change mean fluorescence and number of thrombi (Figure 5).
- Collagen Concentration = 10 µg/mL. ASA (100 µM) did not induce a statistically significant change in surface coverage, tended to reduce mean fluorescence intensity and to increase the number of thrombi, but differences were borderline statistically significant and significantly decreased the mean thrombus area (Figure 5).
- Collagen Concentration = 100 µg/mL. ASA (100 µM) did not induce statistically significant modifications of surface coverage, fluorescence intensity, number of thrombi or mean thrombus area (Figure 5).




Figure 5. ASA inhibition of platelet accumulation at 300/s for different collagen concentrations ($n = 5$). Black: without ASA; grey: with ASA added in vitro. (a) Surface coverage; (b) mean fluorescence intensity; (c) number of thrombi; (d) mean thrombus area. Data are represented as column bar graphs, with means \pm standard errors of the mean, and analyzed by Wilcoxon tests or t-tests as appropriate.

2.5. Cangrelor Inhibition of Platelet Accumulation

Collagen concentrations of 10 and 100 µg/mL. At shear rate of both 300/s and 1600/s, cangrelor (1 µM) did not induce a statistically significant reduction of surface coverage, mean fluorescence intensity, number of thrombi or mean thrombus area (Figures 6 and 7).




Figure 6. Effect of cangrelor at different shear rates on platelet accumulation on collagen (10 µg/mL)-coated perfusion chamber ($n = 5$). Black: without cangrelor; grey: with cangrelor added in vitro. (a) Surface coverage; (b) mean fluorescence intensity; (c) number of thrombi; (d) mean thrombus area. Data are represented as column bar graphs, with means \pm standard errors of the mean, and analyzed by Wilcoxon matched pairs.




Figure 7. Effect of cangrelor at different shear rates on platelet accumulation on collagen (100 µg/mL)-coated m ($n = 5$). Black: without cangrelor; grey: with cangrelor added in vitro. (a) Surface coverage; (b) mean fluorescence intensity; (c) number of thrombi; (d) mean thrombus area. Data are represented as column bar graphs, with means \pm standard errors of the mean, and analyzed by Wilcoxon matched pairs.

3. Discussion

Our study aimed at investigating different critical aspects of microfluidic platelet adhesion assays on collagen type I: (I) the storage temperature of blood before perfusion; (II) the wall shear rate; and (III) the concentration of collagen in the buffered solution used for coating. In addition, our study aimed at assessing the effect of antiplatelet agents targeting COX-1 (acetylsalicylic acid) and P2Y₁₂ (cangrelor) on platelet accumulation under the different experimental conditions considered in our study.

To this purpose, we developed a microfluidic device following the design recommendations given by [24], performed a number of experiments following the protocols suggested by [18] and evaluated the results by comprehensive image analysis, which included not only the typical outputs, such as surface coverage and mean fluorescence intensity, but also the number and area of thrombi, which, as outlined by [25], may change as a function of local flow conditions and platelet function.

Although it has been recommended to store blood samples for platelet function assays at room temperature [26], in our experiments no difference between the storage temperature of blood (at room temperature versus 37 °C) was found for all the WSR studied.

Platelet accumulation was a strongly shear-dependent process, as already observed by many authors, e.g., [19,25]. In our experiments, at 300/s several small and circular thrombi formed, whereas at higher shear rates (1100 and 1700/s), platelet aggregates elongated twofold in the direction of the flow. The same shear dependency of the morphology of platelet aggregates was found by Colace et al. [25], who calculated the width and length of growing thrombi on collagen in the range of shear rates from 100/s to 2000/s. Platelet accumulation increased with increasing shear rate, not only in the horizontal plane (i.e., the glass plane) as measured by surface coverage, but also vertically in the third dimension, as indicated by mean fluorescence intensity. All previous studies reported the same result despite

each work observing the peak platelet deposition at a different shear rate: 300/s [19,20], 500/s [12] and 1500/s [21].

Collagen surface density influenced thrombus formation up to a threshold equal to 1 µg/mL with regard to the amount of platelet deposition (measured by SC and FI) and to 5 µg/mL for the variables quantifying the aggregate morphology (number of thrombi and mean thrombus area). At lower concentrations of collagen (1 and 5 µg/mL), a few dispersed, large thrombi have formed, while at higher concentrations (> 10 µg/mL) many small aggregates are present. Similar results were found by Savage et al. [21] who observed an increase in the total volume of thrombi from 0.01 µg/mL to 0.1 µg/mL and no further changes beyond 0.1 µg/mL, as well as by Neeves et al. [19] who observed a significant difference in surface coverage only up to a collagen concentration of 50 µg/mL.

Under our experimental conditions (shear rate equal to 300/s), ASA reduced surface coverage only on surfaces coated with the lowest concentration of collagen (1 µg/mL) but significantly decreased the mean thrombus area both at 1 µg/mL and 10 µg/mL. This is in agreement with Li and Diamond [22] who found that ex-vivo addition of ASA results in smaller platelet aggregates compared to responses measured with no drugs. In the same work, the authors also reported a decrease in total platelet accumulation (measured in terms of fluorescence intensity) over collagen at 200/s following high dose (500 µM) ASA addition, but the collagen concentration was not provided. The effect of ASA is known to be relevant only after some minutes of perfusion [16,17], when secondary aggregation mediated by thromboxane occurs, while initial platelet adhesion to collagen is not influenced by the presence of aspirin. This suggests that the perfusion time of our experiments should probably have been longer to observe the ASA inhibitory effect at high collagen concentrations. Cangrelor, an antagonist of the P2Y₁₂ receptor, did not cause any significant inhibition of platelet accumulation at any shear rate and concentration of collagen. However, a distinct trend was observed at the higher shear rates (950/s and 1600/s), indicating a marked decrease in surface coverage, fluorescence intensity and mean thrombus area due to the presence of cangrelor. This suggests that a statistical significance would probably be reached by increasing the number of experiments.

In summary, platelet deposition on collagen type I (I) is not affected by the storage temperature of the blood before perfusion (room temperature vs. 37 °C); (II) was a shear-dependent process in the range between 300/s and 1700/s; and (III) is influenced by the collagen concentration used to coat the microchannels up to a concentration of 5 µg/mL. Antiplatelet agents did not show statistically significant inhibitory effects on platelet interaction with collagen-coated surfaces, except for ASA at low concentrations of collagen.

By carefully examining the effect of several assay-dependent variables on platelet deposition on surfaces coated with collagen type I in a microfluidic device, we believe to have characterized different aspects of thrombus formation that should be taken into account before approaching these experiments.

4. Materials and Methods

4.1. Enrollment of Healthy Control Subjects

Healthy subjects ($n = 15$, 3 males; age range: 19–39 years) were recruited among workers of ASST Santi Paolo e Carlo and Università degli Studi di Milano. All studied subjects abstained from drugs known to affect platelet function for at least 10 days before enrolment. The study was approved by the institutional ethical committee of ASST Santi Paolo e Carlo; all subjects signed their informed consent.

4.2. Blood Sampling

Blood samples were collected in the morning from an antecubital vein using a 21-gauge butterfly needle with minimal stasis. The first 3 mL of blood was collected into K-EDTA tubes (Becton Dickinson vacutainer, North Ryde, NSW, Australia) for a complete blood count; the following 10–15 mL was collected in 250 µg/mL INN-desirudin (Canyon Pharmaceuticals, London, United Kingdom), gently mixed, and allowed “to rest” at room temperature for 15 min before use.

4.3. Fabrication of Microfluidic Devices

Microfluidic devices (Figure 8a) consisted of six independent channels (1000 μm wide, 100 μm high and 3.2 cm long). Channels were designed according to previous recommendations, which suggested an aspect ratio of 10:1 (width:height) in order to reduce wall effects and obtain homogenous platelet distribution across the width of the channel [12,19]. Microfluidic devices were fabricated in polydimethylsiloxane (PDMS, Sylgard™ 184, Dow Corning, Midland, MI, USA) from silicon masters using standard soft lithography techniques. PDMS was prepared by mixing pre-polymer and curing agent in a ratio 10:1 (w:w), degassed, poured over the master mold and cured at 80 °C for 3 h. Inlet and outlet fluidic ports were punched with a 1.5 mm diameter biopsy puncher. PDMS chips were permanently bonded to #0.6 microscope cover glasses via air plasma treatment.




Figure 8. Photograph of the microfluidic chip (a) and of the experimental set-up (b). Results of the image-processing algorithm (c), from top to bottom: original image (6.3 \times), segmented binary image and identification of platelet aggregates (red dots represent individual thrombi).

4.4. Perfusion Experiments

Each microfluidic channel was incubated with Horm fibrillar collagen type I (Mascia Brunelli, Milano, Italy) at 4 °C overnight. An isotonic glucose solution (pH 2.7–2.9) was used to achieve the desired collagen concentration (1, 5, 10, 50, 100 or 200 $\mu\text{g}/\text{mL}$). Collagen patterning was obtained by pipetting 2.2 μL into the outlet port of the flow chamber. This allowed to fill only about 2/3 of the channel, leaving uncoated the first one-third. In this way, platelets were prevented from adhering in the proximity of the channel entry, where flow disturbances can induce altered platelet accumulation affecting downstream thrombus formation. Then, it was rinsed with filtered phosphate buffer saline (PBS). Before perfusion, it was incubated with 1% bovine serum albumin in PBS for 30 min at room

temperature, to passivate the chamber surface that had not been coated by collagen. Subsequently, each channel was washed with PBS, connected with the flow system and checked for the absence of air bubbles. The microfluidic device was then placed on the stage of an inverted fluorescence microscope (Axiovert A1 FL, Zeiss, Milan, Italy) equipped with a 16-bit camera (Sony ICX-674 CCD Camera, Crisel Instruments, Rome, Italy) (Figure 8b). Fluorescence microscopy was performed with a mercury light source (HBO 50 AC L1, Zeiss, Milan, Italy) and a FITC filter set.

Blood samples were incubated with the green-fluorescent lipophilic dye 3,3' Dihexyloxacarbocyanine Iodide (DiOC6, 1 μ M; ThermoFisher Scientific, Milan, Italy), which tags platelets, at room temperature for 15 min. In most experiments, blood samples were kept at room temperature before testing; in some experiments, samples were divided in two equal parts, of which one was kept at RT and one at 37 °C for a maximum of 4h. In some experiments, 100 μ M lysine-ASA (Flectadol, Sanofi-Aventis, Milan, Italy) or 1 μ M cangrelor (The Medicines Company, Parsippany-Troy Hills, NJ, USA) was added to blood samples at RT for 10 or 3 min, respectively. Before the beginning of the experiments, whole blood samples that had been kept at RT were incubated at 37 °C for 3 min and then perfused for 4 min using a programmable syringe pump (Mirus Evo Nanopump, Cellix, Crisel Instruments, Rome, Italy) through Tygon tubes (0.5 mm inner diameter) inserted into the fluidic ports (Figure 8b). All experiments were performed at 37 °C within three hours from blood collection.

To investigate the effect of collagen surface density on platelet adhesion and thrombus formation, blood was perfused at 300/s over surfaces coated with buffered solutions containing 6 different collagen concentrations: 1, 5, 10, 50, 100 and 200 μ g/mL ($n = 7$). To assess the effect of wall shear rate, blood was perfused over collagen (200 μ g/mL) at three flow rates, corresponding to 300/s, 1100/s and 1700/s wall shear rates ($n = 7$). Wall shear rate γ was related to volumetric flow rate Q through the following equation:

$$Q = \frac{\gamma wh^2}{6} \quad (1)$$

where w and h refer to the width and height of the microfluidic channel, respectively.

Finally, the inhibitory effect of two antiplatelet drugs (ASA and cangrelor) was assessed under different flow conditions and collagen concentrations. ASA inhibition of platelet accumulation was investigated at 300/s and collagen concentrations equal to 1, 10 and 100 μ g/mL ($n = 5$). The effect of cangrelor was evaluated at 300/s, 950/s and 1600/s with collagen concentrations of 10 μ g/mL and 100 μ g/mL.

4.5. Image Acquisition and Analysis

At the end of blood perfusion (4 min) an image was captured in the zone immediately after the beginning of the collagen patch. Image acquisition was performed using a 10 \times objective lens and a 0.64 \times video adapter, through the MicroManager software. The field view allowed to capture the full width of the channel. Real-time platelet accumulation was also monitored by acquiring an image every 2 s over the duration of the experiment.

Surface coverage, mean fluorescence intensity, number of thrombi and mean thrombus area were calculated using a custom MATLAB (MathWorks, Natick, MA, USA) script. To limit wall effects, images were cropped down to 80% of the channel width, where the wall shear rate is nearly uniform, within 5% of the value at the center [24]. Mean fluorescence intensity was estimated by averaging all the intensity values of the cropped image. Grayscale images were then converted into binary images by an automatic image thresholding method in order to eliminate operator bias. The Otsu's algorithm [27] was chosen as it provided a better performance than other global thresholding techniques (e.g., the triangle method). Otsu's algorithm is a statistical thresholding method, which partition the image intensity histogram into classes so that the between-class variance is maximized. After the thresholding operation, all the segmented images were checked one by one and when inconsistent results were found a background correction of the raw image was performed and then the image was thresholded again. After this step, pixel clusters smaller than the area of a single platelet were removed. The resulting images were used

to calculate the surface coverage by dividing the number of pixels with values greater than zero by the total number of pixels. Finally, individual thrombi were identified, and the mean thrombus area was estimated. Figure 8 shows the results of the image analysis procedure: The central image represents the output of the thresholding operation, i.e., the segmented binary image from which surface coverage was calculated, while the image at the bottom shows the result of the object identification algorithm.

4.6. Statistical Analysis

Statistical analysis of the results was performed using GraphPad Prism 6 (GraphPad Software, Inc., CA, USA). Normal distribution of data was tested with the Shapiro–Wilk normality test. The One-way Analysis of Variance (ANOVA) test or t-tests were used when the normality hypothesis was satisfied. Conversely, non-parametric Kruskal–Wallis or Wilcoxon tests were performed. Statistical significance was assumed for *p*-values lower than 0.05.

Author Contributions: Conceptualization, M.S. and M.C.; formal analysis, M.S., S.B. and G.P.; investigation, M.S., S.B. and T.M.; methodology, M.S., S.B. and A.R.; software, S.B.; supervision, M.C. and A.R.; visualization, T.M.; writing—original draft, M.S., S.B. and M.C.; all authors read and approved the submitted version. All authors have read and agreed to the published version of the manuscript.

Funding: M. Scavone was supported by Fondazione Umberto Veronesi.

Acknowledgments: The authors are grateful to Elena Bossi and Raffaella Adami for their assistance in the laboratory analyses and to Marco Rasponi for his support in the lab-on-chip manufacturing process.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

| | |
|--------|--|
| MFC | microfluidic flow chambers |
| WSR | wall shear rates |
| ASA | acetylsalicylic acid |
| RT | room temperature |
| COX-1 | cyclooxygenase-1 |
| PDMS | polydimethylsiloxane |
| PBS | phosphate-buffered saline |
| K-EDTA | potassium ethylenediaminetetra-acetic acid |

References

1. Kaplan, Z.S.; Jackson, S.P. The role of platelets in atherothrombosis. *Hematol. Am. Soc. Hematol. Educ. Program* **2011**, *2011*, 51–61. [[CrossRef](#)] [[PubMed](#)]
2. Badimon, L.; Padró, T.; Vilahur, G. Atherosclerosis, platelets and thrombosis in acute ischaemic heart disease. *Eur. Heart J. Acute Cardiovasc. Care* **2012**, *1*, 60–74. [[CrossRef](#)] [[PubMed](#)]
3. Corti, R.; Fuster, V.; Badimon, J. Pathogenetic concepts of acute coronary syndromes. *J. Am. Coll. Cardiol.* **2003**, *41*, 7S–14S. [[CrossRef](#)]
4. Sanchis-Gomar, F.; Perez-Quilis, C.; Leischik, R.; Lucia, A. Epidemiology of coronary heart disease and acute coronary syndrome. *Ann. Transl. Med.* **2016**, *4*, 256. [[CrossRef](#)] [[PubMed](#)]
5. Ruggeri, Z.M. Platelets in atherothrombosis. *Nat. Med.* **2002**, *8*, 1227–1234. [[CrossRef](#)] [[PubMed](#)]
6. Jennings, L.K. Role of platelets in atherothrombosis. *Am. J. Cardiol.* **2009**, *103*, 4A–10A. [[CrossRef](#)]
7. Westein, E.; de Witt, S.; Lamers, M.; Cosemans, J.M.; Heemskerk, J.W. Monitoring in vitro thrombus formation with novel microfluidic devices. *Platelets* **2012**, *23*, 501–509. [[CrossRef](#)]
8. Neeves, K.B.; Onasoga, A.A.; Wufus, A.R. The use of microfluidics in hemostasis: Clinical diagnostics and biomimetic models of vascular injury. *Curr. Opin. Hematol.* **2013**, *20*, 417–423. [[CrossRef](#)]
9. Schoeman, R.M.; Marcus Lehmann, M.; Neeves, K.B. Flow chamber and microfluidic approaches for measuring thrombus formation in genetic bleeding disorders. *Platelets* **2017**, *28*, 463–471. [[CrossRef](#)]
10. Lui, M.; Gardiner, M.M.; Arthur, J.F.; Pinar, I.; Lee, W.M.; Ryan, K.; Carberry, J.; Andrews, R.K. Novel Stenotic Microchannels to Study Thrombus Formation in Shear Gradients: Influence of Shear Forces and Human Platelet-Related Factors. *Int. J. Mol. Sci.* **2019**, *20*, 2967. [[CrossRef](#)]

11. Gutierrez, E.; Petrich, B.G.; Shattil, S.J.; Ginsberg, M.H.; Groisman, A.; Kasirer-Friede, A. Microfluidic devices for studies of shear-dependent platelet adhesion. *Lab Chip* **2008**, *8*, 1486–1495. [[CrossRef](#)] [[PubMed](#)]
12. Neeves, K.B.; Maloney, S.F.; Fong, K.P.; Schmaier, A.A.; Kahn, M.L.; Brass, L.F.; Diamond, S.L. Microfluidic focal thrombosis model for measuring murine platelet deposition and stability: PAR4 signaling enhances shear-resistance of platelet aggregates. *J. Thromb. Haemost.* **2008**, *6*. [[CrossRef](#)] [[PubMed](#)]
13. Hansen, R.R.; Wufus, A.R.; Barton, S.T.; Onasoga, A.A.; Johnson-Paben, R.M.; Neeves, K.B. High Content Evaluation of Shear Dependent Platelet Function in a Microfluidic Flow Assay. *Ann. Biomed. Eng.* **2013**, *41*, 250–262. [[CrossRef](#)] [[PubMed](#)]
14. Maurer, E.; Schaff, M.; Receveur, N.; Bourdon, C.; Mercier, L.; Nieswandt, B.; Dubois, C.; Jandrot-Perrus, M.; Goetz, J.G.; Lanza, F.; et al. Fibrillar cellular fibronectin supports efficient platelet aggregation and procoagulant activity. *Thromb. Haemost.* **2015**, *114*, 1175–1188. [[CrossRef](#)] [[PubMed](#)]
15. Kent, N.J.; O'Brien, S.; Basabe-Desmonts, L.; Meade, G.R.; MacCraith, B.D.; Corcoran, B.G.; Kenny, D.; Ricco, A.J. Shear-Mediated Platelet Adhesion Analysis in Less Than 100 μ L of Blood: Toward a POC Platelet Diagnostic. *IEEE Trans. Biomed. Eng.* **2011**, *58*, 826–830. [[CrossRef](#)]
16. Maloney, S.F.; Brass, L.; Diamond, S.L. P2Y₁₂ or P2Y₁ inhibitors reduce platelet deposition in a microfluidic model of thrombosis while apyrase lacks efficacy under flow conditions. *Integr. Biol.* **2010**, *2*, 183–192. [[CrossRef](#)]
17. Li, R.; Fries, S.; Li, X.; Grosser, T.; Diamond, S.L. Microfluidic assay of platelet deposition on collagen by perfusion of whole blood from healthy individuals taking ASA. *Clin. Chem.* **2013**, *59*, 1195–1204. [[CrossRef](#)]
18. Roest, M.; Reininger, A.; Zwaginga, J.J.; King, M.R.; Heemskerk, J.W. Biorheology Subcommittee of the SSC of the ISTH. Flow chamber-based assays to measure thrombus formation in vitro: Requirements for standardization. *J. Thromb. Haemost.* **2011**, *9*, 2322–2324. [[CrossRef](#)]
19. Neeves, K.B.; Onasoga, A.A.; Hansen, R.R.; Lilly, J.J.; Venckunaite, D.; Sumner, M.B.; Irish, A.T.; Brodsky, G. Sources of Variability in Platelet Accumulation on Type 1 Fibrillar Collagen in Microfluidic Flow Assays. *PLoS ONE* **2013**, *8*, e54680. [[CrossRef](#)]
20. Saelman, E.U.; Nieuwenhuis, H.K.; Hese, K.M.; de Groot, P.G.; Heijnen, H.F.; Sage, E.H.; Williams, S.; McKeown, L.; Gralnick, H.R.; Sixma, J.J. Platelet adhesion to collagen types I through VIII under conditions of stasis and flow is mediated by GPIa/IIa (alpha 2 beta 1-integrin). *Blood* **1994**, *83*, 1244–1250. [[CrossRef](#)]
21. Savage, B.; Almus-Jacobs, F.; Ruggeri, Z.M. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. *Cell* **1998**, *94*, 657–666. [[CrossRef](#)]
22. Li, R.; Diamond, S.R. Detection of platelet sensitivity to inhibitors of COX-1, P2Y₁, and P2Y₁₂ using a whole blood microfluidic flow assay. *Thromb. Res.* **2014**, *133*, 209–210. [[CrossRef](#)] [[PubMed](#)]
23. Van Kruchten, R.; Cosemans, J.M.; Heemskerk, J.W. Measurement of whole blood thrombus formation using parallel-plate flow chambers—A practical guide. *Platelets* **2012**, *23*, 229–242. [[CrossRef](#)] [[PubMed](#)]
24. Sarvepalli, D.P.; Schmidtke, D.W.; Nollert, M.U. Design considerations for a microfluidic device to quantify the platelet adhesion to collagen at physiological shear rates. *Ann. Biomed. Eng.* **2009**, *37*, 1331–1341. [[CrossRef](#)]
25. Colace, T.; Falls, E.; Zheng, X.L.; Diamond, S.L. Analysis of morphology of platelet aggregates formed on collagen under laminar blood flow. *Ann. Biomed. Eng.* **2011**, *39*, 922–929. [[CrossRef](#)]
26. McCarty, O.J.T.; Ku, D.; Sugimoto, M.; King, M.R.; Cosemans, M.E.M.; Neeves, K.B. Dimensional analysis and scaling relevant to flow models of thrombus formation: Communication from the SSC of the ISTH. *J. Thromb. Haemost.* **2016**, *14*, 619–622. [[CrossRef](#)]
27. Otsu, N. A threshold selection method from gray level histograms. *IEEE Trans. Syst. Man Cybern.* **1979**, *9*, 62–66. [[CrossRef](#)]



© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).



Article

The MICELI (MICrofluidic, ELectrical, Impedance): Prototyping a Point-of-Care Impedance Platelet Aggregometer

Yana Roka-Moiia ^{1,†}, Silvia Bozzi ^{2,†}, Chiara Ferrari ², Gabriele Mantica ², Annalisa Dimasi ²,
Marco Rasponi ², Andrea Santoleri ², Mariangela Scavone ³, Filippo Consolo ⁴, Marco Cattaneo ³,
Marvin J. Slepian ^{1,*} and Alberto Redaelli ^{2,‡}

¹ Departments of Medicine and Biomedical Engineering, College of Medicine, University of Arizona, Tucson, AZ 85724, USA; rokamoiia@email.arizona.edu

² Department of Electronics, Information and Bioengineering, Politecnico di Milano, Milan 20133, Italy; silvia.bozzi@polimi.it (S.B.); chiara6.ferrari@mail.polimi.it (C.F.); gabriele.mantica@mail.polimi.it (G.M.); annalisa.dimasi@polimi.it (A.D.); marco.rasponi@polimi.it (M.R.); andrea.santoleri@gmail.com (A.S.); alberto.redaelli@polimi.it (A.R.)

³ Divisione di Medicina, Ospedale San Paolo, Dipartimento di Scienze della Salute, Università degli Studi di Milano, Milan 20122, Italy; mariangela.scavone@guest.unimi.it (M.S.); marco.cattaneo@unimi.it (M.C.)

⁴ Università Vita Salute, San Raffaele, Milan 20132, Italy; consolo.filippo@hsr.it

* Correspondence: slepian@email.arizona.edu; Tel.: +1-(520)6268543

† Both first authors contributed equally to this manuscript.

‡ Both authors served as senior authors for this work.

Received: 21 December 2019; Accepted: 7 February 2020; Published: 11 February 2020

Abstract: As key cellular elements of hemostasis, platelets represent a primary target for thrombosis and bleeding management. Currently, therapeutic manipulations of platelet function (antithrombotic drugs) and count (platelet transfusion) are performed with limited or no real-time monitoring of the desired outcome at the point-of-care. To address the need, we have designed and fabricated an easy-to-use, accurate, and portable impedance aggregometer called “MICELI” (MICrofluidic, ELectrical, Impedance). It improves on current platelet aggregation technology by decreasing footprint, assay complexity, and time to obtain results. The current study aimed to optimize the MICELI protocol; validate sensitivity to aggregation agonists and key blood parameters, i.e., platelet count and hematocrit; and verify the MICELI operational performance as compared to commercial impedance aggregometry. We demonstrated that the MICELI aggregometer could detect platelet aggregation in 250 μ L of whole blood or platelet-rich plasma, stimulated by ADP, TRAP-6, collagen, epinephrine, and calcium ionophore. Using hirudin as blood anticoagulant allowed higher aggregation values. Aggregation values obtained by the MICELI strongly correlated with platelet count and were not affected by hematocrit. The operational performance comparison of the MICELI and the Multiplate[®] Analyzer demonstrated strong correlation and similar interdonor distribution of aggregation values obtained between these devices. With the proven reliability of the data obtained by the MICELI aggregometer, it can be further translated into a point-of-care diagnostic device aimed at monitoring platelet function in order to guide pharmacological hemostasis management and platelet transfusions.

Keywords: platelet aggregation; electrical impedance; whole blood aggregometry; point-of-care; platelet function testing

1. Introduction

Platelets are vital blood cells critical for maintenance of vascular integrity and tissue repair [1]. Unfortunately, in many disease states platelets become activated with resultant pathologic thrombosis,

reducing organ blood flow, leading to ischemia, infarction, and death [2]. To prevent inadvertent platelet activation, coagulation, and thrombosis, an increasing percentage of the U.S. population are prescribed a range of antithrombotic medications. However, many of these medications have varying interpatient pharmacodynamic efficacy [3]. For example, while aspirin has been proven to reduce thrombotic risk by 25%, still 10%–20% of aspirin-treated patients experience thrombotic events [4]. Conversely, many patients on appropriate dose therapy experience untoward bleeding consequences, with a net increase in bleeding risk [5,6]. This is particularly problematic when patients present with trauma or acute illness, requiring emergent surgery and intervention.

For patients experiencing massive trauma, falls, intestinal ischemia, and acute arterial insufficiency, an immediate surgical intervention is needed. For many patients encountered in emergency care situations, platelet function is compromised due to long-term use of antithrombotic therapy [7]. To date, there are no specific agents able to reverse the antiplatelet effect of contemporary antithrombotic drugs. Platelet transfusion has previously shown its efficacy in preventing perioperative hemorrhage, though the dosing and administration time remain unclear [8–10]. Therefore, careful monitoring of platelet function at the point-of-care (POC) is recommended by recent surgical guidelines to control risk of bleeding in pre-, peri-, and postoperative settings [7]. However, rapid platelet function testing is often not available at the POC, and surgeons rely only on platelet count and coagulation tests for bleeding risk assessment and platelet transfusion management [11]. The result is elevated procedure-related bleeding with significant morbidity and mortality [12].

Platelet aggregometry is the “gold standard” of platelet function monitoring [13,14]. The magnitude and rate of platelet aggregation are crucial indicators of platelet function and overall blood hemostasis state. To quantify platelet aggregation, benchtop optical and electronic platelet aggregometers are utilized. Light transmission aggregometry (LTA) detects platelet aggregation induced by chemical agonists, e.g., adenosine diphosphate (ADP), collagen, and arachidonic acid, in platelet-rich plasma (PRP) [15]. As light passes through a PRP sample, transmission is recorded via photometry; as platelets aggregate, PRP turbidity decreases, with increased light transmittance detected [16,17]. While LTA provides useful information about platelet function, its utility in clinical laboratory or POC environments is limited due to a series of significant limitations: the need for blood sample processing (to obtain PRP), a large blood volume requirement (6–10 mL) and significant time (>1 h) for a single test, expensive bulky equipment, and the need for trained personnel to run the test and interpret obtained results [3,18].

Electrical impedance aggregometry (EIA) affords an improvement on several limitations of LTA. EIA works via measuring resistance between two electrodes submerged in whole blood or PRP (Figure A3) [19]. The addition of an agonist causes platelets to aggregate around the electrodes, corresponding to an increase in sample resistance [20,21]. EIA allows measurement of platelet aggregation in whole blood, thus eliminating the need for blood sample processing, but currently requires expensive semiautomated equipment and trained personnel to operate it. Despite the reliability and high value of the information provided by both LTA and EIA, their shared limitations minimize their clinical use. Based on the FDA premarket approval, LTA and EIA instruments are generally conducted as “research use only” devices or with restricted “intended use” considerations restraining their use for POC diagnostics [22,23].

To overcome the limitations of commercial aggregometers, we designed and fabricated a portable, accurate, and easy-to-use platelet aggregometer able to measure platelet aggregation in whole blood and PRP. Our platform, called “MICELI” (MICROfluidic, ELectrical, Impedance), is an impedance aggregometer recording the change in resistance resulting from platelet aggregation on electrodes within a miniature polymeric cartridge. Impedance data are converted into aggregation values: maximum amplitude (A_{max}) and area under the curve (AUC) [24]. Only a small sample volume (250 μ L) is required for a single test, and aggregation values indicating platelet function are obtained in under 10 min. The initial testing of the MICELI performed with PRP demonstrated its accuracy and reproducibility [25]. As a portable, accurate, easy-to-use, and low-cost technology, the MICELI

aggregometer has potential for further clinical translation as a POC diagnostic device for platelet function testing. Therefore, our current study aimed to: (1) optimize the MICELI assay protocol, i.e., blood sample volume, storage time, and anticoagulation regimen; (2) validate the device's sensitivity to aggregation agonists and crucial blood characteristics, i.e., platelet count and hematocrit; and (3) verify the MICELI operational performance as compared with the Multiplate[®] Analyzer, a commercial impedance aggregometer.

2. Results

The current study was dedicated to the optimization and internal validation of the MICELI system, a miniature impedance aggregometer designed and fabricated by our team. Optimization of the MICELI aggregometer and assay protocol aimed at addressing the following points: (1) defining the optimal blood sample volume, allowing consistent data acquisition (as indicated by high AUC and Amax, along with low lag time (LT) and noise); (2) establishing the maximum blood sample storage time (as a time window when valid and consistent aggregation data could be collected); and (3) identifying optimal blood anticoagulant, allowing maximal and consistent aggregation measurements. On the other hand, internal validation aimed at evaluating the crucial characteristics of the MICELI system included: (1) sensitivity to classic biochemical agonists and their concentrations, (2) sensitivity to platelet count and hematocrit, and (3) operational performance as compared with the Multiplate[®] Analyzer, a commercial impedance aggregometer.

2.1. Optimization of the MICELI aggregometer and assay protocol

2.1.1. Sample Volume

Uniform platelet aggregation on the electrodes of the MICELI cartridge largely relies on the sample volume. Sufficient blood volume is required to fully submerge electrodes and minimize stirring flow forces that might disturb formation of platelet aggregates on the electrode surface. Low sample volume at comparably high angular speed of stirring (up to 1000 rpm) recommended for aggregation assays may result in high noise, affecting the consistency of impedance data acquisition and low aggregation values [26,27]. Therefore, the sample volume optimization, with a specific focus on the sample to stir bar volume ratio (VR), is usually recommended for the specific device in use.

In our study, we evaluated the effect of three sample volumes (200, 250, and 300 μ L) on platelet aggregation induced by ADP (20 μ M). The VR values for every sample volume were calculated as shown in Figure 1A. The effect of VRs on platelet aggregation parameters, i.e., AUC, Amax, and LT, as well as reproducibility of data acquisition (noise level) were evaluated. We found that VR 20 was characterized by the highest values of AUC and Amax, yet the measurements were quite noisy and resulted in higher standard deviation of aggregation parameters as compared to other VR tests were registered (Figure 1B). VR 25 showed comparable values of aggregation parameters as those of VR 20, however, results were more reproducible, as indicated by low SD and noise. The VR 30 was characterized by significantly lower AUC and Amax, with the same degree of reproducibility as VR 25. Interestingly, among all aggregation parameters LT was not affected by the VR.

Statistical analysis of the results confirmed that the Amax and AUC values obtained for VR 25 were significantly higher than for VR 30 (11.8 ± 2.8 Ohm and 32.6 ± 5.6 Ohm*min vs. 7.9 ± 2.3 Ohm and 24.7 ± 7.4 Ohm*min, $p < 0.05$). Aggregation levels obtained with VR 20 did not significantly differ from VR 25, but were affected by a significantly higher level of noise (0.21 ± 0.05 Ohm vs. 0.41 ± 0.17 Ohm, $p < 0.01$). Therefore, VR 25, which corresponds to a blood sample volume of 250 μ L, was selected as the optimal sample volume for the MICELI aggregometer, allowing acquisition of high aggregation values with good reproducibility and low levels of noise.




Figure 1. The effect of the sample to stir bar volume ratio (VR) on aggregation parameters collected by the MICELI (microfluidic, electrical, impedance) system: (A) calculation of VR for three sample volume tested, i.e., 200, 250, and 300 µL, and siliconized stir bar (#311, Chrono-log Corporation, Havertown, PA); (B) the effect of different VRs on ADP-induced platelet aggregation in ACD-anticoagulated whole blood: 1—area under the curve (AUC), 2—maximum aggregation (A_{max}), 3—lag time, and 4—noise, i.e., the amplitude of the impedance fluctuation over assay time. Data from 4 independent experiments using blood sample from 4 different individuals are reported. Mean ± SD as error bars of aggregation parameters are indicated, ANOVA: * $p < 0.05$, ** $p < 0.01$.

2.1.2. Blood Storage Time

For LTA, it is well documented that platelet aggregation in PRP could be affected by the sample storage time [28,29]. The recommended time interval for assay performance is within 3 h of blood draw [29]. Yet, the effect of storage time on platelet aggregation in whole blood when tested via EIA remained to be established. We evaluated the effect of the blood storage time, as the time interval between blood collection and aggregation test, on platelet aggregation parameters, i.e., AUC, A_{max}, and LT, recorded by the MICELI aggregometer.

We demonstrated that ADP-induced platelet aggregation was sensitive to the time elapsed from blood collection and tended to decrease over the storage time (Figure 2). The maximum aggregation decreased significantly within four hours, as compared with the first and second hour (3.5 ± 1 Ohm vs. 5.6 ± 2.2 Ohm and 5.5 ± 2.2 Ohm, respectively; ANOVA: $p < 0.05$). The area under the curve also tended to decrease over time, in particular between the second and third hour, although the decrease did not reach a level of significance. Lag time was not affected by the storage time. Thus, our results indicate that storage time has a significant impact on ADP-induced platelet aggregation in whole blood, and a delay of greater than two hours should be avoided.




Figure 2. The effect of storage time on ADP-induced platelet aggregation in ACD-anticoagulated whole blood: (A) area under the curve (AUC); (B) maximum aggregation (A_{max}); and (C) lag time. Data from 6 independent experiments using blood samples from 6 different individuals are reported. Mean ± SD as error bars of aggregation parameters are indicated, ANOVA: no asterisk— $p > 0.05$; * $p < 0.05$.

2.1.3. Blood Anticoagulation Regimen

The anticoagulation of blood samples with calcium chelating agents, i.e., sodium citrate, ACD, and EDTA, as well as thrombin inhibitors, i.e., hirudin and heparin, is well established as to agent efficacy in blocking coagulation. Nevertheless, these agents have been demonstrated to affect platelet aggregation in whole blood [30–32]. In our study, we tested four anticoagulants commonly used for platelet aggregometry, i.e., sodium citrate, ACD, hirudin, and heparin. We demonstrated that all three aggregation parameters (AUC, A_{max}, and LT) were largely affected by the anticoagulation regimen selected (Figure 3). As such, hirudin showed the highest values for area under the curve and maximum aggregation as combined with low lag time. Statistically significant differences were observed between citrate and hirudin for both AUC (15.8 ± 7.8 Ohm*min vs. 27.3 ± 6.7 Ohm*min, $p < 0.05$) and A_{max} (5.9 ± 2.8 Ohm vs. 10.4 ± 2.2 Ohm, $p < 0.05$). For lag time, a statistically significant difference was demonstrated between ACD and hirudin (99 ± 30.9 s vs. 62.6 ± 26.1 s, respectively; $p < 0.05$). In conclusion, amongst the four anticoagulants tested, hirudin was shown to be the most appropriate option for measuring platelet aggregation in whole blood using the MICELI aggregometer. The MICELI validation was then performed with the primary focus on hirudinized whole blood samples.




Figure 3. The effect of anticoagulant regimen on ADP-induced platelet aggregation in ACD-anticoagulated whole blood: (A) area under the curve (AUC); (B) maximum aggregation (A_{max}); (C) lag time. Data from 4 independent experiments using blood samples from 4 different individuals are reported. Mean ± SD as error bars of aggregation parameters are indicated, ANOVA: no asterisk— $p > 0.05$; * $p < 0.05$.

2.2. Validation of the MICELI aggregometer

2.2.1. Sensitivity and Precision with Different Aggregation Agonists and Their Concentration

In vivo platelet aggregation occurs as a result of platelet exposure to various biochemical agonists, e.g., ADP, collagen, epinephrine, and thrombin [1]. These agents, as well as their synthetic mimetics, are also used to promote platelet aggregation in vitro [33]. For internal validation of the MICELI aggregometer, four commonly used platelet aggregation agonists were used: ADP, collagen, epinephrine, and thrombin receptor-activating peptide 6 (TRAP-6)—a thrombin mimetic activating platelets via PAR-1-dependent pathway. Additionally, calcium ionophore A23187, a powerful platelet agonist facilitating a rapid increase of intracellular calcium concentration and inducing maximum platelet activation and aggregation response, was used as a positive control [34]. Platelet aggregation in both hirudin-anticoagulated blood and PRP was tested.

We showed that platelet aggregation response was registered for all agonists tested, yet the extent of platelet aggregation significantly varied. For the vast majority of biochemical agonists, platelet aggregation curves appear as steady increase of impedance with a tendency to saturation more evident in PRP than in whole blood (Figure 4a,b). Also, platelet aggregation values recorded in whole blood were higher than those in PRP. As expected, the highest platelet aggregation was detected for calcium ionophore in both whole blood and PRP samples, while epinephrine showed considerably lower aggregation values. In whole blood, significant differences were observed between platelet aggregation induced by epinephrine and calcium ionophore ($17.3 \pm 8.4 \text{ Ohm}\cdot\text{min}$ vs. $37.6 \pm 13.3 \text{ Ohm}\cdot\text{min}$, ANOVA: $p < 0.05$), as well as between epinephrine and TRAP-6 ($17.3 \pm 8.4 \text{ Ohm}\cdot\text{min}$ vs. $28.1 \pm 11.7 \text{ Ohm}\cdot\text{min}$, ANOVA: $p < 0.001$) (Figure 4c). The difference did not reach statistical significance in PRP samples (Figure 4d, ANOVA: $p < 0.05$). ADP induced consistent high-amplitude aggregation in both whole blood and PRP, when collagen was more potent in blood and showed much lower aggregation response in PRP.




Figure 4. Platelet aggregation induced by different agonists in hirudin-anticoagulated whole blood (A,C) and platelet-rich plasma (B,D): AUC—area under the curve. (A,B) Illustrative aggregation curves recorded by the MICELI in whole blood and PRP, correspondingly. Data from 5 independent experiments using blood samples from 5 different individuals are reported. Mean \pm SD as error bars of AUC are indicated, ANOVA: no asterisk- $p > 0.05$; ** $p < 0.01$, *** $p < 0.005$.

To evaluate precision of the MICELI aggregometer, we calculated coefficient of variation (CV) of aggregation values obtained in whole blood and PRP using platelet agonists inducing consistent platelet aggregation, i.e., ADP, TRAP-6, collagen, and calcium ionophore. Thus, interdonor variability was evaluated as CV of aggregation parameters measured across three different donors having similar platelet count and hematocrit levels. Intradonor variability was calculated as CV of aggregation parameters measured for the same donor within the same experiments. The MICELI device demonstrated decent precision as indicated by inter- and intradonor variability of AUC values (Table 1). Both inter- and intradonor variability of the aggregation parameters was significantly lower in PRP than in whole blood for all agonists tested. ADP and TRAP-6 showed lower CV for both inter- and intradonor distribution in PRP and whole blood, while collagen exhibited higher level of variability in whole blood than in PRP. Calcium ionophore-induced aggregation was characterized by good reproducibility regardless of the platelet sample type across all donors tested.

Table 1. Precision of the MICELI aggregometer using different platelet agonists as indicated by intra- and interdonor variability of area under the curve (CV, %).

| Agonist Type | Intradonor Variability ¹ | | Interdonor Variability ² | |
|--------------|-------------------------------------|-------------|-------------------------------------|-------------|
| | PRP | Whole blood | PRP | Whole blood |
| ADP | 16 | 24 | 4 | 18 |
| TRAP-6 | 6 | 23 | 11 | 11 |
| Collagen | 4 | 26 | 14 | 22 |
| Ca ionophore | 23 | 21 | 8 | 6 |

¹ Aggregation tested in one donor, platelet count: 280,000 platelets/ μ L, hematocrit: 39%; ² Aggregation tested in 3 donors, platelet count: 250–290,000 platelets/ μ L, hematocrit: 37–39%.

To test the sensitivity of the MICELI device to agonist concentrations in whole blood, platelet aggregation was induced with ADP and collagen. Threshold agonists' concentrations were chosen based on recommendations of the previous studies aimed to validate platelet aggregometry assays for clinical use [35]. The resulting curves showing a linear, dose-dependent increase of platelet aggregation with the increase of agonist concentration are reported in Figure 5. Platelet aggregation induced by ADP appeared to be less sensitive to increments of agonist concentration than collagen-induced aggregation, as indicated by the notable increase of the Amax in response to the increase of collagen but not ADP concentration (Figure 5a,b). For ADP-induced aggregation, significant differences were found for 1 μ M vs. 10 μ M vs. 20 μ M ADP (16.4 ± 11.7 Ohm*min, 29.3 ± 16.9 Ohm*min, and 33.3 ± 17.7 , ANOVA: $p < 0.05$) with $R^2 = 0.9845$, indicating dissent linear correlation of AUC and ADP concentration in whole blood. Platelet aggregation response to collagen showed significant differences between final collagen concentrations of 1 μ M and 10 μ M (12.5 ± 6.3 Ohm*min vs. 31.9 ± 17.8 Ohm*min, ANOVA: $p < 0.01$) with $R^2 = 0.998$, indicating very strong linear correlation between AUC and collagen concentration. The obtained results prove that the MICELI aggregometer was sensitive to changes in the concentration of both ADP and collagen in whole blood anticoagulated with hirudin.




Figure 5. Platelet aggregation induced by different concentrations of ADP (A,C) and collagen (B,D) in hirudin-anticoagulated whole blood: AUC—area under the curve. (A,B)—illustrative curves of ADP- and collagen-induced aggregation recorded by the MICELI. Data from 4 independent experiments using blood samples from 4 different individuals are reported. Mean \pm SD as error bars of AUC are indicated, ANOVA: no asterisk— $p > 0.05$; *— $p < 0.05$; **— $p < 0.01$.

2.2.2. Sensitivity to platelet count and hematocrit

The influence of platelet count and red blood cell volume (hematocrit) on aggregation parameters has been previously reported for both LTA and EIA [32,36–38]. Thus, we tested the MICELI sensitivity to platelet count and hematocrit in order to establish a lower detection limit for platelet count and optimal operating conditions. To evaluate the effect of platelet count on platelet aggregation parameters, we employed two strategies: (1) platelet count in hirudin-anticoagulated whole blood was defined for every donor, ADP-induced platelet aggregation was recorded, and correlation of platelet count with aggregation parameters was evaluated; (2) platelet count in PRP was manually adjusted with PPP, ADP-induced platelet aggregation was recorded, and correlation of platelet count with aggregation parameters was evaluated. As shown in Figure 6a, the amplitude of platelet aggregation in hirudinized blood positively correlated with platelet count, within the count range of 150,000–400,000 platelets/ μ L with a modest correlation coefficient ($R^2 = 0.7661$). Similarly, the extent of platelet aggregation steeply increased with the elevation of platelet count in PRP within the count range of 100,000–370,000 platelets/ μ L, showing even stronger linear correlation ($R^2 = 0.9862$, Figure 6b). No aggregation was detected in PRP samples containing 50,000 platelets/ μ L. To summarize, the MICELI aggregometer showed high sensitivity to platelet count in hirudin-anticoagulated whole blood and PRP, with the lower detection limit of 100,000 platelets/ μ L.




Figure 6. The extent of platelet aggregation linearly correlates with platelet count in hirudin-anticoagulated whole blood (a) and platelet-rich plasma (b): AUC—area under the curve. In whole blood, the actual platelet count was not adjusted. In PRP, platelet count was manually adjusted by adding platelet-poor plasma. Then, platelet aggregation was induced by 20 μ M ADP. Data from 12 (a) or 6 (b) independent experiments using blood samples from different donors are reported. Mean \pm SD as error bars of AUC are indicated.

Platelet aggregation values showed no significant correlation with hematocrit in hirudin-anticoagulated whole blood, although a slight negative correlation could be noticed ($R^2 = 0.463$, Figure 7a). Our observations revealed that individuals with high hematocrit and lower platelet count tended to show lower platelet aggregation levels than those with low platelet count and moderate or low hematocrit. Yet, another interesting finding emerged; we found that the baseline level of impedance recorded by the MICELI (a “starting point” of the aggregation curve prior to agonist introduction) positively correlated with hematocrit value in hirudinized blood ($R^2 = 0.7393$, Figure 7b). Very strong linear correlation of the baseline impedance with the hematocrit values was further confirmed in the system where hematocrit was manually adjusted with PRP within hematocrit values of 35–50% ($R^2 = 0.9662$). Thus, we concluded that hematocrit did not significantly affect platelet aggregation values tested with the MICELI aggregometer, yet hematocrit values indeed predefined the baseline impedance of the whole blood sample.




Figure 7. The influence of hematocrit on ADP-induced platelet aggregation in hirudin-anticoagulated whole blood. (a) Platelet aggregation is not significantly affected by hematocrit within physiological range 36%–45%; (b) The baseline impedance strongly correlates with hematocrit: AUC—area under the curve. A total of 20 μ M ADP was used to induce platelet aggregation. Data from 12 (a) or 9 (b) independent experiments using blood samples from different individuals are reported. Mean \pm SD as error bars are indicated.

2.2.3. Operational Performance of the MICELI Aggregometer as Compared with Multiplate[®] Analyzer

The Multiplate[®] Analyzer is a semiautomated commercial impedance aggregometer capable of measuring platelet aggregation in whole blood and PRP. In our study, it was used as a reference device for comparison with the MICELI aggregometer. Aggregation response was tested in hirudin-anticoagulated blood samples of six individuals, using each of these devices. Platelet aggregation was induced with different concentrations of ADP (1, 5, or 10 μM). The dose-dependent increase of aggregation parameters with the increase of agonist concentration was reported for both aggregometers (Figure 8). Aggregation parameters obtained by the MICELI and Multiplate[®] showed good correlation, with Pearson coefficients equal to 0.92 and 0.98, for AUC and Amax, respectively. Both aggregometers demonstrated the same sensitivity to ADP concentration. For the MICELI, AUC values were significantly different for 1 and 5 μM ADP ($4.3 \pm 2.5 \text{ Ohm}^*\text{min}$ vs. $8.6 \pm 2.1 \text{ Ohm}^*\text{min}$, $p < 0.05$) and for 1 and 10 μM ADP ($4.3 \pm 2.5 \text{ Ohm}^*\text{min}$ vs. $13.2 \pm 5.9 \text{ Ohm}^*\text{min}$, $p < 0.05$). Similarly, for the Multiplate[®] Analyzer, AUC significantly differed between 1 and 5 μM ADP ($299 \pm 67 \text{ AU}^*\text{min}$ vs. $515 \pm 90 \text{ AU}^*\text{min}$, $p < 0.05$) and between 1 and 10 μM ADP ($299 \pm 67 \text{ AU}^*\text{min}$ vs. $555 \pm 168 \text{ AU}^*\text{min}$, $p < 0.005$). We also have noticed that when aggregation parameters reported by the MICELI linearly increased with the increase of ADP concentration from 1 to 10 μM , with the Multiplate[®] Analyzer, the saturation of aggregation levels observed after 10 μM ADP was added (for both AUC and Amax).




Figure 8. Comparison of aggregation parameters of ADP-induced platelet aggregation recorded by the MICELI aggregometer and Multiplate[®] Analyzer. Platelet aggregation in hirudin-anticoagulated whole blood was induced by 1, 5, or 10 μM ADP: (a) area under the curve (AUC); (b) maximum aggregation (A_{max}). Data from 6 independent experiments using blood samples from 6 different individuals are reported. Mean \pm SD as error bars of aggregation parameters are indicated, ANOVA: no asterisk— $p > 0.05$; * $p < 0.05$; ** $p < 0.01$.

In Table A1, the interdonor distribution of AUC values obtained by the MICELI and the Multiplate[®] Analyzer aggregometers in our lab, as well as AUC values provided in the Multiplate[®] user manual, are reported. The 5[°]–50[°] and the 50[°]–95[°] percentiles obtained for the Multiplate[®] in our study were significantly lower than those reported in the instrument manual. It could be explained by a high interdonor variability and the low number of donors tested. The Multiplate[®] percentile values were very close to the MICELI ones, indicating that the statistical distributions of data obtained with the MICELI and Multiplate[®] are similar.

3. Discussion

In the current study, we optimized and validated the MICELI, a miniature impedance aggregometer designed and fabricated by our team. As a result of this optimization and validation effort, we developed a standard protocol of aggregometry testing using the MICELI; defined the instrument sensitivity to classic biochemical agonists and key blood characteristics, i.e., platelet count and hematocrit;

and compared the MICELI operational performance with the Multiplate® Analyzer, a commercial impedance aggregometer.

In the protocol optimization step, three critical settings of the experimental protocol were evaluated: the sample volume, the reliability of the aggregation measurements over blood storage time, and blood anticoagulation regimen. The optimal blood sample volume for MICELI aggregometry was defined as 250 µL, which allows acquisition of maximum platelet aggregation parameters with high reproducibility and minimum measurement noise. We showed that prolonged sample storage resulted in a steady decline of platelet aggregation. Thus, the optimal time gap for data collection using MICELI system should not exceed 2 h following blood sampling. This finding is in agreement with previous reports showing that impedance aggregometry in whole blood is very sensitive to blood storage time. Dézsi et al. observed a significant drop of ADP-induced aggregation as measured by the Multiplate® Analyzer from 1 to 4 h post blood collection [39], while both Jilma-Stohlawetz et al. and Johnson et al. reported a significant decline of platelet function and the increase of result variability, even after 2–3 h post blood sampling [40,41].

Testing the blood anticoagulation regimen, we showed a significantly weaker platelet aggregation response in blood anticoagulated with sodium citrate and ACD, as compared to hirudin-anticoagulated samples. The anticoagulant preference can be ordered as: hirudin > heparin > ACD >= sodium citrate. The same tendency was observed by other researchers and could be explained by the fact that citrate inhibits coagulation by chelating calcium from the blood sample, while hirudin directly inhibits thrombin maintaining physiologic calcium levels required for platelet aggregation [30,42,43]. Johnson et al. showed that recalcification of citrate-anticoagulated blood resulted in aggregation values similar to those obtained for hirudin [41]. Therefore, our study clearly demonstrated that hirudin is the most suitable anticoagulant for MICELI aggregometry testing, which is in agreement with the current recommendations for other platelet aggregometry assays, such as LTA and Multiplate® [41,43].

After assessing the impact of the preanalytical variables, the standard protocol for the MICELI aggregometry was devised as follows: 1) a sample volume of 250 µL, 2) hirudin anticoagulated whole blood, and 3) an assay time window of 2 h from blood collection. This protocol was further used for the MICELI validation. Within the validation efforts, a series of experiments were performed to investigate the device's capability to measure platelet aggregation induced by different agonists acting via different platelet signaling pathways. For this purpose, four commonly utilized platelet agonists (ADP, TRAP-6, collagen, and epinephrine) were tested as compared with calcium ionophore, a powerful platelet stimulator nonspecifically inducing the increase of intracellular calcium and facilitating a maximum platelet response. We found that the MICELI aggregometer was able to record platelet aggregation induced by all agonists tested, in whole blood and PRP, with high consistency and reproducibility. The platelet agonists' capability to promote platelet aggregation in whole blood is as follows: calcium ionophore > collagen > ADP > TRAP-6 > epinephrine. A significantly lower platelet response to epinephrine detected by the MICELI is in agreement with previous reports showing that platelet response to epinephrine, as measured by impedance aggregometry, is typically absent or very weak [44,45]. Inter- and intradonor variability of the aggregation values assessed by the MICELI was also comparable to those previously reported for the Multiplate® aggregometry system [30].

We then explored MICELI sensitivity to different agonist concentrations, using the most potent physiologically relevant agonists, i.e., ADP and collagen. A strong linear correlation of aggregation parameters with agonist concentration revealed good sensitivity of the MICELI aggregometer to agonist concentration increments. Significant differences were observed between agonist doses, suggesting that the device can detect even micromolar changes in ADP and collagen concentrations in whole blood. Low-level aggregation was detected even at minimal agonist concentrations, 1 µM ADP and 1 µg/mL collagen, recommended for clinical application of EIA [35]. These experiments showed that the MICELI aggregometer could be used to evaluate different pathways of platelet activation and provide comprehensive information on platelet function and the effectiveness of antiplatelet therapy.

The effect of key blood parameters on MICELI results was investigated by assessing the influence of platelet count and hematocrit on platelet aggregation. Platelet aggregation parameters recorded by the MICELI strongly correlated with platelet number in whole blood and PRP. The minimum detection limit of the MICELI, defined as minimal platelet count when aggregation could be recorded, was identified as 100,000 platelets/ μL . Therefore, the MICELI aggregometer could be successfully employed to detect platelet aggregation in donors within the normal platelet range, while platelet function testing in thrombocytopenic or anemic patients might be somewhat challenging with the current MICELI fabrication. Hematocrit did not significantly affect platelet aggregation values, though a slight negative correlation was noticed ($R^2 = 0.463$). Similarly, aggregation values obtained by the Multiplate[®] Analyzer were reported to depend on both platelet count and hematocrit, even within the normal range of these parameters [32,36,38]. Muller et al. specifically reported that the presence of large number of red blood cells was associated with low levels of aggregation detected via impedance aggregometry [38], which corresponds to our observations.

Analyzing aggregation curves obtained by the MICELI, we discovered that the baseline impedance value recorded prior to agonist introduction (see Figure A3a) strongly correlated with the hematocrit value of the sample tested (Figure 7b). In other impedance aggregometers, i.e., Multiplate[®] and CHRONO-LOG[®], the baseline impedance value is not displayed to a user. The device's software normalizes the increment of impedance towards the baseline value of the sample, and the typical starting point of the aggregation curve equals to 0 Ohm (Figure A3c). Nevertheless, our finding clearly demonstrates that the baseline impedance value of a blood sample could be used to collect additional data from the donor blood sample using the same hardware of the MICELI aggregometer. In other words, the MICELI system could be equipped with the capability of electronic measurement of the hematocrit, a crucial blood parameter. The successful use of the Multiplate[®] Analyzer in the hemostatic management of patients with a history of antiplatelet medication use, with concomitant emergent need for neurosurgical therapy, was previously demonstrated in several small-cohort studies [46,47]. Thus, the MICELI aggregometer, when equipped with additional capabilities and translated to a POC diagnostic device, will provide platelet function and hematocrit data, both critical diagnostic parameters for bleeding management and verification of hemostatic transfusion outcomes [47–49].

The last step of the MICELI validation aimed to compare its operational performance with the Multiplate[®] Analyzer. Good correlation has been reported between aggregation parameters of ADP-induced platelet aggregation detected by the MICELI and Multiplate[®] Analyzer (with Pearson's coefficients for AUC and Amax equal to 0.92 and 0.98, correspondingly). The interdonor distribution of the MICELI measurements was also similar to the Multiplate[®], as detected in our lab (Table A1) and reported by the Multiplate[®] user manual and other studies [30,41]. The sensitivity of both devices to ADP concentrations were similar. The MICELI and Multiplate[®] detected platelet aggregation in response to stimulation with 1 μM ADP (minimal concentration tested). However, the Multiplate[®] reported lower aggregation values induced by 10 μM ADP (maximum concentration tested). The last observation might be explained by the fact that the Multiplate[®] protocol requires dilution of a blood sample with saline (1:1), which results in the decrease of platelet count as compared with the nondiluted blood sample used for the MICELI data acquisition. So, the MICELI has a higher ratio between platelet count and electrode surface available. Therefore, when the ADP concentration increases from 5 to 10 μM in the MICELI sample, there are more platelets available for aggregation, while in the Multiplate[®], there are no more platelets available and maximum impedance has almost reached its saturation point. This difference in the MICELI vs. Multiplate[®] protocol might provide a critical benefit when the measurement of platelet function is required in thrombocytopenic or anemic patients with low platelet count. Additional dilution of the blood sample may lead to the Multiplate[®] being unable to record aggregation, while the MICELI, given its equal reliability and operational performance, will still provide valid aggregation data.

The results of the MICELI aggregometer validation underscore the efficacy of this approach and facilitate further design advance towards its translation. The novelty of the prototype lies in the

miniature form factor as compared with bulky competitors as well as the original design of the MICELI cartridge. As utilized in this study the single cartridge prototype was proven as a fully functional device enabling acquisition of real-time aggregation data from a 250 μ L blood aliquot. The cartridge represents a single-well unit with two silver electrodes crossing the well horizontally and is secured from both ends within the walls of the well. Unlike the Multiplate[®] analyzer, the MICELI protocol does not require blood dilution, which decreases the number of pipetting steps and correspondent user error. Analyzing rough impedance data of a donor sample, the MICELI is capable of acquiring other important blood parameters, e.g., hematocrit (given the good positive correlation between blood impedance values and hematocrit).

Based on the results of the MICELI validation and feedback from its in-house utilization, the next immediate steps will include development of the second-generation prototype overcoming limitations of the described system. Thus, the effort was focused on the design and manufacturing of the self-filling cartridge with strict volume control; an agonist in biostable form preloaded in the cartridge well; multi-well cartridge to increase device turnaround; real-time analysis of impedance data and quick readout of the aggregation parameters. These advances will allow the evolution of the present system to one that is effective in the clinic and eventually in the point-of-care.

Limitations. The MICELI aggregometer prototype described in the manuscript shares the limitations of the current impedance aggregometers, e.g., comparably low reproducibility of aggregation data; high intra- and interdonor variability; and a multistep protocol requiring highly accurate pipetting of whole blood samples and agonists. Given the early stage of technology development, the prototype has a fairly primitive look and multicomponent setup.

4. Materials and Methods

4.1. Blood Collection and Anticoagulation

Blood was obtained from 42 healthy adult volunteers (19 females and 23 males) who provided their informed consent for inclusion before they participated in the study and claimed to abstain from medications affecting platelet function for two weeks prior to the experiment. The study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the Institutional Review Board of the University of Arizona (Study Protocol #1810013264). The donor pool approximated the ethnic, racial, and gender categories distribution per 100 enrollees according to the geographic location of the University of Arizona (Pima County, AZ) [50]. Blood was drawn by venipuncture via a 21-gauge needle and anticoagulated with either acid citrate dextrose solution (ACD, 85 mM trisodium citrate, 78 mM citric acid, 111 mM glucose), blood: ACD ratio—10:1, or hirudin (Aniara, West Chester, OH, USA) in final concentration 525 ATU/mL. Alternatively, blood was collected into Vacutainer[®] tubes containing sodium citrate (final concentration—3.2%) or heparin (final concentration—17 IU/mL). Platelet-rich plasma (PRP) was obtained by centrifugation of ACD-anticoagulated blood at 300 \times g for 15 min at room temperature. The remaining blood was recentrifuged at 1200 \times g for 15 min at room temperature to obtain the platelet-poor plasma (PPP) required for platelet count standardization. Whole blood and PRP were stored and handled at room temperature if not otherwise indicated. Platelet count was quantified with Z1 Coulter Particle Counter (Beckman Coulter Inc., Indianapolis, IN, USA). Hematocrit was assessed using routine microhematocrit method [51].

4.2. The MICELI Impedance Aggregometry System Setup

The MICELI system is a multicomponent prototype of a miniature impedance aggregometer capable of evaluation of platelet aggregation in whole blood and PRP. The system consists of a miniature polymeric cartridge, magnetic stirrer, thermostatic chamber, and impedance analyzer communicating with an operator's laptop via Wi-Fi (Figure 9a,c). The MICELI cartridge, a crucial element of the system, is composed from two superimposed polydimethylsiloxane layers (13 mm \times 20 mm) bonded to form a cylindrical reaction well ($d = 8$ mm, $h = 6.88$ mm, $V = 0.35$ mL) (Figure 9b,c). The drawing of the fully

assembled cartridge with its geometric dimensions is reported in Figure A1. Two silver wire electrodes ($d = 0.25$ mm, ALFA AESAR, Haverhill, MA, USA) bridge the reaction well and are connected to the impedance analyzer via small alligator clamps. A siliconized microstir bar (1.64 mm \times 4.78 mm, CHRONO-LOG Corporation, Havertown, PA, USA) was placed on the bottom of the reaction well when cartridge was fully assembled. The magnetic stirrer maintained continuous sample mixing at 250 rpm. Our in-house manufactured thermostatic chamber with a temperature controller allowed us to maintain reaction temperature at 37 °C (Figure A2). The impedance analyzer used in this MICELI setup was a STEMLab 125-10 single board computer (RedPitaya, Solkan, Slovenia) operated by the web-based application provided by the manufacturer. The impedance data acquisition and numerical analysis was performed using MATLAB software (Mathworks, Natick, MA, USA).




Figure 9. The MICELI system, a multicomponent prototype of the miniature impedance aggregometer: (a) workflow of the impedance aggregometry test using the MICELI system; (b) fully assembled MICELI cartridge; (c) the MICELI system components in a portable setup: 1—MICELI cartridge and its CAD drawing, 2—magnetic stirrer, 3—impedance analyzer, 4—power supply.

4.3. Impedance Aggregometry Using the MICELI System

Prior to an experiment, the thermostatic chamber was preheated to 37 °C. Then, 250 μ L of platelet-containing sample (whole blood or PRP) were placed in the MICELI cartridge and impedance data acquisition was started. When whole blood sample was anticoagulated with ACD-A or sodium citrate, recalcification of the sample with 1 mM CaCl_2 was performed to reimburse physiological calcium concentration. Following a 3 min incubation, an aliquot of agonist solution was added and platelet aggregation as the sample impedance increased was recorded for 6 min. The increase of the sample impedance occurs as result of agonist-induced platelet aggregation on the surface of cartridge electrodes (Figure A3A,B). An aggregation curve, i.e., increase of impedance over time, was then recorded and the following aggregation parameters were calculated: area under the curve (AUC, $\text{Ohm}\cdot\text{min}$), maximum aggregation (A_{max} , Ohm), and lag time (LT, s), i.e., a time gap between agonist introduction and aggregation start (Figure A3C).

The following biochemical agonists were applied to induce platelet aggregation: adenosine diphosphate (ADP, Sigma-Aldrich, St. Louis, MO, USA), thrombin receptor-activating peptide 6 (TRAP-6, AnaSpec Inc, Fremont, CA, USA), collagen (Helena Laboratories Corporation, Beaumont, TX, USA); epinephrine, and calcium ionophore A12387 (both from Sigma-Aldrich, St. Louis, MO). Agonists' final concentration and aliquot volume added to the reaction well are listed in Table 2:

Table 2. Final concentrations and aliquot volumes of biochemical agonists used to induce platelet aggregation in the MICELI system.

| Agonist Type | Concentration | Volume, μL |
|-------------------|----------------------------------|-----------------------|
| ADP | 1, 5, 10, 20 μM | 5 ¹ |
| TRAP-6 | 32 μM | 6.4 |
| Collagen | 1, 5, 10 $\mu\text{g}/\text{mL}$ | 25 ¹ |
| Epinephrine | 10 μM | 2.5 |
| Calcium ionophore | 5 μM | 2.5 |

¹ The aliquot volume remained constant for all agonist concentrations tested.

4.4. Impedance Aggregometry Using Multiplate[®] Analyzer

The aggregometry test using the Multiplate[®] Analyzer impedance aggregometer (Roche Diagnostics, Milano, Italy) was performed following the manufacturer's protocol for hirudin-anticoagulated blood. Briefly, hirudin-anticoagulated blood was diluted with saline (1:1). Then, 600 μL of diluted blood was placed in a Multiplate[®] well and incubated for 3 min. Platelet aggregation was initiated by adding an aliquot of ADP (final concentration 1, 5, or 10 μM). Aggregation curve was recorded for 6 min and aggregation parameters, i.e., area under the curve (AUC, AU*min) and maximum aggregation (Amax, AU), were calculated by the device software. The instrument allows duplicate measurement of each well and automatically provides the mean value of the two aggregation readings.

4.5. Statistical Analysis

Aggregation tests using the MICELI aggregometer or the Multiplate[®] Analyzer, as well as hematocrit assay, were performed in duplicates for every condition tested. The arithmetic mean and SD were then calculated. Statistical analysis of the numerical data was performed using GraphPad Prism 8 software (GraphPad Software, Inc., CA, USA). Normal distribution of evaluated parameters was tested with the Shapiro–Wilk normality test. The one-way analysis of variance (ANOVA) test was used when normality hypothesis was satisfied for all the groups tested. Conversely, nonparametric Kruskal–Wallis one-way ANOVA test was performed. Statistical significance was assumed for p -values at least lower than 0.05.

5. Conclusions

We designed and fabricated the MICELI, a miniature, easy-to-use, accurate impedance aggregometer, capable of measuring platelet aggregation in a small volume of whole blood or PRP. Protocol optimization has demonstrated that maximum aggregation values could be obtained in 250 μL of blood sample, hirudin as a blood anticoagulant should be used, and the blood sample must be tested within two hours of blood sampling. The MICELI validation has proven the device capability to detect platelet aggregation stimulated by all conventional agonists, i.e., ADP, TRAP-6, collagen, and epinephrine. The aggregation values recorded by the MICELI strongly correlate with platelet count and are not significantly affected by hematocrit in hirudinized whole blood. Interestingly, the baseline impedance of the blood sample recorded by the MICELI prior to agonist introduction strongly correlates with the hematocrit, potentially allowing the electronic detection of the hematocrit using the MICELI hardware. The operational performance of the MICELI as compared to the Multiplate[®] has further confirmed the reliability of our prototype. Aggregation data by the MICELI strongly correlate with the

Multiplate[®] values and show similar interdonor distribution. The MICELI, as a miniature, accurate, and easy-to-use impedance aggregometer, could be readily further translated to a commercial POC diagnostic device for real-time monitoring of platelet function to guide pharmacological hemostatic management and transfusion outcomes. Keeping in mind that the device is still a prototype, the results are encouraging and pave the way for future development as an automated, low-cost, and easy-to-use POC platelet function test.

6. Patents

International Application # PCT/US18/38955. Systems and Methods for Analyzing of Platelet Function. Filed by Arizona Board of Regents on behalf of the University of Arizona on 22 June 2018. Inventors: Alberto Redaelli and Marvin J. Slepian.

Author Contributions: Joint first authors: Y.R.-M. and S.B. Joint last authors: A.R. and M.J.S. Conceptualization, A.R. and M.J.S.; methodology, Y.R.-M., M.R., and F.C.; software, G.M. and C.F.; validation, G.M., C.F., A.D., M.R., M.S., and A.S.; formal analysis, Y.R.-M., G.M., and C.F.; investigation, Y.R.-M., G.M., and C.F.; resources, A.R. and M.J.S.; data curation, Y.R.-M. and S.B.; writing—Y.R.-M., S.B., G.M., and C.F.; writing—review and editing, Y.R.-M., A.R. and M.J.S.; visualization, G.M., C.F., A.D., and A.S.; supervision, M.C., A.R., and M.J.S. All authors have read and agree to the published version of the manuscript.

Funding: This research was funded by Arizona Center for Accelerated Biomedical Innovation of the University of Arizona, National Collegiate Inventors and Innovators Alliance (E-Team Stage 1 and 2 Grants), and the Italian Ministry of Health (RF-2018-12367710).

Acknowledgments: The authors of the manuscript would like to express their gratitude to Daniel E. Palomares, Annalisa Dimasi, and Adriana Ivich for provided technical support, and to John J. Jackson Sr. for administrative support of the project.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Abbreviations

| | |
|--------|--|
| POC | Point-of-care |
| LTA | Electrical impedance aggregometry |
| EIA | Light transmission aggregometry |
| PRP | Platelet-rich plasma |
| PPP | Platelet-poor plasma |
| ADP | Adenosine diphosphate |
| TRAP-6 | Thrombin receptor-activating peptide 6 |
| AUC | Area under the curve |
| AU | Arbitrary unit |
| ACD | Acid citrate dextrose |
| Amax | Maximal aggregation |
| LT | Lag time |
| VR | Volume ratio |

Appendix A




Figure A1. The drawings of the fully assembled cartridge utilized by the MICELI system with geometric dimensions of the cartridge, reaction well, and electrode channels.




Figure A2. The MICELI aggregometer bench top setup with thermostatic chamber: 1) in-house manufactured thermostatic chamber; 2) impedance analyzer; 3) external unit controlling the thermostatic chamber; and 4) magnetic stirrer.




Figure A3. The impedance aggregometry: (a) basic principle of the electrical impedance aggregometry: 1—platelet-contained sample is placed in the cartridge with electrodes (basal level of sample impedance is recorded), 2—platelet agonist is added to initiate platelet aggregation on electrodes (platelets start to aggregate on electrode surface causing the increase of sample impedance), 3—platelets have coated the electrodes (the maximum impedance value is registered); (b) microscope images of the MICELI cartridge electrodes: left panel—platelet-rich plasma (bright field, 4x magnification); right panel—whole blood (fluorescence microscopy) (c) typical aggregation curve recorded by the MICELI: AUC—area under the curve, Amax—maximum aggregation, LT—lag time.

Table A1. The range of interdonor distribution of AUC values for aggregation, recorded by the MICELI and the Multiplate® Analyzer.

| Statistical Value | MICELI (5 µM ADP) | Multiplate® (5 µM ADP) | Multiplate® User Manual (6.4 µM ADP) |
|-----------------------------------|----------------------|---------------------------|---|
| n | 6 | 6 | 64 |
| Median | 8.65 | 500 | 775 |
| 5° Percentile | 5.83 | 410 | 474 |
| 95° Percentile | 10.77 | 630 | 1076 |
| Reference Range AUC | 8.65–10.67 | 410–630 | 474–1076 |
| 5° and 50° Percentile Difference | –33% | –18% | –39% |
| 50° and 95° Percentile Difference | 26% | 24% | 39% |

References

- Holinstat, M. Normal platelet function. *Cancer Metastasis Rev.* **2017**, *36*, 195–198. [[PubMed](#)]
- Koupenova, M.; Kehrel, B.E.; Corkrey, H.A.; Freedman, J.E. Thrombosis and platelets: An update. *Eur. Heart J.* **2016**, *38*, ehw550.
- Cattaneo, M.; Hayward, C.P.M.; Moffat, K.A.; Pugliano, M.T.; Liu, Y.; Michelson, A.D. Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry: A report from the platelet physiology subcommittee of the SSC of the ISTH. *J. Thromb. Haemost.* **2009**, *7*, 1029. [[PubMed](#)]
- Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. *BMJ* **2002**, *324*, 71–86.
- Grove, E.L.; Hossain, R.; Storey, R.F. Platelet function testing and prediction of procedural bleeding risk. *Thromb. Haemost.* **2013**, *109*, 817–824.
- Cayla, G.; Cuisset, T.; Silvain, J.; Leclercq, F.; Manzo-Silberman, S.; Saint-Etienne, C.; Delarche, N.; Bellemain-Appaix, A.; Range, G.; El Mahmoud, R.; et al. Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): An open-label, blinded-endpoint, randomised controlled superiority trial. *Lancet* **2016**, *388*, 2015–2022.
- Yeung, L.Y.Y.; Sarani, B.; Weinberg, J.A.; McBeth, P.B.; May, A.K. Surgeon's guide to anticoagulant and antiplatelet medications part two: Antiplatelet agents and perioperative management of long-term anticoagulation. *Trauma Surg. Acute Care Open* **2016**, *1*, e000022.
- Vilahur, G.; Choi, B.G.; Zafar, M.U.; Viles-Gonzalez, J.F.; Vorchheimer, D.A.; Fuster, V.; Badimon, J.J. Normalization of platelet reactivity in clopidogrel-treated subjects. *J. Thromb. Haemost.* **2007**, *5*, 82–90.
- Triulzi, D.J.; Assmann, S.F.; Strauss, R.G.; Ness, P.M.; Hess, J.R.; Kaufman, R.M.; Granger, S.; Slichter, S.J. The impact of platelet transfusion characteristics on posttransfusion platelet increments and clinical bleeding in patients with hypoproliferative thrombocytopenia. *Blood* **2012**, *119*, 5553–5562.
- Kerkhoffs, J.-L.H.; Eikenboom, J.C.J.; van de Wattering, L.M.G.; van Wordragen-Vlaswinkel, R.J.; Wijermans, P.W.; Brand, A. The clinical impact of platelet refractoriness: Correlation with bleeding and survival. *Transfusion* **2008**, *48*, 1959–1965.
- Soliman, M.; Hartmann, M. Impedance Aggregometry Reveals Increased Platelet Aggregation during Liver Transplantation. *J. Clin. Med.* **2019**, *8*, 1803. [[CrossRef](#)] [[PubMed](#)]
- Yorkgitis, B.K.; Ruggia-Check, C.; Dujon, J.E. Antiplatelet and anticoagulation medications and the surgical patient. *Am. J. Surg.* **2014**, *207*, 95–101. [[CrossRef](#)] [[PubMed](#)]
- Velik-Salchner, C.; Maier, S.; Innerhofer, P.; Streif, W.; Klingler, A.; Kolbitsch, C.; Fries, D. Point-of-care whole blood impedance aggregometry versus classical light transmission aggregometry for detecting aspirin and clopidogrel: The results of a pilot study. *Anesth. Analg.* **2008**, *107*, 1798–1806. [[CrossRef](#)] [[PubMed](#)]
- Koltai, K.; Kesmarky, G.; Feher, G.; Tibold, A.; Toth, K. Platelet aggregometry testing: Molecular mechanisms, techniques and clinical implications. *Int. J. Mol. Sci.* **2017**, *18*, 1–21. [[CrossRef](#)]
- Born, G.V.R.; Cross, M.J. The aggregation of blood platelets. *J. Physiol.* **1963**, *168*, 178–195. [[CrossRef](#)]
- Froneiro, J.P. *Haemostasis*; Springer Science Business Media: New York, NY, USA, 2013; Volume 992, pp. 227–240.
- Hvas, A.; Falavero, E.J. *Hemostasis and Thrombosis*; Springer: New York, NY, USA, 2017; Volume 1646, pp. 321–331.

18. Choi, J.-L.; Li, S.; Han, J.-Y. Platelet function tests: A review of progresses in clinical application. *Biomed Res. Int.* **2014**, *2014*, 456569. [CrossRef]
19. Cardinal, D.C.; Flower, R.J. The electronic aggregometer: A novel device for assessing platelet behavior in blood. *J. Pharmacol. Methods* **1980**, *3*, 135–158. [CrossRef]
20. Desconclois, C.; Valarche, V.; Boutekedjiret, T.; Raphael, M.; Dreyfus, M.; Proulle, V. Whole Blood Impedance Aggregometry: A New Tool for Severe Inherited Platelet Disorder Diagnosis? *Blood* **2011**, *118*, 5266. [CrossRef]
21. Mullins, E.S.; Stroop, D.; Ingala, D.; Tarango, C.; Luchtman-Jones, L.; Lane, A.; Gruppo, R.A. Comparison of Multiple Electrode Impedance-Based Platelet Aggregometry to Light Transmission Aggregometry for Diagnosis of Qualitative Platelet Defects. *Blood* **2017**, *130*, 1048.
22. 510(k) Number: K161329. Chrono-log Platelet Aggregometer, Model 490 4+4. Department of Health and Human Services Food and Drug Administration Indications for Use. Available online: https://www.accessdata.fda.gov/cdrh_docs/pdf16/K161329.pdf (accessed on 13 December 2019).
23. 510(k) Substantial Equivalence Determination Decision Summary: k103555. Multiplate 5.0 aggregometer. Platelet aggregometer assays: ADPtest (10 μ M ADP) and ASPtest (0.5 mM Arachidonic Acid). Available online: https://www.accessdata.fda.gov/cdrh_docs/reviews/k103555.pdf (accessed on 13 December 2019).
24. Redaelli, A.; Slepian, M.J. Systems and Methods for Analyzing Platelet Function. Available online: <http://hdl.handle.net/11311/1066190> (accessed on 22 June 2018).
25. Santoleri, A.; Dimasi, A.; Consolo, F.; Rasponi, M.; Fiore, G.B.; Slepian, M.J.; Redaelli, A. The MICELI (MICrofluidic, ELectical, Impedance): A New Portable Device for Bedside Platelet Aggregation Measurement. In Proceedings of the ISMCS 2017 25th Anniversary Scientific Congress “Limitations, Controversies, and Gaps in MCS: Pathway to Solutions”, Controversies, Tucson, AZ, USA, 15–18 October 2017; p. 199.
26. US8617468B2—Platelet Aggregation Test and Device—Google Patents. Available online: <https://patents.google.com/patent/US8617468B2/en> (accessed on 13 December 2019).
27. Calatzis, A.; Kriger, B.; Wittwer, M. Cartridge Device For Blood Analysis. U.S. Patent No. 200,701,409,02, 21 June 2007.
28. Silver, W.P.; Keller, M.P.; Teel, R.; Silver, D. Effects of donor characteristics and in vitro time and temperature on platelet aggregometry platelet. *J. Vasc. Surg.* **1993**, *17*, 726–733. [CrossRef]
29. Zhou, L.; Schmaier, A.H. Platelet Aggregation Testing in Platelet-Rich Plasma Description of Procedures With the Aim to Develop Standards in the Field. *Am. J. Clin. Pathol.* **2005**, *123*, 172–183. [CrossRef] [PubMed]
30. Peerschke, E.I.B.; Castellone, D.D.; Stroobants, A.K.; Francis, J. Reference Range Determination for Whole-Blood Platelet Aggregation Using the Multiplate Analyzer. *Am. J. Clin. Pathol.* **2014**, *142*, 647–656. [CrossRef]
31. Kalb, M.L.; Potura, L.; Scharbert, G.; Kozek-Langenecker, S.A. The effect of ex vivo anticoagulants on whole blood platelet aggregation. *Platelets* **2009**, *20*, 7–11. [CrossRef] [PubMed]
32. Seyfert, U.T.; Haubelt, H.; Vogt, A.; Hellstern, P. Variables influencing Multiplate TM whole blood impedance platelet aggregometry and turbidimetric platelet aggregation in healthy individuals. *Platelets* **2007**, *18*, 199–206. [CrossRef]
33. Michelson, A.D.; Frelinger, A.L.; Furman, M.I. Current Options in Platelet Function Testing. *Am. J. Cardiol.* **2006**, *98*, S4–S10. [CrossRef]
34. Rasheed, H.; Tirmizi, A.H.; Salahuddin, F.; Rizvi, N.B.; Arshad, M.; Farooq, S.Z.; Saeed, S.A. Calcium Signaling in Human Platelet Aggregation Mediated by Platelet Activating Factor and Calcium Ionophore, A23187. *J. Biol. Sci.* **2004**, *4*, 117–121. [CrossRef]
35. Sun, P.; McMillan-Ward, E.; Mian, R.; Israels, S.J. Comparison of light transmission aggregometry and multiple electrode aggregometry for the evaluation of patients with mucocutaneous bleeding. *Int. J. Lab. Hematol.* **2019**, *41*, 133–140. [CrossRef]
36. Femia, E.A.; Scavone, M.; Lecchi, A.; Cattaneo, M. Effect of platelet count on platelet aggregation measured with impedance aggregometry (Multiplate™ analyzer) and with light transmission aggregometry. *J. Thromb. Haemost.* **2013**, *11*, 2193–2196. [CrossRef]
37. Hanke, A.A.; Roberg, K.; Monaca, E.; Sellmann, T.; Weber, C.F.; Rahe-Meyer, N.; Görlinger, K. Impact of platelet count on results obtained from multiple electrode platelet aggregometry (multiplate™). *Eur. J. Med. Res.* **2010**, *15*, 214–219. [CrossRef]

38. Müller, M.R.; Salat, A.; Pulaki, S.; Stangl, P.; Ergun, E.; Schreiner, W.; Losert, U.; Wolner, E. Influence of hematocrit and platelet count on impedance and reactivity of whole blood for electrical aggregometry. *J. Pharmacol. Toxicol. Methods* **1995**, *34*, 17–22. [CrossRef]
39. Dézsi, D.A.; Merkely, B.; Skopál, J.; Barabás, E.; Várnai, K.; Faluközy, J.; Veress, G.; Alotti, N.; Aradi, D. Impact of Test Conditions on ADP-Induced Platelet Function Results With the Multiplate Assay: Is Further Standardization Required? *J. Cardiovasc. Pharmacol. Ther.* **2018**, *23*, 149–154. [CrossRef] [PubMed]
40. Jilma-Stohlawetz, P.; Ratzinger, F.; Schörghofer, C.; Jilma, B.; Quehenberger, P. Effect of preanalytical time-delay on platelet function as measured by multiplate, PFA-100 and VerifyNow. *Scand. J. Clin. Lab. Investig.* **2016**, *76*, 249–255. [CrossRef] [PubMed]
41. Johnston, L.R.; Larsen, P.D.; La Flamme, A.C.; Harding, S.A. Methodological considerations for the assessment of ADP induced platelet aggregation using the Multiplate® analyser. *Platelets* **2013**, *24*, 303–307. [CrossRef] [PubMed]
42. Wallén, N.H.; Ladjevardi, M.; Albert, J.; Bröijersén, A. Influence of different anticoagulants on platelet aggregation in whole blood; a comparison between citrate, low molecular mass heparin and hirudin. *Thromb. Res.* **1997**, *87*, 151–157. [CrossRef]
43. Bonello, L.; Tantry, U.S.; Marcucci, R.; Blindt, R.; Angiolillo, D.J.; Becker, R.; Bhatt, D.L.; Cattaneo, M.; Collet, J.P.; Cuisset, T.; et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. *J. Am. Coll. Cardiol.* **2010**, *56*, 919–933. [CrossRef]
44. Mackie, I.J.; Jones, R.; Machin, S.J. Platelet impedance aggregation in whole blood and its inhibition by antiplatelet drugs. *J. Clin. Pathol.* **1984**, *37*, 874–878. [CrossRef]
45. Swart, S.; Pearson, D.; Wood, J.; Barnett, D. Effects of adrenaline and alpha adrenergic antagonists on platelet aggregation in whole blood: Evaluation of electrical impedance aggregometry. *Thromb. Res.* **1984**, *36*, 411–418. [CrossRef]
46. Beynon, C.; Scherer, M.; Jakobs, M.; Jung, C.; Sakowitz, O.W.; Unterberg, A.W. Initial experiences with Multiplate® for rapid assessment of antiplatelet agent activity in neurosurgical emergencies. *Clin. Neurol. Neurosurg.* **2013**, *115*, 2003–2008. [CrossRef]
47. Briggs, A.; Gates, J.D.; Kaufman, R.M.; Calahan, C.; Gormley, W.B.; Havens, J.M. Platelet dysfunction and platelet transfusion in traumatic brain injury. *J. Surg. Res.* **2015**, *193*, 802–806. [CrossRef]
48. Meißner, A.; Schlenke, P. Massive bleeding and massive transfusion. *Transfus. Med. Hemotherapy* **2012**, *39*, 73–84. [CrossRef] [PubMed]
49. Rahe-Meyer, N.; Winterhalter, M.; Boden, A.; Froemke, C.; Piepenbrock, S.; Calatzis, A.; Solomon, C. Platelet concentrates transfusion in cardiac surgery and platelet function assessment by multiple electrode aggregometry. *Acta Anaesthesiol. Scand.* **2009**, *53*, 168–175. [CrossRef] [PubMed]
50. U.S Census Bureau QuickFacts: Pima County, Arizona. Available online: <https://www.census.gov/quickfacts/fact/table/pimacountyarizona/PST045218> (accessed on 12 December 2019).
51. CLSI. *Procedure for Determining Packed Cell Volume by the Microhematocrit Method*, 3rd ed.; CLSI document H07-A3; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2000.



© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).



Review

RasGRP2 Structure, Function and Genetic Variants in Platelet Pathophysiology

Matthias Canault ^{1,*} and Marie-Christine Alessi ^{1,2}

¹ Aix Marseille University, INSERM, INRAE, C2VN, 13005 Marseille, France; marie-christine.alessi@univ-amu.fr

² Hematology laboratory, APHM, CHU Timone, 13005 Marseille, France

* Correspondence: matthias.canault@univ-amu.fr; Tel.: +33-(0)4-91-32-45-07

Received: 18 December 2019; Accepted: 3 February 2020; Published: 6 February 2020

Abstract: RasGRP2 is calcium and diacylglycerol-regulated guanine nucleotide exchange factor I that activates Rap1, which is an essential signaling-knot in “inside-out” α Ib β 3 integrin activation in platelets. Inherited platelet function disorder caused by variants of *RASGRP2* represents a new congenital bleeding disorder referred to as platelet-type bleeding disorder-18 (BDPLT18). We review here the structure of RasGRP2 and its functions in the pathophysiology of platelets and of the other cellular types that express it. We will also examine the different pathogenic variants reported so far as well as strategies for the diagnosis and management of patients with BDPLT18.

Keywords: platelet; RasGRP2; inherited platelet disorder

1. RasGRPs General Description

Cell Signal Transduction Is a Finely Regulated Process That Relies on Several Control Hubs

Members of the RAS family of small guanosine triphosphatases (GTPases; including RAS and Rap) are among the essential regulators of cell signaling. They are acting as binary molecular switches that transmit signal when bound to GTP [1]. Their activation is mediated by guanine-exchange factors (GEFs) that facilitate guanosine diphosphate (GDP)-dissociation and its replacement by GTP [2]. Signal termination is mediated through the action of GTPases-activating proteins (GAPs) [2] that catalyze the hydrolysis of the bound GTP to GDP by increasing the relatively slow intrinsic catalytic activity of the GTPase by $\approx 10^5$ fold [3].

Several families of GEF are described in human cells [4] such as the Son of Sevenless, that activates Ras [5], Epac1 and Epac2, that activate Rap [6] and the Ras guanine-nucleotide releasing proteins (RasGRPs) that act on both Ras and Rap. The RasGRP family consists in four different forms (RasGRP1-4). Their expressions are not ubiquitous but can be overlapping and are rather restricted to specific cell types and tissues, mainly brain, vascular and hematopoietic cells. RasGRP1 expression concentrates essentially to the cerebellum, the cerebral cortex and the amygdala [7] as well as T cells. It is also present in B-, natural killer (NK)- and mast cells but to a lesser extent [8–10]. RasGRP2 expression was initially described in striatum neurons [7] and was then found in platelets and their precursors, the megakaryocytes as well as neutrophils [11–13]. It has now been detected in other hematopoietic-lineage-derived cells such as T lymphocytes [14] but also found in fibroblast-like synoviocytes [15] and endothelial cells [16]. RasGRP3 is highly expressed in B cells [17], [18] but is also expressed in T cells, macrophages, and endothelial cells [17–20]. RasGRP4 is relatively specific to mast cells, although it has also been detected in thymocytes and neutrophils [21–23] in synoviocytes [15].

2. RasGRPs Structure and Domain Organization

RasGRP1-4 are multidomain proteins sharing common structural organization (Figure 1) with a high degree of sequence identity [24]. They contain a central catalytic module composed of two domains: 1) the cell division cycle-25 (CDC-25) homology domain that directly interacts with GTPase and encloses an helical hairpin that dislodges the bound GDP nucleotide from the GTPase; and 2) the Ras exchanger motif (REM) domain, that is essential for the catalytic activity of the RasGRPs through providing structural support for the CDC-25 domain [5] but that is not conserved among all Ras-GEFs. Besides the catalytic core, RasGRPs are composed of a second shared module that consists in a pair of successive helix(E)-loop-helix(F) (EF)-hand domains, with each one being capable of binding one calcium ion. EF hands are typical helix-loop-helix structural motifs that coordinate calcium via acidic residues within the loop. Calcium binding results in important conformational changes within the domain and can also lead to modifications of the structure of other domains of the protein [25]. The remaining part of the RasGRPs consists of a C1 domain that was originally described as a diacylglycerol (DAG) binding cassette on protein kinases C (PKCs), responsible for their membrane localization. The “atypical” C1 domains of RasGRP2 stands out as it binds DAG with a very weak affinity and that DAG (or its analogs, phorbol esters) does not drive RasGRP2/membrane association as for the C1 domains of the other RasGRPs [26].

Finally, RasGRP1 is the only RasGRP family member that has a C-terminal sequence predicted to form a coiled-coil domain that enhances membrane recruitment through electrostatic interactions with phosphoinositides [24].




Figure 1. Structural organization of the Ras guanine-nucleotide releasing proteins (RasGRPs) with amino acid sequence annotation for RasGRP2. The protein domains indicated are the Ras exchange motif (REM), catalytic domain (CDC-25), calcium-binding helix(E)-loop-helix(F) hands (EF), diacylglycerol-binding domain (C1) and the RasGRP1 specific C-terminal coil-coil domain (CC). Circled P and red numbers correspond to phosphorylation sites on serine residues involved in RasGRP2 activity regulation.

3. RasGRP2

RasGRP2, calcium and diacylglycerol-regulated guanine exchange factor I (CalDAG-GEFI, UniPortKB: Q7LDG7-1) is encoded by the *RASGRP2* gene (Ensembl: ENSG00000068831) that is located on chromosome 11 (11q13.1 locus, gene/locus MIM#605577), spans 18.55 kb, and contains 22 exons. Four different isoforms that are produced by alternative splicing (Q7LDG7-1 to -4) have been described so far and nine other potential isoforms have been computationally mapped. *RASGRP2* gene expression is under the control of the transcription factor NE-F2 [27] that was shown to regulate late phase of megakaryocytic differentiation [28] and to be required for proper α IIb β 3 integrin activation and fibrinogen binding [29], key steps in platelet aggregation. Indeed, RasGRP2 expression raises in late stages of megakaryocytic lineage differentiation during polyploidization [30] assuring the presence of sufficient amounts of RasGRP2 in produced platelets.

The canonical isoform 1 of RasGRP2 (Q7LDG7-1) is a 609-amino-acid-long (69.25 kDa) protein that possesses various post-translational modification sites that were identified through high-throughput proteomic analyses (data obtained from PhosphoSitePlus [31]) and could affect the activity and/or the fate of the GEF. Nine serine-, two threonine-, and one tyrosine-phosphorylation sites were identified.

Besides, 10 putative ubiquitination lysine residues and one myristylation site were annotated. Among those, four serine-phospho sites were validated using methods other than discovery mass spectrometry and their implication in the regulation of RasGRP2 activity were further characterized (see chapter RasGRP2 activity regulation).

4. RasGRP2 Functions in Platelets

RasGRP2 diverges from the other members of the RasGRP family as it catalyzes GDP to GTP exchange only for Rap GTPases but not Ras [7]. Rap1 is a ubiquitous protein that plays an essential role in the control of many cellular processes such as cell division, adhesion, and cell migration [32]. In platelets, the most abundant Rap GTPases are Rap1A and B with 125,000 and 300,000 copies/platelet respectively [33] that exhibit functional redundancy [34]. Several Rap GEFs have been detected in platelets such as RasGRP3 [35], PDZ-GEF1 [35] and Epac1 [36], but to date only RasGRP2 was shown to be implicated in platelet function regulation. The initial demonstration of RasGRP2 involvement in platelet function essentially comes from studies performed in mice. Work from the Shattil group in the early 2000s demonstrated that in mouse embryonic stem cell derived megakaryocytes, the retroviral overexpression of RasGRP2 leads to enhanced agonist-induced activation of Rap1 and fibrinogen binding to the α IIb β 3 integrin [27]. Then, using the *Rasgrp2* deficient mice developed by Crittenden and coworkers, the role in vivo of RasGRP2 in Rap1 and in α IIb β 3 integrin “inside-out” activation processes in platelets was unequivocally established [11]. Further work on platelets from these mice led to establish the molecular mechanisms linking RasGRP2/Rap1 and the two pathway models for platelet activation:

Platelet surface receptor activation by most agonists initiate intracellular signaling pathways through the phospholipase C isoforms β or γ (depending on the class of surface receptor enrolled) which hydrolyze phosphoinositide-4,5-bisphosphate (PIP2) to inositol-1,4,5-trisphosphate (IP3) and 1,2-diacyl-glycerol (DAG). IP3 induces the release of Ca²⁺ from intracellular stores into the platelet cytoplasm [37,38] and DAG activates protein kinases C (PKCs) that results in platelet sustained granule secretion, subsequent adenosine diphosphate (ADP) release and P2Y12 receptor activation. These Ca²⁺-sensitive and PKC pathways were shown to act separately but synergistically in the activation of α IIb β 3 integrin [39,40].

Studies with murine RasGRP2-deficient platelets demonstrate that the GEF is predominantly regulated by Ca²⁺ signals and its involvement in integrin activation is independent of the PKC/P2Y12 pathway. Indeed, RasGRP2 is critical for the rapid, but reversible, activation of Rap1 as observed upon low dose thrombin activation, that is dependent on the increase of cytoplasmic Ca²⁺ concentration [11,12]. The second pathway is RasGRP2-independent and leads to slower but sustained Rap1 activation [41]. It involves PKC signaling [12,42], ADP secretion and P2Y12-dependent [41,43,44] activation of PI3K [43,45] that causes inhibition of RASA3 (GAP1IP4BP), the most abundant Rap1 GAP found in platelets [33,46,47]. RASA3 is required to maintain circulating platelets in a quiescent state through antagonization of low-level Rap1 activation and its inhibition prevents GTP hydrolysis from Rap1-GTP and thus enables substantial platelet activation [48]. This two-pathway model of platelet activation (Ca²⁺/RasGRP2 and P2Y12/RASA3) is a balance tightly regulated by several activator and inhibitory signals (see for review [49–51]) that converge to Rap1 activation and downstream favoring α IIb β 3 integrin activation [52].

Consistent with the involvement of RasGRP2 in α IIb β 3 integrin activation, mouse platelets lacking the GEF show a markedly reduced ability to form three-dimensional thrombi when perfused at arterial shear rates both in vitro and in vivo and dramatically prolonged bleeding time [11,41]. RasGRP2-deficient platelets have impaired aggregation in response to any dose of calcium ionophore (A23187) and weak agonists (ADP and the thromboxane A2 analog, U46619) and to low doses of strong ones such as thrombin and collagen [11]. Interestingly, hypomorphic mice expressing minimal levels of human RasGRP2 instead of endogenous RasGRP2 (\approx 10% of expression in controls) showed reduced platelet aggregation and severely impaired arterial and immune complex-mediated thrombosis with

only slightly affected primary hemostasis [53]. Thus, RasGRP2 could represent a therapeutic target for the development of potentially safe antithrombotic drugs with little impact on the bleeding risk.

In parallel, RasGRP2 also contributes to thromboxane A2 generation and release from mouse platelets, thus reinforcing the second wave of platelet activation signal through PKC-mediated ADP secretion and the P2Y12/PI3K-dependent RASA3 inhibition pathway [48,54].

Additionally to integrin “inside-out” activation, clues exist for the possible involvement of RasGRP2 in platelet spreading and integrin “outside-in” signaling. In mice, the loss of Rap1b inhibits platelet spreading over fibrinogen [55] and mouse platelet lacking both RasGRP2 and P2Y12 receptor fail to spread over fibrinogen [56]. Additionally, platelets from RasGRP2 knock-out mice show impaired $\alpha 2\beta 1$ integrin-dependent spreading over collagen [57]. Then, Stefanini and colleagues demonstrated that RasGRP2-deficiency in murine platelets resulted in altered activation of Rac1, the RhoA family GTPase that controls lamellipodia extension and subsequently platelet spreading [56]. In humans, we reported defective spreading over fibrinogen of platelets from patients expressing an inactive form of RasGRP2 [58]. However, other studies on platelets isolated from individuals lacking the GEF showed only minimal spreading impairment [59,60]. Whereas the effect of RasGRP2 deficiency on platelet spreading relies on consequences of defective integrin “inside-out” activation or on its direct involvement in “outside-out” signaling remains to be fully determined.

The signaling module RasGRP2/Rap1 was also shown to play an important role in the conversion of platelets to a pro-coagulant state since RasGRP2-deficiency leads to impaired phosphatidylserine exposure on mouse platelet surface and delayed and reduced fibrin generation at the vascular lesion site [61]. However, the exact molecular mechanism linking activated Rap1-GTP and phosphatidylserine exposure in platelets still remains to be elucidated.

A role for RasGRP2 was also proposed in atherogenesis. Indeed, RasGRP2/Rap1-dependent signal promotes atherosclerotic plaque formation in mice and determines its composition probably through platelet activation and platelet-leukocyte aggregate formation. However, RasGRP2 is also expressed in leukocytes, thus the exact contribution of platelet- and/or leukocyte-associated RasGRP2-dependent signal in atherosclerosis still remains elusive [62].

5. RasGRP2 Functions Outside Platelets

RasGRP2 is expressed by developing and mature neutrophils [11]. It has been then involved in *in vitro* and *in vivo* chemotaxis, adhesion and extravasation in a manner that either depends on integrin or on mechanisms involving E-selectin [13,63,64]. Similarly, RasGRP2 enhances the adhesion ability of human T cells through lymphocyte function-associated antigen-1 (LFA1) and contributes to the interaction with intercellular adhesion molecule-1 (ICAM-1) [14]. In human T cells, the translocation of RasGRP2 to the cell membrane via interaction with polymerized actin was observed in response to TCR stimulation [65] where the GEF co-localizes with its substrate, Rap1 [66]. However, the exact contribution of RasGRP2 to leukocyte function *in vivo* remains a matter of debate because no evidence of immune disorder has been reported in the human cases of RasGRP2 deficiency described so far.

Additionally, several groups reported that RasGRP2 might be involved in oncohematological diseases. RasGRP2 has been identified as the proto-oncogene in acute myelogenous leukemia and its expression was found to be increased in trisomy 12-associated chronic lymphocytic where it is thought to contribute to the drug resistance-associated enhanced integrin signaling [67,68]. Additionally, the RasGRP2/Rap1 axis mediates the chronic lymphocytic leukemia cell adhesion and migration in response to an increase in intracellular Ca²⁺ levels upon CD38 engagement [69].

Regarding RasGRP2 and endothelium, a combination of microarray and expression pattern analysis, allowed to identify *xrasgrp2* in *Xenopus* embryos as a vascular-expressed gene, that is a homolog to the human form of *RASGRP2*. It has then been further involved in vasculogenesis and/or angiogenesis during *Xenopus* embryo development [70]. The endothelial expression of RasGRP2 was also observed in human vascular cells from both venous and arterial origins [16]. Recently, RasGRP2 was suggested to contribute to maintenance of endothelial homeostasis, as its overexpression in human

umbilical vein endothelial cells (HUVECs) prevents TNF- α -induced ROS production and apoptosis via a Rap1 activation-dependent mechanism [71]. Additionally, the overexpressed RasGRP2 in HUVECs also suppresses apoptosis induced through Bax-activation via a Rap1-independent but R-Ras-dependent signaling pathway [72]. Furthermore, the RasGRP2 protein was found to be abundantly increased in the vascular endothelium and in fibroblast-like synoviocytes retrieved from synovial tissues of a subset of patients suffering rheumatoid arthritis [15]. In synoviocytes, RasGRP2 expression is induced in response to growth factors (i.e., platelet derived growth factor, PDGF and vascular endothelial growth factor, VEGF) and transforming growth factor-beta (TGF- β). It controls, through Rap1 activation, both actin-dependent adhesion/migration and interleukin-6 production via a NF- κ B-mediated pathway [15].

RasGRP2 was initially identified as a protein with enriched expression in human and rodent brain basal ganglia and in their axon-terminal regions [7,73]. Crittenden and colleagues further characterized this localized expression in the striatum area. They also found that RasGRP2 expression was markedly down-regulated in the striatum of patients with Huntington's disease [74] and in mice with both Huntington's and Parkinson's diseases that are major extrapyramidal disorders in which striatal abnormalities are the causes of the pathology [74,75]. More recently, RasGRP2 was involved via Rap1 activation in dopamine-dependent neuronal excitability and reward-related behaviors [76]. Thus, RasGRP2 may be an important regulator of specific behaviors but its function in neurologic functions and human pathologies remains largely to be elucidated.

6. RasGRP2 Activity Regulation

RasGRP2 plays critical roles in platelet and other cell type function regulations. Its activity must be finely tuned. The main trigger for the activation of RASGRP2 is calcium; however, other regulation mechanisms have been described such as phosphorylation of serine residues by protein kinase A (PKA) and extracellular signal-regulated kinases 1/2 (ERK1/2) or interaction of its C1 domain with specific membrane phosphoinositides that orientates the GEF towards to a localization to the cell membrane (Figure 2).

6.1. Calcium

As mentioned above, RasGRP2 rapidly activates Rap1 in response to an increase in cytoplasmic calcium concentration [54]. RasGRP2 binds to calcium via its two EF hand domains which have a high affinity for calcium ($K_d < 100$ nM) [77], making RasGRP2 extremely sensitive to activation, since the concentration of cytoplasmic calcium ranges from 25–100 nM in resting platelets and can increase up to micromolar levels upon activation depending on the agonist and the dose [78]. The binding of calcium to the EF hand domains results in major conformational changes [25]. Biochemical and biophysical approaches revealed that calcium binding to EF hands induces global conformational changes in the structure of RasGRP2, most prominently in an auto-inhibitory linker region located between the CDC-25 and the first EF-hand domains, that blocks the catalytic surface of the CDC-25 domain and prevents Rap1 engagement [79].

6.2. Phosphorylation

RasGRP2 phosphorylation was also proposed to be control levers to its guanine-exchange activity. Two studies have demonstrated that PKA phosphorylates RasGP2 on multiple sites (Ser116/Ser117 and Ser587) and that phosphorylation correlates with the inhibition of Rap1 activation in platelets [80,81]. Overexpression of phosphor-mimetic or non-phosphorylatable forms of RasGRP2 in HEK297 cells further confirms this inhibitory effect. Most recent data obtained from platelets, have shown that the PKA-dependent phosphorylation of RasGRP2 on Ser587 is clearly downregulated upon ADP stimulation [82]. This might explain, at least partially, the reversible nature of RasGRP2 activation in activated platelets. However, phosphoproteomic study identified RasGRP2 as a substrate for PKA phosphorylation on Ser116, Ser117, Ser554, and Ser587 in striatum neurons promoting its GTP-exchange

activity on Rap1 [76]. Thus the regulatory effect of PKA on RasGRP2 activity may have to be considered in regards to the cell type it is expressed in.

Using experimental approaches, ERK1/2 has also been proven to phosphorylate RasGRP2 on Ser394 [83]. In HEK293T cells transfected with a phospho-mimetic variant of RasGRP2 the ERK1/2-dependent phosphorylation of Ser394 impairs RasGRP2 nucleotide exchange activity. This defines a negative-feedback loop that regulates the ERK signaling cascade that is activated downstream of Rap1 in platelets [54].




Figure 2. RasGRP2 activation mechanism and activity regulation during α IIb β 3-integrin “inside-out” signaling in platelets. (A) Platelet surface receptor activation by vascular adhesive proteins and/or soluble agonists initiates an intracellular activation signal that induces the release of Ca²⁺ from intracellular stores into the platelet cytoplasm. Ca²⁺ binding to the EF hands induces conformational changes that activate RasGRP2, located at the platelet membrane through the association of its C1 domain with the phosphoinositides PIP2 and PIP3. (B) The membrane-bound, activated RasGRP2 interacts with Rap1 at the proximity of the cell membrane, and facilitates GDP dissociation and its replacement by (guanosine triphosphate) GTP on the GTPase. The guanine-exchange activity of RasGRP2 can be controlled by PKA- and ERK1/2-dependent phosphorylations. The GTP-bound Rap1 favors the recruitment of talin and kindlin 3 onto the β -chain of the α IIb β 3 integrin leading to its conformational change, activation and subsequent platelet aggregation.

6.3. C1 Domain

The C1 domain provides additional regulatory activity. Structural studies by Iwig et al. demonstrated that DAG binds to the C1 domains of the RASGRP1, 3, and 4 unlike RasGRP2 [77]. As an example, the interaction of DAG with the C1 domain of RasGRP1 releases C1 domain dimerization, subsequently causing the protein membrane translocation. In contrast, RasGRP2 C1 domain is monomeric [77] and RasGRP2 deficiency has no effect on platelets aggregation in response to DAG analogs [12,58]. The physiological importance of the C1 domain of RasGRP2 in platelets is highlighted by the dramatic effect of its loss on platelet function in vitro and in vivo in both mice and humans [41,84]. Lipid co-sedimentation assays and molecular dynamics simulations with cellular localization experiments demonstrate that the atypical C1 regulatory domain of RasGRP2 controls subcellular localization by interacting with the membrane phosphoinositides, phosphatidylinositol (4,5)-biphosphate (PIP2) and phosphatidylinositol (3,4,5)-triphosphate (PIP3) [85]. Specific C1 residues

Arg508, Arg513, and Arg530 contribute to PIP2/3 specific binding, facilitating the recruitment of the membrane-associated Rap1 and allowing downstream α IIb β 3 integrin activation.

7. RasGRP2 Variants and RasGRP2-Related Bleeding Disorders

7.1. In Animals

In 1980, a presumably genetic disorder responsible for bleeding in Simmental cattle was described for the first time [86]. The affected cattle showed spontaneous nosebleeds, hematuria, hematomas and excessive bleeding after injuries or surgery. This bleeding was then demonstrated to be the result of a hereditary thrombopathy likely caused by a defect in calcium mobilization or utilization by platelets [86,87]. In 2007, Boudreaux et al. associated this recessively inherited hemorrhagic disease with a mutation in the *RASGRP2* gene [88]. Sequencing *RASGRP2* in samples from the affected calf revealed a homozygous single-nucleotide change in exon 7 (c.701T>C) that results in the p.Pro234Leu transition (Figure 2). This variant was then considered likely to have an impact on the function of the protein. The same team reported, also in 2007, cases in three different dog breeds (Basset Hounds, Eskimo Spitz and Landseers) of recessively inherited *RASGRP2* mutations (Basset hounds: c.509-511delTCT, p.Phe170del; Eskimo Spitz: c.452dupA, p.Asp151Glufs*115; Landseers: c.982C>T, p.Arg328*, Figure 3) [89]. All affected cases suffered recurrent epistaxis, gingival bleedings, and petechiae. Platelet function was also impaired in these animals as aggregation responses to ADP, collagen, calcium ionophore (A23187), and platelet-activating factor (PAF) was markedly reduced.




Figure 3. Localization and predicted consequence of the *RASGRP2* reported variants in Simmental cattle and dog. Sequences of the variants are annotated according to the consensus nomenclature to describe variant effect at the protein level (fs = frameshift, del = deletion, * = change to a stop codon).

7.2. In humans

In 2014, our group identified the first pathogenic variant of *RASGRP2* in three siblings affected by platelet related bleeding disorder. [58] Since this first description, 23 other patients have been recorded and this hemorrhagic pathology has been referenced as bleeding disorder-platelet type-18, BDPLT18 (OMIM# 6158888).

7.3. Diagnosis

The initial step in the diagnosis of BDPLT18 is to determine the medical history of the patient and its related (parents and siblings). The family history of cutaneous and mucosal bleedings along with their severity and frequency should be documented. Additionally, the presence or not of consanguinity in the patient's pedigree must be highlighted. Purpura, petechiae, epistaxis, easy bruising, and menorrhagia are common features of the disease and it is mostly, although not always, diagnosed at an early age. Indeed, all reported patients presented abnormal bleedings that were predominantly epistaxis (96%), mucocutaneous bleedings (84%), menorrhagia (73% of affected females), or following dental extraction (40%) or surgery (40%) (Table 2). Gastrointestinal bleeding occurred in four cases (16%). Intracranial bleeding has so far never been reported. Interestingly, as for Glanzmann thrombasthenia (BDPLT16, OMIM# 187800) patients, the incidence of severe bleedings decreases with age [58,59].

Table 1. Characteristics and bleeding symptoms of the pathogenic *RASGRP2* variants reported to date.

| Genomic Variation | Variant Type | Protein Effect | Sex | Platelet Expression | Age at Diagnosis | Age at Presentation | Bleeding Symptoms | | | | | | | Ref |
|-------------------|----------------|------------------|-----|---------------------|------------------|-----------------------|-------------------|----|---|----|---|----|---|---------|
| | | | | | | | E | SC | M | DE | S | GI | | |
| c.742C>T | Missense | p.Gly248Irp | F | Yes | 55 | 1 year | ■ | ■ | ■ | ■ | ■ | ■ | ■ | [58] |
| | | | H | Yes | 53 | 1 year | ■ | ■ | ■ | ■ | ■ | ■ | ■ | |
| | | | H | Yes | 49 | 1 year | ■ | ■ | ■ | ■ | ■ | ■ | ■ | |
| c.337C>T | Stop codon | p.Arg113* | F | No | 55 | Lifelong | ■ | ■ | ■ | ■ | ■ | ■ | ■ | [59] |
| | | | M | No | 46 | Childhood | ■ | ■ | ■ | ■ | ■ | ■ | ■ | |
| c.1142C>T | Missense | p.Ser381Phe | M | No | 9 | lifelong | ■ | ■ | ■ | ■ | ■ | ■ | ■ | [59] |
| c.1142C>T | Missense | p.Ser381Phe | M | N/D | 41 | Early childhood | ■ | ■ | ■ | ■ | ■ | ■ | ■ | [90] |
| c.659G>A | Missense | p.Arg220Glu | F | N/D | 41 | Early childhood | ■ | ■ | ■ | ■ | ■ | ■ | ■ | [90] |
| c.925A>T | Stop codon | p.Lys309* | F | No | 16 | Before 3 years | ■ | ■ | ■ | ■ | ■ | ■ | ■ | [89] |
| c.1081_1083Δ | Deletion | p.Leu360del | F | No | 16 | Before 3 years | ■ | ■ | ■ | ■ | ■ | ■ | ■ | [89] |
| c.706C>T | Stop codon | p.Gln236* | M | No | 8 | 1 year | ■ | ■ | ■ | ■ | ■ | ■ | ■ | [60] |
| c.887G>A | Missense | p.Cys296Iyr | F | No | 4 | First year | ■ | ■ | ■ | ■ | ■ | ■ | ■ | [60] |
| c.914G>A | Missense | p.Gly305Asp | M | No | 9 | Early childhood | ■ | ■ | ■ | ■ | ■ | ■ | ■ | [89,91] |
| | | | M | Yes (Residual) | 24 | 2 years | ■ | ■ | ■ | ■ | ■ | ■ | ■ | |
| c.199delAA | Frameshift | p.Asn67Leufs*24 | F | No | 23 | 1 year | ■ | ■ | ■ | ■ | ■ | ■ | ■ | [91] |
| c.372-3C>G | Splice variant | p.(Pro125*) | F | N/D | 24 | 2 years | ■ | ■ | ■ | ■ | ■ | ■ | ■ | [91] |
| c.990C>G | Missense | p.Asn330Lys | F | N/D | 21 | 5 years | ■ | ■ | ■ | ■ | ■ | ■ | ■ | [91] |
| c.778C>T | Stop codon | p.Glu260* | F | No | 20 | 1 year | ■ | ■ | ■ | ■ | ■ | ■ | ■ | [91] |
| c.886T>C | Missense | p.Cys296Arg | F | No | 20 | 1 year | ■ | ■ | ■ | ■ | ■ | ■ | ■ | [91] |
| c.1482InsG | Frameshift | p.Arg494Alafs*54 | M | N/D | 60 | 5 years | ■ | ■ | ■ | ■ | ■ | ■ | ■ | [91] |
| c.1482InsG | Frameshift | p.Arg494Alafs*54 | M | N/D | 13 | 1 year | ■ | ■ | ■ | ■ | ■ | ■ | ■ | [91] |
| c.542T>C | Missense | p.Phe181Ser | M | N/D | 13 | 1 year | ■ | ■ | ■ | ■ | ■ | ■ | ■ | [91] |
| | | | M | Yes (Lower MW) | 45 | 5 years | ■ | ■ | ■ | ■ | ■ | ■ | ■ | [84,91] |
| c.1490delIT | Frameshift | p.Phe497Serfs*22 | F | Yes (Lower MW) | 55 | During the first year | ■ | ■ | ■ | ■ | ■ | ■ | ■ | [84,91] |

Table 2. Characteristics and bleeding symptoms of the pathogenic *RASGRP2* variants reported to date.

| Genomic Variation | Variant Type | Protein Effect | Sex | Platelet Expression | Age at Diagnosis | Age at Presentation | Bleeding Symptoms | | | | | | Ref | | |
|---------------------------------|----------------|------------------|-----|---------------------|------------------|-----------------------|----------------------|-----------|-----------|-----------|-----------|-----------|-----------|--|------|
| | | | | | | | E | SC | M | DE | S | GI | | | |
| c.1490delT | Frameshift | p.Phe497Serfs*22 | M | N/D | 57 | 5 years | | | | | | | | | [91] |
| c.1033G>C | Missense | p.Ala345Pro | M | N/D | 61 | 4 years | | | | | | | | | [91] |
| c.1490delT | Frameshift | p.Phe497Serfs*22 | M | N/D | 9 | 3 years | | | | | | | | | [92] |
| c.866A>G | Missense | p.Tyr289Cys | M | N/D | 9 | 3 years | | | | | | | | | [92] |
| c.741C>C | Splice variant | p.(Asp25Ala*15) | M | N/D | 9 | 3 years | | | | | | | | | [92] |
| c.337delC | Deletion | p.Arg113Aspfs*6 | M | N/D | 9 | During the first year | | | | | | | | | [93] |
| c.742G>C | Missense | p.Gly248Arg | F | N/D | 15 | Early childhood | | | | | | | | | [94] |
| Newly identified variant | | | | | | | | | | | | | | | |
| c.1507G>T | Stop codon | p.Glu503* | M | N/D | 14 | Early childhood | | | | | | | | | |
| | | | | | | | % of patients | 96 | 84 | 73 | 40 | 40 | 16 | | |

Blue background corresponds to *RASGRP2* composite heterozygous variants; pink background corresponds to a *RASGRP2* variant associated to a *P2RY12* heterozygous variant; yellow background corresponds to a *RASGRP2* variant associated to a *FERMT3* homozygous variant. E = Epistaxis, SC = Subcutaneous hemorrhage, M = Menorrhagia, DE = Prolonged bleeding after dental extraction, S = Prolonged bleeding after surgery and GI = Gastrointestinal hemorrhage.

Patients affected by BDPLT18 have platelet counts that are typically in the normal range and show normal platelet morphology. The excessive mucocutaneous bleedings are suggestive of severe platelet pathology and after excluding coagulation and von Willebrand factor abnormalities, the main challenge will be to distinguish BDPLT18 from Glanzmann thrombasthenia.

PFA100/200 closure times in response to collagen/ADP or collagen/epinephrine are both prolonged (> 300 sec) [60,95]. Platelet function testing rapidly orientates towards BDPLT18 for it is, until today, the only disorder where platelet aggregation is absent to low dose of agonists (e.g., ADP 5 μ M, collagen 2 μ g/mL, TRAP10 μ M, epinephrine 5 μ M) while the response to ristocetin and high doses of agonists (e.g., ADP 20 μ M, TRAP 50 μ M, collagen 20 μ g/mL, arachidonic acid 1.5 mM) or PMA is maintained. This typical profile is nevertheless subject to variability that may be related to the different commercial sources of reagents used or to patient characteristics. This has been illustrated by Sevivas et al. who studied two homozygous patients from two different families [60]. The RasGRP2 protein was not detectable in platelets from both homozygous patients. While in one patient platelet aggregation was almost absent in response to ADP (10 μ M) or TRAP (25 μ M) and significantly reduced in response to arachidonic acid (1.5 mM), the other patient had more sustained responses to all these agonists at the same doses (i.e., an intermediate response for ADP and PAR agonist and a normal response for arachidonic acid). Clot retraction can either be unaffected [58] or slightly impacted [59]. Flow cytometry using monoclonal antibodies directed against a range of membrane receptors does not reveal quantitative receptor deficiency, notably normal α IIb β 3 integrin surface expression. α IIb β 3 integrin activation by all agonists except PMA was impaired depending on the type of agonist and the dose used, the activation being defective upon stimulation with low doses and normal with high doses of agonists or with PMA. In accordance with a defect in Rap1 activation, granule secretion is reduced upon stimulation with low doses of an agonist [95,96]. Platelets from patients have a decreased ability to bind soluble and immobilized fibrinogen [58–60,95] and form thrombi over collagen at arterial shear rate [58,96], and exhibit a reduced number of filipodia and fail to form lamellipodia. Platelets enigmatically fail to spread on collagen under arterial flow [57].

As part of a differential diagnosis, the exceptional cases of variant-type of Glanzmann Thrombasthenia with normal α IIb β 3 surface expression but associated with a lack of platelet aggregation need to be excluded. Some patients with BDPLT18 were considered to be carriers of a variant form of Glanzmann thrombasthenia before whole exome sequencing unequivocally restored the diagnosis [84]. At this stage, sequencing of the *RASGRP2* gene will confirm the diagnosis and definitively exclude a variant form of Glanzmann thrombasthenia.

7.4. *RASGRP2* Gene Variations

BDPLT18 occurs worldwide; no geographical restriction of the disease appearance was noticed. Deficiency has been described in patients from European, Turkish, Jamaican, Argentinian, Japanese, Korean, and Chinese origins. It could be however more abundant in certain ethnic groups due to the high level of consanguinity within some communities.

The *RASGRP2* gene is highly polymorphic. Single nucleotide substitutions leading to nonsense or missense mutations, splicing defects, start codon loss, frameshifts, small deletions, and insertions are all common (Ensembl, release 98–September 2019) [97]. Most reported families have their own private mutation although some reoccur in unrelated families and identify gene “hotspots”. Twenty-two pathogenic variations have been reported so far (Figure 4 and Table 2). We add here another so far not described variant that affects the C1 domain of RasGRP2 at position 503. The variant was highlighted in a 14-year-old male that suffers severe bleedings that started in his early childhood. Bleeding symptoms are mainly recurrent epistaxis, spontaneous gum bleeding, excessive bleedings upon surgery, and dental extraction. The mutation corresponds to a homozygous G to T transition in exon 13 (c.1507G>T) that leads to the replacement of a glutamic acid residue to a stop codon (p.E503*) (Table 2, “referenced as newly identified variant”).




Figure 4. Localization and predicted consequence of the *RASGRP2* reported variants in humans. The variant reported by Canault et al. [58] is shown in black. The variants identified by Lozano et al. are highlighted in turquoise, by Kato et al. [96] in light purple, by Sevivas et al. [60] in brown, by Westbury et al. [91] in light green, by Desai et al. [84] and Westbury et al. [89] and Westbury et al. in light blue, Lyu et al. [92] in dark green, Yun et al. [90] in purple, Lunghi et al. [93] in dark blue, Manukjan et al. [94] in pink and the newly identified variant id indicated in red. Variants in brackets are prediction of intronic modifications affecting splice regions. Sequences of the variants are annotated according to the consensus nomenclature to describe variant effect at the protein level (fs = frameshift, del = deletion, * = change to a stop codon, variant in brackets represent intronic modification effects (splice variants))

Among these twenty-three pathogenic variations, five were found in two or more families. Notably the p.Arg494Alafs*54 and the p.Phe497Serfs*22 are found in two and three unrelated families, respectively, either in an homozygous or in a compound heterozygous status [84,91]. Twelve of the described variations correspond to drastic modifications such as deletions, stop codon gains or changes of the reading frame (p.Asp25Ala*15, p.Asn67Leufs*24, p.Arg113*, p.Arg113Aspfs*6, p.Pro125*, p.Gln236*, p.Glu260*, p.Lys309*, p.Leu360del, p.Arg494Alafs*54, p.Phe497Serfs*22 and p.Glu503*). Of note is that two of these variants result from mutations in intronic regions (p.Asp25Ala*15 and p.Pro125*). The eleven other variations correspond to substitutions (p.Phe181Ser, p.Arg220Glu, p.Gly248Trp, p.Gly248Arg, p.Tyr289Cys, p.Cys296Tyr, p.Cys296Arg, p.Gly305Asp, p.Asn330Lys, p.Ala345Pro and p.Ser381Phe), all being localized in the CDC-25 homology domain suggesting that these mutations affect residues with strategic positions for RasGRP2 activity or stability. As an example, the p.Gly248Trp transition is the only variant described so far within the CDC-25 homology domain that does not induce a loss of RasGRP2 protein expression in platelets [58]. The mutation causes the substitution of a small neutral amino acid (glycine) by a large polar one (tryptophan) leading to a protrusion within a cavity of the GEF that interacts with Rap1. This modification is predicted to result in a less effective GDP to GTP exchange and a shift of Rap1 to its inactivated, GDP-bound state. Platelets from the p.Gly305Asp homozygous carriers express only residual levels of RasGRP2 protein in platelets [89] suggesting a putative role of this amino acid residue in the protein's stability. Evaluation of RasGRP2 protein expression in platelets from other homozygous carriers (p.Asn67Leufs*24, p.Arg113*, p.Gln236*, p.Cys296Tyr, p.Ser381Phe) and from two compound heterozygous (p.Lys309*/p.Leu360del and p.Glu260*/p.Cys296Arg) revealed a total loss of the RasGRP2 protein expression (Table 2). A shortened RasGRP2 protein was detected in one homozygous p.Phe497Serfs*22 carrier [84]. Overall, these results indicate that BDPLT18 can be classified into quantitative or qualitative deficiencies. The measurement of intraplatelet RasGRP2 levels is of particular interest to provide a better description of the two types of BDPLT18 and to confirm the deleterious nature of novel gene variants that influence RasGRP2 platelet content. Interestingly, two recent publications reported the cases of patients suffering bleeding diathesis that carry *RASGRP2* variants associated with other mutations in the *P2RY12* and *FERMT3* genes. They code for the P2Y12 ADP receptor and kindlin3 respectively, both being involved

in platelet function and α IIb β 3 integrin activation mechanisms. Remarkably, homozygous compound *RASGRP2* (p.Arg113Aspfs*6) and heterozygous *P2RY12* (p.Thr126fs*34) combined deficiencies resulted in more severe platelet aggregation defect and bleeding phenotype than those observed in homozygous *P2Y12* and heterozygous *RasGRP2* variants' carriers [93]. *RASGRP2* and *FERMT3* genes are both located on chromosome 11q13.1. *FERMT3* deficiency results in leukocyte adhesion deficiency type III (LAD-III) that is the pathology characterized by severe platelet dysfunction and Glanzmann-thrombasthenia-like bleedings associated to hyperleukocytosis and immune deficiency and, inconstantly, osteopetrosis [98]. Interestingly, the combination of two homozygous variations in *RASGRP2* (p.Gly248Arg) and *FERMT3* (p.Ser40Leu) identified in the index case resulted in severe and recurrent bleedings but not by the immunological features classically noticed in LADIII patients [94]. Thus, the deleterious nature of this *FERMT3* variant on the expression and function of the encoded protein, kindlin 3, needs to be clearly established.

7.5. Patient Management

BDPLT18 requires specialist management which can be inspired by many of the recommendations established for Glanzmann thrombasthenia patients [99]. Indeed, the deficit in *RasGRP2* leads to a loss of function of the α IIb β 3 integrin, as does Glanzmann thrombasthenia.

All people with such disorders should be registered with a reference center for hemostasis disorders with appropriate facilities for investigation and treatment, and 24/7 access. Affected individuals should also be issued with a card describing their condition, and it is advisable to give the patient and his/her primary care physician written information about the condition and its care as this disorder is uncommon and will mostly be unfamiliar to many medical staff. Advice should be given where necessary about lifestyle issues too (e.g., individuals with severe disorders should avoid contact and fall-risk sports) and patients should avoid medication which interferes with platelet function, (i.e., salicylates, NSAIDs and other antiplatelet agents). For women, the management of menorrhagia is essential because it is a major source of acute and chronic anemia, especially in teenage girls, and it has a strong impact on quality of life. In one young adolescent affected by BDPLT18, massive menorrhagia led to hemorrhagic shock that required red blood cell transfusion [96]. In another one, menorrhagia has been successfully controlled with oral contraceptives and tranexamic acid [59]. Anemia and martial deficiency secondary to bleeding episodes have been frequently reported in patients [58,59,84,91,94,96,100] and should be regularly detected and treated. Pregnancy should be managed in close collaboration with the specialized center in hemostasis, with a written management plan for the affected mother, and also a plan for investigation and management of the neonate, if necessary. We and others recently reported two cases of successful management of bleeding diathesis during the course of pregnancy and peripartum period in two women woman suffering BDPLT18 [90,100]. The neonate is not at risk of inheriting the full platelet function disorder unless the father is a carrier, although it should be noted that minor to no symptoms are seen in individuals who are heterozygous carriers of *RasGRP2* variants. This may be important to consider because of the high rate of consanguinity observed in some communities. Screening of the father's *RASGRP2* gene will identify carrier fathers and thus will help identifying neonates who are potentially at hemorrhagic risk.

As for Glanzmann thrombasthenia, in all BDPLT18 reported patients, bleeding complications have required medical intervention including antifibrinolytic treatment, transfusion of platelet or red blood cell concentrates [58–60,91,94,95] and occasionally desmopressin [60,96]. As an example, in the nine index cases we reported in the Westbury et al. study, seven of them (78%) have required at least one red cell or platelet transfusion indicating severe bleedings [91]. Treatment with antifibrinolytic agents, e.g., tranexamic acid, either orally, as a mouthwash or by intravenous injection may be considered in the case of moderate bleedings. This may prove to be useful to control menorrhagia and other mild bleeding manifestations from mucous membranes, such as epistaxis. Platelet transfusions are appropriate in cases of severe bleedings and when other agents have failed. However, these blood products carry risks of transfusion-transmitted infections and allergic reactions. Platelet and red blood

cell transfusions should not be given without clear indications. Patients with BDPLT18 may be subject to repeated episodes of transfusion, putting them at risk of developing alloantibodies either against HLA or HPA antigens. However, the risk of developing isoantibodies is almost absent because α IIb β 3 integrin is normally expressed on BDPLT18 patient platelet surface, unlike Glanzmann thrombasthenia patients. Thus, the risk of neonatal thrombocytopenia should be lower. Nevertheless, in this population likely to frequently receive platelet concentrate transfusions, the search for alloantibodies before and after transfusions should be carried out to look for the presence of such antibodies and, in case of a positive test, to adapt the patient's management. In Glanzmann thrombasthenia, rFVIIa (NovoSeven®) is preferred to platelet concentrates in the case of poor response to platelet transfusions, immunization against α IIb β 3 integrin or HLA, or when platelet concentrates are not readily available. Injections should be repeated every 2 to 3 h initially; progressive spacing is possible over a few days depending on circumstances and clinical course. The total number of injections required to treat bleeding episodes may vary from one patient to another and depending on the circumstances. Three injections must be made to achieve a hemostatic effect and before evaluating the possible failure of the treatment. We have reported the efficacy of rFVIIa treatment in a young woman with RasGRP2 deficiency during the postpartum period [100]. A preventive strategy with good efficacy consisted in the administration of tranexamic acid associated with platelet concentrates. She underwent an emergency hospitalization 38 days postpartum for a severe hemorrhage during the first postpregnancy menstrual period. Platelet and red blood cell transfusions, intravenous tranexamic acid and fluid infusions allowed hemodynamic stabilization but showed moderate hemostatic efficacy. A single rFVIIa injection (90 μ g/kg) stopped abnormal bleeding. The patient left the hospital four days later. Thus, rFVIIa may be considered as a strategy to manage the hemorrhagic risk in women with BDPLT18 at delivery and during the following days. Recently, another 41-year-old Korean woman successfully delivered a healthy baby by Caesarian section. She was prophylactically transfused with two units of single-donor platelets before surgery and had only moderate blood loss (400 mL) during the surgery. She was then transfused with two units of leukocyte-reduced red blood cells and started an iron replacement therapy. She did not show any other medical issue during the one-month follow-up [90]. As in Glanzmann thrombasthenia, women need to be closely observed and tranexamic acid continued for at least several weeks and to have ready access to the obstetric service in connection with the hemostasis expert center.

Another patient was also successfully treated with rFVIIa alone during an hemorrhagic episode from unspecified origin [95]. In another case, rFVIIa was used during neurosurgery for meningioma removal due to the ineffectiveness of platelet transfusions [84]. Treatment was continued for 4.5 days. Blood loss was moderate and the postoperative period was without major complications. This same patient was also treated as a first-line treatment by rFVIIa during hernia repair surgery with good results. The patient's sister was also successfully treated with rFVIIa to control bleeding during appendectomy in view of the ineffectiveness of platelet transfusions too [84].

Overall, management protocols of bleedings in BDPLT18 patients require the competences of multidisciplinary medical staff. Close monitoring and planned preventive haemostatic strategies are accordingly required to minimize bleedings in these high-risk patients. Even though transfusion protocols based on the use of conventional platelet concentrate are frequently used to treat or prevent bleedings, other therapeutic alternatives exist such as rFVIIa that has proven its efficacy in BDPLT18 patients.

Author Contributions: M.C. and M.-C.A. contributed equally in writing the original draft of the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Conflicts of Interest: The authors have no conflict of interest to disclose.

References

1. Rojas, A.M.; Fuentes, G.; Rausell, A.; Valencia, A. The Ras protein superfamily: Evolutionary tree and role of conserved amino acids. *J. Cell Biol.* **2012**, *196*, 189–201. [[CrossRef](#)] [[PubMed](#)]
2. Wennerberg, K.; Rossman, K.L.; Der, C.J. The Ras superfamily at a glance. *J. Cell Sci.* **2005**, *118*, 843–846. [[CrossRef](#)] [[PubMed](#)]
3. Schweins, T.; Geyer, M.; Scheffzek, K.; Warshel, A.; Kalbitzer, H.R.; Wittinghofer, A. Substrate-assisted catalysis as a mechanism for GTP hydrolysis of p21ras and other GTP-binding proteins. *Nat. Genet.* **1995**, *2*, 36–44. [[CrossRef](#)] [[PubMed](#)]
4. Fukui, T.; Shimizu, T.; Toma-Fukai, S. Structural Insights into the Regulation Mechanism of Small GTPases by GEFs. *Molecules* **2019**, *24*, 3308. [[CrossRef](#)] [[PubMed](#)]
5. Boriack-Sjodin, P.A.; Margarit, S.M.; Bar-Sagi, D.; Kuriyan, J. The structural basis of the activation of Ras by Sos. *Nature* **1998**, *394*, 337–343. [[CrossRef](#)]
6. Rehmann, H.; Das, J.; Knipscheer, P.; Wittinghofer, A.; Bos, J.L. Structure of the cyclic-AMP-responsive exchange factor Epac2 in its auto-inhibited state. *Nature* **2006**, *439*, 625–628. [[CrossRef](#)]
7. Kawasaki, H.; Springett, G.M.; Toki, S.; Canales, J.J.; Harlan, P.; Blumenstiel, J.P.; Chen, E.J.; Bany, I.A.; Mochizuki, N.; Ashbacher, A. A Rap guanine nucleotide exchange factor enriched highly in the basal ganglia. *Proc. Natl. Acad. Sci. USA* **1998**, *95*, 13278–13283. [[CrossRef](#)]
8. Ebinu, J.O. RasGRP, a Ras Guanyl Nucleotide- Releasing Protein with Calcium- and Diacylglycerol-Binding Motifs. *Science* **1998**, *280*, 1082–1086. [[CrossRef](#)]
9. Dower, N.A.; Stang, S.L.; Bottorff, D.A.; Ebinu, J.O.; Dickie, P.; Ostergaard, H.L.; Stone, J.C. RasGRP is essential for mouse thymocyte differentiation and TCR signaling. *Nat. Immunol.* **2000**, *1*, 317–321. [[CrossRef](#)]
10. Lee, S.H.; Yun, S.; Lee, J.; Kim, M.J.; Piao, Z.-H.; Jeong, M.; Chung, J.W.; Kim, T.-D.; Yoon, S.R.; Greenberg, P.D.; et al. RasGRP1 is required for human NK cell function. *J. Immunol. Baltim. Md 1950* **2009**, *183*, 7931–7938.
11. Crittenden, J.R.; Bergmeier, W.; Zhang, Y.; Piffath, C.L.; Liang, Y.; Wagner, D.D.; Housman, D.E.; Graybiel, A.M. CalDAG-GEFI integrates signaling for platelet aggregation and thrombus formation. *Nat. Med.* **2004**, *10*, 982–986. [[CrossRef](#)] [[PubMed](#)]
12. Cifuni, S.M.; Wagner, D.D.; Bergmeier, W. CalDAG-GEFI and protein kinase C represent alternative pathways leading to activation of integrin α IIb β 3 in platelets. *Blood* **2008**, *112*, 1696–1703. [[CrossRef](#)] [[PubMed](#)]
13. Carbo, C.; Duerschmied, D.; Goerge, T.; Hattori, H.; Sakai, J.; Cifuni, S.M.; White, G.C.; Chrzanowska-Wodnicka, M.; Luo, H.R.; Wagner, D.D. Integrin-independent role of CalDAG-GEFI in neutrophil chemotaxis. *J. Leukoc. Boil.* **2010**, *88*, 313–319. [[CrossRef](#)] [[PubMed](#)]
14. Ghandour, H.; Cullere, X.; Alvarez, A.; Luscinskas, F.W.; Mayadas, T.N. Essential role for Rap1 GTPase and its guanine exchange factor CalDAG-GEFI in LFA-1 but not VLA-4 integrin-mediated human T-cell adhesion. *Blood* **2007**, *110*, 3682–3690. [[CrossRef](#)]
15. Nakamura, H.; Shimamura, S.; Yasuda, S.; Kono, M.; Kono, M.; Fujieda, Y.; Kato, M.; Oku, K.; Bohgaki, T.; Shimizu, T.; et al. Ectopic RASGRP2 (CalDAG-GEFI) expression in rheumatoid synovium contributes to the development of destructive arthritis. *Ann. Rheum. Dis.* **2018**, *77*, 1765–1772. [[CrossRef](#)]
16. Nagamine, K.; Matsuda, A.; Hori, T. Identification of the gene regulatory region in human rasgrp2 gene in vascular endothelial cells. *Boil. Pharm. Bull.* **2010**, *33*, 1138–1142. [[CrossRef](#)]
17. Yamashita, S.; Mochizuki, N.; Ohba, Y.; Tobiome, M.; Okada, Y.; Sawa, H.; Nagashima, K.; Matsuda, M. CalDAG-GEFIII activation of Ras, R-ras, and Rap1. *J. Biol. Chem.* **2000**, *275*, 25488–25493. [[CrossRef](#)]
18. Teixeira, C.; Stang, S.L.; Zheng, Y.; Beswick, N.S.; Stone, J.C. Integration of DAG signaling systems mediated by PKC-dependent phosphorylation of RasGRP3. *Blood* **2003**, *102*, 1414–1420. [[CrossRef](#)]
19. Roberts, D.M.; Anderson, A.L.; Hidaka, M.; Swetenburg, R.L.; Patterson, C.; Stanford, W.L.; Bautch, V.L. A Vascular Gene Trap Screen Defines RasGRP3 as an Angiogenesis-Regulated Gene Required for the Endothelial Response to Phorbol Esters. *Mol. Cell. Biol.* **2004**, *24*, 10515–10528. [[CrossRef](#)]
20. Botelho, R.J.; Harrison, R.E.; Stone, J.C.; Hancock, J.F.; Philips, M.R.; Jongstra-Bilen, J.; Mason, D.; Plumb, J.; Gold, M.R.; Grinstein, S. Localized diacylglycerol-dependent stimulation of Ras and Rap1 during phagocytosis. *J. Biol. Chem.* **2009**, *284*, 28522–28532. [[CrossRef](#)]

21. Yang, Y.; Li, L.; Wong, G.W.; Krilis, S.A.; Madhusudhan, M.S.; Sali, A.; Stevens, R.L. RasGRP4, a new mast cell-restricted Ras guanine nucleotide-releasing protein with calcium- and diacylglycerol-binding motifs. Identification of defective variants of this signaling protein in asthma, mastocytosis, and mast cell leukemia patients and demonstration of the importance of RasGRP4 in mast cell development and function. *J. Biol. Chem.* **2002**, *277*, 25756–25774. [[PubMed](#)]
22. Suire, S.; Lécureuil, C.; Anderson, K.E.; Damoulakis, G.; Niewczas, I.; Davidson, K.; Guillou, H.; Pan, D.; Clark, J.; Hawkins, P.T.; et al. GPCR activation of Ras and PI3Kc in neutrophils depends on PLCb2/b3 and the RasGEF RasGRP4. *EMBO J.* **2012**, *31*, 3118–3129. [[CrossRef](#)] [[PubMed](#)]
23. Zhu, M.; Fuller, D.M.; Zhang, W. The role of Ras guanine nucleotide releasing protein 4 in Fc epsilonRI-mediated signaling, mast cell function, and T cell development. *J. Biol. Chem.* **2012**, *287*, 8135–8143. [[CrossRef](#)] [[PubMed](#)]
24. Ksionda, O.; Limnander, A.; Roose, J.P. RasGRP Ras guanine nucleotide exchange factors in cancer. *Front. Boil.* **2013**, *8*, 508–532. [[CrossRef](#)] [[PubMed](#)]
25. Lewit-Bentley, A.; Réty, S. EF-hand calcium-binding proteins. *Curr. Opin. Struct. Boil.* **2000**, *10*, 637–643. [[CrossRef](#)]
26. Johnson, J.E.; Goulding, R.E.; Ding, Z.; Partovi, A.; Anthony, K.V.; Beaulieu, N.; Tazmini, G.; Cornell, R.B.; Kay, R.J. Differential membrane binding and diacylglycerol recognition by C1 domains of RasGRPs. *Biochem. J.* **2007**, *406*, 223–236. [[CrossRef](#)] [[PubMed](#)]
27. Eto, K.; Murphy, R.; Kerrigan, S.W.; Bertoni, A.; Stuhlmann, H.; Nakano, T.; Leavitt, A.D.; Shattil, S.J. Megakaryocytes derived from embryonic stem cells implicate CalDAG-GEFI in integrin signaling. *Proc. Natl. Acad. Sci. USA* **2002**, *99*, 12819–12824. [[CrossRef](#)]
28. Zang, C.; Luyten, A.; Chen, J.; Liu, X.S.; Shivdasani, R.A. NF-E2, FLI1 and RUNX1 collaborate at areas of dynamic chromatin to activate transcription in mature mouse megakaryocytes. *Sci. Rep.* **2016**, *6*, 30255. [[CrossRef](#)]
29. Shiraga, M.; Ritchie, A.; Aidoudi, S.; Baron, V.; Wilcox, D.; White, G.; Ybarrondo, B.; Murphy, G.; Leavitt, A.; Shattil, S. Primary megakaryocytes reveal a role for transcription factor NF-E2 in integrin alpha IIb beta 3 signaling. *J. Cell Biol.* **1999**, *147*, 1419–1430. [[CrossRef](#)]
30. Choi, J.; Baldwin, T.M.; Wong, M.; Bolden, J.E.; Fairfax, K.A.; Lucas, E.C.; Cole, R.; Biben, C.; Morgan, C.; Ramsay, K.A.; et al. Haemopedia RNA-seq: A database of gene expression during haematopoiesis in mice and humans. *Nucleic Acids Res.* **2019**, *47*, D780–D785. [[CrossRef](#)]
31. Hornbeck, P.V.; Zhang, B.; Murray, B.; Kornhauser, J.M.; Latham, V.; Skrzypek, E. PhosphoSitePlus, 2014: Mutations, PTMs and recalibrations. *Nucleic Acids Res.* **2014**, *43*, D512–D520. [[CrossRef](#)] [[PubMed](#)]
32. Jaśkiewicz, A.; Pająk, B.; Orzechowski, A. The Many Faces of Rap1 GTPase. *Int. J. Mol. Sci.* **2018**, *19*, 2848. [[CrossRef](#)] [[PubMed](#)]
33. Burkhart, J.M.; Vaudel, M.; Gambaryan, S.; Radau, S.; Walter, U.; Martens, L.; Geiger, J.; Sickmann, A.; Zahedi, R.P. The first comprehensive and quantitative analysis of human platelet protein composition allows the comparative analysis of structural and functional pathways. *Blood* **2012**, *120*, e73–e82. [[PubMed](#)]
34. Stefanini, L.; Lee, R.H.; Paul, D.S.; O’Shaughnessy, E.C.; Ghalloussi, D.; Jones, D.I.; Boulaftali, Y.; Poe, K.O.; Piatt, R.; Kechele, D.O.; et al. Functional redundancy between RAP1 isoforms in murine platelet production and function. *Blood* **2018**, *132*, 1951–1962. [[CrossRef](#)]
35. Schultess, J.; Danielewski, O.; Smolenski, A.P. Rap1GAP2 is a new GTPase-activating protein of Rap1 expressed in human platelets. *Blood* **2005**, *105*, 3185–3192. [[CrossRef](#)] [[PubMed](#)]
36. Lorenowicz, M.J.; Van Gils, J.; De Boer, M.; Hordijk, P.L.; Fernandez-Borja, M. Epac1-Rap1 signaling regulates monocyte adhesion and chemotaxis. *J. Leukoc. Boil.* **2006**, *80*, 1542–1552. [[CrossRef](#)]
37. Berridge, M.J.; Bootman, M.D.; Roderick, H.L. Calcium signalling: Dynamics, homeostasis and remodeling. *Nat. Rev. Mol. Cell Biol.* **2003**, *4*, 517–529. [[CrossRef](#)]
38. Bird, G.S.; Aziz, O.; Lievreumont, J.-P.; Wedel, B.J.; Trebak, M.; Vazquez, G.; Putney, J.W. Mechanisms of phospholipase C-regulated calcium entry. *Curr. Mol. Med.* **2004**, *4*, 291–301. [[CrossRef](#)]
39. Quinton, T.M.; Kim, S.; Dangelmaier, C.; Dorsam, R.T.; Jin, J.; Daniel, J.L.; Kunapuli, S.P. Protein kinase C- and calcium-regulated pathways independently synergize with Gi pathways in agonist-induced fibrinogen receptor activation. *Biochem. J.* **2002**, *368*, 535–543. [[CrossRef](#)]

40. Quinton, T.M.; Ozdener, F.; Dangelmaier, C.; Daniel, J.L.; Kunapuli, S.P. Glycoprotein VI-mediated platelet fibrinogen receptor activation occurs through calcium-sensitive and PKC-sensitive pathways without a requirement for secreted ADP. *Blood* **2002**, *99*, 3228–3234. [[CrossRef](#)]
41. Stolla, M.; Stefanini, L.; Roden, R.C.; Chavez, M.; Hirsch, J.; Greene, T.; Ouellette, T.D.; Maloney, S.F.; Diamond, S.L.; Poncz, M.; et al. The kinetics of α IIb β 3 activation determines the size and stability of thrombi in mice: Implications for antiplatelet therapy. *Blood* **2011**, *117*, 1005–1013. [[CrossRef](#)] [[PubMed](#)]
42. Franke, B.; van Triest, M.; de Bruijn, K.M.; van Willigen, G.; Nieuwenhuis, H.K.; Negrier, C.; Akkerman, J.W.; Bos, J.L. Sequential regulation of the small GTPase Rap1 in human platelets. *Mol. Cell. Biol.* **2000**, *20*, 779–785. [[CrossRef](#)] [[PubMed](#)]
43. Woulfe, D.; Jiang, H.; Mortensen, R.; Yang, J.; Brass, L.F. Activation of Rap1B by G(i) family members in platelets. *J. Biol. Chem.* **2002**, *277*, 23382–23390. [[CrossRef](#)] [[PubMed](#)]
44. Lova, P.; Paganini, S.; Hirsch, E.; Barberis, L.; Wymann, M.; Sinigaglia, F.; Balduini, C.; Torti, M. A selective role for phosphatidylinositol 3,4,5-trisphosphate in the Gi-dependent activation of platelet Rap1B. *J. Biol. Chem.* **2003**, *278*, 131–138. [[CrossRef](#)]
45. Lova, P.; Paganini, S.; Sinigaglia, F.; Balduini, C.; Torti, M. A Gi-dependent pathway is required for activation of the small GTPase Rap1B in human platelets. *J. Biol. Chem.* **2002**, *277*, 12009–12015. [[CrossRef](#)]
46. Rowley, J.W.; Oler, A.J.; Tolley, N.D.; Hunter, B.N.; Low, E.N.; Nix, D.A.; Yost, C.C.; Zimmerman, G.A.; Weyrich, A.S. Genome-wide RNA-seq analysis of human and mouse platelet transcriptomes. *Blood* **2011**, *118*, e101–e111. [[CrossRef](#)]
47. Simon, L.M.; Edelstein, L.C.; Nagalla, S.; Woodley, A.B.; Chen, E.S.; Kong, X.; Ma, L.; Fortina, P.; Kunapuli, S.; Holinstat, M.; et al. Human platelet microRNA-mRNA networks associated with age and gender revealed by integrated plateletomics. *Blood* **2014**, *123*, e37–e45. [[CrossRef](#)]
48. Stefanini, L.; Paul, D.S.; Robledo, R.F.; Chan, E.R.; Getz, T.M.; Campbell, R.A.; Kechele, D.O.; Casari, C.; Piatt, R.; Caron, K.M.; et al. RASA3 is a critical inhibitor of RAP1-dependent platelet activation. *J. Clin. Investig.* **2015**, *125*, 1419–1432. [[CrossRef](#)]
49. Stefanini, L.; Bergmeier, W. Negative regulators of platelet activation and adhesion. *J. Thromb. Haemost.* **2017**, *16*, 220–230. [[CrossRef](#)]
50. Brass, L.F.; Diamond, S.L.; Stalker, T.J. Platelets and hemostasis: A new perspective on an old subject. *Blood Adv.* **2016**, *1*, 5–9. [[CrossRef](#)]
51. Grover, S.P.; Bergmeier, W.; Mackman, N. Recent highlights of ATVB: Platelet signaling pathways and new inhibitors. *Arterioscler. Thromb. Vasc. Biol.* **2018**, *38*, e28–e35. [[CrossRef](#)] [[PubMed](#)]
52. Lagarrigue, F.; Kim, C.; Ginsberg, M.H. The Rap1-RIAM-talin axis of integrin activation and blood cell function. *Blood* **2016**, *128*, 479–487. [[CrossRef](#)] [[PubMed](#)]
53. Piatt, R.; Paul, D.S.; Lee, R.H.; McKenzie, S.E.; Parise, L.V.; Cowley, D.O.; Cooley, B.C.; Bergmeier, W. Mice Expressing Low Levels of CalDAG-GEFI Exhibit Markedly Impaired Platelet Activation With Minor Impact on Hemostasis. *Arterioscler. Thromb. Vasc. Biol.* **2016**, *36*, 1838–1846. [[CrossRef](#)] [[PubMed](#)]
54. Stefanini, L.; Roden, R.C.; Bergmeier, W. CalDAG-GEFI is at the nexus of calcium-dependent platelet activation. *Blood* **2009**, *114*, 2506–2514. [[CrossRef](#)] [[PubMed](#)]
55. Chrzanowska-Wodnicka, M.; Smyth, S.S.; Schoenwaelder, S.M.; Fischer, T.H.; White, G.C., II. Rap1b is required for normal platelet function and hemostasis in mice. *J. Clin. Investig.* **2005**, *115*, 680. [[CrossRef](#)] [[PubMed](#)]
56. Stefanini, L.; Boulaftali, Y.; Ouellette, T.D.; Holinstat, M.; Désiré, L.; Leblond, B.; Andre, P.; Conley, P.B.; Bergmeier, W. Rap1-Rac1 circuits potentiate platelet activation. *Arterioscler. Thromb. Vasc. Biol.* **2012**, *32*, 434–441. [[CrossRef](#)]
57. Bernardi, B.; Guidetti, G.F.; Campus, F.; Crittenden, J.R.; Graybiel, A.M.; Balduini, C.; Torti, M. The small GTPase Rap1b regulates the cross talk between platelet integrin α 2 β 1 and integrin α IIb β 3. *Blood* **2006**, *107*, 2728–2735. [[CrossRef](#)]
58. Canault, M.; Ghalloussi, D.; Grosdidier, C.; Guinier, M.; Perret, C.; Chelghoum, N.; Germain, M.; Raslova, H.; Peiretti, F.; Morange, P.E.; et al. Human CalDAG-GEFI gene (RASGRP2) mutation affects platelet function and causes severe bleeding. *J. Exp. Med.* **2014**, *211*, 1349–1362. [[CrossRef](#)]
59. Lozano, M.L.; Cook, A.; Bastida, J.M.; Paul, D.S.; Iruin, G.; Cid, A.R.; Adan-Pedroso, R.; Ramón González-Porras, J.; Hernández-Rivas, J.M.; Fletcher, S.J.; et al. Novel mutations in RASGRP2, which encodes CalDAG-GEFI, abrogate Rap1 activation, causing platelet dysfunction. *Blood* **2016**, *128*, 1282–1289.

60. Sevivas, T.; Bastida, J.M.; Paul, D.S.; Caparros, E.; Palma-Barqueros, V.; Coucelo, M.; Marques, D.; Ferrer-Marín, F.; González-Porrás, J.R.; Vicente, V.; et al. Identification of two novel mutations in RASGRP2 affecting platelet CalDAG-GEFI expression and function in patients with bleeding diathesis. *Platelets* **2018**, *29*, 192–195.
61. Ahmad, F.; Boulaftali, Y.; Greene, T.K.; Ouellette, T.D.; Poncz, M.; Feske, S.; Bergmeier, W. Relative contributions of stromal interaction molecule 1 and CalDAG-GEFI to calcium-dependent platelet activation and thrombosis. *J. Thromb. Haemost. JTH* **2011**, *9*, 2077–2086. [[CrossRef](#)] [[PubMed](#)]
62. Boulaftali, Y.; Owens, A.P.; Beale, A.; Piatt, R.; Casari, C.; Lee, R.H.; Conley, P.B.; Paul, D.S.; Mackman, N.; Bergmeier, W. CalDAG-GEFI Deficiency Reduces Atherosclerotic Lesion Development in Mice. *Arterioscler. Thromb. Vasc. Biol.* **2016**, *36*, 792–799. [[CrossRef](#)] [[PubMed](#)]
63. Bergmeier, W.; Goerge, T.; Wang, H.-W.; Crittenden, J.R.; Baldwin, A.C.W.; Cifuni, S.M.; Housman, D.E.; Graybiel, A.M.; Wagner, D.D. Mice lacking the signaling molecule CalDAG-GEFI represent a model for leukocyte adhesion deficiency type III. *J. Clin. Investig.* **2007**, *117*, 1699–1707. [[CrossRef](#)] [[PubMed](#)]
64. Stadtmann, A.; Brinkhaus, L.; Mueller, H.; Rossaint, J.; Bolomini-Vittori, M.; Bergmeier, W.; Van Aken, H.; Wagner, D.D.; Laudanna, C.; Ley, K.; et al. Rap1a activation by CalDAG-GEFI and p38 MAPK is involved in E-selectin-dependent slow leukocyte rolling. *Eur. J. Immunol.* **2011**, *41*, 2074–2085. [[CrossRef](#)] [[PubMed](#)]
65. Katagiri, K.; Shimonaka, M.; Kinashi, T. Rap1-mediated lymphocyte function-associated antigen-1 activation by the T cell antigen receptor is dependent on phospholipase C-gamma1. *J. Biol. Chem.* **2004**, *279*, 11875–11881. [[CrossRef](#)] [[PubMed](#)]
66. Caloca, M.-J.; Zugaza, J.L.; Vicente-Manzanares, M.; Bustelo, X.R.; Sanchez-Madrid, F. F-actin-dependent Translocation of the Rap1 GDP/GTP Exchange Factor RasGRP2. *J. Biol. Chem.* **2004**, *279*, 20435–20446. [[CrossRef](#)]
67. Dupuy, A.J.; Morgan, K.; von Lintig, F.C.; Shen, H.; Acar, H.; Hasz, D.E.; Jenkins, N.A.; Copeland, N.G.; Boss, G.R.; Largaespada, D.A. Activation of the Rap1 guanine nucleotide exchange gene, CalDAG-GEF I, in BXH-2 murine myeloid leukemia. *J. Biol. Chem.* **2001**, *276*, 11804–11811. [[CrossRef](#)]
68. Riches, J.C.; O'Donovan, C.J.; Kingdon, S.J.; McClanahan, F.; Clear, A.J.; Neuberger, D.S.; Werner, L.; Croce, C.M.; Ramsay, A.G.; Rassenti, L.Z.; et al. Trisomy 12 chronic lymphocytic leukemia cells exhibit upregulation of integrin signaling that is modulated by NOTCH1 mutations. *Blood* **2014**, *123*, 4101–4110.
69. Mele, S.; Devereux, S.; Pepper, A.G.; Infante, E.; Ridley, A.J. Calcium-RasGRP2-Rap1 signaling mediates CD38-induced migration of chronic lymphocytic leukemia cells. *Blood Adv.* **2018**, *2*, 1551–1561. [[CrossRef](#)]
70. Nagamine, K.; Matsuda, A.; Asashima, M.; Hori, T. XRASGRP2 expression during early development of Xenopus embryos. *Biochem. Biophys. Res. Commun.* **2008**, *372*, 886–891. [[CrossRef](#)]
71. Sato, T.; Takino, J.-I.; Nagamine, K.; Nishio, K.; Hori, T. RASGRP2 Suppresses Apoptosis via Inhibition of ROS Production in Vascular Endothelial Cells. *Sci. World J.* **2019**, *2019*, 1–8. [[CrossRef](#)] [[PubMed](#)]
72. Takino, J.; Sato, T.; Nagamine, K.; Hori, T. The inhibition of Bax activation-induced apoptosis by RasGRP2 via R-Ras-PI3K-Akt signaling pathway in the endothelial cells. *Sci. Rep.* **2019**, *9*, 16717. [[CrossRef](#)] [[PubMed](#)]
73. Reiner, A.; Deng, Y. Disrupted striatal neuron inputs and outputs in Huntington's disease. *CNS Neurosci. Ther.* **2018**, *24*, 250–280. [[CrossRef](#)] [[PubMed](#)]
74. Crittenden, J.R.; Dunn, D.E.; Merali, F.I.; Woodman, B.; Yim, M.; Borkowska, A.E.; Frosch, M.P.; Bates, G.P.; Housman, D.E.; Lo, D.C.; et al. CalDAG-GEFI down-regulation in the striatum as a neuroprotective change in Huntington's disease. *Hum. Mol. Genet.* **2010**, *19*, 1756–1765. [[CrossRef](#)] [[PubMed](#)]
75. Crittenden, J.R.; Cantuti-Castelvetri, I.; Saka, E.; Keller-McGandy, C.E.; Hernandez, L.F.; Kett, L.R.; Young, A.B.; Standaert, D.G.; Graybiel, A.M. Dysregulation of CalDAG-GEFI and CalDAG-GEFII predicts the severity of motor side-effects induced by anti-parkinsonian therapy. *Proc. Natl. Acad. Sci. USA* **2009**, *106*, 2892–2896. [[CrossRef](#)]
76. Nagai, T.; Nakamuta, S.; Kuroda, K.; Nakauchi, S.; Nishioka, T.; Takano, T.; Zhang, X.; Tsuboi, D.; Funahashi, Y.; Nakano, T.; et al. Phosphoproteomics of the Dopamine Pathway Enables Discovery of Rap1 Activation as a Reward Signal In Vivo. *Neuron* **2016**, *89*, 550–565. [[CrossRef](#)]
77. Iwig, J.S.; Vercoulen, Y.; Das, R.; Barros, T.; Limnander, A.; Che, Y.; Pelton, J.G.; Wemmer, D.E.; Roose, J.P.; Kuriyan, J. Structural analysis of autoinhibition in the Ras-specific exchange factor RasGRP1. *eLife* **2013**, *2*, e00813. [[CrossRef](#)]
78. Siess, W. Molecular mechanisms of platelet activation. *Physiol. Rev.* **1989**, *69*, 58–178. [[CrossRef](#)]

79. Cook, A.A.; Deng, W.; Ren, J.; Li, R.; Sondek, J.; Bergmeier, W. Calcium-induced structural rearrangements release autoinhibition in the Rap-GEF CalDAG-GEFI. *J. Biol. Chem.* **2018**, *293*, 8521–8529. [[CrossRef](#)]
80. Guidetti, G.F.; Manganaro, D.; Consonni, A.; Canobbio, I.; Balduini, C.; Torti, M. Phosphorylation of the guanine-nucleotide-exchange factor CalDAG-GEFI by protein kinase A regulates Ca(2+)-dependent activation of platelet Rap1b GTPase. *Biochem. J.* **2013**, *453*, 115–123. [[CrossRef](#)]
81. Subramanian, H.; Zahedi, R.P.; Sickmann, A.; Walter, U.; Gambaryan, S. Phosphorylation of CalDAG-GEFI by protein kinase A prevents Rap1b activation. *J. Thromb. Haemost.* **2013**, *11*, 1574–1582. [[CrossRef](#)] [[PubMed](#)]
82. Beck, F.; Geiger, J.; Gambaryan, S.; Solari, F.A.; Dell'Aica, M.; Loroch, S.; Mattheij, N.J.; Mindukshev, I.; Pötz, O.; Jurk, K.; et al. Temporal quantitative phosphoproteomics of ADP stimulation reveals novel central nodes in platelet activation and inhibition. *Blood* **2017**, *129*, e1–e12. [[CrossRef](#)] [[PubMed](#)]
83. Ren, J.; Cook, A.A.; Bergmeier, W.; Sondek, J. A negative-feedback loop regulating ERK1/2 activation and mediated by RasGPR2 phosphorylation. *Biochem. Biophys. Res. Commun.* **2016**, *474*, 193–198. [[CrossRef](#)] [[PubMed](#)]
84. Desai, A.; Bergmeier, W.; Canault, M.; Alessi, M.-C.; Paul, D.S.; Nurden, P.; Pillois, X.; Jy, W.; Ahn, Y.S.; Nurden, A.T. Phenotype analysis and clinical management in a large family with a novel truncating mutation in RASGRP2, the CalDAG-GEFI encoding gene. *Res. Pract. Thromb. Haemost.* **2017**, *1*, 128–133. [[CrossRef](#)]
85. Sarker, M.; Goliaei, A.; Golesi, F.; Poggi, M.; Cook, A.; Khan, M.A.I.; Temple, B.R.; Stefanini, L.; Canault, M.; Bergmeier, W.; et al. Subcellular localization of Rap1 GTPase activator CalDAG-GEFI is orchestrated by interaction of its atypical C1 domain with membrane phosphoinositides. *J. Thromb. Haemost.* **2019**. [[CrossRef](#)]
86. Steficek, B.A.; Thomas, J.S.; McConnell, M.F.; Bell, T.G. A primary platelet disorder of consanguineous simmental cattle. *Thromb. Res.* **1993**, *72*, 145–153. [[CrossRef](#)]
87. Aebi, M.; Wiedemar, N.; Zanolari, P.; Drögemüller, C. Inherited thrombopathy in Simmental cattle. *Schweiz Arch Tierheilkd* **2016**, *158*, 102–108. [[CrossRef](#)]
88. Boudreaux, M.K.; Schmutz, S.M.; French, P.S. Calcium Diacylglycerol Guanine Nucleotide Exchange Factor I (CalDAG-GEFI) Gene Mutations in a Thrombopathic Simmental Calf. *Veter- Pathol.* **2007**, *44*, 932–935. [[CrossRef](#)]
89. Boudreaux, M.K.; Catalfamo, J.L.; Klok, M. Calcium-diacylglycerol guanine nucleotide exchange factor I gene mutations associated with loss of function in canine platelets. *Transl. Res. J. Lab. Clin. Med.* **2007**, *150*, 81–92. [[CrossRef](#)]
90. Yun, J.W.; Lee, K.-O.; Jung, C.W.; Oh, S.-Y.; Kim, S.-H.; Choi, C.W.; Kim, H.-J. Hereditary platelet function disorder from RASGRP2 gene mutations encoding CalDAG-GEFI identified by whole-exome sequencing in a Korean woman with severe bleeding. *Haematologica* **2019**, *104*, e274–e276. [[CrossRef](#)]
91. Westbury, S.K.; Canault, M.; Greene, D.; Bermejo, E.; Hanlon, K.; Lambert, M.P.; Millar, C.M.; Nurden, P.; Obaji, S.G.; Revel-Vilk, S.; et al. Expanded repertoire of RASGRP2 variants responsible for platelet dysfunction and severe bleeding. *Blood* **2017**, *130*, 1026–1030. [[CrossRef](#)] [[PubMed](#)]
92. Lyu, S.J.; Ren, W.R.; Zhu, H.L.; Liu, T. [The clinical characteristics and molecular pathogenesis of a variant Glanzmann's thrombasthenia-like pedigree]. *Zhonghua Xue Ye Xue Za Zhi* **2018**, *39*, 807–811.
93. Lunghi, B.; Lecchi, A.; Santacroce, R.; Scavone, M.; Paniccia, R.; Artoni, A.; Gachet, C.; Castaman, G.; Margaglione, M.; Bernardi, F.; et al. Severe bleeding and absent ADP-induced platelet aggregation associated with inherited combined CalDAG-GEFI and P2Y12 deficiencies. *Haematologica* **2019**. [[CrossRef](#)] [[PubMed](#)]
94. Manukjan, G.; Wiegner, V.A.; Reindl, T.; Strauß, G.; Klopocki, E.; Schulze, H.; Andres, O. Novel variants in FERMT3 and RASGRP2-Genetic linkage in Glanzmann-like bleeding disorders. *Pediatr. Blood Cancer* **2019**, *67*, e28078. [[CrossRef](#)]
95. Bermejo, E.; Alberto, M.F.; Paul, D.S.; Cook, A.A.; Nurden, P.; Luceros, A.S.; Nurden, A.T.; Bergmeier, W. Marked bleeding diathesis in patients with platelet dysfunction due to a novel mutation in RASGRP2, encoding CalDAG-GEFI (p.Gly305Asp). *Platelets* **2018**, *29*, 84–86. [[CrossRef](#)]
96. Kato, H.; Nakazawa, Y.; Kurokawa, Y.; Kashiwagi, H.; Morikawa, Y.; Morita, D.; Banno, F.; Honda, S.; Kanakura, Y.; Tomiyama, Y. Human CalDAG-GEFI deficiency increases bleeding and delays α Ib β 3 activation. *Blood* **2016**, *128*, 2729–2733. [[CrossRef](#)] [[PubMed](#)]
97. Hunt, S.E.; McLaren, W.; Gil, L.; Thormann, A.; Schuilenburg, H.; Sheppard, D.; Parton, A.; Armean, I.M.; Trevanion, S.J.; Flicke, P.; et al. Ensembl variation resources. *Database J. Biol. Databases Curation* **2018**, *2018*, 1.

98. Kuijpers, T.W.; van Bruggen, R.; Kamerbeek, N.; Tool, A.T.J.; Hicsonmez, G.; Gurgey, A.; Karow, A.; Verhoeven, A.J.; Seeger, K.; Sanal, O.; et al. Natural history and early diagnosis of LAD-1/variant syndrome. *Blood* **2007**, *109*, 3529–3537. [[CrossRef](#)]
99. Poon, M.-C.; Di Minno, G.; D'Oiron, R.; Zotz, R. New Insights into the Treatment of Glanzmann Thrombasthenia. *Transfus. Med. Rev.* **2016**, *30*, 92–99. [[CrossRef](#)]
100. Canault, M.; Saultier, P.; Fauré, S.; Poggi, M.; Nurden, A.T.; Nurden, P.; Morange, P.E.; Alessi, M.-C.; Gris, J.-C. Peripartum bleeding management in a patient with CalDAG-GEFI deficiency. *Haemoph. Off. J. World Fed. Hemoph.* **2017**, *23*, e533–e535. [[CrossRef](#)]



© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).



Review

Influence of Cardiometabolic Risk Factors on Platelet Function

Cristina Barale and Isabella Russo *

Department of Clinical and Biological Sciences, Turin University, 10043 Orbassano (Turin), Italy;
cristina.barale@unito.it

* Correspondence: isabella.russo@unito.it

Received: 29 November 2019; Accepted: 16 January 2020; Published: 17 January 2020

Abstract: Platelets are key players in the thrombotic processes. The alterations of platelet function due to the occurrence of metabolic disorders contribute to an increased trend to thrombus formation and arterial occlusion, thus playing a major role in the increased risk of atherothrombotic events in patients with cardiometabolic risk factors. Several lines of evidence strongly correlate metabolic disorders such as obesity, a classical condition of insulin resistance, dyslipidemia, and impaired glucose homeostasis with cardiovascular diseases. The presence of these clinical features together with hypertension and disturbed microhemorrhology are responsible for the prothrombotic tendency due, at least partially, to platelet hyperaggregability and hyperactivation. A number of clinical platelet markers are elevated in obese and type 2 diabetes (T2DM) patients, including the mean platelet volume, circulating levels of platelet microparticles, oxidation products, platelet-derived soluble P-selectin and CD40L, thus contributing to an intersection between obesity, inflammation, and thrombosis. In subjects with insulin resistance and T2DM some defects depend on a reduced sensitivity to mediators—such as nitric oxide and prostacyclin—playing a physiological role in the control of platelet aggregability. Furthermore, other alterations occur only in relation to hyperglycemia. In this review, the main cardiometabolic risk factors, all components of metabolic syndrome involved in the prothrombotic tendency, will be taken into account considering some of the mechanisms involved in the alterations of platelet function resulting in platelet hyperactivation.

Keywords: adipose tissue; adipokines; hemostasis; insulin resistance; metabolic syndrome; nitric oxide; oxidative stress; platelets; thrombosis

1. Introduction

Several lines of evidence suggest a strong correlation between metabolic disorders and hemodynamic such as obesity, dyslipidemia, diabetes, hypertension, and cardiovascular (CV) diseases (CVD), with endothelial dysfunction as the initial step toward atherothrombosis (Figure 1). Oxidative stress and a chronic low-grade of inflammation may be considered a “common soil” able to create a feed-forward cycle that can deeply influence the development of a prothrombotic tendency of these metabolic abnormalities.




Figure 1. Potential mechanisms linking cardiometabolic disorders and atherothrombotic vascular diseases.

One of the first epidemiological studies showing the causal relationship between obesity and CVD was the Framingham Heart Study [1,2] and other studies have then confirmed that the waist-to-hip ratio (WHR)—a reliable index of central obesity—was the strongest anthropometric predictor of myocardial infarction [3] and stroke [4,5].

Not only the excess of adipose tissue, but also body fat distribution and the impaired adipose tissue function, rather than total fat mass, better predict CV risk [6]. Actually, atherothrombotic events leading to an elevated risk of CV morbidity and mortality are closely associated to central obesity, which confers a higher degree of CV risk than peripheral adiposity [7,8]. In fact, abdominal adiposity may have a causal, unfavorable effect on plasma triglycerides (TGs) and potentially other cardiometabolic risk factors due to a greater ability to release cytokines and free fatty acids involved in the pathogenesis of both atherothrombosis and insulin resistance [9,10].

The increasing prevalence of obesity, especially in Western Countries, has also contributed to significant increases in the prevalence of other important CV risk factors, including dyslipidemia, insulin resistance, and type 2 diabetes mellitus (T2DM). The presence of a clustering of three or more risk factors in the same individual, including abdominal obesity, atherogenic dyslipidemia, high systolic and diastolic blood pressures, and impaired glucose tolerance has been defined by World Health Organization (WHO) as metabolic syndrome (MS) [11], though there is some minor variation in the definition by other health care organizations. Importantly, each of these cardiometabolic disorders contributes to alter hemostatic balance leading to a prothrombotic phenotype [12]. This review will focus on the role of obesity on prothrombotic tendency in patients affected by MS, being adipocytes able to produce and/or release hormones which deeply influence hemostatic balance, platelet function, pro-inflammatory state and oxidative stress.

2. Definition of Metabolic Syndrome

MS is a multiplex risk factor for atherosclerotic CV disease, with a prevalence of 34% in the general population [13]. However, due to the lacking of a unifying definition, MS can be present in several forms according to the combination of the different components and the exact evaluation of prevalence of MS changes both in United States and in Europe. It has been estimated that at least one quarter of America population is affected by MS and about 84% of them present abdominal obesity on the basis of the criteria indicated by National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III [14–18].

According to the NCEP's ATP III criteria [19], MS is recognized as a condition related to CVD occurring if the patient has three or more of the following: (1) central obesity characterized by waist circumference >102 cm in men and >88 cm in women; (2) fasting blood TGs \geq 150 mg/dL and high-density lipoprotein cholesterol (HDL) \leq 40 mg/dL in men or \leq 50 mg/dL in women; (3) fasting glucose \geq 100 mg/dL; and (4) systolic blood pressure \geq 130 mmHg and/or diastolic blood pressure \geq 85 mmHg. Indeed, elevated high-sensitivity C-reactive protein, increased prothrombotic factors, endothelial dysfunction, microalbuminuria, elevated inflammatory cytokines, decreased adiponectin plasma levels, and alterations in pituitary-adrenal axis could be involved in MS. However, the inclusion of these abnormalities in the classification of MS needs to be confirmed and this continuous score would be more sensitive to small and large changes that do not modify the most recent Joint Interim Statement of the International Diabetes Federation (IDF) Task Force on Epidemiology and Prevention criteria [20].

Despite other definitions also have been proposed [21], all are associated with the presence of central obesity, thus underlining the crucial role of the abdominal adiposity, together with insulin resistance, as causative factor in the pathogenesis of MS. Actually, the condition of insulin resistance represents a significant link among components of MS even if a subject with MS not necessarily is insulin resistant [22]. It is well established that MS is a constellation of cardiometabolic determinants associated with increase not only of CVD but also a three-fold increase in the risk of T2DM [23–25] with significant adverse effects on health-related quality of life [26].

3. Platelets in Hemostasis and Thrombosis

Platelets are key players in primary hemostasis and thrombus formation. Platelet activation become when platelets come in contact with exposed collagen in the areas of vascular damage and the subsequent morphological and physiological changes help in stable platelet plug formation thus contributing to primary hemostasis. Platelet activation process is mediated by surface exposure of receptors (glycoproteins, GPs) and lipid rafts, which modulate signaling and intracellular trafficking. These include GPIIb/IIIa complex, which interacts with von Willebrand factor (vWF), integrin α IIb β 3 (GPIIb/IIIa), which binds vWF and fibrinogen, and GPVI which binds collagen thus ensuring a stable anchorage with subendothelial matrix [27]. Binding of ligands to the GP receptors changes platelet shape as well as triggers the release of platelet granule contents, which lead to the formation of platelet plug.

However, hemostasis or blood coagulation are not the only function of platelets, which are also involved in pathological processes such as chronic inflammation and atherothrombosis. In fact, platelets store cytokines and growth factors in their alpha-, dense granules and lysosomes [28] and the subcellular machinery of the novo protein synthesis involved in the coagulation cascade and inflammatory pathways including interleukin (IL)-1 β , plasminogen activator inhibitor-1 (PAI-1) and tissue factor (TF; Figure 2).

The atherothrombotic process underlies acute coronary and cerebrovascular events where the activation of inflammatory mechanisms is strictly dependent on interaction among different cell types, such as platelets, leukocytes, and cells of the vascular wall. As extensively reviewed [29–31], once adhered to the damaged vessel wall platelets participate in multiple mechanisms promoting thromboinflammation by releasing storage granules and aggregating to form thrombi. As mentioned, platelet adhesion is influenced by adhesion molecules present in the subendothelial matrix components, such as E-selectin [32], vWF [33], collagen, fibronectin, and by the level of shear stress in the circulation [34]. In this phase, platelets are subjected to a number of physiological and cytoskeletal changes, with release of soluble cytokines, chemokines, growth factors, and the rapid translocation of P-selectin from alpha-granule to plasma membrane. When intracellular Ca⁺⁺ concentration exceeds a specific threshold, platelets shift from the resting discoid shape to the activated state with the formation of filopodia and lamellipodia. The recruitment of other platelets, their activation, and aggregation are followed by the formation of three-dimensional aggregates for a number of molecular interaction

triggered by thrombin and generation of endogenous factors such as thromboxane (TX)_{A2} and release of content from storage granules including adenosine 5-diphosphate (ADP), and platelet activating factor (PAF). Stabilization of platelet–platelet interactions is further mediated by the receptor of fibrinogen GPIIb/IIIa. In the primary hemostasis a pivotal role in plug formation is exerted by platelet aggregation with aggregates anchored at site of injury but this clot remains unstable. Clot stabilization characterizes the secondary hemostasis with consolidation of platelet mass through the assembly of coagulation complexes with conversion of soluble fibrinogen into insoluble fibrin by thrombin and platelet retraction. In some pathological settings, a number of factors can impair the normal hemostasis and aberrant thrombus formation has severe pathological consequences, leading to fatal thromboembolism and tissue ischemia of vital organs, ultimately resulting in acute CVD complications, including myocardial infarction, stroke and critical limb ischemia.




Figure 2. Biochemical factors involved in the coagulation cascade and the atherosclerotic process released following platelet activation. AA, arachidonic acid; COX, cyclooxygenase; TXA₂, thromboxane A₂; PDGF, platelet-derived growth factor; TGF-β, transforming growth factor β; EGF, endothelial growth factor; bFGF, fibroblast growth factor; VEGF, vascular endothelial growth factor; IGF, insulin-like growth factor; IL-1β, interleukin-1β; PAI-1, plasminogen activator inhibitor 1; vWF, von Willebrand factor; GP, glycoprotein; PECAM, platelet endothelial cell adhesion molecule; sCD40L, soluble CD40 ligand; sP-selectin, soluble P-selectin; RANTES, regulated on activation, normal T-cell expressed and secreted; MIP-1α, macrophage inflammation protein- 1α; IL-8, interleukin-8; PF4, platelet factor 4; PMPs, platelet-derived microparticles.

In the presence of intact vascular endothelium, the release of prostacyclin (PGI₂) and nitric oxide (NO), two major antiaggregants, regulates the balance between pro- and antiaggregants and prevents the formation of thrombus inside the blood vessel [35]. However, in subjects at risk of arterial thrombosis, this key protective pathway is overcome, resulting in uncontrolled platelet activity.

4. Platelet Function Assays

For the measurement of platelet function there is no gold-standard method showing the real state of “hyper” or “hypo” reactivity that can be used as reliable marker of high risk in disease settings. However, based on the platelet ability to interact with each other as well as with other cells and for peculiar surface expressions it is possible to measure platelet function and activation by using a

number of tools each measuring different aspects of platelet response. Laboratory tests, including light transmission platelet aggregation, lumiaggregometry, impedance aggregometry on whole blood, flow cytometry or enzyme-linked immunoassays (ELISA), are traditionally utilized for the identification of patients with impaired platelet function.

Light transmission aggregometry (LTA), for a long time considered the gold-standard method, is the most widely employed test in clinical hematology to measure the increase in light transmission through a platelet suspension when platelets were stimulated by a specific agonist such as ADP, arachidonic acid (AA), collagen, and epinephrine. LTA allows us to evaluate the tendency of platelets to aggregate and to identify abnormalities such as hyperaggregation [36]. This assay has some major drawbacks: (i) it is relatively non physiological because during the test platelets are stirred under low shear conditions and only form aggregates after the addition of agonists, without mimicking platelet adhesion, activation and aggregation upon vessel wall damage, (ii) the result obtained may be affected by preanalytical and procedural conditions, (iii) not suitable for platelet-rich platelet numbers below $50 \times 10^6/\text{mL}$ and lipemic blood sample, and (iv) its reproducibility is poor. Specific guidelines for LTA have been published in order to correctly perform the procedure [36–38].

Platelet aggregation assessed in whole blood (WB) measures the increase of electrical impedance generated by aggregates upon those fixed to two electrodes. As advantages, WB aggregometry evaluates platelet function under more physiological conditions because of the presence of the other blood components, does not require manipulation of the sample, thus avoiding platelet activation, and all platelet subpopulations are present in WB sample [39].

Flow cytometry assay allows the rapid analysis of physical and antigenic properties of platelets, such as presence of platelet aggregates or leukocyte–platelet aggregates, determination of GP receptor expression (i.e., GPIIb/IIIa, GPIb/IX/V, and GPVI), including conformational changes related to the receptor activation (i.e., GPIIb-IIIa), activation markers (CD62P and CD63), and platelet granule secretion (β -thromboglobulin, thrombospondin-1, vWF, fibrinogen, and P-selectin). In WB samples, the use of a double labeling binding allows the identification of platelets, platelet microparticles, or mixed cell aggregates [40–42]. Although flow cytometry has the advantages to require small volume of blood sample, to perform platelet aggregation also in the presence of low platelet counts, and to analyze platelet function and activation in a physiological environment [43], this approach can be affected by preanalytical manipulations and be prone to artifacts [44,45]. ELISA are now the most commonly used assays for the measurement of platelet activation markers TXA₂ metabolites (serum TXB₂ and urinary 11-dehydro-TXB₂) [46] and alpha-granule factors such as β -thromboglobulin, platelet factor (PF)-4, soluble P-selectin (sP-selectin), and soluble CD40 Ligand (sCD40L) [44,45]. The new Point-of-Care devices (i.e., VerifyNow system, Plateletworks, Platelet Function Analyser-100, and Multiplate Electrode Aggregometry) may be useful supplements to the existing well-known platelet function tests and are mainly utilized for monitoring antiplatelet therapies.

5. Platelet Alterations in Central Obesity

Obesity is a heterogeneous condition and, when located within the abdominal cavity, becomes an independent determinant for cardiometabolic disease causing or exacerbating other cardiovascular and metabolic risk factors, such as dyslipidemia, hypertension, insulin-resistance, and T2DM [47–49]. Apart from metabolic and hemodynamic alterations, central obesity is characterized by a chronic low grade inflammation and systemic oxidative stress that eventually damages the endothelium causing the loss of the endothelium antithrombotic properties. This justifies the assumption of obesity as a pro-thrombotic clinical condition with increased platelet activation and decreased fibrinolysis [50–53], both contributing to atherogenesis and acute atherothrombotic events via increased vascular deposition of platelets and fibrinous products.

Platelets from obese subjects are known as “angrier” because they show a number of abnormalities, which increase platelet aggregability and activation constituting a relevant risk factor for CVD, especially for the development of atherothrombosis [54]. Recently, studies linking proteomic analysis

and aggregation findings have confirmed the presence of alterations in proteins related to platelet signaling [55]. In particular, a higher expression of GPVI, positively correlated with body mass index (BMI), together with higher levels of Src (pTyr418) and tyrosine phosphorylated phospholipase C γ 2, essential for integrin signaling, mechanistically provide possible explanations for platelet hyperreactivity in obesity [55].

Certain adipokines, bioactive peptides secreted by omental adipose tissue, can modulate not only body weight and metabolism but also vascular function [56]. For instance, in the platelet hyperreactivity of obese individuals [57–61], associations with leptin, the satiety hormone produced primarily by the adipose tissue, and adiponectin, an insulin-sensitizing adipokine produced exclusively by adipocytes, have been found. Platelets express the leptin receptor and both leptin and leptin-receptor-deficient mice have been protected from experimental thrombosis [62]. In *in vitro* experiments with human platelets, leptin alone does not induce platelet aggregation but increases the proaggregating effects of sub-threshold concentrations of ADP and thrombin [63]. A specific pathway in the leptin-induced platelet activation involves Janus kinase 2 (JAK2), phosphatidylinositol 3 kinase (PI3K) and phospholipases C γ 2 and A2, with effects on 3',5'-cyclic adenosine monophosphate (cAMP) hydrolysis, GPIIb/IIIa expression, and TX synthesis. Furthermore, independently of other risk factors, high plasma levels of leptin are associated with an increased risk of thrombotic events such as acute myocardial infarction and stroke [63].

Differently from the other secretory products of adipocytes, adiponectin exerts anti-inflammatory effects protecting against thrombosis, insulin-resistance, dyslipidemia, and endothelial dysfunction [55]. Adiponectin, the most abundant secretory protein produced by adipocytes, is synthesized and secreted as a trimer and in multimeric complexes cleaved to forms that are active transducer of signaling [64]. In mouse, adiponectin has been shown to increase fatty acid oxidation, perhaps through the activation of AMP kinase (AMPK). Disruption of adiponectin leads to high-fat diet-induced insulin resistance and levels are low in humans with obesity and insulin resistance while adiponectin levels are increased by insulin-sensitizing peroxisome proliferator-activated receptors (PPAR) γ agonists.

Although adiponectin *per se* does not influence platelet aggregation [65], antithrombotic actions have been attributed to this adipokine. In particular, adiponectin deficient mice show increased platelet response to the proaggregating agents and thrombosis tendency [66], high adiponectin plasma concentrations are associated with a decreased risk of coronary artery diseases and increased bioavailability of NO [67]. Both hyperleptinemia and hypo adiponectinemia in MS are associated with increases in leukocytes and platelet indices with platelet count, platelet distribution width (PDW), mean platelet volume (MPV) values, and platelets/lymphocyte ratio significantly higher in MS patients than in healthy subjects [68].

6. In Vivo Markers of Platelet Activation in Obesity

Activated platelets show peculiar features or express certain proteins that are less detectable in resting platelets, thus these factors can be used as markers of platelet activation. Some of these markers are higher in central obesity than in healthy subjects (Table 1).

Table 1. Markers of platelet activation in obesity.

| Markers |
|---------------------------------------|
| Mean Platelet Volume |
| Thromboxane B ₂ |
| Prostaglandin F ₂ α |
| Soluble P-Selectin |
| Soluble CD40L |
| Platelet-derived Microparticles |

6.1. Mean Platelet Volume

Among the *in vivo* markers of platelet activation in obesity, MPV represents a parameter closely related to platelet hyperactivation [69] and it has been found increased in obese subjects [70,71]. An interventional study carried out on female subjects, showed MPV values significantly higher in the group of obese women, in comparison with the non-obese [70]. A positive correlation was found between not only MPV and BMI but also reduced values of MPV and weight loss. Conversely, in another cross-sectional study on male individuals, it was not observed any significant difference in MPV values between groups with abdominal and without it. However, in the same study, MPV displayed a positive correlation with prothrombin activity [72]. Weight loss after bariatric surgery is also accompanied by a decrease in platelet count and significant changes in MPV, especially 6 months after surgery, corresponding to the period when weight loss was at its maximum [73].

6.2. Arachidonic Acid Metabolites

TXA₂ is an unstable platelet-derived proaggregant agent with persistent biosynthesis in several CVD [74]. Precursor of TX synthesis is AA dissociated from membrane phospholipids following the increased Ca⁺⁺ intracellular levels and phospholipases activity [75]. A crucial role in TXA₂ production is played by the action of the constitutively expressed cyclooxygenase (COX)-1 in platelets and inducible COX-2 in monocytes and other cells in response to inflammatory and mitogenic stimuli. TXA₂ has a short half-life and is nonenzymatically hydrolyzed and further converted into stable metabolites excreted in the urine 2,3-dinor-TXB₂ and 11-dehydro-TXB₂. The urinary excretion of 11-dehydro-TXB₂, which represents the more reliable time-integrated index of systemic TXA₂ synthesized for 70% by platelets, has been found increased in women with abdominal obesity and higher in women with android obesity than in those with gynoid obesity [76]. Noteworthy, serum TXB₂ levels were found lower in insulin sensitive morbidly obese subjects than in the obese subjects and lean subjects, suggesting that reduced platelet activation could play a role in the paradoxical protection of morbidly obese subjects from atherosclerosis, despite the greater levels of leptin and C-reactive protein [77].

Abdominal obesity increases oxidative stress, as demonstrated by the increased levels of lipid peroxidation or protein oxidation products [78]. Indeed, the chronic 'metabolic inflammation' [79], the hallmark of obesity causing insulin resistance and T2DM [80], where the metabolic disorders trigger inflammatory signals, contributes to generate reactive oxygen species (ROS), which influence platelet function by different ways. For instance, isoprostanes are a family of products derived from AA metabolism through ROS-dependent mechanisms.

An oxidation product of AA is 8-iso-prostaglandin F_{2α} (PGF_{2α}), an abundant isoprostane involved in platelet aggregation by activating TX receptor in the presence of sub-threshold concentrations of other agonists. The influence of this isoprostane on platelets can be prevented by TXA₂ receptor antagonism but is completely independent of COX-1 activity [29]. A positive linear correlation between urinary excretion of 11-dehydro-TXB₂ and PGF_{2α} underlines the link of platelet activation with oxidative stress [81].

6.3. Soluble P-Selectin

A pivotal role in the development of vascular complication of atherothrombosis is played by cellular adhesion pathways and selectins are one of the four main adhesion molecule families. Platelets are the major source of P-selectin, a cellular adhesion molecule with procoagulant activity [82] and able to activate leukocyte integrins [83]. The circulating levels of soluble form of P-selectin mirror platelet activation. Stored in the alpha-granules of platelets, in a setting of inflammation P-selectin translocates to the plasma membrane where it can interact with ligands [84] leading to leukocyte-platelet aggregates that promote adhesion and infiltration of inflammatory cells [85–88]. sP-selectin has been associated with adiposity and both clinical and subclinical atherosclerosis [89] and has been shown to predict

atherosclerosis independently of BMI and other CVD risk factors. The enhanced plasma concentrations of P-selectin in overweight and obese insulin resistant subjects [61,90] are reduced after weight loss [61].

6.4. CD40 Ligand

Activated platelets also release the sCD40L, a trimeric transmembrane protein structurally related to tumor necrosis factor (TNF)- α superfamily. CD40 and its immunomodulating CD40L show dual prothrombotic and proinflammatory role further contributing to amplify vascular diseases and atherogenesis [91].

More than 95% of circulating sCD40L derives from platelets, stored in high amounts in cytoplasm in unstimulated platelets, expressed on the platelet surface where it is cleaved to form the soluble trimeric fragment and released within seconds after platelet activation [92]. sCD40L measurement is considered as a platelet-derived marker of cardiovascular risk able to link thrombosis and inflammation [93]. Studies in mice showed that in obesity the genetic or antibody mediated disruption of CD40L signaling ameliorates adipose tissue inflammation and metabolic disorders in insulin resistance [94], thus confirming the role of sCD40L as a platelet-derived marker of the cardiovascular risk able to link thrombosis, inflammation, and altered metabolism [93]. CD40/CD40L interaction is involved in the expression of many proinflammatory and prothrombotic factors, including IL-1, IL-6, IL-8, IL-12, TNF- α , monocyte chemoattractant protein (MCP)-1, and matrix metalloproteinases (MMPs) accelerating the adhesion of monocytes to the vascular endothelium [95–97], promoting a ROS-mediated endothelial injury [98–100] and the rupture of atheromatous plaques [101]. Recent reports have also indicated that patients with acute cerebral ischemia exhibit increased expression of CD40L on platelets and the CD40/CD40L signaling directly modulates cerebral microvascular thrombosis by the mammalian target of rapamycin (mTOR)/S6K signaling pathway activation [102]. Plasma levels of sCD40 are considered reliable markers of in vivo platelet activation and the increased levels found in obesity are reduced by weight loss [61].

6.5. Platelet-Derived Microparticles (PMPs)

Platelet-derived microparticles (PMPs) are small membrane-bound microparticles with a diameter less than 0.1 micron containing bioactive proteins and genetic material (i.e., mRNAs and microRNAs) able to deeply influence phenotypes and functions of recipient cells promoting the development of pathological states [103]. Platelets, activated by various agonists or exposed to high shear stress [104] or increased oxidative stress [57], produce PMPs and elevated levels of circulating PMPs are associated with most of the cardiovascular risk factors including hypertension, obesity, and dyslipidemia [105], appearing indicative of a poor clinical outcome. In obese non-diabetic subjects, elevated circulating levels of PMPs positively correlate with BMI and waist circumference [106]. Weight reduction, by calorie restriction with or without exercise [106] or after gastrectomy, reduces PMP production. Interestingly, another study has recently shown that PMPs from obese subjects were not different in number if compared with non-obese subjects but, as supported by proteomics data, they showed greater heterogeneity in size and distribution with different levels of proteins relevant to thrombosis and tumorigenesis [107].

7. Contribution of Insulin Resistance on Platelet Dysfunction

Insulin is a hormone that mediates its action through the insulin receptor (IR) composed of two monomers comprising an extracellular α -subunit and a transmembrane β -subunit [108]. Insulin binding induces IR autophosphorylation at various tyrosine residues, recruitment of IR substrates (IRS), and activation of mitogen-activated protein kinase (MAPK) and PI3K [109]: the activation of these signaling pathways promotes downstream processes involved in blood glucose control [110]. A less than expected response of target organs to insulin leads to a condition of insulin resistance with hyperinsulinemia for a compensatory increased insulin production by pancreatic β -cells. Insulin-resistance is classically referred to metabolic homeostasis characterizing, in most cases, obesity,

impaired glucose tolerance and T2DM [111]. Indeed, insulin resistance involves also the vascular effects of the hormone [112–114] and it is the common soil of a cluster of metabolic, hemodynamic, thrombotic and inflammatory features deeply involved in atherogenesis and CVD [115]. One of the alterations accounting for the association between insulin resistance and vascular diseases is platelet hyperactivation, also explained by the reduced sensitivity to the physiological and pharmacological antiaggregating agents. Platelet membrane shows functional IR with a density similar to that measured in other target cells of insulin action [116]. In platelets from insulin sensitive subjects, the hormone decreases in vitro platelet aggregation stimulated by common platelet agonists such as ADP, thrombin, catecholamines, PAF, collagen, AA, and angiotensin-II [117,118]. Insulin infusion in euglycemic conditions determines: (i) reduced sensitivity to multiple agonists and deposition to collagen [119]; (ii) impaired primary hemostasis under high shear stress [119]; and (iii) reduced TXA₂ metabolite synthesis also in T1DM [120]. Through NO increase, insulin induces a rapid increase of the cyclic nucleotides 3',5'-cyclic guanosine monophosphate (cGMP) and cAMP with inhibitory effects on platelet aggregation [121]. In conditions of insulin resistance such as central obesity, T2DM with obesity and hypertension, the inhibitory effects of insulin on platelets are impaired [53] (Figure 3). Among the mechanisms involved in the altered insulin actions on platelets, a role is played by the effects on platelets of the abnormal adipokine content in plasma profile of patients with MS and T2DM [122]. In particular, the adipokines resistin, leptin, PAI-1, and retinol binding protein 4 (RBP4) induce insulin resistance in megakaryocytes by interfering with IRS-1 expression with a negative impact on insulin signaling in platelets.

Platelets from obese insulin-resistant individuals are characterized by multi-step defects at level of NO/cGMP/protein kinase cGMP-dependent (PKG) and PGI₂/cAMP/protein-kinase cAMP-dependent (PKA) pathways. In particular, platelets show an impaired NO and PGI₂ ability to increase, respectively, cGMP and cAMP synthesis and a resistance to cGMP and cAMP themselves to activate their specific kinases PKG and PKA [59,60]. Since the cyclic nucleotides exert their effects on platelets mainly through a reduction of intracellular Ca⁺⁺ [123], these data are suggestive for the presence of alterations in Ca⁺⁺ fluxes handling. Actually, elevated cytosolic Ca⁺⁺ concentrations have been found in insulin-resistance states [124] and this could explain the defective action of cyclic nucleotides on platelet function. Of note, this multistep resistance is not emphasized by the presence of T2DM [125] as well as the presence of T2DM without obesity is not associated with this cluster of platelet abnormalities [125]. However, lifestyle interventions aiming to reduce body weight by diet can modify the prothrombotic tendency in obese insulin resistant individuals. Actually, the altered platelet sensitivity to NO/cGMP/PKG and PGI₂/cAMP/PKA pathways in obesity is restored by weight reduction of at least 10% of the initial body weight and this phenomenon is also accompanied by an improvement of insulin resistance and a decrease of markers of inflammation [61] and synthesis of isoprostanes [126]. The central role of the insulin resistance associated with obesity as a pathogenic factor deeply involved in the impairment of the main inhibitory mechanisms of platelet function is confirmed, in the same study, by multiple regression analysis showing the homeostasis model assessment (HOMA) index, a surrogate marker of insulin-resistance, as the parameter more strongly associated with platelet response to the antiaggregating agents. Successful weight loss obtained with drugs, such as the incretin-based therapy, is associated with a significant reduction in TX-dependent platelet activation, possibly mediated, at least in part, by decreased inflammation and lipid peroxidation [127]. In particular, a direct role on platelets by Liraglutide, an analog of the incretin hormone glucagon-like peptide 1 (GLP-1), initially used for the treatment of T2DM and recently introduced as potential weight loss medication, cannot be excluded because Liraglutide has been shown to inhibit platelet activation in animal models [128] and human platelets [129].




Figure 3. Relationships between insulin resistance, increased oxidative stress and inflammation in promoting platelet hyperactivation in obesity. AA, arachidonic acid; A-II, angiotensin-II; cAMP, 3',5'-cyclic adenosine monophosphate; cGMP, 3',5'-cyclic guanosine monophosphate; IR, insulin receptor; MPV, mean volume platelet; NO, nitric oxide; PAF, platelet activating factor; PAR, protease-activated receptor; PGI₂, prostaglandin I₂; PKA, cAMP-dependent protein kinase; PKG, cGMP-dependent protein kinase; ROS, reactive oxygen species; PMP, platelet-derived microparticles; TP, thromboxane receptor; TX, thromboxane.

8. Type 2 Diabetes Mellitus and Alterations of Platelet Function

Platelets from diabetic patients are more prone to form spontaneous microaggregates [130], to adhesion, to aggregation in response to agonists [131], and to be less sensitive to antiaggregants [132]. Biochemical abnormalities associated with these impairments of platelet function can be detected by elevation of intracellular calcium levels and expression of platelet activation markers including PMPs, which in patients with T2DM can be used as potential predictors of CV outcomes [133].

Indeed, several mechanisms are involved in the hyperactive platelet phenotype in diabetic patients. Among them, hyperglycemia, oxidative stress, and altered shear stress, interconnected with associated metabolic conditions (obesity, dyslipidemia, and subclinical inflammation) promote atherogenesis and the tendency to a prothrombotic status (Figure 4), which in T2DM represents an important risk factor for a first CV event and for worse outcomes after a CV event.

8.1. Hyperglycemia

Although some abnormalities in platelet function in T2DM depend on the presence of the insulin resistance condition, some defects occur only in T2DM in relation to hyperglycemia. Hyperglycemia, the basic characteristic feature of diabetes, and glycemic variability are predictive determinants of platelet activation [134] and postprandial hyperglycemia is an independent risk factor for cardiovascular complications [135]. Although the underlying pathogenic mechanisms are multiple, factors promoting oxidative stress are unanimously considered to contribute significantly to platelet activation. Of particular interest, in T2DM patients a marked oxidative response is induced by the consumption of high-calorie meals, which in these individuals determines an abnormal and sustained elevation of blood glucose and lipid levels, mainly TGs, defined as postprandial dysmetabolism [136].




Figure 4. Biochemical imbalance towards factors promoting endothelial dysfunction and platelet hyperactivation involved in the development of atherothrombotic diseases in the presence of multiple cardiometabolic risk factors. eNOS, endothelial nitric oxide synthase; NFκB, nuclear factor kappa B; PAI-1, plasminogen activator inhibitor-1; AP-1 activator protein-1; NO, nitric oxide; PGI₂, prostaglandin I₂; EC, endothelial cell; PMPs, platelet-derived microparticles; MS, metabolic syndrome.

Since the entry of glucose into platelets does not depend on insulin, intraplatelet glucose concentration mirrors blood glucose levels, and chronic hyperglycemia has been clearly identified as a causal factor leading to platelet hyperreactivity, as indicated by enhanced aggregation, increased fibrinogen binding, and TX production [137]. Hyperglycemic spikes trigger ischemic cardiovascular complications in T2DM [138–140] and may elicit arterial thrombosis owing to a transient hyperreactivity of platelets to high shear stress, thus contributing to precipitating arterial thrombotic occlusion at stenotic sites [141]. Furthermore, platelet activation due to high glucose exposure in the absence or in the presence of high shear stress conditions is cause of reduced platelet sensitivity to inhibition by aspirin [142–144]. Recently, a reduced acetylation level of the catalytic Ser529 site associated with an incomplete inhibition of COX-1 activity by aspirin has been found in condition of high glucose and diabetes [145], adding another piece of information, which may contribute to explain the residual platelet hyperreactivity observed in diabetes and implying in T2DM the use of effective therapeutic strategies able to prevent hyperglycemia in order to improve also the protective effects of aspirin against the occurrence of CV events.

Platelet hyperreactivity in T2DM is coupled with biochemical evidence of persistently increased TX-dependent platelet activation [137,146] and in the mechanism by which platelets transduce glucose levels into enhanced TX generation a central role is played by the enzyme aldose reductase, the first enzyme of the polyol pathway. The activity of aldose-reductase is significantly enhanced in vascular cells in T2DM and is thought to contribute to vascular complications by increasing oxidative and osmotic stress. Glucose flux through aldose reductase enzyme generates oxidative stress by distinct mechanisms, including nicotinamide adenine dinucleotide phosphate (NADPH) depletion, decrease of glutathione (GSH) levels, and increase of advanced glycation end products (AGEs), thus promoting ROS formation [147]. ROS also play an important role in signaling upon agonist-induced platelet aggregation, inducing changes in intraplatelet Ca⁺⁺, and acting as second messenger in thrombin- or collagen-activated platelets [148]. The increased oxidative stress derived from hyperglycemia and platelet activation potentiates p38α MAPK/cytosolic phospholipase A₂ signaling, which catalyzes AA release and TXA₂ production. T2DM with enhanced biosynthesis of TX despite aspirin therapy may have underlying endothelial damage and thromboembolic disease [149]. As mentioned earlier, sCD40 is both marker and mediator of platelet activation and its upregulation is involved in the advanced

stage of cerebrovascular disease and increased risk of CV events in T2DM. The increased TX-dependent platelet activation is also associated with enhanced CD40L release [150].

Although mechanisms underlying the pathogenesis of ischemia/reperfusion injury are particularly complex and multifactorial, there is evidence of interactions between platelet function and ischemia/reperfusion injury, especially in diabetic conditions [151].

Diabetic heart is among the most susceptible to ischemia/reperfusion injury and some cardioprotective strategies are compromised in the presence of diabetes because of several mechanisms, including alteration at the mitochondrial level, altered production of ROS, and impairment of antioxidant capacities at various intracellular and extracellular sites [152].

Interestingly, a recent study has shown that the infusion of platelets from healthy subjects in rat isolated hearts exerts cardioprotective effects by reducing infarct size [153] with a mechanism that depends on the platelet capacity to activate cardiac sphingosine-1-phosphate (S1P) receptors and extracellular signal-regulated kinase (ERK)/PI3K/protein kinase C (PKC) pathways. However, platelets from poorly controlled T2DM subjects, as mirrored by high values of glycated hemoglobin (HbA1c), lost their cardioprotective effects, released less S1P, and a positive correlation between infarct size and the amount of ROS produced by diabetic platelets was found [153].

High glucose levels were also found to cause in platelets loss of function and damage to mitochondria, mitochondrial membrane potential dissipation, cytochrome c release, caspase-3 activation, and a subgroup of platelets can undergo apoptosis [154]. Enhanced rate of platelet apoptosis can lead to generation of PMPs that carry thrombotic mediators by providing a new prothrombotic interface for the deposition of fibrin and other blood cells [155].

In addition to up-regulated pro-aggregatory stimuli, platelets from diabetic individuals show reduced sensitivity to the antiaggregating insulin, NO, and PGI₂ [58]. Since some antiplatelet effects of aspirin are related to increased platelet NO synthesis [144] and preservation of NO from its inactivation [156], an impaired platelet sensitivity to NO signaling may account, at least partially, for less protective aspirin effects against thrombotic events in T2DM.

However, the superoxide-mediated impairment of NO effects on platelet function following hyperglycemia can be corrected by acute aggressive glycemic control [157]. Platelet exposure to high glucose also influences the biophysical state of platelet membrane components and changes in fluidity owing to glycation or acetylation of membrane proteins contribute to the intensified intraplatelet Ca⁺⁺ mobilization [158]. High cytosolic Ca⁺⁺ levels deeply influence the procoagulant state of platelet aggregates inducing externalization of phosphatidylserine and thus accelerating the membrane-dependent reactions of blood coagulation [159].

8.2. Oxidative Stress

As mentioned, superoxide radicals have a strong effect for activating platelets and in T2DM oxidative stress is increased for the imbalance between ROS production and antioxidant defenses. High concentrations of ROS influence platelet function by different mechanisms, including decreased NO bioavailability, calcium mobilization abnormalities, over-expression of membrane glycoproteins, and isoprostane formation. A major source of platelet ROS is the enzyme NADPH oxidase (Nox), as demonstrated in platelets from patients affected by chronic granulomatous disease, a rare primary immunodeficiency, that show very low ROS generation and, in the most frequent form, the deficiency of Nox2 subunits. Nox2 is expressed by platelets and its increased activity has been shown to be correlated with platelet activation, isoprostane formation and/or NO inhibition [160,161]. Nox2 activation, platelet recruitment, and isoprostane levels are parallelly increased in diabetic patients and these could be cause of reduced efficacy of aspirin [162].

Oxidation reactions are elevated in patients with T2DM and significantly contribute to form isoprostanes, which are produced from AA through a non-enzymatic process of lipid peroxidation, catalyzed by oxygen-free radicals on cell membranes [163]. Since structurally similar to prostaglandins, once released isoprostanes activate the same receptors. 8-iso-PGF_{2α} influences some aspects of platelet

function such as adhesive reactions and activation by low concentrations of other agonists [134]. In poorly controlled diabetes, plasma levels of 8-iso-PGF_{2α} are increased and correlate with impaired glycemic control and enhanced lipid peroxidation, thus providing a biochemical link between impaired glycemic control and persistent platelet activation [164].

8.3. Shear Stress

The increased tendency of platelets from diabetics to aggregate is tightly regulated not only by the diabetic milieu but also by complex conditions of flow dynamics. Thrombotic complications are deeply influenced by the effects of hemodynamic environment at the site of vessel injury or plaque rupture blood on endothelial cells constantly exposed to multiple physical forces generated by the movement of blood. In normal conditions, the physiological shear stress-induced endothelial release of NO and PGI₂ does not allow platelets to adhere to the vessel wall [165,166]. In response to abnormal blood flow endothelial cells can modify their shape, function and gene expression, which, in turn, affect platelets, whose adhesiveness and activation change. High shear rates (>1000 s⁻¹) promote platelet aggregation critically modulated by vWF, endogenously present in the subendothelial matrix or adsorbed onto injured tissue components exposed to plasma [167], and subjected to conformational changes that determine vWF self-association and vWF fiber formation [168]. Furthermore, vWF activation also requires the formation of disulfide bridges from free thiols [169], this reaction depends on ROS [170] whose levels, as known, are increased in T2DM. Further studies also showed that in T2DM hyperglycemia causes membrane lipid peroxidation and osmotic fragility in red blood cells [171] leading to increase extracellular hemoglobin which directly affects the GPIbα-vWF interaction [172]. In particular, increased platelet adhesion, and microthrombi formation on fibrin(ogen), extracellular matrix, and collagen at high shear stress in the presence of free hemoglobin (≥50 mg/dL) were found. These may have implications on the shear stress-induced platelet aggregability explaining, at least in part, the increased platelet aggregation in whole blood from T2DM patients. Taking into account that T2DM patients show higher plasma concentrations of vWF, correlated with HbA1c and chronic hyperglycemia, we can suppose that the occurrence of a disturbed microhemorrhology in a diabetic environment, characterized also by elevated ROS levels, contributes to exacerbate the prothrombotic phenotype.

9. Role of Dyslipidemia in the Impaired Platelet Reactivity

Dyslipidemia is recognized as an independent risk factor for coronary artery and peripheral vascular disease. In this association a major role is exerted by the effects of accumulation of plasma oxidized lipids on platelet function suggesting a potential causative role for dyslipidemia in the promotion of platelet hyperreactivity in CVD [173,174]. Cholesterol accumulation in plasma membrane alters membrane structure with effects on signaling via surface receptors. Indeed, the mechanisms by which dyslipidemia promotes platelet activity and thrombosis in vivo are multiple also for the heterogeneous nature of lipoproteins.

Platelets become sensitive to a wide spectrum of interactions after low-density lipoprotein cholesterol (LDL) binding to the specific receptor on the platelet membrane: in their native form, LDLs alone do not induce platelet aggregation but increase platelet response to proaggregants; if oxidized, LDLs induce platelet aggregation also in the absence of agonist [175].

The capability of oxidized-LDL (oxLDL) particles to stimulate generation of ROS by lectin-like oxLDL receptor-1 (LOX-1) binding, a major receptor for uptake of oxLDL in endothelial cells, is one the mechanisms involved in the reduced NO bioavailability at all stages of atherosclerosis through the increases in Nox, nuclear factor kappa B (NF-κB), and mitochondrial enzymes involved in oxidative signaling [176,177]. As known, loss and/or impaired NO action can induce platelet activation, and in disease states such as hypercholesterolemia and diabetes, where ROS production is increased, a dysregulated NO metabolism becomes a critical determinant of platelet function. Indeed, diseases like hypercholesterolemia, where high levels of LDL are often accompanied by increased oxLDL,

platelet hyperactivity could also depend on hyporesponsiveness to NO-related pathways [61,178–180]. In fact, platelets from patients with primary hypercholesterolemia, if compared with healthy controls, show higher aggregability to ADP, collagen, AA, higher ROS production, reduced sensitivity to NO, and increased activation of the proaggregant PI3K/Akt and MAPK/ERK-2 pathways. In the same individuals, platelet exposure to GLP-1, an incretin hormone with effects depending on GLP-1 influence on NO-signaling [129], does not exert any of its antiplatelet actions [178]. In this phenomenon, a role could be played by oxLDL ability to generate Nox2-derived ROS through a CD36-PKC pathway with inhibition of cGMP signaling [181], a key protective pathway activated by NO that, if overcome, results in increased platelet activation.

Platelets from patients with hypercholesterolemia show hyperaggregability, increased fibrinogen binding and surface expression of CD62P, increased production of TXA₂ and superoxide anion, whereas plasma derived from the same patients contains increased concentrations of platelet activation markers, such as soluble sCD-40L, PF-4, sP-selectin, and β -thromboglobulin [182–184]. Many of these impaired platelet parameters of platelet aggregation and activation are corrected by lipid-lowering treatments.

In vitro and in vivo studies show that statins, inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and the most relevant drugs used to lower serum cholesterol levels, due to their pleiotropic effects decrease subclinical inflammation, oxidative stress, endothelial dysfunction, platelet aggregation, and activation [185–189], improving platelet sensitivity to NO [178], and aspirin [184], but not to GLP-1 [178]. The causes of the enhanced platelet hyperaggregability and the defective GLP-1 actions in dyslipidemia can be multifactorial, although the strong correlation with LDL underlines the role of cholesterol as a major determinant of platelet hyperreactivity with a putative role also in the impaired response to GLP-1. The modulating effects of GLP-1 on platelet function might have protective roles on the cardiovascular system, thus suggesting that a reduced and/or impaired action of GLP-1 on platelets could be involved in the platelet hyperreactivity described in metabolic disorders such as diabetes [190,191] and dyslipidemia [192,193].

Although statins represent important tools for primary and secondary prevention of CV events in hypercholesterolemia, only a low percentage of patients reach a predefined LDL target thus justifying the development of new approaches to lipid modification. At this purpose, the inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) to reduce plasma LDL is a new approach for the treatment of hypercholesterolemia because it allows us to address the unmet clinical needs of achieving goal LDL levels for the majority of patients with high CV risk. PCSK9 is a major regulator of LDL levels as it promotes the degradation of hepatic LDL receptors, thus its inhibition causes an increase of LDL receptor activity and more circulating LDL is removed [194].

It has been recently shown that in primary hypercholesterolemia the in vivo treatment with PCSK9 inhibitors, beyond their lipid-lowering action, had important inhibitory effects on platelet aggregation and activation [129]. Given the activating direct effect of PCSK9 on platelets [195] and the relationship between PCSK9 and higher platelet reactivity [196–198], it is plausible that PCSK9 can directly influence platelet reactivity, thus PCSK9 inhibitors also would reduce the direct PCSK9 stimulatory effects on platelets.

The typical dyslipidemia in patients with T2DM and/or the MS is characterized by increased plasma TG concentration and low HDL concentration. In such context, the presence of small, dense LDL, more prone to oxidation, leads to a mixed atherogenic dyslipidemia.

Even though LDLs affect platelet function by modulating platelet activity more strongly than hypertriglyceridemia [173,199], there is evidence that TG-rich particles can directly activate platelets [200].

HDL has been shown to mediate various antithrombotic effects [201]. The infusions of reconstituted HDL decreased platelet activation in diabetic subjects [202]; on the contrary, in condition of impaired delivery of cholesterol by HDL from plasma and peripheral tissues, marked increases of platelet activation and thrombosis have been found [203].

10. Hypertension and Platelets

Arterial hypertension is one of the most important worldwide public-health challenges because of its high frequency and a leading preventable cause of premature death. Indeed, hypertension is a multifactorial disease, often clustering with other components of metabolic syndrome such as obesity, dyslipidemia, and insulin-resistance [204] and platelet activation is deeply involved in at least half of deaths due to heart disease and stroke [205–207].

Changes in the biochemical and functional profile of plasma membrane of platelets from hypertensive subjects are suggestive of platelet activation [208]. The increase of shear forces due to elevated blood pressure, especially adjacent to the endothelium, can promote platelet activation and degranulation [209].

Impaired NO availability, increased oxidative stress, altered Ca^{++} metabolism [210], and membrane permeability [211] are some of platelet abnormalities observed in hypertensive patients.

Vascular and endothelial dysfunction are linked to arterial hypertension and may result in a greater propensity for platelets to cause thrombosis. Actually, given the central role of endothelial cells in avoiding platelet adhesion and maintaining normal platelet function, the presence of dysfunctional endothelium would promote platelet adhesion and activation.

An important consequence of endothelial dysfunction is the reduced bioavailability of NO, a key molecule for CV health. This may be a consequence of the endothelial nitric oxide synthase (eNOS) polymorphisms [212], reduced NO production or increased breakdown of NO by ROS [213,214]. In particular, the uncoupled state of eNOS leads to a decrease in NO synthesis and increase in ROS production. The quenching of NO by superoxide anions contributes to impaired vascular smooth muscle cell response [215] and relaxation [216]. Platelets express both the constitutive eNOS, and inducible NOS (iNOS) with distinct molecular structure and characteristics [217]. The constitutive, calcium-dependent eNOS is responsible for NO production in platelets, which in turn inhibits platelet activation and aggregation by increasing cGMP levels [218]. Increase in intraplatelet Ca^{++} [219] and decrease of NO bioavailability [210] could explain, at least partially, the higher platelet aggregation observed in hypertension.

Stimulated platelets release vascular endothelial growth factor (VEGF) [220], one of the most potent angiogenic factors, and elevated VEGF levels have been found in patients with atherosclerotic risk factors, including hypertension [221–223]. The association between sP-selectin and VEGF levels corroborates the hypothesis that platelets are likely to be a relevant source of VEGF in hypertension; in this setting, aspirin inhibits the agonist-induced platelet aggregation and also VEGF release [224].

Intracellular Ca^{++} and Na^+ contents can modify membrane fluidity and microviscosity that, in turn, can influence receptor functions or enzyme activities [225]. Indeed, arterial hypertension is characterized by a number of structural and functional alterations of the cell membrane including changes in membrane permeability, signal transduction, ion transport, receptor functions, because of plasma membrane differential composition, which in turn might disturb the asymmetry of the platelet plasma membrane [226,227]. Recently, structural and biochemical abnormalities in the platelet membrane from hypertensive subjects have been confirmed by studies showing an overexpression of the epithelial sodium channel [228] involved in the regulation of extracellular fluid volume and blood pressure and dispensable in platelets for migration, alpha- and dense-granule secretion and platelet collagen activation [211].

11. Conclusions

Platelets are key players in the thrombotic process in patients with metabolic abnormalities associated with increased risk of CVD.

This review provides an overview of changes in platelet function occurring in metabolic and hemodynamic disorders mainly characterizing the MS, all with an impact on the risk of CV morbidity and mortality owing to atherothrombotic events. Many of impairments in platelets converge on oxidative stress with release of oxidation products, which have a causal link to platelet

hyperaggregability and hyperactivation. The excess of adipose tissue of the trunk and/or abdomen has a strong impact on vascular complications, through the production of PMPs and mediators with paracrine and endocrine actions, which influence platelet response. Platelet indices and biomarkers of platelet activation may have useful clinical value through the whole journey of cardiometabolic diseases for prediction and risk assessment of thrombotic risk. Different methodological approaches for platelet (dys) function investigations are now available and each-one based on different operating principles. However, few assays are able to assess “all in one device” platelet aggregation and activation pathways and standardization and quality controls are still limited despite several efforts.

Insulin resistance, a condition frequently associated with obesity, with or without hyperglycemia, dyslipidemia, and hypertension alters a number of distinct aspects of hemostasis responsible for platelets more prone to aggregate to agonists and less responsive to platelet inhibitors. However, weight reduction is a powerful measure to restore a physiological platelet function in obese subjects.

Author Contributions: I.R. conceptualized the work; I.R. and C.B. provided the resources for this work; I.R. did the original draft preparation; I.R. and C.B. reviewed and edited the text; C.B. drew the figures; I.R. lead the funding acquisition. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Mendis, S. The contribution of the Framingham Heart Study to the prevention of cardiovascular disease: A global perspective. *Prog. Cardiovasc. Dis.* **2010**, *53*, 10–14. [[CrossRef](#)] [[PubMed](#)]
2. Lakka, H.-M.; Laaksonen, D.E.; Lakka, T.A.; Niskanen, L.K.; Kumpusalo, E.; Tuomilehto, J.; Salonen, J.T. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. *JAMA* **2002**, *288*, 2709–2716. [[CrossRef](#)] [[PubMed](#)]
3. Mente, A.; Yusuf, S.; Islam, S.; McQueen, M.J.; Tanomsup, S.; Onen, C.L.; Rangarajan, S.; Gerstein, H.C.; Anand, S.S. INTERHEART Investigators Metabolic syndrome and risk of acute myocardial infarction a case-control study of 26,903 subjects from 52 countries. *J. Am. Coll. Cardiol.* **2010**, *55*, 2390–2398. [[CrossRef](#)] [[PubMed](#)]
4. Novo, S.; Peritore, A.; Guarneri, F.P.; Corrado, E.; Macaione, F.; Evola, S.; Novo, G. Metabolic syndrome (MetS) predicts cardio and cerebrovascular events in a twenty years follow-up. A prospective study. *Atherosclerosis* **2012**, *223*, 468–472. [[CrossRef](#)] [[PubMed](#)]
5. Towfighi, A.; Ovbiagele, B. Metabolic syndrome and stroke. *Curr. Diabetes Rep.* **2008**, *8*, 37–41. [[CrossRef](#)] [[PubMed](#)]
6. Goossens, G.H. The Metabolic Phenotype in Obesity: Fat Mass, Body Fat Distribution, and Adipose Tissue Function. *Obes. Facts* **2017**, *10*, 207–215. [[CrossRef](#)]
7. Grundy, S.M. Obesity, metabolic syndrome, and coronary atherosclerosis. *Circulation* **2002**, *105*, 2696–2698. [[CrossRef](#)]
8. McGill, H.C.; McMahan, C.A.; Herderick, E.E.; Zieske, A.W.; Malcom, G.T.; Tracy, R.E.; Strong, J.P. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group Obesity accelerates the progression of coronary atherosclerosis in young men. *Circulation* **2002**, *105*, 2712–2718. [[CrossRef](#)]
9. Van Gaal, L.F.; Mertens, I.L.; De Block, C.E. Mechanisms linking obesity with cardiovascular disease. *Nature* **2006**, *444*, 875–880. [[CrossRef](#)]
10. Després, J.-P.; Lemieux, I. Abdominal obesity and metabolic syndrome. *Nature* **2006**, *444*, 881–887. [[CrossRef](#)]
11. Alberti, K.G.; Zimmet, P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. *Diabet. Med.* **1998**, *15*, 539–553. [[CrossRef](#)]
12. Russo, I. The prothrombotic tendency in metabolic syndrome: Focus on the potential mechanisms involved in impaired haemostasis and fibrinolytic balance. *Scientifica* **2012**, *2012*, 525374. [[CrossRef](#)] [[PubMed](#)]
13. Ervin, R.B. Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003–2006. *Natl. Health Stat. Rep.* **2009**, *5*, 1–7.

14. Ford, E.S.; Giles, W.H.; Mokdad, A.H. Increasing prevalence of the metabolic syndrome among u.s. Adults. *Diabetes Care* **2004**, *27*, 2444–2449. [[CrossRef](#)]
15. Ford, E.S.; Giles, W.H.; Dietz, W.H. Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey. *JAMA* **2002**, *287*, 356–359. [[CrossRef](#)]
16. Meigs, J.B. Epidemiology of the metabolic syndrome, 2002. *Am. J. Manag. Care* **2002**, *8*, S283–S292.
17. Jacobson, T.A.; Case, C.C.; Roberts, S.; Buckley, A.; Murtaugh, K.M.; Sung, J.C.Y.; Gause, D.; Varas, C.; Ballantyne, C.M. Characteristics of US adults with the metabolic syndrome and therapeutic implications. *Diabetes Obes. Metab.* **2004**, *6*, 353–362. [[CrossRef](#)]
18. Grundy, S.M. Metabolic syndrome pandemic. *Arterioscler. Thromb. Vasc. Biol.* **2008**, *28*, 629–636. [[CrossRef](#)]
19. Grundy, S.M.; Cleeman, J.I.; Daniels, S.R.; Donato, K.A.; Eckel, R.H.; Franklin, B.A.; Gordon, D.J.; Krauss, R.M.; Savage, P.J.; Smith, S.C.; et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. *Circulation* **2005**, *112*, 2735–2752. [[CrossRef](#)]
20. Alberti, K.G.M.M.; Eckel, R.H.; Grundy, S.M.; Zimmet, P.Z.; Cleeman, J.I.; Donato, K.A.; Fruchart, J.-C.; James, W.P.T.; Loria, C.M.; Smith, S.C.; et al. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. *Circulation* **2009**, *120*, 1640–1645.
21. Perrone-Filardi, P.; Paolillo, S.; Costanzo, P.; Savarese, G.; Trimarco, B.; Bonow, R.O. The role of metabolic syndrome in heart failure. *Eur. Heart J.* **2015**, *36*, 2630–2634. [[CrossRef](#)] [[PubMed](#)]
22. Karnchanasorn, R.; Ou, H.-Y.; Chuang, L.-M.; Chiu, K.C. Insulin resistance is not necessarily an essential element of metabolic syndrome. *Endocrine* **2013**, *43*, 92–99. [[CrossRef](#)] [[PubMed](#)]
23. Eckel, R.H.; Grundy, S.M.; Zimmet, P.Z. The metabolic syndrome. *Lancet* **2005**, *365*, 1415–1428. [[CrossRef](#)]
24. Monteiro, R.; Azevedo, I. Chronic inflammation in obesity and the metabolic syndrome. *Med. Inflamm.* **2010**, *2010*, 289645. [[CrossRef](#)]
25. Ford, E.S. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: A summary of the evidence. *Diabetes Care* **2005**, *28*, 1769–1778. [[CrossRef](#)]
26. Sullivan, P.W.; Ghushchyan, V.; Wyatt, H.R.; Wu, E.Q.; Hill, J.O. Impact of cardiometabolic risk factor clusters on health-related quality of life in the U.S. *Obesity* **2007**, *15*, 511–521. [[CrossRef](#)]
27. Rivera, J.; Lozano, M.L.; Navarro-Núñez, L.; Vicente, V. Platelet receptors and signaling in the dynamics of thrombus formation. *Haematologica* **2009**, *94*, 700–711. [[CrossRef](#)]
28. Heijnen, H.; van der Sluijs, P. Platelet secretory behaviour: As diverse as the granules ... or not? *J. Thromb. Haemost.* **2015**, *13*, 2141–2151. [[CrossRef](#)]
29. Davi, G.; Patrono, C. Platelet activation and atherothrombosis. *N. Engl. J. Med.* **2007**, *357*, 2482–2494. [[CrossRef](#)]
30. Ruggeri, Z.M. Platelets in atherothrombosis. *Nat. Med.* **2002**, *8*, 1227–1234. [[CrossRef](#)]
31. Bakogiannis, C.; Sachse, M.; Stamatelopoulos, K.; Stellos, K. Platelet-derived chemokines in inflammation and atherosclerosis. *Cytokine* **2019**, *122*, 154157. [[CrossRef](#)] [[PubMed](#)]
32. Silva, M.; Videira, P.A.; Sackstein, R. E-Selectin Ligands in the Human Mononuclear Phagocyte System: Implications for Infection, Inflammation, and Immunotherapy. *Front. Immunol.* **2017**, *8*, 1878. [[CrossRef](#)] [[PubMed](#)]
33. Holthenrich, A.; Gerke, V. Regulation of von-Willebrand Factor Secretion from Endothelial Cells by the Annexin A2-S100A10 Complex. *Int. J. Mol. Sci.* **2018**, *19*, 1572. [[CrossRef](#)] [[PubMed](#)]
34. Koupenova, M.; Clancy, L.; Corkrey, H.A.; Freedman, J.E. Circulating Platelets as Mediators of Immunity, Inflammation, and Thrombosis. *Circ. Res.* **2018**, *122*, 337–351. [[CrossRef](#)]
35. Gryglewski, R.J.; Botting, R.M.; Vane, J.R. Mediators produced by the endothelial cell. *Hypertension* **1988**, *12*, 530–548. [[CrossRef](#)]
36. Harrison, P.; Mackie, I.; Mumford, A.; Briggs, C.; Liesner, R.; Winter, M.; Machin, S. British Committee for Standards in Haematology Guidelines for the laboratory investigation of heritable disorders of platelet function. *Br. J. Haematol.* **2011**, *155*, 30–44. [[CrossRef](#)]
37. Hayward, C.P.M.; Moffat, K.A.; Raby, A.; Israels, S.; Plumhoff, E.; Flynn, G.; Zehnder, J.L. Development of North American consensus guidelines for medical laboratories that perform and interpret platelet function testing using light transmission aggregometry. *Am. J. Clin. Pathol.* **2010**, *134*, 955–963. [[CrossRef](#)]

38. Cattaneo, M.; Cerletti, C.; Harrison, P.; Hayward, C.P.M.; Kenny, D.; Nugent, D.; Nurden, P.; Rao, A.K.; Schmaier, A.H.; Watson, S.P.; et al. Recommendations for the Standardization of Light Transmission Aggregometry: A Consensus of the Working Party from the Platelet Physiology Subcommittee of SSC/ISTH. *J. Thromb. Haemost.* **2013**. [[CrossRef](#)]
39. Mackie, I.J.; Jones, R.; Machin, S.J. Platelet impedance aggregation in whole blood and its inhibition by antiplatelet drugs. *J. Clin. Pathol.* **1984**, *37*, 874–878. [[CrossRef](#)]
40. Furman, M.I.; Barnard, M.R.; Krueger, L.A.; Fox, M.L.; Shilale, E.A.; Lessard, D.M.; Marchese, P.; Frelinger, A.L.; Goldberg, R.J.; Michelson, A.D. Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. *J. Am. Coll. Cardiol.* **2001**, *38*, 1002–1006. [[CrossRef](#)]
41. Barnard, M.R.; Linden, M.D.; Frelinger, A.L.; Li, Y.; Fox, M.L.; Furman, M.I.; Michelson, A.D. Effects of platelet binding on whole blood flow cytometry assays of monocyte and neutrophil procoagulant activity. *J. Thromb. Haemost.* **2005**, *3*, 2563–2570. [[CrossRef](#)] [[PubMed](#)]
42. Robert, S.; Lacroix, R.; Poncelet, P.; Harhouri, K.; Bouriche, T.; Judicone, C.; Wischhusen, J.; Arnaud, L.; Dignat-George, F. High-sensitivity flow cytometry provides access to standardized measurement of small-size microparticles—Brief report. *Arterioscler. Thromb. Vasc. Biol.* **2012**, *32*, 1054–1058. [[CrossRef](#)] [[PubMed](#)]
43. De Cuyper, I.M.; Meinders, M.; van de Vijver, E.; de Korte, D.; Porcelijn, L.; de Haas, M.; Eble, J.A.; Seeger, K.; Rutella, S.; Pagliara, D.; et al. A novel flow cytometry-based platelet aggregation assay. *Blood* **2013**, *121*, e70–e80. [[CrossRef](#)] [[PubMed](#)]
44. Pakala, R.; Waksman, R. Currently available methods for platelet function analysis: Advantages and disadvantages. *Cardiovasc. Revas. Med.* **2011**, *12*, 312–322. [[CrossRef](#)]
45. Kehrel, B.E.; Brodde, M.F. State of the art in platelet function testing. *Transfus. Med. Hemother.* **2013**, *40*, 73–86. [[CrossRef](#)]
46. Fontana, P.; Zufferey, A.; Daali, Y.; Reny, J.-L. Antiplatelet therapy: Targeting the TxA2 pathway. *J. Cardiovasc. Transl. Res.* **2014**, *7*, 29–38. [[CrossRef](#)]
47. Csige, I.; Ujvárosy, D.; Szabó, Z.; Lórinicz, I.; Paragh, G.; Harangi, M.; Somodi, S. The Impact of Obesity on the Cardiovascular System. *J. Diabetes Res.* **2018**, *2018*, 3407306. [[CrossRef](#)]
48. Afshin, A.; Forouzanfar, M.H.; Reitsma, M.B.; Sur, P.; Estep, K.; Lee, A.; Marczak, L.; Mokdad, A.H.; Moradi-Lakeh, M.; GBD 2015 Obesity Collaborators. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. *N. Engl. J. Med.* **2017**, *377*, 13–27.
49. Tchernof, A.; Després, J.-P. Pathophysiology of human visceral obesity: An update. *Physiol. Rev.* **2013**, *93*, 359–404. [[CrossRef](#)]
50. Kakafika, A.I.; Liberopoulos, E.N.; Karagiannis, A.; Athyros, V.G.; Mikhailidis, D.P. Dyslipidaemia, hypercoagulability and the metabolic syndrome. *Curr. Vasc. Pharmacol.* **2006**, *4*, 175–183. [[CrossRef](#)]
51. Ritchie, S.A.; Connell, J.M.C. The link between abdominal obesity, metabolic syndrome and cardiovascular disease. *Nutr. Metab. Cardiovasc. Dis.* **2007**, *17*, 319–326. [[CrossRef](#)] [[PubMed](#)]
52. Mertens, I.; Van Gaal, L.F. Obesity, haemostasis and the fibrinolytic system. *Obes. Rev.* **2002**, *3*, 85–101. [[CrossRef](#)] [[PubMed](#)]
53. Anfossi, G.; Russo, I.; Trovati, M. Platelet dysfunction in central obesity. *Nutr. Metab. Cardiovasc. Dis.* **2009**, *19*, 440–449. [[CrossRef](#)] [[PubMed](#)]
54. Beavers, C.J.; Heron, P.; Smyth, S.S.; Bain, J.A.; Macaulay, T.E. Obesity and Antiplatelets—Does One Size Fit All? *Thromb. Res.* **2015**, *136*, 712–716. [[CrossRef](#)]
55. Barrachina, M.N.; Sueiro, A.M.; Izquierdo, I.; Hermida-Nogueira, L.; Guitián, E.; Casanueva, F.F.; Farndale, R.W.; Moroi, M.; Jung, S.M.; Pardo, M.; et al. GPVI surface expression and signalling pathway activation are increased in platelets from obese patients: Elucidating potential anti-atherothrombotic targets in obesity. *Atherosclerosis* **2019**, *281*, 62–70. [[CrossRef](#)]
56. Anfossi, G.; Russo, I.; Doronzo, G.; Pomeroy, A.; Trovati, M. Adipocytokines in atherothrombosis: Focus on platelets and vascular smooth muscle cells. *Med. Inflamm.* **2010**, *2010*, 174341. [[CrossRef](#)]
57. Santilli, F.; Vazzana, N.; Liani, R.; Guagnano, M.T.; Davì, G. Platelet activation in obesity and metabolic syndrome. *Obes. Rev.* **2012**, *13*, 27–42. [[CrossRef](#)]
58. Anfossi, G.; Russo, I.; Trovati, M. Platelet resistance to the anti-aggregating agents in the insulin resistant states. *Curr. Diabetes Rev.* **2006**, *2*, 409–430.

59. Anfossi, G.; Russo, I.; Massucco, P.; Mattiello, L.; Doronzo, G.; De Salve, A.; Trovati, M. Impaired synthesis and action of antiaggregating cyclic nucleotides in platelets from obese subjects: Possible role in platelet hyperactivation in obesity. *Eur. J. Clin. Investig.* **2004**, *34*, 482–489. [[CrossRef](#)]
60. Russo, I.; Del Mese, P.; Doronzo, G.; De Salve, A.; Secchi, M.; Trovati, M.; Anfossi, G. Platelet resistance to the antiaggregatory cyclic nucleotides in central obesity involves reduced phosphorylation of vasodilator-stimulated phosphoprotein. *Clin. Chem.* **2007**, *53*, 1053–1060. [[CrossRef](#)]
61. Russo, I.; Traversa, M.; Bonomo, K.; De Salve, A.; Mattiello, L.; Del Mese, P.; Doronzo, G.; Cavalot, F.; Trovati, M.; Anfossi, G. In central obesity, weight loss restores platelet sensitivity to nitric oxide and prostacyclin. *Obesity* **2010**, *18*, 788–797. [[CrossRef](#)] [[PubMed](#)]
62. Bodary, P.F.; Westrick, R.J.; Wickenheiser, K.J.; Shen, Y.; Eitzman, D.T. Effect of leptin on arterial thrombosis following vascular injury in mice. *JAMA* **2002**, *287*, 1706–1709. [[CrossRef](#)] [[PubMed](#)]
63. Vilahur, G.; Ben-Aicha, S.; Badimon, L. New insights into the role of adipose tissue in thrombosis. *Cardiovasc. Res.* **2017**, *113*, 1046–1054. [[CrossRef](#)] [[PubMed](#)]
64. Klötting, N.; Blüher, M. Adipocyte dysfunction, inflammation and metabolic syndrome. *Rev. Endocr. Metab. Disord.* **2014**, *15*, 277–287. [[CrossRef](#)] [[PubMed](#)]
65. Elbatarny, H.S.; Netherton, S.J.; Ovens, J.D.; Ferguson, A.V.; Maurice, D.H. Adiponectin, ghrelin, and leptin differentially influence human platelet and human vascular endothelial cell functions: Implication in obesity-associated cardiovascular diseases. *Eur. J. Pharmacol.* **2007**, *558*, 7–13. [[CrossRef](#)]
66. Kato, H.; Kashiwagi, H.; Shiraga, M.; Tadokoro, S.; Kamae, T.; Ujiie, H.; Honda, S.; Miyata, S.; Ijiri, Y.; Yamamoto, J.; et al. Adiponectin acts as an endogenous antithrombotic factor. *Arterioscler. Thromb. Vasc. Biol.* **2006**, *26*, 224–230. [[CrossRef](#)]
67. Golia, E.; Limongelli, G.; Natale, F.; Fimiani, F.; Maddaloni, V.; Russo, P.E.; Riegler, L.; Bianchi, R.; Crisci, M.; Palma, G.D.; et al. Adipose tissue and vascular inflammation in coronary artery disease. *World J. Cardiol.* **2014**, *6*, 539–554. [[CrossRef](#)]
68. Abdel-Moneim, A.; Mahmoud, B.; Sultan, E.A.; Mahmoud, R. Relationship of leukocytes, platelet indices and adipocytokines in metabolic syndrome patients. *Diabetes Metab. Syndr.* **2019**, *13*, 874–880. [[CrossRef](#)]
69. Yetkin, E. Mean platelet volume not so far from being a routine diagnostic and prognostic measurement. *Thromb. Haemost.* **2008**, *100*, 3–4. [[CrossRef](#)]
70. Coban, E.; Ozdogan, M.; Yazicioglu, G.; Akcit, F. The mean platelet volume in patients with obesity. *Int. J. Clin. Pract.* **2005**, *59*, 981–982. [[CrossRef](#)]
71. Pinto, R.V.L.; Rodrigues, G.; Simões, R.L.; Porto, L.C. Analysis of Post-Sample Collection EDTA Effects on Mean Platelet Volume Values in Relation to Overweight and Obese Patient Status. *Acta Haematol.* **2019**, *142*, 149–153. [[CrossRef](#)] [[PubMed](#)]
72. Montilla, M.; Santi, M.J.; Carrozas, M.A.; Ruiz, F.A. Biomarkers of the prothrombotic state in abdominal obesity. *Nutr. Hosp.* **2014**, *31*, 1059–1066. [[PubMed](#)]
73. Raoux, L.; Moszkowicz, D.; Vychnevskaja, K.; Poghosyan, T.; Beauchet, A.; Clauser, S.; Bretault, M.; Czernichow, S.; Carette, C.; Bouillot, J.-L. Effect of Bariatric Surgery-Induced Weight Loss on Platelet Count and Mean Platelet Volume: A 12-Month Follow-Up Study. *Obes. Surg.* **2017**, *27*, 387–393. [[CrossRef](#)] [[PubMed](#)]
74. Smyth, E.M. Thromboxane and the thromboxane receptor in cardiovascular disease. *Clin. Lipidol.* **2010**, *5*, 209–219. [[CrossRef](#)]
75. Maclouf, J.; Folco, G.; Patrono, C. Eicosanoids and iso-eicosanoids: Constitutive, inducible and transcellular biosynthesis in vascular disease. *Thromb. Haemost.* **1998**, *79*, 691–705.
76. Simeone, P.; Boccatonda, A.; Liani, R.; Santilli, F. Significance of urinary 11-dehydro-thromboxane B2 in age-related diseases: Focus on atherothrombosis. *Ageing Res. Rev.* **2018**, *48*, 51–78. [[CrossRef](#)]
77. Graziani, F.; Biasucci, L.M.; Cialdella, P.; Liuzzo, G.; Giubilato, S.; Della Bona, R.; Pulcinelli, F.M.; Iaconelli, A.; Mingrone, G.; Crea, F. Thromboxane production in morbidly obese subjects. *Am. J. Cardiol.* **2011**, *107*, 1656–1661. [[CrossRef](#)]
78. Vincent, H.K.; Innes, K.E.; Vincent, K.R. Oxidative stress and potential interventions to reduce oxidative stress in overweight and obesity. *Diabetes Obes. Metab.* **2007**, *9*, 813–839. [[CrossRef](#)]
79. Hornig, T.; Hotamisligil, G.S. Linking the inflammasome to obesity-related disease. *Nat. Med.* **2011**, *17*, 164–165. [[CrossRef](#)]

80. Choi, A.M.K.; Nakahira, K. Dampening insulin signaling by an NLRP3 “meta-flammasome”. *Nat. Immunol.* **2011**, *12*, 379–380. [[CrossRef](#)]
81. Audoly, L.P.; Rocca, B.; Fabre, J.E.; Koller, B.H.; Thomas, D.; Loeb, A.L.; Coffman, T.M.; FitzGerald, G.A. Cardiovascular responses to the isoprostanes iPF(2 α)-III and iPE(2)-III are mediated via the thromboxane A(2) receptor in vivo. *Circulation* **2000**, *101*, 2833–2840. [[CrossRef](#)] [[PubMed](#)]
82. André, P.; Hartwell, D.; Hrachovinová, I.; Saffaripour, S.; Wagner, D.D. Pro-coagulant state resulting from high levels of soluble P-selectin in blood. *Proc. Natl. Acad. Sci. USA* **2000**, *97*, 13835–13840. [[CrossRef](#)] [[PubMed](#)]
83. Hamburger, S.A.; McEver, R.P. GMP-140 mediates adhesion of stimulated platelets to neutrophils. *Blood* **1990**, *75*, 550–554. [[CrossRef](#)] [[PubMed](#)]
84. Patel, M.S.; Miranda-Nieves, D.; Chen, J.; Haller, C.A.; Chaikof, E.L. Targeting P-selectin glycoprotein ligand-1/P-selectin interactions as a novel therapy for metabolic syndrome. *Transl. Res.* **2017**, *183*, 1–13. [[CrossRef](#)]
85. Evangelista, V.; Manarini, S.; Coller, B.S.; Smyth, S.S. Role of P-selectin, beta2-integrins, and Src tyrosine kinases in mouse neutrophil-platelet adhesion. *J. Thromb. Haemost.* **2003**, *1*, 1048–1054. [[CrossRef](#)]
86. Da Costa Martins, P.; van den Berk, N.; Ulfman, L.H.; Koenderman, L.; Hordijk, P.L.; Zwaginga, J.J. Platelet-monocyte complexes support monocyte adhesion to endothelium by enhancing secondary tethering and cluster formation. *Arterioscler. Thromb. Vasc. Biol.* **2004**, *24*, 193–199. [[CrossRef](#)]
87. Kim, K.H.; Barazia, A.; Cho, J. Real-time imaging of heterotypic platelet-neutrophil interactions on the activated endothelium during vascular inflammation and thrombus formation in live mice. *J. Vis. Exp.* **2013**. [[CrossRef](#)]
88. Sreeramkumar, V.; Adrover, J.M.; Ballesteros, I.; Cuartero, M.I.; Rossaint, J.; Bilbao, I.; Nacher, M.; Pitaval, C.; Radovanovic, I.; Fukui, Y.; et al. Neutrophils scan for activated platelets to initiate inflammation. *Science* **2014**, *346*, 1234–1238. [[CrossRef](#)]
89. Bielinski, S.J.; Berardi, C.; Decker, P.A.; Kirsch, P.S.; Larson, N.B.; Pankow, J.S.; Sale, M.; de Andrade, M.; Scotte, H.; Tang, W.; et al. P-selectin and subclinical and clinical atherosclerosis: The Multi-Ethnic Study of Atherosclerosis (MESA). *Atherosclerosis* **2015**, *240*, 3–9. [[CrossRef](#)]
90. De Pergola, G.; Pannacciulli, N.; Coviello, M.; Scarangella, A.; Di Roma, P.; Caringella, M.; Venneri, M.T.; Quaranta, M.; Giorgino, R. sP-selectin plasma levels in obesity: Association with insulin resistance and related metabolic and prothrombotic factors. *Nutr. Metab. Cardiovasc. Dis.* **2008**, *18*, 227–232. [[CrossRef](#)]
91. André, P.; Nannizzi-Alaimo, L.; Prasad, S.K.; Phillips, D.R. Platelet-derived CD40L: The switch-hitting player of cardiovascular disease. *Circulation* **2002**, *106*, 896–899. [[CrossRef](#)] [[PubMed](#)]
92. Henn, V.; Slupsky, J.R.; Gräfe, M.; Anagnostopoulos, I.; Förster, R.; Müller-Berghaus, G.; Kroczeck, R.A. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. *Nature* **1998**, *391*, 591–594. [[CrossRef](#)] [[PubMed](#)]
93. Vishnevetsky, D.; Kiyani, V.A.; Gandhi, P.J. CD40 ligand: A novel target in the fight against cardiovascular disease. *Ann. Pharmacother.* **2004**, *38*, 1500–1508. [[CrossRef](#)] [[PubMed](#)]
94. Poggi, M.; Engel, D.; Christ, A.; Beckers, L.; Wijnands, E.; Boon, L.; Driessen, A.; Cleutjens, J.; Weber, C.; Gerdes, N.; et al. CD40L deficiency ameliorates adipose tissue inflammation and metabolic manifestations of obesity in mice. *Arterioscler. Thromb. Vasc. Biol.* **2011**, *31*, 2251–2260. [[CrossRef](#)]
95. Chakrabarti, S.; Rizvi, M.; Pathak, D.; Kirber, M.T.; Freedman, J.E. Hypoxia influences CD40-CD40L mediated inflammation in endothelial and monocytic cells. *Immunol. Lett.* **2009**, *122*, 170–184. [[CrossRef](#)]
96. Jeon, H.J.; Choi, J.-H.; Jung, I.-H.; Park, J.-G.; Lee, M.-R.; Lee, M.-N.; Kim, B.; Yoo, J.-Y.; Jeong, S.-J.; Kim, D.-Y.; et al. CD137 (4-1BB) deficiency reduces atherosclerosis in hyperlipidemic mice. *Circulation* **2010**, *121*, 1124–1133. [[CrossRef](#)]
97. Nomura, S.; Shouzu, A.; Omoto, S.; Inami, N.; Shimazu, T.; Satoh, D.; Kajiuura, T.; Yamada, K.; Urase, F.; Maeda, Y.; et al. Effects of pitavastatin on monocyte chemoattractant protein-1 in hyperlipidemic patients. *Blood Coagul. Fibrinolysis* **2009**, *20*, 440–447. [[CrossRef](#)]
98. Aggarwal, A.; Blum, A.; Schneider, D.J.; Sobel, B.E.; Dauerman, H.L. Soluble CD40 ligand is an early initiator of inflammation after coronary intervention. *Coron. Artery Dis.* **2004**, *15*, 471–475. [[CrossRef](#)]

99. Cipollone, F.; Chiarelli, F.; Davi, G.; Ferri, C.; Desideri, G.; Fazio, M.; Iezzi, A.; Santilli, F.; Pini, B.; Cuccurullo, C.; et al. Enhanced soluble CD40 ligand contributes to endothelial cell dysfunction in vitro and monocyte activation in patients with diabetes mellitus: Effect of improved metabolic control. *Diabetologia* **2005**, *48*, 1216–1224. [[CrossRef](#)]
100. Ueland, T.; Aukrust, P.; Yndestad, A.; Otterdal, K.; Frøland, S.S.; Dickstein, K.; Kjekshus, J.; Gullestad, L.; Damås, J.K. Soluble CD40 ligand in acute and chronic heart failure. *Eur. Heart J.* **2005**, *26*, 1101–1107. [[CrossRef](#)]
101. Oviedo-Orta, E.; Bermudez-Fajardo, A.; Karanam, S.; Benbow, U.; Newby, A.C. Comparison of MMP-2 and MMP-9 secretion from T helper 0, 1 and 2 lymphocytes alone and in coculture with macrophages. *Immunology* **2008**, *124*, 42–50. [[CrossRef](#)] [[PubMed](#)]
102. Jiang, R.-H.; Xu, X.-Q.; Wu, C.-J.; Lu, S.-S.; Zu, Q.-Q.; Zhao, L.-B.; Liu, S.; Shi, H.-B. The CD40/CD40L system regulates rat cerebral microvasculature after focal ischemia/reperfusion via the mTOR/S6K signaling pathway. *Neurol. Res.* **2018**, *40*, 717–723. [[CrossRef](#)] [[PubMed](#)]
103. Dovizio, M.; Bruno, A.; Contursi, A.; Grande, R.; Patrignani, P. Platelets and extracellular vesicles in cancer: Diagnostic and therapeutic implications. *Cancer Metastasis Rev.* **2018**, *37*, 455–467. [[CrossRef](#)] [[PubMed](#)]
104. George, J.N.; Thoi, L.L.; McManus, L.M.; Reimann, T.A. Isolation of human platelet membrane microparticles from plasma and serum. *Blood* **1982**, *60*, 834–840. [[CrossRef](#)]
105. Zahran, A.M.; Sayed, S.K.; Abd El Hafeez, H.A.; Khalifa, W.A.; Mohamed, N.A.; Hetta, H.F. Circulating microparticle subpopulation in metabolic syndrome: Relation to oxidative stress and coagulation markers. *Diabetes Metab. Syndr. Obes.* **2019**, *12*, 485–493. [[CrossRef](#)]
106. Murakami, T.; Horigome, H.; Tanaka, K.; Nakata, Y.; Ohkawara, K.; Katayama, Y.; Matsui, A. Impact of weight reduction on production of platelet-derived microparticles and fibrinolytic parameters in obesity. *Thromb. Res.* **2007**, *119*, 45–53. [[CrossRef](#)]
107. Grande, R.; Dovizio, M.; Marcone, S.; Szklianna, P.B.; Bruno, A.; Ehardt, H.A.; Cassidy, H.; Ní Áinle, F.; Caprodossi, A.; Lanuti, P.; et al. Platelet-Derived Microparticles from Obese Individuals: Characterization of Number, Size, Proteomics, and Crosstalk with Cancer and Endothelial Cells. *Front. Pharmacol.* **2019**, *10*, 7. [[CrossRef](#)]
108. Belfiore, A.; Frasca, F.; Pandini, G.; Sciacca, L.; Vigneri, R. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. *Endocr. Rev.* **2009**, *30*, 586–623. [[CrossRef](#)]
109. White, M.F.; Kahn, C.R. The insulin signaling system. *J. Biol. Chem.* **1994**, *269*, 1–4.
110. Taniguchi, C.M.; Emanuelli, B.; Kahn, C.R. Critical nodes in signalling pathways: Insights into insulin action. *Nat. Rev. Mol. Cell Biol.* **2006**, *7*, 85–96. [[CrossRef](#)]
111. Reaven, G.M. Insulin resistance/compensatory hyperinsulinemia, essential hypertension, and cardiovascular disease. *J. Clin. Endocrinol. Metab.* **2003**, *88*, 2399–2403. [[CrossRef](#)] [[PubMed](#)]
112. Baron, A.D. Insulin resistance and vascular function. *J. Diabetes Complicat.* **2002**, *16*, 92–102. [[CrossRef](#)]
113. Muniyappa, R.; Quon, M.J. Insulin action and insulin resistance in vascular endothelium. *Curr. Opin. Clin. Nutr. Metab. Care* **2007**, *10*, 523–530. [[CrossRef](#)] [[PubMed](#)]
114. Anfossi, G.; Russo, I.; Doronzo, G.; Trovati, M. Contribution of insulin resistance to vascular dysfunction. *Arch. Physiol. Biochem.* **2009**, *115*, 199–217. [[CrossRef](#)]
115. Dandona, P.; Aljada, A.; Chaudhuri, A.; Mohanty, P.; Garg, R. Metabolic syndrome: A comprehensive perspective based on interactions between obesity, diabetes, and inflammation. *Circulation* **2005**, *111*, 1448–1454. [[CrossRef](#)]
116. Falcon, C.; Pfliegler, G.; Deckmyn, H.; Vermynen, J. The platelet insulin receptor: Detection, partial characterization, and search for a function. *Biochem. Biophys. Res. Commun.* **1988**, *157*, 1190–1196. [[CrossRef](#)]
117. Russo, I.; Massucco, P.; Mattiello, L.; Cavalot, F.; Anfossi, G.; Trovati, M. Comparison between the effects of the rapid recombinant insulin analog aspart and those of human regular insulin on platelet cyclic nucleotides and aggregation. *Thromb. Res.* **2002**, *107*, 31–37. [[CrossRef](#)]
118. Russo, I.; Massucco, P.; Mattiello, L.; Anfossi, G.; Trovati, M. Comparison between the effects of the rapid recombinant insulin analog Lispro (Lys B28, Pro B29) and those of human regular insulin on platelet cyclic nucleotides and aggregation. *Thromb. Res.* **2003**, *109*, 323–327. [[CrossRef](#)]

119. Westerbacka, J.; Yki-Järvinen, H.; Turpeinen, A.; Rissanen, A.; Vehkavaara, S.; Syrjäälä, M.; Lassila, R. Inhibition of platelet-collagen interaction: An in vivo action of insulin abolished by insulin resistance in obesity. *Arterioscler. Thromb. Vasc. Biol.* **2002**, *22*, 167–172. [[CrossRef](#)]
120. Mayfield, R.K.; Halushka, P.V.; Wohltmann, H.J.; Lopes-Virella, M.; Chambers, J.K.; Loadholt, C.B.; Colwell, J.A. Platelet function during continuous insulin infusion treatment in insulin-dependent diabetic patients. *Diabetes* **1985**, *34*, 1127–1133. [[CrossRef](#)]
121. Trovati, M.; Anfossi, G.; Massucco, P.; Mattiello, L.; Costamagna, C.; Piretto, V.; Mularoni, E.; Cavalot, F.; Bosia, A.; Ghigo, D. Insulin stimulates nitric oxide synthesis in human platelets and, through nitric oxide, increases platelet concentrations of both guanosine-3', 5'-cyclic monophosphate and adenosine-3', 5'-cyclic monophosphate. *Diabetes* **1997**, *46*, 742–749. [[CrossRef](#)] [[PubMed](#)]
122. Gerrits, A.J.; Gitz, E.; Koekman, C.A.; Visseren, F.L.; van Haeften, T.W.; Akkerman, J.W.N. Induction of insulin resistance by the adipokines resistin, leptin, plasminogen activator inhibitor-1 and retinol binding protein 4 in human megakaryocytes. *Haematologica* **2012**, *97*, 1149–1157. [[CrossRef](#)] [[PubMed](#)]
123. Kawahara, Y.; Yamanishi, J.; Fukuzaki, H. Inhibitory action of guanosine 3',5'-monophosphate on thrombin-induced calcium mobilization in human platelets. *Thromb. Res.* **1984**, *33*, 203–209. [[CrossRef](#)]
124. Resnick, L.M. Cellular ions in hypertension, insulin resistance, obesity, and diabetes: A unifying theme. *J. Am. Soc. Nephrol.* **1992**, *3*, S78–S85.
125. Anfossi, G.; Mularoni, E.M.; Burzacca, S.; Ponziani, M.C.; Massucco, P.; Mattiello, L.; Cavalot, F.; Trovati, M. Platelet resistance to nitrates in obesity and obese NIDDM, and normal platelet sensitivity to both insulin and nitrates in lean NIDDM. *Diabetes Care* **1998**, *21*, 121–126. [[CrossRef](#)]
126. Davi, G.; Guagnano, M.T.; Ciabattoni, G.; Basili, S.; Falco, A.; Marinopiccoli, M.; Nutini, M.; Sensi, S.; Patrono, C. Platelet activation in obese women: Role of inflammation and oxidant stress. *JAMA* **2002**, *288*, 2008–2014. [[CrossRef](#)]
127. Simeone, P.; Liani, R.; Tripaldi, R.; Di Castelnuovo, A.; Guagnano, M.T.; Tartaro, A.; Bonadonna, R.C.; Federico, V.; Cipollone, F.; Consoli, A.; et al. Thromboxane-Dependent Platelet Activation in Obese Subjects with Prediabetes or Early Type 2 Diabetes: Effects of Liraglutide- or Lifestyle Changes-Induced Weight Loss. *Nutrients* **2018**, *10*, 1872. [[CrossRef](#)]
128. Cameron-Vendrig, A.; Reheman, A.; Siraj, M.A.; Xu, X.R.; Wang, Y.; Lei, X.; Afroze, T.; Shikatani, E.; El-Mounayri, O.; Noyan, H.; et al. Glucagon-Like Peptide 1 Receptor Activation Attenuates Platelet Aggregation and Thrombosis. *Diabetes* **2016**, *65*, 1714–1723. [[CrossRef](#)]
129. Barale, C.; Buracco, S.; Cavalot, F.; Frascaroli, C.; Guerrasio, A.; Russo, I. Glucagon-like peptide 1-related peptides increase nitric oxide effects to reduce platelet activation. *Thromb. Haemost.* **2017**, *117*, 1115–1128. [[CrossRef](#)]
130. Matsuno, H.; Tokuda, H.; Ishisaki, A.; Zhou, Y.; Kitajima, Y.; Kozawa, O. P2Y12 receptors play a significant role in the development of platelet microaggregation in patients with diabetes. *J. Clin. Endocrinol. Metab.* **2005**, *90*, 920–927. [[CrossRef](#)]
131. Watala, C. Blood platelet reactivity and its pharmacological modulation in (people with) diabetes mellitus. *Curr. Pharm. Des.* **2005**, *11*, 2331–2365. [[CrossRef](#)] [[PubMed](#)]
132. Braunwald, E.; Angiolillo, D.; Bates, E.; Berger, P.B.; Bhatt, D.; Cannon, C.P.; Furman, M.I.; Gurbel, P.; Michelson, A.D.; Peterson, E.; et al. Investigating the mechanisms of hyporesponse to antiplatelet approaches. *Clin. Cardiol.* **2008**, *31*, 121–127. [[CrossRef](#)] [[PubMed](#)]
133. Santilli, F.; Marchisio, M.; Lanuti, P.; Boccatonda, A.; Miscia, S.; Davi, G. Microparticles as new markers of cardiovascular risk in diabetes and beyond. *Thromb. Haemost.* **2016**, *116*, 220–234. [[CrossRef](#)] [[PubMed](#)]
134. Santilli, F.; Simeone, P.; Liani, R.; Davi, G. Platelets and diabetes mellitus. *Prostaglandins Other Lipid Mediat.* **2015**, *120*, 28–39. [[CrossRef](#)]
135. Aryangat, A.V.; Gerich, J.E. Type 2 diabetes: Postprandial hyperglycemia and increased cardiovascular risk. *Vasc. Health Risk Manag.* **2010**, *6*, 145–155. [[PubMed](#)]
136. Sottero, B.; Gargiulo, S.; Russo, I.; Barale, C.; Poli, G.; Cavalot, F. Postprandial Dysmetabolism and Oxidative Stress in Type 2 Diabetes: Pathogenetic Mechanisms and Therapeutic Strategies. *Med. Res. Rev.* **2015**, *35*, 968–1031. [[CrossRef](#)] [[PubMed](#)]
137. Davi, G.; Catalano, I.; Averna, M.; Notarbartolo, A.; Strano, A.; Ciabattoni, G.; Patrono, C. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. *N. Engl. J. Med.* **1990**, *322*, 1769–1774. [[CrossRef](#)]

138. Temelkova-Kurktschiev, T.S.; Koehler, C.; Henkel, E.; Leonhardt, W.; Fuecker, K.; Hanefeld, M. Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. *Diabetes Care* **2000**, *23*, 1830–1834. [[CrossRef](#)]
139. Donahue, R.P.; Abbott, R.D.; Reed, D.M.; Yano, K. Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry. Honolulu Heart Program. *Diabetes* **1987**, *36*, 689–692. [[CrossRef](#)]
140. Glucose tolerance and mortality: Comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis of Diagnostic criteria in Europe. *Lancet* **1999**, *354*, 617–621.
141. Gresele, P.; Guglielmini, G.; De Angelis, M.; Ciferri, S.; Ciofetta, M.; Falcinelli, E.; Lalli, C.; Ciabattini, G.; Davi, G.; Bolli, G.B. Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus. *J. Am. Coll. Cardiol.* **2003**, *41*, 1013–1020. [[CrossRef](#)]
142. Barstad, R.M.; Orvim, U.; Hamers, M.J.; Tjønnfjord, G.E.; Brosstad, F.R.; Sakariassen, K.S. Reduced effect of aspirin on thrombus formation at high shear and disturbed laminar blood flow. *Thromb. Haemost.* **1996**, *75*, 827–832. [[CrossRef](#)] [[PubMed](#)]
143. Folts, J.D.; Schafer, A.I.; Loscalzo, J.; Willerson, J.T.; Muller, J.E. A perspective on the potential problems with aspirin as an antithrombotic agent: A comparison of studies in an animal model with clinical trials. *J. Am. Coll. Cardiol.* **1999**, *33*, 295–303. [[CrossRef](#)]
144. Russo, I.; Viretto, M.; Barale, C.; Mattiello, L.; Doronzo, G.; Pagliarino, A.; Cavalot, F.; Trovati, M.; Anfossi, G. High glucose inhibits the aspirin-induced activation of the nitric oxide/cGMP/cGMP-dependent protein kinase pathway and does not affect the aspirin-induced inhibition of thromboxane synthesis in human platelets. *Diabetes* **2012**, *61*, 2913–2921. [[CrossRef](#)]
145. Finamore, F.; Reny, J.-L.; Malacarne, S.; Fontana, P.; Sanchez, J.-C. A high glucose level is associated with decreased aspirin-mediated acetylation of platelet cyclooxygenase (COX)-1 at serine 529: A pilot study. *J. Proteomics* **2019**, *192*, 258–266. [[CrossRef](#)]
146. Ferroni, P.; Basili, S.; Falco, A.; Davi, G. Platelet activation in type 2 diabetes mellitus. *J. Thromb. Haemost.* **2004**, *2*, 1282–1291. [[CrossRef](#)]
147. Chung, S.S.M.; Ho, E.C.M.; Lam, K.S.L.; Chung, S.K. Contribution of polyol pathway to diabetes-induced oxidative stress. *J. Am. Soc. Nephrol.* **2003**, *14*, S233–S236. [[CrossRef](#)]
148. Wachowicz, B.; Olas, B.; Zbikowska, H.M.; Buczyński, A. Generation of reactive oxygen species in blood platelets. *Platelets* **2002**, *13*, 175–182. [[CrossRef](#)]
149. Tang, W.H.; Stitham, J.; Gleim, S.; Di Febbo, C.; Porreca, E.; Fava, C.; Tacconelli, S.; Capone, M.; Evangelista, V.; Levantesi, G.; et al. Glucose and collagen regulate human platelet activity through aldose reductase induction of thromboxane. *J. Clin. Investig.* **2011**, *121*, 4462–4476. [[CrossRef](#)]
150. Santilli, F.; Davi, G.; Consoli, A.; Cipollone, F.; Mezzetti, A.; Falco, A.; Taraborelli, T.; Devangelio, E.; Ciabattini, G.; Basili, S.; et al. Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus. *J. Am. Coll. Cardiol.* **2006**, *47*, 391–397. [[CrossRef](#)]
151. Russo, I.; Penna, C.; Musso, T.; Popara, J.; Alloatti, G.; Cavalot, F.; Pagliaro, P. Platelets, diabetes and myocardial ischemia/reperfusion injury. *Cardiovasc. Diabetol.* **2017**, *16*, 71. [[CrossRef](#)] [[PubMed](#)]
152. Przyklenk, K.; Maynard, M.; Greiner, D.L.; Whittaker, P. Cardioprotection with postconditioning: Loss of efficacy in murine models of type-2 and type-1 diabetes. *Antioxid. Redox Signal.* **2011**, *14*, 781–790. [[CrossRef](#)] [[PubMed](#)]
153. Russo, I.; Femminò, S.; Barale, C.; Tullio, F.; Geuna, S.; Cavalot, F.; Pagliaro, P.; Penna, C. Cardioprotective Properties of Human Platelets Are Lost in Uncontrolled Diabetes Mellitus: A Study in Isolated Rat Hearts. *Front. Physiol.* **2018**, *9*, 875. [[CrossRef](#)] [[PubMed](#)]
154. Tang, W.H.; Stitham, J.; Jin, Y.; Liu, R.; Lee, S.H.; Du, J.; Atteya, G.; Gleim, S.; Spollett, G.; Martin, K.; et al. Aldose reductase-mediated phosphorylation of p53 leads to mitochondrial dysfunction and damage in diabetic platelets. *Circulation* **2014**, *129*, 1598–1609. [[CrossRef](#)]
155. Thushara, R.M.; Hemshekhar, M.; Basappa, Kemparaju, K.; Rangappa, K.S.; Girish, K.S. Biologicals, platelet apoptosis and human diseases: An outlook. *Crit. Rev. Oncol. Hematol.* **2015**, *93*, 149–158. [[CrossRef](#)]
156. Williams, P.C.; Coffey, M.J.; Coles, B.; Sanchez, S.; Morrow, J.D.; Cockcroft, J.R.; Lewis, M.J.; O'Donnell, V.B. In vivo aspirin supplementation inhibits nitric oxide consumption by human platelets. *Blood* **2005**, *106*, 2737–2743. [[CrossRef](#)]

157. Worthley, M.I.; Holmes, A.S.; Willoughby, S.R.; Kucia, A.M.; Heresztyn, T.; Stewart, S.; Chirkov, Y.Y.; Zeitz, C.J.; Horowitz, J.D. The deleterious effects of hyperglycemia on platelet function in diabetic patients with acute coronary syndromes mediation by superoxide production, resolution with intensive insulin administration. *J. Am. Coll. Cardiol.* **2007**, *49*, 304–310. [[CrossRef](#)]
158. Watala, C.; Boncer, M.; Golański, J.; Koziolkiewicz, W.; Trojanowski, Z.; Walkowiak, B. Platelet membrane lipid fluidity and intraplatelet calcium mobilization in type 2 diabetes mellitus. *Eur. J. Haematol.* **1998**, *61*, 319–326. [[CrossRef](#)]
159. Obydeny, S.I.; Sveshnikova, A.N.; Ataullakhanov, F.I.; Pantelev, M.A. Dynamics of calcium spiking, mitochondrial collapse and phosphatidylserine exposure in platelet subpopulations during activation. *J. Thromb. Haemost.* **2016**, *14*, 1867–1881. [[CrossRef](#)]
160. Pignatelli, P.; Carnevale, R.; Di Santo, S.; Bartimoccia, S.; Sanguigni, V.; Lenti, L.; Finocchi, A.; Mendolicchio, L.; Soresina, A.R.; Plebani, A.; et al. Inherited human gp91phox deficiency is associated with impaired isoprostane formation and platelet dysfunction. *Arterioscler. Thromb. Vasc. Biol.* **2011**, *31*, 423–434. [[CrossRef](#)]
161. Carnevale, R.; Loffredo, L.; Nocella, C.; Bartimoccia, S.; Sanguigni, V.; Soresina, A.; Plebani, A.; Azzari, C.; Martire, B.; Pignata, C.; et al. Impaired platelet activation in patients with hereditary deficiency of p47phox. *Br. J. Haematol.* **2018**, *180*, 454–456. [[CrossRef](#)] [[PubMed](#)]
162. Cangemi, R.; Pignatelli, P.; Carnevale, R.; Nigro, C.; Proietti, M.; Angelico, F.; Lauro, D.; Basili, S.; Violi, F. Platelet isoprostane overproduction in diabetic patients treated with aspirin. *Diabetes* **2012**, *61*, 1626–1632. [[CrossRef](#)] [[PubMed](#)]
163. Lawson, J.A.; Rokach, J.; FitzGerald, G.A. Isoprostanes: Formation, analysis and use as indices of lipid peroxidation in vivo. *J. Biol. Chem.* **1999**, *274*, 24441–24444. [[CrossRef](#)] [[PubMed](#)]
164. Davi, G.; Ciabattoni, G.; Consoli, A.; Mezzetti, A.; Falco, A.; Santarone, S.; Pennese, E.; Vitacolonna, E.; Bucciarelli, T.; Costantini, F.; et al. In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: Effects of improved metabolic control and vitamin E supplementation. *Circulation* **1999**, *99*, 224–229. [[CrossRef](#)] [[PubMed](#)]
165. Grabowski, E.F.; Jaffe, E.A.; Weksler, B.B. Prostacyclin production by cultured endothelial cell monolayers exposed to step increases in shear stress. *J. Lab. Clin. Med.* **1985**, *105*, 36–43. [[PubMed](#)]
166. Schlossmann, J.; Feil, R.; Hofmann, F. Signaling through NO and cGMP-dependent protein kinases. *Ann. Med.* **2003**, *35*, 21–27. [[CrossRef](#)] [[PubMed](#)]
167. Mazzucato, M.; Santomaso, A.; Canu, P.M.; Ruggeri, Z.; De Marco, L. Flow dynamics and haemostasis. *Ann. dell'Istituto Super. Sanità* **2007**, *43*, 130–138.
168. Westein, E.; Hofer, T.; Calkin, A.C. Thrombosis in diabetes: A shear flow effect? *Clin. Sci.* **2017**, *131*, 1245–1260. [[CrossRef](#)]
169. Choi, H.; Aboulfatova, K.; Pownall, H.J.; Cook, R.; Dong, J. Shear-induced disulfide bond formation regulates adhesion activity of von Willebrand factor. *J. Biol. Chem.* **2007**, *282*, 35604–35611. [[CrossRef](#)]
170. Rehder, D.S.; Borges, C.R. Cysteine sulfenic acid as an intermediate in disulfide bond formation and nonenzymatic protein folding. *Biochemistry* **2010**, *49*, 7748–7755. [[CrossRef](#)]
171. Jain, S.K. Hyperglycemia can cause membrane lipid peroxidation and osmotic fragility in human red blood cells. *J. Biol. Chem.* **1989**, *264*, 21340–21345. [[PubMed](#)]
172. Da, Q.; Teruya, M.; Guchhait, P.; Teruya, J.; Olson, J.S.; Cruz, M.A. Free hemoglobin increases von Willebrand factor-mediated platelet adhesion in vitro: Implications for circulatory devices. *Blood* **2015**, *126*, 2338–2341. [[CrossRef](#)] [[PubMed](#)]
173. Carvalho, A.C.; Colman, R.W.; Lees, R.S. Platelet function in hyperlipoproteinemia. *N. Engl. J. Med.* **1974**, *290*, 434–438. [[CrossRef](#)] [[PubMed](#)]
174. Pawlowska, Z.; Swiatkowska, M.; Krzeslowska, J.; Pawlicki, L.; Cierniewski, C.S. Increased platelet-fibrinogen interaction in patients with hypercholesterolemia and hypertriglyceridemia. *Atherosclerosis* **1993**, *103*, 13–20. [[CrossRef](#)]
175. Relou, I.A.M.; Hackeng, C.M.; Akkerman, J.-W.N.; Malle, E. Low-density lipoprotein and its effect on human blood platelets. *Cell. Mol. Life Sci.* **2003**, *60*, 961–971. [[CrossRef](#)]
176. Ou, H.-C.; Song, T.-Y.; Yeh, Y.-C.; Huang, C.-Y.; Yang, S.-F.; Chiu, T.-H.; Tsai, K.-L.; Chen, K.-L.; Wu, Y.-J.; Tsai, C.-S.; et al. EGCG protects against oxidized LDL-induced endothelial dysfunction by inhibiting LOX-1-mediated signaling. *J. Appl. Physiol.* **2010**, *108*, 1745–1756. [[CrossRef](#)]

177. Naseem, K.M. The role of nitric oxide in cardiovascular diseases. *Mol. Aspects Med.* **2005**, *26*, 33–65. [[CrossRef](#)]
178. Barale, C.; Frascaroli, C.; Cavalot, F.; Russo, I. Hypercholesterolemia impairs the Glucagon-like peptide 1 action on platelets: Effects of a lipid-lowering treatment with simvastatin. *Thromb. Res.* **2019**, *180*, 74–85. [[CrossRef](#)]
179. Willoughby, S.R.; Stewart, S.; Holmes, A.S.; Chirkov, Y.Y.; Horowitz, J.D. Platelet nitric oxide responsiveness: A novel prognostic marker in acute coronary syndromes. *Arterioscler. Thromb. Vasc. Biol.* **2005**, *25*, 2661–2666. [[CrossRef](#)]
180. Riba, R.; Nicolaou, A.; Troxler, M.; Homer-Vaniasinkam, S.; Naseem, K.M. Altered platelet reactivity in peripheral vascular disease complicated with elevated plasma homocysteine levels. *Atherosclerosis* **2004**, *175*, 69–75. [[CrossRef](#)]
181. Magwenzi, S.; Woodward, C.; Wraith, K.S.; Aburima, A.; Raslan, Z.; Jones, H.; McNeil, C.; Wheatcroft, S.; Yuldasheva, N.; Febbraio, M.; et al. Oxidized LDL activates blood platelets through CD36/NOX2-mediated inhibition of the cGMP/protein kinase G signaling cascade. *Blood* **2015**, *125*, 2693–2703. [[CrossRef](#)] [[PubMed](#)]
182. Akkerman, J.W.N. From low-density lipoprotein to platelet activation. *Int. J. Biochem. Cell Biol.* **2008**, *40*, 2374–2378. [[CrossRef](#)] [[PubMed](#)]
183. Barale, C.; Bonomo, K.; Frascaroli, C.; Morotti, A.; Guerrasio, A.; Cavalot, F.; Russo, I. Platelet function and activation markers in primary hypercholesterolemia treated with anti-PCSK9 monoclonal antibody: A 12-month follow-up. *Nutr. Metab. Cardiovasc. Dis.* **2019**. [[CrossRef](#)] [[PubMed](#)]
184. Barale, C.; Frascaroli, C.; Senkeev, R.; Cavalot, F.; Russo, I. Simvastatin Effects on Inflammation and Platelet Activation Markers in Hypercholesterolemia. *Biomed. Res. Int.* **2018**, *2018*, 6508709. [[CrossRef](#)]
185. Kanshana, J.S.; Khanna, V.; Singh, V.; Jain, M.; Misra, A.; Kumar, S.; Farooqui, M.; Barthwal, M.K.; Dikshit, M. Progression and Characterization of the Accelerated Atherosclerosis in Iliac Artery of New Zealand White Rabbits: Effect of Simvastatin. *J. Cardiovasc. Pharmacol.* **2017**, *69*, 314–325. [[CrossRef](#)]
186. Chu, F.; Wang, M.; Ma, H.; Zhu, J. Simvastatin Modulates Interaction Between Vascular Smooth Muscle Cell/Macrophage and TNF- α -Activated Endothelial Cell. *J. Cardiovasc. Pharmacol.* **2018**, *71*, 268–274. [[CrossRef](#)]
187. Diamantis, E.; Kyriakos, G.; Quiles-Sanchez, L.V.; Farmaki, P.; Troupis, T. The Anti-Inflammatory Effects of Statins on Coronary Artery Disease: An Updated Review of the Literature. *Curr. Cardiol. Rev.* **2017**, *13*, 209–216. [[CrossRef](#)]
188. Kinlay, S.; Selwyn, A.P. Effects of statins on inflammation in patients with acute and chronic coronary syndromes. *Am. J. Cardiol.* **2003**, *91*, 9B–13B. [[CrossRef](#)]
189. Sadowitz, B.; Maier, K.G.; Gahtan, V. Basic science review: Statin therapy—Part I: The pleiotropic effects of statins in cardiovascular disease. *Vasc. Endovasc. Surg.* **2010**, *44*, 241–251. [[CrossRef](#)]
190. Sobol, A.B.; Watala, C. The role of platelets in diabetes-related vascular complications. *Diabetes Res. Clin. Pract.* **2000**, *50*, 1–16. [[CrossRef](#)]
191. Vinik, A.I.; Erbas, T.; Park, T.S.; Nolan, R.; Pittenger, G.L. Platelet dysfunction in type 2 diabetes. *Diabetes Care* **2001**, *24*, 1476–1485. [[CrossRef](#)]
192. Okerson, T.; Chilton, R.J. The cardiovascular effects of GLP-1 receptor agonists. *Cardiovasc. Ther.* **2012**, *30*, e146–e155. [[CrossRef](#)] [[PubMed](#)]
193. Ban, K.; Noyan-Ashraf, M.H.; Hofer, J.; Bolz, S.-S.; Drucker, D.J.; Husain, M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. *Circulation* **2008**, *117*, 2340–2350. [[CrossRef](#)] [[PubMed](#)]
194. Seidah, N.G. Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors in the treatment of hypercholesterolemia and other pathologies. *Curr. Pharm. Des.* **2013**, *19*, 3161–3172. [[CrossRef](#)] [[PubMed](#)]
195. Camera, M.; Rossetti, L.; Barbieri, S.S.; Zanotti, I.; Canciani, B.; Trabattini, D.; Ruscica, M.; Tremoli, E.; Ferri, N. PCSK9 as a Positive Modulator of Platelet Activation. *J. Am. Coll. Cardiol.* **2018**, *71*, 952–954. [[CrossRef](#)] [[PubMed](#)]
196. Navarese, E.P.; Kolodziejczak, M.; Winter, M.-P.; Alimohammadi, A.; Lang, I.M.; Buffon, A.; Lip, G.Y.; Siller-Matula, J.M. Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: The PCSK9-REACT study. *Int. J. Cardiol.* **2017**, *227*, 644–649. [[CrossRef](#)] [[PubMed](#)]

197. Li, S.; Zhu, C.-G.; Guo, Y.-L.; Xu, R.-X.; Zhang, Y.; Sun, J.; Li, J.-J. The relationship between the plasma PCSK9 levels and platelet indices in patients with stable coronary artery disease. *J. Atheroscler. Thromb.* **2015**, *22*, 76–84. [[CrossRef](#)] [[PubMed](#)]
198. Pastori, D.; Nocella, C.; Farcomeni, A.; Bartimoccia, S.; Santulli, M.; Vasaturo, F.; Carnevale, R.; Menichelli, D.; Violi, F.; Pignatelli, P.; et al. Relationship of PCSK9 and Urinary Thromboxane Excretion to Cardiovascular Events in Patients with Atrial Fibrillation. *J. Am. Coll. Cardiol.* **2017**, *70*, 1455–1462. [[CrossRef](#)]
199. Harmon, J.T.; Tandon, N.N.; Hoeg, J.M.; Jamieson, G.A. Thrombin binding and response in platelets from patients with dyslipoproteinemias: Increased stimulus-response coupling in type II hyperlipoproteinemia. *Blood* **1986**, *68*, 498–505. [[CrossRef](#)]
200. Yamazaki, M.; Uchiyama, S.; Xiong, Y.; Nakano, T.; Nakamura, T.; Iwata, M. Effect of remnant-like particle on shear-induced platelet activation and its inhibition by antiplatelet agents. *Thromb. Res.* **2005**, *115*, 211–218. [[CrossRef](#)]
201. Mineo, C.; Deguchi, H.; Griffin, J.H.; Shaul, P.W. Endothelial and antithrombotic actions of HDL. *Circ. Res.* **2006**, *98*, 1352–1364. [[CrossRef](#)] [[PubMed](#)]
202. Calkin, A.C.; Drew, B.G.; Ono, A.; Duffy, S.J.; Gordon, M.V.; Schoenwaelder, S.M.; Sviridov, D.; Cooper, M.E.; Kingwell, B.A.; Jackson, S.P. Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux. *Circulation* **2009**, *120*, 2095–2104. [[CrossRef](#)] [[PubMed](#)]
203. Ma, Y.; Ashraf, M.Z.; Podrez, E.A. Scavenger receptor BI modulates platelet reactivity and thrombosis in dyslipidemia. *Blood* **2010**, *116*, 1932–1941. [[CrossRef](#)]
204. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). *JAMA* **2001**, *285*, 2486–2497.
205. Kearney, P.M.; Whelton, M.; Reynolds, K.; Muntner, P.; Whelton, P.K.; He, J. Global burden of hypertension: Analysis of worldwide data. *Lancet* **2005**, *365*, 217–223. [[CrossRef](#)]
206. Diodati, J.G.; Cannon, R.O.; Hussain, N.; Quyyumi, A.A. Inhibitory effect of nitroglycerin and sodium nitroprusside on platelet activation across the coronary circulation in stable angina pectoris. *Am. J. Cardiol.* **1995**, *75*, 443–448. [[CrossRef](#)]
207. Cooke, J.P.; Dzau, V.J. Nitric oxide synthase: Role in the genesis of vascular disease. *Annu. Rev. Med.* **1997**, *48*, 489–509. [[CrossRef](#)]
208. Nityanand, S.; Pande, I.; Bajpai, V.K.; Singh, L.; Chandra, M.; Singh, B.N. Platelets in essential hypertension. *Thromb. Res.* **1993**, *72*, 447–454. [[CrossRef](#)]
209. Torsellini, A.; Becucci, A.; Citi, S.; Cozzolino, F.; Guidi, G.; Lombardi, V.; Vercelli, D.; Veloci, M. Effects of pressure excursions on human platelets. In vitro studies on betathromboglobulin (beta-TG) and platelet factor 4 (PF4) release and on platelet sensitivity to ADP-aggregation. *Haematologica* **1982**, *67*, 860–866.
210. Camilletti, A.; Moretti, N.; Giacchetti, G.; Faloia, E.; Martarelli, D.; Mantero, F.; Mazzanti, L. Decreased nitric oxide levels and increased calcium content in platelets of hypertensive patients. *Am. J. Hypertens.* **2001**, *14*, 382–386. [[CrossRef](#)]
211. Cerecedo, D.; Martínez-Vieyra, I.; Alonso-Rangel, L.; Benítez-Cardoza, C.; Ortega, A. Epithelial sodium channel modulates platelet collagen activation. *Eur. J. Cell Biol.* **2014**, *93*, 127–136. [[CrossRef](#)] [[PubMed](#)]
212. Galluccio, E.; Cassina, L.; Russo, I.; Gelmini, F.; Setola, E.; Rampoldi, L.; Citterio, L.; Rossodivita, A.; Kamami, M.; Colombo, A.; et al. A novel truncated form of eNOS associates with altered vascular function. *Cardiovasc. Res.* **2014**, *101*, 492–502. [[CrossRef](#)] [[PubMed](#)]
213. Lüscher, T.F.; Barton, M. Biology of the endothelium. *Clin. Cardiol.* **1997**, *20*, II–3–10. [[PubMed](#)]
214. Taddei, S.; Ghiadoni, L.; Virdis, A.; Versari, D.; Salvetti, A. Mechanisms of endothelial dysfunction: Clinical significance and preventive non-pharmacological therapeutic strategies. *Curr. Pharm. Des.* **2003**, *9*, 2385–2402. [[CrossRef](#)] [[PubMed](#)]
215. Russo, I.; Viretto, M.; Doronzo, G.; Barale, C.; Mattiello, L.; Anfossi, G.; Trovati, M. A short-term incubation with high glucose impairs VASP phosphorylation at serine 239 in response to the nitric oxide/cGMP pathway in vascular smooth muscle cells: Role of oxidative stress. *Biomed. Res. Int.* **2014**, *2014*, 328959. [[CrossRef](#)] [[PubMed](#)]

216. Paolocci, N.; Biondi, R.; Bettini, M.; Lee, C.I.; Berlowitz, C.O.; Rossi, R.; Xia, Y.; Ambrosio, G.; L'Abbate, A.; Kass, D.A.; et al. Oxygen radical-mediated reduction in basal and agonist-evoked NO release in isolated rat heart. *J. Mol. Cell. Cardiol.* **2001**, *33*, 671–679. [[CrossRef](#)]
217. Marletta, M.A. Nitric oxide synthase structure and mechanism. *J. Biol. Chem.* **1993**, *268*, 12231–12234.
218. Moncada, S.; Higgs, A. The L-arginine-nitric oxide pathway. *N. Engl. J. Med.* **1993**, *329*, 2002–2012.
219. Dean, W.L.; Pope, J.E.; Brier, M.E.; Aronoff, G.R. Platelet calcium transport in hypertension. *Hypertension* **1994**, *23*, 31–37. [[CrossRef](#)]
220. Möhle, R.; Green, D.; Moore, M.A.; Nachman, R.L.; Rafii, S. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. *Proc. Natl. Acad. Sci. USA* **1997**, *94*, 663–668. [[CrossRef](#)]
221. Blann, A.D.; Belgore, F.M.; Constans, J.; Conri, C.; Lip, G.Y. Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of fluvastatin or fenofibrate. *Am. J. Cardiol.* **2001**, *87*, 1160–1163. [[CrossRef](#)]
222. Tsai, W.-C.; Li, Y.-H.; Huang, Y.-Y.; Lin, C.-C.; Chao, T.-H.; Chen, J.-H. Plasma vascular endothelial growth factor as a marker for early vascular damage in hypertension. *Clin. Sci.* **2005**, *109*, 39–43. [[CrossRef](#)] [[PubMed](#)]
223. Belgore, F.M.; Blann, A.D.; Li-Saw-Hee, F.L.; Beevers, D.G.; Lip, G.Y. Plasma levels of vascular endothelial growth factor and its soluble receptor (SFlt-1) in essential hypertension. *Am. J. Cardiol.* **2001**, *87*, 805–807. [[CrossRef](#)]
224. Ferroni, P.; Martini, F.; D'Alessandro, R.; Magnapera, A.; Raparelli, V.; Scarno, A.; Davì, G.; Basili, S.; Guadagni, F. In vivo platelet activation is responsible for enhanced vascular endothelial growth factor levels in hypertensive patients. *Clin. Chim. Acta* **2008**, *388*, 33–37. [[CrossRef](#)]
225. Zicha, J.; Kunes, J.; Devynck, M.A. Abnormalities of membrane function and lipid metabolism in hypertension: A review. *Am. J. Hypertens.* **1999**, *12*, 315–331. [[CrossRef](#)]
226. Chap, H.J.; Zwaal, R.F.; van Deenen, L.L. Action of highly purified phospholipases on blood platelets. Evidence for an asymmetric distribution of phospholipids in the surface membrane. *Biochim. Biophys. Acta* **1977**, *467*, 146–164. [[CrossRef](#)]
227. Bevers, E.M.; Comfurius, P.; Zwaal, R.F. Changes in membrane phospholipid distribution during platelet activation. *Biochim. Biophys. Acta* **1983**, *736*, 57–66. [[CrossRef](#)]
228. García-Rubio, D.; Rodríguez-Varela, M.; Martínez-Vieyra, I.; de la Mora, M.B.; Méndez-Méndez, J.V.; Durán-Álvarez, J.C.; Cerecedo, D. Alterations to the contents of plasma membrane structural lipids are associated with structural changes and compartmentalization in platelets in hypertension. *Exp. Cell Res.* **2019**, *385*, 111692. [[CrossRef](#)]



© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).



Review

The “Janus Face” of Platelets in Cancer

Maria Valeria Catani *, Isabella Savini, Valentina Tullio and Valeria Gasperi *

Department of Experimental Medicine, Tor Vergata University of Rome, 00133 Rome, Italy; savini@uniroma2.it (I.S.); valentinatullio.nu@gmail.com (V.T.)

* Correspondence: catani@uniroma2.it (M.V.C.); gasperi@med.uniroma2.it (V.G.); Tel.: +39-06-72596465 (M.V.C.); +39-06-72596465 (V.G.)

Received: 11 December 2019; Accepted: 22 January 2020; Published: 25 January 2020

Abstract: Besides their vital role in hemostasis and thrombosis, platelets are also recognized to be involved in cancer, where they play an unexpected central role: They actively influence cancer cell behavior, but, on the other hand, platelet physiology and phenotype are impacted by tumor cells. The existence of this platelet-cancer loop is supported by a large number of experimental and human studies reporting an association between alterations in platelet number and functions and cancer, often in a way dependent on patient, cancer type and treatment. Herein, we shall report on an update on platelet-cancer relationships, with a particular emphasis on how platelets might exert either a protective or a deleterious action in all steps of cancer progression. To this end, we will describe the impact of (i) platelet count, (ii) bioactive molecules secreted upon platelet activation, and (iii) microvesicle-derived miRNAs on cancer behavior. Potential explanations of conflicting results are also reported: Both intrinsic (heterogeneity in platelet-derived bioactive molecules with either inhibitory or stimulatory properties; features of cancer cell types, such as aggressiveness and/or tumour stage) and extrinsic (heterogeneous characteristics of cancer patients, study design and sample preparation) factors, together with other confounding elements, contribute to “the Janus face” of platelets in cancer. Given the difficulty to establish the univocal role of platelets in a tumor, a better understanding of their exact contribution is warranted, in order to identify an efficient therapeutic strategy for cancer management, as well as for better prevention, screening and risk assessment protocols.

Keywords: microvesicles; miRNAs; paraneoplastic thrombocytosis and thrombocytopenia; platelet activation; platelet-derived bioactive molecules; platelet-tumor crosstalk

1. Introduction

Platelets were described for the first time in 1882, when the Italian pathologist Giulio Bizzozero identified in the blood vessels “very thin platelets, disc-shaped, with parallel surfaces or rarely lens-shaped structures, round or oval and with a diameter 2–3 times smaller than the diameter of the red cells ... ” that “when they are circulating in the blood stream of a living animal a small injury to the vessel wall, or contact with a foreign body is sufficient for them to become viscous, to adhere to one another and so form a white thrombus” [1]. Platelets, indeed, are small, anucleated cytoplasmic fragments derived from large (30–100 μm) progenitor cells, the megakaryocytes, formed in bone marrow, lungs and blood [2–5], which are vitally involved in thrombosis and hemostasis [6]. Nevertheless, besides this primary function, platelets are also recognized to affect immune and inflammatory responses, thus participating in regulation of biological mechanisms underlying a broad range of human disorders. A large body of experimental and clinical evidences, indeed, shows that platelet activation and dysfunction are implicated in diabetes, cardiovascular disease, chronic back pain, sepsis, Alzheimer’s disease, multiple sclerosis, psychiatric disorders and other central and peripheral pathological conditions [7–11]. In this context, the unexpected central role of platelets in cancer biology

is noteworthy: They actively influence cancer cell behavior, but, on the other hand, platelet physiology and phenotype are impacted by tumor cells [12]. Indeed, a large number of experimental and human investigations support the hypothesis that tumor cells are able to modulate the RNA profile, number and activity of platelets that, once “educated”, would regulate the tumor microenvironment and progression in a way dependent on the patient, cancer type and treatment. Nonetheless, the exact molecular mechanisms underlying this platelet-cancer loop are not yet well defined, often due to contradictory data.

Therefore, based on this background, the present review will focus on platelet-cancer crosstalk and their mutual impact, especially considering how platelets might exert either a protective or a deleterious role in all steps of cancer progression.

2. Paraneoplastic Thrombocytosis and Thrombocytopenia in Cancer

In healthy subjects, platelet count ranges from 150,000 to 450,000/ μ L, with age-, sex-, race- and genetic background-specific reference intervals [13,14]. A fine-tuned control of both platelet number and function exists, being ensured by the delicate balance among their (i) production, (ii) maintenance in the circulation (average life span of 8–10 days) and (iii) clearance of senescent cells (via hepatic and splenic macrophages, as well by apoptosis) [15–17].

In the light of the central roles played by platelets in a multitude of biological events, abnormalities in their number that often accompany various pathologies are clearly relevant, and this also applies to cancer.

Although, with some inter-individual variations, a platelet count of $\geq 450 \times 10^9/L$ is a generally accepted value used to identify a clinically significant thrombocytosis [18], which has a multitude of potential etiologies. In particular, it can be classified as (i) primary thrombocytosis, when it occurs as the result of genetic or chronic myeloid disorders [19–21] or (ii) secondary or reactive thrombocytosis, when it occurs as a comorbidity of another underlying disease independent of a vascular event, including cancer. In the latter case, the pathology is called paraneoplastic thrombocytosis [22,23]. According to the clinical evidence that patients with a high platelet count have a higher risk to develop venous thromboembolism (VTE) [24], cancer patients frequently show activated coagulation pathways, resulting in a four-fold increase in thrombosis risk [25].

The first evidence of paraneoplastic thrombocytosis dates back to 1964, when Levin and Conley found that, among their hospitalized cancer patients, at least 40% had thrombocytosis [26]. Since then, an ever-growing body of studies has reported a significant association between thrombocytosis and solid tumors, with a range of thrombocytosis incidence at initial diagnosis of 4–55% [27–31]. This evidence may assume clinical implications, if we consider that a large amount of retrospective and meta-analysis studies point out to the correlation among higher platelet count and tumor progression, advanced-stage disease, vascular thromboembolic complications and poor survival in patients with different solid tumors, such as esophageal cancer, bladder cancer, inflammatory breast cancer and epithelial ovarian cancers (see Table 1) [28,31–38].

Conversely, such a correlation has not been found by other authors [29,39–41], or it appears strictly dependent on inflammatory components, as described by a recent retrospective study of 3654 patients with stage I–III breast cancer, of whom 6.5% had a diagnosis of Inflammatory Breast Cancer (IBC), the most aggressive form of breast tumors [37]. What emerged from this study is that thrombocytosis, more prevalent in IBC patients, correlated with poor overall survival in these subjects, but not in non-IBC individuals [37].

It must not be overlooked that some investigations reporting a correlation among platelet count, metastasis and shortened survival had some limitations, such as a low platelet count threshold ($< 200 \times 10^9/L$) not clinically correct to define a patient as having real thrombocytosis [33,34,37,42]. In addition, heterogeneity in sample size, clinical stages, treatment and follow-up, smoking history and inclusion/exclusion criteria may make it difficult to establish a univocal association between thrombocytosis and poor prognosis in cancer patients.

Table 1. Main findings on the relationship between high platelet count¹ and cancer.

| Cancer | Study | Platelet Cut-Off | Main Findings | Ref. |
|------------|--|--------------------------|--|------|
| | - Retrospective 584 adenocarcinoma patients with or without pre-operative neoadjuvant chemo-radiation therapy 2.4% with high PLT | 450 × 10 ⁹ /L | - Death rates: 50% with normal PLT (median survival time: 76.9 months), 86% with high PLT (median survival time: 23.2 months) - No differences in age, gender, tumor T or N stages - Median survival time in patients without neoadjuvant therapy: 35.8 months with high PLT, 11.2 months with normal PLT (HR = 3.02, p = 0.032) - Median survival time in patients with neoadjuvant therapy: 16.2 months with high PLT, 52.1 months with normal PLT (HR = 2.31, p = 0.021) | [43] |
| | - Retrospective 374 squamous cell carcinoma patients with non-neoadjuvant therapy 21.1% with high PLT | 293 × 10 ⁹ /L | - PLT increased in patients with large and deep tumors, nodal involvement, and distant metastasis - CRP levels increased in patients with high PLT (p = 0.001) - Worse survival in patients with high PLT, especially in advanced tumor stage patients | [33] |
| Esophageal | - Retrospective 425 squamous cell carcinoma patients subjected to esophagectomy 48.4% with high PLT | 205 × 10 ⁹ /L | - Overall 5-year survival: 60.7% with PLT below cut off value, 31.6% with PLT above cut off value (p < 0.0001) - 5-year survival with no involvement of nodes: similar rates independent of PLT - 5-year survival with involvement of nodes: 32.0% with PLT below cut off value, 12.7% with PLT above cut off value (p = 0.004) | [34] |
| | - Retrospective 119 squamous cell carcinoma patients subjected to esophagectomy 20.2% with high PLT | 300 × 10 ⁹ /L | - No association between high PLT and disease-free (HR = 0.918, 95% CI = 0.524 – 1.608, p = 0.765) or overall (HR = 1.072, 95% CI = 0.618 – 1.891, p = 0.809) survival | [41] |
| | - Retrospective 112 patients subjected to esophagectomy 4% with high PLT | 400 × 10 ⁹ /L | - No correlation between PLT and patient survival (p < 0.644) | [39] |
| | - Retrospective 381 patients (93% squamous cell carcinoma and 7% adenocarcinoma) subjected to esophagectomy 3.4% with high PLT | 400 × 10 ⁹ /L | - Higher PLT in patients with adenocarcinoma (p = 0.003) - No correlation between PLT and prognostic factors - No correlation among PLT, site and degree of tumor penetration, lymph node involvement, distant metastasis, degree of differentiation, vascular, lymphatic and perineural invasion, presence of multiple cancers | [40] |

Table 1. *Cont.*

| Cancer | Study | Platelet Cut-Off | Main Findings | Ref. |
|--------------------|-------|--|--|------|
| Cervical | - | 400 × 10 ⁹ /L (seven studies) | - | [32] |
| | - | 300 × 10 ⁹ /L (six studies) | High PLT before surgery and/or chemotherapy associated with poor overall (HR = 1.50, 95% CI = 1.19 – 1.88; p = 0.001), progression-free (HR = 1.33, 95% CI = 1.07 – 1.64, p = 0.010) and recurrence-free (HR = 1.66, 95% CI = 1.20 – 2.28, p = 0.002) survival | |
| | - | 200 × 10 ⁹ /L (five studies) Not specified (one study) | | |
| Epithelial ovarian | - | Retrospective | - | [28] |
| | - | 619 patients 31% with high PLT | High PLT associated with advanced-stage disease, vascular thromboembolic complications, higher preoperative levels of cancer antigen 125 and shortened survival | |
| Lung | - | Retrospective | - | [31] |
| | - | 234 patients with Stage I non-small cell lung cancer | Correlation among PLT, disease progression (HR = 5.314, 95% CI = 2.750 – 10.269, p < 0.05) and death (HR = 3.139, 95% CI = 1.227 – 8.034, p < 0.05) | |
| | - | 400 × 10 ⁹ /L (6 studies) 300 × 10 ⁹ /L (5 studies) 214.5 × 10 ⁹ /L (1 study) | High PLT associated with overall survival (HR = 1.74, 95% CI = 1.39–2.19, p < 0.001), advanced TNM stage (OR = 2.65, 95% CI = 1.77 – 3.97; p = 0.367), smoking history (OR = 2.70, 95% CI = 1.79 – 4.08, p = 0.373) No correlation between high PLT associated and squamous cell carcinoma (OR = 1.54, 95% CI = 0.77 – 3.07, p = 0.017) | |

CI: confidence interval; CRP: C-reactive protein; HR: hazard ratio; OR: odds ratio; PLT: platelet count. ¹ With respect to the cut-off values set by the authors.

However, available literature data suggest that thrombocytosis is a paraneoplastic event not depending on elongation of platelet half-life survival [44], but on increased thrombopoietin (TPO)-dependent thrombopoiesis, together with the action of inflammatory cancer-derived cytokines. TPO is normally produced and secreted by the liver, kidney and bone marrow at a fixed rate and it promotes megakaryocyte growth and platelet generation, by binding to its receptor c-MPL and triggering activation of the Janus kinase (JAK)/signal transducer and activator of the transcription (STAT) pathway [45]. It is well documented that increased circulating TPO levels might be one of the mechanisms accounting for cancer-related thrombocytosis, as demonstrated by elevated TPO levels in plasma of cancer patients with a high platelet count [46–48]. Two different and complementary mechanisms have been proposed, both encompassing tumors that represent a TPO source per se and, moreover, secrete factors targeting hepatic TPO synthesis. In particular, it has been reported that certain cancer cells, besides expressing TPO receptors on their surface [49], are also able to produce and release functional TPO [47,50], thus contributing to the rise in blood TPO levels. Additionally, cancer cells release a plethora of humoral factors and cytokines, and some of them have been shown to upregulate hepatic TPO biosynthesis; this is the case of the pleiotropic cytokine interleukin (IL)-6, a major mediator of inflammation and activator of STAT3 [51], whose deregulated overexpression has been associated with tumor progression [28,52–55]. Both IL-6 and its receptors (IL-6R and sIL-6R) are, indeed, upregulated in tumors [56–61] and their increased content in plasma of cancer patients correlates with a poor diagnosis [28,56,61,62], thus indicating clinical utility of IL-6 as a biomarker or therapeutic target in cancer management. An elegant model proposed by several authors suggests that IL-6 plays a crucial role in inducing cancer-related thrombocytosis, via up-regulation of hepatic TPO transcription [28,53–55]. In particular, this molecular model hypothesizes that cancer cells release large amounts of IL-6 that, in turn, determines complex chains of events (i.e., an increase in platelet count, tumor growth and metastasis) reinforcing themselves through a feed-forward loop. This hypothesis has been confirmed by the study of Stone and co-workers [28], who analyzed 619 patients with epithelial ovarian cancer and of whom 30% had thrombocytosis at the time of initial diagnosis. The researchers found that TPO and IL-6 levels were high in patients who had thrombocytosis, as compared with those who did not, and that an increase in IL-6 levels positively correlated with plasma TPO levels and thrombocytosis, while negatively correlating with patient survival. Further proofs of the crucial role of IL-6 in paraneoplastic thrombocytosis have also been provided by molecular/genetic and pharmacological experiments: Silencing of *Il-6* and *tpo* genes fully abrogated thrombocytosis in murine ovarian cancer, and siltuximab (humanized anti-IL-6 antibody) significantly reduced tumor growth and platelet count, both in murine and human ovarian cancers [28].

Other circulating factors released by cancer cells and known to stimulate thrombopoiesis and megakaryopoiesis are granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF), whose blood levels are increased in cancer patients with thrombocytosis [63].

A more in-depth analysis of basal cytokine profile in 81 newly diagnosed IBC patients revealed that patients with thrombocytosis, although not differing in IL-6 levels with respect to IBC subjects without thrombocytosis, showed a positive correlation between serum levels of Growth-Regulated Oncogene (GRO) and Transforming Growth Factor (TGF)- β and IBC-related thrombocytosis [37]. In this context, it should be underlined that both cancer cells and activated platelets are able to release GRO and TGF- β [64–66], thus suggesting that the observed increase in their content might be a consequence rather than a cause of thrombocytosis. In addition, the study has several limitations, above all the lowering of the thrombocytosis threshold from 450 to 300 $\times 10^9/L$. Therefore, more studies are needed to establish a real relationship between these two cytokines and platelets in the context of tumor biology.

While thrombocytosis is more frequently reported to be associated with increased mortality, some findings also suggest the presence of cancer-related thrombocytopenia. For example, a strong trend toward increased mortality has been found in thrombocytopenic patients (hazard ratio (HR) = 1.50, but without reaching statistical significance) [43], although it is conceivable that thrombocytopenia

might be a surrogate for general debility and/or other clinical factors, such as possible sepsis and hematological abnormalities that could contribute to overall mortality.

Thrombocytopenia is a frequent complication in solid tumors [67]. The degree and incidence of this disease depends on the type of malignancy, tumor stage and treatment approach [68]. It has also been described as a complement of local cancer recurrence and may be considered a paraneoplastic syndrome [69]. Some tumors can alter the platelet count below $100 \times 10^9/L$, leading to thrombocytopenia, and therefore cancer patients have a high risk of hemorrhagic complications [68]. The first evidence of low platelet count and bleeding episodes in patients with malignancies came from Gaydos in 1962: He demonstrated that bleeding episodes in patients with leukemia were frequently associated with a decreased platelet count [70]. Since then, other studies reported similar bleeding events in solid tumor patients [71,72].

Single nucleotide polymorphisms (SNPs) and mutations in genes encoding for cytokines and transcription factors are both two major causes of thrombocytopenia in solid tumors, including lung, breast, ovary and colorectal cancers [72]. Just as an example, the -31 T > C SNP of the *il-1 β* gene was up-regulated in solid tumors associated with thrombocytopenia [73,74]. It is unclear how IL-1 β can induce thrombocytopenia in solid tumors, but it is known that -31 T > C SNP can increase susceptibility to thrombocytopenia in these malignancies [72]. A strong association between IL-1 β -31 T > C SNP and *Helicobacter pylori* infection has also been reported: The two phenomena collaborate themselves to increase the risk of gastric cancer with hemorrhagic complications [75,76]. IL-6 is also involved in thrombocytopenic mechanisms, as well as in paraneoplastic thrombocytosis. The IL-6 -174 G/C SNP has been reported in many malignancies, including adenocarcinoma, lung, colorectal, gastric and ovarian cancers [73,77,78]. This polymorphism also has been correlated with a poor prognosis, because it can induce antibody production against platelets, increasing the risk of thrombocytopenia [72].

As mentioned before, several transcription factors can be associated with thrombocytopenia, due to their involvement in platelet production. For example, overexpression of GATA3, a member of the GATA family of transcription factors that control maturation of hematopoietic stem cells, can stimulate platelet clearance, worsening the prognosis in breast cancer [79]. Another example is represented by Homeobox (HOX) genes that control proliferation and maturation of hematopoietic stem cells: Hypermethylation of *hoxa11*, for example, increased the incidence of thrombocytopenia and risk of poor prognosis in lung, gastric and breast cancers [80,81]. Although few studies have evaluated genetic changes in the incidence of thrombocytopenia, it seems that investigations on the mechanisms accounting for this phenomenon may be useful for the prevention of bleeding in solid tumors and for choosing the appropriate treatment [72].

Clinical observations of the impact of platelet count on cancer biology have been supported by studies employing platelet-depleted or transgenic mice [82]. A significant reduction in neovascularization has been observed in different transgenic mice-rendered thrombocytopenia [83], with GPIIb α /IL4R transgenic mice (lacking the receptor for the von Willebrand factor as well as other adhesive and pro-coagulant proteins) showing the most severe phenotype [83,84]. Furthermore, in a mammary carcinoma murine model, platelet depletion increased the efficacy of the chemotherapy, by favoring drug delivery and tumoricidal action [85]. Thus, currently available animal models of platelet dysfunction may provide a framework for better understanding the molecular mechanisms through which thrombocytosis or thrombocytopenia impact cancer progression.

3. Platelet-Derived Bioactive Compounds

It is now recognized that tumor cells and platelets strictly influence each other, thus establishing the so-called "platelet-tumor loop". The need for recruiting platelets is supported by several evidences: (i) tumor cells sequester platelets in order to escape themselves from immune system surveillance [86,87]; (ii) platelets associate with cancer emboli, thus prolonging survival of circulating tumor cells and promoting their arrest and adhesion to endothelium for transmigrating to metastatic sites [86,88]; and (iii) platelets secrete a plethora of tumor, angiogenic, growth and permeability factors, which can

regulate tumor growth, epithelial to mesenchymal transition and metastasis (see below). Noteworthy, circulating hyperactivated platelets, as well as exhausted platelets (i.e., with totally or partially depleted granules, as a consequence of previous activation), are commonly found in subjects with different tumor types, concomitant with the high incidence of VTE [89].

In order to grow and develop metastasis, tumor cells concurrently influence platelet behavior by up-regulating synthesis and/or release of several compounds able to promote platelet activation and aggregation [90–92]. For example, when compared to benign tumors, malignant cells show higher generation of thrombin, one of the most potent platelet activators with strong pro-coagulating properties [93], but also able (when bound to thrombomodulin expressed on endothelium) to attenuate the thrombotic cascade [94,95]. Accordingly, blood thrombin concentrations negatively predict both success to surgery/chemotherapy and survival of patients with gynecological tumors [96]. A cohort study enrolling 112 patients with different cancers revealed that, although without association with disease state, rise in thrombin levels were dependent on tumor site, with lung cancers having more significant increases compared to brain and pancreas cancers [97]. Detrimental effects of increased thrombin generation seem to rely on its ability in promoting, in concert with its targets (among them, protease-activated receptor-1 and -4), cancer adhesion to platelets or endothelium via up-regulation of pro-inflammatory cytokines, adhesion molecules, angiogenic factors, and matrix-degrading proteases, thereby dramatically increasing tumor growth, angiogenesis, invasion, and metastasis [98]. Proofs of the “tumor cell-induced platelet aggregation” also come from quantitative analysis of circulating neutrophil elastase (which proteolytically activates integrin α IIb β 3) and serglycin (a pro-apoptotic and half-life cytokine regulating protein) in melanoma patients; while levels of the former were found up-regulated in cancer subjects, content of the latter was low [99], thus indicating the role of activated platelets in promoting cancer progression.

Although data on the molecular mechanisms underlying platelet hyperactivation are still not well-defined and often contradictory, nonetheless they suggest the involvement of some platelet bioactive molecules. Among them, those contained in α -granules play a pivotal role during platelet-cancer crosstalk (Table 2).

Table 2. Main platelet-derived proteins involved in cancer.

| Molecule | Main Findings | Role in Cancer | Ref. |
|--------------------------------------|--|----------------|--------------|
| P-selectin | ↑ tumor cell extravasation by promoting cancer cell interaction with platelets and endothelium | | [98,100–103] |
| | ↑ platelet activation by increasing thrombin generation | | |
| TF | ↑ monocyte TF exposure Clotting cascade activation | NEGATIVE | [100] |
| VEGF | ↑ cancer cell survival, ↑ angiogenesis, ↑ tumor growth, ↑ metastasis | | [101] |
| EGF | ↑ cancer growth and angiogenesis ↑ MK maturation | | [102] |
| Ang-1 | ↑ mesenchymal and epithelial cell proliferation ↑ pro-angiogenic effect of other cytokines | | [103] |
| PDGF-BB | ↑ vessel development and maturation ↑ cancer cell proliferation, survival and invasion | | [104,105] |
| Endostatin, TSP-1, angiostatin | ↑ tumor stroma changes ↑ blood vessel maturation ↓ tumor cell growth and dissemination ↓ metastasis | POSITIVE | [106] |
| | ↓ angiogenesis | | [107,108] |

Ang-1: angiopoietin-1; EGF: endothelial growth factor; MK: megakaryocytes; NK: natural kill cells; PAI-1: plasminogen activator inhibitor-1; PDGF-BB: Platelet-derived growth factor BB; TF: tumor necrosis factor; TSP-1: thrombospondin-1; VEGF Vascular endothelial growth factor.

Besides P-selectin and other clotting proteins (such as thrombospondin, fibrinogen, fibronectin integrin α II β 3, integrin α V β 3, factor V, and the von Willebrand factor), α -granules contain growth and

pro-angiogenic factors (including Platelet-Derived Growth Factor (PDGF), Vascular Endothelial Growth Factor (VEGF), TGF- β , Epidermal Growth Factor (EGF) and Angiopoetin-1 (Ang-1)), which are secreted following platelet activation and, either directly or indirectly, promote tumorigenesis. For example, besides directly promoting cancer progression and tumor cell extravasation (by facilitating interaction of cancer cells with platelets and endothelium) [109,110], P-selectin may indirectly exacerbate cancer evolution by triggering thrombin generation [111] and rapid monocyte exposure of tissue factor (TF) [100]. The latter protein, primarily involved in activation of the clotting cascade, positively affects tumor growth and metastasis: TF (produced by cancer cells) present in the tumor microenvironment may increase cell survival and/or angiogenesis, while TF present in the bloodstream (deriving from both monocytes and circulating cancer cells) has been shown to enhance thrombosis, tumor growth and metastasis. Several studies showed that P-selectin (either soluble or membrane-bound) changes in cancer patients, although controversial data have been documented. Some clinical studies found high P-selectin levels in cancer patients, with or without correlation to tumor clinical advancement [97,112]; conversely, recent observational and longitudinal studies enrolling patients with heterogeneous cancers found a decrease in platelet surface expression of this protein, which, together with diminished integrin α IIb β 3 exposure, thrombin and collagen receptor responsiveness and monocyte-platelet aggregate formation, correlates with risk of mortality and VTE [113,114]. Nevertheless, a lack of data on platelet activation changes in relation to cancer evolution makes it difficult to clarify whether decreased platelet reactivity is a consequence of continuous pre-activation in patients with poor prognosis or, rather, it represents a cancer-independent event, or even it is the result of a lack of protective effects exerted by activated platelets.

PDGF also has been implicated in tumorigenesis: It acts on tumor cells, thereby favoring proliferation, survival and invasion [104,105], and, in the meanwhile, creates a favorable microenvironment for tumor cells by inducing changes into tumor stroma and promoting blood vessel maturation (especially in advanced stages of angiogenesis) [115]. Accordingly, anti-PDGF drugs significantly inhibit tumor growth and metastasis, although downregulation of PDGF-BB (one of the five isoforms) signaling is associated with tumor cell dissemination and metastasis [106]. In the latter case, a protective role of PDGF-BB has been suggested, since its overexpression, by increasing tumor pericyte content, decreases colorectal and pancreatic cancer growth [116]. However, data on PDGF-BB content in cancer patients are controversial: Concentrations of secreted PDGF-BB, for example, have been found to be significantly high in the serum of colorectal carcinoma patients [117], but low in liver cancer patients with recurrence [118].

Among platelet-derived growth factors/cytokines, VEGF, EGF and Ang-1 play a crucial role in cancer angiogenesis [101–103]. Concerning the pro-angiogenic effect, the mutual influence of platelets and tumor cells also is not fully determined. A recent study performed on twenty-four women with active breast cancer and ten healthy controls showed that breast cancer and its chemotherapeutic treatment influence platelet phenotype, by increasing VEGF release and modulating the response to antiplatelet therapy [119]. Noticeably, an autocrine–paracrine loop, occurring in the bone marrow microenvironment and involving VEGFR-1-dependent megakaryocyte maturation has been documented [120]. Such evidence, together with the finding that tumor-derived IL-6 leads to enhanced megakaryocyte VEGF expression and a higher platelet VEGF load (concomitantly associated with fast tumor growth kinetics and poor diagnosis), strongly suggest a cooperation between platelets and cancer in promoting angiogenesis [121]. Conversely, low EGF levels have been found in cancer subjects with recurrence, and an inverse correlation between its concentrations and survival [118] has been documented in these subjects. Low serum Ang-1 levels, related to poor diagnosis, were also found in subjects with certain types of cancer [118]. On the contrary, patients with lung and ovarian cancer show high Ang-1 concentrations not related to patient survival [122].

In proteomic studies, α -granules also have been shown to contain a plethora of angiogenesis inhibitors, including endostatin, platelet factor-4, thrombospondin-1, α_2 -macroglobulin, plasminogen activator inhibitor-1 and angiostatin. Therefore, activated platelets can organize regulatory proteins in

the α -granules in order to selectively address the release of pro- or anti-angiogenic factors, depending on which different sets of α -granules are segregated [107,108]. Although cancer cells might have the ability to provoke preferential release of pro-angiogenic mediators from platelet α -granules, in order to create a dynamic microenvironment favorable for their growth and survival [107], several experimental and clinical data point out that platelet secretion in the tumorigenic microenvironment might also be oriented towards an anti-angiogenic effect. Such a hypothesis is supported by several findings: (i) significantly higher endostatin levels have been found in hepatocellular carcinoma patients, as well as in gastric cancer subjects [123,124]; (ii) increases in circulating thrombospondin-1 have been found to positively correlate with survival of patients with gynecological and non-small cell lung cancer [125,126]; and (iii) higher levels of angiostatin have been found in serum of prostate cancer patients [127], as well as in urine of patients with epithelial ovarian cancer [128].

Platelets also secrete other factors, which can interfere with all steps of cancer development and metastasis. Serotonin, a monoamine synthesized by enterochromaffin cells in the intestinal mucosa, is largely (about 95%) sequestered by platelets in dense granules, from which it is released in response to various stimuli [12]. A large body of experimental data support both stimulatory and inhibitory properties of serotonin on tumor onset and progression [129–134]. Such different behavior is much likely due to the ability of serotonin to act in a concentration-dependent manner, as well as in its capability to activate distinct signaling pathways, depending on the receptor subtype present at various tumor stages. Coherently, high serotonin levels, correlating with the tumor stage, distant metastases and a poor prognosis, have been found in the serum of patients with different solid tumors [131,135–137], whereas low concentrations have been found in hepatocellular carcinoma patients, who showed recurrence after partial hepatectomy [118]; in untreated breast adenocarcinoma or malignant melanoma patients, where the phenotype (also associated with a high ATP/ADP ratio and index of delta storage pool deficiency) was more marked in regionally spread malignant tumors [138].

Platelets are also important producers of eicosanoids, lipids derived from polyunsaturated fatty acids (PUFAs), through the catalytic action of cyclooxygenase (COX) and lipoxygenase (LOX). Eicosanoids are crucially involved in several pathophysiological conditions [139], and the intersection between changes in certain platelet-derived eicosanoids and cancer appears particularly intriguing. For example, a multi-omics analysis of serum from metastatic melanoma patients revealed a rise in the concentration of 12-hydroxyeicosatetraenoic acid (HETE) and 15-HETE eicosanoids, which are respectively produced by platelet 12-LOX and COX-1 [99]. These two platelet-derived eicosanoids have also been shown to exert pro-malignant effects in several cancer types, by activating mitogen and angiogenic pathways [139–142]. Coherently, blockage of COX-1 by aspirin causes the loss of platelet ability to transform human colon carcinoma cells into mesenchymal-like cells [139,143] and the long-term use of low-dose aspirin is associated with a reduction in risk of various cancers [144].

Finally, activated platelets release lysophosphatidic acid (LPA), a bioactive lipid growth factor, which has been shown to promote cell proliferation, survival, migration, tumor cell invasion and reversal of differentiation, through multiple G protein-coupled receptor (LPA1-6) cascades [145]. Several studies have found a relationship between plasma LPA levels and ovarian carcinoma; for example, a meta-analysis, comparing LPA levels in the serum of 980 ovarian cancer patients, 872 benign controls and 668 healthy controls, showed higher LPA plasma levels in the cancer group with respect to the benign and healthy control samples [146], thus suggesting that the raised detection of plasma LPA might be a potential diagnostic biomarker. Nonetheless, this finding is not supported by a recent lipidomic study that did not find any change in the content of this lipid in serum of ovarian cancer patients [147]. Discrepancies in the results can be explained taking into the account that, due to its susceptibility to sample processing procedure (e.g., plasma storage time at room temperature and anticoagulant used for blood drawing), LPA can artificially increase. In the light of this finding, therefore, it appears important to consider these confounding factors, in order to reduce to the minimum potential errors in measuring plasma LPA.

4. Platelet Microvesicle-Derived miRNAs

Upon activation, platelets release microvesicles (MVs), which are vesicular fragments with a diameter ranging from 0.5 to 1 μm , that express parental antigens (such as P-selectin and integrin $\alpha\text{IIb}\beta\text{3}$) and contain a plethora of mediators (growth factors, cytokines, inflammatory molecules, mRNAs and miRNAs) able to exert biological effects. These platelet MVs, accounting for 70–90% of all MVs circulating in the bloodstream, contribute to regulation of the tumor microenvironment and cancer-cell interactions [148–150]. Accordingly, cancer patients usually show increased levels of circulating MVs (in a way, that is different depending on tumor type, but it is directly proportional to tumor stage), which may be prognostic for monitoring tumor progression and response to specific therapeutics [151].

Although the role of MVs in cancer progression is multi-faceted and not fully understood, nonetheless it is becoming clear that MVs represent one of crucial determinants in tumor biology. Firstly, surface expression of platelet antigens leads to shedding of MVs displaying pro-coagulant and pro-thrombotic features. Therefore, MVs, together with activated platelets, enhance coagulation (which is further exacerbated by cancer-triggered activation of more platelets), thus playing an additional role in cancer progression [152]. Secondly, MVs are able to enhance angiogenesis: They stimulate the expression of pro-angiogenic molecules [including matrix metalloproteinase (MMP)-9, VEGF, IL-8 and hepatocyte growth factor (HGF)] in tumor cells [153] and drive capillary tube formation by stimulating endothelial cells [27,82,154].

Noteworthy, a bidirectional effect occurs as cancer cells can induce platelet activation and MV release; subsequently, a paracrine positive feedback mechanism is established, since MVs, taken up by cancer cells, potentiate the invasive phenotype through stimulation of migration [148,155]. Interestingly, although different cancer cells are able to induce platelet-derived MV release, only the most aggressive ones are responsive to MV action and, furthermore, only some subsets of MVs can positively feed back to cancer cells [155]. These findings suggest that i) cancer/platelet interplay is complex and strongly dependent on features of tumor cell type and ii) composition of MVs may differ depending on the stimulus given to platelets [155]. These findings may clarify discrepancies observed by authors in studies using different platelet preparations, agonists and cancer cell types. Just as an example, our recent work [156] showed that MVs, once internalized by cancer cells, inhibit migration rather than enhancing invasive properties; this may be explained considering that MV release was induced not by cancer cells but, instead, by a different stimulus (namely, arachidonic acid) that led to MV enrichment of specific bioactive molecules. Therefore, depending on MV composition, the effects on tumors may be completely different. A further point of discrimination may reside in MV internalization, since we found that, albeit taken up, the bioactive molecules delivered to cancer cells had different stability and, thus, exert their action in a time-and concentration-dependent fashion [156].

Among the bioactive molecules contained inside MVs, microRNAs (miRNAs) deserve a particular mention. Human platelets, indeed, contain an abundant repertoire of miRNAs that are released through MVs; depending on the nature of the agonists or stimuli activating platelets, the miRNA content of MVs can vary, but it always mirrors the content found in the platelets from which MVs derive [157]. It is exactly this heterogeneity of composition that may account for the observed differences in terms of molecular targets, mechanisms of action and effects on cancer cells (Table 3) [152]. If, on one side, cancer-promoting effects of MVs have been described (especially related to their content in growth factors, inflammatory cytokines and angiogenic factors), it is also true, on the other hand, that the ability to deliver miRNAs to recipient cells (including cancer cells) suggests a potential tumor-suppressive role.

Table 3. Main findings on the cancer-related role of miRNAs, potentially delivered by platelet MVs.

| miRNA | Experimental Settings | Main Findings | Targets | Ref. |
|----------------------------|---|--|-------------------------|-----------|
| miR-223 | Platelet MV delivery to lung A549 cancer cells | ↑ cell invasion | EPB41L3 | [158] |
| | Transfection of breast MCF-7 and prostate PC-3 cancer cells | ↓ vitality, ↑ effects of the anti-tumor celestrol | NF-κB | [159] |
| | Transfection of breast MDA-MB-231 and MCF-7 cancer cells | ↓ migration, ↑ anoikis cell death, ↑ sensitivity to chemotherapy | STAT5A | [160] |
| | Incubation of MDA-MB-231 cells with CM derived from stable transduced MEFs or HEK293 cells | ↑ sensitivity to TRAIL-induced apoptosis | HAX-1 | [161] |
| miR-939 | Transfection of breast MCF-7, SKBR3, MDA-MB-231 and MDA-MB-435 cancer cells | ↓ formation of new blood vessels | endothelial β1 integrin | [162] |
| | Transient transfection of primary endothelial cells | ↑ epithelial to mesenchymal transition | E-cadherin and vimentin | [163] |
| miR-24-3p | Platelet MV delivery to ovarian SKOV3 cancer cells | resistance to etoposide plus cisplatin therapy | ATG4A | [164] |
| miR-24 | Transfection of small-cell lung H446 cancer cells | ↓ tumor growth, ↑ apoptosis | mt-Nd2 and Snora75 | [165] |
| miR-130a | Platelet MV delivery to Lewis lung and colon MC-38 carcinoma cells miRNA microarray in drug-resistant ovarian A2780 carcinoma cells Transfection of cervix HeLa carcinoma cells | drug resistance | M-CSF | [166] |
| miR-27a, miR-451 | Transfection of MDR ovarian A2780 and cervical KB-V1 carcinoma cells | ↑ endothelial tube formation | MDR1 | [167] |
| | Platelet MV delivery to primary endothelial cells | ↓ cancer progression | thrombospondin-1 | [168,169] |
| miR-let-7a, miR-27b | Transfection of breast MDAMB231 and MCF7 cancer cells | cell cycle arrest, ↓ migration, ↑ sensitivity to cisplatin | ADAM9 | [170] |
| | Transfection of breast BT-549 cancer cells | ↑ proliferation | VEGF | [171] |
| miR-126 | Platelet MV delivery to breast BT-549, MDA-MB-468, BT-20 and MCF-7 cancer cells | | ND | [156] |
| | Transfection of lung A549, Y-90 and SPC-A1 carcinoma cells | | | [171] |

ND: not determined. ADAM9: ADAM Metalloproteinase Domain 9; ATG4A: autophagy-associated gene 4A; CM: conditioned medium; EPB41L3: Erythrocyte Membrane Protein Band 4.1 Like 3; HAX-1: HS-1-associated protein X-1; β: M-CSF; macrophage colony-stimulating factor; MDR1: multidrug resistance gene; MEF: mouse embryonic fibroblasts; mt-Nd2: Mitochondrial NADH dehydrogenase 2; MV: microvesicle; NF-κB: nuclear factor-κB; Snora75: Small Nucleolar RNA, H/ACA Box 75; STAT5A: signal transducer and activator of transcription 5A; TRAIL: TNF-related apoptosis-inducing ligand; VEGF: vascular endothelial growth factor.

Platelet MVs can, indeed, be viewed as intercellular carriers that transfer inside cells specific molecules able to negatively modulate gene expression, with both positive and negative consequences. In this context, it should be underlined that most of the studies reporting differential effects of specific miRNAs in cancer employed transfection experiments, where miRNA expression was artificially increased and, to the best of our knowledge, only few of them checked the effects in more physiological (delivery of platelet-derived MVs) conditions.

Transfer of miRNAs to target cells has been shown to promote tumor progression [157]: miR-939 delivered by platelet MVs induces, in ovarian cancer cells, epithelial to mesenchymal transition, by down-regulating E-cadherin and up-regulating vimentin expression [163], while miR-223 has been shown to stimulate lung cancer cell invasion, by targeting tumor suppressor EPB41L3 [158]. Besides targeting tumor suppressor genes and oncogenes, several miRNAs enriched in MVs (miR-223, miR-24, miR-27a, miR-155, miR-195, let-7a/b) may also be implicated in therapy resistance. In small-cell lung cancer, miR-24-3p contributes to resistance to combination therapy (etoposide plus cisplatin), by targeting the autophagy-associated gene 4A [164]; other miRNAs that may be involved in drug resistance include miR-130a (which targets the pro-metastatic macrophage colony-stimulating factor (M-CSF)), and miR-27a and miR-451 (which target the multi drug resistance transporter 1) [166,167,172,173].

MVs also deliver angiogenic signals [27]: Transfer of miRNA let-7a or miR-27b in endothelial cells down-regulates the expression of the anti-angiogenic modulator thrombospondin-1, thus enhancing platelet-dependent endothelial tube formation [168,169].

However, what the available literature data suggest is that platelet-derived MVs may support cancer progression and metastatic dissemination at late stages, while it seems likely that they exert tumor suppressive roles at earlier stages. Michael's group found that circulating MVs directly infiltrating lung and colon cancer cells deliver miR-24 that suppress tumor growth; this miRNA localizes to mitochondria where it inhibits mt-Nd2 and Snora75, resulting in mitochondrial dysfunction and induction of apoptotic cell death [165]. Similarly, miR-223 inhibits migration, stimulates anoikis cell death and enhances chemo-sensitivity in different cancer cell types [159–161]. We and others have demonstrated that also platelet-specific miR-126 exert tumor suppressive roles; this miRNA may be a predictor for tumor relapse in postmenopausal breast cancer patients treated with tamoxifen [174], impairs cancer progression through direct repression of MMP-9 [170], and MV-mediated delivery into breast cancer cells induces cell cycle arrest, inhibition of migration and sensitivity to cisplatin [156]. Finally, miR-126 and miR-223 exert antagonistic effects on angiogenesis: miR-126 stimulates VEGF-induced proliferation in endothelial cells [171], while miR-223 exerts an inhibitory effect on formation of new blood vessels, by targeting endothelial β 1 integrin [162].

The ability of MVs to acquire distinct roles, depending on their repertoire of proteins and miRNAs, suggest that they may be used as biomarkers with diagnostic and therapeutic implications [175]. For example, plasma levels of platelet MVs, together with VEGF, IL-6 and RANTES, have been found to be increased in patients with stage IV gastric cancer [176]. Elevated amounts of endothelial and platelet MVs (that significantly decreased after chemotherapy) have been found in the plasma of non-small cell lung cancer patients, thus suggesting a predictive role for prognostic clinical outcome [177].

5. Conclusions

Although some symptoms of cancer, such as breast lumps, are classic “alarm” symptoms, others are ambiguous and more likely caused by other conditions. Accordingly, different studies demonstrated that alterations in platelet number or/and activity often occur in cancer patients. This finding, together with the evidence that platelets may basically affect all steps of tumor development, prompts researchers to carry out more studies for fully understanding the mechanisms underlying cancer-related platelet dysfunction.

Environmental cancer-related stimuli encountered by platelets are intricate, as are the intracellular signaling pathways regulating platelet responses to the stimuli themselves. Moreover, due to

heterogeneity in the cargo of growth factors, cytokines, microRNAs and other bioactive molecules and platelets may potentially release either stimulators or inhibitors in all cancer steps (Figure 1).




Figure 1. Schematic representation of the main platelet effects on tumor biology. See text for details. In black: platelet-derived bioactive molecules with positive effects. In blue: platelet-derived compounds with negative effects. In red: platelet-derived compounds with both positive and negative effects. Lines with dot indicate either stimulation or inhibition, depending on the platelet-derived bioactive molecule. 12/15 HETEs: 12 and 15 hydroxyeicosatetraenoic acid; Ang-1: Angiopoietin; LPA: lysophosphatidic acid; EGF: Endothelial Growth Factor; P-sel: P-selectin; PDGF: Platelet-Derived Growth Factor; TGF-β: tumor growth factor-β; VEGF: vascular endothelial growth factor.

Accordingly, on one hand, there are a great deal of proofs of deadly interaction between platelets and cancer cells, but, on the other hand, some experimental and clinical data also indicate a protective role. Besides to complexity of platelet signaling in cancer, the scenario is further complicated by other confounding factors extrinsically related to platelets: (i) most of results come from retrospective studies, analyzing a wide range of patients with heterogeneous characteristics, such as age, sex, race, cancer type and stage, as well as treatments not always related to cancer; (ii) some studies have been carried out in cancer patients post-diagnosis and changes in platelets have not been monitored with respect to cancer progression over time, so that it is difficult to establish the exact contribution of platelets and if their changes are the cause or rather a consequence of tumor; and (iii) some of the bioactive compounds, whose plasma concentrations have been shown to be correlated with cancer progression, are also released by other cells, including cancer cells themselves; therefore, the effect on cancer, whether positive or negative, is not necessarily due to platelets.

Other questions still need to be answered: Why do platelet changes occur in some types of cancer and not in others? How does the platelet–cancer relationship change with age, sex and cancer progression over time? Although the heterogeneity and adaptive potential of the tumor features make a “one-size-fits-all” approach for targeting platelet–cancer interactions difficult, a better understanding of the interplay might provide efficient tools for cancer prevention, screening, risk assessment and management.

Author Contributions: M.V.C. and V.G. conceptualized the work and did the original draft preparation; V.T. provided the resources for this work and contributed to draft preparation; I.S. reviewed the text; V.G. drew the table and figures. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

| | |
|--------|--|
| Ang-1 | Angiopoetin-1 |
| COX | Cyclooxygenase |
| EGF | Epidermal growth factor |
| G-CSF | Granulocyte colony-stimulating factor |
| GM-CSF | Granulocyte-macrophage colony-stimulating factor |
| GRO | Growth-regulated oncogene |
| HETE | Hydroxyeicosatraenoic acid |
| HGF | Hepatocyte growth factor |
| HOA | Homeobox |
| HR | Hazard ratio |
| JAK | Janus kinase |
| IBC | Inflammatory breast cancer |
| IL | Interleukin |
| LOX | Lipoxygenase |
| LPA | Lysophosphatidic acid |
| M-CSF | Macrophage colony-stimulating factor |
| miRNA | MicroRNA |
| MMP | Matrix metalloproteinase |
| MV | Microvesicle |
| PDGF | Platelet-derived growth factor |
| PUFA | Polyunsaturated fatty acid |
| SNP | Single nucleotide polymorphisms |
| STAT | Signal transducer and activator of transcription |
| TF | Tissue factor |
| TGF | Transforming growth factor |
| TPO | Thrombopoietin |
| VEGF | Vascular endothelial growth factor |
| VTE | Venous thromboembolism |

References

1. Bizzozero, J. Ueber einen neuen Formbestandtheil des Blutes und dessen Rolle bei der Thrombose und der Blutgerinnung—Untersuchungen. *Arch. Pathol. Anat. Physiol. Klin. Med.* **1882**, *90*, 261–332. [[CrossRef](#)]
2. Lefrançois, E.; Ortiz-Muñoz, G.; Caudrillier, A.; Mallavia, B.; Liu, F.; Sayah, D.M.; Thornton, E.E.; Headley, M.B.; David, T.; Coughlin, S.R.; et al. The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors. *Nature* **2017**, *544*, 105–109. [[CrossRef](#)] [[PubMed](#)]
3. Schulze, H.; Stegner, D. Imaging platelet biogenesis in vivo. *Res. Pract. Thromb. Haemost.* **2018**, *2*, 461–468. [[CrossRef](#)] [[PubMed](#)]
4. Humphrey, J.H. Origin of Blood Platelets. *Nature* **1955**, *176*, 38. [[CrossRef](#)] [[PubMed](#)]
5. Wright, J.H. The histogenesis of the blood platelets. *J. Morphol.* **1910**, *21*, 263–278. [[CrossRef](#)]
6. Vinholt, P.J. The role of platelets in bleeding in patients with thrombocytopenia and hematological disease. *Clin. Chem. Lab. Med.* **2019**, *57*, 1808–1817. [[CrossRef](#)]
7. Mezger, M.; Nording, H.; Sauter, R.; Graf, T.; Heim, C.; von Bubnoff, N.; Ensminger, S.M.; Langer, H.F. Platelets and Immune Responses During Thromboinflammation. *Front. Immunol.* **2019**, *10*, 1731. [[CrossRef](#)]
8. Assinger, A.; Schrottmaier, W.C.; Salzmann, M.; Rayes, J. Platelets in Sepsis: An Update on Experimental Models and Clinical Data. *Front. Immunol.* **2019**, *10*, 1687. [[CrossRef](#)]
9. Mohammed, S.; Yu, J. Platelet-rich plasma injections: An emerging therapy for chronic discogenic low back pain. *J. Spine Surg.* **2018**, *4*, 115–122. [[CrossRef](#)]
10. Nieswandt, B.; Kleinschnitz, C.; Stoll, G. Ischaemic stroke: A thrombo-inflammatory disease? *J. Physiol.* **2011**, *589*, 4115–4123. [[CrossRef](#)]
11. Saluk-Bijak, J.; Dziedzic, A.; Bijak, M. Pro-Thrombotic Activity of Blood Platelets in Multiple Sclerosis. *Cells* **2019**, *8*, 110. [[CrossRef](#)] [[PubMed](#)]

12. Ghoshal, K.; Bhattacharyya, M. Overview of Platelet Physiology: Its Hemostatic and Nonhemostatic Role in Disease Pathogenesis. *Sci. World J.* **2014**, *2014*, 781857. [[CrossRef](#)] [[PubMed](#)]
13. Biino, G.; Santimone, I.; Minelli, C.; Sorice, R.; Frongia, B.; Traglia, M.; Ulivi, S.; Di Castelnuovo, A.; Gögele, M.; Nutile, T.; et al. Age- And Sex-Related Variations in Platelet Count in Italy: A Proposal of Reference Ranges Based on 40987 Subjects' Data. *PLoS ONE* **2013**, *8*, e54289. [[CrossRef](#)] [[PubMed](#)]
14. Eicher, J.D.; Lettre, G.; Johnson, A.D. The genetics of platelet count and volume in humans. *Platelets* **2018**, *29*, 125–130. [[CrossRef](#)]
15. Catani, M.V.; Gasperi, V.; Evangelista, D.; Finazzi Agrò, A.; Avigliano, L.; Maccarrone, M. Anandamide extends platelets survival through CB1-dependent Akt signaling. *Cell. Mol. Life Sci.* **2010**, *67*, 601–610. [[CrossRef](#)]
16. Grozovsky, R.; Giannini, S.; Hoffmeister, K.M. Novel mechanisms of platelet clearance and thrombopoietin regulation. *Curr. Opin. Hematol.* **2017**, *22*, 445–451. [[CrossRef](#)]
17. Grozovsky, R.; Giannini, S.; Falet, H.; Hoffmeister, K.M. Novel mechanisms of platelet clearance and thrombopoietin regulation. *Curr. Opin. Hematol.* **2015**, *22*, 445–451. [[CrossRef](#)]
18. Tefferi, A.; Thiele, J.; Orazi, A.; Kvasnicka, H.M.; Barbui, T.; Hanson, C.A.; Barosi, G.; Verstovsek, S.; Birgegard, G.; Mesa, R.; et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: Recommendations from an ad hoc international expert panel. *Blood* **2007**, *110*, 1092–1097. [[CrossRef](#)]
19. Barbui, T.; Thiele, J.; Gisslinger, H.; Finazzi, G.; Vannucchi, A.M.; Tefferi, A. The 2016 revision of WHO classification of myeloproliferative neoplasms: Clinical and molecular advances. *Blood Rev.* **2016**, *30*, 453–459. [[CrossRef](#)]
20. Song, J.; Hussaini, M.; Zhang, H.; Shao, H.; Qin, D.; Zhang, X.; Ma, Z.; Hussaini Naqvi, S.M.; Zhang, L.; Moscinski, L.C. Comparison of the Mutational Profiles of Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocytosis. *Am. J. Clin. Pathol.* **2017**, *147*, 444–452. [[CrossRef](#)]
21. Chia, T.L.; Chesney, T.R.; Isa, D.; Mnatzakanian, G.; Colak, E.; Belmont, C.; Hirpara, D.; Veigas, P.V.; Acuna, S.A.; Rizoli, S.; et al. Thrombocytosis in splenic trauma: In-hospital course and association with venous thromboembolism. *Injury* **2017**, *48*, 142–147. [[CrossRef](#)] [[PubMed](#)]
22. Griesshammer, M.; Bangerter, M.; Sauer, T.; Wennauer, R.; Bergmann, L.; Heimpel, H. Aetiology and clinical significance of thrombocytosis: Analysis of 732 patients with an elevated platelet count. *J. Intern. Med.* **1999**, *245*, 295–300. [[CrossRef](#)] [[PubMed](#)]
23. Santhosh-Kumar, C.R.; Yohannan, M.D.; Higgy, K.E.; Al-Mashhadani, S.A. Thrombocytosis in adults: Analysis of 777 patients. *J. Intern. Med.* **1991**, *229*, 493–495. [[CrossRef](#)] [[PubMed](#)]
24. Khorana, A.A.; Francis, C.W.; Culakova, E.; Lyman, G.H. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. *Cancer* **2005**, *104*, 2822–2829. [[CrossRef](#)] [[PubMed](#)]
25. Wang, S.; Li, Z.; Xu, R. Human cancer and platelet interaction, a potential therapeutic target. *Int. J. Mol. Sci.* **2018**, *19*, 1246. [[CrossRef](#)] [[PubMed](#)]
26. Levin, J. Thrombocytosis Associated With Malignant Disease. *Arch. Intern. Med.* **1964**, *114*, 497. [[CrossRef](#)]
27. Wojtukiewicz, M.Z.; Sierko, E.; Hempel, D.; Tucker, S.C.; Honn, K.V. Platelets and cancer angiogenesis nexus. *Cancer Metastasis Rev.* **2017**, *36*, 249–262. [[CrossRef](#)]
28. Stone, R.L.; Nick, A.M.; McNeish, I.A.; Balkwill, F.; Han, H.D.; Bottsford-Miller, J.; Rupaimoole, R.; Armaiz-Pena, G.N.; Pecot, C.V.; Coward, J.; et al. Paraneoplastic Thrombocytosis in Ovarian Cancer. *N. Engl. J. Med.* **2012**, *366*, 610–618. [[CrossRef](#)]
29. Zhang, X.; Ran, Y. Prognostic role of elevated platelet count in patients with lung cancer: A systematic review and meta-analysis. *Int. J. Clin. Exp. Med.* **2015**, *8*, 5379–5387.
30. Gu, D.; Szallasi, A. Thrombocytosis portends adverse prognosis in colorectal cancer: A meta-analysis of 5,619 patients in 16 individual studies. *Anticancer Res.* **2017**, *37*, 4717–4726.
31. Ji, Y.; Sheng, L.; Du, X.; Qiu, G.; Su, D. Elevated platelet count is a strong predictor of poor prognosis in stage I non-small cell lung cancer patients. *Platelets* **2015**, *26*, 138–142. [[CrossRef](#)] [[PubMed](#)]
32. Cao, W.; Yao, X.; Cen, D.; Zhi, Y.; Zhu, N.; Xu, L. Prognostic role of pretreatment thrombocytosis on survival in patients with cervical cancer: A systematic review and meta-analysis. *World J. Surg. Oncol.* **2019**, *17*, 132. [[CrossRef](#)] [[PubMed](#)]

33. Shimada, H.; Oohira, G.; Okazumi, S.; Matsubara, H.; Nabeya, Y.; Hayashi, H.; Takeda, A.; Gunji, Y.; Ochiai, T. Thrombocytosis associated with poor prognosis in patients with esophageal carcinoma: A study with no competing interests declared. *J. Am. Coll. Surg.* **2004**, *198*, 737–741. [[CrossRef](#)] [[PubMed](#)]
34. Feng, J.F.; Huang, Y.; Lu, W.S.; Chen, Q.X. Preoperative platelet count in esophageal squamous cell carcinoma: Is it a prognostic factor? *Langenbeck's Arch. Surg.* **2013**, *398*, 1115–1122. [[CrossRef](#)] [[PubMed](#)]
35. Wan, S.; Lai, Y.; Myers, R.E.; Li, B.; Hyslop, T.; London, J.; Chatterjee, D.; Palazzo, J.P.; Burkart, A.L.; Zhang, K.; et al. Preoperative platelet count associates with survival and distant metastasis in surgically resected colorectal cancer patients. *J. Gastrointest. Cancer* **2013**, *44*, 293–304. [[CrossRef](#)]
36. Lee, M.; Kim, S.W.; Nam, E.J.; Yim, G.W.; Kim, S.; Kim, Y.T. The impact of pretreatment thrombocytosis and persistent thrombocytosis after adjuvant chemotherapy in patients with advanced epithelial ovarian cancer. *Gynecol. Oncol.* **2011**, *122*, 238–241. [[CrossRef](#)]
37. Harano, K.; Kogawa, T.; Wu, J.; Yuan, Y.; Cohen, E.N.; Lim, B.; Reuben, J.M.; Ueno, N.T. Thrombocytosis as a prognostic factor in inflammatory breast cancer. *Breast Cancer Res. Treat.* **2017**, *166*, 819–832. [[CrossRef](#)]
38. Moschini, M.; Suardi, N.; Pellucchi, F.; Rocchini, L.; La Croce, G.; Capitanio, U.; Briganti, A.; Damiano, R.; Montorsi, F.; Colombo, R. Impact of preoperative thrombocytosis on pathological outcomes and survival in patients treated with radical cystectomy for bladder carcinoma. *Anticancer Res.* **2014**, *34*, 3225–3230.
39. Dutta, S.; Crumley, A.B.C.; Fullarton, G.M.; Horgan, P.G.; McMillan, D.C. Comparison of the prognostic value of tumour and patient related factors in patients undergoing potentially curative resection of gastric cancer. *Am. J. Surg.* **2012**, *204*, 294–299. [[CrossRef](#)]
40. Aminian, A.; Karimian, F.; Mirsharifi, R.; Alibakhshi, A.; Dashti, H.; Jahangiri, Y.; Safari, S.; Ghaderi, H.; Noaparast, M.; Hasani, S.; et al. Significance of platelet count in esophageal carcinomas. *Saudi J. Gastroenterol.* **2011**, *17*, 134. [[CrossRef](#)]
41. Wang, J.; Liu, H.; Shao, N.; Tan, B.; Song, Q.; Jia, Y.; Cheng, Y. The clinical significance of preoperative plasma fibrinogen level and platelet count in resectable esophageal squamous cell carcinoma. *World J. Surg. Oncol.* **2015**, *13*, 157. [[CrossRef](#)] [[PubMed](#)]
42. Liu, H.B.; Gu, X.L.; Ma, X.Q.; Lv, T.F.; Wu, Y.; Xiao, Y.Y.; Yuan, D.M.; Li, Y.F.; Song, Y. Preoperative platelet count in predicting lymph node metastasis and prognosis in patients with non-small cell lung cancer. *Neoplasma* **2012**, *60*, 203–208. [[CrossRef](#)] [[PubMed](#)]
43. Agoston, A.T.; Srivastava, A.; Zheng, Y.; Bueno, R.; Odze, R.D.; Szallasi, Z. Paraneoplastic thrombocytosis is associated with increased mortality and increased rate of lymph node metastasis in oesophageal adenocarcinoma. *Pathology* **2017**, *49*, 471–475. [[CrossRef](#)] [[PubMed](#)]
44. Tranum, B.L.; Haut, A. Thrombocytosis: Platelet kinetics in neoplasia. *J. Lab. Clin. Med.* **1974**, *84*, 615–619.
45. Kuter, D.J. The biology of thrombopoietin and thrombopoietin receptor agonists. *Int. J. Hematol.* **2013**, *98*, 10–23. [[CrossRef](#)]
46. Tsukishiro, S.; Suzumori, N.; Nishikawa, H.; Arakawa, A.; Suzumori, K. Preoperative serum thrombopoietin levels are higher in patients with ovarian cancer than with benign cysts. *Eur. J. Obstet. Gynecol. Reprod. Biol.* **2008**, *140*, 67–70. [[CrossRef](#)]
47. Furuhashi, M.; Miyabe, Y.; Oda, H. A Case of Thrombopoietin-Producing Ovarian Carcinoma Confirmed by Immunohistochemistry. *Gynecol. Oncol.* **1999**, *74*, 278–281. [[CrossRef](#)]
48. Weryńska, B.; Ramlau, R.; Podolak-Dawidziak, M.; Jankowska, R.; Prajs, I.; Usnarska-Zubkiewicz, L.; Kuliczkowski, K. Serum thrombopoietin levels in patients with reactive thrombocytosis due to lung cancer and in patients with essential thrombocythemia. *Neoplasma* **2003**, *50*, 447–451.
49. Columbyova, L.; Loda, M.; Scadden, D.T. Thrombopoietin Receptor Expression in Human Cancer Cell Lines and Primary Tissues. *Cancer Res.* **1995**, *55*, 3509–3512.
50. Besbes, S.; Shah, S.; Al-Dybiat, I.; Mirshahi, S.; Helfer, H.; Najah, H.; Fourgeaud, C.; Pocard, M.; Ghedira, I.; Soria, J.; et al. Thrombopoietin Secretion by Human Ovarian Cancer Cells. *Int. J. Cell Biol.* **2017**, *2017*, 1873834. [[CrossRef](#)]
51. Hodge, D.R.; Hurt, E.M.; Farrar, W.L. The role of IL-6 and STAT3 in inflammation and cancer. *Eur. J. Cancer* **2005**, *41*, 2502–2512. [[CrossRef](#)] [[PubMed](#)]
52. Guo, Y.; Xu, F.; Lu, T.; Duan, Z.; Zhang, Z. Interleukin-6 signaling pathway in targeted therapy for cancer. *Cancer Treat. Rev.* **2012**, *38*, 904–910. [[CrossRef](#)] [[PubMed](#)]

53. Kaser, A.; Brandacher, G.; Steurer, W.; Kaser, S.; Offner, F.A.; Zoller, H.; Theurl, I.; Widder, W.; Molnar, C.; Ludwiczek, O.; et al. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: Role in inflammatory thrombocytosis. *Blood* **2001**, *98*, 2720–2725. [[CrossRef](#)] [[PubMed](#)]
54. Wolber, E.-M.; Fandrey, J.; Frackowski, U.; Jelkmann, W. Hepatic Thrombopoietin mRNA Is Increased in Acute Inflammation. *Thromb. Haemost.* **2001**, *86*, 1421–1424. [[PubMed](#)]
55. Wolber, E.M.; Jelkmann, W. Interleukin-6 increases thrombopoietin production in human hepatoma cells HepG2 and Hep3B. *J. Interferon Cytokine Res.* **2000**, *20*, 499–506. [[CrossRef](#)]
56. Kumari, N.; Dwarakanath, B.S.; Das, A.; Bhatt, A.N. Role of interleukin-6 in cancer progression and therapeutic resistance. *Tumor Biol.* **2016**, *37*, 11553–11572. [[CrossRef](#)] [[PubMed](#)]
57. Conze, D.; Weiss, L.; Regen, P.S.; Rincón, M.; Weaver, D.; Bhushan, A.; Johnson, P. Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. *Cancer Res.* **2001**, *61*, 8851–8858.
58. Nagasaki, T.; Hara, M.; Nakanishi, H.; Takahashi, H.; Sato, M.; Takeyama, H. Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis: Anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour-stroma interaction. *Br. J. Cancer* **2014**, *110*, 469–478. [[CrossRef](#)]
59. Higashihara, M.; Sunaga, S.; Tange, T.; Oohashi, H.; Kurokawa, K. Increased secretion of Interleukin-6 in malignant mesothelioma cells from a patient with marked thrombocytosis. *Cancer* **1992**, *70*, 2105–2108. [[CrossRef](#)]
60. Shinriki, S.; Jono, H.; Ota, K.; Ueda, M.; Kudo, M.; Ota, T.; Oike, Y.; Endo, M.; Ibusuki, M.; Hiraki, A.; et al. Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivo growth of human oral squamous cell carcinoma. *Clin. Cancer Res.* **2009**, *15*, 5426–5434. [[CrossRef](#)]
61. Chen, F.; Teachey, D.T.; Pequignot, E.; Frey, N.; Porter, D.; Maude, S.L.; Grupp, S.A.; June, C.H.; Melenhorst, J.J.; Lacey, S.F. Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy. *J. Immunol. Methods* **2016**, *434*, 1–8. [[CrossRef](#)] [[PubMed](#)]
62. Vainer, N.; Dehlendorff, C.; Johansen, J.S. Systematic literature review of IL-6 as a biomarker or treatment target in patients with gastric, bile duct, pancreatic and colorectal cancer. *Oncotarget* **2018**, *9*, 29820–29841. [[CrossRef](#)] [[PubMed](#)]
63. Suzuki, A.; Takahashi, T.; Nakamura, K.; Tsuyuoka, R.; Okuno, Y.; Enomoto, T.; Fukumoto, M.; Imura, H. Thrombocytosis in patients with tumors producing colony-stimulating factor. *Blood* **1992**, *80*, 2052–2059. [[CrossRef](#)] [[PubMed](#)]
64. Assoian, R.K.; Komoriya, A.; Meyers, C.A.; Miller, D.M.; Sporn, M.B. Transforming growth factor- β in human platelets. Identification of a major storage site, purification, and characterization. *J. Biol. Chem.* **1983**, *258*, 7155–7160. [[PubMed](#)]
65. Lian, S.; Zhai, X.; Wang, X.; Zhu, H.; Zhang, S.; Wang, W.; Wang, Z.; Huang, J. Elevated expression of growth-regulated oncogene-alpha in tumor and stromal cells predicts unfavorable prognosis in pancreatic cancer. *Medicine* **2016**, *95*, e4328. [[CrossRef](#)] [[PubMed](#)]
66. Yung, M.M.H.; Tang, H.W.M.; Cai, P.C.H.; Leung, T.H.Y.; Ngu, S.F.; Chan, K.K.L.; Xu, D.; Yang, H.; Ngan, H.Y.S.; Chan, D.W. GRO- α and IL-8 enhance ovarian cancer metastatic potential via the CXCR2-mediated TAK1/NF κ B signaling cascade. *Theranostics* **2018**, *8*, 1270–1285. [[CrossRef](#)]
67. Phakathi, B.P.; Mannell, A.; Nietz, S. Early stage breast cancer with concomitant primary hyperparathyroidism and autoimmune thrombocytopenia: A case report. *S. Afr. J. Surg.* **2018**, *56*, 64–65. [[CrossRef](#)]
68. Liebman, H.A. Thrombocytopenia in cancer patients. *Thromb. Res.* **2014**, *133*, S63–S69. [[CrossRef](#)]
69. Khasraw, M.; Faraj, H.; Sheikh, A. Thrombocytopenia in solid tumors. *Eur. J. Clin. Med. Oncol.* **2010**, *2*, 89–92.
70. Gaydos, L.A.; Freireich, E.J.; Mantel, N. The quantitative relation between platelet count and hemorrhage in patients with acute leukemia. *N. Engl. J. Med.* **1962**, *266*, 905–909. [[CrossRef](#)]
71. Avvisati, G.; Tirindelli, M.C.; Annibali, O. Thrombocytopenia and hemorrhagic risk in cancer patients. *Crit. Rev. Oncol. Hematol.* **2003**, *48*, 13–16. [[CrossRef](#)] [[PubMed](#)]
72. Ghanavat, M.; Ebrahimi, M.; Rafieemehr, H.; Maniati, M.; Behzad, M.M.; Shahrabi, S. Thrombocytopenia in solid tumors: Prognostic significance. *Oncol. Rev.* **2019**, *13*, 43–48. [[CrossRef](#)] [[PubMed](#)]
73. Pooja, S.; Chaudhary, P.; Nayak, L.V.; Rajender, S.; Saini, K.S.; Deol, D.; Kumar, S.; Bid, H.K.; Konwar, R. Polymorphic variations in IL-1 β , IL-6 and IL-10 genes, their circulating serum levels and breast cancer risk in Indian women. *Cytokine* **2012**, *60*, 122–128. [[CrossRef](#)]

74. Rodríguez-Berriguete, G.; Sánchez-Espiridión, B.; Cansino, J.R.; Olmedilla, G.; Martínez-Onsurbe, P.; Sánchez-Chapado, M.; Paniagua, R.; Fraile, B.; Royuela, M. Clinical significance of both tumor and stromal expression of components of the IL-1 and TNF- α signaling pathways in prostate cancer. *Cytokine* **2013**, *64*, 555–563. [[CrossRef](#)] [[PubMed](#)]
75. Xue, H.; Lin, B.; Ni, P.; Xu, H.; Huang, G. Interleukin-1B and interleukin-1 RN polymorphisms and gastric carcinoma risk: A meta-analysis. *J. Gastroenterol. Hepatol.* **2010**, *25*, 1604–1617. [[CrossRef](#)] [[PubMed](#)]
76. Ying, H.Y.; Yu, B.W.; Yang, Z.; Yang, S.S.; Bo, L.H.; Shan, X.Y.; Wang, H.J.; Zhu, Y.J.; Wu, X.S. Interleukin-1B 31 C>T polymorphism combined with Helicobacter pylori-modified gastric cancer susceptibility: Evidence from 37 studies. *J. Cell. Mol. Med.* **2016**, *20*, 526–536. [[CrossRef](#)] [[PubMed](#)]
77. Hefler, L.A.; Grimm, C.; Ackermann, S.; Malur, S.; Radjabi-Rahat, A.R.; Leodolter, S.; Beckmann, M.W.; Zeillinger, R.; Koelbl, H.; Tempfer, C.B. An interleukin-6 gene promoter polymorphism influences the biological phenotype of ovarian cancer. *Cancer Res.* **2003**, *63*, 3066–3068.
78. Talar-Wojnarowska, R.; Gasiorowska, A.; Smolarz, B.; Romanowicz-Makowska, H.; Kulig, A.; Malecka-Panas, E. Clinical significance of interleukin-6 (Il-6) gene polymorphism and Il-6 serum level in pancreatic adenocarcinoma and chronic pancreatitis. *Dig. Dis. Sci.* **2009**, *54*, 683–689. [[CrossRef](#)]
79. Takaku, M.; Grimm, S.A.; Wade, P.A. GATA3 in breast cancer: Tumor suppressor or oncogene? *Gene Expr.* **2015**, *16*, 163–168. [[CrossRef](#)]
80. Li, Q.; Chen, C.; Ren, X.; Sun, W. DNA methylation profiling identifies the HOXA11 gene as an early diagnostic and prognostic molecular marker in human lung adenocarcinoma. *Oncotarget* **2017**, *8*, 33100–33109. [[CrossRef](#)]
81. Xia, B.; Shan, M.; Wang, J.; Zhong, Z.; Geng, J.; He, X.; Vu, T.; Zhang, D.; Pang, D. Homeobox A11 hypermethylation indicates unfavorable prognosis in breast cancer. *Oncotarget* **2017**, *8*, 9794–9805. [[CrossRef](#)] [[PubMed](#)]
82. Franco, A.T.; Ware, J. Pathophysiology 2: The Role of Platelets in Cancer Biology. In *Cancer Treatment and Research*; Springer: Cham, Switzerland, 2019; pp. 37–54.
83. Kisucka, J.; Butterfield, C.E.; Duda, D.G.; Eichenberger, S.C.; Saffaripour, S.; Ware, J.; Ruggeri, Z.M.; Jain, R.K.; Folkman, J.; Wagner, D.D. Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage. *Proc. Natl. Acad. Sci. USA* **2006**, *103*, 855–860. [[CrossRef](#)] [[PubMed](#)]
84. Jain, S.; Zuka, M.; Liu, J.; Russell, S.; Dent, J.; Guerrero, J.A.; Forsyth, J.; Maruszak, B.; Gartner, T.K.; Felding-Habermann, B.; et al. Platelet glycoprotein Iba supports experimental lung metastasis. *Proc. Natl. Acad. Sci. USA* **2007**, *104*, 9024–9028. [[CrossRef](#)] [[PubMed](#)]
85. Demers, M.; Ho-Tin-Noé, B.; Schatzberg, D.; Yang, J.J.; Wagner, D.D. Increased Efficacy of Breast Cancer Chemotherapy in Thrombocytopenic Mice. *Cancer Res.* **2011**, *71*, 1540–1549. [[CrossRef](#)] [[PubMed](#)]
86. Seth, R.; Tai, L.H.; Falls, T.; De Souza, C.T.; Bell, J.C.; Carrier, M.; Atkins, H.; Boushey, R.; Auer, R.A. Surgical stress promotes the development of cancer metastases by a coagulation-dependent mechanism involving natural killer cells in a murine model. *Ann. Surg.* **2013**, *258*, 158–168. [[CrossRef](#)]
87. Clar, K.L.; Hinterleitner, C.; Schneider, P.; Salih, H.R.; Maurer, S. Inhibition of NK reactivity against solid tumors by platelet-derived RANKL. *Cancers* **2019**, *11*, 277. [[CrossRef](#)]
88. Chaffer, C.L.; Weinberg, R.A. A perspective on cancer cell metastasis. *Science* **2011**, *331*, 1559–1564. [[CrossRef](#)]
89. Farge, D.; Bounameaux, H.; Brenner, B.; Cajfinger, F.; Debourdeau, P.; Khorana, A.A.; Pabinger, I.; Solymoss, S.; Douketis, J.; Kakkar, A. International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. *Lancet Oncol.* **2016**, *17*, e452–e466. [[CrossRef](#)]
90. Zarà, M.; Canobbio, I.; Visconte, C.; Canino, J.; Torti, M.; Guidetti, G.F. Molecular mechanisms of platelet activation and aggregation induced by breast cancer cells. *Cell. Signal.* **2018**, *48*, 45–53. [[CrossRef](#)]
91. Reddel, C.; Tan, C.; Chen, V. Thrombin Generation and Cancer: Contributors and Consequences. *Cancers* **2019**, *11*, 100. [[CrossRef](#)]
92. Chang, J.; Jiang, L.; Wang, Y.; Yao, B.; Yang, S.; Zhang, B.; Zhang, M.-Z. 12/15 lipoxigenase regulation of colorectal tumorigenesis is determined by the relative tumor levels of its metabolite 12-HETE and 13-HODE in animal models. *Oncotarget* **2015**, *6*, 2879. [[CrossRef](#)] [[PubMed](#)]
93. Duvernay, M.T.; Temple, K.J.; Maeng, J.G.; Blobaum, A.L.; Stauffer, S.R.; Lindsley, C.W.; Hamm, H.E. Contributions of Protease-Activated Receptors PAR1 and PAR4 to Thrombin-Induced GPIIb/IIIa Activation in Human Platelets. *Mol. Pharmacol.* **2017**, *91*, 39–47. [[CrossRef](#)] [[PubMed](#)]

94. Dahlbäck, B. Pro- and anticoagulant properties of factor V in pathogenesis of thrombosis and bleeding disorders. *Int. J. Lab. Hematol.* **2016**, *38*, 4–11. [[CrossRef](#)] [[PubMed](#)]
95. Xiao, J.; Melvin, R.L.; Salsbury, F.R. Mechanistic insights into thrombin's switch between "slow" and "fast" forms. *Phys. Chem. Chem. Phys.* **2017**, *19*, 24522–24533. [[CrossRef](#)] [[PubMed](#)]
96. Abu Saadeh, F.; Langhe, R.; Galvin, D.M.; Toole, S.O.; O'Donnell, D.M.; Gleeson, N.; Norris, L.A. Procoagulant activity in gynaecological cancer patients; The effect of surgery and chemotherapy. *Thromb. Res.* **2016**, *139*, 135–141. [[CrossRef](#)] [[PubMed](#)]
97. Reitter, E.M.; Kaider, A.; Ay, C.; Quehenberger, P.; Marosi, C.; Zielinski, C.; Pabinger, I. Longitudinal analysis of hemostasis biomarkers in cancer patients during antitumor treatment. *J. Thromb. Haemost.* **2016**, *14*, 294–305. [[CrossRef](#)]
98. Adams, G.N.; Rosenfeldt, L.; Frederick, M.; Miller, W.; Waltz, D.; Kombrinck, K.; McElhinney, K.E.; Flick, M.J.; Monia, B.P.; Revenko, A.S.; et al. Colon cancer growth and dissemination relies upon thrombin, Stromal PAR-1, and fibrinogen. *Cancer Res.* **2015**, *75*, 4235–4243. [[CrossRef](#)]
99. Muqaku, B.; Eisinger, M.; Meier, S.M.; Tahir, A.; Pukrop, T.; Haferkamp, S.; S lany, A.; Reichle, A.; Gerner, C. Multi-omics analysis of serum samples demonstrates reprogramming of organ functions via systemic calcium mobilization and platelet activation in metastatic melanoma. *Mol. Cell. Proteom.* **2017**, *16*, 86–99. [[CrossRef](#)]
100. McCarty, O.J.T.; Mousa, S.A.; Bray, P.F.; Konstantopoulos, K. Immobilized platelets support human colon carcinoma cell tethering, rolling, and firm adhesion under dynamic flow conditions. *Blood* **2000**, *96*, 1789–1797. [[CrossRef](#)]
101. Li, S.S.; Ip, C.K.M.; Tang, M.Y.H.; Tang, M.K.S.; Tong, Y.; Zhang, J.; Hassan, A.A.; Mak, A.S.C.; Yung, S.; Chan, T.M.; et al. Sialyl Lewisx-P-selectin cascade mediates tumor–mesothelial adhesion in ascitic fluid shear flow. *Nat. Commun.* **2019**, *10*, 2406. [[CrossRef](#)]
102. Del Conde, I.; Nabi, F.; Tonda, R.; Thiagarajan, P.; López, J.A.; Kleiman, N.S. Effect of P-selectin on phosphatidylserine exposure and surface-dependent thrombin generation on monocytes. *Arterioscler. Thromb. Vasc. Biol.* **2005**, *25*, 1065–1070. [[CrossRef](#)] [[PubMed](#)]
103. Ivanov, I.I.; Apta, B.H.R.; Bonna, A.M.; Harper, M.T. Platelet P-selectin triggers rapid surface exposure of tissue factor in monocytes. *Sci. Rep.* **2019**, *9*, 13397. [[CrossRef](#)] [[PubMed](#)]
104. Jiang, L.; Luan, Y.; Miao, X.; Sun, C.; Li, K.; Huang, Z.; Xu, D.; Zhang, M.; Kong, F.; Li, N. Platelet releasate promotes breast cancer growth and angiogenesis via VEGF-integrin cooperative signalling. *Br. J. Cancer* **2017**, *117*, 695–703. [[CrossRef](#)] [[PubMed](#)]
105. Yang, J.G.; Wang, L.L.; Ma, D.C. Effects of vascular endothelial growth factors and their receptors on megakaryocytes and platelets and related diseases. *Br. J. Haematol.* **2018**, *180*, 321–334. [[CrossRef](#)] [[PubMed](#)]
106. Sigismund, S.; Avanzato, D.; Lanzetti, L. Emerging functions of the EGFR in cancer. *Mol. Oncol.* **2018**, *12*, 3–20. [[CrossRef](#)] [[PubMed](#)]
107. Vega, S.; Kondo, A.; Suzuki, M.; Arai, H.; Jiapaer, S.; Sabit, H.; Nakada, M.; Ikeuchi, T.; Ishijima, M.; Arikawa-Hirasawa, E.; et al. Fibulin-7 is overexpressed in glioblastomas and modulates glioblastoma neovascularization through interaction with angiopoietin-1. *Int. J. Cancer* **2019**, *145*, 2157–2169. [[CrossRef](#)] [[PubMed](#)]
108. Nissen, L.J.; Cao, R.; Hedlund, E.M.; Wang, Z.; Zhao, X.; Wetterskog, D.; Funa, K.; Bråkenhielm, E.; Cao, Y. Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. *J. Clin. Investig.* **2007**, *117*, 2766–2777. [[CrossRef](#)]
109. Kumar, S.; Lu, B.; Davra, V.; Hornbeck, P.; Machida, K.; Birge, R.B. Crk tyrosine phosphorylation regulates PDGF-BB-inducible Src activation and breast tumorigenicity and metastasis. *Mol. Cancer Res.* **2018**, *16*, 173–183. [[CrossRef](#)]
110. Pietras, K.; Pahler, J.; Bergers, G.; Hanahan, D. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. *PLoS Med.* **2008**, *5*, 0123–0138. [[CrossRef](#)]
111. Hosaka, K.; Yang, Y.; Seki, T.; Nakamura, M.; Andersson, P.; Rouhi, P.; Yang, X.; Jensen, L.; Lim, S.; Feng, N.; et al. Tumour PDGF-BB expression levels determine dual effects of anti-PDGF drugs on vascular remodelling and metastasis. *Nat. Commun.* **2013**, *4*, 2129. [[CrossRef](#)]
112. Battinelli, E.M.; Markens, B.A.; Italiano, J.E. Release of angiogenesis regulatory proteins from platelet alpha granules: Modulation of physiologic and pathologic angiogenesis. *Blood* **2011**, *118*, 1359–1369. [[CrossRef](#)] [[PubMed](#)]

113. Italiano, J.E.; Richardson, J.L.; Patel-Hett, S.; Battinelli, E.; Zaslavsky, A.; Short, S.; Ryeom, S.; Folkman, J.; Klement, G.L. Angiogenesis is regulated by a novel mechanism: Pro- and antiangiogenic proteins are organized into separate platelet α granules and differentially released. *Blood* **2008**, *111*, 1227–1233. [[CrossRef](#)] [[PubMed](#)]
114. Dymicka-Piekarska, V.; Matowicka-Karna, J.; Osada, J.; Kemon, H.; Butkiewicz, A.M. Changes in platelet CD 62P expression and soluble P-selectin concentration in surgically treated colorectal carcinoma. *Adv. Med. Sci.* **2006**, *51*, 304–308. [[PubMed](#)]
115. Riedl, J.; Kaidler, A.; Marosi, C.; Prager, G.W.; Eichelberger, B.; Assinger, A.; Pabinger, I.; Panzer, S.; Ay, C. Decreased platelet reactivity in patients with cancer is associated with high risk of venous thromboembolism and poor prognosis. *Thromb. Haemost.* **2017**, *117*, 90–98. [[CrossRef](#)] [[PubMed](#)]
116. Riedl, J.; Kaidler, A.; Marosi, C.; Prager, G.; Eichelberger, B.; Koder, S.; Panzer, S.; Pabinger, I.; Ay, C. PO-63—Exhausted platelets in cancer patients with high risk of venous thromboembolism and poor prognosis. *Thromb. Res.* **2016**, *140*, S199–S200. [[CrossRef](#)]
117. McCarty, M.F.; Somcio, R.J.; Stoeltzing, O.; Wey, J.; Fan, F.; Liu, W.; Bucana, C.; Ellis, L.M. Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content. *J. Clin. Investig.* **2007**, *117*, 2114–2122. [[CrossRef](#)]
118. Üçüncü, M.; Serilmez, M.; Sarı, M.; Bademler, S.; Karabulut, S. The Diagnostic Significance of PDGF, EphA7, CCR5, and CCL5 Levels in Colorectal Cancer. *Biomolecules* **2019**, *9*, 464. [[CrossRef](#)]
119. Aryal, B.; Shimizu, T.; Kadono, J.; Furoi, A.; Komokata, T.; Kitazono, I.; Koriyama, C.; Yamakuchi, M.; Hashiguchi, T.; Imoto, Y. Post-resection exhaustion of intra-platelet serotonin: Also an indicator of early hepatocellular carcinoma recurrence? *J. Cancer* **2017**, *8*, 3984–3991. [[CrossRef](#)]
120. Holmes, C.E.; Lewis, J.E.; Schneider, D.J.; Bambace, N.M.; Sharma, D.; Lal, I.; Wood, M.E.; Muss, H.B. Platelet phenotype changes associated with breast cancer and its treatment. *Platelets* **2016**, *27*, 703–711. [[CrossRef](#)]
121. Dirix, L.Y.; Salgado, R.; Weytjens, R.; Colpaert, C.; Benoy, I.; Huget, P.; Van Dam, P.; Prové, A.; Lemmens, J.; Vermeulen, P. Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer. *Br. J. Cancer* **2002**, *86*, 389–395. [[CrossRef](#)]
122. Sallinen, H.; Heikura, T.; Koponen, J.; Kosma, V.M.; Heinonen, S.; Ylä-Herttuala, S.; Anttila, M. Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer. *BMC Cancer* **2014**, *14*, 696. [[CrossRef](#)] [[PubMed](#)]
123. Faried, A.; Mobarak, L.; El Gohary, K.K.; El-deeb, H.H.; El-feky, S.; Ahmed, A.; Zaki, N.A.; Alkhalegy, A.A. Serum levels of Arginase Isoenzyme Activity, Alpha- Fetoprotein-L3 and Endostatin as Biomarkers for Hepatocellular Carcinoma in Egyptian Patients. *Donn. J. Biomed. Res.* **2016**, *3*, 1–5.
124. Wang, Z.H.; Zhu, Z.T.; Xiao, X.Y.; Sun, J. Correlation of serum levels of endostatin with tumor stage in gastric cancer: A systematic review and meta-analysis. *BioMed Res. Int.* **2015**, *2015*, 623939. [[CrossRef](#)] [[PubMed](#)]
125. Cymbaluk-Ploska, A.; Chudecka-Glaz, A.; Pius-Sadowska, E.; Machalilski, B.; Menkiszak, J. Thrombospondin-I concentrations behavior in plasma of patients with ovarian cancer. *Cancer Biomark.* **2017**, *20*, 31–39. [[CrossRef](#)]
126. Rouanne, M.; Adam, J.; Goubar, A.; Robin, A.; Ohana, C.; Louvet, E.; Cormier, J.; Mercier, O.; Dorfmüller, P.; Fattal, S.; et al. Osteopontin and thrombospondin-1 play opposite roles in promoting tumor aggressiveness of primary resected non-small cell lung cancer. *BMC Cancer* **2016**, *16*, 483. [[CrossRef](#)]
127. Wiśniewski, T.; Zyromska, A.; Makarewicz, R.; Zekanowska, E. Osteopontin and angiogenic factors as new biomarkers of prostate cancer. *Urol. J.* **2019**, *16*, 134–140.
128. Drenberg, C.D.; Saunders, B.O.; Wilbanks, G.D.; Chen, R.; Nicosia, R.F.; Kruk, P.A.; Nicosia, S.V. Urinary angiostatin levels are elevated in patients with epithelial ovarian cancer. *Gynecol. Oncol.* **2010**, *117*, 117–124. [[CrossRef](#)]
129. Nocito, A.; Dahm, F.; Jochum, W.; Jae, H.J.; Georgiev, P.; Bader, M.; Graf, R.; Clavien, P.A. Serotonin regulates macrophage-mediated angiogenesis in a mouse model of colon cancer allografts. *Cancer Res.* **2008**, *68*, 5152–5158. [[CrossRef](#)]
130. Kelly, C.M.; Juurlink, D.N.; Gomes, T.; Duong-Hua, M.; Pritchard, K.I.; Austin, P.C.; Paszat, L.F. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: A population based cohort study. *BMJ* **2010**, *340*, 355. [[CrossRef](#)]
131. Alpini, G.; Invernizzi, P.; Gaudio, E.; Venter, J.; Kopriva, S.; Bernuzzi, F.; Onori, P.; Franchitto, A.; Coufal, M.; Frampton, G.; et al. Serotonin metabolism is dysregulated in cholangiocarcinoma, which has implications for tumor growth. *Cancer Res.* **2008**, *68*, 9184–9193. [[CrossRef](#)]

132. Svejda, B.; Kidd, M.; Timberlake, A.; Harry, K.; Kazberouk, A.; Schimmack, S.; Lawrence, B.; Pfragner, R.; Modlin, I.M. Serotonin and the 5-HT7 receptor: The link between hepatocytes, IGF-1 and small intestinal neuroendocrine tumors. *Cancer Sci.* **2013**, *104*, 844–855. [[CrossRef](#)]
133. Müller, K.; Gilbertz, K.P.; Meineke, V. Serotonin and ionizing radiation synergistically affect proliferation and adhesion molecule expression of malignant melanoma cells. *J. Dermatol. Sci.* **2012**, *68*, 89–98. [[CrossRef](#)] [[PubMed](#)]
134. Lübbe, A.S.; Huhnt, W. Microvessel diameters of human colon adenocarcinoma during acute treatment with serotonin. *Int. J. Microcirc. Exp.* **1994**, *14*, 218–225. [[CrossRef](#)] [[PubMed](#)]
135. Dowling, P.; Hughes, D.J.; Larkin, A.M.; Meiller, J.; Henry, M.; Meleady, P.; Lynch, V.; Pardini, B.; Naccarati, A.; Levy, M.; et al. Elevated levels of 14-3-3 proteins, serotonin, gamma enolase and pyruvate kinase identified in clinical samples from patients diagnosed with colorectal cancer. *Clin. Chim. Acta* **2015**, *441*, 133–141. [[CrossRef](#)] [[PubMed](#)]
136. Abdel-Razik, A.; Elhelaly, R.; Elzehery, R.; El-Diasty, A.; Abed, S.; Elhammady, D.; Tawfik, A. Could serotonin be a potential marker for hepatocellular carcinoma? A prospective single-center observational study. *Eur. J. Gastroenterol. Hepatol.* **2016**, *28*, 599–605. [[CrossRef](#)] [[PubMed](#)]
137. Jungwirth, N.; Haerberle, L.; Schrott, K.M.; Wullich, B.; Krause, F.S. Serotonin used as prognostic marker of urological tumors. *World J. Urol.* **2008**, *26*, 499–504. [[CrossRef](#)] [[PubMed](#)]
138. Mannucci, P.M.; Cattaneo, M.; Teresa Canciani, M.; Maniezzo, M.; Vaglini, M.; Cascinelli, N. Early presence of activated (“exhausted”) platelets in malignant tumors (breast adenocarcinoma and malignant melanoma). *Eur. J. Cancer Clin. Oncol.* **1989**, *25*, 1413–1417. [[CrossRef](#)]
139. Crescente, M.; Menke, L.; Chan, M.V.; Armstrong, P.C.; Warner, T.D. Eicosanoids in platelets and the effect of their modulation by aspirin in the cardiovascular system (and beyond). *Br. J. Pharmacol.* **2019**, *176*, 988–999. [[CrossRef](#)]
140. Guo, Y.; Zhang, W.; Giroux, C.; Cai, Y.; Ekambaram, P.; Dilly, A.K.; Hsu, A.; Zhou, S.; Maddipati, K.R.; Liu, J.; et al. Identification of the orphan G protein-coupled receptor GPR31 as a receptor for 12-(S)-hydroxyeicosatetraenoic acid. *J. Biol. Chem.* **2011**, *286*, 33832–33840. [[CrossRef](#)]
141. Porro, B.; Songia, P.; Squellerio, I.; Tremoli, E.; Cavalca, V. Analysis, physiological and clinical significance of 12-HETE: A neglected platelet-derived 12-lipoxygenase product. *J. Chromatogr. B Anal. Technol. Biomed. Life Sci.* **2014**, *964*, 26–40. [[CrossRef](#)]
142. Rauzi, F.; Kirkby, N.S.; Edin, M.L.; Whiteford, J.; Zeldin, D.C.; Mitchell, J.A.; Warner, T.D. Aspirin inhibits the production of proangiogenic 15(S)-HETE by platelet cyclooxygenase-1. *FASEB J.* **2016**, *30*, 4256–4266. [[CrossRef](#)] [[PubMed](#)]
143. Kanikarla-Marie, P.; Kopetz, S.; Hawk, E.T.; Millward, S.W.; Sood, A.K.; Gresele, P.; Overman, M.; Honn, K.; Menter, D.G. Bioactive lipid metabolism in platelet “first responder” and cancer biology. *Cancer Metastasis Rev.* **2018**, *37*, 439–454. [[CrossRef](#)] [[PubMed](#)]
144. Tsoi, K.K.F.; Ho, J.M.W.; Chan, F.C.H.; Sung, J.J.Y. Long-term use of low-dose aspirin for cancer prevention: A 10-year population cohort study in Hong Kong. *Int. J. Cancer* **2019**, *145*, 267–273. [[CrossRef](#)] [[PubMed](#)]
145. Lin, Y.C.; Chen, C.C.; Chen, W.M.; Lu, K.Y.; Shen, T.L.; Jou, Y.C.; Shen, C.H.; Ohbayashi, N.; Kanaho, Y.; Huang, Y.L.; et al. LPA1/3 signaling mediates tumor lymphangiogenesis through promoting CRT expression in prostate cancer. *Biochim. Biophys. Acta-Mol. Cell Biol. Lipids* **2018**, *1863*, 1305–1315. [[CrossRef](#)] [[PubMed](#)]
146. Li, Y.Y.; Zhang, W.C.; Zhang, J.L.; Zheng, C.J.; Zhu, H.; Yu, H.M.; Fan, L.M. Plasma levels of lysophosphatidic acid in ovarian cancer versus controls: A meta-analysis. *Lipids Health Dis.* **2015**, *14*, 72. [[CrossRef](#)] [[PubMed](#)]
147. Yagi, T.; Shoaib, M.; Kuschner, C.; Nishikimi, M.; Becker, L.B.; Lee, A.T.; Kim, J. Challenges and inconsistencies in using lysophosphatidic acid as a biomarker for ovarian cancer. *Cancers* **2019**, *11*, 520. [[CrossRef](#)]
148. Mezouar, S.; Mege, D.; Darbousset, R.; Farge, D.; Debourdeau, P.; Dignat-George, F.; Panicot-Dubois, L.; Dubois, C. Involvement of platelet-derived microparticles in tumor progression and thrombosis. *Semin. Oncol.* **2014**, *41*, 346–358. [[CrossRef](#)]
149. Goubran, H.A.; Kotb, R.R.; Stakiw, J.; Emara, M.E.; Burnouf, T. Regulation of Tumor Growth and Metastasis: The Role of Tumor Microenvironment. *Cancer Growth Metastasis* **2014**, *7*, CGM-S11285. [[CrossRef](#)]
150. Goubran, H.A.; Stakiw, J.; Radosevic, M.; Burnouf, T. Platelet-cancer interactions. *Semin. Thromb. Hemost.* **2014**, *40*, 296–305.
151. Rak, J. Microparticles in cancer. *Semin. Thromb. Hemost.* **2010**, *36*, 888–906. [[CrossRef](#)]

152. Lazar, S.; Goldfinger, L.E. Platelet Microparticles and miRNA Transfer in Cancer Progression: Many Targets, Modes of Action, and Effects Across Cancer Stages. *Front. Cardiovasc. Med.* **2018**, *5*, 13. [[CrossRef](#)] [[PubMed](#)]
153. Janowska-Wieczorek, A.; Wysoczynski, M.; Kijowski, J.; Marquez-Curtis, L.; Machalinski, B.; Ratajczak, J.; Ratajczak, M.Z. Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. *Int. J. Cancer* **2005**, *113*, 752–760. [[CrossRef](#)] [[PubMed](#)]
154. Prokopi, M.; Pula, G.; Mayr, U.; Devue, C.; Gallagher, J.; Xiao, Q.; Boulanger, C.M.; Westwood, N.; Urbich, C.; Willeit, J.; et al. Proteomic analysis reveals presence of platelet microparticles in endothelial progenitor cell cultures. *Blood* **2009**, *114*, 723–732. [[CrossRef](#)]
155. Zarà, M.; Guidetti, G.; Boselli, D.; Villa, C.; Canobbio, I.; Seppi, C.; Visconte, C.; Canino, J.; Torti, M. Release of Prometastatic Platelet-Derived Microparticles Induced by Breast Cancer Cells: A Novel Positive Feedback Mechanism for Metastasis. *TH Open* **2017**, *1*, e155–e163. [[CrossRef](#)] [[PubMed](#)]
156. Gasperi, V.; Vangapandu, C.; Savini, I.; Ventimiglia, G.; Adorno, G.; Catani, M.V. Polyunsaturated fatty acids modulate the delivery of platelet microvesicle-derived microRNAs into human breast cancer cell lines. *J. Nutr. Biochem.* **2019**, *74*, 108242. [[CrossRef](#)] [[PubMed](#)]
157. Provost, P. The clinical significance of platelet microparticle-associated microRNAs. *Clin. Chem. Lab. Med.* **2017**, *55*, 657–666. [[CrossRef](#)]
158. Liang, H.; Yan, X.; Pan, Y.; Wang, Y.; Wang, N.; Li, L.; Liu, Y.; Chen, X.; Zhang, C.Y.; Gu, H.; et al. MicroRNA-223 delivered by platelet-derived microvesicles promotes lung cancer cell invasion via targeting tumor suppressor EBP41L3. *Mol. Cancer* **2015**, *14*, 58. [[CrossRef](#)]
159. Cao, L.; Zhang, X.; Cao, F.; Wang, Y.; Shen, Y.; Yang, C.; Uzan, G.; Peng, B.; Zhang, D. Inhibiting inducible miR-223 further reduces viable cells in human cancer cell lines MCF-7 and PC3 treated by celastrol. *BMC Cancer* **2015**, *15*, 873. [[CrossRef](#)]
160. Pinatol, E.M.; Orso, F.; Penna, E.; Cimino, D.; Elia, A.R.; Circosta, P.; Dentelli, P.; Brizzi, M.F.; Provero, P.; Taverna, D. miR-223 is a coordinator of breast cancer progression as revealed by bioinformatics predictions. *PLoS ONE* **2014**, *9*, e84859. [[CrossRef](#)]
161. Sun, X.; Li, Y.; Zheng, M.; Zuo, W.; Zheng, W. MicroRNA-223 increases the sensitivity of triple-negative breast cancer stem cells to TRAIL-induced apoptosis by targeting HAX-1. *PLoS ONE* **2016**, *11*, e0162754. [[CrossRef](#)]
162. Shi, L.; Fisslthaler, B.; Zippel, N.; Frömel, T.; Hu, J.; Elgheznavy, A.; Heide, H.; Popp, R.; Fleming, I. MicroRNA-223 antagonizes angiogenesis by targeting β 1 integrin and preventing growth factor signaling in endothelial cells. *Circ. Res.* **2013**, *113*, 1320–1330. [[CrossRef](#)] [[PubMed](#)]
163. Tang, M.; Jiang, L.; Lin, Y.; Wu, X.; Wang, K.; He, Q.; Wang, X.; Li, W. Platelet microparticle-mediated transfer of miR-939 to epithelial ovarian cancer cells promotes epithelial to mesenchymal transition. *Oncotarget* **2017**, *8*, 97464–97475. [[CrossRef](#)] [[PubMed](#)]
164. Pan, B.; Chen, Y.; Song, H.; Xu, Y.; Wang, R.; Chen, L. Mir-24-3p downregulation contributes to VP16-DDP resistance in small-cell lung cancer by targeting ATG4A. *Oncotarget* **2015**, *6*, 317–331. [[CrossRef](#)] [[PubMed](#)]
165. Michael, J.V.; Wurtzel, J.G.T.; Mao, G.F.; Rao, A.K.; Kolpakov, M.A.; Sabri, A.; Hoffman, N.E.; Rajan, S.; Tomar, D.; Madesh, M.; et al. Platelet microparticles infiltrating solid tumors transfer miRNAs that suppress tumor growth. *Blood* **2017**, *130*, 567–580. [[CrossRef](#)] [[PubMed](#)]
166. Sorrentino, A.; Liu, C.G.; Addario, A.; Peschle, C.; Scambia, G.; Ferlini, C. Role of microRNAs in drug-resistant ovarian cancer cells. *Gynecol. Oncol.* **2008**, *111*, 478–486. [[CrossRef](#)] [[PubMed](#)]
167. Zhu, H.; Wu, H.; Liu, X.; Evans, B.R.; Medina, D.J.; Liu, C.G.; Yang, J.M. Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. *Biochem. Pharmacol.* **2008**, *76*, 582–588. [[CrossRef](#)]
168. Anene, C.; Graham, A.M.; Boyne, J.; Roberts, W. Platelet microparticle delivered microRNA-Let-7a promotes the angiogenic switch. *Biochim. Biophys. Acta-Mol. Basis Dis.* **2018**, *1864*, 2633–2643. [[CrossRef](#)]
169. Miao, X.; Rahman, M.F.U.; Jiang, L.; Min, Y.; Tan, S.; Xie, H.; Lee, L.; Wang, M.; Malmström, R.E.; Lui, W.O.; et al. Thrombin-reduced miR-27b attenuates platelet angiogenic activities in vitro via enhancing platelet synthesis of anti-angiogenic thrombospondin-1. *J. Thromb. Haemost.* **2018**, *16*, 791–801. [[CrossRef](#)]
170. Wang, C.Z.; Yuan, P.; Li, Y. miR-126 regulated breast cancer cell invasion by targeting ADAM9. *Int. J. Clin. Exp. Pathol.* **2015**, *8*, 6547–6553. [[PubMed](#)]
171. Liu, B.; Peng, X.C.; Zheng, X.L.; Wang, J.; Qin, Y.W. MiR-126 restoration down-regulate VEGF and inhibit the growth of lung cancer cell lines in vitro and in vivo. *Lung Cancer* **2009**, *66*, 169–175. [[CrossRef](#)]

172. Penson, R.T.; Oliva, E.; Skates, S.J.; Glyptis, T.; Fuller, A.F.; Goodman, A.; Seiden, M.V. Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: A study in serial samples. *Gynecol. Oncol.* **2004**, *93*, 98–106. [[CrossRef](#)] [[PubMed](#)]
173. Nam, E.J.; Yoon, H.; Kim, S.W.; Kim, H.; Kim, Y.T.; Kim, J.H.; Kim, J.W.; Kim, S. MicroRNA expression profiles in serous ovarian carcinoma. *Clin. Cancer Res.* **2008**, *14*, 2690–2695. [[CrossRef](#)] [[PubMed](#)]
174. Hoppe, R.; Achinger-Kawecka, J.; Winter, S.; Fritz, P.; Lo, W.Y.; Schroth, W.; Brauch, H. Increased expression of miR-126 and miR-10a predict prolonged relapse-free time of primary oestrogen receptor-positive breast cancer following tamoxifen treatment. *Eur. J. Cancer* **2013**, *49*, 3598–3608. [[CrossRef](#)] [[PubMed](#)]
175. Dovizio, M.; Bruno, A.; Contursi, A.; Grande, R.; Patrignani, P. Platelets and extracellular vesicles in cancer: Diagnostic and therapeutic implications. *Cancer Metastasis Rev.* **2018**, *37*, 455–467. [[CrossRef](#)]
176. Kim, H.K.; Song, K.S.; Park, Y.S.; Kang, Y.H.; Lee, Y.J.; Lee, K.R.; Kim, H.K.; Ryu, K.W.; Bae, J.M.; Kim, S. Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: Possible role of a metastasis predictor. *Eur. J. Cancer* **2003**, *39*, 184–191. [[CrossRef](#)]
177. Wang, C.C.; Tseng, C.C.; Chang, H.C.; Huang, K.T.; Fang, W.F.; Chen, Y.M.; Yang, C.T.; Hsiao, C.C.; Lin, M.C.; Ho, C.K.; et al. Circulating microparticles are prognostic biomarkers in advanced non-small cell lung cancer patients. *Oncotarget* **2017**, *8*, 75952–75967. [[CrossRef](#)]



© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).



Review

Platelet Concentrates in Musculoskeletal Medicine

Erminia Mariani ^{1,2,*} and Lia Pulsatelli ¹

¹ Laboratorio di Immunoreumatologia e rigenerazione tissutale, IRCCS Istituto Ortopedico Rizzoli, Via di Barbiano 1/10, 40136 Bologna, Italy; lia.pulsatelli@ior.it

² Dipartimento di Scienze Mediche e Chirurgiche, Alma Mater Studiorum-University of Bologna, Via Massarenti 9, 40138 Bologna, Italy

* Correspondence: erminia.mariani@unibo.it; Tel.: +39-051-6366803

Received: 16 December 2019; Accepted: 6 February 2020; Published: 16 February 2020

Abstract: Platelet concentrates (PCs), mostly represented by platelet-rich plasma (PRP) and platelet-rich fibrin (PRF) are autologous biological blood-derived products that may combine plasma/platelet-derived bioactive components, together with fibrin-forming protein able to create a natural three-dimensional scaffold. These types of products are safely used in clinical applications due to the autologous-derived source and the minimally invasive application procedure. In this narrative review, we focus on three main topics concerning the use of platelet concentrate for treating musculoskeletal conditions: (a) the different procedures to prepare PCs, (b) the composition of PCs that is related to the type of methodological procedure adopted and (c) the clinical application in musculoskeletal medicine, efficacy and main limits of the different studies.

Keywords: platelet-rich plasma; platelet-rich fibrin; preparation; composition; musculoskeletal diseases

1. Introduction

In the last 10 years, autologous biological blood-derived products have been largely investigated as useful therapeutic tools for treating musculoskeletal conditions (such as osteoarthritis, muscle injuries, tendinopathies and intervertebral disc degeneration) [1–3]. Platelet concentrates (PCs), mostly represented by platelet-rich plasma (PRP) and platelet-rich fibrin (PRF), are included in this type of biology-oriented autologous therapeutic strategy that may combine plasma/platelet-derived bioactive components (cytokines, chemokines, growth-factors and enzymes) with fibrin-forming protein able to create a natural three-dimensional scaffold [4].

This approach allows us to deliver biomolecules released by a concentrated pool of activated platelets to the target tissue site of injury, thus effectively contributing to the modulation of inflammatory process, angiogenesis and immune response, as well as promoting the healing and repair of injured tissues [5,6]. Moreover, biological blood-derived products have been recognized to have antimicrobial effects, such as being able to inhibit and/or to inactivate different bacterial strains [6–8].

The potential clinical application of these biologic products in musculoskeletal medicine relies on their capability of modulating the joint environment and their beneficial role in reducing the local inflammation and promoting cartilage and synovium anabolism [5,9–12].

These types of therapeutic strategies provide advantages in clinical applications due to the autologous-derived source, safety profile, easiness to obtain and the minimally invasive application procedure. On the other hand, clinical efficacy is still controversial, and solid evidence and consensus supporting the therapeutic application are still to be achieved.

Indeed, there are already some issues to be addressed concerning the high variability of platelet concentrate products, which mainly depends on patients' characteristics (age, sex, circadian rhythms and drug regimen) [13–16], as well as on the lack of standardized methods for platelet isolation/collection/activation and on heterogeneity among therapeutic protocols applied in clinical practice.

In this narrative review, we focus on three main challenging topics concerning the use of platelet concentrate for treating musculoskeletal conditions: (a) the different procedures to prepare platelet concentrate, (b) the composition of these products that is mainly related to the type of methodological procedure adopted and (c) the clinical application in musculoskeletal conditions and level of efficacy.

Short History of Platelet Concentrates

The concept of PRP originally was developed in transfusion medicine. In this field, the PRP term was used in 1954 by Kingsley [17] to identify thrombocyte concentrate for treating patients with severe thrombopenia.

The history of the techniques to obtain blood-derived products for improving tissue healing started in 1970 with the studies of Matras [18] on fibrin glue use in a rat model.

Subsequently, an autologous product termed “platelet–fibrinogen–thrombin mixture” was developed, including, in fibrin glue, a significant concentration of platelets, in order to reinforce the fibrin polymerization [19].

In the following years, the role of platelets in supporting tissue healing was confirmed and clinically demonstrated by using a blood-derived product called “platelet-derived wound healing factors or formula-PDWHF” [20] for treating skin ulcers.

About ten years later, Whitman et al. [21] published a clinical study on the results obtained in oral and maxillofacial surgery by using a “platelet gel” obtained by a gradient density cell separator.

However, the term of PRP in regenerative medicine associated to the notion of platelet growth factors to promote tissue healing was truly introduced by Marx et al. in 1998 [22], in a study that reported the effect of platelet-rich product on bone healing in maxillofacial surgery.

After these publications, the term “PRP” was generically associated with all the multiple formulations of platelet concentrates. Afterward, an end-product characterized by a fibrin matrix denser and more stable than in other PRP formulations was produced and called platelet-rich fibrin matrix (PRFM) or pure platelet-rich fibrin (P-PRF).

In 2001, a different form of platelet concentrates was proposed and identified as leukocyte- and platelet-rich fibrin (L-PRF) [23]. These preparations are organized as a high-density fibrin and were considered as a “second generation” platelet concentrates. This family of platelet concentrates appears to be particularly suitable for oral clinical application.

2. Preparation Procedure

2.1. Platelet-Rich Plasma

PRP is obtained from autologous blood by using commercial kits or “in-house techniques”, aiming to provide a product characterized by a supra-physiological platelet concentration that can be used as liquid or activated gel form [14,24–26].

Despite the broad spectrum of protocols for PRP preparation, a common sequence of key steps [27,28] can be identified involving peripheral blood drawing from the patients by venipuncture, blood centrifugation to retrieve platelet-enriched fraction and platelet stimulation to release bioactive molecules.

In each of these phases, potential sources of variability may be identified, mainly ascribed to volume of blood samples drawn, type of anticoagulant, centrifugation protocols, material of collection tubes and type of platelet-activating agents [14,24].

The great variability in the different procedures results in a wide heterogeneity among PRP preparations in terms of platelet concentration, presence/absence of leukocytes and erythrocytes, and ultimately in terms of biological potential [14,24].

2.1.1. Anticoagulants

There are multiple choices of anticoagulants (ethylene diamine tetra-acetic acid-EDTA, citrate dextrose-A, tri-sodium citrate and heparin) that are used for blood collection and that can differently affect PRP quality [29].

Lei and colleagues [30] investigated the effect of heparin, citrate, acid citrate dextrose (ACD) and citrate-theophylline-adenosine-dipyridamole (CTAD) on platelet-rich plasma quality, to determine the appropriate anticoagulants for PRP production.

ACD and CTAD appear to be more effective compared to heparin and citrate in maintaining the integrity of platelet structures and in preventing their spontaneous activation. ACD-PRP and CTAD-PRP released more TGF-beta1 and significantly increased the proliferation rate of human marrow stromal cells compared to heparin- and citrate-PRP, thus showing ACD and CTAD appropriate anticoagulants for PRP production [30].

An animal model study, aiming to investigate the influence of sodium citrate and ACD- solution A anticoagulants on cell count and growth factor concentration in pure platelet-rich gel supernatants, reported an increased number of platelets and leukocytes in sodium citrate PRP compared to homologous acid–citrate–dextrose solution A PRP fraction, but no difference concerning growth factor concentration [31].

Another “in vitro” study explored the effects of sodium citrate (SC), EDTA, or anticoagulant ACD- solution A, on PRP characteristics and on mesenchymal stromal cell (MSC) culture [29]. A higher platelet count was observed in blood collected with EDTA, even if an increase of mean platelet volume has been reported after the two centrifugation steps. Conversely, following the centrifugation procedure, platelet yield was higher in SC product. SC and ACD showed similar efficacy in inducing MSC proliferation [29].

These findings support the most frequent use of citrate-based anticoagulants for PRP preparations [29].

A very recent comparative study [32] evaluated the effects of EDTA, heparin sodium (HS) and SC on PRP quality and on bone marrow stem cells' functionality.

Compared to HS and SC, EDTA has been shown to preserve platelet structure, minimize their spontaneous activation and sustain growth factor release for a more extended time.

Overall, these findings underline that also the choice of the best anticoagulant represents an open issue to address for optimizing PRP formulation.

To overcome this criticism, a study published in 2018 described a novel approach of PRP preparation without any additive, named temperature controlled PRP (t-PRP), by which the coagulation was previously inhibited in hypothermic environment. In this study, t-PRP was compared to PRP obtained by ACD-A blood.

Overall, t-PRP showed a more physiologic pH, higher platelet yield, slower release and degradation of growth factors. Furthermore, animal model experiments demonstrated that t-PRP was able to promote wound healing [33].

2.1.2. Isolation Protocols

PRP can be obtained according to two basic protocols designed as plasma-based and buffy-coat-based procedures [14,34]. Plasma-based methods retrieve platelets, while minimizing leukocyte and erythrocyte fractions. For this purpose, a slower and shorter spin regimen is applied in plasma-based protocols. Platelets concentration is usually twofold to threefold increased above baseline whole blood levels (300,000 to 500,000 platelets/ μ L) [14,34].

Alternatively, the main goal of protocols for buffy-coat systems is to maximize platelet isolation during the centrifugation procedure, by high spin rates and long spin regimens. PRP obtained by this method is characterized by a high platelet recovery, increasing about threefold to eightfold compared to baseline levels (500,000 to 1,500,000 platelets/ μ L) and by the presence of variable concentrations of leukocytes and erythrocytes [14,34]. This type of PRP preparation is generally called leucocyte-rich PRP (L-PRP).

Specific protocols developed to obtain PRP by using either a commercial device/kit or manual/homemade procedures derive from multiple modifications of these two basic protocols (plasma-based and buffy-coat-based).

Most of commercially available systems produce PRP by buffy-coat-based method [35], and several comparative studies were reported, aiming to analyze different common commercial separation systems, essentially evaluating final PRP products in terms of platelets concentrations and growth factors release [24,35] (Table 1).

Table 1. Centrifugation protocol and composition of platelet-rich plasma (PRP) produced by common commercial PRP systems.

| Device | Centrifugation Force (g) | Centrifugation Time (min) | Platelet Concentration $\times 10^3/\mu\text{L}$ | Leukocyte Concentration $\times 10^3/\mu\text{L}$ | PDGF-AB pg/mL | TGF- β 1 pg/mL | VEGF pg/mL |
|------------------|--------------------------|---------------------------|--|---|-----------------|----------------------|------------|
| ACP | 350 | 5 | 500 | <1 | 3133–22,180 | 456–73,867 | 59–246,78 |
| GPSIII | 1100 | 15 | 273.6–1560 | 15–52 | 5900–65,000 | 2647–153,863 | 1304–1991 |
| Cascade | 1100/1450 | 6/15 | 600–2900 | <1 | 6100–13,300 | 20–180 | 0–600 |
| SmartPrep | 1250/1050 | 14/7–10 | 800–2600 | <1–20 | 123,100–293,500 | 22,400–132,000 | / |
| Magellan | 610/1240 | 4/6 | 600–1500 | 8–35 | 23,700–45,100 | 100–300 | 400–2000 |
| JP2000 | 1000/800 | 6/8 | 850 | 26.1 | 93,500 | 1563 | 42,000 |
| GLO | 1800/1800 | 3/6 | 891 | 10 | 67,300 | 1329 | 39,000 |
| KIOCERA | 600/2000 | 7/5 | 1312 | 14 | 76,200 | 1508.2 | 44,000 |
| Selphyl | 525 | 15 | 88 | 0.3 | 12,200 | 384 | 28,200 |
| MyCells | 2054 | 7 | 800 | 4.9 | 72,200 | 1328 | 39,200 |
| Dr Shin's System | 1720 | 8 | 650 | 14.9 | 37,000 | 938 | 31,000 |

Data (cumulative range or average) were obtained from the following references: [24,35,36].

As expected, overall findings underlined that commercially buffy-coat-based systems (such as SmartPrep, GPS III and Magellan systems) yield higher concentrations of platelets and leukocytes compared to plasma-based systems (such as ACP and Cascade). Among buffy-coat systems, generally, GPS III preparations demonstrated the highest concentration of platelets and leukocytes [35].

Wide variations of centrifugal force and total centrifugation time among the different common commercial systems were described, respectively, ranging from about 350 to 2000 g, and from 5 to 20 min [35]. The majority of the systems use a dual-spin method; the first centrifugation usually has a lower speed compared to the second one [24,35].

Conflicting results were reported concerning optimal centrifugation rate to maximize platelet concentration, avoiding their activation or damage. Indeed, there is evidence underlining that increasing centrifugation force results in higher platelet concentration [37]. Conversely, other studies reported an inverse relationship between platelet yields and gravitational force [38,39]; furthermore, an elevated centrifugal speed could induce platelet activation [40].

Very recently, Croisè et al. [40] performed a literature review, aiming to check multiple studies focused on PRP protocol optimization. Fourteen included studies were commented upon, and each of them suggested different centrifugation procedures in terms of speed and duration time, number of centrifugations and, consequently, variable platelet concentration enrichments (from no enrichment to about 8.5 times more than peripheral blood). Overall these results underline that, to date, there is no consensus on the optimal centrifugation regimen to obtain a good-quality PRP, in terms of best platelet yields, avoiding structural and/or functional alterations and optimal relative concentration of blood components.

Recently, in order to obtain a standardized PRP formulation, Gato-Calvo et al. [41] developed a novel methodology, defining the optimal content of PRP, based on absolute platelet concentration. This approach allows us to obtain an end-product not influenced by the variability of the donor basal platelet counts, thus improving the reproducibility of PRP effects.

Another source of variability may derive from the material of blood-collection tubes. Some studies have demonstrated that PCs obtained by blood collected in glass or silica-coated tubes presented different buffy-coat morphology, fibrin architecture and platelet/leukocyte distribution in the PC matrix [42]. Furthermore, silica micro-particles may be released by tube walls during centrifugation procedures, entrapped in PC matrix, thus modifying platelet distribution in the end-product [43].

2.1.3. Activation Process

Activation triggers two responses during PRP preparation: the release of the bioactive molecules stored in platelet alpha-granules, and the matrix formation by fibrinogen cleavage [44]. Clot formation entraps released growth factors (GFs), thus enabling bioactive molecules to be delivered and confined at the injured target site.

Activation process may be induced by endogenous and exogenous factors. Among exogenous factors, the most common activators are thrombin, calcium chloride and a mixture of calcium chloride plus thrombin [14,34,45]. Endogenous activation relies on the exposure of native collagen or other coagulation factor (such as adenosine diphosphate-ADP, thrombospondin and platelet-activator factor), spontaneously inducing clot formation at injured site [45].

In general, thrombin triggers a rapid platelet aggregation and stimulates a fast release of GFs [14,34,46]. Calcium chloride and collagen sustain a slower long-term release [34,46,47]. Furthermore, some findings reported that collagen activation results in a lower amount of released GFs compared to thrombin and calcium chloride [47].

A very recent study compared the effects of three different activation factors, thrombin, collagen I and ADP, on PRP quality and on bone marrow stem cells' (BMSCs) functionality. Collagen I-PRP has been shown to induce the most rapid increasing of BMSC number compared to the rate observed with ADP- or thrombin-activated PRP. In addition, BMSC seeded in Collagen-I-activated PRP induced a significantly higher gene expression of osteogenic differentiation markers, osteocalcin

and RUNX2, compared to thrombin and ADP. Thrombin induced a rapid and direct GF release, while collagen-I-activated PRP showed a sustained and slow GF release. The lowest total release was observed for ADP-activated PRP [32].

The different kinetic release is a crucial issue that might influence the availability of bioactive molecules, so affecting treatment outcome. Indeed, given GFs' short half-life (from minutes to hours), if they are not promptly used upon platelet release, their degradation may occur before additional receptors, that are involved in the repair process, become available on cell surfaces [34].

Photo-activation has been suggested as an alternative method to trigger platelet activation: a very recent paper [48] described in vitro characterization of platelet photo-activation (polychromatic light source, in the range near-infrared region), in comparison with resting platelets and calcium chloride mediated PRP activation. That study showed that photo-activation of PRP induced a significantly more prolonged release and higher amount of platelet-derived growth factor (PDGF), basic fibroblast growth factor (FGF), and transforming growth factor (TGF)-beta than PRP activated with calcium chloride. Future clinical studies should be performed to verify the potential of using the photo-activation approach in PRP formulation.

2.2. Platelet-Rich Fibrin

This type of PC essentially includes two categories of different preparations organized as a high-density fibrin solid form: leukocyte-poor or pure platelet-rich fibrin (P-PRF) and leukocyte- and platelet-rich fibrin (L-PRF) [25,49]

Concerning P-PRF preparation, there is only one formulation, commercially known as Fibrinet (Platelet Rich Fibrin Matrix-PRFM, Cascade medical, Wayne, NJ, USA) [25,49]. P-PRF is obtained by a double-centrifugation method analogous to other PRP protocol, but it differs since the clotting phase is a dynamic process occurring during the second centrifugation, after adding CaCl₂ [25,49].

L-PRF is a leukocyte-rich product, and compared to PRP, L-PRF preparation is easier and lacks biochemical modifications (no exogenous activation or anticoagulant are required), and unlike PRP, PRF end-products are characteristically organized in tridimensional architecture [25,49].

L-PRF protocol was developed by Choukroun et al. [23] as an open-access technique, based on one-step centrifugation without anticoagulant and blood activators. L-PRF is considered to be a second-generation platelet concentrate [25,50]. Briefly, venous blood collected in glass tube without anticoagulants is centrifuged at low speed, and clot formation is immediately triggered. Three layers become evident after centrifugation: the red blood cells (RBCs) bottom layer, a PRF clot in the middle and the acellular plasma top layer [50].

This procedure allows to harvest almost all the platelets and more than 50% of the leukocytes from the peripheral blood [50]. L-PRF clot appears to be organized in a strong fibrin architecture and presents a specific tridimensional distribution of the platelets and leukocytes [50].

The original open-access experimental method has evolved into a regulated medical device system and is marketed with CE/FDA clearance (Intra-Lock, Boca-Raton, FL, USA). This system is the only certificated L-PRF system available on the market, and it uses the original protocol and devices [51]. This method shows a high efficiency in platelet and leukocyte collection and in leukocyte preservation [25].

Many variations of the original method were proposed, using different centrifuges and/or different protocols. These modifications result in modified-PRF product compared to the original L-PRF.

P-PRF procedure is more expensive and complex compared to L-PRF protocol. Furthermore, this latter procedure allows to simultaneously obtain a large number of end-products [25].

To the best of our knowledge only one paper [52] compared PRFM and PRF products, in terms of growth factor release. In this study, PRFM and PRF were obtained by "home-made" protocols and appeared to have a different kinetic release. PRFM presented an early robust boost of growth factors, while PRF release was more gradual and constant up to 23 days. On the contrary, Lucarelli et al. [53] has shown that Fibrinet PRFM releases elevated levels of growth factors (such as PDGF, TGFβ and

VEGF) in the first 24 h, whereas other growth factors, such as bone morphogenic protein (BMP)-2 and -7 were undetectable.

Conversely, L-PRF products sustained a large growth factor release for up to seven days [50]. Interestingly, BMP-2 was detected in L-PRF releasate strengthening the regenerative potential of this PC [51]. It is hypothesized that the presence of leukocytes may have a relevant impact on the amount and the pattern of the released growth factors, and a potential synergistic effect between leukocytes and platelets has been suggested [25,50,51].

Centrifuge characteristics and centrifugation protocols have been shown to impact fibrin architecture, cellular distribution and growth factor release. Therefore, various PRF preparations could be associated to different biological profile and clinical potential [51]. Up to now, the different PRF preparations are not clearly characterized, and further investigations on the effects of protocol modifications need to be provided.

3. Classification Systems

The heterogeneity of PC preparation methods can impact on the functional characteristics and on the potential therapeutic efficacy of the final products, giving each PC formulation unique properties. The majority of the studies do not provide a full characterization of the various PC composition, so a reliable comparison among studies still remains a challenging issue [54].

Several classification systems (Table 2) have been developed over the years in attempt to help comparison among studies and to foster standardization of PC preparation process. However currently, no consensus on classification systems has yet been achieved [54].

Table 2. Summary of classification systems for platelet concentrates (PCs).

| Study | Classification | Parameters |
|---|--|--|
| Dohan Ehrenfest et al. (2009) [25] (2012, 2014) [49,55] | Pure PRP, Leukocyte-rich PRP; Pure PRF, Leukocyte-rich PRF | <ul style="list-style-type: none"> • Leukocyte content • Presence/absence of fibrin |
| DeLong et al. (2012) [34] | PAW (Platelet Activation, White blood cells) | <ul style="list-style-type: none"> • Platelet absolute number (from baseline to above $1250 \times 10^3/\mu\text{L}$) • Activation method • White Blood Cells and neutrophil content (above/below baseline) |
| Mishra et al. (2012) [56] | Sports medicine classification of platelet rich plasma. | <ul style="list-style-type: none"> • Platelet concentration (< or ≥ 5 times baseline) • White Blood Cell presence/absence • Activation or no activation prior to application |
| Mautner et al. (2015) [57] | PLRA (Platelet Leukocyte Red blood cells and activation) | <ul style="list-style-type: none"> • Platelet count (absolute number/μL) • Leukocyte content (as positive/negative) • Percentage of neutrophils • Red Blood Cells contents (as positive/negative) • Activation (yes or no for exogenous activation) |

Table 2. Cont.

| Study | Classification | Parameters |
|----------------------------|---|--|
| Magalon et al. (2012) [58] | DEPA (Dose of platelet Efficiency, Purity and activation) | <ul style="list-style-type: none"> • Dose (platelet number × PRP volume) • Efficiency (proportion of platelet recovery) • Purity (proportion of platelet compared with Red Blood Cells and leukocytes) • Exogenous activation (yes/no) |
| Lana et al. (2017) [59] | MARSPILL (Method, Activation, Red blood cells, Spin, Platelets, Image guidance, Leukocytes and Light activation) | <ul style="list-style-type: none"> • Method (automated manner or manually) • Number of spins • Platelet concentration (Fold basal) • Leukocyte content (< or ≥15 times baseline) • Red Blood Cell content (< or >baseline) • Photo-activation (yes/no) • Image guidance (yes/no) |
| Harrison P (2018) [60] | ISTH (International Society on Thrombosis and Hemostasis) classification | <ul style="list-style-type: none"> • Activation • Platelet count (<900 × 10³ μL; 900–1700 × 10³ μL; >1700 × 10³ μL) • Preparation method • Leukocyte contents (as positive/negative) • Red Blood Cells contents (as positive/negative) |

4. Composition

4.1. Platelets

The human blood platelet normal concentration ranges from 150,000 to 400,000/μL [61]. There is no consensus on the optimal concentration of platelets in PCs.

Platelet concentration was compared for its healing effect, and different optimal levels were identified for different applications [14,34].

PRP platelet concentration greatly differs in PRP obtained by the various commercial systems.

Plasma-based PRP systems usually contain a platelet concentration between baseline and 3x baseline (less or equal to 750 × 10³ platelets/μL), and they are defined as low-yielding devices (such as ACP, Cascade, Endoret and RegenPrep) [35]. On the other hand, buffy-coat-based systems yield platelet concentration above 3x, ranging from 4x to 6x (greater than 750 × 10³ platelets/μL to 1800 × 10³ platelets/μL). These systems are classified as high-yielded devices that produce PRP (GPS III, SmartPrep and Magellan) [35].

In vitro, in vivo and clinical studies have demonstrated successful results for PRP formulations with both a moderate (2x and 3x) and high platelet concentrations (from 4x to 6x) [14]. In particular, an in vitro study evidenced that the best angiogenic effect of PRP was obtained with 1500 × 10³ platelets/μL, thus underlining the role of platelet concentrations on the clinical application when the increased angiogenesis contributes to the healing process [14,62].

Platelet concentration greater than 6x (>1800 × 10³ platelets/μL) may be detrimental or have side effects [63]. In fact, an excessive platelet amount may lead to cellular apoptosis, downregulation and desensitization of growth factor receptors, resulting in a paradoxical inhibitory effect [34].

Another source of variation is the platelet-counting mode. Indeed, it has been reported that, to achieve accurate platelet count, proper sample preparation is required and manual mode in the hematology analyzer is recommended, because automatic mode, allowing the sample to settle, may underestimate the absolute platelet count [34,64].

4.2. Leukocytes

As previously stated, leukocyte content in PCs depends on PRP preparation procedures.

Plasma-based process reduced leukocyte count up to 22 times the baseline, almost eliminating this cellular fraction. Buffy-coat-based procedures actively concentrate leukocytes from threefold to fivefold the baseline [65]. Furthermore, different buffy-coat methods produce a PRP formulation with different proportions of neutrophils, lymphocytes and monocytes [65]. Indeed, it has recently been reported that different centrifugation regimens, in terms of spin numbers and speed, modified lymphocyte/granulocyte ratio in the final products [66].

The inclusion of leukocytes in PC preparations remains a widely debated concern, as both beneficial and detrimental effects have been suggested.

Deleterious effects are mainly ascribed to leukocyte capacity to release inflammatory cytokines and metallo-proteinases, which can promote pro-inflammatory and catabolic effects on targeted tissue [67–70]. Furthermore, the massive release of reactive oxygen species by neutrophils causes tissue damage, by inhibiting healing process [71,72].

On the other hand, potential beneficial effects rely on leukocyte's role in tissue healing, in regulating inflammatory process [73–75] and in antibacterial activity [76,77] that may switch the inflammatory process toward a regenerative phase.

These potential effects are suggested and corroborated by the following main evidence:

- The presence of leukocytes contributes to potentiate total amount of released GFs [35]. Indeed, several studies have reported a positive correlation between leukocyte count and GF concentration [35,78–80].
- Leukocytes have anti-nociceptive action by releasing anti-inflammatory cytokines (IL-4, IL-10 and IL-13) and opioid peptides (beta-endorphin, Met-enkephalin and dynorphin-A) [25,81].
- Circulating monocytes differentiate into macrophage once they migrate into connective tissue and may switch from M1 (pro-inflammatory) to M2 (anti-inflammatory) phenotype [82,83] in response to micro-environmental signals and stimuli (such as neutrophil-derived micro-vesicles [4,84]).
- M2 macrophages have several functions in tissue remodeling, promoting angiogenesis, cell proliferation and extracellular matrix deposition [83,85], and they may contribute to resolution of inflammation [4].
- Proteinases secreted by leukocytes are able to modulate the activity of secreted growth factors, converting inactive form to active one and contributing to matrix remodeling in tissue healing [71,75].
- Neutrophils are essential for killing bacteria and other microorganisms [86]. Since platelets also contribute to the antibacterial response [6–8], leukocytes may synergize with platelets and potentiate PRP antimicrobial effects.

Furthermore, growing evidence on the relevance of leukocyte–platelet interaction and of their relative proportions in PRP preparation has been reported [4,44,50,66,87]. Indeed, leukocyte–platelet interaction may promote biosynthesis of other factors that facilitate the resolution of inflammation, such as lipoxins that are potent anti-inflammatory proteins able to limit neutrophil activation, so promoting the resolution phase of the healing process [44,88,89].

In addition, the interrelationship between platelets, blood cellular components and fibrin may have a key role in proper platelet function and growth factor release [4,50,87], and the relative platelet/leukocyte and lymphocyte/granulocyte ratios might drive the balance between catabolic and anabolic factors [66].

Therefore, future research efforts should not focalize on the concentrations of single PC component but on the optimal relative combination of platelets, leukocytes, growth factors and fibrin within the final preparation for the different clinical application fields.

4.3. Red Blood Cells

Red Blood Cells (RBCs) can be damaged as a result of high shear force during blood collection or during inadequate centrifugation process, so causing hemolysis with the release of hemoglobin and its degradation products, heme and iron. The presence of these hemolytic-related products lead to several deleterious effects, such as radical oxygen reactions, endothelial dysfunction, vascular endothelium damage, pro-inflammation response and tissue injury [90].

RBC damage also causes the release of migration inhibitory factor (MIF), which has been recognized as a very strong inflammatory cytokine [90]. MIF concentration in whole blood is 1000-fold increased than in plasma. Since leukocytes and platelets have been shown to minimally contribute to MIF concentration, RBCs represent the major reservoir of this factor [91], which is also functionally active [91].

MIF plays a pathophysiological role in promoting and maintaining OA pain [92]. Furthermore, MIF levels in plasma and synovial fluid have been found to be positively correlated to disease severity in knee OA [93]. Blood-induced joint damage has been highlighted by various *in vitro* studies. In fact, blood exposure results in increased synoviocyte cell death and pro-inflammatory mediator production [94], induction of chondrocyte apoptosis and cartilage degradation [95–97].

On the other hand, effects of free heme may be inhibited by its degradation or by specific binding proteins. The heme–heme oxygenase (HO) system is formed after HO-mediated heme degradation. Growing evidence support the protective HO system activity and its effector molecules against oxidative and inflammatory responses and cell damage and suggest that the heme-HO system may represents a novel and important target in the control of wound healing [98–100].

Even if RBC content is reduced or absent in PC preparations, the detrimental effect of RBCs should be addressed for optimization of PC performance.

4.4. Growth Factors

GFs and protein are stored in the platelet alpha-granules and are released by activation of the platelets. Over 300 proteins were identified in the platelet releasate [101].

Multiple pieces of evidence have suggested that platelet-derived growth factor (PDGF), transforming growth factor beta (TGF-beta), vascular endothelial growth factor (VEGF), insulin-like growth factor (IGF) and epidermal growth factor (EGF) are the most crucial factors implicated in tissue repair [102]. PDGF, TGF-beta and VEGF appear to be the most investigated, and the concentration of these GFs is often considered as a marker of PC preparation quality [24,35,102].

In PRP preparations, approximately 70% of platelet growth factors are secreted within the first 10 min following activation, and almost 95% within the first hour [103,104]. Platelets may continue to produce small amounts of growth factors during the residual life span (8–10 days) [103,104]. Conversely, PRF presents a more intense, slow and constant long-term release, up to 5–7 days [50,105].

Together with platelets, leukocytes also contribute to the release of some growth factors, as highlighted by several studies that reported a positive correlation between the amounts of released GFs and the number of leukocytes [35,78,79].

Multiple comparative studies have investigated GF released by PRP obtained by various commercial separation systems. A large heterogeneity in the GF concentrations and kinetic release have been shown when comparing multiple PRP preparations obtained by different commercial separation systems [106].

A recently published review underlined that growth-factor concentrations reported by the different studies appeared to be hardly comparable, due to wide variations of these results, not only among the different systems but also when comparing the same separation systems among the different

studies [35]. This variability may be essentially ascribed to two criticisms: the different commercial kits used for growth-factor dosage [35], and the incomplete removal of platelets and erythrocytes that may impact the results [107]. Due to these limitations, a comparison between studies appears to be barely reliable, not allowing consistent evidence-based results concerning growth factor content profile of different PRP preparations.

Furthermore, the great inter-individual variability of GF concentration needs to be taken into consideration [107,108]. A study performed on a large number of OA patients (n = 105) showed a wide individual variation of PRP growth factors, with a coefficient of variation ranging from 5.30 to 78.45. In particular, basic FGF and TGF-beta1 showed, respectively, the highest and the lowest variation [109].

Concerning PRF, different GF releases by different formulations have been shown. Comparing original L-PRF to modified-PRF formulations, conflicting results were reported. Kobayashi et al. [105] demonstrated that significantly higher GF levels were released by advanced-PRF (A-PRF) compared to original L-PRF. On the other hand, Dohan Ehrenfest et al. [51] reported a much stronger release of GFs from original L-PRF than from A-PRF membrane.

Nowadays, the literature data highlights that biological profiles in terms of content, amount and release kinetics associated to different PCs need to be further investigated, in order to better understand GF potentiality of the various PCs in clinical applications.

5. Clinical Efficacy

5.1. Osteoarthritis

Osteoarthritis (OA) is a debilitating osteo-articular disease, triggered by a trauma to the joint, and it is associated with a progressive erosion of articular cartilage, subchondral bone sclerosis, excessive stiffness and pain.

Numerous clinical trials and case series, carried out using PRP administration in patients with OA, supported PRP for the symptomatic effect, reduction of pain, improvement in the degenerative injuries and safety of administration, but they have not reached an univocal consensus.

5.1.1. Knee Osteoarthritis

Knee OA is a chronic disease of joints that is characterized by pain and progressive disabilities, usually developing as the sufferer ages [110]. The most common treatments, both non-pharmacological and pharmacological, show positive outcomes, but their effectiveness is not long-lasting. Thus, surgical knee replacement is often the last chance for the relief of symptoms [111,112]

One of the first PRP studies establishing the safety of intra-articular use of this autologous preparation dates back to 2008 [113] (Table 3).

Table 3. Evidence of PRP treatment in knee OA (reported by year of study and grouped by treatment).

| Treatment/ Control | Reference | Patient Number | Main Results |
|--------------------------------|--|----------------|--|
| PRGF/HA | Sanchez et al. [113] | 60 | Significantly higher rate of response to PRGF than HA treatment as concerning knee pain, stiffness and physical function scores, up to 24 and 48 weeks |
| | Sanchez et al. [114] Vaquerizo et al. [115] | 176 96 | |
| | Raeissadat et al. [116] | 69 | No difference between PRGF and HA treatments in alleviating pain and improving function |
| PRGF | Wang-Saegusa et al. [117] | 261 | Improvement in function and QoL were described |
| PRGF (1 cycle)/PRGF (2 cycles) | Vaquerizo et al. [118] | 48 | PRGF 2 cycles showed improved stiffness and QoL, but not pain decrease |
| PRP | Kon et al. [119] | 100 | Significant improvement of knee pain, function and QoL during therapy; improvement has been described to last for a short (2 months) or a medium/long period (6–12 months) follow-up and subsequently worsen; however, the improvement remained higher than the basal condition; further improvement at 18 months can be obtained by yearly repetition of PRP injection; better results were obtained in younger patients, lower degree of cartilage degeneration and short disease duration; worse results were observed in over-80-years-old patients; PRP injection was associated with inflammation decrease and anti-ageing physiological function increase; improved symptoms and pain were not dependent on the cartilage damage degree, as determined by MRI |
| | Filardo et al. [120] | 90 | |
| | Gobbi et al. [121] | 50 | |
| | Halpern et al. [122] | 22 | |
| | Gobbi et al. [123] | 93 | |
| | Hassan et al. [124] | 20 | |
| | Bottegoni et al. [125] | 60 | |
| | Chen et al. [126] | 24 | |
| | Huang et al. [127] | 127 | |
| | Fawzy et al. [128] | 60 | |
| Taniguchi et al. [129] | 10 | | |
| Burchard et al. [130] | 59 | | |
| Socuoglu et al. [131] | 42 | | |
| PRP/HA | Cerza et al. [132] | 120 | PRP compared with HA showed better clinical outcomes and QoL; clinical improvement was evident at 3–6 months and up to 12 months of follow-up; PRP treatment was effective in initial stages/low grade of knee OA but not in patients with grade III arthrosis; in middle-aged subjects with moderate OA, PRP and HA induced similar improvements |
| | Filardo et al. [133] | 109 | |
| | Spakova et al. [134] | 120 | |
| | Say et al. [135] | 90 | |
| | Guler et al. [136] | 132 | |
| | Raeissadat et al. [137] | 160 | |
| | Montanez-Heredia et al. [138] | 55 | |
| | Ahmad et al. [139] | 89 | |
| | Louis et al. [140] | 56 | |
| | Filardo et al. [141] | 192 | |
| Di Martino et al. [142] | 192 | | |
| PRP/High MWAH /Low MW HA | Kon et al. [143] | 150 | PRP displayed greater and longer efficacy than HA, as concerning pain, symptom and function improvement; better outcomes were obtained in young and active subjects and lower degree of cartilage damage; worse results were achieved in older patients and more damaged cartilage; in older patients, effects similar to viscosupplementation were obtained |
| PRP/PRP+HA/HA | Lana et al. [144] | 105 | PRP was effective in mild/moderate knee OA; PRP+HA displayed a greater pain and functional limitation decrease than HA alone at 1 year post-injection; increased function compared to PRP alone at 1 and 3 months |
| PRP/PRP+HA/HA /normal saline | Yu et al. [145] | 360 | Combined PRP + HA treatment improved pain, stiffness and physical function compared with PRP or HA alone |
| PRP/HA /normal saline | Lin et al. [146] | 87 | Leukocyte-poor PRP provided functional improvement for at least 1 year in mild/moderate OA |
| PRP/HA/ ozone | Duymus et al. [147] | 102 | PRP was more effective than HA and ozone |
| PRP/PRP+ozone | Dernek et al. [148] | 80 | Similar efficacy was demonstrated by PRP alone or PRP+ozone; PRP+ozone-treated patients experienced less post-injection pain and a faster recovery |

Table 3. Cont.

| Treatment/ Control | Reference | Patient Number | Main Results |
|--|--|----------------|--|
| PRP/HA /CS | Huang et al. [149] | 120 | Pain decrease was significant in all groups compared to baseline; PRP showed a better recovery in physical function and decreasing pain at 6, 9 and 12 months |
| MP+PRP/ PRP/MP | Camurcu et al. [150] | 115 | MP+PRP injection determined better clinical improvement compared to PRP and MP alone |
| PRP double spinning/ PRGF single spinning | Filardo et al. [151] | 144 | Both treatments displayed similar clinical improvement compared to the baseline and at the follow-up; more pain and swelling reaction were present in PRP patients; younger patients with a low degree of cartilage degeneration showed better results |
| PRP (6x) + maintenance dose (3x) | Hart et al. [152] | 50 | PRP decreased pain and improved QoL in low-degree cartilage degeneration. MRI did not confirm cartilage improvement |
| PRP (1x) /PRP (2x)/ normal saline | Patel et al. [153] | 78 | Improvement in clinical parameters in both PRP groups; no difference between 1 or 2 injections; results deteriorated after 6 months |
| PRP (1x) /PRP(3x)/ HA/normal saline | Gormeli et al. [154] | 162 | PRP and HA treatments are proposed for all OA stages; multiple PRP injections achieved better clinical results in early OA, but did not influence results in advanced OA |
| PRP large volume | Guillibert et al. [155] | 57 | Large PRP volume was associated with functional and pain improvement. No MRI difference was reported |
| PRP+exercise/ exercise | Rayegani et al. [156] | 62 | Short-term improvement of pain, stiffness and QoL in PRP-treated patients compared to the control group was shown |
| LP-PRP | Duif et al. [157] | 58 | Improvement of pain and knee function was reported |
| LP-PRP /saline | Smith et al. [158] | 30 | Scores in the LP-PRP group were better than in the saline group, starting at 2 weeks throughout |
| LP-PRP/ acetaminophen | Simental-Mendia et al. [159] | 65 | Better clinical outcomes following LP-PRP treatment were reported |
| LP-PRP /HA | Cole et al. [160] | 99 | Similar primary outcomes between HA and PRP were observed at any time point; patient-reported outcome favored PRP; mild OA and low BMI displayed better outcome. |
| LP-PRP/ HA/NSAID | Buendia- Lopez et al. [161] | 106 | PRP decreased pain and improved physical function; PRP displayed better results; no modification in cartilage MRI was observed |
| PRP/ normal saline | Huang et al. [162] Elik et al. [163] | 366 60 | PRP improved clinical symptoms, improved QoL, decreased joint inflammation and did not increase thickness of cartilage |
| PRP/SH | Li et al. [164] (Chinese) | 30 | Significant differences pre- and post-injection in both groups; PRP was better than SH at 6 months |
| PRP/CS | Forogh et al. [165] | 41 | Pain, ADL and QoL improvement in the PRP-treated group was greater than in the CS group |
| PRP/PRL | Rahimzadeh et al. [166] | 42 | Decreased pain and improved physical function and QoL were observed after both treatments; PRP was more effective |
| Photo- activated PRP/HA | Paterson et al. [167] | 23 | Feasibility and safety of PA-PRP treatment were demonstrated; PA-PRP improved pain, symptoms and function; no differences between PA-PRP and HA were observed |
| PRP+SVF from adipose tissue | Bansal et al. [168] | 10 | PRP+SVF decreased pain, particularly after 3 months |
| PRP+intra osseous | Sanchez et al. [169] | 14 | Knee-joint function improvement and pain decrease were observed in patients with severe OA |
| PRP+intra- osseous/PRP | Sanchez et al. [170] | 60 | Intraosseous +intra-articular PRP injections induced better clinical outcome |
| PRP+intra- osseous/PRP/HA | Su et al. [171] | 86 | Intra-articular +intraosseous PRP infiltrations were not superior at 2 months, but they were superior at 6 and 12 months |

Afterward, different studies demonstrated the positive effects of PRGF/PRP injection, either when used alone or when compared to hyaluronic acid (HA) one, in the knee OA patients [114,115,117,119–140]. These PCs were reported not only to have an effect on clinical symptoms (by decreasing pain and improving function), but also on synovial fluid and protein amounts, as well as on cartilaginous degeneration.

However, a recent study reporting results of a follow-up up to six years does not confirm superiority of PRP [142].

The superiority of PRP was also established by comparison with normal saline (physiological control), as indicated by early improving WOMAC (the Western Ontario and McMaster Universities Osteoarthritis) scores, and maintained up to six months [153,158,163], but slightly decreased afterward, in agreement with the anti-inflammatory action supposed for PRP [172].

Similarly, in a trial including 366 young patients (18–30 years old), positive outcomes were reported after intra-lesional PRP administration [162]. In general, better results were obtained in young patients, with low body mass index [117,122].

PRP was reported as better in terms of clinical improvement compared to oral NSAID administration [161], as synergistic and protective, when added to methylprednisolone [150] and comparable to HA and corticosteroids after three months, superior to both the other treatments in the long-term [149].

Both PRP and HA have a biological origin and may be critical for tissue healing at the beginning of OA development. In *in vitro* studies, the combination of PRP with HA may display synergistic effects on fibroblast migration [173,174], thus suggesting a better effect of PRP–HA combination than PRP alone [175].

In agreement, a recent randomized clinical trial in mild/moderate knee OA reported better outcomes of the patients treated with PRP–HA combination when compared to PRP (up to three months) or to HA (up to 12 months) groups [144].

Furthermore, the synergy between combined PRP and HA treatment was further investigated and compared with each of them alone and with a placebo, via intra-articular injections in a total of 360 patients with knee osteoarthritis [145], demonstrating significantly reduced pain and decreased immune response, as well as PRP treatment compared with low and high molecular weight HA [143].

Even if clinical studies on PRP–HA combined therapy are limited and there are several peculiar aspects of HA alone (such as molecular weight), of the PRP–HA mix (such as ideal combination and dosage schedule), the preliminary data are worth of being deepened.

The PRP administration schedule in OA knee, widely reported with different numbers of injections, different time intervals and duration, represents a further aspect to be defined.

Patel [153], first compared the effect of one with two PRP injections and showed similarly improved WOMAC scores. A following double-blind placebo-controlled randomized trial demonstrated that the patient group that had undergone three PRP injections presented a better score than groups treated with a single dose of PRP or HA [154].

A clinical efficacy of PRP was also described when PRP was alternatively used at annual intervals or at the request of the patient when the effect ended [123]. Moreover, the administration in two phases foreseeing six doses at weekly intervals, and then a three month suspension and a maintenance dose (three injections at three-month intervals), presented interesting functional improvements [152].

A single administration of very pure PRP offered a significant clinical benefit as one injection of HA [140], and a similar improvement was obtained by a single administration of about 9 mL of PRP [155].

An enlarged delivery approach was also described, firstly for the treatment of severe OA [169] and more recently for the treatment of mild to moderate forms [170,171]. In these studies, the intra-articular injection of PRP was associated with concomitant intraosseous PRP injections into the subchondral bone, obtaining significant results.

A significant improvement of pain and functional scores, as well as decreases of the inflammatory response, were also obtained by the concomitant injection of PRP both intra-articular and in peri-meniscal soft tissue structures, thus widening the PRP effect on pes anserine tendons, bursa, medial collateral ligament and medial meniscus [176].

A systematic review on PRGF [177] reported the efficacy of PRGF in pain improvement, but also pointed out the limits of the included studies that prevented to perform a meta-analysis. The

heterogeneity of the primary outcomes, PRGF and HA administration schedules, HA molecular weight, the small number of studies fulfilling the eligibility criteria and the lack of placebo treated group were the main drawbacks.

PRP was described as effective, alternative and superior to HA treatment for long-term improvement of joint function and pain in patient with knee osteoarthritis, mainly in early-moderate disease compared to advanced disease. The limits reported in a narrative review [178], in a recent meta-analyses [179,180] and in a systematic review [181] evidenced the variability of OA severity (K-L I-IV), as well as age, sex and BMI in patients treated in the different studies. In addition, main criticisms concerned the number of injections, optimal dosage of PRP, administration schedule, heterogeneous PRP preparations and formulation discrepancies, absence of published studies supporting specific protocols of injection and lack of indications on the appropriate regimen for different OA severity degrees. The limited size of pooled patients that can under-power the statistical analysis to reach a significant threshold of difference in outcome measures, and the lack of a placebo group shades the evidence of PRP effects.

5.1.2. Hip Osteoarthritis

Although various trials have faced up to the use of on PRP use for knee OA, few studies have focused on the treatment of hip OA with PRP. These studies are summarized in Table 4.

Table 4. Evidence of PRP treatment in hip osteoarthritis (reported by year of study and grouped by treatment).

| Treatment/ Control | Reference | Patient Number | Main Results |
|---------------------------|------------------------|----------------|---|
| PRP | Sanchez et al. [182] | 40 | Study supported safety, tolerability and efficacy of PRP treatment; PRR improved pain and function in mild/moderate OA, up to six months |
| | Singh et al. [183] | 36 | |
| PRP/HA | Battaglia et al. [184] | 100 | PRP showed immediate short-term improvement of pain and function; at 12 months, HA effect was more evident |
| | Di Sante et al. [185] | 43 | |
| | Doria et al. [186] | 80 | |
| PRP/PRP+ HA/HA | Dallari et al. [187] | 111 | PRP did not display better results than HA in patients with moderate OA PRP induced a significant stable pain relief, functional recovery and QoL improvement, up to 12 months; side effects were not observed; improvement was better than PRP+HA or HA alone |
| PRP+intra-osseous/ PRP | Fitz et al. [188] | Not reported | Intra-articular + intraosseous PRP infiltrations induced improvements at 6 months, but not in the long-term |

A recent study [188] described the intraosseous infiltration of PRP for the treatment of hip osteoarthritis, in agreement with knee reported ones. Future studies are required to confirm the potential advantage of this new application of PRP.

Meta-analysis results of a randomized clinical trial that compared the effectiveness of PRP versus hyaluronic acid (HA) in hip OA underlined that PRP treatment was related to a significant reduction of VAS at two months. Both PRP and hyaluronic acid appeared to be comparable in terms of functional recovery [189].

The systematic review on the use of ultrasound-guided PRP injections in the treatment of hip osteoarthritis concluded that this route of administration appears to be well tolerated. Furthermore, though the level of evidence is relatively low, PRP treatment may lead to efficacious long-term and clinically significant reduction of pain and functional improvement [190].

Overall, intra-articular injection of PRP in hip OA patients has been demonstrated to be safe and have some efficacy in pain reduction and in functional improvement. When compared with HA, PRP showed to induce a better early pain relief; however, over 12 months, PRP and HA had comparable effects.

Future large-size trials that include a placebo group are needed. These studies should increase the level of evidence for the actual potential efficacy of PRP as an alternative conservative treatment to delay surgery in hip OA patients.

5.1.3. Ankle Osteoarthritis

Osteoarthritis of the ankle is less common than the previously described localization of OA. Data concerning the use of PRP in ankle OA are obtained by case series. Four injections of PRP at weekly intervals induced improvement of function, pain and patient satisfaction [191], and similar improvements in pain and function up to 24 weeks after treatment were obtained after the administration of three injections every two weeks [192].

The limited data show some benefit in short–medium time, demonstrate the safety of the therapy and can be considered to be an alternative to postpone the need for surgery, but the comparisons with other injectable controls are lacking; therefore, no definitive conclusion can be made about the benefit of PRP in ankle OA.

5.2. Tendinopathies

Tendon tissue is poorly vascularized, and this characteristic is responsible for the limited healing capacity and the lesion irreversibility resulting in tendinopathies, which frequently occur in athletes [193].

5.2.1. Achilles Tendinopathy

Achilles tendinopathy is a painful condition. Physical stress leads to tendon micro-trauma, and the inflammatory and degenerative responses that follow are responsible for local pain, swelling and stiffness [194]. Its treatment is difficult, and sufferers easily relapse due to the poor curative effects of the conservative treatment approach. The reason for PRP application lies in the tendency of the tendinopathy to become chronic after the use of nonsurgical approaches.

The outcomes after PRP administration are variable, and the main results are reported in Table 5.

Table 5. Evidence of PRP treatment in Achilles tendinopathy (reported by year of study and grouped by treatment).

| Treatment/ Control | Reference | Patient number | Main results |
|---|-----------------------|----------------|--|
| PRP | Gaweda et al. [195] | 14 | Lasting improvement of the clinical symptoms and imaging results were obtained; improvement was maintained at least for two years from treatment; low complication rate was reported; US-guided tenotomy, followed by PRP treatment, was safe, effective and associated with US improvement; PRP led to tendon matrix healing; effective also in patients who failed to respond to traditional non operative techniques; retrospective study demonstrated that 78% of PRP-injected patients presented clinical improvement and averted surgical intervention at 6-month follow-up; response was less evident in old subjects |
| | Volpi et al. [196] | 15 | |
| | Finoff et al. [197] | 41 | |
| | Deans et al. [198] | 26 | |
| | Ferrero et al. [199] | 30 | |
| | Monto et al. [200] | 30 | |
| | Murawski et al. [201] | 32 | |
| | Gueffi et al. [202] | 73 | |
| | Salini et al. [203] | 44 | |
| | Owens et al. [204] | 10 | Moderate improvement in functional outcome was reported; MRI remained largely unchanged |
| PRP repeated | Filardo et al. [205] | 27 | Repeated PRP injections produced overall good outcomes, with stable results up to a midterm follow-up; prolonged symptomatology indicated a difficult return to sport |
| PRP/normal saline | de Jonge et al. [206] | 54 | PRP injection in addition to eccentric exercises did not result in clinical and/or ultra-sonographic improvement; tendon diameter increased |
| | Krogh et al. [207] | 24 | |
| LP-PRP/ LR-PRP | Hanisch et al. [208] | 84 | No significant differences were observed between patients treated with LR-PRP and LP-PRP |
| PRP+HA | Gentile et al. [209] | 10 | Treatment was efficacious for tissue healing and regeneration in post-surgical complications of Achilles tendon |
| PRP+ (ESWT) | Erroi et al. [210] | 45 | Both PRP and ESWT treatments were similarly efficacious and safe in physically active people |
| PRP/surgery+ PRP | Oloff et al. [211] | 26 | Both PRP alone or PRP+ surgical debridement improved clinical outcomes and MRI |
| PRP/eccentric loading | Kearney et al. [212] | 20 | No differences between PRP and eccentric loading program as concerning clinical effectiveness |
| PRP+ eccentric exercise/normal saline+ eccentric exercise | de Vos et al. [213] | 54 | Patients treated with PRP+ eccentric exercises did not present greater improvement in pain and activity; PRP did not increment tendon structure or modified neovascularization degree |
| | de Vos et al. [214] | 54 | |
| PRP/HVI steroid/ normal saline | Boesen et al. [215] | 60 | Both HVI steroid or PRP seemed efficacious in improving pain and activity and in decreasing tendon thickness and intra-tendinous vascularity |

Case series for chronic Achilles tendinopathy [195–200,211], retrospective studies [201,204] and prospective studies [208–210,215] have described promising efficacy of PRP treatment with lasting improvements [205].

Other studies did not show a superiority of PRP injection over saline solution [206,207,213] and no differences between patients treated with leukocyte-rich or -poor PRP [208]

Evidence for the efficacy of PRP in Achilles tendinopathy is not in agreement, and despite the important clinical significance, a strong basis for the use of PRP for Achilles tendinopathy was not demonstrated by meta-analyses and a systematic review [216–219].

5.2.2. Lateral Epicondyle Tendinopathy

Lateral epicondyle tendinopathy, also known as “tennis elbow” is a common cause of pain and disability. Symptoms have been attributed to micro-trauma to extensor carpi radialis brevis tendon and the resulting angiofibroblastic tendinosis [220].

Different therapeutic approaches have been used, and steroid injections are considered to be the gold standard. Recently, PRP also became popular in treating this disease, with effects opposite to those of steroids, by stimulating the healing process and down-modulating inflammatory response.

The majority of the studies compared PRP efficacy with steroid one; however, other treatment comparisons have been reported (Table 6).

Table 6. Evidence of PRP treatment in lateral epicondyle tendinopathy (reported by year of study and grouped by treatment).

| Treatment/Control | Reference | Patient Number | Main Results |
|-------------------------------------|------------------------------|----------------|---|
| PRP | Mishra et al. [221] | 140 | PRP was successful in refractory forms and preventing the need for surgery; it was safe and improved function, with effects lasting five years after the initial injection |
| | Hachtman et al. [222] | 31 | |
| | Brkljac et al. [223] | 34 | |
| | Brkljac et al. [224] | 31 | |
| PRP/Autologous blood | Creaney et al. [225] | 150 | PRP seemed to be an effective treatment, superior to autologous blood in short-term, but not in long-term, follow-up; PRP appeared useful in patients resistant to first-line physical therapy |
| | Thanasas et al. [226] | 28 | |
| | Raissadat et al. [227] | 75 | |
| PRP/normal saline | Montalvan et al. [228] | 50 | PRP treatment was not more effective than saline until 6- and 12-month follow-up |
| | Schöffel et al. [229] | 50 | |
| LR-PRP/LP-PRP | Yerlikaya et al. [230] | 90 | Neither LR-PRP nor LP-PRP did not seem to affect pain and function in the short-term; leukocyte number was not associated with local inflammation post-injection |
| PRP/active control | Mishra et al. [231] | 230 | No differences between treatments were observed at 12 weeks; clinical improvements in PRP-treated patients were observed at 24 weeks |
| PRP/CS | Peerbooms et al. [232] | 100 | PRP reduced pain and significantly increased function, exceeding the effect of corticosteroid injection, up to 2 years of follow-up; PRP enabled lesion healing; CS induced a short-term relief at 6 weeks, but favored tendon degeneration |
| | Gosens et al. [233] | 100 | |
| | Gautam et al. [234] | 30 | |
| | Khaliq et al. [235] | 102 | |
| | Varshney et al. [236] | 83 | |
| | Gupta et al. [237] | 80 | |
| PRP/beta-methasone | Lebiedzinski et al. [238] | 120 | PRP allowed better results at 12 months; PRP therapeutic effect was long-lasting; betamethasone gave more rapid improvement |
| PRP/dexa-methasone | Palacio et al. [239] | 60 | Both treatments were similarly effective |
| PRP/methyl-prednisolone | Yadav et al. [240] | 65 | Both PRP and methyl-prednisolone were effective; PRP showed a more prolonged efficacy |
| PRP/bupivacaine | Behera et al. [241] | 25 | Leukocyte-poor PRP injection enabled good improvement in pain and function |
| PRP/laser therapy | Tonk et al. [242] | 81 | Better results were obtained following PRP injection on the long-term period; low-level laser therapy was better in the short-term |
| PRP/ESWT | Alessio-Mazzola et al. [243] | 63 | PRP injection showed a more rapid efficacy than ESWT |
| PRP/triamcinolone/normal saline | Seetharamaiah et al. [244] | 80 | Better pain relief were obtained following PRP injection over a short-term period |
| PRP/glucocorticoids/normal saline | Krogh et al. [245] | 60 | No treatment was superior to saline in regard to pain reduction; glucocorticoids had a short-term pain-relief effect and reduced both color Doppler activity and tendon thickness, compared with PRP and saline |
| PRP+dry needling/dry needling | Stenhouse et al. [246] | 28 | Additional PRP showed a trend to greater clinical improvement in the short-term; no difference between the two treatments was demonstrated at each follow-up |
| PRP+arthroscopic debridement | Merolla et al. [247] | 101 | Both PRP injections and arthroscopic debridement were efficacious in short-/medium-term; pain intensified at 2 years in PRP patients; arthroscopic administration favored pain and grip-strength improvement |
| PRP/US-guided percutaneous tenotomy | Boden et al. [248] | 62 | PRP and US-guided percutaneous tenotomy were both successful in improving pain, function and QoL |

Initial results have been promising [221,222]. The first randomized controlled trials displayed PRP treatment improvements in function and pain, exceeding the effect of steroid injections up to one [232] and two [233] years

Following trials, comparing PRP treatment with saline [228,229,245], steroid [232–240,245] autologous whole blood [225–227] and bupivacaine [241] showed variable effectiveness in reducing pain and improving function.

Studies showing similar therapeutic effects between PRP and whole blood [225–227] suggest that circulating platelet concentrations are enough for obtaining recovery. However, the limited patient number and the absence of placebo arm make questionable these results.

As far as we know, the results of a multicenter randomized controlled IMPROVE trial are not yet available. The four-arms of lateral epicondylitis treatment will compare PRP, whole blood injection and tendon fenestration, each associated with physical therapy and sham superficial subcutaneous

soft tissue injection, plus physical therapy. Expected results should significantly impact clinical practice [249].

Despite the heterogeneity of data, a seven-year retrospective study [250] and several meta-analyses, differing for inclusion criteria are available for evaluation the effectiveness of PRP in the treatment of lateral epicondylitis [251–255].

These reviews demonstrated short-term benefits for corticosteroids, but a long-term effectiveness for PRP in regard to improving functional capacity and alleviating pain. The critical factors identified mostly mirror those evidenced in other anatomical sites. Volume and number of administrations, various treatment combination, lack of standardization for PRP preparation and for exercise protocol, different measures for outcome evaluation and different follow-up times need deeper assessments.

5.2.3. Plantar Fasciopathy

Plantar fasciopathy (PF), also known as “plantar fasciitis”, affects the proximal insertion of the plantar fascia in the os calcis, causing pain. Tissue thickening and degenerative structural changes are more common than inflammatory findings, so the “plantar fasciopathy” definition better identifies this disorder [256].

The fascia plays a role of primary importance in the transmission of body weight to the foot while walking and running. Plantar fasciitis is very common in athletes, but can also occur in overweight or obese subjects.

Corticosteroids, autologous blood injection and extracorporeal shock wave therapy (ESWT) represent treatment options that have been used with varying results.

At present, a uniform therapy for the management of Plantar fasciopathy is missing; therefore, many studies have considered PRP to be an intriguing alternative option to favor healing in the plantar fascia without significant risk [257] (Table 7).

Table 7. Evidence of PRP treatment in plantar fasciitis (reported by year of study and treatment type).

| Treatment/ Control | Reference | Patient Number | Main Results |
|-----------------------------|----------------------------|----------------|--|
| PRP | Ragab et al. [258] | 25 | PRP injection may have a reparative effect, leading to resolution of symptoms; findings indicated a role in the management of chronic intractable plantar fasciitis; QoL improved; PRP injection was safe; it cannot impair the biomechanical function of the foot; no side effects were reported |
| | Kumar et al. [259] | 44 | |
| | Martinelli et al. [260] | 14 | |
| | O'Malley et al. [261] | 23 | |
| | Wilson et al. [262] | 24 | |
| PRP/PPP | Malahias et al. [263] | 36 | PRP and PPP gave similar results; both treatments provided improvement at 3- and 6-month follow-up |
| PRP/normal saline | Johnson-Lynn et al. [264] | 28 | PRP and placebo gave similar improvement in symptoms |
| PRP/CS | Aksahin et al. [265] | 60 | Both treatments were safe and effective in improving pain and function at 3 and 6 months; at 12 months, PRP was significantly more effective, making it better and more durable than CS injection; taking into consideration the potential complication of corticosteroid treatment, PRP injection seemed to be safer and had, at least, the same effectivity in the treatment |
| | Tiwari et al. [266] | 60 | |
| | Omar et al. [267] | 30 | |
| | Shetty et al. [268] | 60 | |
| | Jain et al. [269] | 60 | |
| | Sherpy et al. [270] | 50 | |
| | Vahdatpour et al. [271] | 32 | |
| | Acosta-Olivo et al. [272] | 28 | |
| | Jain et al. [273] | 80 | |
| | Monto et al. [274] | 40 | |
| Say et al. [275] | 50 | | |
| Peerbooms et al. [276] | 115 | | |
| PRP/ methyl-prednisolone | Jiménez-Pérez et al. [277] | 40 | PRP injection showed better, long-lasting clinical and imaging effects than methylprednisolone |
| PRP/CS/ normal saline | Mahindra et al. [278] | 75 | PRP was as effective as, or more effective than, corticosteroid injection at 3-months follow-up |
| | Shetty et al. [279] | 90 | PRP and corticosteroids showed superior results to placebo; long-term results and low reinjection and/or surgery rate make PRP more attractive than CS |
| PRP+ct/ESWT+ct | Chew et al. [280] | 54 | Either PRP or ESWT treatment resulted in modestly and similarly improved pain and functional scores, compared with conventional treatments alone, over a 6-month follow-up; PRP demonstrated greater improvements in plantar fascia thickness reduction |

Table 7. Cont.

| Treatment/ Control | Reference | Patient Number | Main Results |
|-----------------------|----------------------|----------------|---|
| PRP/DP | Kim et al. [281] | 21 | Each treatment was effective in chronic recalcitrant cases; PRP also may lead to a better initial improvement compared with DP |
| PRP/KT | Gonnade et al. [282] | 64 | PRP injection of high platelet counts was more effective and long-lasting than phonophoresis with kinesiotaping; no adverse effects were reported |
| PRP/LDR | Gogna et al. [283] | 40 | PRP and LDR showed similar improvement in pain, functional activity and fascia thickness |

Early cohort studies have described the positive effect of PRP injection on relieving pain [260] and improving function [259], as well as on tissue structure [258] for chronic plantar fasciopathy.

The most recent randomized controlled trials comparing PRP, corticosteroids and normal saline administration describe a similar or a superior effect of PRP compared to corticosteroid injection and normal saline in reducing pain and increasing functional scores for chronic plantar fasciopathy [278,279].

Numerous other studies obtained variable results by the comparison of PRP and corticosteroid treatments: PRP was described as being either able to favor early pain relief and functional improvement [267,275] with prolonged effects [266,269,271,274,278] or to be likewise effective up to six months [265,268,270,272,273,276].

Trials comparing PRP with other treatment options for plantar fasciopathy showed a better initial PRP response but similar effects at six months; when PRP was compared with prolotherapy [281], no significant differences compared to extracorporeal shockwave [280] or plasma injection [263], superior and long-lasting effects compared to KT [282].

The latest systematic reviews and meta-analyses comparing PRP to other therapeutic approaches supported the use of PRP for the lack of complications or side effects [284], but, above all, for its superiority to corticoids, especially in long-term pain relief [285,286]; however, small sample number, study heterogeneities, adverse events and the lack of recording PF recurrence following treatment may decrease reliability of outcome measures.

5.2.4. Patellar Tendinopathy

Inferior pole patellar tendinopathy, generally known as jumper's knee, is mostly common among athletes who engage in sports involving frequent jumping, such as volleyball and basketball, but it is also observed in people who do not carry out sporting activities [287]. The main evidence on PRP treatment in patellar tendinopathy is reported in Table 8.

Table 8. Evidence of PRP treatment in patellar tendinopathy (reported by year of study and treatment type).

| Treatment/ Control | Reference | Patient Number | Main Results |
|-------------------------------------|-------------------------|----------------|---|
| PRP | Volpi et al. [196] | 15 | Significant pain and clinical improvement after 3 months, lasting results up to 2 years; MRI improvement in patellar tendon structure was observed |
| | Ferrero et al. [199] | 28 | |
| | Mautner et al. [288] | 27 | |
| | Crescibene et al. [289] | 7 | |
| | Kaux et al. [290] | 20 | |
| | Bowman et al. [291] | 3 | Symptoms worsening were described following PRP treatment; poor benefit at 4 months |
| | Manfreda et al. [292] | 17 | |
| PRP (multiple) | Filardo et al. [293] | 43 | Multiple injections provided good clinical outcomes and stable results, up to medium-term follow-up; patients with bilateral disease and a long history of pain obtained poorer results |
| PRP(3x) | Charoussat et al. [294] | 28 | Satisfactory results in athletes with chronic tendinopathy and faster return to previous sport practice were reported |
| PRP(2x)/PRP(1x) | Zayni et al. [295] | 40 | PRP (2x) determined better results than a single one injection |
| | Kaux et al. [296] | 20 | No differences between PRP (2x) and one injection were observed |
| PRP/Physiotherapy | Filardo et al. [297] | 31 | PRP treatment significantly improved knee function and quality of life |
| PRP/PRP+ previous treatment | Gosens et al. [298] | 36 | PRP provided a significant improvement; no differences were observed between groups |
| PRP/ESWT | Vetrano et al. [299] | 46 | PRP led to better midterm clinical results |
| PRP/HVI image guided saline | Abate et al. [300] | 54 | Association of both resulted in greater improvement and tendon repair |
| PRP+dry needling/dry needling | Dragoo et al. [301] | 23 | PRP provided faster recovery at 12 weeks; no clinical difference at the final 26-week follow-up was observed |
| LR-PRP/ LP-PRP/ normal saline | Scott et al. [302] | 38 | LR-PRP or LP-PRP were no more effective than saline for the improvement of symptoms |

PRP has been administered in several studies as a biological therapy for patellar tendinopathy, improving pain and MRI tendon structure, and significantly increasing functional outcomes, with long-lasting stable results up to two years, thus improving quality of life [196,199,288–290,303],

Multiple injections were found to be better than a single one for patellar tendinopathy, either in case series [293,294] or in a randomized prospective study [295], but the effect of two repeated injections or one single injection was also reported to be similar [296].

PRP treatment displayed better results than ESWT [299] and physiotherapy [297]. Dry-needling used for PRP administration made recovery faster than dry-needling alone; however, beneficial effects on pain and function only lasted three months, without improvement in QoL [301]. Furthermore, no clinical differences were observed when PRP was administered following other inefficacious treatments [298], or among leukocyte-rich or -poor PRP and saline [302].

Not long ago, no randomized controlled quality studies supported the use of PRP over conservative therapies, except in therapy-resistant cases [293,304]. However, recently, a systematic review [305] and meta-analyses of randomized trials have recommended the use of PRP for the management of patellar tendinopathy, due to its superiority to other nonsurgical therapies [306], in long-term pain relief and improvement in knee function [307]. Even if eccentric exercises seem to be the strategic choice in the short-term, in complex cases, multiple PRP injections can be considered to be an option [308]. Variability on follow-up length, or its absence, and number of interventions are the main limitations of these studies.

5.3. Muscle Injuries

The use of PRP for the treatment of muscle injuries raised significant interest in the last years.

Similar to tendon healing, the initial muscle healing begins with an inflammatory response, followed by proliferation and differentiation of cells and tissue remodeling.

Acute hamstring injury is one of the most common muscle injuries affecting athletic patients, causing a decline in competition performance [309,310].

Some studies described positive results after injection of PRP in patients with injured skeletal muscles, and no negative side effects were reported [311,312] (Table 9).

Table 9. Evidence of PRP treatment in muscle injuries (reported by year of study and treatment type).

| Treatment/Control | Reference | Patient Number | Main Results |
|--|------------------------------|----------------|--|
| PRP | Bernuzzi et al. [311] | 53 | PRP injection under US guide induced a complete muscle-function recovery; pain disappeared; PRP did not accelerate healing but showed excellent muscle repair and small scar |
| | Zanon et al. [312] | 25 | |
| PRP/normal saline | Reurink et al. [313] | 80 | PRP injection did not demonstrate superiority to normal saline on short-term; no benefits were found up to 12 months in subjective, clinical, MRI measures, return to play and rate of re-injury |
| | Reurink et al. [314] | 80 | |
| | Punduk et al. [315] | 12 | |
| PRP/control | Martinez-Zapata et al. [316] | 71 | PRP did not significantly shorten the time of healing compared to the control group |
| PRP+conservative treatment/conservative treatment | Bubnov et al. [317] | 30 | PRP induced a better physical recovery, decreased pain and promoted faster regeneration than conventional conservative treatment |
| | Wetzel et al. [318] | 15 | |
| PRP/CS | Park et al. [319] | 56 | PRP injection induced more favorable response than CS one week after injection |
| PRP+rehabilitation/rehabilitation | A Hamid et al. [320] | 28 | PRP injection+ rehabilitation program induced an earlier full recovery than rehabilitation alone; lower score of pain severity was observed in PRP group; PRP reduced time and costs to reach a complete functional recovery |
| | Rossi et al. [321] | 75 | |
| | Borrione et al. [322] | 61 | |
| | Guillodo et al. [323] | 34 | |
| PRP+rehabilitation/PPP+rehabilitation/rehabilitation | Hamilton et al. [324] | 90 | PRP injection+rehabilitation did not show benefit on intensive standardized rehabilitation program alone; PRP induced a more rapid return to sport than PPP |

Contrasting results were obtained when PRP was compared to saline [313–315].

In general, an earlier comeback to sports activity, together with lower scores of pain severity and no significant increase of the re-injury risk, has been observed in patients/athletes who have undergone PRP administration, combined with a rehabilitation program, compared to patients treated with a rehabilitation program alone [320–322].

In particular, as a randomized clinical trial, this study showed positive outcomes in the PRP group as concerning convalescence time and returning to play [321].

Despite some favorable results, these studies do not have enough statistical power to support evidence-based adoption of PRP administration for skeletal muscle injury in clinical practice, as recently widely debated [325,326]. In general, current clinical evidence are conflicting, and univocal findings on the efficacy of PRP injections in the treatment of muscle injuries have not been achieved. Therefore, further human studies are strongly required to assess and validate the effectiveness of PRP for skeletal muscle regenerative purposes.

Platelet growth factors, specifically myostatin and TGF-β1, have been shown to have harmful effects to muscle regeneration. Indeed, TGF-beta1 is involved in the regulation of the level of fibrosis during muscle-injury repair, which is an important link in the complete restoration of muscle function [327]. An vitro study [328] demonstrated that platelet-poor plasma (PPP) or PRP with a second spin to remove the platelets induced differentiation of myoblasts into muscle cells.

However, since experimental evidence has not received a large consensus [329,330], further studies are needed to define the exact PPP-growth-factor content, its effect on myogenic precursors and its role on skeletal muscle regeneration. In addition, human clinical trials will be required to further explore the potential beneficial effects of muscle injuries treated with PPP.

These overall findings underline that none of the therapeutic options so far adopted have led to reliable results [325,326]. Even if skeletal muscle tissue exhibits an intrinsic remarkable regenerative potentiality in response to injury, in the case of extended damage, a dysregulated activity of different muscle interstitial cells occurs, resulting in aberration of tissue repair and maladaptive fibrotic scar or adipose tissue infiltration [331]. In this context, the morpho-functional recovery of injured skeletal muscle still remains a scientific challenge, and the identification of strategies that efficaciously improve the endogenous skeletal muscle regenerative mechanisms represents an unmet need.

6. Conclusions and Future Perspectives

PC use has gained popularity for the treatment of musculoskeletal diseases, even if conflicting results have been reported concerning clinical efficacy. Inconsistencies of clinical results rely on the huge heterogeneity of PC preparations, mainly ascribed to individual characteristics, different preparation protocols and variability in composition, as well as on different methodological limits of the protocols adopted in the clinical studies that have been previously underlined.

In addition to the different critical aspects already considered, the indistinct employment of words to refer to fresh, frozen/thawed or activated preparations increases confusion. Therefore, also a simple aspect such as a classification nomenclature comprehensive of all PCs, with the same characteristics allowing an overall clinical outcome comparison, could contribute to define the clinical use and improve our knowledge of PRP.

Besides being a paramount component of PRP, platelets have been proposed as carriers of pharmacological or biological molecules [332]; therefore, “future” PRP could be implemented with suitable molecules favoring specific biological functions.

The possibility of encapsulating PRP with a combination of HA, gelatin and biodegradable scaffolds displayed interesting results in *in vitro* studies of bone regeneration [333], and a new delivery system linking fibrinogen with high molecular weight HA (RegenoGel™) (merging the respective regenerative/wound healing properties and viscoelastic characteristics) showed positive outcomes in mild/severe osteoarthritis. In addition, this system can be used as a carrier for microRNA or inhibitory molecules (ADAMTs), allowing the preparation of specifically targeted custom-made devices [334,335].

Encouraging *in vitro* and in animal model studies has demonstrated that PRP combined with different biomaterials prolonged and improved growth factor release [336]; however, the possibility to translate these engineered biomaterials in the clinical practice to develop novel therapeutic strategies remains a future perspective.

Author Contributions: The authors similarly contributed to preparation of the paper. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by “5 per mille funds”.

Conflicts of Interest: The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

Abbreviations

| | |
|-------|---|
| ACD | acid citrate dextrose |
| ADL | activities of daily living |
| ADP | adenosine diphosphate |
| A-PRF | advanced-platelet-rich fibrin |
| ACP | autologous conditioned plasma |
| BMSCs | bone marrow stem cells |
| BMP | bone morphogenic protein |
| CTAD | citrate-theophylline-adenosine-dipyridamole |
| ct | conventional treatment |
| CS | Corticosteroid |

| | |
|----------|---|
| DP | dextrose prolotherapy |
| DEPA | dose of platelet efficiency, purity and activation |
| EGF | epidermal growth factor |
| EDTA | ethylene diamine tetra-acetic acid |
| ESWT | extracorporeal shock wave therapy |
| FG | fibroblast growth factor |
| GFs | growth factors |
| HO | heme oxygenase |
| HS | heparin sodium |
| HVI | high volume injection |
| HA | hyaluronic acid |
| IGF | insulin-like growth factor |
| ISTH | International Society on Thrombosis and Haemostasis |
| KT | kinesio therapy |
| KOOS | knee injury and osteoarthritis outcome score |
| LE | lateral epicondyle |
| L-PRF | leukocyte- and platelet-rich fibrin |
| LP-PRP | leukocyte-poor PRP |
| L-PRP | leukocyte-rich PRP |
| LR-PRP | leukocyte-rich PRP |
| MRI | magnetic resonance imaging |
| MSC | mesenchymal stem cells |
| MARSPILL | method, activation, red blood cells, spin, platelets, image guidance, leukocytes and light activation |
| MIF | migration inhibitory factor |
| OA | osteoarthritis |
| PAW | photoactivated |
| PDWHF | platelet-derived wound healing factors or formula- |
| PF | plantar fasciopathy |
| PRFM | platelet-rich fibrin matrix |
| PRGF | plasma rich in growth factors |
| PAW | platelet activation, white blood cells |
| PCs | platelet concentrates |
| PLRA | platelet leukocyte red blood cells and activation |
| PRP | platelet rich-plasma |
| PDGF | platelet-derived growth factor |
| PPP | platelet-poor plasma |
| PRF | platelet-rich fibrin |
| P-PRF | pure platelet-rich fibrin |
| QoL | quality of life |
| RBCs | red blood cells |
| SC | sodium citrate |
| t-PRP | temperature controlled PRP |
| TGF | transforming growth factor |
| US | ultra-sound |
| VEGF | vascular endothelial growth factor |
| VAS | visual analogue scale |
| WOMAC | the Western Ontario and McMaster Universities Osteoarthritis Index |

References

1. Le, A.D.K.; Enweze, L.; DeBaun, M.R.; Drago, J.L. Current Clinical Recommendations for Use of Platelet-Rich Plasma. *Curr. Rev. Musculoskelet. Med.* **2018**, *11*, 624–634. [[CrossRef](#)] [[PubMed](#)]
2. Dhillon, M.S.; Behera, P.; Patel, S.; Shetty, V. Orthobiologics and platelet rich plasma. *Indian J. Orthop.* **2014**, *48*, 1–9. [[CrossRef](#)] [[PubMed](#)]

3. O'Connell, B.; Wragg, N.M.; Wilson, S.L. The use of PRP injections in the management of knee osteoarthritis. *Cell Tissue Res.* **2019**, *376*, 143–152. [[CrossRef](#)] [[PubMed](#)]
4. Anitua, E.; Nurden, P.; Prado, R.; Nurden, A.T.; Padilla, S. Autologous fibrin scaffolds: When platelet- and plasma-derived biomolecules meet fibrin. *Biomaterials* **2019**, *192*, 440–460. [[CrossRef](#)] [[PubMed](#)]
5. Boswell, S.G.; Cole, B.J.; Sundman, E.A.; Karas, V.; Fortier, L.A. Platelet-rich plasma: A milieu of bioactive factors. *Arthroscopy* **2012**, *28*, 429–439. [[CrossRef](#)] [[PubMed](#)]
6. Deppermann, C.; Kubers, P. Start a fire, kill the bug: The role of platelets in inflammation and infection. *Innate Immun.* **2018**, *24*, 335–348. [[CrossRef](#)]
7. Pham, T.A.V.; Tran, T.T.P.; Luong, N.T.M. Antimicrobial Effect of Platelet-Rich Plasma against *Porphyromonas gingivalis*. *Int. J. Dent.* **2019**, *2019*, 7329103. [[CrossRef](#)]
8. Mariani, E.; Filardo, G.; Canella, V.; Berlingeri, A.; Bielli, A.; Cattini, L.; Landini, M.P.; Kon, E.; Marcacci, M.; Facchini, A. Platelet-rich plasma affects bacterial growth in vitro. *Cytotherapy* **2014**, *16*, 1294–1304. [[CrossRef](#)]
9. Rashid, H.; Kwok, C.K. Should Platelet-Rich Plasma or Stem Cell Therapy Be Used to Treat Osteoarthritis? *Rheum. Dis. Clin. N. Am.* **2019**, *45*, 417–438. [[CrossRef](#)]
10. Qian, Y.; Han, Q.; Chen, W.; Song, J.; Zhao, X.; Ouyang, Y.; Yuan, W.; Fan, C. Platelet-Rich Plasma Derived Growth Factors Contribute to Stem Cell Differentiation in Musculoskeletal Regeneration. *Front. Chem.* **2017**, *5*, 89. [[CrossRef](#)]
11. Mazzocca, A.D.; McCarthy, M.B.; Chowanec, D.M.; Dugdale, E.M.; Hansen, D.; Cote, M.P.; Bradley, J.P.; Romeo, A.A.; Arciero, R.A.; Beitzel, K. The positive effects of different platelet-rich plasma methods on human muscle, bone, and tendon cells. *Am. J. Sports Med.* **2012**, *40*, 1742–1749. [[CrossRef](#)] [[PubMed](#)]
12. Lim, W.; Park, S.H.; Kim, B.; Kang, S.W.; Lee, J.W.; Moon, Y.L. Relationship of cytokine levels and clinical effect on platelet-rich plasma-treated lateral epicondylitis. *J. Orthop. Res.* **2018**, *36*, 913–920. [[CrossRef](#)] [[PubMed](#)]
13. Weibrich, G.; Kleis, W.K.; Hafner, G.; Hitzler, W.E. Growth factor levels in platelet-rich plasma and correlations with donor age, sex, and platelet count. *J. Craniomaxillofac. Surg.* **2002**, *30*, 97–102. [[CrossRef](#)] [[PubMed](#)]
14. Lansdown, D.A.; Fortier, L.A. Platelet-Rich Plasma: Formulations, Preparations, Constituents, and Their Effects. *Oper. Tech. Sports Med.* **2017**, *25*, 7–12. [[CrossRef](#)]
15. Montagnana, M.; Salvagno, G.L.; Lippi, G. Circadian variation within hemostasis: An underrecognized link between biology and disease? *Semin. Thromb. Hemost.* **2009**, *35*, 23–33. [[CrossRef](#)]
16. Mannava, S.; Whitney, K.E.; Kennedy, M.I.; King, J.; Dornan, G.J.; Klett, K.; Chahla, J.; Evans, T.A.; Huard, J.; LaPrade, R.F. The Influence of Naproxen on Biological Factors in Leukocyte-Rich Platelet-Rich Plasma: A Prospective Comparative Study. *Arthroscopy* **2019**, *35*, 201–210. [[CrossRef](#)]
17. Kingsley, C.S. Blood coagulation; evidence of an antagonist to factor VI in platelet-rich human plasma. *Nature* **1954**, *173*, 723–724. [[CrossRef](#)]
18. Matras, H. Effect of various fibrin preparations on reimplantations in the rat skin. *Osterreichische Z. Stomatol.* **1970**, *67*, 338–359.
19. Rosenthal, A.R.; Egbert, P.R.; Harbury, C.; Hopkins, J.L.; Rubenstein, E. Use of platelet-fibrinogen-thrombin mixture to seal experimental penetrating corneal wounds. *Albrecht Graefes Archiv. Klin. Exp. Ophthalmol.* **1978**, *207*, 111–115. [[CrossRef](#)]
20. Knighton, D.R.; Ciresi, K.F.; Fiegel, V.D.; Austin, L.L.; Butler, E.L. Classification and treatment of chronic nonhealing wounds. Successful treatment with autologous platelet-derived wound healing factors (PDWHF). *Ann. Surg.* **1986**, *204*, 322–330. [[CrossRef](#)]
21. Whitman, D.H.; Berry, R.L.; Green, D.M. Platelet gel: An autologous alternative to fibrin glue with applications in oral and maxillofacial surgery. *J. Oral Maxillofac. Surg.* **1997**, *55*, 1294–1299. [[CrossRef](#)]
22. Marx, R.E.; Carlson, E.R.; Eichstaedt, R.M.; Schimmele, S.R.; Strauss, J.E.; Georgeff, K.R. Platelet-rich plasma: Growth factor enhancement for bone grafts. *Oral Surg. Oral Med. Oral Pathol. Endodontology.* **1998**, *85*, 638–646. [[CrossRef](#)]
23. Choukroun, J.; Adda, F.; Schoeffler, C.; Vervelle, A. Une opportunit  en paro-implantologie: Le PRF. *Implantodontie* **2001**, *42*, 55–62.
24. Amin, I.; Gellhorn, A.C. Platelet-Rich Plasma Use in Musculoskeletal Disorders: Are the Factors Important in Standardization Well Understood? *Phys. Med. Rehabil. Clin. N. Am.* **2019**, *30*, 439–449. [[CrossRef](#)]

25. Dohan Ehrenfest, D.M.; Rasmusson, L.; Albrektsson, T. Classification of platelet concentrates: From pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). *Trends Biotechnol.* **2009**, *27*, 158–167. [[CrossRef](#)]
26. Yung, Y.L.; Fu, S.C.; Cheuk, Y.C.; Qin, L.; Ong, M.T.; Chan, K.M.; Yung, P.S. Optimisation of platelet concentrates therapy: Composition, localisation, and duration of action. *Asia Pac. J. Sports Med. Arthrosc. Rehabil. Technol.* **2017**, *7*, 27–36. [[CrossRef](#)]
27. Anitua, E.; Troya, M.; Zalduendo, M.; Orive, G. Personalized plasma-based medicine to treat age-related diseases. *Mater. Sci. Eng. C Mater. Biol. Appl.* **2017**, *74*, 459–464. [[CrossRef](#)]
28. Dhillon, R.S.; Schwarz, E.M.; Maloney, M.D. Platelet-rich plasma therapy-future or trend? *Arthritis Res. Ther.* **2012**, *14*, 219. [[CrossRef](#)]
29. Do Amaral, R.J.; da Silva, N.P.; Haddad, N.F.; Lopes, L.S.; Ferreira, F.D.; Filho, R.B.; Cappelletti, P.A.; de Mello, W.; Cordeiro-Spinetti, E.; Balduino, A. Platelet-Rich Plasma Obtained with Different Anticoagulants and Their Effect on Platelet Numbers and Mesenchymal Stromal Cells Behavior In Vitro. *Stem Cells Int.* **2016**, *2016*, 7414036. [[CrossRef](#)]
30. Lei, H.; Gui, L.; Xiao, R. The effect of anticoagulants on the quality and biological efficacy of platelet-rich plasma. *Clin. Biochem.* **2009**, *42*, 1452–1460. [[CrossRef](#)]
31. Gonzalez, J.C.; Lopez, C.; Carmona, J.U. Implications of anticoagulants and gender on cell counts and growth factor concentration in platelet-rich plasma and platelet-rich gel supernatants from rabbits. *Vet. Comp. Orthop. Traumatol.* **2016**, *29*, 115–124. [[CrossRef](#)] [[PubMed](#)]
32. Zhang, N.; Wang, K.; Li, Z.; Luo, T. Comparative study of different anticoagulants and coagulants in the evaluation of clinical application of platelet-rich plasma (PRP) standardization. *Cell Tissue Bank.* **2019**, *20*, 61–75. [[CrossRef](#)] [[PubMed](#)]
33. Du, L.; Miao, Y.; Li, X.; Shi, P.; Hu, Z. A Novel and Convenient Method for the Preparation and Activation of PRP without Any Additives: Temperature Controlled PRP. *Biomed. Res. Int.* **2018**, *2018*, 1761865. [[CrossRef](#)] [[PubMed](#)]
34. DeLong, J.M.; Russell, R.P.; Mazzocca, A.D. Platelet-rich plasma: The PAW classification system. *Arthroscopy* **2012**, *28*, 998–1009. [[CrossRef](#)]
35. Oudelaar, B.W.; Peerbooms, J.C.; Huis In 't Veld, R.; Vochteloo, A.J.H. Concentrations of Blood Components in Commercial Platelet-Rich Plasma Separation Systems: A Review of the Literature. *Am. J. Sports Med.* **2019**, *47*, 479–487. [[CrossRef](#)] [[PubMed](#)]
36. Weibrich, G.; Kleis, W.K.; Buch, R.; Hitzler, W.E.; Hafner, G. The Harvest Smart PRP system versus the Friadent-Schutze platelet-rich plasma kit. *Clin. Oral Implant. Res.* **2003**, *14*, 233–239. [[CrossRef](#)]
37. Fukaya, M.; Ito, A. A New Economic Method for Preparing Platelet-rich Plasma. *Plast. Reconstr. Surg. Glob. Open* **2014**, *2*, e162. [[CrossRef](#)]
38. Amable, P.R.; Carias, R.B.; Teixeira, M.V.; da Cruz Pacheco, I.; Correa do Amaral, R.J.; Granjeiro, J.M.; Borojevic, R. Platelet-rich plasma preparation for regenerative medicine: Optimization and quantification of cytokines and growth factors. *Stem Cell Res. Ther.* **2013**, *4*, 67. [[CrossRef](#)]
39. Yin, W.; Xu, H.; Sheng, J.; Zhu, Z.; Jin, D.; Hsu, P.; Xie, X.; Zhang, C. Optimization of pure platelet-rich plasma preparation: A comparative study of pure platelet-rich plasma obtained using different centrifugal conditions in a single-donor model. *Exp. Ther. Med.* **2017**, *14*, 2060–2070. [[CrossRef](#)]
40. Croise, B.; Pare, A.; Joly, A.; Louisy, A.; Laure, B.; Goga, D. Optimized centrifugation preparation of the platelet rich plasma: Literature review. *J. Stomatol. Oral Maxillofac. Surg.* **2019**. [[CrossRef](#)]
41. Gato-Calvo, L.; Hermida-Gomez, T.; Romero, C.R.; Burguera, E.F.; Blanco, F.J. Anti-Inflammatory Effects of Novel Standardized Platelet Rich Plasma Releasates on Knee Osteoarthritic Chondrocytes and Cartilage in vitro. *Curr. Pharm. Biotechnol.* **2019**, *20*, 920–933. [[CrossRef](#)] [[PubMed](#)]
42. Bonazza, V.; Borsani, E.; Buffoli, B.; Castrezzi, S.; Rezzani, R.; Rodella, L.F. How the different material and shape of the blood collection tube influences the Concentrated Growth Factors production. *Microsc. Res. Tech.* **2016**, *79*, 1173–1178. [[CrossRef](#)] [[PubMed](#)]
43. Tsujino, T.; Masuki, H.; Nakamura, M.; Isobe, K.; Kawabata, H.; Aizawa, H.; Watanabe, T.; Kitamura, Y.; Okudera, H.; Okuda, K.; et al. Striking Differences in Platelet Distribution between Advanced-Platelet-Rich Fibrin and Concentrated Growth Factors: Effects of Silica-Containing Plastic Tubes. *J. Funct. Biomater.* **2019**, *10*. [[CrossRef](#)] [[PubMed](#)]

44. Parrish, W.R.;ROIDES, B. Physiology of Blood Components in Wound Healing: An Appreciation of Cellular Co-Operativity in Platelet Rich Plasma Action. *J. Exerc. Sports Orthop.* **2017**, *4*, 1–14. [[CrossRef](#)]
45. Davis, V.L.; Abukabda, A.B.; Radio, N.M.; Witt-Enderby, P.A.; Clafshenkel, W.P.; Cairone, J.V.; Rutkowski, J.L. Platelet-rich preparations to improve healing. Part II: Platelet activation and enrichment, leukocyte inclusion, and other selection criteria. *J. Oral Implantol.* **2014**, *40*, 511–521. [[CrossRef](#)]
46. Harrison, S.; Vavken, P.; Kevy, S.; Jacobson, M.; Zurakowski, D.; Murray, M.M. Platelet activation by collagen provides sustained release of anabolic cytokines. *Am. J. Sports Med.* **2011**, *39*, 729–734. [[CrossRef](#)]
47. Cavallo, C.; Roffi, A.; Grigolo, B.; Mariani, E.; Pratelli, L.; Merli, G.; Kon, E.; Marcacci, M.; Filardo, G. Platelet-Rich Plasma: The Choice of Activation Method Affects the Release of Bioactive Molecules. *Biomed. Res. Int.* **2016**, *2016*, 6591717. [[CrossRef](#)]
48. Irmak, G.; Demirtas, T.T.; Gumusderelioglu, M. Sustained Release of Growth Factors from Photoactivated Platelet Rich Plasma (PRP). *Eur. J. Pharm. Biopharm.* **2019**. [[CrossRef](#)]
49. Dohan Ehrenfest, D.M.; Andia, I.; Zumstein, M.A.; Zhang, C.Q.; Pinto, N.R.; Bielecki, T. Classification of platelet concentrates (Platelet-Rich Plasma-PRP, Platelet-Rich Fibrin-PRF) for topical and infiltrative use in orthopedic and sports medicine: Current consensus, clinical implications and perspectives. *Muscles Ligaments Tendons J.* **2014**, *4*, 3–9. [[CrossRef](#)]
50. Dohan Ehrenfest, D.M.; Bielecki, T.; Jimbo, R.; Barbe, G.; Del Corso, M.; Inchingolo, F.; Sammartino, G. Do the fibrin architecture and leukocyte content influence the growth factor release of platelet concentrates? An evidence-based answer comparing a pure platelet-rich plasma (P-PRP) gel and a leukocyte- and platelet-rich fibrin (L-PRF). *Curr. Pharm. Biotechnol.* **2012**, *13*, 1145–1152. [[CrossRef](#)]
51. Dohan Ehrenfest, D.M.; Pinto, N.R.; Pereda, A.; Jimenez, P.; Corso, M.D.; Kang, B.S.; Nally, M.; Lanata, N.; Wang, H.L.; Quirynen, M. The impact of the centrifuge characteristics and centrifugation protocols on the cells, growth factors, and fibrin architecture of a leukocyte- and platelet-rich fibrin (L-PRF) clot and membrane. *Platelets* **2018**, *29*, 171–184. [[CrossRef](#)] [[PubMed](#)]
52. Chatterjee, A.; Debnath, K. Comparative evaluation of growth factors from platelet concentrates: An in vitro study. *J. Indian Soc. Periodontol.* **2019**, *23*, 322–328. [[CrossRef](#)] [[PubMed](#)]
53. Lucarelli, E.; Beretta, R.; Dozza, B.; Tazzari, P.L.; O'Connell, S.M.; Ricci, F.; Pierini, M.; Squarzone, S.; Pagliaro, P.P.; Oprita, E.I.; et al. A recently developed bifacial platelet-rich fibrin matrix. *Eur. Cell Mater.* **2010**, *20*, 13–23. [[CrossRef](#)] [[PubMed](#)]
54. Rossi, L.A.; Murray, I.R.; Chu, C.R.; Muschler, G.F.; Rodeo, S.A.; Piuze, N.S. Classification systems for platelet-rich plasma. *Bone Jt. J.* **2019**, *101*, 891–896. [[CrossRef](#)] [[PubMed](#)]
55. Dohan Ehrenfest, D.M.; Bielecki, T.; Mishra, A.; Borzini, P.; Inchingolo, F.; Sammartino, G.; Rasmussen, L.; Everts, P.A. In search of a consensus terminology in the field of platelet concentrates for surgical use: Platelet-rich plasma (PRP), platelet-rich fibrin (PRF), fibrin gel polymerization and leukocytes. *Curr. Pharm. Biotechnol.* **2012**, *13*, 1131–1137. [[CrossRef](#)] [[PubMed](#)]
56. Mishra, A.; Harmon, K.; Woodall, J.; Vieira, A. Sports medicine applications of platelet rich plasma. *Curr. Pharm. Biotechnol.* **2012**, *13*, 1185–1195. [[CrossRef](#)]
57. Mautner, K.; Malanga, G.A.; Smith, J.; Shiple, B.; Ibrahim, V.; Sampson, S.; Bowen, J.E. A call for a standard classification system for future biologic research: The rationale for new PRP nomenclature. *PM R* **2015**, *7*, S53–S59. [[CrossRef](#)]
58. Magalon, J.; Chateau, A.L.; Bertrand, B.; Louis, M.L.; Silvestre, A.; Giraudo, L.; Veran, J.; Sabatier, F. DEPA classification: A proposal for standardising PRP use and a retrospective application of available devices. *BMJ Open Sport Exerc. Med.* **2016**, *2*, e000060. [[CrossRef](#)]
59. Lana, J.; Purita, J.; Paulus, C.; Huber, S.C.; Rodrigues, B.L.; Rodrigues, A.A.; Santana, M.H.; Madureira, J.L., Jr.; Malheiros Luzo, A.C.; Belangero, W.D.; et al. Contributions for classification of platelet rich plasma-proposal of a new classification: MARSPELL. *Regen. Med.* **2017**, *12*, 565–574. [[CrossRef](#)]
60. Harrison, P.; Subcommittee on Platelet, P. The use of platelets in regenerative medicine and proposal for a new classification system: Guidance from the SSC of the ISTH. *J. Thromb. Haemost.* **2018**, *16*, 1895–1900. [[CrossRef](#)]
61. Grozovsky, R.; Giannini, S.; Falet, H.; Hoffmeister, K.M. Regulating billions of blood platelets: Glycans and beyond. *Blood* **2015**, *126*, 1877–1884. [[CrossRef](#)] [[PubMed](#)]

62. Giusti, I.; Rughetti, A.; D'Ascenzo, S.; Millimaggi, D.; Pavan, A.; Dell'Orso, L.; Dolo, V. Identification of an optimal concentration of platelet gel for promoting angiogenesis in human endothelial cells. *Transfusion* **2009**, *49*, 771–778. [[CrossRef](#)] [[PubMed](#)]
63. Weibrich, G.; Hansen, T.; Kleis, W.; Buch, R.; Hitzler, W.E. Effect of platelet concentration in platelet-rich plasma on peri-implant bone regeneration. *Bone* **2004**, *34*, 665–671. [[CrossRef](#)] [[PubMed](#)]
64. Woodell-May, J.E.; Ridderman, D.N.; Swift, M.J.; Higgins, J. Producing accurate platelet counts for platelet rich plasma: Validation of a hematology analyzer and preparation techniques for counting. *J. Craniofacial Surg.* **2005**, *16*, 749–756. [[CrossRef](#)] [[PubMed](#)]
65. Fitzpatrick, J.; Bulsara, M.K.; McCrory, P.R.; Richardson, M.D.; Zheng, M.H. Analysis of Platelet-Rich Plasma Extraction: Variations in Platelet and Blood Components Between 4 Common Commercial Kits. *Orthop. J. Sports Med.* **2017**, *5*, 2325967116675272. [[CrossRef](#)]
66. Melo, B.A.G.; Luzo, A.C.M.; Lana, J.; Santana, M.H.A. Centrifugation Conditions in the L-PRP Preparation Affect Soluble Factors Release and Mesenchymal Stem Cell Proliferation in Fibrin Nanofibers. *Molecules* **2019**, *24*. [[CrossRef](#)]
67. Anitua, E.; Zaldueño, M.; Troya, M.; Padilla, S.; Orive, G. Leukocyte inclusion within a platelet rich plasma-derived fibrin scaffold stimulates a more pro-inflammatory environment and alters fibrin properties. *PLoS ONE* **2015**, *10*, e0121713. [[CrossRef](#)]
68. Assirelli, E.; Filardo, G.; Mariani, E.; Kon, E.; Roffi, A.; Vaccaro, F.; Marcacci, M.; Facchini, A.; Pulsatelli, L. Effect of two different preparations of platelet-rich plasma on synoviocytes. *Knee Surg. Sports Traumatol. Arthrosc.* **2015**, *23*, 2690–2703. [[CrossRef](#)]
69. Cavallo, C.; Filardo, G.; Mariani, E.; Kon, E.; Marcacci, M.; Pereira Ruiz, M.T.; Facchini, A.; Grigolo, B. Comparison of platelet-rich plasma formulations for cartilage healing: An in vitro study. *J. Bone Joint Surg. Am.* **2014**, *96*, 423–429. [[CrossRef](#)]
70. McCarrel, T.M.; Minas, T.; Fortier, L.A. Optimization of leukocyte concentration in platelet-rich plasma for the treatment of tendinopathy. *J. Bone Jt. Surg. Am.* **2012**, *94*, e143. [[CrossRef](#)]
71. Pavlovic, V.; Ciric, M.; Jovanovic, V.; Stojanovic, P. Platelet Rich Plasma: A short overview of certain bioactive components. *Open Med. (Wars)* **2016**, *11*, 242–247. [[CrossRef](#)] [[PubMed](#)]
72. Anitua, E.; Sanchez, M.; Nurden, A.T.; Nurden, P.; Orive, G.; Andia, I. New insights into and novel applications for platelet-rich fibrin therapies. *Trends Biotechnol.* **2006**, *24*, 227–234. [[CrossRef](#)] [[PubMed](#)]
73. Li, T.; Ma, Y.; Wang, M.; Wang, T.; Wei, J.; Ren, R.; He, M.; Wang, G.; Boey, J.; Armstrong, D.G.; et al. Platelet-rich plasma plays an antibacterial, anti-inflammatory and cell proliferation-promoting role in an in vitro model for diabetic infected wounds. *Infect. Drug Resist.* **2019**, *12*, 297–309. [[CrossRef](#)] [[PubMed](#)]
74. Nurden, A.T. Platelets, inflammation and tissue regeneration. *Thromb. Haemost.* **2011**, *105* (Suppl. S1), S13–S33. [[CrossRef](#)]
75. Bielecki, T.; Dohan Ehrenfest, D.M.; Everts, P.A.; Wiczowski, A. The role of leukocytes from L-PRP/L-PRF in wound healing and immune defense: New perspectives. *Curr. Pharm. Biotechnol.* **2012**, *13*, 1153–1162. [[CrossRef](#)]
76. Rane, D.; Patil, T.; More, V.; Patra, S.S.; Bodhale, N.; Dandapat, J.; Sarkar, A. Neutrophils: Interplay between host defense, cellular metabolism and intracellular infection. *Cytokine* **2018**, *112*, 44–51. [[CrossRef](#)]
77. Moojen, D.J.; Everts, P.A.; Schure, R.M.; Overvest, E.P.; van Zundert, A.; Knappe, J.T.; Castelein, R.M.; Creemers, L.B.; Dhert, W.J. Antimicrobial activity of platelet-leukocyte gel against *Staphylococcus aureus*. *J. Orthop. Res.* **2008**, *26*, 404–410. [[CrossRef](#)]
78. Magalon, J.; Bausset, O.; Serratrice, N.; Giraudou, L.; Aboudou, H.; Veran, J.; Magalon, G.; Dignat-Georges, F.; Sabatier, F. Characterization and comparison of 5 platelet-rich plasma preparations in a single-donor model. *Arthroscopy* **2014**, *30*, 629–638. [[CrossRef](#)]
79. Castillo, T.N.; Pouliot, M.A.; Kim, H.J.; Drago, J.L. Comparison of growth factor and platelet concentration from commercial platelet-rich plasma separation systems. *Am. J. Sports Med.* **2011**, *39*, 266–271. [[CrossRef](#)]
80. Kobayashi, Y.; Saita, Y.; Nishio, H.; Ikeda, H.; Takazawa, Y.; Nagao, M.; Takaku, T.; Komatsu, N.; Kaneko, K. Leukocyte concentration and composition in platelet-rich plasma (PRP) influences the growth factor and protease concentrations. *J. Orthop. Sci.* **2016**, *21*, 683–689. [[CrossRef](#)]
81. Celik, M.O.; Labuz, D.; Henning, K.; Busch-Dienstfertig, M.; Gaveriaux-Ruff, C.; Kieffer, B.L.; Zimmer, A.; Machelska, H. Leukocyte opioid receptors mediate analgesia via Ca(2+)-regulated release of opioid peptides. *Brain Behav. Immun.* **2016**, *57*, 227–242. [[CrossRef](#)] [[PubMed](#)]

82. Arnold, L.; Henry, A.; Poron, F.; Baba-Amer, Y.; van Rooijen, N.; Plonquet, A.; Gherardi, R.K.; Chazaud, B. Inflammatory monocytes recruited after skeletal muscle injury switch into antiinflammatory macrophages to support myogenesis. *J. Exp. Med.* **2007**, *204*, 1057–1069. [[CrossRef](#)] [[PubMed](#)]
83. Lana, J.F.; Macedo, A.; Ingrao, I.L.G.; Huber, S.C.; Santos, G.S.; Santana, M.H.A. Leukocyte-rich PRP for knee osteoarthritis: Current concepts. *J. Clin. Orthop. Trauma* **2019**, *10*, S179–S182. [[CrossRef](#)] [[PubMed](#)]
84. Eken, C.; Sadallah, S.; Martin, P.J.; Treves, S.; Schifferli, J.A. Ectosomes of polymorphonuclear neutrophils activate multiple signaling pathways in macrophages. *Immunobiology* **2013**, *218*, 382–392. [[CrossRef](#)] [[PubMed](#)]
85. Lawrence, T.; Natoli, G. Transcriptional regulation of macrophage polarization: Enabling diversity with identity. *Nat. Rev. Immunol.* **2011**, *11*, 750–761. [[CrossRef](#)] [[PubMed](#)]
86. Winterbourn, C.C.; Kettle, A.J.; Hampton, M.B. Reactive Oxygen Species and Neutrophil Function. *Annu. Rev. Biochem.* **2016**, *85*, 765–792. [[CrossRef](#)] [[PubMed](#)]
87. Parrish, W.R.; Roides, B.; Hwang, J.; Mafilios, M.; Story, B.; Bhattacharyya, S. Normal platelet function in platelet concentrates requires non-platelet cells: A comparative in vitro evaluation of leucocyte-rich (type 1a) and leucocyte-poor (type 3b) platelet concentrates. *BMJ Open Sport Exerc. Med.* **2016**, *2*, e000071. [[CrossRef](#)]
88. Kantarci, A.; Van Dyke, T.E. Lipoxins in chronic inflammation. *Crit. Rev. Oral Biol. Med.* **2003**, *14*, 4–12. [[CrossRef](#)]
89. Serhan, C.N. Resolution phase of inflammation: Novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. *Annu. Rev. Immunol.* **2007**, *25*, 101–137. [[CrossRef](#)]
90. Everts, P.A.; Malanga, G.A.; Paul, R.V.; Rothenberg, J.B.; Stephens, N.; Mautner, K.R. Assessing clinical implications and perspectives of the pathophysiological effects of erythrocytes and plasma free hemoglobin in autologous biologics for use in musculoskeletal regenerative medicine therapies. A review. *Regen. Ther.* **2019**, *11*, 56–64. [[CrossRef](#)]
91. Karsten, E.; Hill, C.J.; Herbert, B.R. Red blood cells: The primary reservoir of macrophage migration inhibitory factor in whole blood. *Cytokine* **2018**, *102*, 34–40. [[CrossRef](#)] [[PubMed](#)]
92. Zhang, P.L.; Liu, J.; Xu, L.; Sun, Y.; Sun, X.C. Synovial Fluid Macrophage Migration Inhibitory Factor Levels Correlate with Severity of Self-Reported Pain in Knee Osteoarthritis Patients. *Med. Sci. Monit.* **2016**, *22*, 2182–2186. [[CrossRef](#)] [[PubMed](#)]
93. Liu, M.; Hu, C. Association of MIF in serum and synovial fluid with severity of knee osteoarthritis. *Clin. Biochem.* **2012**, *45*, 737–739. [[CrossRef](#)] [[PubMed](#)]
94. Braun, H.J.; Kim, H.J.; Chu, C.R.; Drago, J.L. The effect of platelet-rich plasma formulations and blood products on human synoviocytes: Implications for intra-articular injury and therapy. *Am. J. Sports Med.* **2014**, *42*, 1204–1210. [[CrossRef](#)]
95. Jansen, N.W.; Roosendaal, G.; Bijlsma, J.W.; DeGroot, J.; Theobald, M.; Lafeber, F.P. Degenerated and healthy cartilage are equally vulnerable to blood-induced damage. *Ann. Rheum. Dis.* **2008**, *67*, 1468–1473. [[CrossRef](#)]
96. Hooiveld, M.J.; Roosendaal, G.; van den Berg, H.M.; Bijlsma, J.W.; Lafeber, F.P. Haemoglobin-derived iron-dependent hydroxyl radical formation in blood-induced joint damage: An in vitro study. *Rheumatology* **2003**, *42*, 784–790. [[CrossRef](#)]
97. Hooiveld, M.; Roosendaal, G.; Wenting, M.; van den Berg, M.; Bijlsma, J.; Lafeber, F.P. Short-Term Exposure of Cartilage to Blood Results in Chondrocyte Apoptosis. *Am. J. Pathol.* **2003**, *162*, 943–951. [[CrossRef](#)]
98. Wagener, F.A.; Scharstuhl, A.; Tyrrell, R.M.; Von den Hoff, J.W.; Jozkowicz, A.; Dulak, J.; Russel, F.G.; Kuijpers-Jagtman, A.M. The heme-heme oxygenase system in wound healing; implications for scar formation. *Curr. Drug Targets* **2010**, *11*, 1571–1585. [[CrossRef](#)]
99. Lundvig, D.M.; Immenschuh, S.; Wagener, F.A. Heme oxygenase, inflammation, and fibrosis: The good, the bad, and the ugly? *Front. Pharmacol.* **2012**, *3*, 81. [[CrossRef](#)]
100. Vijayan, V.; Wagener, F.; Immenschuh, S. The macrophage heme-heme oxygenase-1 system and its role in inflammation. *Biochem. Pharmacol.* **2018**, *153*, 159–167. [[CrossRef](#)]
101. Coppinger, J.A.; Maguire, P.B. Insights into the platelet releasate. *Curr. Pharm. Des.* **2007**, *13*, 2640–2646. [[CrossRef](#)] [[PubMed](#)]
102. Mazzucco, L.; Borzini, P.; Gope, R. Platelet-derived factors involved in tissue repair-from signal to function. *Transfus. Med. Rev.* **2010**, *24*, 218–234. [[CrossRef](#)] [[PubMed](#)]
103. Le, A.D.K.; Enweze, L.; DeBaun, M.R.; Drago, J.L. Platelet-Rich Plasma. *Clin. Sports Med.* **2019**, *38*, 17–44. [[CrossRef](#)] [[PubMed](#)]

104. Foster, T.E.; Puskas, B.L.; Mandelbaum, B.R.; Gerhardt, M.B.; Rodeo, S.A. Platelet-rich plasma: From basic science to clinical applications. *Am. J. Sports Med.* **2009**, *37*, 2259–2272. [[CrossRef](#)]
105. Kobayashi, E.; Fluckiger, L.; Fujioka-Kobayashi, M.; Sawada, K.; Sculean, A.; Schaller, B.; Miron, R.J. Comparative release of growth factors from PRP, PRF, and advanced-PRF. *Clin. Oral Investig.* **2016**, *20*, 2353–2360. [[CrossRef](#)]
106. Mazzucco, L.; Balbo, V.; Cattana, E.; Guaschino, R.; Borzini, P. Not every PRP-gel is born equal. Evaluation of growth factor availability for tissues through four PRP-gel preparations: Fibrinet, RegenPRP-Kit, Plateletex and one manual procedure. *Vox Sang.* **2009**, *97*, 110–118. [[CrossRef](#)]
107. Mazzocca, A.D.; McCarthy, M.B.; Chowanec, D.M.; Cote, M.P.; Romeo, A.A.; Bradley, J.P.; Arciero, R.A.; Beitzel, K. Platelet-rich plasma differs according to preparation method and human variability. *J. Bone Jt. Surg. Am.* **2012**, *94*, 308–316. [[CrossRef](#)]
108. Oh, J.H.; Kim, W.; Park, K.U.; Roh, Y.H. Comparison of the Cellular Composition and Cytokine-Release Kinetics of Various Platelet-Rich Plasma Preparations. *Am. J. Sports Med.* **2015**, *43*, 3062–3070. [[CrossRef](#)]
109. Ha, C.W.; Park, Y.B.; Jang, J.W.; Kim, M.; Kim, J.A.; Park, Y.G. Variability of the Composition of Growth Factors and Cytokines in Platelet-Rich Plasma From the Knee With Osteoarthritis. *Arthroscopy* **2019**, *35*, 2878–2884. [[CrossRef](#)]
110. Lane, N.E.; Brandt, K.; Hawker, G.; Peeva, E.; Schreyer, E.; Tsuji, W.; Hochberg, M.C. OARSI-FDA initiative: Defining the disease state of osteoarthritis. *Osteoarthr. Cartil.* **2011**, *19*, 478–482. [[CrossRef](#)]
111. Bannuru, R.R.; Osani, M.C.; Vaysbrot, E.E.; Arden, N.K.; Bennell, K.; Bierma-Zeinstra, S.M.A.; Kraus, V.B.; Lohmander, L.S.; Abbott, J.H.; Bhandari, M.; et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. *Osteoarthr. Cartil.* **2019**, *27*, 1578–1589. [[CrossRef](#)]
112. Zhang, W.; Moskowitz, R.W.; Nuki, G.; Abramson, S.; Altman, R.D.; Arden, N.; Bierma-Zeinstra, S.; Brandt, K.D.; Croft, P.; Doherty, M.; et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. *Osteoarthr. Cartil.* **2008**, *16*, 137–162. [[CrossRef](#)]
113. Sanchez, M.; Anitua, E.; Azofra, J.; Aguirre, J.J.; Andia, I. Intra-articular injection of an autologous preparation rich in growth factors for the treatment of knee OA: A retrospective cohort study. *Clin. Exp. Rheumatol.* **2008**, *26*, 910–913.
114. Sanchez, M.; Fiz, N.; Azofra, J.; Usabiaga, J.; Aduriz Recalde, E.; Garcia Gutierrez, A.; Albillos, J.; Garate, R.; Aguirre, J.J.; Padilla, S.; et al. A randomized clinical trial evaluating plasma rich in growth factors (PRGF-Endoret) versus hyaluronic acid in the short-term treatment of symptomatic knee osteoarthritis. *Arthroscopy* **2012**, *28*, 1070–1078. [[CrossRef](#)]
115. Vaquerizo, V.; Plasencia, M.A.; Arribas, I.; Seijas, R.; Padilla, S.; Orive, G.; Anitua, E. Comparison of intra-articular injections of plasma rich in growth factors (PRGF-Endoret) versus Durolane hyaluronic acid in the treatment of patients with symptomatic osteoarthritis: A randomized controlled trial. *Arthroscopy* **2013**, *29*, 1635–1643. [[CrossRef](#)]
116. Raeissadat, S.A.; Rayegani, S.M.; Ahangar, A.G.; Abadi, P.H.; Mojgani, P.; Ahangar, O.G. Efficacy of Intra-articular Injection of a Newly Developed Plasma Rich in Growth Factor (PRGF) Versus Hyaluronic Acid on Pain and Function of Patients with Knee Osteoarthritis: A Single-Blinded Randomized Clinical Trial. *Clin. Med. Insights Arthritis Musculoskelet. Disord.* **2017**, *10*, 1179544117733452. [[CrossRef](#)]
117. Wang-Saegusa, A.; Cugat, R.; Ares, O.; Seijas, R.; Cusco, X.; Garcia-Balletbo, M. Infiltration of plasma rich in growth factors for osteoarthritis of the knee short-term effects on function and quality of life. *Arch. Orthop. Trauma Surg.* **2011**, *131*, 311–317. [[CrossRef](#)]
118. Vaquerizo, V.; Padilla, S.; Aguirre, J.J.; Begona, L.; Orive, G.; Anitua, E. Two cycles of plasma rich in growth factors (PRGF-Endoret) intra-articular injections improve stiffness and activities of daily living but not pain compared to one cycle on patients with symptomatic knee osteoarthritis. *Knee Surg. Sports Traumatol. Arthrosc.* **2018**, *26*, 2615–2621. [[CrossRef](#)]
119. Kon, E.; Buda, R.; Filardo, G.; Di Martino, A.; Timoncini, A.; Cenacchi, A.; Fornasari, P.M.; Giannini, S.; Marcacci, M. Platelet-rich plasma: Intra-articular knee injections produced favorable results on degenerative cartilage lesions. *Knee Surg. Sports Traumatol. Arthrosc.* **2010**, *18*, 472–479. [[CrossRef](#)]
120. Filardo, G.; Kon, E.; Buda, R.; Timoncini, A.; Di Martino, A.; Cenacchi, A.; Fornasari, P.M.; Giannini, S.; Marcacci, M. Platelet-rich plasma intra-articular knee injections for the treatment of degenerative cartilage lesions and osteoarthritis. *Knee Surg. Sports Traumatol. Arthrosc.* **2011**, *19*, 528–535. [[CrossRef](#)]

121. Gobbi, A.; Karnatzikos, G.; Mahajan, V.; Malchira, S. Platelet-rich plasma treatment in symptomatic patients with knee osteoarthritis: Preliminary results in a group of active patients. *Sports Health* **2012**, *4*, 162–172. [[CrossRef](#)]
122. Halpern, B.; Chaudhury, S.; Rodeo, S.A.; Hayter, C.; Bogner, E.; Potter, H.G.; Nguyen, J. Clinical and MRI outcomes after platelet-rich plasma treatment for knee osteoarthritis. *Clin. J. Sport Med.* **2013**, *23*, 238–239. [[CrossRef](#)] [[PubMed](#)]
123. Gobbi, A.; Lad, D.; Karnatzikos, G. The effects of repeated intra-articular PRP injections on clinical outcomes of early osteoarthritis of the knee. *Knee Surg. Sports Traumatol. Arthrosc.* **2015**, *23*, 2170–2177. [[CrossRef](#)] [[PubMed](#)]
124. Hassan, A.S.; El-Shafey, A.M.; Ahmed, H.S.; Hamed, M.S. Effectiveness of the intra-articular injection of platelet rich plasma in the treatment of patients with primary knee osteoarthritis. *Egypt. Rheumatol.* **2015**, *37*, 119–124. [[CrossRef](#)]
125. Bottegoni, C.; Dei Giudici, L.; Salvemini, S.; Chiurazzi, E.; Bencivenga, R.; Gigante, A. Homologous platelet-rich plasma for the treatment of knee osteoarthritis in selected elderly patients: An open-label, uncontrolled, pilot study. *Ther. Adv. Musculoskelet. Dis.* **2016**, *8*, 35–41. [[CrossRef](#)] [[PubMed](#)]
126. Chen, C.P.C.; Cheng, C.H.; Hsu, C.C.; Lin, H.C.; Tsai, Y.R.; Chen, J.L. The influence of platelet rich plasma on synovial fluid volumes, protein concentrations, and severity of pain in patients with knee osteoarthritis. *Exp. Gerontol.* **2017**, *93*, 68–72. [[CrossRef](#)]
127. Huang, P.H.; Wang, C.J.; Chou, W.Y.; Wang, J.W.; Ko, J.Y. Short-term clinical results of intra-articular PRP injections for early osteoarthritis of the knee. *Int. J. Surg.* **2017**, *42*, 117–122. [[CrossRef](#)]
128. Fawzy, R.M.; Hashaad, N.I.; Mansour, A.I. Decrease of serum biomarker of type II Collagen degradation (Coll2-1) by intra-articular injection of an autologous plasma-rich-platelet in patients with unilateral primary knee osteoarthritis. *Eur. J. Rheumatol.* **2017**, *4*, 93–97. [[CrossRef](#)]
129. Taniguchi, Y.; Yoshioka, T.; Kanamori, A.; Aoto, K.; Sugaya, H.; Yamazaki, M. Intra-articular platelet-rich plasma (PRP) injections for treating knee pain associated with osteoarthritis of the knee in the Japanese population: A phase I and IIa clinical trial. *Nagoya J. Med. Sci.* **2018**, *80*, 39–51. [[CrossRef](#)]
130. Burchard, R.; Huflage, H.; Soost, C.; Richter, O.; Bouillon, B.; Graw, J.A. Efficiency of platelet-rich plasma therapy in knee osteoarthritis does not depend on level of cartilage damage. *J. Orthop. Surg. Res.* **2019**, *14*, 153. [[CrossRef](#)]
131. Sucuoglu, H.; Ustunsoy, S. The short-term effect of PRP on chronic pain in knee osteoarthritis. *Agri* **2019**, *31*, 63–69. [[CrossRef](#)] [[PubMed](#)]
132. Cerza, F.; Carni, S.; Carcangiu, A.; Di Vavo, I.; Schiavilla, V.; Pecora, A.; De Biasi, G.; Ciuffreda, M. Comparison between hyaluronic acid and platelet-rich plasma, intra-articular infiltration in the treatment of gonarthrosis. *Am. J. Sports Med.* **2012**, *40*, 2822–2827. [[CrossRef](#)] [[PubMed](#)]
133. Filardo, G.; Kon, E.; Di Martino, A.; Di Matteo, B.; Merli, M.L.; Cenacchi, A.; Fornasari, P.M.; Marcacci, M. Platelet-rich plasma vs hyaluronic acid to treat knee degenerative pathology: Study design and preliminary results of a randomized controlled trial. *BMC Musculoskelet. Disord.* **2012**, *13*, 229. [[CrossRef](#)] [[PubMed](#)]
134. Spakova, T.; Rosocha, J.; Lacko, M.; Harvanova, D.; Gharaibeh, A. Treatment of knee joint osteoarthritis with autologous platelet-rich plasma in comparison with hyaluronic acid. *Am. J. Phys. Med. Rehabil.* **2012**, *91*, 411–417. [[CrossRef](#)]
135. Say, F.; Gurler, D.; Yener, K.; Bulbul, M.; Malkoc, M. Platelet-rich plasma injection is more effective than hyaluronic acid in the treatment of knee osteoarthritis. *Acta Chir. Orthop. Traumatol. Cechoslov.* **2013**, *80*, 278–283.
136. Guler, O.; Mutlu, S.; Isyar, M.; Seker, A.; Kayaalp, M.E.; Mahirogullari, M. Comparison of short-term results of intraarticular platelet-rich plasma (PRP) and hyaluronic acid treatments in early-stage gonarthrosis patients. *Eur. J. Orthop. Surg. Traumatol.* **2015**, *25*, 509–513. [[CrossRef](#)]
137. Raeissadat, S.A.; Rayegani, S.M.; Hassanabadi, H.; Fathi, M.; Ghorbani, E.; Babae, M.; Azma, K. Knee Osteoarthritis Injection Choices: Platelet-Rich Plasma (PRP) Versus Hyaluronic Acid (A one-year randomized clinical trial). *Clin. Med. Insights Arthritis Musculoskelet. Disord.* **2015**, *8*, 1–8. [[CrossRef](#)]
138. Montanez-Heredia, E.; Irizar, S.; Huertas, P.J.; Otero, E.; Del Valle, M.; Prat, I.; Diaz-Gallardo, M.S.; Peran, M.; Marchal, J.A.; Hernandez-Lamas Mdel, C. Intra-Articular Injections of Platelet-Rich Plasma versus Hyaluronic Acid in the Treatment of Osteoarthritic Knee Pain: A Randomized Clinical Trial in the Context of the Spanish National Health Care System. *Int. J. Mol. Sci.* **2016**, *17*. [[CrossRef](#)]

139. Ahmad, H.S.; Farrag, S.E.; Okasha, A.E.; Kadry, A.O.; Ata, T.B.; Monir, A.A.; Shady, I. Clinical outcomes are associated with changes in ultrasonographic structural appearance after platelet-rich plasma treatment for knee osteoarthritis. *Int. J. Rheum. Dis.* **2018**, *21*, 960–966. [[CrossRef](#)]
140. Louis, M.L.; Magalon, J.; Jouve, E.; Borne, C.E.; Mattei, J.C.; Chagnaud, C.; Rochwerger, A.; Veran, J.; Sabatier, F. Growth Factors Levels Determine Efficacy of Platelets Rich Plasma Injection in Knee Osteoarthritis: A Randomized Double Blind Noninferiority Trial Compared with Viscosupplementation. *Arthroscopy* **2018**, *34*, 1530–1540. [[CrossRef](#)]
141. Filardo, G.; Di Matteo, B.; Di Martino, A.; Merli, M.L.; Cenacchi, A.; Fornasari, P.; Marcacci, M.; Kon, E. Platelet-Rich Plasma Intra-articular Knee Injections Show No Superiority Versus Viscosupplementation: A Randomized Controlled Trial. *Am. J. Sports Med.* **2015**, *43*, 1575–1582. [[CrossRef](#)] [[PubMed](#)]
142. Di Martino, A.; Di Matteo, B.; Papio, T.; Tentoni, F.; Selleri, F.; Cenacchi, A.; Kon, E.; Filardo, G. Platelet-Rich Plasma Versus Hyaluronic Acid Injections for the Treatment of Knee Osteoarthritis: Results at 5 Years of a Double-Blind, Randomized Controlled Trial. *Am. J. Sports Med.* **2019**, *47*, 347–354. [[CrossRef](#)] [[PubMed](#)]
143. Kon, E.; Mandelbaum, B.; Buda, R.; Filardo, G.; Delcogliano, M.; Timoncini, A.; Fornasari, P.M.; Giannini, S.; Marcacci, M. Platelet-rich plasma intra-articular injection versus hyaluronic acid viscosupplementation as treatments for cartilage pathology: From early degeneration to osteoarthritis. *Arthroscopy* **2011**, *27*, 1490–1501. [[CrossRef](#)] [[PubMed](#)]
144. Lana, J.F.; Weglein, A.; Sampson, S.E.; Vicente, E.F.; Huber, S.C.; Souza, C.V.; Ambach, M.A.; Vincent, H.; Urban-Paffaro, A.; Onodera, C.M.; et al. Randomized controlled trial comparing hyaluronic acid, platelet-rich plasma and the combination of both in the treatment of mild and moderate osteoarthritis of the knee. *J. Stem Cells Regen. Med.* **2016**, *12*, 69–78.
145. Yu, W.; Xu, P.; Huang, G.; Liu, L. Clinical therapy of hyaluronic acid combined with platelet-rich plasma for the treatment of knee osteoarthritis. *Exp. Ther. Med.* **2018**, *16*, 2119–2125. [[CrossRef](#)]
146. Lin, K.Y.; Yang, C.C.; Hsu, C.J.; Yeh, M.L.; Renn, J.H. Intra-articular Injection of Platelet-Rich Plasma Is Superior to Hyaluronic Acid or Saline Solution in the Treatment of Mild to Moderate Knee Osteoarthritis: A Randomized, Double-Blind, Triple-Parallel, Placebo-Controlled Clinical Trial. *Arthroscopy* **2019**, *35*, 106–117. [[CrossRef](#)]
147. Duyumus, T.M.; Mutlu, S.; Dernek, B.; Komur, B.; Aydogmus, S.; Kesiktaş, F.N. Choice of intra-articular injection in treatment of knee osteoarthritis: Platelet-rich plasma, hyaluronic acid or ozone options. *Knee Surg. Sports Traumatol. Arthrosc.* **2017**, *25*, 485–492. [[CrossRef](#)]
148. Dernek, B.; Kesiktaş, F.N. Efficacy of combined ozone and platelet-rich-plasma treatment versus platelet-rich-plasma treatment alone in early stage knee osteoarthritis. *J. Back Musculoskelet. Rehabil.* **2019**, *32*, 305–311. [[CrossRef](#)]
149. Huang, Y.; Liu, X.; Xu, X.; Liu, J. Intra-articular injections of platelet-rich plasma, hyaluronic acid or corticosteroids for knee osteoarthritis: A prospective randomized controlled study. *Orthopade* **2019**, *48*, 239–247. [[CrossRef](#)]
150. Camurcu, Y.; Sofu, H.; Ucpunar, H.; Kockara, N.; Cobden, A.; Duman, S. Single-dose intra-articular corticosteroid injection prior to platelet-rich plasma injection resulted in better clinical outcomes in patients with knee osteoarthritis: A pilot study. *J. Back Musculoskelet. Rehabil.* **2018**, *31*, 603–610. [[CrossRef](#)]
151. Filardo, G.; Kon, E.; Pereira Ruiz, M.T.; Vaccaro, F.; Guitaldi, R.; Di Martino, A.; Cenacchi, A.; Fornasari, P.M.; Marcacci, M. Platelet-rich plasma intra-articular injections for cartilage degeneration and osteoarthritis: Single- versus double-spinning approach. *Knee Surg. Sports Traumatol. Arthrosc.* **2012**, *20*, 2082–2091. [[CrossRef](#)] [[PubMed](#)]
152. Hart, R.; Safi, A.; Komzak, M.; Jajtner, P.; Puskeiler, M.; Hartova, P. Platelet-rich plasma in patients with tibiofemoral cartilage degeneration. *Arch. Orthop. Trauma Surg.* **2013**, *133*, 1295–1301. [[CrossRef](#)] [[PubMed](#)]
153. Patel, S.; Dhillon, M.S.; Aggarwal, S.; Marwaha, N.; Jain, A. Treatment with platelet-rich plasma is more effective than placebo for knee osteoarthritis: A prospective, double-blind, randomized trial. *Am. J. Sports Med.* **2013**, *41*, 356–364. [[CrossRef](#)] [[PubMed](#)]
154. Gormeli, G.; Gormeli, C.A.; Ataoglu, B.; Colak, C.; Aslanturk, O.; Ertem, K. Multiple PRP injections are more effective than single injections and hyaluronic acid in knees with early osteoarthritis: A randomized, double-blind, placebo-controlled trial. *Knee Surg. Sports Traumatol. Arthrosc.* **2017**, *25*, 958–965. [[CrossRef](#)]

155. Guilibert, C.; Charpin, C.; Raffray, M.; Benmenni, A.; Dehaut, F.X.; El Ghobeira, G.; Giorgi, R.; Magalon, J.; Arniaud, D. Single Injection of High Volume of Autologous Pure PRP Provides a Significant Improvement in Knee Osteoarthritis: A Prospective Routine Care Study. *Int. J. Mol. Sci.* **2019**, *20*. [[CrossRef](#)]
156. Rayegani, S.M.; Raeissadat, S.A.; Taheri, M.S.; Babae, M.; Bahrami, M.H.; Eliaspour, D.; Ghorbani, E. Does intra articular platelet rich plasma injection improve function, pain and quality of life in patients with osteoarthritis of the knee? A randomized clinical trial. *Orthop. Rev. (Pavia)* **2014**, *6*, 5405. [[CrossRef](#)]
157. Duif, C.; Vogel, T.; Topcuoglu, F.; Spyrou, G.; von Schulze Pellengahr, C.; Lahner, M. Does intraoperative application of leukocyte-poor platelet-rich plasma during arthroscopy for knee degeneration affect postoperative pain, function and quality of life? A 12-month randomized controlled double-blind trial. *Arch. Orthop. Trauma Surg.* **2015**, *135*, 971–977. [[CrossRef](#)]
158. Smith, P.A. Intra-articular Autologous Conditioned Plasma Injections Provide Safe and Efficacious Treatment for Knee Osteoarthritis: An FDA-Sanctioned, Randomized, Double-blind, Placebo-controlled Clinical Trial. *Am. J. Sports Med.* **2016**, *44*, 884–891. [[CrossRef](#)]
159. Simental-Mendia, M.; Vilchez-Cavazos, J.F.; Pena-Martinez, V.M.; Said-Fernandez, S.; Lara-Arias, J.; Martinez-Rodriguez, H.G. Leukocyte-poor platelet-rich plasma is more effective than the conventional therapy with acetaminophen for the treatment of early knee osteoarthritis. *Arch. Orthop. Trauma Surg.* **2016**, *136*, 1723–1732. [[CrossRef](#)]
160. Cole, B.J.; Karas, V.; Hussey, K.; Pilz, K.; Fortier, L.A. Hyaluronic Acid Versus Platelet-Rich Plasma: A Prospective, Double-Blind Randomized Controlled Trial Comparing Clinical Outcomes and Effects on Intra-articular Biology for the Treatment of Knee Osteoarthritis. *Am. J. Sports Med.* **2017**, *45*, 339–346. [[CrossRef](#)]
161. Buendia-Lopez, D.; Medina-Quiros, M.; Fernandez-Villacanas Marin, M.A. Clinical and radiographic comparison of a single LP-PRP injection, a single hyaluronic acid injection and daily NSAID administration with a 52-week follow-up: A randomized controlled trial. *J. Orthop. Traumatol.* **2018**, *19*, 3. [[CrossRef](#)] [[PubMed](#)]
162. Huang, G.; Hua, S.; Yang, T.; Ma, J.; Yu, W.; Chen, X. Platelet-rich plasma shows beneficial effects for patients with knee osteoarthritis by suppressing inflammatory factors. *Exp. Ther. Med.* **2018**, *15*, 3096–3102. [[CrossRef](#)]
163. Elik, H.; Dogu, B.; Yilmaz, F.; Begoglu, F.A.; Kuran, B. The Efficiency of Platelet Rich Plasma Treatment in patients with knee osteoarthritis. *J. Back Musculoskelet. Rehabil.* **2019**. [[CrossRef](#)] [[PubMed](#)]
164. Li, M.; Zhang, C.; Ai, Z.; Yuan, T.; Feng, Y.; Jia, W. [Therapeutic effectiveness of intra-knee-articular injection of platelet-rich plasma on knee articular cartilage degeneration]. *Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi* **2011**, *25*, 1192–1196. [[PubMed](#)]
165. Forogh, B.; Mianehsaz, E.; Shoaee, S.; Ahadi, T.; Raissi, G.R.; Sajadi, S. Effect of single injection of platelet-rich plasma in comparison with corticosteroid on knee osteoarthritis: A double-blind randomized clinical trial. *J. Sports Med. Phys. Fit.* **2016**, *56*, 901–908.
166. Rahimzadeh, P.; Imani, F.; Faiz, S.H.R.; Entezary, S.R.; Zamanabadi, M.N.; Alebouyeh, M.R. The effects of injecting intra-articular platelet-rich plasma or prolotherapy on pain score and function in knee osteoarthritis. *Clin. Interv. Aging* **2018**, *13*, 73–79. [[CrossRef](#)]
167. Paterson, K.L.; Nicholls, M.; Bennell, K.L.; Bates, D. Intra-articular injection of photo-activated platelet-rich plasma in patients with knee osteoarthritis: A double-blind, randomized controlled pilot study. *BMC Musculoskelet. Disord.* **2016**, *17*, 67. [[CrossRef](#)]
168. Bansal, H.; Comella, K.; Leon, J.; Verma, P.; Agrawal, D.; Koka, P.; Ichim, T. Intra-articular injection in the knee of adipose derived stromal cells (stromal vascular fraction) and platelet rich plasma for osteoarthritis. *J. Transl. Med.* **2017**, *15*, 141. [[CrossRef](#)]
169. Sanchez, M.; Delgado, D.; Sanchez, P.; Muinos-Lopez, E.; Paiva, B.; Granero-Molto, F.; Prosper, F.; Pompei, O.; Perez, J.C.; Azofra, J.; et al. Combination of Intra-Articular and Intraosseous Injections of Platelet Rich Plasma for Severe Knee Osteoarthritis: A Pilot Study. *Biomed. Res. Int.* **2016**, *2016*, 4868613. [[CrossRef](#)]
170. Sanchez, M.; Delgado, D.; Pompei, O.; Perez, J.C.; Sanchez, P.; Garate, A.; Bilbao, A.M.; Fiz, N.; Padilla, S. Treating Severe Knee Osteoarthritis with Combination of Intra-Osseous and Intra-Articular Infiltrations of Platelet-Rich Plasma: An Observational Study. *Cartilage* **2019**, *10*, 245–253. [[CrossRef](#)]

171. Su, K.; Bai, Y.; Wang, J.; Zhang, H.; Liu, H.; Ma, S. Comparison of hyaluronic acid and PRP intra-articular injection with combined intra-articular and intraosseous PRP injections to treat patients with knee osteoarthritis. *Clin. Rheumatol.* **2018**, *37*, 1341–1350. [[CrossRef](#)] [[PubMed](#)]
172. Patel, S.; Dhillon, M.S. The Anti-inflammatory and Matrix Restorative Mechanisms of Platelet-Rich Plasma in Osteoarthritis: Letter to the Editor. *Am. J. Sports Med.* **2014**, *42*. [[CrossRef](#)] [[PubMed](#)]
173. Anitua, E.; Sanchez, M.; De la Fuente, M.; Zalduendo, M.M.; Orive, G. Plasma rich in growth factors (PRGF-Endoret) stimulates tendon and synovial fibroblasts migration and improves the biological properties of hyaluronic acid. *Knee Surg. Sports Traumatol. Arthrosc.* **2012**, *20*, 1657–1665. [[CrossRef](#)] [[PubMed](#)]
174. Marmotti, A.; Bruzzone, M.; Bonasia, D.E.; Castoldi, F.; Rossi, R.; Piras, L.; Maiello, A.; Realmuto, C.; Peretti, G.M. One-step osteochondral repair with cartilage fragments in a composite scaffold. *Knee Surg. Sports Traumatol. Arthrosc.* **2012**, *20*, 2590–2601. [[CrossRef](#)]
175. Andia, I.; Abate, M. Knee osteoarthritis: Hyaluronic acid, platelet-rich plasma or both in association? *Expert Opin. Biol. Ther.* **2014**, *14*, 635–649. [[CrossRef](#)]
176. Chen, C.P.C.; Chen, J.L.; Hsu, C.C.; Pei, Y.C.; Chang, W.H.; Lu, H.C. Injecting autologous platelet rich plasma solely into the knee joint is not adequate in treating geriatric patients with moderate to severe knee osteoarthritis. *Exp. Gerontol.* **2019**, *119*, 1–6. [[CrossRef](#)]
177. Anitua, E.; Sanchez, M.; Aguirre, J.J.; Prado, R.; Padilla, S.; Orive, G. Efficacy and safety of plasma rich in growth factors intra-articular infiltrations in the treatment of knee osteoarthritis. *Arthroscopy* **2014**, *30*, 1006–1017. [[CrossRef](#)]
178. Bennell, K.L.; Hunter, D.J.; Paterson, K.L. Platelet-Rich Plasma for the Management of Hip and Knee Osteoarthritis. *Curr. Rheumatol. Rep.* **2017**, *19*, 24. [[CrossRef](#)]
179. Dai, W.L.; Zhou, A.G.; Zhang, H.; Zhang, J. Efficacy of Platelet-Rich Plasma in the Treatment of Knee Osteoarthritis: A Meta-analysis of Randomized Controlled Trials. *Arthroscopy* **2017**, *33*, 659–670. [[CrossRef](#)]
180. Han, Y.; Huang, H.; Pan, J.; Lin, J.; Zeng, L.; Liang, G.; Yang, W.; Liu, J. Meta-analysis Comparing Platelet-Rich Plasma vs. Hyaluronic Acid Injection in Patients with Knee Osteoarthritis. *Pain Med.* **2019**, *20*, 1418–1429. [[CrossRef](#)]
181. Di, Y.; Han, C.; Zhao, L.; Ren, Y. Is local platelet-rich plasma injection clinically superior to hyaluronic acid for treatment of knee osteoarthritis? A systematic review of randomized controlled trials. *Arthritis Res. Ther.* **2018**, *20*, 128. [[CrossRef](#)] [[PubMed](#)]
182. Sanchez, M.; Guadilla, J.; Fiz, N.; Andia, I. Ultrasound-guided platelet-rich plasma injections for the treatment of osteoarthritis of the hip. *Rheumatology* **2012**, *51*, 144–150. [[CrossRef](#)] [[PubMed](#)]
183. Singh, J.R.; Haffey, P.; Valimohamed, A.; Gellhorn, A. The Effectiveness of Autologous Platelet-Rich Plasma for Osteoarthritis of the Hip: A Retrospective Analysis. *Pain Med.* **2019**. [[CrossRef](#)] [[PubMed](#)]
184. Battaglia, M.; Guaraldi, F.; Vannini, F.; Rossi, G.; Timoncini, A.; Buda, R.; Giannini, S. Efficacy of ultrasound-guided intra-articular injections of platelet-rich plasma versus hyaluronic acid for hip osteoarthritis. *Orthopedics* **2013**, *36*, e1501–e1508. [[CrossRef](#)]
185. Di Sante, L.; Villani, C.; Santilli, V.; Valeo, M.; Bologna, E.; Imparato, L.; Paoloni, M.; Iagnocco, A. Intra-articular hyaluronic acid vs platelet-rich plasma in the treatment of hip osteoarthritis. *Med. Ultrason.* **2016**, *18*, 463–468. [[CrossRef](#)]
186. Doria, C.; Mosele, G.R.; Caggiari, G.; Puddu, L.; Ciurlia, E. Treatment of Early Hip Osteoarthritis: Ultrasound-Guided Platelet Rich Plasma versus Hyaluronic Acid Injections in a Randomized Clinical Trial. *Joints* **2017**, *5*, 152–155. [[CrossRef](#)]
187. Dallari, D.; Stagni, C.; Rani, N.; Sabbioni, G.; Pelotti, P.; Torricelli, P.; Tschon, M.; Giavaresi, G. Ultrasound-Guided Injection of Platelet-Rich Plasma and Hyaluronic Acid, Separately and in Combination, for Hip Osteoarthritis: A Randomized Controlled Study. *Am. J. Sports Med.* **2016**, *44*, 664–671. [[CrossRef](#)]
188. Fiz, N.; Perez, J.C.; Guadilla, J.; Garate, A.; Sanchez, P.; Padilla, S.; Delgado, D.; Sanchez, M. Intraosseous Infiltration of Platelet-Rich Plasma for Severe Hip Osteoarthritis. *Arthrosc. Tech.* **2017**, *6*, e821–e825. [[CrossRef](#)]
189. Ye, Y.; Zhou, X.; Mao, S.; Zhang, J.; Lin, B. Platelet rich plasma versus hyaluronic acid in patients with hip osteoarthritis: A meta-analysis of randomized controlled trials. *Int. J. Surg.* **2018**, *53*, 279–287. [[CrossRef](#)]
190. Ali, M.; Mohamed, A.; Ahmed, H.E.; Malviya, A.; Atchia, I. The use of ultrasound-guided platelet-rich plasma injections in the treatment of hip osteoarthritis: A systematic review of the literature. *J. Ultrason.* **2018**, *18*, 332–337. [[CrossRef](#)]

191. Repetto, I.; Biti, B.; Cerruti, P.; Trentini, R.; Felli, L. Conservative Treatment of Ankle Osteoarthritis: Can Platelet-Rich Plasma Effectively Postpone Surgery? *J. Foot Ankle Surg.* **2017**, *56*, 362–365. [[CrossRef](#)] [[PubMed](#)]
192. Fukawa, T.; Yamaguchi, S.; Akatsu, Y.; Yamamoto, Y.; Akagi, R.; Sasho, T. Safety and Efficacy of Intra-articular Injection of Platelet-Rich Plasma in Patients With Ankle Osteoarthritis. *Foot Ankle Int.* **2017**, *38*, 596–604. [[CrossRef](#)] [[PubMed](#)]
193. Rajabi, H.; Sheikhan Shahin, H.; Norouzian, M.; Mehrabani, D.; Dehghani Nazhvani, S. The Healing Effects of Aquatic Activities and Allogenic Injection of Platelet-Rich Plasma (PRP) on Injuries of Achilles Tendon in Experimental Rat. *World J. Plast. Surg.* **2015**, *4*, 66–73. [[PubMed](#)]
194. Sinnott, C.; White, H.M.; Cuchna, J.W.; Van Lunen, B.L. Autologous Blood and Platelet-Rich Plasma Injections in the Treatment of Achilles Tendinopathy: A Critically Appraised Topic. *J. Sport Rehabil.* **2017**, *26*, 279–285. [[CrossRef](#)]
195. Gaweda, K.; Tarczynska, M.; Krzyzanowski, W. Treatment of Achilles tendinopathy with platelet-rich plasma. *Int. J. Sports Med.* **2010**, *31*, 577–583. [[CrossRef](#)]
196. Volpi, P.; Quaglia, A.; Schoenhuber, H.; Melegati, G.; Corsi, M.M.; Banfi, G.; de Girolamo, L. Growth factors in the management of sport-induced tendinopathies: Results after 24 months from treatment. A pilot study. *J. Sports Med. Phys. Fit.* **2010**, *50*, 494–500.
197. Finnoff, J.T.; Fowler, S.P.; Lai, J.K.; Santrach, P.J.; Willis, E.A.; Sayeed, Y.A.; Smith, J. Treatment of chronic tendinopathy with ultrasound-guided needle tenotomy and platelet-rich plasma injection. *PM R* **2011**, *3*, 900–911. [[CrossRef](#)]
198. Deans, V.M.; Miller, A.; Ramos, J. A prospective series of patients with chronic Achilles tendinopathy treated with autologous-conditioned plasma injections combined with exercise and therapeutic ultrasonography. *J. Foot Ankle Surg.* **2012**, *51*, 706–710. [[CrossRef](#)]
199. Ferrero, G.; Fabbro, E.; Orlandi, D.; Martini, C.; Lacelli, F.; Serafini, G.; Silvestri, E.; Sconfienza, L.M. Ultrasound-guided injection of platelet-rich plasma in chronic Achilles and patellar tendinopathy. *J. Ultrasound* **2012**, *15*, 260–266. [[CrossRef](#)]
200. Monto, R.R. Platelet rich plasma treatment for chronic Achilles tendinosis. *Foot Ankle Int.* **2012**, *33*, 379–385. [[CrossRef](#)]
201. Murawski, C.D.; Smyth, N.A.; Newman, H.; Kennedy, J.G. A single platelet-rich plasma injection for chronic midsubstance achilles tendinopathy: A retrospective preliminary analysis. *Foot Ankle Spec.* **2014**, *7*, 372–376. [[CrossRef](#)]
202. Guelfi, M.; Pantalone, A.; Vanni, D.; Abate, M.; Guelfi, M.G.; Salini, V. Long-term beneficial effects of platelet-rich plasma for non-insertional Achilles tendinopathy. *Foot Ankle Surg.* **2015**, *21*, 178–181. [[CrossRef](#)]
203. Salini, V.; Vanni, D.; Pantalone, A.; Abate, M. Platelet Rich Plasma Therapy in Non-insertional Achilles Tendinopathy: The Efficacy is Reduced in 60-years Old People Compared to Young and Middle-Age Individuals. *Front. Aging Neurosci.* **2015**, *7*, 228. [[CrossRef](#)] [[PubMed](#)]
204. Owens, R.F., Jr.; Ginnetti, J.; Conti, S.F.; Latona, C. Clinical and magnetic resonance imaging outcomes following platelet rich plasma injection for chronic midsubstance Achilles tendinopathy. *Foot Ankle Int.* **2011**, *32*, 1032–1039. [[CrossRef](#)] [[PubMed](#)]
205. Filardo, G.; Kon, E.; Di Matteo, B.; Di Martino, A.; Tesei, G.; Pelotti, P.; Cenacchi, A.; Marcacci, M. Platelet-rich plasma injections for the treatment of refractory Achilles tendinopathy: Results at 4 years. *Blood Transfus.* **2014**, *12*, 533–540. [[CrossRef](#)] [[PubMed](#)]
206. De Jonge, S.; de Vos, R.J.; Weir, A.; van Schie, H.T.; Bierma-Zeinstra, S.M.; Verhaar, J.A.; Weinans, H.; Tol, J.L. One-year follow-up of platelet-rich plasma treatment in chronic Achilles tendinopathy: A double-blind randomized placebo-controlled trial. *Am. J. Sports Med.* **2011**, *39*, 1623–1629. [[CrossRef](#)]
207. Krogh, T.P.; Ellingsen, T.; Christensen, R.; Jensen, P.; Fredberg, U. Ultrasound-Guided Injection Therapy of Achilles Tendinopathy With Platelet-Rich Plasma or Saline: A Randomized, Blinded, Placebo-Controlled Trial. *Am. J. Sports Med.* **2016**, *44*, 1990–1997. [[CrossRef](#)]
208. Hanisch, K.; Wedderkopp, N. Platelet-rich plasma (PRP) treatment of noninsertional Achilles tendinopathy in a two case series: No significant difference in effect between leukocyte-rich and leukocyte-poor PRP. *Orthop. Res. Rev.* **2019**, *11*, 55–60. [[CrossRef](#)]
209. Gentile, P.; De Angelis, B.; Agovino, A.; Orlandi, F.; Migner, A.; Di Pasquali, C.; Cervelli, V. Use of Platelet Rich Plasma and Hyaluronic Acid in the Treatment of Complications of Achilles Tendon Reconstruction. *World J. Plast. Surg.* **2016**, *5*, 124–132.

210. Erroi, D.; Sigona, M.; Suarez, T.; Trischitta, D.; Pavan, A.; Vulpiani, M.C.; Vetrano, M. Conservative treatment for Insertional Achilles Tendinopathy: Platelet-rich plasma and focused shock waves. A retrospective study. *Muscles Ligaments Tendons J.* **2017**, *7*, 98–106. [[CrossRef](#)]
211. Oloff, L.; Elmi, E.; Nelson, J.; Crain, J. Retrospective Analysis of the Effectiveness of Platelet-Rich Plasma in the Treatment of Achilles Tendinopathy: Pretreatment and Posttreatment Correlation of Magnetic Resonance Imaging and Clinical Assessment. *Foot Ankle Spec.* **2015**, *8*, 490–497. [[CrossRef](#)] [[PubMed](#)]
212. Kearney, R.S.; Parsons, N.; Costa, M.L. Achilles tendinopathy management: A pilot randomised controlled trial comparing platelet-rich plasma injection with an eccentric loading programme. *Bone Jt. Res.* **2013**, *2*, 227–232. [[CrossRef](#)] [[PubMed](#)]
213. De Vos, R.J.; Weir, A.; van Schie, H.T.; Bierma-Zeinstra, S.M.; Verhaar, J.A.; Weinans, H.; Tol, J.L. Platelet-rich plasma injection for chronic Achilles tendinopathy: A randomized controlled trial. *JAMA* **2010**, *303*, 144–149. [[CrossRef](#)] [[PubMed](#)]
214. De Vos, R.J.; Weir, A.; Tol, J.L.; Verhaar, J.A.; Weinans, H.; van Schie, H.T. No effects of PRP on ultrasonographic tendon structure and neovascularisation in chronic midportion Achilles tendinopathy. *Br. J. Sports Med.* **2011**, *45*, 387–392. [[CrossRef](#)] [[PubMed](#)]
215. Boesen, A.P.; Hansen, R.; Boesen, M.I.; Malliaras, P.; Langberg, H. Effect of High-Volume Injection, Platelet-Rich Plasma, and Sham Treatment in Chronic Midportion Achilles Tendinopathy: A Randomized Double-Blinded Prospective Study. *Am. J. Sports Med.* **2017**, *45*, 2034–2043. [[CrossRef](#)]
216. Zhang, Y.J.; Xu, S.Z.; Gu, P.C.; Du, J.Y.; Cai, Y.Z.; Zhang, C.; Lin, X.J. Is Platelet-rich Plasma Injection Effective for Chronic Achilles Tendinopathy? A Meta-analysis. *Clin. Orthop. Relat. Res.* **2018**, *476*, 1633–1641. [[CrossRef](#)]
217. Chen, X.; Jones, I.A.; Park, C.; Vangsness, C.T., Jr. The Efficacy of Platelet-Rich Plasma on Tendon and Ligament Healing: A Systematic Review and Meta-analysis With Bias Assessment. *Am. J. Sports Med.* **2018**, *46*, 2020–2032. [[CrossRef](#)]
218. Liu, C.J.; Yu, K.L.; Bai, J.B.; Tian, D.H.; Liu, G.L. Platelet-rich plasma injection for the treatment of chronic Achilles tendinopathy: A meta-analysis. *Medicine* **2019**, *98*, e15278. [[CrossRef](#)]
219. Wang, Y.; Han, C.; Hao, J.; Ren, Y.; Wang, J. Efficacy of platelet-rich plasma injections for treating Achilles tendonitis: Systematic review of high-quality randomized controlled trials. *Orthopade* **2019**, *48*, 784–791. [[CrossRef](#)]
220. Drago, J.L.; Meadows, M.C. The use of biologics for the elbow: A critical analysis review. *J. Shoulder Elbow Surg.* **2019**, *28*, 2053–2060. [[CrossRef](#)]
221. Mishra, A.; Pavelko, T. Treatment of chronic elbow tendinosis with buffered platelet-rich plasma. *Am. J. Sports Med.* **2006**, *34*, 1774–1778. [[CrossRef](#)] [[PubMed](#)]
222. Hechtman, K.S.; Uribe, J.W.; Botto-vanDemden, A.; Kiebzak, G.M. Platelet-rich plasma injection reduces pain in patients with recalcitrant epicondylitis. *Orthopedics* **2011**, *34*, 92. [[CrossRef](#)] [[PubMed](#)]
223. Brkljac, M.; Kumar, S.; Kallou, D.; Hirehal, K. The effect of platelet-rich plasma injection on lateral epicondylitis following failed conservative management. *J. Orthop.* **2015**, *12*, S166–S170. [[CrossRef](#)] [[PubMed](#)]
224. Brkljac, M.; Conville, J.; Sonar, U.; Kumar, S. Long-term follow-up of platelet-rich plasma injections for refractory lateral epicondylitis. *J. Orthop.* **2019**, *16*, 496–499. [[CrossRef](#)] [[PubMed](#)]
225. Creaney, L.; Wallace, A.; Curtis, M.; Connell, D. Growth factor-based therapies provide additional benefit beyond physical therapy in resistant elbow tendinopathy: A prospective, single-blind, randomised trial of autologous blood injections versus platelet-rich plasma injections. *Br. J. Sports Med.* **2011**, *45*, 966–971. [[CrossRef](#)] [[PubMed](#)]
226. Thanasas, C.; Papadimitriou, G.; Charalambidis, C.; Paraskevopoulos, I.; Papanikolaou, A. Platelet-rich plasma versus autologous whole blood for the treatment of chronic lateral elbow epicondylitis: A randomized controlled clinical trial. *Am. J. Sports Med.* **2011**, *39*, 2130–2134. [[CrossRef](#)] [[PubMed](#)]
227. Raeissadat, S.A.; Rayegani, S.M.; Hassanabadi, H.; Rahimi, R.; Sedighipour, L.; Rostami, K. Is Platelet-rich plasma superior to whole blood in the management of chronic tennis elbow: One year randomized clinical trial. *BMC Sports Sci. Med. Rehabil.* **2014**, *6*, 12. [[CrossRef](#)]
228. Montalvan, B.; Le Goux, P.; Klouche, S.; Borgel, D.; Hardy, P.; Breban, M. Inefficacy of ultrasound-guided local injections of autologous conditioned plasma for recent epicondylitis: Results of a double-blind placebo-controlled randomized clinical trial with one-year follow-up. *Rheumatology* **2016**, *55*, 279–285. [[CrossRef](#)]

229. Schoffl, V.; Willauschus, W.; Sauer, F.; Kupper, T.; Schoffl, I.; Lutter, C.; Gelse, K.; Dickschas, J. Autologous Conditioned Plasma Versus Placebo Injection Therapy in Lateral Epicondylitis of the Elbow: A Double Blind, Randomized Study. *Sportverletz Sportschaden* **2017**, *31*, 31–36. [[CrossRef](#)]
230. Yerlikaya, M.; Talay Calis, H.; Tomruk Sutbeyaz, S.; Sayan, H.; Ibis, N.; Koc, A.; Karakukcu, C. Comparison of Effects of Leukocyte-Rich and Leukocyte-Poor Platelet-Rich Plasma on Pain and Functionality in Patients With Lateral Epicondylitis. *Arch. Rheumatol.* **2018**, *33*, 73–79. [[CrossRef](#)]
231. Mishra, A.K.; Skrepnik, N.V.; Edwards, S.G.; Jones, G.L.; Sampson, S.; Vermillion, D.A.; Ramsey, M.L.; Karli, D.C.; Rettig, A.C. Efficacy of platelet-rich plasma for chronic tennis elbow: A double-blind, prospective, multicenter, randomized controlled trial of 230 patients. *Am. J. Sports Med.* **2014**, *42*, 463–471. [[CrossRef](#)] [[PubMed](#)]
232. Peerbooms, J.C.; Sluimer, J.; Bruijn, D.J.; Gosens, T. Positive effect of an autologous platelet concentrate in lateral epicondylitis in a double-blind randomized controlled trial: Platelet-rich plasma versus corticosteroid injection with a 1-year follow-up. *Am. J. Sports Med.* **2010**, *38*, 255–262. [[CrossRef](#)] [[PubMed](#)]
233. Gosens, T.; Peerbooms, J.C.; van Laar, W.; den Oudsten, B.L. Ongoing positive effect of platelet-rich plasma versus corticosteroid injection in lateral epicondylitis: A double-blind randomized controlled trial with 2-year follow-up. *Am. J. Sports Med.* **2011**, *39*, 1200–1208. [[CrossRef](#)] [[PubMed](#)]
234. Gautam, V.K.; Verma, S.; Batra, S.; Bhatnagar, N.; Arora, S. Platelet-rich plasma versus corticosteroid injection for recalcitrant lateral epicondylitis: Clinical and ultrasonographic evaluation. *J. Orthop. Surg.* **2015**, *23*, 1–5. [[CrossRef](#)] [[PubMed](#)]
235. Khaliq, A.; Khan, I.; Inam, M.; Saeed, M.; Khan, H.; Iqbal, M.J. Effectiveness of platelets rich plasma versus corticosteroids in lateral epicondylitis. *J. Pak. Med. Assoc.* **2015**, *65*, S100–S104. [[PubMed](#)]
236. Varshney, A.; Maheshwari, R.; Juyal, A.; Agrawal, A.; Hayer, P. Autologous Platelet-rich Plasma versus Corticosteroid in the Management of Elbow Epicondylitis: A Randomized Study. *Int. J. Appl. Basic Med. Res.* **2017**, *7*, 125–128. [[CrossRef](#)] [[PubMed](#)]
237. Gupta, P.K.; Acharya, A.; Khanna, V.; Roy, S.; Khillan, K.; Sambandam, S.N. PRP versus steroids in a deadlock for efficacy: Long-term stability versus short-term intensity-results from a randomised trial. *Musculoskelet. Surg.* **2019**. [[CrossRef](#)]
238. Lebie dzinski, R.; Synder, M.; Buchcic, P.; Polguj, M.; Grzegorzewski, A.; Sibinski, M. A randomized study of autologous conditioned plasma and steroid injections in the treatment of lateral epicondylitis. *Int. Orthop.* **2015**, *39*, 2199–2203. [[CrossRef](#)]
239. Palacio, E.P.; Schiavetti, R.R.; Kanematsu, M.; Ikeda, T.M.; Mizobuchi, R.R.; Galbiatti, J.A. Effects of platelet-rich plasma on lateral epicondylitis of the elbow: Prospective randomized controlled trial. *Rev. Bras. Ortop.* **2016**, *51*, 90–95. [[CrossRef](#)]
240. Yadav, R.; Kothari, S.Y.; Borah, D. Comparison of Local Injection of Platelet Rich Plasma and Corticosteroids in the Treatment of Lateral Epicondylitis of Humerus. *J. Clin. Diagn. Res.* **2015**, *9*, RC05–RC07. [[CrossRef](#)]
241. Behera, P.; Dhillon, M.; Aggarwal, S.; Marwaha, N.; Prakash, M. Leukocyte-poor platelet-rich plasma versus bupivacaine for recalcitrant lateral epicondylar tendinopathy. *J. Orthop. Surg.* **2015**, *23*, 6–10. [[CrossRef](#)] [[PubMed](#)]
242. Tonk, G.; Kumar, A.; Gupta, A. Platelet rich plasma versus laser therapy in lateral epicondylitis of elbow. *Indian J. Orthop.* **2014**, *48*, 390–393. [[CrossRef](#)] [[PubMed](#)]
243. Alessio-Mazzola, M.; Repetto, I.; Biti, B.; Trentini, R.; Formica, M.; Felli, L. Autologous US-guided PRP injection versus US-guided focal extracorporeal shock wave therapy for chronic lateral epicondylitis: A minimum of 2-year follow-up retrospective comparative study. *J. Orthop. Surg.* **2018**, *26*, 2309499017749986. [[CrossRef](#)] [[PubMed](#)]
244. Seetharamaiah, V.B.; Gantaguru, A.; Basavarajanna, S. A comparative study to evaluate the efficacy of platelet-rich plasma and triamcinolone to treat tennis elbow. *Indian J. Orthop.* **2017**, *51*, 304–311. [[CrossRef](#)]
245. Krogh, T.P.; Fredberg, U.; Stengaard-Pedersen, K.; Christensen, R.; Jensen, P.; Ellingsen, T. Treatment of lateral epicondylitis with platelet-rich plasma, glucocorticoid, or saline: A randomized, double-blind, placebo-controlled trial. *Am. J. Sports Med.* **2013**, *41*, 625–635. [[CrossRef](#)]
246. Stenhouse, G.; Sookur, P.; Watson, M. Do blood growth factors offer additional benefit in refractory lateral epicondylitis? A prospective, randomized pilot trial of dry needling as a stand-alone procedure versus dry needling and autologous conditioned plasma. *Skelet. Radiol.* **2013**, *42*, 1515–1520. [[CrossRef](#)]

247. Merolla, G.; Dellabiancia, F.; Ricci, A.; Mussoni, M.P.; Nucci, S.; Zanolì, G.; Paladini, P.; Porcellini, G. Arthroscopic Debridement Versus Platelet-Rich Plasma Injection: A Prospective, Randomized, Comparative Study of Chronic Lateral Epicondylitis With a Nearly 2-Year Follow-Up. *Arthroscopy* **2017**, *33*, 1320–1329. [[CrossRef](#)]
248. Boden, A.L.; Scott, M.T.; Dalwadi, P.P.; Mautner, K.; Mason, R.A.; Gottschalk, M.B. Platelet-rich plasma versus Tenex in the treatment of medial and lateral epicondylitis. *J. Shoulder Elbow Surg.* **2019**, *28*, 112–119. [[CrossRef](#)]
249. Chiavaras, M.M.; Jacobson, J.A.; Carlos, R.; Maida, E.; Bentley, T.; Simunovic, N.; Swinton, M.; Bhandari, M. Impact of Platelet Rich plasma Over alternative therapies in patients with lateral Epicondylitis (IMPROVE): Protocol for a multicenter randomized controlled study: A multicenter, randomized trial comparing autologous platelet-rich plasma, autologous whole blood, dry needle tendon fenestration, and physical therapy exercises alone on pain and quality of life in patients with lateral epicondylitis. *Acad. Radiol.* **2014**, *21*, 1144–1155. [[CrossRef](#)]
250. Hastie, G.; Soufi, M.; Wilson, J.; Roy, B. Platelet rich plasma injections for lateral epicondylitis of the elbow reduce the need for surgical intervention. *J. Orthop.* **2018**, *15*, 239–241. [[CrossRef](#)]
251. Arirachakaran, A.; Sukthuyat, A.; Sisayanarane, T.; Laoratanavoraphong, S.; Kanchanatawan, W.; Kongtharvonskul, J. Platelet-rich plasma versus autologous blood versus steroid injection in lateral epicondylitis: Systematic review and network meta-analysis. *J. Orthop. Traumatol.* **2016**, *17*, 101–112. [[CrossRef](#)]
252. Mi, B.; Liu, G.; Zhou, W.; Lv, H.; Liu, Y.; Wu, Q.; Liu, J. Platelet rich plasma versus steroid on lateral epicondylitis: Meta-analysis of randomized clinical trials. *Phys. Sportsmed.* **2017**, *45*, 97–104. [[CrossRef](#)]
253. Ben-Nafa, W.; Munro, W. The effect of corticosteroid versus platelet-rich plasma injection therapies for the management of lateral epicondylitis: A systematic review. *SICOT J.* **2018**, *4*, 11. [[CrossRef](#)] [[PubMed](#)]
254. Houck, D.A.; Kraeutler, M.J.; Thornton, L.B.; McCarty, E.C.; Bravman, J.T. Treatment of Lateral Epicondylitis With Autologous Blood, Platelet-Rich Plasma, or Corticosteroid Injections: A Systematic Review of Overlapping Meta-analyses. *Orthop. J. Sports Med.* **2019**, *7*, 2325967119831052. [[CrossRef](#)] [[PubMed](#)]
255. Barnett, J.; Bernacki, M.N.; Kainer, J.L.; Smith, H.N.; Zaharoff, A.M.; Subramanian, S.K. The effects of regenerative injection therapy compared to corticosteroids for the treatment of lateral Epicondylitis: A systematic review and meta-analysis. *Arch. Physiother.* **2019**, *9*, 12. [[CrossRef](#)] [[PubMed](#)]
256. Monteagudo, M.; de Albornoz, P.M.; Gutierrez, B.; Tabuenca, J.; Alvarez, I. Plantar fasciopathy: A current concepts review. *EFORT Open Rev.* **2018**, *3*, 485–493. [[CrossRef](#)]
257. Henning, P.R.; Grear, B.J. Platelet-rich plasma in the foot and ankle. *Curr. Rev. Musculoskelet. Med.* **2018**, *11*, 616–623. [[CrossRef](#)]
258. Ragab, E.M.; Othman, A.M. Platelets rich plasma for treatment of chronic plantar fasciitis. *Arch. Orthop. Trauma Surg.* **2012**, *132*, 1065–1070. [[CrossRef](#)]
259. Kumar, V.; Millar, T.; Murphy, P.N.; Clough, T. The treatment of intractable plantar fasciitis with platelet-rich plasma injection. *Foot* **2013**, *23*, 74–77. [[CrossRef](#)]
260. Martinelli, N.; Marinozzi, A.; Carni, S.; Trovato, U.; Bianchi, A.; Denaro, V. Platelet-rich plasma injections for chronic plantar fasciitis. *Int. Orthop.* **2013**, *37*, 839–842. [[CrossRef](#)]
261. O'Malley, M.J.; Vosseller, J.T.; Gu, Y. Successful use of platelet-rich plasma for chronic plantar fasciitis. *HSS J.* **2013**, *9*, 129–133. [[CrossRef](#)] [[PubMed](#)]
262. Wilson, J.J.; Lee, K.S.; Miller, A.T.; Wang, S. Platelet-rich plasma for the treatment of chronic plantar fasciopathy in adults: A case series. *Foot Ankle Spec.* **2014**, *7*, 61–67. [[CrossRef](#)] [[PubMed](#)]
263. Malahias, M.A.; Mavrogenis, A.F.; Nikolaou, V.S.; Megaloikononimos, P.D.; Kazas, S.T.; Chronopoulos, E.; Babis, G.C. Similar effect of ultrasound-guided platelet-rich plasma versus platelet-poor plasma injections for chronic plantar fasciitis. *Foot* **2019**, *38*, 30–33. [[CrossRef](#)] [[PubMed](#)]
264. Johnson-Lynn, S.; Cooney, A.; Ferguson, D.; Bunn, D.; Gray, W.; Coorsh, J.; Kakwani, R.; Townshend, D. A Feasibility Study Comparing Platelet-Rich Plasma Injection With Saline for the Treatment of Plantar Fasciitis Using a Prospective, Randomized Trial Design. *Foot Ankle Spec.* **2019**, *12*, 153–158. [[CrossRef](#)] [[PubMed](#)]
265. Aksahin, E.; Dogruyol, D.; Yuksel, H.Y.; Hapa, O.; Dogan, O.; Celebi, L.; Bicimoglu, A. The comparison of the effect of corticosteroids and platelet-rich plasma (PRP) for the treatment of plantar fasciitis. *Arch. Orthop. Trauma Surg.* **2012**, *132*, 781–785. [[CrossRef](#)] [[PubMed](#)]

266. Tiwari, M.; Bhargava, R. Platelet rich plasma therapy: A comparative effective therapy with promising results in plantar fasciitis. *J. Clin. Orthop. Trauma* **2013**, *4*, 31–35. [[CrossRef](#)] [[PubMed](#)]
267. Omar, A.S.; Ibrahim, M.E.; Ahmed, A.S.; Said, M. Local injection of autologous platelet rich plasma and corticosteroid in treatment of lateral epicondylitis and plantar fasciitis: Randomized clinical trial. *Egypt. Rheumatol.* **2012**, *34*, 43–49. [[CrossRef](#)]
268. Shetty, V.D.; Dhillon, M.; Hegde, C.; Jagtap, P.; Shetty, S. A study to compare the efficacy of corticosteroid therapy with platelet-rich plasma therapy in recalcitrant plantar fasciitis: A preliminary report. *Foot Ankle Surg.* **2014**, *20*, 10–13. [[CrossRef](#)]
269. Jain, K.; Murphy, P.N.; Clough, T.M. Platelet rich plasma versus corticosteroid injection for plantar fasciitis: A comparative study. *Foot* **2015**, *25*, 235–237. [[CrossRef](#)]
270. Shery, N.A.; Hammad, M.A.; Hagrass, H.A.; Samir, H.S.; Abu-ElMaaty, S.E.; Mortadaa, M.A. Local injection of autologous platelet rich plasma compared to corticosteroid treatment of chronic plantar fasciitis patients: A clinical and ultrasonographic follow-up study. *Egypt. Rheumatol.* **2016**, *38*, 247–252. [[CrossRef](#)]
271. Vahdatpour, B.; Kianimehr, L.; Moradi, A.; Haghighat, S. Beneficial effects of platelet-rich plasma on improvement of pain severity and physical disability in patients with plantar fasciitis: A randomized trial. *Adv. Biomed. Res.* **2016**, *5*, 179. [[CrossRef](#)] [[PubMed](#)]
272. Acosta-Olivo, C.; Elizondo-Rodriguez, J.; Lopez-Cavazos, R.; Vilchez-Cavazos, F.; Simental-Mendia, M.; Mendoza-Lemus, O. Plantar Fasciitis-A Comparison of Treatment with Intralesional Steroids versus Platelet-Rich Plasma A Randomized, Blinded Study. *J. Am. Podiatr. Med. Assoc.* **2017**, *107*, 490–496. [[CrossRef](#)] [[PubMed](#)]
273. Jain, S.K.; Suprshant, K.; Kumar, S.; Yadav, A.; Kearns, S.R. Comparison of Plantar Fasciitis Injected With Platelet-Rich Plasma vs Corticosteroids. *Foot Ankle Int.* **2018**, *39*, 780–786. [[CrossRef](#)] [[PubMed](#)]
274. Monto, R.R. Platelet-rich plasma efficacy versus corticosteroid injection treatment for chronic severe plantar fasciitis. *Foot Ankle Int.* **2014**, *35*, 313–318. [[CrossRef](#)] [[PubMed](#)]
275. Say, F.; Gurler, D.; Inkaya, E.; Bulbul, M. Comparison of platelet-rich plasma and steroid injection in the treatment of plantar fasciitis. *Acta Orthop. Traumatol. Turc.* **2014**, *48*, 667–672. [[CrossRef](#)]
276. Peerbooms, J.C.; Lodder, P.; den Oudsten, B.L.; Doorgeest, K.; Schuller, H.M.; Gosens, T. Positive Effect of Platelet-Rich Plasma on Pain in Plantar Fasciitis: A Double-Blind Multicenter Randomized Controlled Trial. *Am. J. Sports Med.* **2019**, *47*, 3238–3246. [[CrossRef](#)]
277. Jimenez-Perez, A.E.; Gonzalez-Arablo, D.; Diaz, A.S.; Maderuelo, J.A.; Ramos-Pascua, L.R. Clinical and imaging effects of corticosteroids and platelet-rich plasma for the treatment of chronic plantar fasciitis: A comparative non randomized prospective study. *Foot Ankle Surg.* **2019**, *25*, 354–360. [[CrossRef](#)]
278. Mahindra, P.; Yamin, M.; Selhi, H.S.; Singla, S.; Soni, A. Chronic Plantar Fasciitis: Effect of Platelet-Rich Plasma, Corticosteroid, and Placebo. *Orthopedics* **2016**, *39*, e285–e289. [[CrossRef](#)]
279. Shetty, S.H.; Dhond, A.; Arora, M.; Deore, S. Platelet-Rich Plasma Has Better Long-Term Results Than Corticosteroids or Placebo for Chronic Plantar Fasciitis: Randomized Control Trial. *J. Foot Ankle Surg.* **2019**, *58*, 42–46. [[CrossRef](#)]
280. Chew, K.T.; Leong, D.; Lin, C.Y.; Lim, K.K.; Tan, B. Comparison of autologous conditioned plasma injection, extracorporeal shockwave therapy, and conventional treatment for plantar fasciitis: A randomized trial. *PM R* **2013**, *5*, 1035–1043. [[CrossRef](#)]
281. Kim, E.; Lee, J.H. Autologous platelet-rich plasma versus dextrose prolotherapy for the treatment of chronic recalcitrant plantar fasciitis. *PM R* **2014**, *6*, 152–158. [[CrossRef](#)] [[PubMed](#)]
282. Gonnade, N.; Bajpayee, A.; Elhence, A.; Lokhande, V.; Mehta, N.; Mishra, M.; Kaur, A. Regenerative efficacy of therapeutic quality platelet-rich plasma injections versus phonophoresis with kinesiotaping for the treatment of chronic plantar fasciitis: A prospective randomized pilot study. *Asian J. Transfus. Sci.* **2018**, *12*, 105–111. [[CrossRef](#)] [[PubMed](#)]
283. Gogna, P.; Gaba, S.; Mukhopadhyay, R.; Gupta, R.; Rohilla, R.; Yadav, L. Plantar fasciitis: A randomized comparative study of platelet rich plasma and low dose radiation in sportspersons. *Foot* **2016**, *28*, 16–19. [[CrossRef](#)] [[PubMed](#)]
284. Chiew, S.K.; Ramasamy, T.S.; Amini, F. Effectiveness and relevant factors of platelet-rich plasma treatment in managing plantar fasciitis: A systematic review. *J. Res. Med. Sci.* **2016**, *21*, 38. [[CrossRef](#)]
285. Yang, W.Y.; Han, Y.H.; Cao, X.W.; Pan, J.K.; Zeng, L.F.; Lin, J.T.; Liu, J. Platelet-rich plasma as a treatment for plantar fasciitis: A meta-analysis of randomized controlled trials. *Medicine* **2017**, *96*, e8475. [[CrossRef](#)]

286. Singh, P.; Madanipour, S.; Bhamra, J.S.; Gill, I. A systematic review and meta-analysis of platelet-rich plasma versus corticosteroid injections for plantar fasciopathy. *Int. Orthop.* **2017**, *41*, 1169–1181. [[CrossRef](#)]
287. Zwerver, J.; Bredeweg, S.W.; van den Akker-Scheek, I. Prevalence of Jumper's knee among nonelite athletes from different sports: A cross-sectional survey. *Am. J. Sports Med.* **2011**, *39*, 1984–1988. [[CrossRef](#)]
288. Mautner, K.; Colberg, R.E.; Malanga, G.; Borg-Stein, J.P.; Harmon, K.G.; Dharamsi, A.S.; Chu, S.; Homer, P. Outcomes after ultrasound-guided platelet-rich plasma injections for chronic tendinopathy: A multicenter, retrospective review. *PM R* **2013**, *5*, 169–175. [[CrossRef](#)]
289. Crescibene, A.; Napolitano, M.; Sbano, R.; Costabile, E.; Almolla, H. Infiltration of Autologous Growth Factors in Chronic Tendinopathies. *J. Blood Transfus.* **2015**, *2015*, 924380. [[CrossRef](#)]
290. Kaux, J.F.; Bruyere, O.; Croisier, J.L.; Forthomme, B.; Le Goff, C.; Crielaard, J.M. One-year follow-up of platelet-rich plasma infiltration to treat chronic proximal patellar tendinopathies. *Acta Orthop. Belg.* **2015**, *81*, 251–256.
291. Bowman, K.F., Jr.; Muller, B.; Middleton, K.; Fink, C.; Harner, C.D.; Fu, F.H. Progression of patellar tendinitis following treatment with platelet-rich plasma: Case reports. *Knee Surg. Sports Traumatol. Arthrosc.* **2013**, *21*, 2035–2039. [[CrossRef](#)]
292. Manfreda, F.; Palmieri, D.; Antinolfi, P.; Rinonapoli, G.; Caraffa, A. Can platelet-rich plasma be an alternative to surgery for resistant chronic patellar tendinopathy in sportive people? Poor clinical results at 1-year follow-up. *J. Orthop. Surg.* **2019**, *27*, 2309499019842424. [[CrossRef](#)]
293. Filardo, G.; Kon, E.; Di Matteo, B.; Pelotti, P.; Di Martino, A.; Marcacci, M. Platelet-rich plasma for the treatment of patellar tendinopathy: Clinical and imaging findings at medium-term follow-up. *Int. Orthop.* **2013**, *37*, 1583–1589. [[CrossRef](#)]
294. Charousset, C.; Zaoui, A.; Bellaiche, L.; Bouyer, B. Are multiple platelet-rich plasma injections useful for treatment of chronic patellar tendinopathy in athletes? a prospective study. *Am. J. Sports Med.* **2014**, *42*, 906–911. [[CrossRef](#)]
295. Zayni, R.; Thaunat, M.; Fayard, J.M.; Hager, J.P.; Carrillon, Y.; Clechet, J.; Gadea, F.; Archbold, P.; Sonnery Cottet, B. Platelet-rich plasma as a treatment for chronic patellar tendinopathy: Comparison of a single versus two consecutive injections. *Muscles Ligaments Tendons J.* **2015**, *5*, 92–98. [[CrossRef](#)]
296. Kaux, J.F.; Croisier, J.L.; Forthomme, B.; Le Goff, C.; Buhler, F.; Savanier, B.; Delcour, S.; Gothot, A.; Crielaard, J.M. Using platelet-rich plasma to treat jumper's knees: Exploring the effect of a second closely-timed infiltration. *J. Sci. Med. Sport* **2016**, *19*, 200–204. [[CrossRef](#)]
297. Filardo, G.; Kon, E.; Della Villa, S.; Vincentelli, F.; Fornasari, P.M.; Marcacci, M. Use of platelet-rich plasma for the treatment of refractory jumper's knee. *Int. Orthop.* **2010**, *34*, 909–915. [[CrossRef](#)]
298. Gosens, T.; Den Oudsten, B.L.; Fievez, E.; van 't Spijker, P.; Fievez, A. Pain and activity levels before and after platelet-rich plasma injection treatment of patellar tendinopathy: A prospective cohort study and the influence of previous treatments. *Int. Orthop.* **2012**, *36*, 1941–1946. [[CrossRef](#)]
299. Vetrano, M.; Castorina, A.; Vulpiani, M.C.; Baldini, R.; Pavan, A.; Ferretti, A. Platelet-rich plasma versus focused shock waves in the treatment of jumper's knee in athletes. *Am. J. Sports Med.* **2013**, *41*, 795–803. [[CrossRef](#)]
300. Abate, M.; Di Carlo, L.; Verna, S.; Di Gregorio, P.; Schiavone, C.; Salini, V. Synergistic activity of platelet rich plasma and high volume image guided injection for patellar tendinopathy. *Knee Surg. Sports Traumatol. Arthrosc.* **2018**, *26*, 3645–3651. [[CrossRef](#)]
301. Drago, J.L.; Wasterlain, A.S.; Braun, H.J.; Nead, K.T. Platelet-rich plasma as a treatment for patellar tendinopathy: A double-blind, randomized controlled trial. *Am. J. Sports Med.* **2014**, *42*, 610–618. [[CrossRef](#)] [[PubMed](#)]
302. Scott, A.; LaPrade, R.F.; Harmon, K.G.; Filardo, G.; Kon, E.; Della Villa, S.; Bahr, R.; Moksnes, H.; Torgalsen, T.; Lee, J.; et al. Platelet-Rich Plasma for Patellar Tendinopathy: A Randomized Controlled Trial of Leukocyte-Rich PRP or Leukocyte-Poor PRP Versus Saline. *Am. J. Sports Med.* **2019**, *47*, 1654–1661. [[CrossRef](#)] [[PubMed](#)]
303. Filardo, G.; Di Matteo, B.; Kon, E.; Merli, G.; Marcacci, M. Platelet-rich plasma in tendon-related disorders: Results and indications. *Knee Surg. Sports Traumatol. Arthrosc.* **2018**, *26*, 1984–1999. [[CrossRef](#)] [[PubMed](#)]
304. Liddle, A.D.; Rodriguez-Merchan, E.C. Platelet-Rich Plasma in the Treatment of Patellar Tendinopathy: A Systematic Review. *Am. J. Sports Med.* **2015**, *43*, 2583–2590. [[CrossRef](#)] [[PubMed](#)]

305. Jeong, D.U.; Lee, C.R.; Lee, J.H.; Pak, J.; Kang, L.W.; Jeong, B.C.; Lee, S.H. Clinical applications of platelet-rich plasma in patellar tendinopathy. *Biomed. Res. Int.* **2014**, *2014*, 249498. [[CrossRef](#)] [[PubMed](#)]
306. Dupley, L.; Charalambous, C.P. Platelet-Rich Plasma Injections as a Treatment for Refractory Patellar Tendinosis: A Meta-Analysis of Randomised Trials. *Knee Surg. Relat. Res.* **2017**, *29*, 165–171. [[CrossRef](#)] [[PubMed](#)]
307. Vander Doelen, T.; Jelley, W. Non-surgical treatment of patellar tendinopathy: A systematic review of randomized controlled trials. *J. Sci. Med. Sport* **2020**, *23*, 118–124. [[CrossRef](#)]
308. Andriolo, L.; Altamura, S.A.; Reale, D.; Candrian, C.; Zaffagnini, S.; Filardo, G. Nonsurgical Treatments of Patellar Tendinopathy: Multiple Injections of Platelet-Rich Plasma Are a Suitable Option: A Systematic Review and Meta-analysis. *Am. J. Sports Med.* **2019**, *47*, 1001–1018. [[CrossRef](#)]
309. Ekstrand, J.; Healy, J.C.; Walden, M.; Lee, J.C.; English, B.; Hagglund, M. Hamstring muscle injuries in professional football: The correlation of MRI findings with return to play. *Br. J. Sports Med.* **2012**, *46*, 112–117. [[CrossRef](#)]
310. Orchard, J.W.; Seward, H.; Orchard, J.J. Results of 2 decades of injury surveillance and public release of data in the Australian Football League. *Am. J. Sports Med.* **2013**, *41*, 734–741. [[CrossRef](#)]
311. Bernuzzi, G.; Petraglia, F.; Pedrini, M.F.; De Filippo, M.; Pogliacomini, F.; Verdano, M.A.; Costantino, C. Use of platelet-rich plasma in the care of sports injuries: Our experience with ultrasound-guided injection. *Blood Transfus.* **2014**, *12* (Suppl. S1), s229–s234. [[CrossRef](#)] [[PubMed](#)]
312. Zanon, G.; Combi, M.; Combi, A.; Perticarini, L.; Sammarchi, L.; Benazzo, F. Platelet-rich plasma in the treatment of acute hamstring injuries in professional football players. *Joints* **2016**, *4*, 17–23. [[CrossRef](#)] [[PubMed](#)]
313. Reurink, G.; Goudswaard, G.J.; Moen, M.H.; Weir, A.; Verhaar, J.A.; Bierma-Zeinstra, S.M.; Maas, M.; Tol, J.L.; Dutch Hamstring Injection Therapy Study, I. Platelet-rich plasma injections in acute muscle injury. *N. E. J. Med.* **2014**, *370*, 2546–2547. [[CrossRef](#)] [[PubMed](#)]
314. Reurink, G.; Goudswaard, G.J.; Moen, M.H.; Weir, A.; Verhaar, J.A.; Bierma-Zeinstra, S.M.; Maas, M.; Tol, J.L.; Dutch, H.L.T.s.I. Rationale, secondary outcome scores and 1-year follow-up of a randomised trial of platelet-rich plasma injections in acute hamstring muscle injury: The Dutch Hamstring Injection Therapy study. *Br. J. Sports Med.* **2015**, *49*, 1206–1212. [[CrossRef](#)] [[PubMed](#)]
315. Punduk, Z.; Oral, O.; Ozkayin, N.; Rahman, K.; Varol, R. Single dose of intra-muscular platelet rich plasma reverses the increase in plasma iron levels in exercise-induced muscle damage: A pilot study. *J. Sport Health Sci.* **2016**, *5*, 109–114. [[CrossRef](#)]
316. Martinez-Zapata, M.J.; Orozco, L.; Balius, R.; Soler, R.; Bosch, A.; Rodas, G.; Til, L.; Peirau, X.; Urrutia, G.; Gich, I.; et al. Efficacy of autologous platelet-rich plasma for the treatment of muscle rupture with haematoma: A multicentre, randomised, double-blind, placebo-controlled clinical trial. *Blood Transfus.* **2016**, *14*, 245–254. [[CrossRef](#)]
317. Bubnov, R.; Yevseenko, V.; Semeniv, I. Ultrasound guided injections of platelets rich plasma for muscle injury in professional athletes. Comparative study. *Med. Ultrason.* **2013**, *15*, 101–105. [[CrossRef](#)]
318. Wetzel, R.J.; Patel, R.M.; Terry, M.A. Platelet-rich plasma as an effective treatment for proximal hamstring injuries. *Orthopedics* **2013**, *36*, e64–e70. [[CrossRef](#)]
319. Park, P.Y.S.; Cai, C.; Bawa, P.; Kumaravel, M. Platelet-rich plasma vs. steroid injections for hamstring injury—is there really a choice? *Skelet. Radiol.* **2019**, *48*, 577–582. [[CrossRef](#)]
320. A Hamid, M.S.; Mohamed Ali, M.R.; Yusof, A.; George, J.; Lee, L.P. Platelet-rich plasma injections for the treatment of hamstring injuries: A randomized controlled trial. *Am. J. Sports Med.* **2014**, *42*, 2410–2418. [[CrossRef](#)]
321. Rossi, L.A.; Molina Romoli, A.R.; Bertona Altieri, B.A.; Burgos Flor, J.A.; Scordo, W.E.; Elizondo, C.M. Does platelet-rich plasma decrease time to return to sports in acute muscle tear? A randomized controlled trial. *Knee Surg. Sports Traumatol. Arthrosc.* **2017**, *25*, 3319–3325. [[CrossRef](#)] [[PubMed](#)]
322. Borriore, P.; Fossati, C.; Pereira, M.T.; Giannini, S.; Davico, M.; Minganti, C.; Pigozzi, F. The use of platelet-rich plasma (PRP) in the treatment of gastrocnemius strains: A retrospective observational study. *Platelets* **2018**, *29*, 596–601. [[CrossRef](#)] [[PubMed](#)]
323. Guillodo, Y.; Madouas, G.; Simon, T.; Le Dauphin, H.; Saraux, A. Platelet-rich plasma (PRP) treatment of sports-related severe acute hamstring injuries. *Muscles Ligaments Tendons J.* **2015**, *5*, 284–288. [[CrossRef](#)]

324. Hamilton, B.; Tol, J.L.; Almusa, E.; Boukarroum, S.; Eirale, C.; Farooq, A.; Whiteley, R.; Chalabi, H. Platelet-rich plasma does not enhance return to play in hamstring injuries: A randomised controlled trial. *Br. J. Sports Med.* **2015**, *49*, 943–950. [[CrossRef](#)] [[PubMed](#)]
325. Grassi, A.; Napoli, F.; Romandini, I.; Samuelsson, K.; Zaffagnini, S.; Candrian, C.; Filardo, G. Is Platelet-Rich Plasma (PRP) Effective in the Treatment of Acute Muscle Injuries? A Systematic Review and Meta-Analysis. *Sports Med.* **2018**, *48*, 971–989. [[CrossRef](#)] [[PubMed](#)]
326. Sheth, U.; Dwyer, T.; Smith, I.; Wasserstein, D.; Theodoropoulos, J.; Takhar, S.; Chahal, J. Does Platelet-Rich Plasma Lead to Earlier Return to Sport When Compared With Conservative Treatment in Acute Muscle Injuries? A Systematic Review and Meta-analysis. *Arthroscopy* **2018**, *34*, 281–288. [[CrossRef](#)] [[PubMed](#)]
327. Andia, I.; Abate, M. Platelet-rich plasma: Combinational treatment modalities for musculoskeletal conditions. *Front. Med.* **2018**, *12*, 139–152. [[CrossRef](#)]
328. Miroshnychenko, O.; Chang, W.T.; Dragoo, J.L. The Use of Platelet-Rich and Platelet-Poor Plasma to Enhance Differentiation of Skeletal Myoblasts: Implications for the Use of Autologous Blood Products for Muscle Regeneration. *Am. J. Sports Med.* **2017**, *45*, 945–953. [[CrossRef](#)]
329. Scully, D.; Naseem, K.M.; Matsakas, A. Platelet biology in regenerative medicine of skeletal muscle. *Acta Physiol. (Oxf.)* **2018**, *223*, e13071. [[CrossRef](#)]
330. Hammond, J.W.; Hinton, R.Y.; Curl, L.A.; Muriel, J.M.; Lovering, R.M. Use of autologous platelet-rich plasma to treat muscle strain injuries. *Am. J. Sports Med.* **2009**, *37*, 1135–1142. [[CrossRef](#)]
331. Chellini, F.; Tani, A.; Zecchi-Orlandini, S.; Sassoli, C. Influence of Platelet-Rich and Platelet-Poor Plasma on Endogenous Mechanisms of Skeletal Muscle Repair/Regeneration. *Int. J. Mol. Sci.* **2019**, *20*. [[CrossRef](#)] [[PubMed](#)]
332. Zhang, X.; Wang, J.; Chen, Z.; Hu, Q.; Wang, C.; Yan, J.; Dotti, G.; Huang, P.; Gu, Z. Engineering PD-1-Presenting Platelets for Cancer Immunotherapy. *Nano Lett.* **2018**, *18*, 5716–5725. [[CrossRef](#)] [[PubMed](#)]
333. Son, S.R.; Sarkar, S.K.; Nguyen-Thuy, B.L.; Padalhin, A.R.; Kim, B.R.; Jung, H.I.; Lee, B.T. Platelet-rich plasma encapsulation in hyaluronic acid/gelatin-BCP hydrogel for growth factor delivery in BCP sponge scaffold for bone regeneration. *J. Biomater. Appl.* **2015**, *29*, 988–1002. [[CrossRef](#)] [[PubMed](#)]
334. Garcia, J.P.; Stein, J.; Cai, Y.; Riemers, F.; Wexselblatt, E.; Wengel, J.; Tryfonidou, M.; Yayon, A.; Howard, K.A.; Creemers, L.B. Fibrin-hyaluronic acid hydrogel-based delivery of antisense oligonucleotides for ADAMTS5 inhibition in co-delivered and resident joint cells in osteoarthritis. *J. Control. Release* **2019**, *294*, 247–258. [[CrossRef](#)]
335. Lolli, A.; Sivasubramaniyan, K.; Vainieri, M.L.; Oieni, J.; Kops, N.; Yayon, A.; van Osch, G. Hydrogel-based delivery of anti-miR-221 enhances cartilage regeneration by endogenous cells. *J. Control. Release* **2019**, *309*, 220–230. [[CrossRef](#)]
336. Dhillon, M.S.; Patel, S.; Bansal, T. Improving PRP for use in osteoarthritis knee- upcoming trends and futuristic view. *J. Clin. Orthop. Trauma* **2019**, *10*, 32–35. [[CrossRef](#)]



© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).



Review

Platelet Features and Derivatives in Osteoporosis: A Rational and Systematic Review on the Best Evidence

Francesca Salamanna, Melania Maglio *, Maria Sartori, Matilde Tschon and Milena Fini

Laboratory of Preclinical and Surgical Studies, IRCCS Istituto Ortopedico Rizzoli, Via di Barbiano 1/10, 40136 Bologna, Italy; francesca.salamanna@ior.it (F.S.); maria.sartori@ior.it (M.S.); matilde.tschon@ior.it (M.T.); milena.fini@ior.it (M.F.)

* Correspondence: melania.maglio@ior.it; Tel.: +39-051-636-6006

Received: 29 January 2020; Accepted: 2 March 2020; Published: 4 March 2020

Abstract: *Background:* With the increase in aging population, the rising prevalence of osteoporosis (OP) has become an important medical issue. Accumulating evidence showed a close relationship between OP and hematopoiesis and emerging proofs revealed that platelets (PLTs), unique blood elements, rich in growth factors (GFs), play a critical role in bone remodeling. The aim of this review was to evaluate how PLT features, size, volume, bioactive GFs released, existing GFs in PLTs and PLT derivatives change and behave during OP. *Methods:* A systematic search was carried out in PubMed, Scopus, Web of Science Core Collection and Cochrane Central Register of Controlled Trials databases to identify preclinical and clinical studies in the last 10 years on PLT function/features and growth factor in PLTs and on PLT derivatives during OP. The methodological quality of included studies was assessed by QUIPS tool for assessing risk of bias in the clinical studies and by the SYRCL tool for assessing risk of bias in animal studies. *Results:* In the initial search, 2761 studies were obtained, only 47 articles were submitted to complete reading, and 23 articles were selected for the analysis, 13 on PLT function/features and growth factor in PLTs and 10 on PLT derivatives. Risk of bias of almost all animal studies was high, while the in the clinical studies risk of bias was prevalently moderate/low for the most of the studies. The majority of the evaluated studies highlighted a positive correlation between PLT size/volume and bone mineralization and an improvement in bone regeneration ability by using PLTs bioactive GFs and PLT derivatives. *Conclusions:* The application of PLT features as OP markers and of PLT-derived compounds as therapeutic approach to promote bone healing during OP need to be further confirmed to provide clear evidence for the real efficacy of these interventions and to contribute to the clinical translation.

Keywords: platelet function; platelet derivatives; osteoporosis; bone

1. Introduction

Although the bone tissue has the exclusive ability to self-repair and regenerate, in several situations this capability results inadequate or linked to complications. Osteoporosis (OP) is defined by the World Health Organization (WHO) as a “*progressive systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture*” [1] (Figure 1).

Affecting about 200 million people in the world, with considerable morbidity and mortality, OP is one of the main epidemics of the 21st century (International Osteoporosis Foundation [2]). Fractures resulting from OP are the main cause of morbidity and mortality, bringing elevated social-economic burden on both families and health care system [3].

Several risk factors, i.e., clinical, medical, behavioral, nutritional and genetic, are related to OP [4]. One of the main causes of OP is the postmenopausal state which involves increased degree of imbalance of bone resorption and formation in favor of bone resorption [5]. Osteoclasts, originating

from hematopoietic cells, are mainly responsible for bone resorption. Despite the hematopoietic origin of osteoclasts, the hematological changes occurring during OP are not yet well elucidated. In the last decade, some studies found that platelet (PLT), fragments of cytoplasm derived from the megakaryocytes of the bone marrow, have a critical role in skeletal homeostasis, modulating bone formation and resorption [6–8].




Figure 1. Schematic representation of osteoporosis disease.

PLTs are 2–3 μm in diameter and around their periphery a contractile microtubules ring containing actin and myosin is present. PLTs have several intracellular structures, i.e., lysosomes and two types of granules, dense granule organelles, containing adenosine triphosphate (ATP), adenosine diphosphate (ADP), serotonin, and calcium, and the alpha (α) granules, containing growth factors (GFs), clotting factors, and other proteins (Figure 2) [9]. PLTs also act as a reserve for glycogen [9].




Figure 2. Schematic overview of PLT structure (diagrammatic representation) in the equatorial plane.

These GFs play a central role in the healing process and tissue regeneration, being used as messengers to regulate various processes [10]. Tissue repair begins with PLT clot formation, activation of the coagulation cascade and PLT degranulation, and release of platelets growth factors (PGFs). These PGFs join to specific target tyrosine growth factor receptors, which then activate intracellular signal transduction pathways [11,12]. Several preclinical and clinical studies highlighted the supportive effect of PLTs on bone formation showing that platelet-derived growth factors (PDGFs) favor bone formation by affecting cell proliferation, chemotaxis differentiation, and extracellular matrix synthesis [13,14]. On the other hand, preclinical in vitro studies showed the role of PLTs in osteoclastogenesis and bone resorption, but the exact mechanism has not been yet proposed [13,14]. These unique biological properties of PLTs emphasize why their derivatives were increasingly used in the clinical scenario to support the healing process in different pathological conditions, including musculoskeletal diseases [15–17]. In comparison to the use of a single recombinant GF in high concentrations, the employment of PLT derivatives have the advantage of offering several synergistic GFs able to cooperate in a specific site and for a specific goal. For this reason PLT derivatives (i.e., platelet poor plasma, PPP; platelet-rich plasma, PRP; platelet-rich fibrin, PRF; leucocyte and platelet-rich fibrin, L-PRF) [18] are considered an attractive option for bone tissue regeneration (Figure 3), containing a high concentration of local GFs including PDGF, transforming growth factor (TGF), platelet-derived angiogenesis factor (PDAF), platelet-derived endothelial growth factor (PDEGF), vascular endothelial growth factor (VEGF) and many others able to modulate the regenerative process [19].




Figure 3. PLT concentrates preparation, types/classes, and illustration/presentation of PLT derivatives. Schematic drawing of the classical preparation protocols of PRP and PRF.

It has been observed that PLT derivatives (e.g., PRF, PPP, PRF) improved proliferation and osteogenic activity of bone marrow mesenchymal stem cells (BMSCs) and osteoblasts [20–22]. Additionally, in vivo studies have revealed that clots of PLT derivatives, also in combination with different materials/scaffolds, improved bone regeneration by promoting the expression of TGF- β and bone morphogenetic protein-2 (BMP-2) [23–27]. Several clinical studies have also applied PLT derivatives, alone and in association with natural and synthetic biomaterials, in patients with different

grades of bone defects, reporting improved bone regeneration, early bone formation, bone-depth reduction and more mature bone [28–31]. However, the exact function of PLTs and its derivatives on bone resorption and bone formation is still complex to understand because of the multifaceted interactions between GFs, inflammatory mediators, and cytokines. Consequently PLTs role and skills during OP and their relationship with bone loss are even more complex to understand and conflicting results have been obtained [32–34].

To date, many key questions remain unanswered and controversial, in particular concerning PLT function, size, volume, role of bioactive GFs released and use of PLT derivatives during OP pathogenesis. Thus, we carried out a systematic review in which we wondered: How do PLTs work and what changes occur in their function, features and/or structure (volume, size, number) during OP? How do GFs released by PLTs or GFs existing in PLTs and PLT derivatives “work” during OP? Which are the main derivatives used in OP? and How are they used? In the present systematic review we tried to highlight and answer to these points, attempting to give an up-to-date tool for researchers and clinicians involved in PLT-mediated bone tissue regenerative applications in OP condition.

2. Methods

2.1. Eligibility Criteria

The PICOS model was used to formulate the questions for this study: (1) studies that considered cells, animals and patients with OP (Population), (2) studies where one of the primary aims were to evaluate PLTs and PLTs derivatives during OP (Interventions), (3) studies that presented a control interventions (Comparisons), (3) studies that reported the effects/functions/roles of PLTs and PLTs derivatives during OP (Outcomes) and (4) preclinical (in vitro and in vivo) and clinical studies (Study design). Studies from 27 July 2009 to 27 July 2019 were included in this review if they met the PICOS criteria.

We excluded studies investigating (1) PLTs functions and/or PLTs derivatives in pathological conditions different from OP, (2) pathological conditions where OP is a bone manifestation of another disease (i.e., diabetes, Gaucher disease, cancer, rheumatic diseases), (3) osteonecrosis of the jaw due to OP therapy, (4) PLT functions and/or PLT derivatives during the administration of drugs active on bone metabolism (e.g., alendronate, zoledronate, denosumab, raloxifene), (5) drug (e.g., glucocorticoid)-induced osteoporosis. Additionally, we excluded case reports, abstracts, editorials, letters, comment to Editor, reviews, meta-analysis, book chapters and articles not written in English.

2.2. Information Source and Search Strategies

Our literature review involved a systematic search conducted on 27 July 2019. We performed our review according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [35]. The search was carried out on PubMed, MEDLINE, ProQuest, Scopus, Web of Science Core Collection and Cochrane Central Register of Controlled Trials databases to identify preclinical and clinical studies on PLT functions/features and use of PLT derivatives in OP condition. Search was conducted combining the terms “Osteoporosis” AND “Platelets”; for each of these terms, free words and controlled vocabulary specific to each bibliographic database were combined using the operator “OR”. The combination of free-vocabulary and/or MeSH terms for the identification of studies in PubMed/MEDLINE, ProQuest, Scopus, Web of Science Core Collection and Cochrane Central Register of Controlled Trials were reported in Table 1. In addition, reference lists of relevant studies were searched for other potentially appropriate publications.

Table 1. Search terms used in the PubMed, ProQuest, Scopus, Web of Science Core Collection and Cochrane Central Register of Controlled Trials.

| Database | Search Items |
|--|--|
| PubMed | <p>(((((("blood platelets"[MeSH Terms] OR ("blood"[All Fields] AND "platelets"[All Fields]) OR "blood platelets"[All Fields] OR "platelet"[All Fields]) OR ("blood platelets"[MeSH Terms] OR ("blood"[All Fields] AND "platelets"[All Fields]) OR ("blood"[All Fields] AND "platelets"[All Fields]) OR "platelet"[All Fields]) OR "blood platelets"[All Fields] OR "platelets"[All Fields]) OR ((("blood platelets"[MeSH Terms] OR ("blood"[All Fields] AND "platelets"[All Fields]) OR "blood platelets"[All Fields] OR "platelet"[All Fields]) AND functions[All Fields])) OR ((("blood platelets"[MeSH Terms] OR ("blood"[All Fields] AND "platelets"[All Fields]) OR "blood platelets"[All Fields] OR "platelet"[All Fields]) AND ("Changes"[Journal] OR "changes"[All Fields]))) OR ((("blood platelets"[MeSH Terms] OR ("blood"[All Fields] AND "platelets"[All Fields]) OR "blood platelets"[All Fields] OR "platelet"[All Fields]) AND "size"[All Fields])) OR ((("blood platelets"[MeSH Terms] OR ("blood"[All Fields] AND "platelets"[All Fields]) OR "blood platelets"[All Fields] OR "platelet"[All Fields]) AND ("Structure"[Journal] OR "structure"[All Fields]))) OR ((("blood platelets"[MeSH Terms] OR ("blood"[All Fields] AND "platelets"[All Fields]) OR "blood platelets"[All Fields] OR "platelet"[All Fields]) AND size[All Fields])) AND (((((((("osteoporosis, postmenopausal"[MeSH Terms] OR ("osteoporosis"[All Fields] AND "postmenopausal"[All Fields]) OR "postmenopausal osteoporosis"[All Fields] OR "osteoporosis"[All Fields] OR "osteoporosis"[MeSH Terms] OR ("bone demineralization, pathologic"[MeSH Terms] OR ("bone"[All Fields] AND "demineralization"[All Fields] AND "pathologic"[All Fields]) OR "pathologic bone demineralization"[All Fields] OR ("bone"[All Fields] AND "demineralization"[All Fields]) OR "bone demineralization"[All Fields])) OR ("bone density"[MeSH Terms] OR ("bone"[All Fields] AND "density"[All Fields]) OR "bone density"[All Fields])) OR ("osteoporotic fractures"[MeSH Terms] OR ("osteoporotic"[All Fields] AND "fractures"[All Fields]) OR "osteoporotic fractures"[All Fields])) OR ("bone diseases, metabolic"[MeSH Terms] OR ("bone"[All Fields] AND "diseases"[All Fields] AND "metabolic"[All Fields]) OR "metabolic bone diseases"[All Fields] OR "osteopenia"[All Fields])) OR ("bone diseases, metabolic"[MeSH Terms] OR ("bone"[All Fields] AND "diseases"[All Fields] AND "metabolic"[All Fields]) OR "metabolic bone diseases"[All Fields] OR ("bone"[All Fields] AND "loss"[All Fields]) OR "bone loss"[All Fields])) OR ("bone density"[MeSH Terms] OR ("bone"[All Fields] AND "density"[All Fields]) OR "bone density"[All Fields]) OR bmd[All Fields]) AND ("2009/07/27"[PDAT]: "2019/07/27"[PDAT])</p> |
| ProQuest | <p>(platelet AND (bdl(1007527) AND pd(20090727-20190727))) AND (osteoporosis AND (bdl(1007527) AND pd(20090727-20190727))) Applied limits: Database: Biological Science Collection British Nursing Database Health Research Premium Collection <i>Part of the search defined by the query is performed in these databases.</i> Restricted based on: Database: Biological Science Collection; Health Research Premium Collection; Biological Science Index; MEDLINE®; TOXLINE</p> |
| Web of Science Core Collection | <p>(TS = platelet OR TS = platelets OR TS = platelet functions OR TS = platelet changes OR TS = platelet structure OR TS = platelet size) AND (TS = osteoporosis OR TS = bone demineralization OR TS = bone density OR TS = Osteoporotic Fractures OR TS = osteopenia OR TS = bone loss OR TS = bone density OR TS = bmd)—with Publication Year from 2009 to 2019</p> |
| Scopus | <p>(TITLE-ABS-KEY (platelet) OR TITLE-ABS-KEY (platelets) OR TITLE-ABS-KEY (platelet AND functions) OR TITLE-ABS-KEY (platelet AND changes) OR TITLE-ABS-KEY (platelet AND structure) OR TITLE-ABS-KEY (platelet AND size) AND TITLE-ABS-KEY (osteoporosis) OR TITLE-ABS-KEY (bone AND demineralization) AND TITLE-ABS-KEY (bone AND density) OR TITLE-ABS-KEY (osteoporotic AND fractures) OR TITLE-ABS-KEY (osteopenia) OR TITLE-ABS-KEY (bone AND loss) OR TITLE-ABS-KEY (bone AND density) OR TITLE-ABS-KEY (bmd) OR TITLE-ABS-KEY (bone AND mass)) AND DOCTYPE (ar) AND PUBYEAR > 2008</p> |
| Cochrane Central Register of Controlled Trials | <p>(((((platelet) OR platelets) OR platelet functions) OR platelet changes) OR platelet structure) OR platelet size)) AND (((((((osteoporosis) OR bone demineralization) OR bone density) OR Osteoporotic Fractures) OR osteopenia) OR bone loss) OR bone density) OR bmd) in All Text—with Publication Year from 2009 to 2019</p> |

2.3. Study Selection and Data Extraction

Possible relevant articles were screened using title and abstract by one reviewer (FS) and articles that did not meet the inclusion criteria were excluded. After screening the title and abstract, articles were submitted to a public reference manager (Mendeley; "www.mendeley.com") to eliminate duplicates. Subsequently, the remaining full text articles were retrieved and examined by two reviewers (FS, MM). Any disagreement was resolved through discussion until a consensus was reached, or with the involvement of a third reviewer (MF).

Data from the retrieved studies were tabulated taking into consideration studies that evaluated PLT functions/features and growth factor in PLTs (Table 2) during OP and studies that evaluated PLT derivatives in OP (Table 3). Each table was split-up based on preclinical and clinical studies. We extracted the following data from the articles on PLT functions/features and growth factor in PLTs during OP: Reference, Aim, Study design, Methodology, Platelet function, Link between platelet and OP, Main results (Table 2). The extracted data for the studies on PLT derivatives in OP were: Reference, Aim, Study type, Platelet formulation, Platelets concentration, White blood cells content, Activation method, Platelet application, Experimental design, Main results.

2.4. Assessment of Methodological Quality

Two reviewers (FS and MM) independently assessed the methodological quality of selected studies (Tables 4 and 5). In case of disagreement, they attempted to reach consensus; if this failed, a third reviewer (MF) made the final decision. The methodological quality of the clinical studies was assessed using the Quality in Prognosis Studies (QUIPS) tool [36,37]. Studies were assessed on six domains: study participation, study attrition, prognostic factor measurement, outcome measurement, study confounding, and statistical analysis and reporting. Methodological quality appraisal of included *in vivo* studies was performed according to the Systematic Review Centre for Laboratory Animal Experimentation (SYRCLE) tool [38], which has been specifically designed to assess the risk of bias of animal studies. We have not assessed risk of bias for *in vitro* studies because, to our knowledge, no standard quality assessment tool exists for the type of *in vitro* studies included in this review.

3. Results

3.1. Study Selection and Characteristics

The initial literature search retrieved 2928 studies. Of those, 1169 studies were identified using PubMed/MEDLINE, 167 using ProQuest, 134 using Scopus, 1141 were found in Web of Science Core Collection and 317 using Cochrane Central Register of Controlled Clinical Trials. After screening the title and abstract 107 articles were run through Mendeley to eliminate duplicate articles. The resulting 49 complete articles were then reviewed to establish whether the publication met the inclusion criteria and 23 were considered eligible for this review. From the reference lists of the selected articles no additional publications were found. Search strategy and study inclusion and exclusion criteria are detailed in Figure 4.

We divided the extracted data in two tables, taking into consideration studies that evaluated PLT functions/features and growth factor in PLTs during OP ($n = 13$) (Table 2) and studies that used PLT derivatives in OP ($n = 10$) (Table 3). Each table was split-up based on preclinical and clinical studies.




Figure 4. PRISMA flowchart for the selection of studies.

Table 2. Preclinical (in vitro and in vivo) and clinical studies on PLT functions/features and growth factor in PLTs during osteoporosis.

| Reference | Aim | Study Design | Methodology | Platelet Function | Link Between Platelet and Osteoporosis | Main Results |
|--------------------------|--|---|---|-------------------|---|---|
| Pountos et al. 2010 [39] | Effect of BMP-2, BMP-7, PTH, and PDGF on proliferation and osteogenic differentiation of OP MSCs | MSCs isolated from trabecular bone of 10 OP patients (4 male and 6 female) treated with a 10 ⁶ range of concentrations (0.001 to 100 ng/mL) of PDGF-BB | Functional assays of proliferation and osteogenic differentiation | PDGF-BB | PDGF-BB have a positive effect on osteogenic differentiation of OP MSCs | MSC proliferation stimulated by BMP-7 and PDGF-BB |
| | | | | | | |
| Xie et al. 2014 [40] | Role of PDGF-BB in OVX mice | OVX C57BL/6 female mice injected with 1 µg PDGF-BB into the bone marrow cavity | Micro-CT, immunocytochemistry, immunofluorescence and histomorphometry. | PDGF-BB | Local PDGF-BB administration can temporally increase angiogenesis and spatially promote bone formation to couple angiogenesis with osteogenesis in bone modeling and remodeling | ↑PDGF-BB concentrations, VEGF concentrations, vessel volume, CD31hi Emcnhi cells, proliferation of endothelial cells in metaphysis, trabecular bone volume, thickness and number, cortical bone thickness, serum osteocalcin concentration in OVX mice treated with PDGF-BB |
| | | | | | | |
| Zhang et al. 2014 [41] | Effect on osteointegration of nanotube arrays loaded with rhPDGF-BB | OVX rat femur implantation: - oxalic acid-etched titanium rods - titanium rods modified with TiO ₂ nanotube arrays - PDGF group (titanium rods immersed in 100 µg/mL rhPDGF-BB) - PDGF + Vacuum extraction (vacuum pump -PDGF + Vacuum group-for 10 min) | Static and dynamic histomorphometry and biomechanical test | PDGF-BB | Immobilization of rhPDGF-BB on nanotube arrays as implant surface modification strategy in orthopedic applications in osteoporotic patients | rhPDGF-BB immobilized on the nanotube surface ↑ new bone formation and osseointegration |
| | | | | | | |
| Tang et al. 2017 [42] | Association between low plasma PDGF-BB levels and oestradiol | Sprague-Dawley rat: -Sham -OVX -OVX+oestradiol (100 mg/kg/d) -OVX+PDGF-BB (1mg/5 d/wk) | Plasma oestradiol and PDGF-BB levels measured using ELISA kits | PDGF-BB | Plasma PDGF-BB levels play a major role in OVX rats | ↓PDGF-BB levels in OVX rats than SHAM group. Oestradiol replacement ↑ plasma PDGF-BB levels, while PDGF-BB systematic treatment not affect plasma oestradiol levels |

Table 2. *Cont.*

| Reference | Aim | Study Design | Methodology | Platelet Function | Link Between Platelet and Osteoporosis | Main Results |
|---------------------------|--|--|--|------------------------------------|--|--|
| <i>Clinical studies</i> | | | | | | |
| Kim et al. 2011 [43] | Association between peripheral blood cell (PLT, WBC, RBC) counts BMD | Case-control study 17 OP patients 167 osteopenic patients 154 control subjects | DXA, biochemical parameters | PLTs count | Positive relationship between blood cell counts and BMD | WBC, RBC and PLT counts significantly associated with BMD |
| Li et al. 2012 [44] | Relationship between PLT count, MPV, and BMD | Case-control study 111 OP patients 171 osteopenic patients 128 control subjects | DXA, biochemical parameters | PLTs count and MPV | MPV negatively correlated with BMD | Negative correlation between MPV and the lumbar and femoral neck BMD. Univariate and multivariate analysis: MPV significantly associated with lumbar spine L2–L4 BMD and femoral neck BMD |
| D'Amelio et al. 2012 [45] | Correlation between PLTs vitamin D receptor expression and OP | Case-control study 77 postmenopausal OP patients 33 healthy control of childbearing age 49 healthy control men 11 healthy women matched with age and postmenopausal period | DXA, markers of bone metabolism and vitamin D receptor levels | PLTs vitamin D receptor expression | Reduced level of PLT vitamin D receptor is correlate to OP | ↓PLTs vitamin D receptor expression in OP patients respect to healthy postmenopausal controls. PLTs vitamin D receptor not influenced by gender. PLTs vitamin D receptor predict 65% of the BMD variation. |
| Alkal et al. 2014 [32] | Correlation between BMD and MPV and PDW | Case-control study 30 OP patients 30 osteopenic patients 20 control subjects | DXA, full laboratory test | MPV PDW | Significant role of PDW and MPV in the postmenopausal OP development | ↓MPV and PDW in OP than the normal BMD patients. PDW positively correlated with FTT and L1–4T scores. Age and PDW independently related to FTT and LTT scores. |
| Kim et al. 2015 [34] | Association between plasma PAF, OP vertebral fracture and BMD | Case-control study 73 OP patients with vertebral fracture 73 OP patients without vertebral fracture | Radiography, DXA, biochemical parameters, plasma PAF concentration | PAF | Plasma PAF levels inversely correlated with BMD | 34.6% ↑ plasma PAF levels in postmenopausal women with vertebral fracture than subjects without vertebral fracture |

Table 2. *Cont.*

| Reference | Aim | Study Design | Methodology | Platelet Function | Link Between Platelet and Osteoporosis | Main Results |
|---------------------------|---|---|--|----------------------|---|--|
| Ayrpak et al. 2016 [46] | Correlation between BMD and MPV | Case-control study 126 OP patients 37 osteopenic patients 12 control subjects | DXA, laboratory tests including complete blood count (CBC), calcium, phosphorus, serum 25-hydroxyvitamin D (25OHD), and intact parathormone (iPTH) | MPV | MPV correlated with BMD in postmenopausal OP women. | MPV significantly associated with BMD in normal weight and overweight-obese OP patients. |
| Tang et al. 2017 [42] | Association between low plasma PDGF-BB levels and oestradiol in postmenopausal OP | Case-control study 28 postmenopausal OP patients 69 control young woman 24 age-matched women | DXA, plasma oestradiol and PDGF-BB levels | PDGF-BB | Plasma PDGF-BB levels maintained by oestrogen in normal young women and play a major role in postmenopausal OP | [Plasma oestradiol and PDGF-BB levels in postmenopausal women, especially in OP patients. PDGF-BB levels were positively correlated with oestradiol levels and inversely correlated with age |
| Vural et al. 2017 [47] | Correlation between PLT functions, vitamin D and BMD | Case-control study 124 OP patients 151 osteopenic patients 87 control subjects | DXA, biochemical parameters | MPV | No correlation between MPV and OP. MPV considered a less important indicator in serum 25-hydroxyvitamin D levels and OP | No difference in MPV and PLT counts between groups. No correlation between MPV and serum 25-hydroxyvitamin D levels. Correlation between PLT count and lumbar spine (L1–4) T score |
| Koseoglu et al. 2017 [48] | Correlation between PLT/lymphocyte ratio and low BMD in postmenopausal woman | Case-control study 179 OP and osteopenic patients 32 control subjects | DXA, biochemical parameters | PLT/lymphocyte ratio | PLT/lymphocyte ratio as new inflammatory marker for bone loss and low BMD | ↑PLT/lymphocyte ratio in OP and osteopenic patients than in the control subjects. Negative correlation between lumbar and femur neck BMD and PLT/lymphocyte ratio |
| Eroglu et al. 2019 [33] | Correlation between PLT/lymphocyte and BMD | Case-control study 48 OP patients 112 osteopenic patients 92 control subjects | DXA, biochemical parameters | PLT/lymphocyte ratio | Negative correlation Between PLT/lymphocyte and BMD | ↑PLT/lymphocyte ratio in OP and osteopenic patients. |

MPV: mean platelet volume; PDW platelet distribution width; FTT: femur total T; L1–4T: lumbar 1–4T; PAF: platelet-activating factor; WBC: peripheral blood white blood cell RBC: red blood cell.

Table 3. Preclinical studies on PLT derivatives.

| Reference | Aim | Study Type | Platelet Formulation | Platelets Concentration | White Blood Cells Content | Activation Method | Platelets Application | Experimental Design | Main Results |
|-------------------------------|--|----------------------|----------------------|--|---------------------------|--|---|---|---|
| Lo et al. 2009 [49] | Transplantation of PRP/NIH3T3-G cells to induced bone regeneration in OP | in vitro and in vivo | Human PRP | NS | NS | Exogenous-bovine thrombin | NIH3T3-G alone, BMCs alone and NIH3T3 G/BMC co-culture Bone marrow cavity of the tibia | OVX-SAMP8 mice treated with PRP/NIH3T3-G | PRP/NIH3T3-G treatment prevent OP development |
| Liu et al. 2011 [50] | Balance between adipogenesis and osteogenesis in bone regeneration by PRP for age-related OP | in vitro and in vivo | Human PRP | NS | NS | Exogenous-bovine thrombin | Mouse pre-adipocytes (3T3-L1) and osteoblast cell line (7F2) co-culture Bone marrow cavity of the hind femur | OVX-SAMP8 mice treated with PRP | PRP treatment exert its action promoting bone regeneration and suppressing adipogenesis within the marrow |
| Clatschenkel et al. 2012 [51] | Incorporation of melatonin and/or PRP into CA scaffolds to enhance bone regeneration in OP | in vivo | OVX rat PRP | NS | NS | NS | Calvaria critical-sized defect | OVX rats treated with CA scaffold with PRP and melatonin, associated or not | PRP not improves bone formation |
| Chen et al. 2013 [52] | PRP to promote healing of OP fractures | in vitro and in vivo | OVX rat PRP | High: $8.21 \pm 0.4 \times 10^9$ Medium: $2.65 \pm 0.2 \times 10^9$ Low: $0.85 \pm 0.16 \times 10^9$ PPP8 + 0.5×10^6 (PLTs/mL) | NS | Exogenous-thrombin/ CaCl ₂ | BMSCs culture Femoral fracture | OVX rats treated with high-, medium- and low-concentration PRP and with PPP | Medium-concentration of PRP is the more suitable in promoting fracture healing |
| Cho et al. 2014 [53] | Incorporation of PRP into CPC to enhance bone regeneration in OP | in vivo | OVX rat PRP | 4.12×10^9 (PLTs/mL) | NS | NS | Vertebral body critical-size defects | OVX rats treated with CPC associated to PRP | PRP accelerates osteoconduction and improves trabecular bone microarchitecture and BMD |
| Jiang et al. 2016 [54] | PRP treatment and TiO ₂ nanoporous modification on the stability of titanium implants in OP | in vivo | Human PRP | 2×10^9 (PLTs/mL) | NS | Exogenous-calcium enriched batroxobin | Bone marrow cavity of the hind tibia | OVX rats treated with TiO ₂ associated to PRP | PRP treatment improves implant biomechanical stability |

Table 3. *Cont.*

| Reference | Aim | Study Type | Platelet Formulation | Platelets Concentration | White Blood Cells Content | Activation Method | Platelets Application | Experimental Design | Main Results |
|-------------------------------|--|------------|----------------------|---------------------------------------|---------------------------|--------------------|--------------------------------------|---|--|
| Wei et al. 2016 [55] | PRP in combination with BMSCs for the treatment of OP defect | in vivo | Rats PRP | NS | NS | Exogenous-thrombin | Tibia critical size defects defect | OVX rats treated with allogenic BMSC associated to PRP | PRP combined with BMSCs promotes bone defects healing |
| Rocha et al. 2017 [56] | PRP and MSCs, associated or not, in the repair of bone failures in secondary OP | in vivo | Equine PRP | 200 × 10 ³ (PLTs/ μ L) | NS | NS | Tibia failures | Rabbits submitted to ovariectomysalpingohysterectomy and hypercortisolism treated with allogenic BMSCs and PRP; associated or not | PRP contributes positively to the repair of bone failure, but less than the treatment with MSCs and similarly to the association of both |
| Sakata et al. 2018 [57] | Bone regeneration of OP defects by PRP and β -TCP | in vivo | Rats PRP | NS | NS | NS | Vertebral body critical-size defects | OVX rats treated with β -TCP associated to PRP | PRP associated to β -TCP sponge facilitates bone regeneration in OVX lumbar vertebral bone defect |
| Engler-Pinto et al. 2019 [58] | L-PRF associated or not with bovine bone graft on the healing of OP bone defects | in vivo | Rats L-PRF | NS | NS | NS | Calvaria critical size defects | OVX rats treated with bovine bone graft associated to PRP | L-PRF clot improves bone formation but less than the use of L-PRF associated to bovine bone graft |

NS: not specified; PRP/NIH3T3-G: NIH3T3-G pre-differentiated into osteoblast-like cells using PRP; OVX-SAMP8: ovariectomized senescence-accelerated mice; CA: calcium aluminate; CPC: calcium phosphate cement; β -TCP: β -tricalciumphosphate.

3.2. Assessment of Methodological Quality

Risks of bias assessments for each clinical study were summarized in Table 4. The overall risk of bias across studies was low to moderate for the majority of the studies ($n = 8$; 75%), with the exception of two studies that have high risk due the lack of information [33,45], for at least one aspect of study attrition [45], prognostic factor measurement [33] and outcome measurement [45].

Risks of bias assessments for each in vivo study were summarized in Table 5. Risk of bias of animal studies was high for almost all the examined studies. Among the 13 included in vivo studies, three for PLT functions during OP and 10 for PLT derivatives in OP, 10 of them have not declared the method of sequence generation [41,42,49–53,56,57], in one study the method was unclear [55] and in the remaining two studies the method of sequence generation was clearly declared [40,58]. The majority ($n = 7$) of the studies showed that groups were similar concerning baseline characteristics (i.e., age, weight, sex) and two studies showed that allocation was adequately concealed [40,58]. One study reported that animals were housed randomly during the experiment [40] and another reported the blinding of investigators [52]. Only one study reported that the animals were selected at random for outcome assessment [41] and another one reported the blinding of outcome assessors [52]. Almost all the studies included all the animals in the analyses ($n = 10$), reported and detailed the primary outcome ($n = 12$) and were apparently free of other problems that could result in high risk of bias ($n = 8$) (Table 5).

Table 4. QUIPS tool for assessing risk of bias in the clinical studies.

| Study | QUIPS | | | | | |
|---------------------------|---------------------|-----------------|-------------------------------|---------------------|-------------------------------------|----------|
| | Study Participation | Study Attrition | Prognostic Factor Measurement | Outcome Measurement | Confounding Measurement and Account | Analysis |
| Kim et al. 2011 [43] | Low | Low | Moderate | Moderate | Moderate | Low |
| Li et al. 2012 [44] | Low | Low | Low | Moderate | Low | Low |
| D'Amelio et al. 2012 [45] | Moderate | High | Moderate | High | Moderate | Moderate |
| Akbal et al. 2014 [32] | Low | Low | Low | Moderate | Low | Low |
| Kim et al. 2015 [34] | Low | Low | Low | Low | Low | Low |
| Aypak et al. 2016 [46] | Low | Low | Low | Moderate | Moderate | Moderate |
| Tang et al. 2017 [42] | Low | Moderate | Moderate | Moderate | Moderate | Moderate |
| Vural et al. 2017 [47] | Low | Low | Low | Moderate | Low | Moderate |
| Koseoglu et al. 2017 [48] | Low | Low | Low | Moderate | Moderate | Low |
| Eroglu et al. 2019 [33] | Low | Moderate | High | Moderate | Moderate | Low |

PLT functions/features and growth factor in PLTs during osteoporosis

low (good) indicator,
 moderate indicator,
 high (bad) indicator.

Table 5. SYRCLE’s tool for assessing risk of bias in the in vivo studies.

| Study | SYRCLE | | | | | | | | | | Other Sources of Bias |
|--|--------------------------|------------------------|------------------|----------|-------------------|----------------|-------------------------|-----------------------------|-------|----------------|-----------------------|
| | Sequence Generation | Selection Bias | Performance Bias | | | Detection Bias | | Attrition Bias | | Reporting Bias | |
| | Baseline Characteristics | Allocation Concealment | Random Housing | Blinding | Random Assessment | Blinding | Incomplete Outcome Data | Selective Outcome Reporting | Other | | |
| Xie et al. 2014 [40] | Yes | Yes | Yes | No | Unclear | No | No | Yes | No | No | |
| Zhang et al. 2014 [41] | No | Yes | Unclear | Unclear | Yes | No | No | Yes | No | No | |
| Tang et al. 2017 [42] | No | Unclear | Unclear | Unclear | Unclear | Unclear | No | Yes | Yes | Yes | |
| <i>PLT functions/factors and growth factor in PLTs during osteoporosis</i> | | | | | | | | | | | |
| Lo et al. 2009 [49] | No | Unclear | Unclear | Unclear | No | No | No | Yes | No | No | |
| Liu et al. 2011 [50] | No | No | No | No | No | No | No | Unclear | No | No | |
| Chafshinkel et al. [51] | No | Yes | No | No | No | No | Unclear | Yes | Yes | Unclear | |
| Chen et al. 2013 [52] | No | Unclear | No | Yes | No | Yes | No | Yes | No | No | |
| Cho et al. 2014 [53] | No | No | No | No | No | Unclear | Yes | Yes | No | Yes | |
| Jiang et al. 2016 [54] | No | Yes | No | No | No | No | No | Yes | No | Unclear | |
| Wei et al. 2016 [55] | Unclear | Yes | Unclear | No | No | No | No | Yes | Yes | No | |
| Rocha et al. 2017 [56] | No | No | No | No | No | No | Unclear | Yes | Yes | No | |
| Sakata et al. 2018 [57] | No | Yes | Unclear | No | No | No | Unclear | Yes | Yes | Yes | |
| Engler-Pinto et al. 2019 [58] | Yes | Yes | Yes | No | No | No | No | Yes | Yes | No | |

□ positive (good) indicator, □ unclear, □ negative (bad) indicator.

4. Study Results

4.1. Platelet Functions/Features and Growth Factor in PLTs in Osteoporosis

Articles that evaluated PLT functions/features and growth factor in PLTs during OP were prevalently clinical ($n = 9$), two were in vivo studies, one was both in vivo and clinical and another was exclusively in vitro (Table 2). In this last [39], starting from the evidence of the reduced healing capability of MSCs during OP, a comparison between the effect of BMP-2, BMP-7, parathyroid hormone (PTH) and PDGF on proliferation and osteogenic differentiation of MSCs derived from OP patients was performed. MSCs isolated from trabecular bone showed to be more sensitive to high dose of PDGF-BB, as well of BMP-7 in comparison to the other stimulations, in terms of alkaline phosphatase (ALP) activity and calcium release, in a dose dependent manner. The critical role of the PDGF-BB was also investigated in two in vivo studies [40,41]. Zhang et al. showed that the immobilization of PDGF-BB on titanium nanotube arrays was effective in stimulating osteogenesis both in vitro, on BMSCs isolated from OVX rats, and in an in vivo model of osteointegration in OVX rat femurs [41]. Exploiting the use of a *Ctsk*^{-/-} mouse model, in which higher levels of PDGF-BB have been found to be secreted by pre-osteoclasts, Xie et al. [40] investigated instead the bone remodeling rate in relationship with angiogenesis stimulation. Results showed that PDGF-BB promotes angiogenesis, recruiting MSCs and endothelial progenitor cells (EPCs) and stimulating CD31hiEmcni vessel and bone formation in OVX mice [40]. Additionally, in vitro tube formation assays performed with conditioned medium from pre-osteoclasts and osteoclasts isolated after bone marrow flushing confirmed the results. Always focusing on the PDGF-BB function Tang et al. [42], in an in vivo study on OVX rats and in a prospective clinical study involving young woman, postmenopausal and OP postmenopausal woman, showed that the levels of oestradiol and PDGF-BB correlate with patients age and that the lowest levels are found in the postmenopausal OP cohort.

Several clinical studies evaluated the relationship between PLT and OP status based on Bone Mineral Density (BMD) value considering different cohorts of woman, i.e., healthy, osteopenic and OP [44,46,47]. The investigation on mean PLT volume (MPV) [46,47] and PLT distribution width (PDW) [46] showed that the levels of these markers were reduced in OP patients and that they correlated with BMD T-score. In addition, in a bigger clinical study (175 patients, 72% osteoporotic) it was also seen that MPV inversely correlate with body mass index [46]. On the contrary, performing the same evaluation on the same cohorts of patients, Vural et al. found no differences in MPV and PLT, neither founded any possible relationship between vitamin D levels and MPV [47]. However, D'Amelio et al. [45] evaluating woman with postmenopausal OP and using as control healthy man and woman matched for age and postmenopausal period, showed that PLT vitamin D receptor was less expressed in OP patients. Additionally PLT vitamin D receptor level can be related to the variation of BMD independently from the health status of patients. The lower expression of the receptor also induced a worst response to vitamin D and a consequent increase in PTH levels [45]. In addition, evaluating postmenopausal OP patients, the PLT/lymphocyte ratio was found to correlate with low BMD [33,48], in particular in reference to the femoral and lumbar district [48], which is also related to low vitamin D levels, supporting the hypothesis that inflammation correlates with vitamin D levels [48]. The relationship between peripheral blood cell count and BMD in OP was investigated also by Kim et al. which observed that PLTs count, as well as white and red blood cells counts, correlate with BMD in OP patients [43]. Finally, Kim et al. evaluated the level of plasma PLT activating factor (PAF) in OP woman with radiological evident vertebral fracture. After assessing BMD and serum calcium levels, results showed that PAF levels correlated with the presence of vertebral fracture, as well as with BMD in all sites except for femoral neck, and that PAF levels increase in parallel with ALP levels [34].

4.2. Platelet Derivatives in Osteoporosis

All 10 articles on PLT derivatives in OP were about vivo or both in vivo and in vitro studies. With the exception of the study by Rocha et al. [56] that used rabbits submitted to elective

ovariosalpingohysterectomy as OP animal model all the other studies employed ovariectomized (OVX) mice and rats to induce OP (Table 3). All studies used PRP as PLT products with the exception of a study which used L-PRF [58]. Six of these studies (60%) also employed a scaffold/biomaterial (calcium phosphate, calcium aluminate/calcium aluminate-melatonin, β -tricalcium phosphate, bovine bone graft, nanoporous TiO₂, hemostatic sponge) to incorporate the PLTs derivatives and subsequently evaluated bone regeneration in calvaria [51,58], tibia [54,56] and in caudal and lumbar vertebrae [53,57]. Clafshenkel et al. [51] evaluating a calcium aluminate and calcium aluminate-melatonin scaffolds implanted in a critical size calvaria defect of OVX rats, showed that the addition of PRP did not significantly improve degree, intensity and abundance of osteoid tissue mineralization and bone formation in either of the two scaffolds [51]. Differently, Engler-Pinto et al. [58] using the same animal model to evaluate L-PRF alone, blood clot alone, bovine bone graft alone, or a combination of L-PRF with bovine bone graft, showed that the association of L-PRF to bovine bone graft potentiate the bone healing and the production of VEGF, osteocalcin (OCN) and BMP-2/4 [58]. Increased osteogenic efficiency were also observed evaluating the healing of a long bone defect (tibia) in OVX animals treated with TiO₂ nanoporous implant associated with PRP [54]. Additionally, it was seen that PRP in association with TiO₂ not only promoted the osteogenesis but also increased the expression of RUNX2 and COL1 genes and suppressed osteoclastogenesis with increased expression of OPG and decreased levels of RANKL [54]. Despite calvaria defects and long bones defects are the most frequently models used to evaluate bone regeneration and healing during OP, also vertebrae, despite the higher cancellous bone content and the different anatomical and biomechanical properties, were used to evaluate the role of scaffold/biomaterial in association to PRP [53,57]. Two in vivo studies in OVX animals showed that incorporating PRP into calcium phosphate cement [53] and β -TCP sponge [57] accelerated osteoconduction in the caudal [53] and lumbar [57] site, also demonstrating an improvement of the trabecular bone microarchitecture. Additionally, calcium phosphate cements associated to PRP improve the bone mineral density [53] and increase the stiffness of the affected vertebral bodies [57]. Finally, Rocha et al. [56] used a hydrolyzed collagen sponge made from freeze-dried sterile porcine gelatine as carrier for allogenic BMSCs and PRP, alone or in combination, to evaluate the repair of bone failure in tibiae of osteoporotic rabbits secondary to estrogenic deprivation and iatrogenic hypercortisolism [56]. Results suggested that PRP contributed positively to repair of bone failure, but less than the group treated with BMSC and similarly to the association of both [56].

Differently from the above mentioned studies, four studies (40%) used PRP without scaffold/biomaterial to analyze the balance between adipogenesis and osteogenesis in bone regeneration [50], to induce bone regeneration from embryonic fibroblasts [49], to evaluate PRP association to BMSCs [55], to analyze PRP effect in the treatment of OP fractures and to clarify PRP best concentration of use [52]. By using an OVX senescence-accelerated mice (SAMP8) model in which genetically modified NIH3T3 embryonic fibroblasts (pre-differentiated into osteoblast-like cells using PRP) were injected into the bone marrow cavity, an improvement in BMD scores and in the skeletal bone architecture were detected [49]. Using the same animal model it was also seen that PRP alone exerted its action by promoting bone regeneration and suppressing adipogenesis within the marrow [50]. PRP-induced osteogenesis was confirmed by simultaneously up-regulating osteogenesis-promoting genes RUNX2, OPN and OCN and down-regulating adipogenesis regulators such as PPAR- γ 2 and leptin in bone marrow cells of PRP treated animals [50]. Allogenic BMSCs in combination with PRP were also used for the treatment of OP bone defects in an OVX rat model showing that bone defects of OVX rats treated with PRP and BMSCs were completely repaired, whereas those treated with PRP or BMSCs alone exhibited slower healing [55]. In addition, higher expression levels of RUNX2, OSX, and OPN were found in rats treated with PRP and BMSCs [55]. Autologous BMSCs cultured with high-, medium-, low-concentration PRP and with PPP from OVX rats were also used to treat fracture healing in an OVX animal model [52]. Results highlighted that the medium-concentration of PRP showed faster healing than the other groups, with a faster bridging of the fracture gaps and higher bridging rate [52].

5. Discussion

To date OP management still remains a difficult task for clinicians and based on the progressively increase of aging population the global implications of OP and impaired bone healing are considerable. In the past decade, an increasing number of studies explored the use of new and advanced markers as well as of bioactive factors able to promote bone formation/regeneration during OP [59,60]. Although promising results have been documented both for OP markers and bioactive factors, the available evidence does not yet support their use and further investigation for their clinical use, in particular for PLTs and their derivatives, are mandatory [61]. Thus, the aim of the present systematic review was to evaluate the PLT function, i.e., size, volume, bioactive GFs released, and the usage of their derivatives during OP in order to understand the potential of PLT function as OP markers and the physiopathological mechanisms that underlie the regenerative effects of their derivatives.

In this review, preclinical studies on PLTs function/features and growth factor in PLTs during OP mainly deal with PDGF, a naturally molecule released from the α -granules of PLTs, as part of the clotting process that occurs in response to injury [62]. Homodimer BB constitutes a dimeric glycoprotein of PDGF and is considered the universal PDGF isoform, rendering it the most logical form of the protein to develop as a therapeutic [62]. The ability to simultaneously influence cellular chemotaxis, mitogenesis and angiogenesis gives to PDGF a fundamental role in musculoskeletal repair and regeneration also in OP condition [63]. In this review, PDGF-BB administered in vitro in OP MSCs and in vivo in OVX small animal models respectively stimulated osteogenesis, proliferation and improve angiogenesis and implant osteointegration. In addition, it was found that in OVX animal model, bone marrow levels of PDGF-BB, which was partially produced by preosteoclasts, were drastically decreased. This probably occurred because an increase in mature bone resorption by osteoclasts reduced preosteoclasts and consequently PDGF-BB secretion in OVX animals. Therefore, PDGF-BB is likely mediated by oestrogen in bone metabolism. In fact, it was demonstrated that plasma PDGF-BB levels are maintained by oestrogen in normal young women and play a major role in postmenopausal OP [42]. However, despite numerous studies suggested PDGF-BB as potential therapeutic target during OP, before moving toward the next step, further studies will ascertain the exact mechanisms of PDGF-BB on increasing new bone formation and improving angiogenesis in OP conditions. In addition, clinical studies for dose, delivery site and mode optimization will be mandatory in order to examine the side effects, overall safety and effectiveness of PDGF-BB. In this review the examined clinical studies also found a positive correlation between PLT size, distribution width, volume changes and low BMD due to OP with also a correlation with low levels of PLT vitamin D receptor that underlined a lower ability to respond to vitamin D in OP condition. On the other hand, some other studies demonstrated that PLT size cannot be used as a predictive marker of vitamin D status and BMD during OP. However, as reported by Varol et al. [64] accurate measurements of PLT count and volume are fundamental factors for diagnostic, therapeutic, and research purposes, thus to avoid artefactual results. Unfortunately, not all the studies analyzed detail the procedures used to obtain PLT count and volume and not all used a standardized procedure. An additional mechanism always available with routine blood counts, which explains the relation between PLTs and OP, was found in the correlation between PLT/lymphocyte ratio and OP, since PLT/lymphocyte ratio seems to be a discriminative factor for low BMD. The possibility to exploit data related to PLT size, distribution width, volume changes and PLT/lymphocyte ratio, obtained from a simple and routine investigation, to diagnose and correlate a specific pathological condition is undoubtedly fascinating. However, despite in this review the clinical studies suggested that these parameters may be used as potential OP predictors, a consensus has not been reached and there are still limited results. To date, these aspects strongly restrict the clinical translation and further studies, including larger patient groups, are mandatory and could allow identifying a subset of patients who are at greater risk for developing OP and who may benefit from early screening, intervention, and additional research.

Another key question concerning PLTs regards the role and use of their derivatives during OP. The rationale for PLT derivatives use in bone healing process is due to the abundance and accessibility

of key GFs and other signaling molecules in PLTs [65–67]. To date, PLT derivatives have been used for the improvement of bone fracture healing, such as common fracture healing, diabetic fracture healing, and nonunion [16,68]. Although not yet definite, it appears that most research supports a positive role for PLT derivatives in bone regeneration. However, the majority of these studies were done in non-OP condition and consequently it is not clear whether the impact of PLT derivatives would be compromised by OP. Thus, in the present review we searched preclinical and clinical studies on PLT derivatives employed in OP condition. However, our search strategy provided only preclinical studies and this is probably due to the fact that the use of PLTs derivatives in OP still requires a better understanding of the physiopathological mechanisms that underlie their real regenerative effects. All preclinical studies examined in this review used PRP as PLT products with the exception of one study which used L-PRF and most of them used a scaffold/biomaterial to incorporate the PLTs derivatives. Most of the examined studies demonstrated that PRP improve overall bone quality in OP animal models by promoting osteogenesis while suppressing adipogenesis in bone marrow. Moreover, PRP seems to stimulate the differentiation of embryonic fibroblasts into osteoblast-like cells; the transplantation of these PRP-treated cells also significantly improved bone architecture in OP animal models. It has also been demonstrated that PRP treatment combined with BMSCs may enhance the formation of new bone. However, a minority of studies (2/10) reported that the use of PRP associated to a scaffold and/or to BMSCs did not improve degree, intensity, mineralization and bone formation. Thus, in spite of numerous experimental evidences showed in this review, the use of PLT derivatives during OP is still subject of controversy also considering the high risk of bias of most animal studies. Several explanations for this dispute could be first of all due to the different interval between implantation and investigation as well as to the volume of whole blood and final volume of PLT derivative, final PLT and GFs concentration, methods that PLT derivatives is produced, activator agents, presence or absence of leukocytes and red blood cells, the origin of platelet derivative used (autologous, allogeneic or xenogeneic). Additionally, specific factors associated to the surgical approach, i.e., size of the bone defect, type and nature of the bone implant, bone graft substitute and bone fixation device could also affect the efficacy. Thus, despite the use of PLT derivatives increased in the past years mainly due to the easy use and biosafety that facilitates the translation in humans, to date further research should be performed to fully reveal the characteristics of the relationship between PLT derivatives and OP. These researches would be of fundamental importance as they would allow a rapid clinical translation of the PLT derivatives in the clinical theatre, leading to an improvement in the patient's quality of life and a reduction in the ever-increasing financial burden for governments and society due to OP.

6. Conclusions

Given the fundamental role of PLT features (size, volume, width distribution, GFs released and growth factor that exists in the PLTs) and PLT derivatives in musculoskeletal repair and regeneration, their future role in OP is expected to expand. Additional researches are under way to further improve our understanding on PLT as markers for OP and on PLT derivatives as therapeutic treatment to enhance bone healing and control inflammation during OP. These future investigations will hopefully continue to shed more light on how PLTs could best used to further improve the outcomes of OP patients in the clinical *scenario*.

Author Contributions: F.S. and M.F. designed the review. F.S. and M.M. performed the literature search. F.S. and M.M. analyzed the obtained articles. F.S., M.M. and M.F. wrote the paper. F.S., M.M. and M.S. collected and assembled the data. M.T. revised the manuscript critically. F.S., M.F., M.M. and M.S. finally approved the article. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Acknowledgments: This work was supported by grants from IRCCS Istituto Ortopedico Rizzoli (Ricerca Corrente) and by the 5 × 1000 Project, year 2017. The authors gratefully acknowledge Silvia Bassini for the support in the realization of the figures of this review.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Curtis, E.M.; Harvey, N.C.; Cooper, C. The burden of osteoporosis. In *Osteoporosis: A Life Course Epidemiology Approach to Skeletal Health*; Harvey, N.C., Cooper, C., Eds.; CRC Press: Boca Raton, FL, USA, 2018; pp. 1–20.
2. Johnell, O.; Kanis, J.A. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. *Osteoporos. Int.* **2006**, *17*, 1726–1733. [[CrossRef](#)] [[PubMed](#)]
3. Kanis, J.A.; Cooper, C.; Rizzoli, R.; Reginster, J.Y.; Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF). Executive summary of European guidance for the diagnosis and management of osteoporosis in postmenopausal women. *Aging Clin. Exp. Res.* **2019**, *31*, 15–17. [[CrossRef](#)] [[PubMed](#)]
4. Al Anouti, F.; Taha, Z.; Shamim, S.; Khalaf, K.; Al Kaabi, L.; Alsafar, H. An insight into the paradigms of osteoporosis: From genetics to biomechanics. *Bone Rep.* **2019**, *11*, 100216. [[CrossRef](#)] [[PubMed](#)]
5. Black, D.M.; Rosen, C.J. Postmenopausal Osteoporosis. *N. Engl. J. Med.* **2016**, *374*, 2096–2097. [[CrossRef](#)] [[PubMed](#)]
6. Bord, S.; Frith, E.; Ireland, D.C.; Scott, M.A.; Craig, J.I.; Compston, J.E. Megakaryocytes modulate osteoblast synthesis of type-I collagen, osteoprotegerin, and RANKL. *Bone* **2005**, *36*, 812–819. [[CrossRef](#)]
7. Ciovacco, W.A.; Goldberg, C.G.; Taylor, A.F.; Lemieux, J.M.; Horowitz, M.C.; Donahue, H.J.; Kacena, M.A. The role of gap junctions in megakaryocyte-mediated osteoblast proliferation and differentiation. *Bone* **2009**, *44*, 80–86. [[CrossRef](#)]
8. Kacena, M.A.; Nelson, T.; Clough, M.E.; Lee, S.K.; Lorenzo, J.A.; Gundberg, C.M.; Horowitz, M.C. Megakaryocyte-mediated inhibition of osteoclast development. *Bone* **2006**, *39*, 991–999. [[CrossRef](#)]
9. Maynard, D.M.; Heijnen, H.F.; Horne, M.K.; White, J.G.; Gahl, W.A. Proteomic analysis of platelet alpha-granules using mass spectrometry. *J. Thromb. Haemost.* **2007**, *5*, 1945–1955. [[CrossRef](#)]
10. Singh, A.; Ali, S.; Srivastava, R.N. Platelet-rich plasma in osteoporotic fractures: A review of literature. *J. Orthop. Traumatol. Rehabil.* **2014**, *7*, 123–138. [[CrossRef](#)]
11. Lieberman, J.R.; Daluiski, A.; Einhorn, T.A. The role of growth factors in the repair of bone. Biology and clinical applications. *J. Bone Jt. Surg. Am.* **2002**, *84*, 1032–1044. [[CrossRef](#)]
12. Tabata, Y. Tissue regeneration based on growth factor release. *Tissue Eng.* **2003**, *9* (Suppl. 1), 5–15. [[CrossRef](#)]
13. Sharif, P.S.; Abdollahi, M. The role of platelets in bone remodeling. *Inflamm. Allergy Drug Targets* **2010**, *9*, 393–399. [[CrossRef](#)] [[PubMed](#)]
14. Khan, F.A.; Parayaruthottam, P.; Roshan, G.; Menon, V.; Fidha, M.; Fernandes, A.K. Platelets and Their Pathways in Dentistry: Systematic Review. *J. Int. Soc. Prev. Community Dent.* **2017**, *7* (Suppl. 2), 55–60. [[CrossRef](#)] [[PubMed](#)]
15. Lang, S.; Loibl, M.; Herrmann, M. Platelet-Rich Plasma in Tissue Engineering: Hype and Hope. *Eur. Surg. Res.* **2018**, *59*, 265–275. [[CrossRef](#)]
16. Oryan, A.; Alidadi, S.; Moshiri, A. Platelet-rich plasma for bone healing and regeneration. *Expert Opin. Biol. Ther.* **2016**, *16*, 213–232. [[CrossRef](#)] [[PubMed](#)]
17. Salamanna, F.; Veronesi, F.; Maglio, M.; Della Bella, E.; Sartori, M.; Fini, M. New and emerging strategies in platelet-rich plasma application in musculoskeletal regenerative procedures: General overview on still open questions and outlook. *Biomed Res. Int.* **2015**, *2015*, 846045. [[CrossRef](#)]
18. Dohan Ehrenfest, D.M.; Rasmusson, L.; Albrektsson, T. Classification of platelet concentrates: From pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). *Trends Biotechnol.* **2009**, *27*, 158–167. [[CrossRef](#)]
19. Camargo, P.M.; Lekovic, V.; Weinlaender, M.; Vasilic, N.; Madzarevic, M.; Kenney, E.B. Platelet-rich plasma and bovine porous bone mineral combined with guided tissue regeneration in the treatment of intrabony defects in humans. *J. Periodontal. Res.* **2002**, *37*, 300–306. [[CrossRef](#)]
20. Uggeri, J.; Belletti, S.; Guizzardi, S.; Poli, T.; Cantarelli, S.; Scandroglio, R.; Gatti, R. Dose-dependent effects of platelet gel releasate on activities of human osteoblasts. *J. Periodontol.* **2007**, *78*, 1985–1991. [[CrossRef](#)]

21. Man, Y.; Wang, P.; Guo, Y.; Xiang, L.; Yang, Y.; Qu, Y.; Gong, P.; Deng, L. Angiogenic and osteogenic potential of platelet-rich plasma and adipose-derived stem cell laden alginate microspheres. *Biomaterials* **2012**, *33*, 8802–8811. [[CrossRef](#)]
22. Parsons, P.; Butcher, A.; Hesselden, K.; Ellis, K.; Maughan, J.; Milner, R.; Scott, M.; Alley, C.; Watson, J.T.; Horner, A. Platelet-rich concentrate supports human mesenchymal stem cell proliferation, bone morphogenetic protein-2 messenger RNA expression, alkaline phosphatase activity, and bone formation in vitro: A mode of action to enhance bone repair. *J. Orthop. Trauma* **2008**, *22*, 595–604. [[CrossRef](#)] [[PubMed](#)]
23. Mariano, R.; Messori, M.; de Moraes, A.; Nagata, M.; Furlaneto, F.; Avelino, C.; Paula, F.; Ferreira, S.; Pinheiro, M.; de Sene, J.P. Bone healing in critical-size defects treated with platelet-rich plasma: A histologic and histometric study in the calvaria of diabetic rat. *Oral. Surg. Oral. Med. Oral. Pathol. Oral. Radiol. Endod.* **2010**, *109*, 72–78. [[CrossRef](#)] [[PubMed](#)]
24. Simman, R.; Hoffmann, A.; Bohinc, R.J.; Peterson, W.C.; Russ, A.J. Role of platelet-rich plasma in acceleration of bone fracture healing. *Ann. Plast. Surg.* **2008**, *61*, 337–344. [[CrossRef](#)] [[PubMed](#)]
25. Torres, J.; Tamimi, F.M.; Tresguerres, I.F.; Alkhraisat, M.H.; Khraisat, A.; Lopez-Cabarro, E.; Blanco, L. Effect of solely applied platelet-rich plasma on osseous regeneration compared to Bio-Oss: A morphometric and densitometric study on rabbit calvaria. *Clin. Implant. Dent. Relat. Res.* **2008**, *10*, 106–112. [[CrossRef](#)] [[PubMed](#)]
26. Giovanini, A.F.; Gonzaga, C.C.; Zielak, J.C.; Deliberador, T.M.; Kuczera, J.; Göringher, I.; de Oliveira Filho, M.A.; Baratto-Filho, F.; Urban, C.A. Platelet-rich plasma (PRP) impairs the craniofacial bone repair associated with its elevated TGF- β levels and modulates the co-expression between collagen III and α -smooth muscle actin. *J. Orthop. Res.* **2011**, *29*, 457–463. [[CrossRef](#)] [[PubMed](#)]
27. Cheng, X.; Lei, D.; Mao, T.; Yang, S.; Chen, F.; Wu, W. Repair of critical bone defects with injectable platelet rich plasma/bone marrow-derived stromal cells composite: Experimental study in rabbits. *Ulus. Travma. Acil. Cerrahi. Derg.* **2008**, *14*, 87–95.
28. Célio-Mariano, R.; de Melo, W.M.; Carneiro-Avelino, C. Comparative radiographic evaluation of alveolar bone healing associated with autologous platelet-rich plasma after impacted mandibular third molar surgery. *J. Oral. Maxillofac. Surg.* **2012**, *70*, 19–24. [[CrossRef](#)]
29. Poeschl, P.W.; Ziya-Ghazvini, F.; Schicho, K.; Buchta, C.; Moser, D.; Seemann, R.; Ewers, R.; Schopper, C. Application of platelet-rich plasma for enhanced bone regeneration in grafted sinus. *J. Oral. Maxillofac. Surg.* **2012**, *70*, 657–664. [[CrossRef](#)]
30. Pappalardo, S.; Guarnieri, R. Efficacy of Platelet-Rich-Plasma (PRP) and Highly Purified Bovine Xenograft (Laddec®) Combination in Bone Regeneration after Cyst Enucleation: Radiological and Histological Evaluation. *J. Oral. Maxillofac. Res.* **2013**, *4*, 3. [[CrossRef](#)]
31. Gupta, G. Clinical and radiographic evaluation of intra-bony defects in localized aggressive periodontitis patients with platelet rich plasma/hydroxyapatite graft: A comparative controlled clinical trial. *Contemp. Clin. Dent.* **2014**, *5*, 445–451. [[CrossRef](#)]
32. Akbal, A.; Gökmen, F.; Gencer, M.; Inceer, B.S.; Kömürçü, E. Mean platelet volume and platelet distribution width can be related to bone mineralization. *Osteoporos. Int.* **2014**, *25*, 2291–2295. [[CrossRef](#)]
33. Eroglu, S.; Karatas, G. Platelet/lymphocyte ratio is an independent predictor for osteoporosis. *Saudi Med. J.* **2019**, *40*, 360–366. [[CrossRef](#)] [[PubMed](#)]
34. Kim, H.; Kim, B.J.; Ahn, S.H.; Lee, S.H.; Koh, J.M. Higher plasma platelet-activating factor levels are associated with increased risk of vertebral fracture and lower bone mineral density in postmenopausal women. *J. Bone Miner. Metab.* **2015**, *33*, 701–707. [[CrossRef](#)] [[PubMed](#)]
35. Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G.; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. *PLoS Med.* **2009**, *6*, e1000097. [[CrossRef](#)] [[PubMed](#)]
36. Hayden, J.A.; Côté, P.; Bombardier, C. Evaluation of the quality of prognosis studies in systematic reviews. *Ann. Intern. Med.* **2006**, *144*, 427–437. [[CrossRef](#)]
37. Hayden, J.A.; van der Windt, D.A.; Cartwright, J.L.; Côté, P.; Bombardier, C. Assessing bias in studies of prognostic factors. *Ann. Intern. Med.* **2013**, *158*, 280–286. [[CrossRef](#)]
38. Hooijmans, C.R.; Rovers, M.M.; de Vries, R.B.; Leenaars, M.; Ritskes-Hoitinga, M.; Langendam, M.W. SYRCLE's risk of bias tool for animal studies. *BMC Med. Res. Methodol.* **2014**, *14*, 43. [[CrossRef](#)]

39. Pountos, I.; Georgouli, T.; Henshaw, K.; Bird, H.; Jones, E.; Giannoudis, P.V. The effect of bone morphogenetic protein-2, bone morphogenetic protein-7, parathyroid hormone, and platelet-derived growth factor on the proliferation and osteogenic differentiation of mesenchymal stem cells derived from osteoporotic bone. *J. Orthop. Trauma* **2010**, *24*, 552–556. [[CrossRef](#)]
40. Xie, H.; Cui, Z.; Wang, L.; Xia, Z.; Hu, Y.; Xian, L.; Li, C.; Xie, L.; Crane, J.; Wan, M.; et al. PDGF-BB secreted by preosteoclasts induces angiogenesis during coupling with osteogenesis. *Nat. Med.* **2014**, *20*, 1270–1278. [[CrossRef](#)]
41. Zhang, W.; Jin, Y.; Qian, S.; Li, J.; Chang, Q.; Ye, D.; Pan, H.; Zhang, M.; Cao, H.; Liu, X.; et al. Vacuum extraction enhances rhPDGF-BB immobilization on nanotubes to improve implant osseointegration in ovariectomized rats. *Nanomedicine* **2014**, *10*, 1809–1818. [[CrossRef](#)]
42. Tang, L.; Xia, Z.; Luo, Z.; Long, H.; Zhu, Y.; Zhao, S. Low plasma PDGF-BB levels are associated with estradiol in postmenopausal osteoporosis: PDGF-BB mediated by estradiol in women. *J. Int. Med. Res.* **2017**, *45*, 1332–1339. [[CrossRef](#)] [[PubMed](#)]
43. Kim, H.L.; Cho, H.Y.; Park, I.Y.; Choi, J.M.; Kim, M.; Jang, H.J.; Hwang, S.M. The positive association between peripheral blood cell counts and bone mineral density in postmenopausal women. *Yonsei Med. J.* **2011**, *52*, 739–745. [[CrossRef](#)] [[PubMed](#)]
44. Li, X.S.; Zhang, J.R.; Meng, S.Y.; Li, Y.; Wang, R.T. Mean platelet volume is negatively associated with bone mineral density in postmenopausal women. *J. Bone Miner. Metab.* **2012**, *30*, 660–665. [[CrossRef](#)] [[PubMed](#)]
45. D'Amelio, P.; Cristofaro, M.A.; De Vivo, E.; Ravazzoli, M.; Grosso, E.; Di Bella, S.; Aime, M.; Cotto, N.; Silvagno, F.; Isaia, G.C.; et al. Platelet vitamin D receptor is reduced in osteoporotic patients. *Panminerva Med.* **2012**, *54*, 225–231. [[PubMed](#)]
46. Aypak, C.; Türedi, Ö.; Bircan, M.A.; Civelek, G.M.; Araz, M. Association between mean platelet volume and bone mineral density in postmenopausal women. *J. Phys. Ther. Sci.* **2016**, *28*, 1753–1758. [[CrossRef](#)] [[PubMed](#)]
47. Vural, M.; Mert, M.; Erhan, B.; Gunduz, B.; Keles, B.Y.; Erdem, A.E.; Bozan, A.; Arslan, H. Is there any relationship between mean platelet volume, bone mineral density and vitamin d in postmenopausal women? *Acta Med. Mediterr.* **2017**, *33*, 443.
48. Koseoglu, S.B. Bone loss & platelet-to-lymphocyte ratio. *Biomark. Med.* **2017**, *11*, 5–10.
49. Lo, W.C.; Chiou, J.F.; Gelovani, J.G.; Cheong, M.L.; Lee, C.M.; Liu, H.Y.; Wu, C.H.; Wang, M.F.; Lin, C.T.; Deng, W.P. Transplantation of embryonic fibroblasts treated with platelet-rich plasma induces osteogenesis in SAMP8 mice monitored by molecular imaging. *J. Nucl. Med.* **2009**, *50*, 765–773. [[CrossRef](#)]
50. Liu, H.Y.; Wu, A.T.; Tsai, C.Y.; Chou, K.R.; Zeng, R.; Wang, M.F.; Chang, W.C.; Hwang, S.M.; Su, C.H.; Deng, W.P. The balance between adipogenesis and osteogenesis in bone regeneration by platelet-rich plasma for age-related osteoporosis. *Biomaterials* **2011**, *32*, 6773–6780. [[CrossRef](#)]
51. Clafshenkel, W.P.; Rutkowski, J.L.; Palchesko, R.N.; Romeo, J.D.; McGowan, K.A.; Gawalt, E.S.; Witt-Enderby, P.A. A novel calcium aluminate-melatonin scaffold enhances bone regeneration within a calvarial defect. *J. Pineal Res.* **2012**, *53*, 206–218. [[CrossRef](#)]
52. Chen, L.; Yang, X.; Huang, G.; Song, D.; Ye, X.S.; Xu, H.; Li, W. Platelet-rich plasma promotes healing of osteoporotic fractures. *Orthopedics* **2013**, *36*, 687–694. [[CrossRef](#)] [[PubMed](#)]
53. Cho, A.R.; Kim, H.K.; Kwon, J.Y.; Kim, T.K.; Choi, Y.M.; Kim, K.H. The incorporation of platelet-rich plasma into calcium phosphate cement enhances bone regeneration in osteoporosis. *Pain Physician* **2014**, *17*, 737–745.
54. Jiang, N.; Du, P.; Qu, W.; Li, L.; Liu, Z.; Zhu, S. The synergistic effect of TiO₂ nanoporous modification and platelet-rich plasma treatment on titanium-implant stability in ovariectomized rats. *Int. J. Nanomed.* **2016**, *11*, 4719–4733.
55. Wei, B.; Huang, C.; Zhao, M.; Li, P.; Gao, X.; Kong, J.; Niu, Y.; Huang, R.; Quan, J.; Wei, J.; et al. Effect of Mesenchymal Stem Cells and Platelet-Rich Plasma on the Bone Healing of Ovariectomized Rats. *Stem Cells Int.* **2016**, *2016*, 9458396. [[CrossRef](#)] [[PubMed](#)]
56. Rocha, M.A.C.; Silva, L.M.C.; Oliveira, W.A.; Bezerra, D.O.; Silva, G.C.D.; Silva, L.D.S.; Medeiros, B.L.D.N.; Baêta, S.A.F.; Carvalho, M.A.M.; Argôlo, N.M. Allogeneic mesenchymal stem cells and xenogenic platelet rich plasma, associated or not, in the repair of bone failures in rabbits with secondary osteoporosis. *Acta Cir. Bras.* **2017**, *32*, 767–780. [[CrossRef](#)] [[PubMed](#)]

57. Sakata, M.; Tonomura, H.; Itsuji, T.; Ishibashi, H.; Takatori, R.; Mikami, Y.; Nagae, M.; Matsuda, K.I.; Tabata, Y.; Tanaka, M.; et al. Bone Regeneration of Osteoporotic Vertebral Body Defects Using Platelet-Rich Plasma and Gelatin β -Tricalcium Phosphate Sponges. *Tissue Eng. Part A* **2018**, *24*, 1001–1010. [[CrossRef](#)]
58. Engler-Pinto, A.; Siéssere, S.; Calefi, A.; Oliveira, L.; Ervolino, E.; de Souza, S.; Furlaneto, F.; Messori, M.R. Effects of leukocyte- and platelet-rich fibrin associated or not with bovine bone graft on the healing of bone defects in rats with osteoporosis induced by ovariectomy. *Clin. Oral. Implant. Res.* **2019**, *30*, 962–976. [[CrossRef](#)]
59. Goltzman, D. The Aging Skeleton. *Adv. Exp. Med. Biol.* **2019**, *1164*, 153–160.
60. Compston, J.E.; McClung, M.R.; Leslie, W.D. Osteoporosis. *Lancet* **2019**, *393*, 364–376. [[CrossRef](#)]
61. Dede, A.D.; Callan, M. Treatment of osteoporosis: Whom, how and for how long? *Br. J. Hosp. Med. (Lond.)* **2018**, *79*, 259–264. [[CrossRef](#)]
62. Caplan, A.L.; Correa, D. PDGF in bone formation and regeneration: New insights into a novel mechanism involving MSCs. *J. Orthop. Res.* **2011**, *29*, 1795–1803. [[CrossRef](#)] [[PubMed](#)]
63. Graham, S.; Leonidou, A.; Lester, M.; Heliotis, M.; Mantalaris, A.; Tsiridis, E. Investigating the role of PDGF as a potential drug therapy in bone formation and fracture healing. *Expert Opin. Investig. Drugs* **2009**, *18*, 1633–1654. [[CrossRef](#)] [[PubMed](#)]
64. Varol, E. The relationship between platelet indices and postmenopausal osteoporosis. *Osteoporos. Int.* **2015**, *26*, 1871–1872. [[CrossRef](#)] [[PubMed](#)]
65. Barrientos, S.; Stojadinovic, O.; Golinko, M.S.; Brem, H.; Tomic-Canic, M. Growth factors and cytokines in wound healing. *Wound Repair Regen.* **2008**, *16*, 585–601. [[CrossRef](#)]
66. Suzuki, S.; Morimoto, N.; Ikada, Y. Gelatin gel as a carrier of platelet-derived growth factors. *J. Biomater. Appl.* **2013**, *28*, 595–606. [[CrossRef](#)]
67. Veronesi, F.; Pagani, S.; Torricelli, P.; Filardo, G.; Cavallo, C.; Grigolo, B.; Fini, M. PRP and MSCs on tenocytes artificial wound healing: An in vitro study comparing fresh and frozen PRP. *Histol. Histopathol.* **2018**, *33*, 1323–1334.
68. Scully, D.; Naseem, K.M.; Matsakas, A. Platelet biology in regenerative medicine of skeletal muscle. *Acta Physiol. (Oxf.)* **2018**, *223*, 13071. [[CrossRef](#)] [[PubMed](#)]



© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).

MDPI
St. Alban-Anlage 66
4052 Basel
Switzerland
Tel. +41 61 683 77 34
Fax +41 61 302 89 18
www.mdpi.com

International Journal of Molecular Sciences Editorial Office
E-mail: ijms@mdpi.com
www.mdpi.com/journal/ijms



MDPI
St. Alban-Anlage 66
4052 Basel
Switzerland

Tel: +41 61 683 77 34
Fax: +41 61 302 89 18

www.mdpi.com



ISBN 978-3-03936-691-0